<SEC-DOCUMENT>0001055726-25-000026.txt : 20250513
<SEC-HEADER>0001055726-25-000026.hdr.sgml : 20250513
<ACCEPTANCE-DATETIME>20250513160052
ACCESSION NUMBER:		0001055726-25-000026
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		73
CONFORMED PERIOD OF REPORT:	20250331
FILED AS OF DATE:		20250513
DATE AS OF CHANGE:		20250513

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			INOVIO PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0001055726
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				330969592
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-14888
		FILM NUMBER:		25939787

	BUSINESS ADDRESS:	
		STREET 1:		660 W. GERMANTOWN PIKE
		STREET 2:		SUITE 110
		CITY:			PLYMOUTH MEETING
		STATE:			PA
		ZIP:			19462
		BUSINESS PHONE:		8584103134

	MAIL ADDRESS:	
		STREET 1:		660 W. GERMANTOWN PIKE
		STREET 2:		SUITE 110
		CITY:			PLYMOUTH MEETING
		STATE:			PA
		ZIP:			19462

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INOVIO BIOMEDICAL CORP
		DATE OF NAME CHANGE:	20050404

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GENETRONICS BIOMEDICAL CORP
		DATE OF NAME CHANGE:	20011116

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GENETRONICS BIOMEDICAL LTD
		DATE OF NAME CHANGE:	19980213
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>ino-20250331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:382d2453-c46c-4ade-9f50-1f9566f15edb,g:9bfa17de-2275-45c6-a4f6-49112bde99df,d:cec13c599da34407bd5c5256baff0b0b-->
<html xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:ino="http://www.inovio.com/20250331" xmlns="http://www.w3.org/1999/xhtml" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2024" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2024" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>ino-20250331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-26">false</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-27">2025</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-28">Q1</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-29">0001055726</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="f-30">12/31</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" id="f-394">http://fasb.org/us-gaap/2024#FairValueAdjustmentOfWarrants</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="ino-20250331.xsd"/></ix:references><ix:resources><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="position"><xbrli:measure>ino:position</xbrli:measure></xbrli:unit><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="y"><xbrli:measure>utr:Y</xbrli:measure></xbrli:unit><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:unit id="segment"><xbrli:measure>ino:segment</xbrli:measure></xbrli:unit><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-05-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:December2024OfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-12-16</xbrli:startDate><xbrli:endDate>2024-12-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ino:December2024OfferingWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:December2024OfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ino:December2024OfferingWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:December2024OfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:December2024OfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-12-16</xbrli:startDate><xbrli:endDate>2024-12-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:UnderwrittenRegisteredDirectOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-18</xbrli:startDate><xbrli:endDate>2024-04-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:UnderwrittenRegisteredDirectOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:UnderwrittenRegisteredDirectOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-18</xbrli:startDate><xbrli:endDate>2024-04-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:UnderwrittenRegisteredDirectOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:UnderwrittenRegisteredDirectOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-18</xbrli:startDate><xbrli:endDate>2024-04-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:A2024SalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:A2024SalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-01</xbrli:startDate><xbrli:endDate>2024-03-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ino:December2024OfferingWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:UnderwrittenRegisteredDirectOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:A2024SalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-08-13</xbrli:startDate><xbrli:endDate>2024-08-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:A2024SalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:A2021SalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-09</xbrli:startDate><xbrli:endDate>2021-11-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:A2021SalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2023IncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2023IncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2023IncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2016IncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2016IncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2022InducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2022InducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2007IncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2007IncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ino:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ino:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-137"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-138"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-139"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-140"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-141"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ino:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-142"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ino:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-143"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ino:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-144"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:NonEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-145"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:NonEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-146"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-147"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ino:RestrictedStockUnitsRSUsMilestoneBasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-148"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ino:RestrictedStockUnitsRSUsMarketBasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-149"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ino:RestrictedStockUnitsRSUsTotalShareholderReturnMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-150"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-151"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ino:RestrictedStockUnitsRSUsMarketBasedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-152"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ino:RestrictedStockUnitsRSUsMarketBasedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-153"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">ino:December2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-154"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">ino:December2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-155"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ino:RestrictedStockUnitsPerformanceBasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-156"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ino:StockOptionsPerformanceBasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-157"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ino:StockOptionsPerformanceBasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-12-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-158"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:PlumblineLifeSciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-159"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:PlumblineLifeSciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-160"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:PlumblineLifeSciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-161"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-01-01</xbrli:startDate><xbrli:endDate>2016-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-162"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:TheWistarInstituteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-163"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:TheWistarInstituteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-164"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:TheWistarInstituteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-08-01</xbrli:startDate><xbrli:endDate>2024-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-165"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:TheWistarInstituteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-166"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:TheWistarInstituteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-167"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-168"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-169"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:TheWistarInstituteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-170"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:TheWistarInstituteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-171"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:TheWistarInstituteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-172"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:TheWistarInstituteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-173"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ino:SanDiegoOfficeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-174"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ino:PlymouthMeetingPennsylvaniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-175"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-176"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-177"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ino:SanDiegoCaliforniaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-01</xbrli:startDate><xbrli:endDate>2023-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-178"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ino:SanDiegoCaliforniaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-01</xbrli:startDate><xbrli:endDate>2023-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-179"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ino:PlymouthMeetingPennsylvaniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-180"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:ApolloBioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-181"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:ApolloBioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-182"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LassaFeverAndMERSVaccineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-183"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LassaFeverAndMERSVaccineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-184"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LassaFeverAndMERSVaccineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-185"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-186"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-187"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-188"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-189"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-190"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-191"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ino:ReportableSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-192"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ino:ReportableSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-193"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ino:ResearchAndDevelopmentCostAxis">ino:INO3107Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-194"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ino:ResearchAndDevelopmentCostAxis">ino:INO3107Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-195"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ino:ResearchAndDevelopmentCostAxis">ino:INO3112AndOtherImmunoOncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-196"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ino:ResearchAndDevelopmentCostAxis">ino:INO3112AndOtherImmunoOncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-197"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ino:ResearchAndDevelopmentCostAxis">ino:OtherProgramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-198"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ino:ResearchAndDevelopmentCostAxis">ino:OtherProgramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-199"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ino:ResearchAndDevelopmentCostAxis">ino:EngineeringAndDeviceRelatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-200"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ino:ResearchAndDevelopmentCostAxis">ino:EngineeringAndDeviceRelatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ino:ResearchAndDevelopmentCostAxis">ino:StockBasedCompensationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ino:ResearchAndDevelopmentCostAxis">ino:StockBasedCompensationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ino:ResearchAndDevelopmentCostAxis">ino:OtherUnallocatedExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-204"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ino:ResearchAndDevelopmentCostAxis">ino:OtherUnallocatedExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="icec13c599da34407bd5c5256baff0b0b_1"></div><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%"> UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">WASHINGTON, D.C. 20549</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:33.333%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">10-Q</ix:nonNumeric> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:3.201%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.599%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="f-2">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF&#160;1934</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">      </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"> FOR THE QUARTERLY PERIOD ENDED <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-3">MARCH 31, 2025</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">OR</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:3.335%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.465%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="f-4">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF&#160;1934</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">       FOR THE TRANSITION PERIOD FROM&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; TO &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">COMMISSION FILE NO.&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-14888</ix:nonNumeric> </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:186.00pt"><tr><td style="width:1.0pt"/><td style="width:184.00pt"/><td style="width:1.0pt"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><img src="ino-20250331_g1.jpg" alt="inoviologosw.jpg" style="height:64px;margin-bottom:5pt;vertical-align:text-bottom;width:204px" id="i-1"/></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-6">INOVIO PHARMACEUTICALS, INC.</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.276%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.260%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:40.164%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-7">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-8">33-0969592</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-9">660 W. Germantown Pike</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine2" id="f-10">Suite 110</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-11">Plymouth Meeting</ix:nonNumeric>,&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-12">Pennsylvania</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-13">19462</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Zip Code)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">REGISTRANT&#8217;S TELEPHONE NUMBER, INCLUDING AREA CODE: (<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-14">267</ix:nonNumeric>)&#160;<ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-15">440-4200</ix:nonNumeric> </span></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">SECURITIES REGISTERED PURSUANT TO SECTION&#160;12(B) OF THE ACT:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.069%"><tr><td style="width:1.0%"/><td style="width:41.965%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.936%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:40.799%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of Each Class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of Each Exchange on Which Registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-16">COMMON STOCK, $0.001 PAR VALUE</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-17">INO</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-18">Nasdaq</ix:nonNumeric> Capital Market</span></div></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:33.333%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the Registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus" id="f-19">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;No&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityInteractiveDataCurrent" id="f-20">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and "emerging growth company" in Rule&#160;12b-2 of the Exchange Act. (Check one):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:19.867%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:50.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.077%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.490%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Large accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="f-21">Non-accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9746;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntitySmallBusiness" format="ixt:fixed-true" id="f-22">&#9746;</ix:nonNumeric></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-23">&#9744;</ix:nonNumeric></span></div></td></tr></table></div><div style="text-indent:24.75pt"><span><br/></span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:3pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">        &#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-24">&#9746;</ix:nonNumeric></span></div><div style="margin-top:3pt;text-indent:24.75pt"><span><br/></span></div><div style="margin-top:3pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The number of shares outstanding of the Registrant&#8217;s Common Stock, $0.001 par value, was <ix:nonFraction unitRef="shares" contextRef="c-2" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-25">36,674,436</ix:nonFraction> as of May&#160;9, 2025.</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:186.00pt"><tr><td style="width:1.0pt"/><td style="width:184.00pt"/><td style="width:1.0pt"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="height:27pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="icec13c599da34407bd5c5256baff0b0b_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INOVIO PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORM 10-Q</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the Quarterly Period Ended March&#160;31, 2025</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:81.916%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.884%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#icec13c599da34407bd5c5256baff0b0b_13">Part I.  Financial Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icec13c599da34407bd5c5256baff0b0b_13">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:24.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icec13c599da34407bd5c5256baff0b0b_13">Item&#160;1. Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icec13c599da34407bd5c5256baff0b0b_13">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:42.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icec13c599da34407bd5c5256baff0b0b_16">a) Condensed Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icec13c599da34407bd5c5256baff0b0b_16">2</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:42.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icec13c599da34407bd5c5256baff0b0b_19">b) Condensed Consolidated Statements of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icec13c599da34407bd5c5256baff0b0b_19">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:42.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icec13c599da34407bd5c5256baff0b0b_25">c) Condensed Consolidated Statements of Comprehensive Loss</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icec13c599da34407bd5c5256baff0b0b_25">4</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:42.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icec13c599da34407bd5c5256baff0b0b_28">d) Condensed Consolidated Statements of Stockholders' Equity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icec13c599da34407bd5c5256baff0b0b_28">5</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:42.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icec13c599da34407bd5c5256baff0b0b_34">e) Condensed Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icec13c599da34407bd5c5256baff0b0b_34">6</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:42.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icec13c599da34407bd5c5256baff0b0b_37">f) Notes to Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icec13c599da34407bd5c5256baff0b0b_37">7</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:24.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icec13c599da34407bd5c5256baff0b0b_112">Item&#160;2. Management's Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icec13c599da34407bd5c5256baff0b0b_112">22</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:24.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icec13c599da34407bd5c5256baff0b0b_130">Item&#160;3. Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icec13c599da34407bd5c5256baff0b0b_130">27</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:24.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icec13c599da34407bd5c5256baff0b0b_133">Item&#160;4. Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icec13c599da34407bd5c5256baff0b0b_133">27</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#icec13c599da34407bd5c5256baff0b0b_136">Part II.  Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icec13c599da34407bd5c5256baff0b0b_136">29</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:24.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icec13c599da34407bd5c5256baff0b0b_139">Item&#160;1. Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icec13c599da34407bd5c5256baff0b0b_139">29</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:24.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icec13c599da34407bd5c5256baff0b0b_142">Item&#160;1A. Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icec13c599da34407bd5c5256baff0b0b_142">29</a></span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:24.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icec13c599da34407bd5c5256baff0b0b_148">Item&#160;5. Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icec13c599da34407bd5c5256baff0b0b_148">57</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:24.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icec13c599da34407bd5c5256baff0b0b_151">Item&#160;6. Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icec13c599da34407bd5c5256baff0b0b_151">57</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#icec13c599da34407bd5c5256baff0b0b_154">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icec13c599da34407bd5c5256baff0b0b_154">59</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="text-indent:24.75pt"><span><br/></span></div><div style="margin-bottom:17pt;margin-top:17pt"><span><br/></span></div><div id="icec13c599da34407bd5c5256baff0b0b_10"></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">SUMMARY OF THE MATERIAL RISKS ASSOCIATED WITH OUR BUSINESS</span></div><div><span><br/></span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is subject to a number of risks, including risks that may prevent us from achieving our business objectives or may adversely affect our business, financial condition, results of operations, cash flows and prospects. These risks are discussed more fully in Item 1A. Risk Factors herein. These risk factors include, but are not limited to, the following: </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have incurred significant losses in recent years, expect to incur significant net losses in the foreseeable future and may never become profitable. </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have limited sources of revenue and our success is dependent on our ability to develop our DNA medicines and proprietary device technology. </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We will need substantial additional capital to develop our DNA medicines and proprietary device technology, which may prove difficult or costly to obtain. </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we are unable to obtain FDA approval of our proprietary devices and DNA medicine candidates, we will not be able to commercialize them in the United States. In particular, because our product candidates are drug-device combination products comprising an electroporation device for delivery of a biologic, additional time may be required to obtain regulatory approval for our product candidates because of the complexity involved with developing and manufacturing a drug-device combination product. In addition, if the FDA and similar regulatory agencies do not provide marketing authorization for our CELLECTRA delivery devices, then we will not be able to bring to market our DNA medicines that rely on delivery by such a device. </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">DNA medicines are a novel approach to treating and preventing disease, and our CELLECTRA delivery devices are a novel approach to administering medicines, and negative perception of the efficacy, safety, or tolerability of any investigational medicines we develop or our devices could adversely affect our ability to conduct our business, advance our investigational medicines, or obtain regulatory approvals. </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we and the contract manufacturers upon whom we rely fail to produce our proprietary devices and DNA medicine candidates in the volumes that we require on a timely basis, or at all, or if these contractors fail to comply with their obligations to us or with stringent regulations, we may face delays in the development and commercialization of our proprietary devices and DNA medicine candidates. </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we lose or are unable to secure collaborators or partners, or if our collaborators or partners do not apply adequate resources to their relationships with us, our product development and potential for profitability will suffer. </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have agreements with government agencies that are subject to termination and uncertain future funding. Termination or cessation of funding could have a negative impact on our ability to develop some of the product candidates in our pipeline and/or require us to seek alternative funding sources to advance those candidates. </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are currently subject to litigation and may become subject to additional litigation, which could harm our business, financial condition and reputation. </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We face intense and increasing competition and steps taken by our competitors, such as the introduction of a new, disruptive technology may impede our ability to develop and commercialize our DNA medicines.</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have entered into collaborations with Chinese companies and may rely on clinical materials manufactured in China for our development efforts. Uncertainties regarding the interpretation and enforcement of Chinese laws, rules and regulations, a trade war, political unrest or unstable economic conditions in China could materially adversely affect our business, financial condition and results of operations. </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">It is difficult and costly to generate and protect our intellectual property and our proprietary technologies, and we may not be able to ensure their protection.  </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we are sued for infringing intellectual property rights of third parties, it will be costly and time-consuming, and an unfavorable outcome in that litigation would have a material adverse effect on our business. </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are subject to stringent and evolving U.S. and foreign laws, regulations, and rules, contractual obligations, industry standards, policies and other obligations related to data privacy and security. Our actual or perceived failure, or the failure of third parties with whom we work, to comply with such obligations could lead to material adverse business consequences.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="icec13c599da34407bd5c5256baff0b0b_13"></div><hr style="page-break-after:always"/><div style="min-height:18pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Part I.  Financial Information</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1.&#160;&#160;&#160;&#160;Financial Statements</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="icec13c599da34407bd5c5256baff0b0b_16"></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INOVIO PHARMACEUTICALS, INC.  </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED BALANCE SHEETS</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.855%"><tr><td style="width:1.0%"/><td style="width:74.516%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.946%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.513%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="0" id="f-31">39,915,447</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="0" id="f-32">65,813,297</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:ShortTermInvestments" format="ixt:num-dot-decimal" scale="0" id="f-33">28,447,097</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:ShortTermInvestments" format="ixt:num-dot-decimal" scale="0" id="f-34">28,300,232</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable from affiliated entity</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="0" id="f-35">1,310,237</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="0" id="f-36">1,199,056</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="0" id="f-37">2,221,668</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="0" id="f-38">2,517,465</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="0" id="f-39">71,894,449</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="0" id="f-40">97,830,050</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="0" id="f-41">3,347,824</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="0" id="f-42">3,659,818</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in affiliated entity</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-43">2,308,975</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-44">1,613,844</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="0" id="f-45">7,741,757</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="0" id="f-46">8,113,840</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-47">1,979,654</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-48">1,979,654</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="0" id="f-49">87,272,659</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="0" id="f-50">113,197,206</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-51">12,919,788</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-52">16,200,013</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses due to affiliated entity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-53">469,637</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="0" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-54">1,351,163</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued clinical trial expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="ino:AccruedClinicalTrialExpenseCurrent" format="ixt:num-dot-decimal" scale="0" id="f-55">1,819,237</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="ino:AccruedClinicalTrialExpenseCurrent" format="ixt:num-dot-decimal" scale="0" id="f-56">2,021,860</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock warrant liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:DerivativeLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-57">9,542,316</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:DerivativeLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-58">13,255,188</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="0" id="f-59">2,575,902</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="0" id="f-60">2,497,360</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-61">27,326,880</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-62">35,325,584</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability, net of current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-63">8,695,055</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-64">9,367,827</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="0" id="f-65">36,021,935</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="0" id="f-66">44,693,411</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="0" id="f-67">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="0" id="f-68">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="0" id="f-69">36,674</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="0" id="f-70">36,099</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="0" id="f-71">1,801,789,329</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="0" id="f-72">1,799,362,625</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="0" id="f-73">1,749,913,959</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="0" id="f-74">1,730,219,262</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-75">661,320</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-76">675,667</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Inovio Pharmaceuticals, Inc. stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-77">51,250,724</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-78">68,503,795</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-79">87,272,659</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-80">113,197,206</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to unaudited condensed consolidated financial statements.</span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="icec13c599da34407bd5c5256baff0b0b_19"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INOVIO PHARMACEUTICALS, INC.</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"/><td style="width:71.585%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.887%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.470%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue from collaborative arrangements </span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="f-81">65,343</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="0" id="f-82">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="0" id="f-83">16,090,902</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="0" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="0" id="f-84">20,913,790</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="0" id="f-85">9,024,970</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="0" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="0" id="f-86">10,571,179</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="0" id="f-87">25,115,872</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="0" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="0" id="f-88">31,484,969</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-89">25,050,529</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="0" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-90">31,484,969</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other income (expense):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:InvestmentIncomeInterest" format="ixt:num-dot-decimal" scale="0" id="f-91">808,077</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="0" name="us-gaap:InvestmentIncomeInterest" format="ixt:num-dot-decimal" scale="0" id="f-92">1,500,290</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:InterestExpenseNonoperating" format="ixt:fixed-zero" scale="0" id="f-93">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="0" name="us-gaap:InterestExpenseNonoperating" format="ixt:num-dot-decimal" scale="0" id="f-94">177,833</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of common stock warrant liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:FairValueAdjustmentOfWarrants" format="ixt:num-dot-decimal" scale="0" id="f-95">3,712,872</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="0" name="us-gaap:FairValueAdjustmentOfWarrants" format="ixt:fixed-zero" scale="0" id="f-96">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) on investment in affiliated entity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="ino:ChangeInValueOfInvestmentsInAffiliatedCompany" format="ixt:num-dot-decimal" scale="0" id="f-97">695,131</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="0" sign="-" name="ino:ChangeInValueOfInvestmentsInAffiliatedCompany" format="ixt:num-dot-decimal" scale="0" id="f-98">126,018</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized gain on available-for-sale equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="0" id="f-99">140,234</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="0" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="0" id="f-100">500,877</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="0" id="f-101">482</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="0" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="0" id="f-102">682,218</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-103">19,694,697</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-104">30,469,871</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss per share </span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Basic and diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-105"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-106">0.51</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-9" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-107"><ix:nonFraction unitRef="usdPerShare" contextRef="c-9" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-108">1.31</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average number of common shares used to compute net loss per share </span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Basic and diluted</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-109"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-110">38,613,653</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-9" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-111"><ix:nonFraction unitRef="shares" contextRef="c-9" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-112">23,291,512</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:1pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to unaudited condensed consolidated financial statements.</span></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="icec13c599da34407bd5c5256baff0b0b_25"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INOVIO PHARMACEUTICALS, INC.</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:74.741%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-113">19,694,697</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-114">30,469,871</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other comprehensive loss:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Foreign currency translation </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:fixed-zero" scale="0" id="f-115">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="0" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-116">32,403</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Unrealized gain (loss) on short-term investments, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-117">14,347</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="0" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-118">46,016</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Comprehensive loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-119">19,680,350</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="0" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-120">30,483,484</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:1pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to unaudited condensed consolidated financial statements.</span></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="icec13c599da34407bd5c5256baff0b0b_28"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INOVIO PHARMACEUTICALS, INC.</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"/><td style="width:35.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.292%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.508%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.292%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.567%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.567%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.567%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.341%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:6.601%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="45" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2025</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Preferred stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number<br/>of&#160;shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number<br/>of shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>paid-in<br/>capital</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>deficit</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>other<br/>comprehensive<br/>loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>stockholders&#8217;<br/>equity</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-10" decimals="INF" name="us-gaap:SharesIssued" scale="0" id="f-121">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="0" id="f-122">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-11" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-123">36,099,991</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-124">36,099</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-125">1,799,362,625</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-126">1,730,219,262</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-127">675,667</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-128">68,503,795</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock for cash, net of financing costs</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-15" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" id="f-129">518,670</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" id="f-130">519</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" id="f-131">1,101,630</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-132">1,102,149</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vesting of RSUs, net of tax payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-15" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-133">55,694</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="f-134">56</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="0" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-135">74,275</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-136">74,219</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="0" id="f-137">1,399,349</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="0" id="f-138">1,399,349</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-139">19,694,697</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-140">19,694,697</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized gain on short-term investments, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="0" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-141">14,347</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-142">14,347</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at March 31, 2025</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-19" decimals="INF" name="us-gaap:SharesIssued" scale="0" id="f-143">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="0" id="f-144">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-20" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-145">36,674,355</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-146">36,674</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-147">1,801,789,329</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-148">1,749,913,959</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-23" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-149">661,320</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-150">51,250,724</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"/><td style="width:35.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.292%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.508%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.292%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.567%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.567%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.567%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.341%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:6.601%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="45" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Preferred stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number<br/>of&#160;shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number<br/>of shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>paid-in<br/>capital</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>deficit</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>other<br/>comprehensive<br/>loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>stockholders&#8217;<br/>equity</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-24" decimals="INF" name="us-gaap:SharesIssued" scale="0" id="f-151">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="0" id="f-152">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-25" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-153">22,793,075</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-154">22,792</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-155">1,740,954,074</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-156">1,622,965,136</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-157">662,601</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-158">117,349,129</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock for cash, net of financing costs</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-30" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" id="f-159">543,620</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" id="f-160">544</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" id="f-161">5,224,589</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-162">5,225,133</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vesting of RSUs, net of tax payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-30" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-163">34,558</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="f-164">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-31" decimals="0" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-165">174,282</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="0" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-166">174,248</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="0" id="f-167">2,525,433</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="0" id="f-168">2,525,433</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-32" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-169">30,469,871</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-170">30,469,871</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized loss on short-term investments, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-33" decimals="0" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-171">46,016</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="0" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-172">46,016</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="0" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-173">32,403</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="0" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-174">32,403</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at March 31, 2024</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-34" decimals="INF" name="us-gaap:SharesIssued" scale="0" id="f-175">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="0" id="f-176">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-35" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-177">23,371,253</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-35" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-178">23,370</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-36" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-179">1,748,529,814</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-37" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-180">1,653,435,007</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-38" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-181">676,214</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-39" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-182">94,441,963</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to unaudited condensed consolidated financial statements.</span></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="icec13c599da34407bd5c5256baff0b0b_34"></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INOVIO PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-top:5pt;text-align:center;text-indent:-9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"><tr><td style="width:1.0%"/><td style="width:71.696%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.121%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.124%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-183">19,694,697</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-184">30,469,871</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="0" id="f-185">371,367</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="0" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="0" id="f-186">424,473</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" format="ixt:num-dot-decimal" scale="0" id="f-187">372,083</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="0" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" format="ixt:num-dot-decimal" scale="0" id="f-188">335,257</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of common stock warrant liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:FairValueAdjustmentOfWarrants" format="ixt:num-dot-decimal" scale="0" id="f-189">3,712,872</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="0" name="us-gaap:FairValueAdjustmentOfWarrants" format="ixt:fixed-zero" scale="0" id="f-190">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-191">1,399,349</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="0" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-192">2,525,433</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash interest on senior convertible notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="ino:NonCashInterestIncomeExpense" format="ixt:fixed-zero" scale="0" id="f-193">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="0" name="ino:NonCashInterestIncomeExpense" format="ixt:num-dot-decimal" scale="0" id="f-194">355,654</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of discounts on investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" scale="0" id="f-195">386</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="0" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" format="ixt:num-dot-decimal" scale="0" id="f-196">684,651</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on sales of short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:GainLossOnSaleOfOtherInvestments" scale="0" id="f-197">482</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="0" sign="-" name="us-gaap:GainLossOnSaleOfOtherInvestments" format="ixt:num-dot-decimal" scale="0" id="f-198">691,168</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Gain) loss on equity investment in affiliated entity</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="ino:ChangeInValueOfInvestmentsInAffiliatedCompany" format="ixt:num-dot-decimal" scale="0" id="f-199">695,131</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="0" sign="-" name="ino:ChangeInValueOfInvestmentsInAffiliatedCompany" format="ixt:num-dot-decimal" scale="0" id="f-200">126,018</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized gain on available-for-sale equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="0" id="f-201">140,234</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="0" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="0" id="f-202">500,877</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable from affiliated entity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="0" id="f-203">111,181</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="0" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="0" id="f-204">145,854</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="0" id="f-205">295,797</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="0" id="f-206">1,897,016</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses, including due to affiliated entity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="0" id="f-207">4,161,751</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="0" id="f-208">3,160,238</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued clinical trial expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="ino:IncreaseDecreaseInAccruedClinicalTrialExpense" format="ixt:num-dot-decimal" scale="0" id="f-209">202,623</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="0" name="ino:IncreaseDecreaseInAccruedClinicalTrialExpense" format="ixt:num-dot-decimal" scale="0" id="f-210">657,104</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets and liabilities, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="ino:IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet" format="ixt:num-dot-decimal" scale="0" id="f-211">594,230</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="0" sign="-" name="ino:IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet" format="ixt:num-dot-decimal" scale="0" id="f-212">11,791</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grant funding liability, including from affiliated entity</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="ino:IncreaseDecreaseinDeferredGrantFundingCurrent" format="ixt:fixed-zero" scale="0" id="f-213">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="0" sign="-" name="ino:IncreaseDecreaseinDeferredGrantFundingCurrent" format="ixt:num-dot-decimal" scale="0" id="f-214">87,489</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="0" id="f-215">26,874,027</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="0" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="0" id="f-216">28,759,956</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Purchases of investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:PaymentsToAcquireShortTermInvestments" format="ixt:fixed-zero" scale="0" id="f-217">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="0" name="us-gaap:PaymentsToAcquireShortTermInvestments" format="ixt:num-dot-decimal" scale="0" id="f-218">9,751,047</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sale or maturity of investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:ProceedsFromSaleOfShortTermInvestments" format="ixt:num-dot-decimal" scale="0" id="f-219">7,620</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="0" name="us-gaap:ProceedsFromSaleOfShortTermInvestments" format="ixt:num-dot-decimal" scale="0" id="f-220">55,169,260</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of capital assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="f-221">59,373</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="0" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="f-222">35,578</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net cash (used in) provided by investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="0" id="f-223">51,753</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="0" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="0" id="f-224">45,382,635</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repayment of convertible senior notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:RepaymentsOfConvertibleDebt" format="ixt:fixed-zero" scale="0" id="f-225">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="0" name="us-gaap:RepaymentsOfConvertibleDebt" format="ixt:num-dot-decimal" scale="0" id="f-226">16,415,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock, net of issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="0" id="f-227">1,102,149</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="0" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="0" id="f-228">5,225,133</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taxes paid related to net share settlement of equity awards </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="ino:ProceedsFromPaymentsForStockOptionsExercisedAndExerciseOfWarrantsNetOfTaxWithholdings" format="ixt:num-dot-decimal" scale="0" id="f-229">74,219</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="0" sign="-" name="ino:ProceedsFromPaymentsForStockOptionsExercisedAndExerciseOfWarrantsNetOfTaxWithholdings" format="ixt:num-dot-decimal" scale="0" id="f-230">174,248</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net cash provided by (used in) financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="0" id="f-231">1,027,930</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="0" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="0" id="f-232">11,364,115</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:fixed-zero" scale="0" id="f-233">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="0" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="f-234">32,403</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Decrease) Increase in cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="0" id="f-235">25,897,850</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="0" id="f-236">5,290,967</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents, beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="f-237">65,813,297</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="f-238">14,310,862</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash and cash equivalents, end of period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="f-239">39,915,447</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-39" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="f-240">19,601,829</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental disclosures:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts accrued for purchases of fixed assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:fixed-zero" scale="0" id="f-241">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="0" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="0" id="f-242">442,976</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest paid</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:InterestPaidNet" format="ixt:fixed-zero" scale="0" id="f-243">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="0" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="0" id="f-244">533,487</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:center;text-indent:-9pt"><span><br/></span></div><div style="text-align:center;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to unaudited condensed consolidated financial statements.</span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="icec13c599da34407bd5c5256baff0b0b_37"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INOVIO PHARMACEUTICALS, INC.</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div id="icec13c599da34407bd5c5256baff0b0b_40"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">1. <ix:nonNumeric contextRef="c-1" name="us-gaap:NatureOfOperations" id="f-245" continuedAt="f-245-1" escape="true">Organization and Operations</ix:nonNumeric></span></div><ix:continuation id="f-245-1"><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Inovio Pharmaceuticals, Inc. (the &#8220;Company&#8221; or &#8220;INOVIO&#8221;) is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer and infectious diseases. INOVIO's platform harnesses the power of in vivo protein production, featuring optimized design and delivery of DNA medicines that teach the body to manufacture its own disease-fighting tools. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">INOVIO uses proprietary technology to design DNA plasmids, which are small circular DNA molecules that work like software the body&#8217;s cells can download to produce specific proteins to target and fight disease. The Company's proprietary investigational CELLECTRA devices are designed to deliver the plasmids into the body's cells for optimal effect, without the use of chemical adjuvants, lipid nanoparticles or viral vectors. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INOVIO's lead candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease of the respiratory tract caused by HPV infection. In its completed Phase 1/2 clinical trial of INO-3107 for the treatment of HPV-6 and HPV-11-associated RRP, 81.3% of patients experienced a reduction in the number of surgical interventions in the year following administration of INO-3107, when compared with the year prior to treatment. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to its development efforts with INO-3107, INOVIO is actively developing or planning to develop DNA medicines for other indications, including HPV-related oropharyngeal squamous cell carcinoma (OPSCC) and anal dysplasia; glioblastoma multiforme (GBM), a deadly form of brain cancer; and a potential vaccine booster to protect against the Ebola virus. The Company was previously conducting clinical trials of a DNA medicine candidate for the treatment of HPV-related cervical high-grade squamous intraepithelial lesions (HSIL) but announced in 2023 that it was ceasing development for this indication in the United States. However, its collaborator ApolloBio Corporation continues to conduct a Phase 3 clinical trial of this candidate in China and plans to seek regulatory approval for and potentially commercialize the candidate in that jurisdiction. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, Coherus Biosciences, Defense Advanced Research Projects Agency (DARPA), HIV Vaccines Trial Network, International Vaccine Institute (IVI), Kaneka Eurogentec, National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID), Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter BioLogics, the University of Pennsylvania and The Wistar Institute.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INOVIO was incorporated in Delaware in June 2001 and has its principal executive offices in Plymouth Meeting, Pennsylvania.</span></div></ix:continuation><div style="margin-top:5pt;text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:120%">&#160;</span></div><div id="icec13c599da34407bd5c5256baff0b0b_43"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="c-1" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" id="f-246" continuedAt="f-246-1" escape="true">Basis of Presentation, Liquidity and Risks and Uncertainties</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="f-247" continuedAt="f-247-1" escape="true"><ix:continuation id="f-246-1" continuedAt="f-246-2"><div style="margin-bottom:3pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation</span></div><div style="margin-top:4.5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements of Inovio have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) as contained in the Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") for interim financial information and with instructions to Form&#160;10-Q and Article&#160;10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The condensed consolidated balance sheet as of March&#160;31, 2025, the condensed consolidated statements of operations, the condensed consolidated statements of comprehensive loss, the condensed consolidated statements of stockholders' equity and the condensed consolidated statements of cash flows for the three months ended March 31, 2025 and 2024 are unaudited, but include all adjustments (consisting of normal recurring adjustments) that the Company considers necessary for a fair presentation of the financial position, results of operations, cash flows and changes in stockholders' equity for the periods presented. </span></div><div style="margin-top:4.5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of operations for the three months ended March 31, 2025 shown herein are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2025, or for any other period. These unaudited financial statements, and notes thereto, should be read in conjunction with the audited consolidated financial statements for the year ended December&#160;31, 2024, included in the Company's Annual Report on Form&#160;10-K filed with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) on March&#160;18, 2025. The balance sheet at December&#160;31, 2024 has been derived from the audited financial statements at that date, but does not include all of the information and footnotes required by U.S. GAAP for complete financial statements. </span></div></ix:continuation></ix:nonNumeric><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icec13c599da34407bd5c5256baff0b0b_7">Table of </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#icec13c599da34407bd5c5256baff0b0b_7">Contents</a></span></div></div><ix:continuation id="f-247-1" continuedAt="f-247-2"><ix:continuation id="f-246-2" continuedAt="f-246-3"><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These unaudited condensed consolidated financial statements include the accounts of Inovio Pharmaceuticals, Inc. and its subsidiary. As of March&#160;31, 2025 and December 31, 2024, the Company consolidated its wholly-owned subsidiary Inovio Asia LLC. All intercompany accounts and transactions were eliminated upon consolidation. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Liquidity </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurred a net loss of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="f-248">19.7</ix:nonFraction> million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the three months ended March 31, 2025. The Company had working capital of $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="ino:WorkingCapital" scale="6" id="f-249">44.6</ix:nonFraction> million and an accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-8" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="9" id="f-250">1.7</ix:nonFraction> billion as of March&#160;31, 2025. The Company has incurred losses in each year since its inception and expects to continue to incur significant expenses and operating losses for the foreseeable future in connection with the research and preclinical and clinical development of its product candidates. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 16, 2024, the Company closed an underwritten public offering (the "December 2024 Offering"), relating to the issuance and sale of <ix:nonFraction unitRef="shares" contextRef="c-40" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-251">10,000,000</ix:nonFraction> shares of its common stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="c-41" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-252">0.001</ix:nonFraction> per share, and warrants to purchase <ix:nonFraction unitRef="shares" contextRef="c-42" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-253">10,000,000</ix:nonFraction> shares of common stock (the &#8220;Warrants&#8221;), at an offering price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-43" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-254">3.00</ix:nonFraction> per share and accompanying Warrant. The exercise price of the Warrants is $<ix:nonFraction unitRef="usdPerShare" contextRef="c-43" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-255">3.76</ix:nonFraction> per share. The net proceeds from the December 2024 Offering were $<ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="f-256">27.6</ix:nonFraction>&#160;million, after deducting the underwriting discounts and commissions and offering expenses paid by the Company. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 18, 2024, the Company closed an underwritten registered direct offering (the &#8220;April 2024 Offering&#8221;) relating to the issuance and sale of <ix:nonFraction unitRef="shares" contextRef="c-45" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-257">2,536,258</ix:nonFraction> shares (the &#8220;Shares&#8221;) of its common stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="c-46" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-258">0.001</ix:nonFraction> per share, at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-46" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-259">7.693</ix:nonFraction> per share and pre-funded warrants to purchase up to <ix:nonFraction unitRef="shares" contextRef="c-47" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-260">2,135,477</ix:nonFraction> shares of common stock (the &#8220;Pre-Funded Warrants&#8221;) at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-48" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-261">7.692</ix:nonFraction> per Pre-Funded Warrant, which represents the per share price for the Shares less the $<ix:nonFraction unitRef="usdPerShare" contextRef="c-48" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-262">0.001</ix:nonFraction> per share exercise price for each Pre-Funded Warrant. The net proceeds from the April 2024 Offering were $<ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-5" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" format="ixt:num-dot-decimal" scale="6" id="f-263">33.2</ix:nonFraction>&#160;million, after deducting the underwriting discounts and commissions and offering expenses paid by the Company. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Going Concern </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s cash, cash equivalents and short-term investments of $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" scale="6" id="f-264">68.4</ix:nonFraction> million as of March&#160;31, 2025 are expected to be sufficient to support the Company's planned operations into the first quarter of 2026. The Company's current financial resources may not be sufficient to support its planned operations beyond this date without securing additional financing.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to continue to fund future research and development activities, the Company will need to seek additional capital. This may occur through strategic alliance and licensing arrangements, grant agreements and/or future public or private debt or equity financings including At-the-Market Equity Offering Sales Agreements (&#8220;Sales Agreements&#8221;). The Company has a history of conducting debt and equity financings, including the receipt of net proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="f-265">60.8</ix:nonFraction>&#160;million from equity offerings during the year ending December 31, 2024, and the receipt of net proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="f-266">1.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="f-267">6.1</ix:nonFraction>&#160;million under Sales Agreements during the three months ended March 31, 2025 and year ended December 31, 2024, respectively. However, sufficient funding may not be available in the future, or if available, may be on terms that significantly dilute or otherwise adversely affect the rights of existing stockholders. If adequate funds are not available, the Company may need to delay, reduce the scope of or put on hold one or more of its clinical and/or preclinical programs.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s ability to continue its operations is dependent upon its ability to obtain additional capital in the future and achieve profitable operations. The Company expects to continue to rely on outside sources of financing to meet its capital needs and may never achieve positive cash flow. In light of these factors, management believes that there is substantial doubt about the Company's ability to continue as a going concern beyond the first quarter of 2026. The Company's condensed consolidated financial statements as of and for the three months ended March 31, 2025 do not include any adjustments that might result from the outcome of this uncertainty. The Company has evaluated subsequent events after the balance sheet date through the date it issued these condensed consolidated financial statements.</span></div></ix:continuation></ix:continuation><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-247-2"><ix:continuation id="f-246-3">The Company is, and from time to time&#160;may in the future be, subject to various legal proceedings and claims arising in the ordinary course of business. The Company assesses contingencies to determine the degree of probability and range of possible loss for potential accrual in its consolidated financial statements. An estimated loss contingency is accrued in the consolidated financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Legal proceedings, including litigation, government investigations and enforcement actions, could result in material costs, occupy significant management resources and entail civil and criminal penalties, even if the Company ultimately prevails.&#160;Any of the foregoing consequences could result in serious harm to the Company&#8217;s business, results of operations and financial condition.</ix:continuation></ix:continuation> </span></div><div style="margin-top:5pt;text-indent:27pt"><span><br/></span></div><div id="icec13c599da34407bd5c5256baff0b0b_49"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="c-1" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="f-268" continuedAt="f-268-1" escape="true">Critical Accounting Policies</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:CollaborativeArrangementAccountingPolicy" id="f-269" continuedAt="f-269-1" escape="true"><ix:continuation id="f-268-1" continuedAt="f-268-2"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaboration Agreements and Revenue Recognition</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company assesses whether its collaboration agreements are subject to Accounting Standards Codification ("ASC") Topic 808: Collaborative Arrangements (&#8220;Topic 808&#8221;) based on whether they involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within the scope of Topic 808 and the Company concludes that its collaboration partner is not a customer, the </span></div></ix:continuation></ix:nonNumeric><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icec13c599da34407bd5c5256baff0b0b_7">Table of </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#icec13c599da34407bd5c5256baff0b0b_7">Contents</a></span></div></div><ix:continuation id="f-268-2"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="f-269-1">Company presents such payments as a reduction of research and development expense. If payments from the collaboration partner to the Company represent consideration from a customer, then the Company accounts for those payments within the scope of Accounting Standards Update (&#8220;ASU&#8221;) 2014-09, Revenue from Contracts with Customers (&#8220;Topic 606&#8221;).</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="f-270" escape="true"><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses - Clinical Trial Accruals</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company's activities have largely consisted of research and development efforts related to developing its proprietary device technology and DNA medicine candidates. For clinical trial expenses, judgements used in estimating accruals rely on estimates of total costs incurred based on participant enrollment, completion of studies and other events. Accrued clinical trial costs are subject to revisions as trials progress. Revisions are charged to expense in the period in which the facts that give rise to the revision become known. Historically, revisions have not resulted in material changes to research and development expense; however, a modification in the protocol of a clinical trial or cancellation of a trial could result in a charge to the Company's results of operations.</span></div></ix:nonNumeric></ix:continuation><div style="margin-top:5pt"><span><br/></span></div><div id="icec13c599da34407bd5c5256baff0b0b_55"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="c-1" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="f-272" continuedAt="f-272-1" escape="true"><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueDisclosuresTextBlock" id="f-271" continuedAt="f-271-1" escape="true">Short-term Investments and Fair Value Measurements</ix:nonNumeric></ix:nonNumeric></span></div><ix:continuation id="f-272-1" continuedAt="f-272-2"><ix:continuation id="f-271-1" continuedAt="f-271-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" id="f-273" escape="true"><div style="margin-bottom:3pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of available-for-sale securities as of March&#160;31, 2025 and December&#160;31, 2024:</span></div><div style="margin-bottom:3pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:25.839%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.812%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2025</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Maturity&#160;(in&#160;years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Market&#160;Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">---</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-53" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="0" id="f-274">25,926,415</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-53" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="0" id="f-275">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-53" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="0" id="f-276">1,305,472</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-53" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-277">24,620,943</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than <ix:nonNumeric contextRef="c-54" name="ino:DebtSecuritiesAvailableforSaleContractualMaturity" format="ixt-sec:duryear" id="f-278">1</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-55" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="0" id="f-279">2,980,607</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-55" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:num-dot-decimal" scale="0" id="f-280">9,268</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-55" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="0" id="f-281">276</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-55" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-282">2,989,599</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency mortgage-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-56" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="0" id="f-283">1,243,914</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-56" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="0" id="f-284">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-56" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="0" id="f-285">407,359</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-56" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-286">836,555</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="0" id="f-287">30,150,936</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:num-dot-decimal" scale="0" id="f-288">9,268</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="0" id="f-289">1,713,107</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-290">28,447,097</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:25.839%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.812%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2024</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Maturity&#160;(in&#160;years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Market&#160;Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">---</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-57" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="0" id="f-291">25,926,415</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-57" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="0" id="f-292">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-57" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="0" id="f-293">1,445,706</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-57" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-294">24,480,709</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than <ix:nonNumeric contextRef="c-58" name="ino:DebtSecuritiesAvailableforSaleContractualMaturity" format="ixt-sec:duryear" id="f-295">1</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-59" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="0" id="f-296">2,980,273</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-59" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:num-dot-decimal" scale="0" id="f-297">9,750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-59" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="0" id="f-298">281</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-59" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-299">2,989,742</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency mortgage-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-60" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="0" id="f-300">1,260,745</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-60" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="0" id="f-301">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-60" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="0" id="f-302">430,964</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-60" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-303">829,781</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="0" id="f-304">30,167,433</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:num-dot-decimal" scale="0" id="f-305">9,750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="0" id="f-306">1,876,951</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-307">28,300,232</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*No single maturity date.</span></div></ix:nonNumeric><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During the three months ended March 31, 2025 and 2024, the Company recorded gross realized gains on investments of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-2" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" scale="0" id="f-308">200</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-2" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" scale="0" id="f-309">200</ix:nonFraction>, respectively, and gross realized losses on investments of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-2" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" scale="0" id="f-310">700</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" format="ixt:num-dot-decimal" scale="0" id="f-311">691,000</ix:nonFraction>, respectively. During the three months ended March 31, 2025 and 2024, the Company recorded net unrealized gains on available-for-sale equity securities of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="0" id="f-312">140,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="0" id="f-313">501,000</ix:nonFraction>, respectively. No&#160;material balances were&#160;reclassified out of accumulated&#160;other comprehensive loss for the three months ended March 31, 2025 and 2024. Interest and dividends on investments classified as available-for-sale are included in interest income in the condensed consolidated statements of operations. As of March&#160;31, 2025, the Company had <ix:nonFraction unitRef="position" contextRef="c-3" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" scale="0" id="f-314">19</ix:nonFraction> available-for-sale securities with an aggregate total unrealized loss of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:UnrealizedGainLossOnInvestments" scale="6" id="f-315">1.7</ix:nonFraction> million. All of these securities had been in a loss position for longer than 12 months as of March&#160;31, 2025.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company periodically reviews its portfolio of available-for-sale debt securities to determine if any investment is impaired due to credit loss or other potential valuation concerns. For the debt securities where the fair value of the investment is less than the amortized cost basis, the Company has assessed at the individual security level for various quantitative factors including, but not limited to, the nature of the investments, changes in credit ratings, interest rate fluctuations, industry analyst reports, and the severity of impairment. Unrealized losses on available-for-sale debt securities as of&#160;March&#160;31, 2025&#160;were primarily due to changes in interest rates</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">and not due to increased credit risks associated with specific securities. Based on the credit quality of the available-for-sale debt securities that are in an unrealized loss position, and the Company&#8217;s estimates of future cash flows to be collected from those securities, the Company believes the unrealized losses are not credit losses. Accordingly, at March&#160;31, 2025, the Company has not recorded an allowance for credit losses related to its available-for-sale debt securities.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="f-316" continuedAt="f-316-1" escape="true"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following table presents the Company&#8217;s assets that were measured at fair value on a recurring basis, determined using the following inputs as of March&#160;31, 2025:</span></div></ix:nonNumeric></ix:continuation></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icec13c599da34407bd5c5256baff0b0b_7">Table of </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#icec13c599da34407bd5c5256baff0b0b_7">Contents</a></span></div></div><ix:continuation id="f-272-2" continuedAt="f-272-3"><ix:continuation id="f-271-2" continuedAt="f-271-3"><ix:continuation id="f-316-1"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:35.796%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.737%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.689%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2025</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices<br/>in Active Markets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other Unobservable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Mutual funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-61" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-317">24,620,943</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-62" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-318">24,620,943</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-63" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="f-319">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-64" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="f-320">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-65" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-321">2,989,599</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-66" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="f-322">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-67" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-323">2,989,599</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-68" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="f-324">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-69" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-325">836,555</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-70" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="f-326">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-71" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-327">836,555</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-72" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="f-328">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-73" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-329">28,447,097</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-74" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-330">24,620,943</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-75" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-331">3,826,154</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-76" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="f-332">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in affiliated entity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-73" decimals="0" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="0" id="f-333">2,308,975</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-74" decimals="0" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="0" id="f-334">2,308,975</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-75" decimals="0" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="0" id="f-335">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-76" decimals="0" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="0" id="f-336">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-73" decimals="0" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="f-337">30,756,072</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-74" decimals="0" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="f-338">26,929,918</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-75" decimals="0" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="f-339">3,826,154</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-76" decimals="0" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="f-340">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock warrant liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-73" decimals="0" name="ino:CommonStockWarrantLiabilityFairValue" format="ixt:num-dot-decimal" scale="0" id="f-341">9,542,316</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-74" decimals="0" name="ino:CommonStockWarrantLiabilityFairValue" format="ixt:fixed-zero" scale="0" id="f-342">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-75" decimals="0" name="ino:CommonStockWarrantLiabilityFairValue" format="ixt:fixed-zero" scale="0" id="f-343">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-76" decimals="0" name="ino:CommonStockWarrantLiabilityFairValue" format="ixt:num-dot-decimal" scale="0" id="f-344">9,542,316</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-73" decimals="0" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="f-345">9,542,316</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-74" decimals="0" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="f-346">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-75" decimals="0" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="f-347">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-76" decimals="0" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="f-348">9,542,316</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s assets that were measured at fair value on a recurring basis, determined using the following inputs as of December&#160;31, 2024:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:35.796%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.737%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.689%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices<br/>in Active Markets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other Unobservable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Mutual funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-77" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-349">24,480,709</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-78" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-350">24,480,709</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-79" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="f-351">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-80" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="f-352">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-81" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-353">2,989,742</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-82" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="f-354">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-83" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-355">2,989,742</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-84" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="f-356">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-85" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-357">829,781</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-86" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="f-358">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-87" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-359">829,781</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="f-360">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-89" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-361">28,300,232</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-90" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-362">24,480,709</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-91" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-363">3,819,523</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-92" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="f-364">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in affiliated entity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-89" decimals="0" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="0" id="f-365">1,613,844</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-90" decimals="0" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="0" id="f-366">1,613,844</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-91" decimals="0" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="0" id="f-367">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-92" decimals="0" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="0" id="f-368">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-89" decimals="0" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="f-369">29,914,076</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-90" decimals="0" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="f-370">26,094,553</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-91" decimals="0" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="f-371">3,819,523</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-92" decimals="0" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="f-372">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock warrant liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-89" decimals="0" name="ino:CommonStockWarrantLiabilityFairValue" format="ixt:num-dot-decimal" scale="0" id="f-373">13,255,188</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-90" decimals="0" name="ino:CommonStockWarrantLiabilityFairValue" format="ixt:fixed-zero" scale="0" id="f-374">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-91" decimals="0" name="ino:CommonStockWarrantLiabilityFairValue" format="ixt:fixed-zero" scale="0" id="f-375">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-92" decimals="0" name="ino:CommonStockWarrantLiabilityFairValue" format="ixt:num-dot-decimal" scale="0" id="f-376">13,255,188</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-89" decimals="0" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="f-377">13,255,188</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-90" decimals="0" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="f-378">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-91" decimals="0" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="f-379">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-92" decimals="0" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="f-380">13,255,188</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Level 1 assets at March&#160;31, 2025 consisted of mutual funds and the Company&#8217;s investment in its affiliated entity, Plumbline Life Sciences, Inc. (PLS). See Note 10 for additional information. The Company accounts for its investment in <ix:nonFraction unitRef="shares" contextRef="c-93" decimals="INF" name="us-gaap:InvestmentOwnedBalanceShares" format="ixt:num-dot-decimal" scale="0" id="f-381">597,808</ix:nonFraction> common shares of PLS based on the closing price of the shares on the Korea New Exchange Market on the applicable balance sheet date. Unrealized gains and losses on the Company's equity securities are reported in the consolidated statement of ope</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">rations as unrealized gain or loss on available-for-sale equity securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">or as a gain or loss on investment in affiliated entity.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 assets at March&#160;31, 2025 consisted of certificates of deposit and U.S. agency mortgage-backed securities held by the Company that are initially valued at the transaction price and subsequently valued, at the end of each reporting period, typically utilizing market observable data. The Company obtains the fair value of its Level 2 assets from a professional pricing service, which may use quoted market prices for identical or comparable instruments, or inputs other than quoted prices that are observable either directly or indirectly. The professional pricing service gathers quoted market prices and observable inputs from a variety of industry data providers. The valuation techniques used to measure the fair value of the Company's Level 2 financial instruments were derived from non-binding market consensus prices that are corroborated by observable market data, </span></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icec13c599da34407bd5c5256baff0b0b_7">Table of </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#icec13c599da34407bd5c5256baff0b0b_7">Contents</a></span></div></div><ix:continuation id="f-272-3"><ix:continuation id="f-271-3"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">quoted market prices for similar instruments, or pricing models such as discounted cash flow techniques. The Company validates the quoted market prices provided by the primary pricing service by comparing the service's assessment of the fair values of the Company's investment portfolio balance against the fair values of the Company's investment portfolio balance obtained from an independent source.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no Level 3 assets held as of March&#160;31, 2025 or December 31, 2024.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 liabilities held as of March&#160;31, 2025 and December 31, 2024 consisted of liabilities associated with the Warrants to purchase common stock issued in the Company's underwritten public offering that closed in December 2024. See Note 7 for additional information about the liability-classified warrants.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reassesses the fair value of the common stock warrant liability at each reporting date utilizing a Black-Scholes pricing model. <ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="f-382" continuedAt="f-382-1" escape="true">The following assumptions were used to estimate the fair value of the warrant liability:</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="f-382-1"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.016%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.905%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.198%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">March 31, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="number" contextRef="c-94" decimals="3" name="ino:WarrantLiabilityMeasurementInput" scale="-2" id="f-383">4.0</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="number" contextRef="c-95" decimals="3" name="ino:WarrantLiabilityMeasurementInput" scale="-2" id="f-384">4.4</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Expected volatility</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="number" contextRef="c-96" decimals="3" name="ino:WarrantLiabilityMeasurementInput" scale="-2" id="f-385">94</ix:nonFraction>%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="number" contextRef="c-97" decimals="3" name="ino:WarrantLiabilityMeasurementInput" scale="-2" id="f-386">111</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Expected life in years</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="y" contextRef="c-98" decimals="1" name="ino:WarrantLiabilityMeasurementInput" id="f-387">4.7</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="y" contextRef="c-99" decimals="0" name="ino:WarrantLiabilityMeasurementInput" id="f-388">5</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Dividend yield</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="number" contextRef="c-100" decimals="3" name="ino:WarrantLiabilityMeasurementInput" format="ixt:fixed-zero" scale="-2" id="f-389">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="number" contextRef="c-101" decimals="3" name="ino:WarrantLiabilityMeasurementInput" format="ixt:fixed-zero" scale="-2" id="f-390">&#8212;</ix:nonFraction></span></td></tr></table></div></ix:continuation><div><span><br/></span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in these assumptions as well as fluctuations in the Company's stock price between the valuation dates can have a </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">significant impact on the fair value of the common stock warrant liability. Expected volatility was based on historical volatility. Historical volatility was computed using daily pricing observations for recent periods. The Company believes this method produced an estimate that was representative of the Company&#8217;s expectations of future volatility over the expected term. Expected term is calculated based on the remaining contractual term of the Warrants. The risk-free rate was based on the U.S. Treasury rate that corresponds to the expected term of the Warrants. As a result of these calculations, the Company recorded a decrease in fair value of the liability of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" format="ixt:num-dot-decimal" scale="6" id="f-391">3.7</ix:nonFraction>&#160;million on the condensed consolidated statement of operations for the three months ended March&#160;31, 2025. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="f-392" escape="true"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the change in fair value of the Company&#8217;s total Level 3 financial liabilities for the three months ended March&#160;31, 2025:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:83.110%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.690%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock Warrant Liability</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="0" id="f-393">13,255,188</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-394">Decrease in fair value of liability</span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" format="ixt:num-dot-decimal" scale="0" id="f-395">3,712,872</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2025</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="0" id="f-396">9,542,316</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation></ix:continuation><div style="margin-top:5pt;text-indent:27pt"><span><br/></span></div><div id="icec13c599da34407bd5c5256baff0b0b_61"></div><div style="margin-top:5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="c-1" name="us-gaap:OtherCurrentAssetsTextBlock" id="f-397" continuedAt="f-397-1" escape="true">Certain Balance Sheet Items</ix:nonNumeric></span></div><ix:continuation id="f-397-1"><ix:nonNumeric contextRef="c-1" name="ino:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" id="f-398" escape="true"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid and other current assets consisted of the following:</span></div><div style="text-indent:-4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.289%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.291%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid clinical expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="ino:PrepaidClinicalExpensesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-399">1,013,742</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="ino:PrepaidClinicalExpensesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-400">627,962</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other prepaid expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:OtherPrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="0" id="f-401">1,207,926</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:OtherPrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="0" id="f-402">1,889,503</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="0" id="f-403">2,221,668</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="0" id="f-404">2,517,465</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="text-indent:-4.5pt"><span><br/></span></div><div style="padding-left:27pt;text-indent:-31.5pt"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" id="f-405" escape="true"><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable and accrued expenses consisted of the following:</span></div><div style="text-indent:-4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.289%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.291%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade accounts payable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:AccountsPayableTradeCurrentAndNoncurrent" format="ixt:num-dot-decimal" id="f-406">5,054,582</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:AccountsPayableTradeCurrentAndNoncurrent" format="ixt:num-dot-decimal" id="f-407">5,091,503</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:AccruedSalariesCurrent" format="ixt:num-dot-decimal" id="f-408">6,322,421</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:AccruedSalariesCurrent" format="ixt:num-dot-decimal" id="f-409">10,007,180</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-410">1,542,785</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-411">1,101,330</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-412">12,919,788</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-413">16,200,013</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-indent:-4.5pt"><span><br/></span></div><div id="icec13c599da34407bd5c5256baff0b0b_67"></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="c-1" name="us-gaap:DebtDisclosureTextBlock" id="f-414" continuedAt="f-414-1" escape="true">Convertible Debt</ix:nonNumeric></span></div><ix:continuation id="f-414-1" continuedAt="f-414-2"><div style="margin-bottom:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Convertible Senior Notes </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icec13c599da34407bd5c5256baff0b0b_7">Table of </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#icec13c599da34407bd5c5256baff0b0b_7">Contents</a></span></div></div><ix:continuation id="f-414-2"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In 2019, the Company completed a private placement of $<ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-415">78.5</ix:nonFraction>&#160;million aggregate principal amount of its <ix:nonFraction unitRef="number" contextRef="c-102" decimals="4" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-416">6.50</ix:nonFraction>% convertible senior notes due 2024 (the &#8220;Notes&#8221;). The Notes were sold in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. Net proceeds from the offering were $<ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfDebt" format="ixt:num-dot-decimal" scale="6" id="f-417">75.7</ix:nonFraction>&#160;million.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Notes were senior unsecured obligations of the Company and accrued interest payable in cash semi-annually in arrears on March 1 and September 1 of each year at a rate of <ix:nonFraction unitRef="number" contextRef="c-102" decimals="4" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-418">6.50</ix:nonFraction>% per annum. The Notes matured on March 1, 2024 and the Company paid the then remaining $<ix:nonFraction unitRef="usd" contextRef="c-104" decimals="-5" name="us-gaap:RepaymentsOfConvertibleDebt" format="ixt:num-dot-decimal" scale="6" id="f-419">16.9</ix:nonFraction>&#160;million obligation in full, including accrued interest.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">For the three months ended March 31, 2024,&#160;the Company recognized $<ix:nonFraction unitRef="usd" contextRef="c-105" decimals="-3" name="us-gaap:InterestExpenseOperating" format="ixt:num-dot-decimal" scale="0" id="f-420">178,000</ix:nonFraction> of interest expense related to the Notes, all of which related to the contractual interes</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">t coupon.</span></div></ix:continuation><div style="margin-top:5pt;text-indent:24.75pt"><span><br/></span></div><div id="icec13c599da34407bd5c5256baff0b0b_73"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="c-1" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="f-421" continuedAt="f-421-1" escape="true">Stockholders&#8217; Equity</ix:nonNumeric></span></div><ix:continuation id="f-421-1" continuedAt="f-421-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfStockByClassTextBlock" id="f-422" escape="true"><div style="margin-bottom:10pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the Company's authorized and issued common and preferred stock as of March&#160;31, 2025 and December&#160;31, 2024: </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"/><td style="width:42.095%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.473%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.473%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.136%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.106%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outstanding as of</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Authorized</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Issued</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common Stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-423"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-424">0.001</ix:nonFraction></ix:nonFraction> per share</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-425">600,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-426">36,674,355</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-427">36,674,355</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-428">36,099,991</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series&#160;C Preferred Stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="c-106" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-429"><ix:nonFraction unitRef="usdPerShare" contextRef="c-107" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-430">0.001</ix:nonFraction></ix:nonFraction> per share</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-106" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-431">1,091</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-106" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-432">1,091</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-106" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="f-433">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-107" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="f-434">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:5pt;text-indent:27pt"><span><br/></span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Offering of Common Stock and Warrants</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 16, 2024, the Company closed the December 2024 Offering (see &#8220;Liquidity&#8221; in Note 2 above). </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each Warrant issued in the December 2024 Offering has an initial exercise price per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-108" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-435">3.76</ix:nonFraction>, subject to certain adjustments. The Warrants may be exercised at any time, in whole or in part, until expiration on December 16, 2029. In the event there is no effective registration statement covering the shares of common stock underlying a Warrant exercise, the Warrants may be exercised via cashless exercise. A holder (together with its affiliates and other attribution parties) may not exercise any portion of a Warrant to the extent that immediately prior to or after giving effect to such exercise the holder would own more than <ix:nonFraction unitRef="number" contextRef="c-108" decimals="4" name="ino:ClassOfWarrantOrRightCommonStockOwnershipPercent" scale="-2" id="f-436">4.99</ix:nonFraction>% (or, for certain holders who so elected prior to the issuance of the Warrants, <ix:nonFraction unitRef="number" contextRef="c-108" decimals="4" name="ino:ClassOfWarrantOrRightCommonStockOwnershipPriorToIssuancePercent" scale="-2" id="f-437">9.99</ix:nonFraction>%) of the Company&#8217;s outstanding Common Stock immediately after exercise, which percentage may be changed at the holder&#8217;s election to a lower or higher percentage not in excess of <ix:nonFraction unitRef="number" contextRef="c-108" decimals="4" name="ino:ClassOfWarrantOrRightCommonStockOwnershipMaximumPercent" scale="-2" id="f-438">19.99</ix:nonFraction>% upon 61 days&#8217; notice to the Company subject to the terms of the Warrants. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the Warrants are not indexed to the Company&#8217;s common stock, the Company recorded a liability for the Warrants at fair value upon issuance on the Company's condensed consolidated balance sheet. The common stock warrant liability is remeasured to fair value at the end of each reporting period. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2025 and December 31, 2024, no Warrants issued in the December 2024 Offering had been exercised.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 18, 2024, the Company closed the April 2024 Offering (see &#8220;Liquidity&#8221; in Note 2 above). </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each Pre-Funded Warrant issued in the April 2024 Offering has an initial exercise price per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-48" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-439">0.001</ix:nonFraction>, subject to certain adjustments. The Pre-Funded Warrants may be exercised at any time until exercised in full. A holder (together with its affiliates and other attribution parties) may not exercise any portion of a Pre-Funded Warrant to the extent that immediately prior to or after giving effect to such exercise the holder would own more than <ix:nonFraction unitRef="number" contextRef="c-46" decimals="4" name="ino:ClassOfWarrantOrRightCommonStockOwnershipPercent" scale="-2" id="f-440">9.99</ix:nonFraction>% of the Company&#8217;s outstanding Common Stock immediately after exercise, which percentage may be changed at the holder&#8217;s election to a lower or higher percentage not in excess of <ix:nonFraction unitRef="number" contextRef="c-109" decimals="4" name="ino:ClassOfWarrantOrRightCommonStockOwnershipPercent" scale="-2" id="f-441">19.99</ix:nonFraction>% upon 61 days&#8217; notice to the Company subject to the terms of the Pre-Funded Warrants. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the Pre-Funded Warrants issued in the April 2024 Offering are indexed to the Company's own shares of common stock (and otherwise meet the requirements to be classified in equity), the Company recorded the consideration received from the issuance of the Pre-Funded Warrants as additional paid-in capital on the Company's condensed consolidated balance sheet as of March 31, 2025 and December 31, 2024.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2025 and December 31, 2024, no Pre-Funded Warrants had been exercised.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">At-The-Market Sales Agreements</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 13, 2024, the Company entered into an Equity Distribution Agreement (the "2024 Sales Agreement") with an outside sales agent (the "Sales Agent") for the offer and sale of its common stock for an aggregate offering price of up to $<ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-5" name="ino:StockSalesAgreementMaximumAuthorizedAmount" format="ixt:num-dot-decimal" scale="6" id="f-442">60.0</ix:nonFraction>&#160;million. The 2024 Sales Agreement provides that the Sales Agent is entitled to compensation in an amount equal to up to <ix:nonFraction unitRef="number" contextRef="c-110" decimals="3" name="ino:SaleOfStockSalesProceedsOfAnyCommonStockPercentage" scale="-2" id="f-443">3.0</ix:nonFraction>% of the gross sales proceeds of any common stock sold through the Sales Agent under the 2024 Sales Agreement, and the Company has provided the Sales Agent with certain indemnification rights. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icec13c599da34407bd5c5256baff0b0b_7">Table of </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#icec13c599da34407bd5c5256baff0b0b_7">Contents</a></span></div></div><ix:continuation id="f-421-2" continuedAt="f-421-3"><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2025, the Company sold <ix:nonFraction unitRef="shares" contextRef="c-51" decimals="INF" name="ino:StockSaleAgreementAggregateNumberofSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-444">518,670</ix:nonFraction> shares of its common stock under the 2024 Sales Agreement. The sales were made at a weighted average price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-51" decimals="2" name="ino:StockSaleAgreementWeightedAveragePricePerShare" scale="0" id="f-445">2.16</ix:nonFraction> per share, resulting in aggregate net proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-3" name="ino:StockSaleAgreementAggregateProceedsFromIssuanceOfStock" scale="6" id="f-446">1.1</ix:nonFraction> million. As of March&#160;31, 2025, there was $<ix:nonFraction unitRef="usd" contextRef="c-111" decimals="-5" name="ino:StockSaleAgreementRemainingCapacityAmount" format="ixt:num-dot-decimal" scale="6" id="f-447">57.9</ix:nonFraction>&#160;million of remaining capacity under the 2024 Sales Agreement.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 9, 2021, the Company entered into an ATM Equity Offering</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">SM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Sales Agreement (the &#8220;2021 Sales Agreement&#8221;) with outside sales agents (collectively, the &#8220;Sales Agents&#8221;) for the offer and sale of its common stock for an aggregate offering price of up to $<ix:nonFraction unitRef="usd" contextRef="c-112" decimals="-5" name="ino:StockSalesAgreementMaximumAuthorizedAmount" format="ixt:num-dot-decimal" scale="6" id="f-448">300.0</ix:nonFraction>&#160;million. The 2021 Sales Agreement provides that the Sales Agents were entitled to compensation in an amount equal to up to <ix:nonFraction unitRef="number" contextRef="c-112" decimals="3" name="ino:SaleOfStockSalesProceedsOfAnyCommonStockPercentage" scale="-2" id="f-449">3.0</ix:nonFraction>% of the gross sales proceeds of any common stock sold through the Sales Agents under the 2021 Sales Agreement. During the three months ended March 31, 2024, the Company sold <ix:nonFraction unitRef="shares" contextRef="c-113" decimals="INF" name="ino:StockSaleAgreementAggregateNumberofSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-450">543,620</ix:nonFraction> shares of its common stock under the 2021 Sales Agreement at a weighted average price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-113" decimals="2" name="ino:StockSaleAgreementWeightedAveragePricePerShare" scale="0" id="f-451">9.76</ix:nonFraction> per share, resulting in aggregate net proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-113" decimals="-5" name="ino:StockSaleAgreementAggregateProceedsFromIssuanceOfStock" format="ixt:num-dot-decimal" scale="6" id="f-452">5.2</ix:nonFraction>&#160;million. The 2021 Sales Agreement was terminated in August 2024 in connection with the entry into the 2024 Sales Agreement described above.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Options and Restricted Stock Units</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Board of Directors adopted the 2023 Omnibus Incentive Plan (the &#8220;2023 Plan&#8221;) on March 24, 2023, pursuant to which the Company may grant stock options, restricted stock awards, restricted stock units ("RSUs") and other stock-based awards or short-term cash incentive awards to employees, directors and consultants. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2023 Plan was approved by stockholders on May 16, 2023. The aggregate number of shares of the Company&#8217;s common stock that may be issued under the 2023 Plan will not exceed the sum of <ix:nonFraction unitRef="shares" contextRef="c-114" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-453">1,166,666</ix:nonFraction> shares plus any shares that may return from time to time from the 2016 Omnibus Incentive Plan (as amended, the &#8220;2016 Plan&#8221;) as a result of expirations, terminations or forfeitures of awards outstanding under the 2016 Plan as of May 16, 2023. At March&#160;31, 2025, the Company had <ix:nonFraction unitRef="shares" contextRef="c-115" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="f-454">24,460</ix:nonFraction> shares of common stock available for future grant under the 2023 Plan, <ix:nonFraction unitRef="shares" contextRef="c-115" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-455">464,887</ix:nonFraction> shares underlying outstanding RSUs and <ix:nonFraction unitRef="shares" contextRef="c-115" decimals="INF" name="us-gaap:CommonStockOtherSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-456">732,165</ix:nonFraction> shares underlying options outstanding to purchase common stock under the 2023 Plan. The awards granted and available for future grant under the 2023 Plan generally vest over <ix:nonNumeric contextRef="c-116" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-457">three years</ix:nonNumeric> and have a maximum contractual term of <ix:nonNumeric contextRef="c-116" name="ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm" format="ixt-sec:durwordsen" id="f-458">ten years</ix:nonNumeric>. The 2023 Plan terminates by its terms on March&#160;24, 2033. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following adoption of the 2023 Plan, no further awards may be made under the 2016 Plan, but outstanding awards continue to be governed by their existing terms. At March&#160;31, 2025, the Company had <ix:nonFraction unitRef="shares" contextRef="c-117" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-459">90,642</ix:nonFraction> shares underlying outstanding but unvested RSUs and options outstanding to purchase <ix:nonFraction unitRef="shares" contextRef="c-117" decimals="INF" name="us-gaap:CommonStockOtherSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-460">902,123</ix:nonFraction> shares of common stock under the 2016 Plan. The outstanding awards granted under the 2016 Plan generally vest over <ix:nonNumeric contextRef="c-118" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-461">three years</ix:nonNumeric> and have a maximum contractual term of <ix:nonNumeric contextRef="c-118" name="ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm" format="ixt-sec:durwordsen" id="f-462">ten years</ix:nonNumeric>. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 24, 2022, the Company's board of directors adopted a stock-based incentive plan (the "2022 Inducement Plan"), which provides for the discretionary grant of nonstatutory stock options, stock appreciation rights, restricted stock awards, RSU awards, performance awards, and other awards to individuals as a material inducement to entering into employment with the Company. The aggregate number of shares of the Company&#8217;s common stock that may be issued under the 2022 Inducement Plan will not exceed <ix:nonFraction unitRef="shares" contextRef="c-119" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-463">166,666</ix:nonFraction> shares. At March&#160;31, 2025, the Company had <ix:nonFraction unitRef="shares" contextRef="c-120" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="f-464">85,378</ix:nonFraction> shares of common stock available for future grant under the 2022 Inducement Plan, <ix:nonFraction unitRef="shares" contextRef="c-120" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-465">18,191</ix:nonFraction> shares underlying outstanding but unvested RSUs and options outstanding to purchase <ix:nonFraction unitRef="shares" contextRef="c-120" decimals="INF" name="us-gaap:CommonStockOtherSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-466">52,634</ix:nonFraction> shares of common stock under the 2022 Inducement Plan. The 2022 Inducement Plan can be terminated by the Company's board of directors at any time.</span></div></ix:continuation><div style="margin-top:5pt;text-indent:27pt"><ix:continuation id="f-421-3" continuedAt="f-421-4"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Amended and Restated 2007 Omnibus Incentive Plan (the "2007 Incentive Plan") was adopted on M</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-421-4">arch&#160;31, 2007 and terminated by its terms on March&#160;31, 2017. At March&#160;31, 2025, the Company had options outstanding to purchase <ix:nonFraction unitRef="shares" contextRef="c-121" decimals="INF" name="us-gaap:CommonStockOtherSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-467">61,262</ix:nonFraction> shares of common stock under the 2007 Incentive Plan. The outstanding awards granted under the 2007 Incentive Plan are fully vested and generally have a maximum contractual term of <ix:nonNumeric contextRef="c-122" name="ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm" format="ixt-sec:durwordsen" id="f-468">ten years</ix:nonNumeric>.</ix:continuation> </span></div><div><span><br/></span></div><div id="icec13c599da34407bd5c5256baff0b0b_76"></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.  <ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerShareTextBlock" id="f-469" continuedAt="f-469-1" escape="true">Net Loss Per Share </ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerSharePolicyTextBlock" id="f-470" escape="true"><ix:continuation id="f-469-1" continuedAt="f-469-2"><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is computed by dividing the net loss for the period by the weighted average number of shares of common stock outstanding during the period. The outstanding Pre-Funded Warrants (see Note 7) are included in the weighted-average common shares outstanding in the basic net loss per share calculation for the three months ended March 31, 2025 given their nominal exercise price.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Diluted net loss per share is calculated in accordance with the treasury stock method for the outstanding Warrants, stock options and RSUs and refle</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cts the potential dilution that would occur if securities or other con</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">tracts to issue common stock were exercised or converted to common stock. The calculation of diluted net loss per share requires that, to the extent the average market price of the underlying shares for the reporting period exceeds the exercise price of the options or other securities and the presumed exercise of such securities are dilutive to net loss per share for the period, an adjustment to the net loss used in the calculation is required to remove the change in fair value of such securities from the numerator for the period. Likewise, an adjustment to the denominator is required to reflect the related dilutive shares, if any. For the three months ended March 31, 2025 and 2024, basic and diluted net loss per share were the same, as the assumed exercise or settlement of common stock warrants, stock options, service-based RSUs and performance-and market-based RSUs would have been anti-dilutive.</span></div></ix:continuation></ix:nonNumeric><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icec13c599da34407bd5c5256baff0b0b_7">Table of </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#icec13c599da34407bd5c5256baff0b0b_7">Contents</a></span></div></div><ix:continuation id="f-469-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock" id="f-471" escape="true"><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted net loss per share for the three months ended March 31, 2025 and 2024 are calculated as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.882%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.128%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.960%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-472">19,694,697</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-473">30,469,871</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Shares used to compute net loss per share, basic and diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Weighted-average common shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="ino:WeightedAverageNumberOfSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-474">36,478,176</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-9" decimals="0" name="ino:WeightedAverageNumberOfSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-475">23,291,512</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Weighted-average shares underlying pre-funded warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="ino:IncrementalCommonSharesAttributableToBasicAndDilutiveEffectOfPreFundedWarrants" format="ixt:num-dot-decimal" scale="0" id="f-476">2,135,477</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-9" decimals="0" name="ino:IncrementalCommonSharesAttributableToBasicAndDilutiveEffectOfPreFundedWarrants" format="ixt:fixed-zero" scale="0" id="f-477">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Weighted-average common shares outstanding used to compute basic and diluted net loss per share</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-478"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-479">38,613,653</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-9" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-480"><ix:nonFraction unitRef="shares" contextRef="c-9" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-481">23,291,512</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Basic and diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-482"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-483">0.51</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-9" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-484"><ix:nonFraction unitRef="usdPerShare" contextRef="c-9" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-485">1.31</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span><br/></span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.882%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.128%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.960%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">          <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="f-486" continuedAt="f-486-1" escape="true">The following table summarizes potential shares of common stock that were excluded from the diluted net loss per share calculation because of their anti-dilutive effect: </ix:nonNumeric></span></div><ix:continuation id="f-486-1"><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.882%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.128%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.960%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-123" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-487">10,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-124" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="0" id="f-488">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-125" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-489">1,748,184</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-126" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-490">1,355,178</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service-based restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-127" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-491">573,720</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-128" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-492">392,120</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance-and market-based restricted stock units</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-129" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-493">128,800</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-130" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="0" id="f-494">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible preferred stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-131" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="f-495">275</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-132" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="f-496">275</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-497">12,450,979</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-9" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-498">1,747,573</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:continuation></ix:continuation><div style="text-indent:27pt"><span><br/></span></div><div id="icec13c599da34407bd5c5256baff0b0b_79"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.  <ix:nonNumeric contextRef="c-1" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="f-499" continuedAt="f-499-1" escape="true">Stock-Based Compensation</ix:nonNumeric></span></div><ix:continuation id="f-499-1" continuedAt="f-499-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:CompensationRelatedCostsPolicyTextBlock" id="f-500" escape="true"><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurs stock-based compensation expense related to service-based RSUs, performance-based RSUs and stock options. The fair value of restricted stock is determined by the closing price of the Company's common stock reported on the Nasdaq Capital Market on the date of grant. The Company estimates the fair value of stock options granted using the Black-Scholes option pricing model. The Black-Scholes option pricing model was developed for use in estimating the fair value of traded options, which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of subjective assumptions, including the expected stock price volatility and expected option life. The Company amortizes the fair value of the awards on a straight-line basis over the requisite vesting period of the awards. Expected volatility is based on historical volatility. The expected life of options granted is based on historical expected life. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant. The dividend yield is based on the fact that no dividends have been paid historically and none are currently expected to be paid in the foreseeable future. The Company recognizes forfeitures as they occur.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="f-501" escape="true"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average assumptions used in the Black-Scholes model for option grants to employees and directors are presented below:</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-133" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-502">4.07</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-134" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-503">4.21</ix:nonFraction>%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-133" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-504">107</ix:nonFraction>%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-134" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-505">105</ix:nonFraction>%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life in years</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-133" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-506">5.6</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-134" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-507">5.5</ix:nonNumeric></span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-133" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="0" id="f-508">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-134" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="0" id="f-509">&#8212;</ix:nonFraction></span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icec13c599da34407bd5c5256baff0b0b_7">Table of </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#icec13c599da34407bd5c5256baff0b0b_7">Contents</a></span></div></div><ix:continuation id="f-499-2" continuedAt="f-499-3"><div style="margin-bottom:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total employee and director stock-based compensation expense recognized in the condensed consolidated statements of operations for the three months ended March 31, 2025 and 2024 was $<ix:nonFraction unitRef="usd" contextRef="c-135" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="f-510">1.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-136" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="f-511">2.4</ix:nonFraction> million, respectively, of which $<ix:nonFraction unitRef="usd" contextRef="c-137" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="f-512">547,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-138" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-513">1.0</ix:nonFraction> million, respectively, was included in research and development expenses, and $<ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="f-514">821,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-140" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-515">1.4</ix:nonFraction> million, respectively, was included in general and administrative expenses. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2025, there was $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="f-516">1.9</ix:nonFraction> million of total unrecognized compensation expense related to unvested stock options, which is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="c-1" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-517">1.5</ix:nonNumeric> years.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average grant date fair value per share, calculated using the Black-Scholes option pricing model, was $<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-518">1.60</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="c-9" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-519">6.77</ix:nonFraction> for employee and director stock options granted during the three months ended March 31, 2025 and 2024, respectively.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2025, there was $<ix:nonFraction unitRef="usd" contextRef="c-141" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="f-520">2.2</ix:nonFraction> million of total unrecognized compensation expense related to unvested service-based RSUs, which is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="c-142" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-521">2.0</ix:nonNumeric> years.  </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average grant date fair value per share was $<ix:nonFraction unitRef="usdPerShare" contextRef="c-142" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-522">1.95</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="c-143" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-523">8.39</ix:nonFraction> for service-based RSUs granted during the three months ended March 31, 2025 and 2024, respectively.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of stock options granted to non-employees was estimated using the Black-Scholes pricing model. Total stock-based compensation expense for stock options and RSUs granted to non-employees for the three months ended March 31, 2025 and 2024 was $<ix:nonFraction unitRef="usd" contextRef="c-144" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-524">32,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-145" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-525">103,000</ix:nonFraction>, respectively. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Performance-and Market-Based RSUs </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2024, the Company granted performance-and market-based RSUs (such performance-based grants, the "PSU Awards") to key employees under the 2023 Plan. Each PSU was expressed as a target number of RSUs. With respect to the PSU Awards, the Company's Board of Directors established specified performance goals and corresponding performance periods over which the goals must be attained, the satisfaction of which are conditions to earning the PSU Awards and vesting of the underlying RSUs. As of March&#160;31, 2025, <ix:nonFraction unitRef="shares" contextRef="c-146" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-526">83,800</ix:nonFraction> performance-and market-based RSU's were outstanding.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Of the target number of RSUs underlying each PSU Award, up to <ix:nonFraction unitRef="number" contextRef="c-147" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="f-527">70</ix:nonFraction>% (the "Milestone-based RSUs") will vest based on the achievement of specified milestones relating to the development, regulatory status and commercialization of the Company&#8217;s lead product candidate INO-3107 (each, a "Milestone," and collectively, the "Milestones"). Each Milestone has a specified deadline for achievement ranging between the end of 2025 and the end of 2027.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The remaining <ix:nonFraction unitRef="number" contextRef="c-148" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="f-528">30</ix:nonFraction>% of the target number of RSUs underlying each PSU Award (the "Market-based RSUs") will be eligible to vest based on the Company&#8217;s achievement of total stockholder return relative to a peer group consisting of companies in the Russell 2000 Biotechnology Subsector index (the &#8220;Relative TSR&#8221;) over the period beginning on June 1, 2024 and ending on December 31, 2027 (the &#8220;Performance Period&#8221;), expressed as a percentile ranking.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of Market-based RSUs, if any, actually earned based on the achievement of the Relative TSR goal may range from <ix:nonFraction unitRef="number" contextRef="c-149" decimals="2" name="ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPercentage" scale="-2" id="f-529">50</ix:nonFraction>% of the target number of RSUs for performance at a specified threshold percentile, to <ix:nonFraction unitRef="number" contextRef="c-150" decimals="2" name="ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPercentage" scale="-2" id="f-530">100</ix:nonFraction>% of the target number of RSUs for performance at the target percentile, and up to <ix:nonFraction unitRef="number" contextRef="c-1" decimals="2" name="ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPercentage" scale="-2" id="f-531">150</ix:nonFraction>% of the target number of RSUs for performance at or above a specified maximum percentile. In the event that actual Relative TSR performance is between the threshold and target levels or between the target and maximum levels, the number of RSUs earned based on Relative TSR will be determined based on linear interpolation between the specified percentiles. If the Company&#8217;s actual Relative TSR performance is below the threshold percentile, then no RSUs would be earned based on Relative TSR. The number of RSUs earned based on Relative TSR may not exceed the target number of RSUs eligible to vest based on Relative TSR if the Company&#8217;s total stockholder return is negative for the Performance Period.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company values the Milestone-based RSUs based on the grant date closing price per share. The Company recognizes stock-based compensation expense over the performance period, if it is probable that the performance condition will be achieved. Adjustments to stock-based compensation expense are made, as needed, each reporting period based on changes in the Company's estimate of the number of units that are probable of vesting. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company values the Market-based RSUs on the grant date using the Monte Carlo simulation method, a generally accepted statistical technique used to simulate a range of possible future stock prices for the Company and the peer group. The determination of fair value is affected by the Company's stock price and a number of assumptions including the expected volatility and the risk-free interest rate. The Company will recognize stock-based compensation expense ratably over the performance period of the award. The market-based RSUs will cliff-vest at the end of the <ix:nonNumeric contextRef="c-148" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-532">three-year</ix:nonNumeric> period ranging from <ix:nonFraction unitRef="number" contextRef="c-151" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" format="ixt-sec:numwordsen" scale="-2" id="f-533">zero</ix:nonFraction> percent to <ix:nonFraction unitRef="number" contextRef="c-152" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="f-534">150</ix:nonFraction> percent of the target number of awards granted. </span></div><ix:nonNumeric contextRef="c-1" name="ino:ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" id="f-535" continuedAt="f-535-1" escape="true"><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The significant assumptions used in the Monte Carlo simulation method were as follows:</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icec13c599da34407bd5c5256baff0b0b_7">Table of </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#icec13c599da34407bd5c5256baff0b0b_7">Contents</a></span></div></div><ix:continuation id="f-499-3"><ix:continuation id="f-535-1"><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:80.040%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.760%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-148" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-536">4.60</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-148" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-537">90</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life in years</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-148" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-538">3.61</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-148" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="0" id="f-539">&#8212;</ix:nonFraction></span></td></tr></table></div></ix:continuation><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The grant date fair value of the Milestone-based RSUs was $<ix:nonFraction unitRef="usd" contextRef="c-147" decimals="-3" name="ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" format="ixt:num-dot-decimal" scale="0" id="f-540">643,000</ix:nonFraction> based on the grant date closing price per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-147" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-541">10.96</ix:nonFraction>. As of March&#160;31, 2025, the underlying performance milestones of the Milestone-based RSUs were determined to be not probable of achievement, and <ix:nonFraction unitRef="usd" contextRef="c-147" decimals="INF" name="us-gaap:ShareBasedCompensation" format="ixt:fixed-zero" scale="0" id="f-542"><ix:nonFraction unitRef="usd" contextRef="c-147" decimals="INF" name="us-gaap:ShareBasedCompensation" format="ixt:fixed-zero" scale="0" id="f-543">no</ix:nonFraction></ix:nonFraction> stock-based compensation expense was recognized for the three months then ended.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The grant date fair value of the Market-based RSUs was $<ix:nonFraction unitRef="usd" contextRef="c-148" decimals="-3" name="ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" format="ixt:num-dot-decimal" scale="0" id="f-544">269,000</ix:nonFraction> based on the fair value of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-148" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-545">10.69</ix:nonFraction> per share as determined using the Monte Carlo simulation method. For the three months ended March 31, 2025, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="c-148" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-546">19,000</ix:nonFraction> in stock-based compensation for the Market-based RSUs.  </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">December 2024 Performance-Based Awards</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2024, the Company granted performance-based stock options and RSUs (such performance-based grants, the "December 2024 Awards") to key employees under the 2023 Plan. Each award was expressed as a target number of stock options and RSUs. With respect to the December 2024 Awards, the Company's Board of Directors established specified performance goals and a corresponding performance period over which the goals must be attained, the satisfaction of which are conditions to earning the December 2024 Awards and vesting of the underlying stock options and RSUs. As of March&#160;31, 2025, December 2024 Awards were outstanding covering <ix:nonFraction unitRef="shares" contextRef="c-153" decimals="0" name="ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardUnderlyingCommonStock" format="ixt:num-dot-decimal" scale="0" id="f-547">25,686</ix:nonFraction> shares of common stock underlying stock options and <ix:nonFraction unitRef="shares" contextRef="c-154" decimals="0" name="ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardUnderlyingCommonStock" format="ixt:num-dot-decimal" scale="0" id="f-548">19,314</ix:nonFraction> shares of common stock underlying RSUs.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The grant date fair value of the performance-based RSUs was $<ix:nonFraction unitRef="usd" contextRef="c-155" decimals="-3" name="ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsGrantDateFairValue" format="ixt:num-dot-decimal" scale="0" id="f-549">34,000</ix:nonFraction> based on the grant date closing price per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-155" decimals="2" name="ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantDateClosingSharePrice" scale="0" id="f-550">1.78</ix:nonFraction>. The grant date fair value of the performance-based stock options was $<ix:nonFraction unitRef="usd" contextRef="c-156" decimals="-3" name="ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsGrantDateFairValue" format="ixt:num-dot-decimal" scale="0" id="f-551">38,000</ix:nonFraction> based on the Black-Scholes per share value of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-157" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-552">1.46</ix:nonFraction>. As of March&#160;31, 2025, the underlying performance milestones of the December 2024 Awards were determined to be not probable of achievement, and <ix:nonFraction unitRef="usd" contextRef="c-147" decimals="INF" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt-sec:numwordsen" id="f-553">no</ix:nonFraction> stock-based compensation expense was recognized for the three months then ended.</span></div></ix:continuation><div style="margin-top:5pt;text-indent:27pt"><span><br/></span></div><div id="icec13c599da34407bd5c5256baff0b0b_85"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10.  <ix:nonNumeric contextRef="c-1" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="f-554" continuedAt="f-554-1" escape="true">Related Party Transactions</ix:nonNumeric></span></div><ix:continuation id="f-554-1" continuedAt="f-554-2"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Plumbline Life Sciences, Inc.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company owned <ix:nonFraction unitRef="shares" contextRef="c-158" decimals="INF" name="us-gaap:InvestmentOwnedBalanceShares" format="ixt:num-dot-decimal" scale="0" id="f-555">597,808</ix:nonFraction> shares of common stock in PLS as of March&#160;31, 2025, representing an ownership interest of <ix:nonFraction unitRef="number" contextRef="c-158" decimals="3" name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" scale="-2" id="f-556">16.7</ix:nonFraction>%. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's investment in PLS is recorded as investment in affiliated entity on the condensed consolidated balance sheet as of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2025 and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and was valued at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-159" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="f-557">2.3</ix:nonFraction> million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-160" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="f-558">1.6</ix:nonFraction> million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, respectively, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">based on the closing price of the shares on the Korea New Exchange Market at the applicable balance sheet date</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. O</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ne of the Company's directors, Dr.&#160;David B. Weiner, acts as a consultant to PLS.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Wistar Institute</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dr. Weiner is a director of the Vaccine Center of The Wistar Institute ("Wistar") and an Executive Vice President of Wistar.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, the Company entered into collaborative research agreements with Wistar&#160;for preventive and therapeutic DNA-based immunotherapy applications and products developed by&#160;Dr. Weiner and Wistar for the treatment of cancers and infectious diseases. Under the terms of the agreement, the Company reimbursed Wistar for all direct and indirect costs incurred in the conduct of the collaborative research, not to exceed $<ix:nonFraction unitRef="usd" contextRef="c-161" decimals="-5" name="ino:CollaborativeAgreementExpensesToReimburse" scale="6" id="f-559">3.1</ix:nonFraction> million during the <ix:nonNumeric contextRef="c-161" name="ino:CollaborativeArrangementTerm" format="ixt-sec:durwordsen" id="f-560">five-year</ix:nonNumeric> term of the agreements. In 2021, upon expiration of the 2016 agreements, the Company entered into new collaborative research agreements with Wistar&#160;with the same terms. The Company has the exclusive right to in-license new intellectual property developed under this agreement.  </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, the Company received a $<ix:nonFraction unitRef="usd" contextRef="c-162" decimals="-5" name="ino:CollaborativeAgreementAwardedAmount" format="ixt:num-dot-decimal" scale="6" id="f-561">10.7</ix:nonFraction>&#160;million sub-grant through Wistar, which was amended in 2021 to $<ix:nonFraction unitRef="usd" contextRef="c-163" decimals="-5" name="ino:CollaborativeAgreementAmendedAmount" format="ixt:num-dot-decimal" scale="6" id="f-562">13.6</ix:nonFraction>&#160;million, for the preclinical development and translational studies of DNA-Encoded Monoclonal Antibodies (DMAbs) as countermeasures for COVID-19. In August 2024, the sub-grant was amended to a total of $<ix:nonFraction unitRef="usd" contextRef="c-164" decimals="-5" name="ino:CollaborativeAgreementAmendedAmount" format="ixt:num-dot-decimal" scale="6" id="f-563">12.5</ix:nonFraction>&#160;million in funding through September 2025.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, the Company received a $<ix:nonFraction unitRef="usd" contextRef="c-165" decimals="-5" name="ino:CollaborativeAgreementAwardedAmount" format="ixt:num-dot-decimal" scale="6" id="f-564">1.2</ix:nonFraction>&#160;million sub-grant through Wistar, which was amended in 2024 to $<ix:nonFraction unitRef="usd" contextRef="c-166" decimals="-5" name="ino:CollaborativeAgreementAwardedAmount" format="ixt:num-dot-decimal" scale="6" id="f-565">2.4</ix:nonFraction>&#160;million with funding through November 2024, with an option for an additional $<ix:nonFraction unitRef="usd" contextRef="c-166" decimals="-5" name="ino:CollaborativeAgreementAwardedOptionAmount" format="ixt:num-dot-decimal" scale="6" id="f-566">4.2</ix:nonFraction>&#160;million in funding that extends the sub-grant through November 2027. The Company will support the Wistar lead consortium in the research and development of synthetic DNA-launched nanoparticles (DLNPs) for vaccination against HIV infection.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred grant funding recognized from Wistar and recorded as contra-research and development expense is related to work performed by the Company on the research sub-contract agreements. For the three months ended March 31, 2025 and 2024, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="c-167" decimals="-3" name="ino:GrantProceedsReceived" format="ixt:num-dot-decimal" scale="0" id="f-567">286,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-168" decimals="-3" name="ino:GrantProceedsReceived" format="ixt:num-dot-decimal" scale="0" id="f-568">140,000</ix:nonFraction>, respectively. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icec13c599da34407bd5c5256baff0b0b_7">Table of </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#icec13c599da34407bd5c5256baff0b0b_7">Contents</a></span></div></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-554-2">Research and development expenses recorded from Wistar relate primarily to collaborative research agreements. Research and development expenses recorded from Wistar for the three months ended March 31, 2025 and 2024 were $<ix:nonFraction unitRef="usd" contextRef="c-169" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="f-569">0</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-170" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="0" id="f-570">475,000</ix:nonFraction>, respectively. At March&#160;31, 2025 and December&#160;31, 2024, the Company had an accounts receivable balance of $<ix:nonFraction unitRef="usd" contextRef="c-171" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="f-571">1.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-172" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="f-572">1.2</ix:nonFraction> million, respectively, and an accounts payable and accrued liability balance of $<ix:nonFraction unitRef="usd" contextRef="c-171" decimals="-3" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-573">470,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-172" decimals="-5" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="6" id="f-574">1.4</ix:nonFraction> million, respectively, related to Wistar.</ix:continuation> </span></div><div style="margin-top:5pt;text-indent:27pt"><span><br/></span></div><div id="icec13c599da34407bd5c5256baff0b0b_88"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11.  <ix:nonNumeric contextRef="c-1" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="f-575" continuedAt="f-575-1" escape="true">Commitments and Contingencies                                                  </ix:nonNumeric></span></div><ix:continuation id="f-575-1" continuedAt="f-575-2"><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases approximately <ix:nonFraction unitRef="sqft" contextRef="c-173" decimals="0" name="ino:LesseeOperatingLeaseAreaofLandUnderLease" format="ixt:num-dot-decimal" scale="0" id="f-576">56,600</ix:nonFraction> square feet of office, laboratory, and manufacturing space in San Diego, California and approximately <ix:nonFraction unitRef="sqft" contextRef="c-174" decimals="0" name="ino:LesseeOperatingLeaseAreaofLandUnderLease" format="ixt:num-dot-decimal" scale="0" id="f-577">57,400</ix:nonFraction> square feet of office space in Plymouth Meeting, Pennsylvania under various non-cancellable operating lease agreements with remaining lease terms as of March&#160;31, 2025</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of <ix:nonNumeric contextRef="c-175" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" format="ixt-sec:duryear" id="f-578">2.2</ix:nonNumeric> to <ix:nonNumeric contextRef="c-176" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" format="ixt-sec:duryear" id="f-579">4.8</ix:nonNumeric> ye</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ars, which represent the non-cancellable periods of the leases. The Company has excluded the extension options from its lease terms in the calculation of future lease payments as they are not reasonably certain to be exercised. The Company's lease payments consist primarily of fixed rental payments for the right to use the underlying leased assets over the lease terms as well as payments for common area maintenance and administrative services. The Company has received customary incentives from its landlords, such as reimbursements for tenant improvements and rent abatement periods, which effectively reduce the total lease payments owed for these leases.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The base rent adjusts periodically throughout the term of the lease. Rent payments under the lease will include base rent with an annual increase of approximately <ix:nonFraction unitRef="number" contextRef="c-177" decimals="2" name="ino:LesseeOperatingLeaseBaseRatePercentageIncreaseDecrease" format="ixt-sec:numwordsen" scale="-2" id="f-580">two</ix:nonFraction> to <ix:nonFraction unitRef="number" contextRef="c-178" decimals="2" name="ino:LesseeOperatingLeaseBaseRatePercentageIncreaseDecrease" format="ixt-sec:numwordsen" scale="-2" id="f-581">three</ix:nonFraction> percent, and additional monthly fees to cover the Company's share of certain facility expenses, including utilities, property taxes, insurance and maintenance. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company performed an evaluation of its contracts with customers and suppliers in accordance with ASC Topic 842 and determined that, except for the real estate leases described above and various copier leases, none of its other contracts contain a right-of-use asset. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease right-of-use assets and liabilities on the condensed consolidated balance sheet represents the present value of the remaining lease payments over the remaining lease terms. Payments for additional monthly fees to cover the Company's share of certain facility expenses are not included in operating lease right-of-use assets and liabilities. The Company uses its incremental borrowing rate to calculate the present value of its lease payments, as the implicit rates in the leases are not readily determinable.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="f-582" escape="true"><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">As of March&#160;31, 2025, the maturities of the Company's operating lease liabilities were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.449%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.351%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2025</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" format="ixt:num-dot-decimal" scale="0" id="f-583">2,637,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="0" id="f-584">3,592,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="0" id="f-585">2,992,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="0" id="f-586">2,319,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:num-dot-decimal" scale="0" id="f-587">2,132,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total remaining lease payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="0" id="f-588">13,672,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: present value adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="0" id="f-589">2,401,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="0" id="f-590">11,271,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="0" id="f-591">2,576,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-592">8,695,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-3" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-593">4.1</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-3" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-594">9.0</ix:nonFraction>%</span></td></tr></table></div></ix:nonNumeric><div style="margin-top:3pt;text-indent:27pt"><span><br/></span></div><div style="margin-top:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease costs included in operating expenses in the condensed consolidated statements of operations for the three months ended March 31, 2025 and 2024 were $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="0" id="f-595">515,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="0" id="f-596">837,000</ix:nonFraction>, respectively. Operating lease costs consisting of the fixed lease payments included in operating lease liabilities are recorded on a straight-line basis over the lease terms. Variable lease costs are recorded as incurred.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2023, the Company entered into agreements to sublease a total of approximately <ix:nonFraction unitRef="sqft" contextRef="c-179" decimals="0" name="ino:LesseeOperatingLeaseAreaofLandUnderLease" format="ixt:num-dot-decimal" scale="0" id="f-597">11,400</ix:nonFraction> square feet in its Plymouth Meeting headquarters with sublease terms through December 31, 2026.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icec13c599da34407bd5c5256baff0b0b_7">Table of </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#icec13c599da34407bd5c5256baff0b0b_7">Contents</a></span></div></div><ix:continuation id="f-575-2"><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2024, the Company amended the sublease agreements for its Plymouth Meeting headquarters to extend one sublease term through December 31, 2027 and the other through December 31, 2029.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company is a party to a variety of agreements pursuant to which it may be obligated to indemnify the other party. It is not possible to predict the maximum potential amount of future payments under these types of agreements due to the conditional nature of the Company's obligations and the unique facts and circumstances involved in each particular agreement. Historically, payments made by the Company under these types of agreements have not had a material effect on its business, consolidated results of operations or financial condition.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">VGXI Litigation</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, the Company filed a complaint in the Court of Common Pleas of Montgomery County, Pennsylvania against VGXI, Inc. and GeneOne Life Science, Inc., or GeneOne, and together with VGXI, Inc. collectively referred to as VGXI, alleging that VGXI had materially breached the Company&#8217;s supply agreement with them. The complaint seeks declaratory judgments, specific performance of the agreement, injunctive relief, an accounting, damages, attorneys&#8217; fees, interest, costs and other relief from VGXI. In June 2020, the Company filed a petition for preliminary injunction, which was denied.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following an appeal by the Company, in July 2020, VGXI filed counterclaims against the Company, alleging that the Company had breached the supply agreement, as well as misappropriation of trade secrets and unjust enrichment. The counterclaims seek injunctive relief, damages, attorneys&#8217; fees, interest, costs and other relief from the Company. VGXI also filed a third-party complaint against Ology Bioservices, Inc., a contract manufacturing organization that the Company had engaged to provide services similar to those that were being provided by VGXI, but VGXI later discontinued its third-party claims. The Company filed an answer to VGXI&#8217;s counterclaims, disputing the allegations and the claims raised in VGXI&#8217;s filing. In October 2020, the Company filed a notice of discontinuance of appeal with the Pennsylvania Superior Court. A trial date for the litigation has not been set.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company intends to aggressively prosecute the claims set forth in its complaint against VGXI and to vigorously defend itself against VGXI&#8217;s counterclaims.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">GeneOne Litigation</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, GeneOne filed a complaint in the Court of Common Pleas of Montgomery County, Pennsylvania against the Company, alleging that the Company had breached the CELLECTRA Device License Agreement, or the Agreement, between the Company and GeneOne. The Company terminated the Agreement in October 2020. The complaint asserts claims for breach of contract, declaratory judgment, unfair competition, and unjust enrichment. The complaint seeks injunctive relief, an accounting, damages, disgorgement of profits, attorneys&#8217; fees, interest, and other relief from the Company. The Company filed preliminary objections to the complaint, which were overruled by the court. In September 2021, the Company filed an answer to the complaint, new matter, and counterclaims. The Company&#8217;s counterclaims allege that GeneOne breached the Agreement and assert claims for breach of contract and declaratory judgment.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The counterclaims seek damages, interest, expenses, attorney&#8217;s fees, and costs. In October 2021, GeneOne filed its answer to the Company&#8217;s counterclaims and new matter. On February 29, 2024, the Company filed a motion for summary judgment. On April 1, 2024, GeneOne filed an opposition to the Company&#8217;s motion for summary judgment. On June 28, 2024, the court denied the motion for summary judgment. The court has set a trial date of August 19, 2025.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company intends to aggressively prosecute the claims set forth in its counterclaims against GeneOne and to vigorously defend itself against the claims in GeneOne&#8217;s complaint. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Matters</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company may be involved in disputes, including litigation, relating to claims arising out of operations in the normal course of its business. Any of these claims could subject the Company to costly legal expenses and, while the Company generally believes that it has adequate insurance to cover many different types of liabilities, its insurance carriers may deny coverage or its policy limits may be inadequate to fully satisfy any damage awards or settlements. If this were to happen, the payment of any such awards could have a material adverse effect on the Company's consolidated results of operations and financial position. Additionally, any such claims, whether or not successful, could damage the Company's reputation and business. Except as described above, the Company is not a party to any legal proceedings, the adverse outcome of which, in management&#8217;s opinion, individually or in the aggregate, would be reasonably expected to have a material adverse effect on the Company&#8217;s consolidated results of operations or financial position.</span></div></ix:continuation><div style="margin-top:5pt;text-indent:27pt"><span><br/></span></div><div id="icec13c599da34407bd5c5256baff0b0b_91"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12. <ix:nonNumeric contextRef="c-1" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="f-598" continuedAt="f-598-1" escape="true">Collaborative Agreements</ix:nonNumeric></span></div><ix:continuation id="f-598-1" continuedAt="f-598-2"><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Advaccine Biopharmaceuticals Suzhou Co., Ltd. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icec13c599da34407bd5c5256baff0b0b_7">Table of </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#icec13c599da34407bd5c5256baff0b0b_7">Contents</a></span></div></div><ix:continuation id="f-598-2"><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, the Company entered into a Collaboration and License Agreement with Advaccine Biopharmaceuticals Suzhou Co., Ltd. (&#8220;Advaccine&#8221;), which was amended and restated in 2021 (as amended and restated, the &#8220;Advaccine Agreement&#8221;). Under the terms of the Advaccine Agreement, the Company granted to Advaccine the exclusive right to develop, manufacture and commercialize the Company&#8217;s vaccine candidate INO-4800 within the territories of China, Taiwan, Hong Kong and Macau (referred to collectively as &#8220;Greater China&#8221;) and 33 additional countries in Asia. The 2021 amendment related to a collaboration between the Company and Advaccine to jointly conduct a global Phase 3 segment of the Company&#8217;s clinical trial of INO-4800 that was planned. The parties were jointly participating in the trial and were to equally share the global development costs for the trial, including the Company&#8217;s manufacturing costs to supply INO-4800. Advaccine agreed to be fully responsible for conducting the trial in Greater China, including its costs and expenses incurred. The Company has discontinued its internally funded efforts to develop INO-4800 as a COVID-19 heterologous booster vaccine. Advaccine continues to develop INO-4800 with its own resources under the terms of the Advaccine Agreement.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the 2021 amendment, the Company determined that the global Phase 3 trial component of the agreement was a collaboration and not a contract with a customer and therefore accounted for the 2021 amendment under ASC Topic 808. Reimbursements from Advaccine were recognized as contra-research development expense on the condensed consolidated statement of operations once earned and collectibility was assured. No funding was received from Advaccine during the three months ended March 31, 2024 or 2025.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ApolloBio Corporation </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, the Company entered into an Amended and Restated License and Collaboration Agreement (the "ApolloBio Agreement"),</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with ApolloBio Corporation ("ApolloBio"), which was amended in June 2023. Under the terms of the ApolloBio Agreement, the Company granted to ApolloBio the exclusive right to develop and commercialize&#160;VGX-3100, its DNA immunotherapy product candidate designed to treat&#160;pre-cancers&#160;caused by HPV, within the agreed upon territories.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is entitled to receive up to an aggregate of $<ix:nonFraction unitRef="usd" contextRef="c-180" decimals="-5" name="ino:CollaborationAgreementAdditionalRevenueToBeAchieved" scale="6" id="f-599">20.0</ix:nonFraction> million, less required income, withholding or other taxes, upon the achievement of specified milestones related to the regulatory approval of&#160;VGX-3100&#160;in accordance with the ApolloBio Agreement. In the event that&#160;VGX-3100 is approved for marketing, the Company will be entitled to receive royalty payments based on a tiered percentage of annual net sales, with such percentage being in the&#160;low-&#160;to&#160;mid-teens,&#160;subject to reduction in the event of generic competition in a particular territory. ApolloBio&#8217;s obligation to pay royalties will continue for <ix:nonNumeric contextRef="c-180" name="ino:CollaborationAgreementRoyaltyPeriod" format="ixt-sec:duryear" id="f-600">10</ix:nonNumeric> years after the first commercial sale in a particular territory or, if later, until the expiration of the&#160;last-to-expire&#160;patent covering the licensed products in the specified territory.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> During the three months ended March 31, 2025 and 2024, the Company received $<ix:nonFraction unitRef="usd" contextRef="c-180" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="f-601">65,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-181" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="f-602">0</ix:nonFraction>, respectively, from the ApolloBio Agreement that was recorded as revenue.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Coalition for Epidemic Preparedness Innovations </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company previously entered into agreements with the Coalition for Epidemic Preparedness Innovations (CEPI), pursuant to which the Company intended to develop vaccine candidates against Lassa fever and MERS. As part of the arrangement between the parties, CEPI agreed to fund up to an aggregate of $<ix:nonFraction unitRef="usd" contextRef="c-182" decimals="-6" name="ino:CollaborativeAgreementFundingToBeReceived" format="ixt:num-dot-decimal" scale="6" id="f-603">56</ix:nonFraction>&#160;million of costs over a <ix:nonNumeric contextRef="c-182" name="ino:CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment" format="ixt-sec:durwordsen" id="f-604">five-year</ix:nonNumeric> period for preclinical studies, as well as planned Phase 1 and Phase 2 clinical trials, to be conducted by the Company and collaborators, with funding from CEPI based on the achievement of identified milestones. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, the Company announced that it and CEPI would discontinue the development of these product candidates targeting Lassa fever and MERS, following the initial analysis of data from the studies conducted by the Company and funded by CEPI. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2025 and 2024, <ix:nonFraction unitRef="usd" contextRef="c-182" decimals="-5" name="ino:CollaborativeAgreementFundingReceived" format="ixt-sec:numwordsen" id="f-605"><ix:nonFraction unitRef="usd" contextRef="c-183" decimals="-5" name="ino:CollaborativeAgreementFundingReceived" format="ixt-sec:numwordsen" id="f-606">no</ix:nonFraction></ix:nonFraction> amounts were recorded as contra-research and development expense related to the CEPI grants. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the third quarter of 2024</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company received funding of $<ix:nonFraction unitRef="usd" contextRef="c-184" decimals="-5" name="ino:CollaborativeAgreementFundingReceived" format="ixt:num-dot-decimal" scale="6" id="f-607">1.6</ix:nonFraction>&#160;million in connection with the final close-out of these grants.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bill &amp; Melinda Gates Foundation</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, Gates awarded and funded the Company a grant of $<ix:nonFraction unitRef="usd" contextRef="c-185" decimals="-5" name="ino:CollaborativeAgreementFundingReceived" scale="6" id="f-608">2.2</ix:nonFraction> million to advance the development of DMAbs to address issues in infectious disease prevention and therapy. This technology has high relevance for the control of influenza and HIV. This next-generation approach to the delivery of monoclonal antibodies would make the technology accessible to low and middle-income countries. In 2019, Gates funded an additional $<ix:nonFraction unitRef="usd" contextRef="c-186" decimals="-5" name="ino:CollaborativeAgreementFundingReceived" scale="6" id="f-609">1.1</ix:nonFraction> million for the project. During the three months ended March 31, 2025 and 2024, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="c-187" decimals="-3" name="ino:CollaborativeAgreementFundingReceived" scale="0" id="f-610">0</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-188" decimals="-3" name="ino:CollaborativeAgreementFundingReceived" format="ixt:num-dot-decimal" scale="0" id="f-611">39,000</ix:nonFraction>, respectively, as contra-research and development expense related to the grant.</span></div></ix:continuation><div style="margin-top:5pt;text-indent:27pt"><span><br/></span></div><div id="icec13c599da34407bd5c5256baff0b0b_94"></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13. <ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxDisclosureTextBlock" id="f-612" continuedAt="f-612-1" escape="true">Income Taxes </ix:nonNumeric></span></div><ix:continuation id="f-612-1" continuedAt="f-612-2"><div style="margin-bottom:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses an estimated annual effective tax rate, which is based on expected annual income, statutory tax rates and tax planning opportunities available in the various jurisdictions in which the Company operates, to determine its quarterly provision for income taxes. Certain significant or unusual items are separately recognized in the quarter in which they occur and </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icec13c599da34407bd5c5256baff0b0b_7">Table of </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#icec13c599da34407bd5c5256baff0b0b_7">Contents</a></span></div></div><ix:continuation id="f-612-2" continuedAt="f-612-3"><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">can be a source of variability in the effective tax rates from quarter to quarter.&#160;Due to the adoption of ASU 2019-12 which removes the exception under ASC 740-20-45-7 to consider all sources of income in order to determine the tax benefit resulting from a loss from continuing operations, ASC 740-20-45-7 no longer applies.</span></div></ix:continuation><div style="margin-bottom:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-612-3">&#160;For the three months ended March 31, 2025 and 2024, the Company did not record any income tax provision/(benefit) due to the Company&#8217;s history of net operating losses generated and the maintenance of a full valuation allowance against its net deferred tax assets.</ix:continuation> </span></div><div style="margin-bottom:5pt;text-indent:27pt"><span><br/></span></div><div id="icec13c599da34407bd5c5256baff0b0b_97"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14. <ix:nonNumeric contextRef="c-1" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="f-613" continuedAt="f-613-1" escape="true">Geneos Therapeutics, Inc. </ix:nonNumeric></span></div><ix:continuation id="f-613-1" continuedAt="f-613-2"><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, the Company formed Geneos Therapeutics ("Geneos") to develop and commercialize neoantigen-based personalized cancer therapies. The Company's Chief Scientific Officer Dr. Laurent Humeau is on the Board of Directors of Geneos. The Company's director Dr.&#160;David B. Weiner is the Chairman of the Scientific Advisory Board of Geneos.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2025, the Company held <ix:nonFraction unitRef="number" contextRef="c-189" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="f-614">23</ix:nonFraction>% of the outstanding equity of Geneos on an as-converted to common stock basis. The Company accounts for its common stock investment in Geneos as an equity method investment under ASC 323. Due to continuing net losses of Geneos, the Company&#8217;s investment had been reduced to $<ix:nonFraction unitRef="usd" contextRef="c-190" decimals="-3" name="us-gaap:EquityMethodInvestments" scale="0" id="f-615"><ix:nonFraction unitRef="usd" contextRef="c-189" decimals="-3" name="us-gaap:EquityMethodInvestments" scale="0" id="f-616">0</ix:nonFraction></ix:nonFraction> as of each of March 31, 2025 and December 31, 2024. The Company has not made any further investment in Geneos. The Company will not reduce its investment below $<ix:nonFraction unitRef="usd" contextRef="c-189" decimals="-3" name="ino:EquityMethodInvestmentsMinimum" scale="0" id="f-617">0</ix:nonFraction> and will not record its share of further net losses of Geneos, as the Company has no obligation to fund Geneos.</span></div></ix:continuation><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-613-2">The Company continues to exclusively license its immunotherapy platform and CELLECTRA&#160;technology to Geneos to be used in the field of personalized, neoantigen-based therapy for cancer. The license agreement provides for potential royalty payments to the Company in the event that Geneos commercializes any products using the licensed technology. The Company is not obligated to use any of its assets to fund the future operations of Geneos.</ix:continuation>  </span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div id="icec13c599da34407bd5c5256baff0b0b_1226"></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15. <ix:nonNumeric contextRef="c-1" name="us-gaap:SegmentReportingDisclosureTextBlock" id="f-618" continuedAt="f-618-1" escape="true">Segment Information</ix:nonNumeric></span></div><ix:continuation id="f-618-1" continuedAt="f-618-2"><div style="margin-bottom:5pt;margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates as <ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" id="f-619">one</ix:nonFraction> reportable segment in the United States, which includes all activities related to the development and commercialization of its DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's Chief Executive Officer (CEO) is its Chief Operating Decision Maker (CODM), responsible for allocating resources and assessing Company performance using aggregated financial information. Utilizing aggregated financial information enables the CODM to determine the most appropriate resource allocation across the organization, research and development projects or other initiatives consistent with the Company's corporate objectives. The CODM primarily uses total net loss as reported on the statements of operations and comprehensive loss to measure segment loss, supplemented by certain additional significant expense details reflected in the table below. The measure of segment assets is reported on the consolidated balance sheet as total assets.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="f-620" continuedAt="f-620-1" escape="true"><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Detailed information regarding the Company's single operating segment's revenues, expenses and operating loss are as follows:  </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icec13c599da34407bd5c5256baff0b0b_7">Table of </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#icec13c599da34407bd5c5256baff0b0b_7">Contents</a></span></div></div><ix:continuation id="f-620-1"><ix:continuation id="f-618-2"><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.075%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue from collaborative arrangements </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-191" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="f-621">65,343</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-192" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="0" id="f-622">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Less: </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;INO-3107</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-193" decimals="0" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="0" id="f-623">3,507,342</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-194" decimals="0" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="0" id="f-624">7,645,664</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;INO-3112 and other Immuno-oncology</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-195" decimals="0" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="0" id="f-625">1,315,084</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-196" decimals="0" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="0" id="f-626">2,020,750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other programs (a)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-197" decimals="0" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="0" id="f-627">107,425</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-198" decimals="0" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="0" id="f-628">623,666</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Engineering and device-related</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-199" decimals="0" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="0" id="f-629">5,061,810</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-200" decimals="0" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="0" id="f-630">3,751,261</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-201" decimals="0" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="0" id="f-631">553,394</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-202" decimals="0" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="0" id="f-632">1,060,487</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other unallocated expenses </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-203" decimals="0" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="0" id="f-633">5,545,847</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-204" decimals="0" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="0" id="f-634">5,811,962</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-191" decimals="0" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="0" id="f-635">9,024,970</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-192" decimals="0" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="0" id="f-636">10,571,179</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-191" decimals="0" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="0" id="f-637">25,115,872</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-192" decimals="0" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="0" id="f-638">31,484,969</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-191" decimals="0" name="us-gaap:InvestmentIncomeInterest" format="ixt:num-dot-decimal" scale="0" id="f-639">808,077</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-192" decimals="0" name="us-gaap:InvestmentIncomeInterest" format="ixt:num-dot-decimal" scale="0" id="f-640">1,500,290</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-191" decimals="0" name="us-gaap:InterestExpenseNonoperating" format="ixt:fixed-zero" scale="0" id="f-641">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-192" decimals="0" name="us-gaap:InterestExpenseNonoperating" format="ixt:num-dot-decimal" scale="0" id="f-642">177,833</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of common stock warrant liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-191" decimals="0" name="us-gaap:FairValueAdjustmentOfWarrants" format="ixt:num-dot-decimal" scale="0" id="f-643">3,712,872</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-192" decimals="0" name="us-gaap:FairValueAdjustmentOfWarrants" format="ixt:fixed-zero" scale="0" id="f-644">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) on investment in affiliated entity</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-191" decimals="0" name="ino:ChangeInValueOfInvestmentsInAffiliatedCompany" format="ixt:num-dot-decimal" scale="0" id="f-645">695,131</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-192" decimals="0" sign="-" name="ino:ChangeInValueOfInvestmentsInAffiliatedCompany" format="ixt:num-dot-decimal" scale="0" id="f-646">126,018</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized gain on available-for-sale equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-191" decimals="0" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="0" id="f-647">140,234</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-192" decimals="0" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="0" id="f-648">500,877</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-191" decimals="0" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="0" id="f-649">482</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-192" decimals="0" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="0" id="f-650">682,218</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-191" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-651">19,694,697</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-192" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-652">30,469,871</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:24.75pt"><span><br/></span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Net of contributions received from grant agreements and recorded as contra-research and development expense.</span></div></ix:continuation></ix:continuation><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">         </span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><div id="icec13c599da34407bd5c5256baff0b0b_112"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icec13c599da34407bd5c5256baff0b0b_7">Table of </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#icec13c599da34407bd5c5256baff0b0b_7">Contents</a></span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2.&#160;&#160;&#160;&#160;MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="margin-top:4.5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This Quarterly Report contains forward-looking statements, as defined in Section&#160;27A of the Securities Act of 1933, as amended, and Section&#160;21E of the Securities Exchange Act of 1934, as amended. These statements relate to future events or our future financial performance. In some cases, you can identify forward-looking statements by terminology such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;potential&#8221; or &#8220;continue,&#8221; the negative of such terms or other comparable terminology. These statements are only predictions. Actual events or results may differ materially.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Although we believe that the expectations reflected in the forward-looking statements are reasonable based on our current expectations and projections, we cannot guarantee future results, levels of activity, performance or achievements. Moreover, neither we, nor any other person, assume responsibility for the accuracy and completeness of the forward-looking statements. We are under no obligation to update any of the forward-looking statements after the filing of this Quarterly Report to conform such statements to actual results or to changes in our expectations.</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following discussion of our financial condition and results of operations should be read in conjunction with our condensed consolidated financial statements and the related notes and other financial information appearing elsewhere in this Quarterly Report and our audited consolidated financial statements and related notes for the year ended December 31, 2024 included in our Annual Report on Form 10-K, or 2024 Annual Report, filed with the U.S. Securities and Exchange Commission, or SEC, on March 18, 2025. Readers are also urged to carefully review and consider the various disclosures made by us that attempt to advise interested parties of the factors that affect our business, including without limitation the disclosures made in Item&#160;1A of Part&#160;II of this Quarterly Report under the captions &#8220;Risk Factors&#8221; and &#8220;Management's Discussion and Analysis of Financial Condition and Results of Operations,&#8221; and the disclosures made in our 2024 Annual Report under the caption &#8220;Risk Factors&#8221; and in our audited consolidated financial statements and related notes. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk factors that could cause actual results to differ from those contained in the forward-looking statements include but are not limited to: our history of losses; our lack of products that have received regulatory approval; uncertainties inherent in clinical trials and product development programs, including but not limited to the fact that preclinical and clinical results may not be indicative of results achievable in other trials or for other indications, that the studies or trials may not be successful or achieve desired results, that preclinical studies and clinical trials may not commence, have sufficient enrollment or be completed in the time periods anticipated, that results from one study may not necessarily be reflected or supported by the results of other similar studies, that results from an animal study may not be indicative of results achievable in human studies, that clinical testing is expensive and can take many years to complete, that the outcome of any clinical trial is uncertain and failure can occur at any time during the clinical trial process, and that our proprietary device technology and DNA medicine candidates may fail to show the desired safety and efficacy traits in clinical trials; the availability of funding; the ability to manufacture our DNA medicine candidates; the availability or potential availability of alternative therapies or treatments for the conditions targeted by us or our collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that we and our collaborators hope to develop; our ability to receive development, regulatory and commercialization event-based payments under our collaborative agreements; whether our proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity; and the impact of government healthcare laws and proposals.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">INOVIO, CELLECTRA, the INOVIO logo, and our other trademarks or service marks appearing in this Quarterly Report are our property. Solely for convenience, the trademarks and trade names in this report are referred to without the &#174; and TM symbols, but such references should not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto. Products or service names of other companies mentioned in this Quarterly Report may be trademarks, trade names or service marks of their respective owners.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">References herein to &#8220;we,&#8221; &#8220;our,&#8221; &#8220;us,&#8221; &#8220;INOVIO&#8221; or the &#8220;Company&#8221; refer to INOVIO Pharmaceuticals, Inc. and its consolidated subsidiaries. References herein to &#8220;DNA medicines&#8221; refers to our product candidates in development for diseases associated with human papillomavirus (HPV), cancer, and infectious diseases.</span></div><div style="margin-top:9pt;text-indent:27pt"><span><br/></span></div><div id="icec13c599da34407bd5c5256baff0b0b_115"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are a clinical-stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases. Our platform harnesses the power of in vivo protein production, featuring optimized design and delivery of DNA medicines that teach the body to manufacture its own disease-fighting tools. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icec13c599da34407bd5c5256baff0b0b_7">Table of </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#icec13c599da34407bd5c5256baff0b0b_7">Contents</a></span></div></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use proprietary technology to design DNA plasmids, which are small circular DNA molecules that work like software the body&#8217;s cells can download to produce specific proteins to target and fight disease. Our proprietary investigational CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> devices are designed to deliver the plasmids into the body&#8217;s cells for optimal effect, without the use of chemical adjuvants, lipid nanoparticles or viral vectors.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our lead candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis, or RRP, a chronic, rare and debilitating disease characterized by the growth of small tumors, or papillomas, in the respiratory tract primarily caused by HPV-6 and/or HPV-11 genotypes. Although mostly benign, these papillomas can cause severe, sometimes life-threatening airway obstruction and respiratory complications. The standard of care for RRP is repeated invasive surgery. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2023, we received feedback from the U.S. Food and Drug Administration, or FDA, that the data from this completed trial could be used to support the submission of a Biologic License Application, or BLA, for review under the FDA&#8217;s accelerated approval program. As part of submitting our BLA under the accelerated program, we will need to satisfy all FDA filing requirements and initiate a confirmatory clinical trial prior to BLA submission. We previously expected to be able to submit our BLA by the end of 2024; however, during our device testing process we identified a manufacturing issue involving the single-use disposable administration component of the CELLECTRA 5PSP device that we plan to use in the confirmatory trial and that will be submitted for approval for commercial use. We resolved the manufacturing issue in the first quarter of 2025 and are currently on track to begin a rolling submission of the BLA in mid-2025 and to request priority review, with a goal of receiving file acceptance by the FDA by the end of 2025.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are developing INO-3112, a DNA medicine candidate targeting HPV 16/18 combined with a DNA plasmid encoding for human IL-12 as an immune activator, for the treatment of oropharyngeal squamous cell carcinoma, or OPSCC, a type of head and neck cancer commonly known as throat cancer. We have entered into a clinical collaboration and supply agreement with Coherus BioSciences, Inc. to evaluate the combination of INO-3112 and LOQTORZI (toripalimab-tpzi) in a clinical trial for patients with locoregionally advanced, high-risk, HPV16/18 positive OPSCC. Under the terms of the supply agreement, Coherus will provide LOQTORZI for a planned Phase 3 clinical trial. We have also gained alignment with FDA on the design of the planned Phase 3 trial in the United States and received initial feedback from European regulatory authorities on the proposed design of the trial in Europe. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also developing INO-5401, an immunotherapy consisting of three DNA plasmids encoding for three tumor associated antigens, for the treatment of glioblastoma multiforme, or GBM, an aggressive type of brain cancer that accounts for more than 50% of all primary malignant brain tumors. GBM is one of the most complex, deadly, and treatment-resistant cancers.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our development efforts with the product candidates described above, we are actively developing or planning to develop DNA medicines for other indications, including HPV-related anal dysplasia; cancers in people with certain gene mutations; and a potential vaccine booster to protect against the Ebola virus. We were previously conducting clinical trials of a DNA medicine candidate for the treatment of HPV-related cervical high-grade squamous intraepithelial lesions, or HSIL, but announced in 2023 that we were ceasing development for this indication in the United States. However, our collaborator ApolloBio Corporation continues to conduct a Phase 3 clinical trial of this candidate in China and plans to seek regulatory approval for and potentially commercialize the candidate in that jurisdiction.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, Coherus Biosciences, Defense Advanced Research Projects Agency (DARPA), HIV Vaccines Trial Network, International Vaccine Institute (IVI), Kaneka Eurogentec, National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID), Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter BioLogics, the University of Pennsylvania and The Wistar Institute.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our DNA medicine candidates are in the research and development phase. We have not generated any revenues from the sale of any products, and we do not expect to generate any material revenues unless and until we obtain marketing approval for and successfully commercialize INO-3107 and our other product candidates. We earn revenue from license fees and milestone revenue and collaborative research and development agreements and contracts. Our DNA medicine candidates will require significant additional research and development efforts, including extensive preclinical and clinical testing. All DNA medicine candidates that we advance to clinical testing will require regulatory approval prior to commercial use, and will require significant costs for commercialization. We may not be successful in our research and development efforts, and we may never generate sufficient product revenue to be profitable.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2025, we had an accumulated deficit of $1.7 billion. We expect to continue to incur substantial operating losses in the future due to our commitment to our research and development programs, the funding of preclinical studies, clinical trials and regulatory activities and the costs of general and administrative activities.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div id="icec13c599da34407bd5c5256baff0b0b_118"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icec13c599da34407bd5c5256baff0b0b_7">Table of </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#icec13c599da34407bd5c5256baff0b0b_7">Contents</a></span></div></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no significant changes to our critical accounting estimates since December 31, 2024. For a description of our critical accounting estimates and significant judgments used in the preparation of our condensed consolidated financial statements, refer to Note 3 to our Condensed Consolidated Financial Statements included in this Quarterly Report, as well as Item 7, &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; in our 2024 Annual Report and Note 2 to our audited Consolidated Financial Statements contained in our 2024 Annual Report. </span></div><div style="margin-top:5pt;text-indent:27pt"><span><br/></span></div><div id="icec13c599da34407bd5c5256baff0b0b_124"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue was $65,000 and $0 for the three months ended March 31, 2025 and 2024, respectively, all of which was derived under the collaborative arrangement with ApolloBio.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Research and development expenses consist of expenses incurred in performing research and development activities, including compensation and benefits for full-time research and development employees, facilities expenses, overhead expenses, cost of laboratory supplies, clinical trial and related clinical manufacturing expenses, fees paid to contract research organizations and other consultants, and outside expenses. We utilize a labor reporting system to record employee compensation on a project-by-project basis. Unallocated research and development expenses include engineering and device-related expenses that are not allocable to a specific project, as well as stock-based compensation, other employee-related expenses that are not related to a specific project, and facilities and depreciation expenses.    </span></div><div style="margin-top:5pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Research and development costs are expensed as incurred. Non-refundable advance payments for goods or services to be received in the future for use in research and development activities are deferred and capitalized. The capitalized amounts are expensed as the related goods are delivered or the services are performed.</span></div><div style="margin-top:5pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following table summarizes our research and development expense by product candidate for the three months ended March 31, 2025 and 2024:</span></div><div style="margin-top:5pt;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.298%"><tr><td style="width:1.0%"/><td style="width:37.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.024%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.575%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.024%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.575%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.388%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.575%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.770%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase (Decrease)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(dollars in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">INO-3107</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,507&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,646&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,139)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">INO-3112 and other Immuno-oncology </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,316&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,021&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(705)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other research and development programs (a)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">623&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(516)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(83)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Engineering and device-related </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,062&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,751&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,311&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">553&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,060&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(507)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other unallocated expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,546&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,813&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(267)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,091&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,914&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,823)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:5pt;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.736%"><tr><td style="width:1.0%"/><td style="width:37.788%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.949%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.880%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.949%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.325%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.021%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:5pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Net of contributions received from grant agreements and recorded as contra-research and development expense.</span></div><div style="margin-top:5pt;text-indent:27pt"><span><br/></span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in research and development expenses for the three-month period year over year was primarily the result of:</span></div><div style="margin-top:5pt;padding-left:72pt;text-indent:-27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">$3.3 million in lower drug manufacturing and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">immunology expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> related to INO-3107; </span></div><div style="margin-top:5pt;padding-left:72pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">$913,000 in lower contract labor; </span></div><div style="margin-top:5pt;padding-left:72pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">$714,000 of lower expensed inventory; </span></div><div style="margin-top:5pt;padding-left:72pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">$639,000 in lower drug manufacturing expenses for other programs; and</span></div><div style="margin-top:5pt;padding-left:72pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">$507,000 in lower employee and consultant stock-based compensation, as a result of the lower weighted average grant date fair value for the awards granted during 2025.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These decreases were offset by:</span></div><div style="margin-top:5pt;padding-left:72pt;text-indent:-27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">$926,000 in higher engineering professional and outside services related to our device development; and</span></div><div style="margin-top:5pt;padding-left:72pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">$244,000 in higher clinical study expenses and outside services related to INO-3107.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contributions received from current grant agreements and recorded as contra-research and development expense were $286,000 and $179,000 for the three months ended March 31, 2025 and 2024, respectively. The increase for the three-month period year over year was due to the increase in expenses earned under the sub-grants through Wistar, among other variances.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icec13c599da34407bd5c5256baff0b0b_7">Table of Contents</a></span></div></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and administrative expenses. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses, which include business development expenses and patent expenses, were $9.0 million and $10.6 million for the three months ended March 31, 2025 and 2024, respectively. Decreases for the three-month period year over year included:</span></div><div style="margin-top:5pt;padding-left:72pt;text-indent:-27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:23.5pt">$745,000 in lower legal expenses due a decrease in litigation activity;</span></div><div style="margin-top:5pt;padding-left:72pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:23.5pt">$619,000 in lower employee and consultant stock-based compensation, as a result of the lower weighted average grant date fair value for the awards granted during 2025; and</span></div><div style="margin-top:5pt;padding-left:72pt;text-indent:-27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:23.5pt">$322,000 in lower rent expense.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-based compensation. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employee</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">s</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">tock-based compensation expense is measured at the grant date, based on the fair value of the award, and is recognized as expense over the requisite vesting period. Total employee and director stock-based compensation expense for the three months ended March 31, 2025 and 2024 was $1.4 million and $2.4 million, of which $547,000 and $1.0 million was included in research and development expenses and $821,000 and $1.4 million was included in general and administrative expenses, respectively. The decrease was due to a lower weighted average grant date fair value for the awards granted during 2025.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest income. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income for the three months ended March 31, 2025 and 2024 was $808,000 and $1.5 million, respectively. The decrease for the three-month period year over year was primarily due to a lower short-term investment balance.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest expense. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense for the three months ended March 31, 2025 and 2024 was $0 and $178,000, respectively. The prior year interest expense related to our senior convertible promissory notes that were repaid in full on March 1, 2024.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Change in Fair Value of Common Stock Warrant Liability. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in fair value of our common stock warrant liability change is related to the revaluation of the liability associated with the Warrants, as defined below, we issued in December 2024 and was primarily the result of a decrease in our stock price during the period. We record the fair value of these Warrants at each balance sheet date and will record gain or loss on the statement of operations for changes between balance sheet dates.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gain (loss) on investment in affiliated entity. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The gain (loss) resulted from the change in the fair market value of our investment in PLS of $695,000 and $(126,000), respectively. We record our investment in PLS at its market value based on the closing price of the shares on the Korea New Exchange Market at each balance sheet date, with changes in fair value reflected in the condensed consolidated statements of operations.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net unrealized gain on available-for-sale equity securities. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net unrealized gain on available-for-sale equity securities for the three months ended March 31, 2025 and 2024 of $140,000 and $501,000, respectively, resulted from a change in the fair market value of the investments.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other expense, net. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expense, net, for the three months ended March 31, 2025 and 2024 of $500 and $682,000, respectively, related primarily to the realized loss on short-term investments sold during the periods.</span></div><div style="margin-top:5pt;text-indent:27pt"><span><br/></span></div><div id="icec13c599da34407bd5c5256baff0b0b_127"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Historically, our primary uses of cash have been to finance research and development activities including clinical trial activities for the advancement of DNA medicine candidates. Since inception, we have satisfied our cash requirements principally from proceeds from the sale of equity securities, indebtedness and grants and government contracts.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Working Capital and Liquidity</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2025, we had cash, cash equivalents and short-term investments of $68.4 million and working capital of $44.6 million, as compared to $94.1 million and $62.5 million, respectively, as of December&#160;31, 2024. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Activities</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities was $26.9 million and $28.8 million for the three months ended March 31, 2025 and 2024, respectively. The variance was primarily due to the timing and changes in working capital balances, offset by decreased operating expenses.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing Activities</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash (used in) provided by investing activities was $(52,000) and $45.4 million for the three months ended March 31, 2025 and 2024, respectively. The variance was primarily the result of timing differences in short-term investment purchases, sales and maturities.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:5pt;text-indent:27pt"><span><br/></span></div></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financing Activities</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by (used in) financing activities was $1.0 million and $(11.4) million for the three months ended March 31, 2025 and 2024, respectively. The variance was primarily due to the repayment of our convertible senior notes of $16.4 million in March 2024, offset by net proceeds of $5.2 million from the sale of common stock under the Sales Agreements (defined below) during the three months ended March 31, 2024, compared to $1.1 million received during the three months ended March 31, 2025.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Offering of Common Stock and Warrants</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 16, 2024, we closed an underwritten public offering, or the December 2024 Offering, relating to the issuance and sale of 10,000,000 shares of the common stock, and accompanying warrants to purchase 10,000,000 shares of common stock, or the Warrants, at an offering price of $3.00 per share and accompanying Warrant. The net proceeds from the December 2024 Offering were $27.6 million, after deducting the underwriting discounts and commissions and offering expenses paid by us. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Offering of Common Stock and Pre-Funded Warrants</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 18, 2024, we closed an underwritten registered direct offering, or the April 2024 Offering, relating to the issuance and sale of 2,536,258 shares of common stock at a price of $7.693 per share and pre-funded warrants to purchase up to 2,135,477 shares of common stock, or the Pre-Funded Warrants, at a price of $7.692 per Pre-Funded Warrant, which represents the per share price for the shares less the $0.001 per share exercise price for each Pre-Funded Warrant. The net proceeds from the April 2024 Offering were $33.2 million, after deducting the underwriting discounts and commissions and offering expenses paid by us. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">At-The-Market Sales Agreements</span></div><div style="margin-top:5pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On August 13, 2024, we entered into an Equity Distribution Agreement, or the 2024 Sales Agreement, with an outside sales agent, or Sales Agent, for the offer and sale of our common stock for an aggregate offering price of up to $60.0&#160;million. The 2024 Sales Agreement provides that the Sales Agent is entitled to compensation in an amount equal to up to 3.0% of the gross sales proceeds of any common stock sold through the Sales Agent under the 2024 Sales Agreement, and we have provided the Sales Agent with certain indemnification rights. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2025, we sold 518,670 shares of common stock under the 2024</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales Agreement. The sales were made at a weighted average price of $2.16 per share, resulting in aggregate net proceeds of</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$1.1 million. During the year ended December 31, 2024, we sold 133,900 shares of common stock under the 2024 Sales Agreement. The sales were made at a weighted average price of $7.02 per share, resulting in aggregate net proceeds of $925,000. As of March&#160;31, 2025, there was $57.9 million of remaining capacity under the 2024 Sales Agreement.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 9, 2021, we entered into an ATM Equity Offering</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">SM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Sales Agreement, or the 2021 Sales Agreement, with outside sale</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s agents, under which we were able to offer and sell shares of our common stock with aggregate gross proceeds of up to $300.0 million.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> the </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">three months ended March 31, 2024</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, we sold 543,620 shares of our common stock under the 2021 Sales Agreement at a weighted average price of $9.76 per share, resulting in aggregate net proceeds of $5.2 million. We terminated the 2021 Sales Agreement in August 2024 in connection with the entry into the 2024 Sales Agreement described above.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Issuances of Common Stock</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2025 and 2024, no </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">stock options were exercised and tax payments of $74,000 and $174,000, respectively, were made related to net share settlement of RSU awards.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Funding Requirements</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2025, we had an accumulated deficit of $1.7 billion, and we expect to continue to operate at a loss for the near term. The amount of our accumulated deficit will continue to increase, as it will be expensive to continue research and development efforts. Our current cash resources </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">will not be sufficient to complete the clinical development of our product candidates beyond INO-3107, and we anticipate that additional financing will be required in order to complete the development of and to commercialize and generate revenues from the sale of INO-3107 or any other product candidates that may receive regulatory approval. If these activities are successful and if we receive approval from the FDA to market our DNA medicine candidates, then we will need to raise additional funding to market and sell the approved products and equipment. In addition to the potential issuance of equity or debt securities in order to raise capital, we are also evaluating potential collaborations as an additional way to fund our operations.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We expect our cash runway to extend into the first quarter of 2026, without giving effect to any further capital raising activities that we may undertake.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to continue operations is dependent upon our ability to obtain additional capital in the future and achieve profitable operations. We expect to continue to rely on outside sources of financing to meet our capital needs and we may never achieve positive cash flow. In light of these factors, management believes that there is substantial doubt about our ability to </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:5pt;text-indent:27pt"><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">continue as a going concern beyond the first quarter of 2026. The condensed consolidated financial statements as of and for the three months ended March 31, 2025 do not include any adjustments that might result from the outcome of this uncertainty.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have existing supply agreements with contract manufacturers to manufacture drug substance. At March&#160;31, 2025, we had approximately $605,000 in </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">minimum purchase obligations in connection with these agreements. We expect to satisfy these obligations from existing cash over the next twelve months.  </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2025, there have been no significant changes to our contractual obligations and commitments described under Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations in our 2024 Annual Report.</span></div><div style="margin-top:5pt;text-indent:27pt"><span><br/></span></div><div id="icec13c599da34407bd5c5256baff0b0b_130"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3.&#160;&#160;&#160;&#160;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="margin-top:5pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Rate Risk</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of U.S. interest rates. Under our current policies, we do not use interest rate derivative instruments to manage exposure to interest rate changes. We attempt to increase the safety and preservation of our invested principal funds by limiting default risk, market risk and reinvestment risk. We mitigate default risk by investing in short-term investment-grade securities. Over the past several years, there has been a pronounced overall increase in prevailing interest rates in the United States, which has contributed to the accumulated unrealized loss of $1.7 million in the market value of our investment portfolio as of March&#160;31, 2025.</span></div><div style="margin-top:5pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Risk</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate primarily in the United States and most transactions during the three months ended March 31, 2025 were made in United States dollars. Accordingly, we do not have any material exposure to foreign currency rate fluctuations, with the exception of certain cash and cash equivalents held in South Korea that are denominated in South Korean Won and the valuation of our equity investment in PLS, which is denominated in South Korean Won and then translated into United States dollars. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain transactions are denominated primarily in foreign currencies, including South Korean Won, Euros, British Pounds and Canadian Dollars. These transactions give rise to monetary assets and liabilities that are denominated in currencies other than the U.S. dollar. The value of these monetary assets and liabilities are subject to changes in currency exchange rates from the time the transactions are originated until settlement in cash. As a result, our financial results could be affected by factors such as changes in foreign currency exchange rates or weak economic conditions in foreign markets where we conduct business.</span></div><div style="margin-top:4.5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not use derivative financial instruments for speculative purposes and do not engage in exchange rate hedging or hold or issue foreign exchange contracts for trading purposes. </span></div><div style="margin-top:5pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inflation Risk</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inflation generally affects us by increasing our cost of labor. Although inflation has increased generally in the United States in recent years, we do not believe that inflation has had a material effect on our business, financial condition or results of operations during the three months ended March 31, 2025.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="icec13c599da34407bd5c5256baff0b0b_133"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4.&#160;&#160;&#160;&#160;CONTROLS AND PROCEDURES</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-top:4.5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain disclosure controls and procedures, which are designed to ensure that information required to be disclosed in the reports we file or submit under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in the SEC's rules&#160;and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer, or CEO, and Chief Financial Officer, or CFO, as appropriate to allow timely decisions regarding required disclosures. </span></div><div style="margin-top:4.5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In designing and evaluating our disclosure controls and procedures, management recognizes that disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the disclosure controls and procedures are met. Additionally, in designing disclosure controls and procedures, our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible disclosure controls and procedures. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a control system, misstatements due to error or fraud may occur and not be detected.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icec13c599da34407bd5c5256baff0b0b_7">Table of Contents</a></span></div></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on an evaluation carried out as of the end of the period covered by this Quarterly Report, under the supervision and with the participation of our management, including our CEO and CFO, our CEO and CFO have concluded that, as of the end of such period, our disclosure controls and procedures (as defined in Rule&#160;13a-15(e)&#160;and 15d-15(e)&#160;under the Securities Exchange Act of 1934) were effective as of March&#160;31, 2025 at the reasonable assurance level. </span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-top:4.5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have not been any changes in our internal control over financial reporting that occurred during the quarter ended March&#160;31, 2025 that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. </span></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><div id="icec13c599da34407bd5c5256baff0b0b_136"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Part II. Other Information</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div id="icec13c599da34407bd5c5256baff0b0b_139"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1.&#160;&#160;&#160;&#160;LEGAL PROCEEDINGS </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">VGXI Litigation</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, we filed a complaint in the Court of Common Pleas of Montgomery County, Pennsylvania against VGXI, Inc. and GeneOne Life Science, Inc., or GeneOne, and together with VGXI, Inc. collectively referred to as VGXI, alleging that VGXI had materially breached our supply agreement with them. The complaint seeks declaratory judgments, specific performance of the agreement, injunctive relief, an accounting, damages, attorneys&#8217; fees, interest, costs and other relief from VGXI. In June 2020, the Company filed a petition for preliminary injunction, which was denied.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following our appeal, in July 2020 VGXI filed counterclaims against us, alleging that we had breached the supply agreement, as well as misappropriation of trade secrets and unjust enrichment. The counterclaims seek injunctive relief, damages, attorneys&#8217; fees, interest, costs and other relief from us. VGXI also filed a third-party complaint against Ology Bioservices, Inc., a contract manufacturing organization that we had engaged to provide services similar to those that were being provided by VGXI, but VGXI later discontinued its third-party claims. We filed an answer to VGXI&#8217;s counterclaims, disputing the allegations and the claims raised in VGXI&#8217;s filing. In October 2020, we filed a notice of discontinuance of appeal with the Pennsylvania Superior Court. A trial date for the litigation has not been set.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to aggressively prosecute the claims set forth in our complaint against VGXI and to vigorously defend ourselves against VGXI&#8217;s counterclaims.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">GeneOne Litigation</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, GeneOne filed a complaint in the Court of Common Pleas of Montgomery County, Pennsylvania against us, alleging that we had breached the CELLECTRA Device License Agreement, or the Agreement, between us and GeneOne. We terminated the Agreement in October 2020. The complaint asserts claims for breach of contract, declaratory judgment, unfair competition, and unjust enrichment. The complaint seeks injunctive relief, an accounting, damages, disgorgement of profits, attorneys&#8217; fees, interest, and other relief from us. We filed preliminary objections to the complaint, which were overruled. In September 2021, we filed an answer to the complaint, new matter, and counterclaims. Our counterclaims allege that GeneOne breached the Agreement and assert claims for breach of contract and declaratory judgment. The counterclaims seek damages, interest, expenses, attorney&#8217;s fees, and costs. In October 2021, GeneOne filed its answer to our counterclaims and new matter. In 2024, we filed a motion for summary judgment, which was denied. The court has set a trial date of August 19, 2025.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to aggressively prosecute the claims set forth in our counterclaims against GeneOne and to vigorously defend ourselves against the claims in GeneOne&#8217;s complaint. </span></div><div style="margin-top:5pt"><span><br/></span></div><div id="icec13c599da34407bd5c5256baff0b0b_142"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1A.&#160;&#160;&#160;&#160;  RISK FACTORS</span></div><div style="margin-top:4.5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our business is subject to numerous risks. You should carefully consider and evaluate each of the following factors as well as the other information in this Quarterly Report on Form&#160;10-Q, including our financial statements and the related notes, and the risk factors discussed in our 2024 Annual Report, which we filed with the SEC on March 18, 2025, in evaluating our business and prospects. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently consider immaterial may also impair our business operations. If any of the following risks actually occur, our business and financial results could be harmed. In that case, the trading price of our common stock could decline. You should also consider the more detailed description of our business contained in our 2024 Annual Report. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Financial Position and Need for Additional Capital</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have incurred significant losses in recent years, expect to incur significant net losses in the foreseeable future and may never become profitable.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have experienced significant operating losses over the last several years. As of March&#160;31, 2025, our accumulated deficit was $1.7 billion. We have generated limited revenues, primarily consisting of license revenue, grant funding and interest income. We expect to continue to incur substantial additional operating losses for at least the next several years as we advance our clinical trials and research and development activities and seek to commercialize INO-3107, which, if approved, would be our first marketed product. We may never successfully commercialize INO-3107 or our other DNA medicine candidates or proprietary device technology and thus may never have any significant future revenues or achieve and sustain profitability.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have limited sources of revenue and our success is dependent on our ability to develop our DNA medicines and proprietary device technology.  </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not currently generate any revenue from the commercial sale of products. Our ability to generate future revenues depends heavily on our success in: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developing and securing United States and/or foreign regulatory approvals for our DNA medicine candidates, including securing regulatory approval for conducting clinical trials with DNA medicine candidates; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">developing our proprietary device technology; and </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">commercializing INO-3107 or any other products for which we receive approval from the FDA and foreign regulatory authorities. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our proprietary device and DNA medicine candidates will require extensive additional clinical study and evaluation, regulatory approval in multiple jurisdictions, substantial investment and significant marketing efforts before we generate any revenues from product sales. We are not permitted to market or promote our proprietary device and DNA medicine candidates as combination products before we receive regulatory approval from the FDA or comparable foreign regulatory authorities. If we do not receive regulatory approval for and successfully commercialize any products, we will not generate any revenues from sales of proprietary devices and DNA medicine products, and we may not be able to continue our operations. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">A small number of licensing partners and government contracts have accounted for a substantial portion of our revenue. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the past we have derived a significant portion of our revenue from a limited number of licensing partners and government grants and contracts, and we expect that a significant portion of our revenue will continue to be derived from a limited number of licensing partners and/or government grants and contracts unless and until we are able to commercialize our product candidates. Revenue can fluctuate significantly depending on the timing of upfront and event-based payments and work performed. If we fail to sign additional future contracts with major licensing partners and the government, if a contract is delayed or deferred, or if an existing contract expires or is canceled and we fail to replace the contract with new business, our revenue would be adversely affected. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will need substantial additional capital to develop our DNA medicines and proprietary device technology, which may prove difficult or costly to obtain.  </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Conducting the costly and time-consuming research, pre-clinical studies and clinical testing necessary to obtain regulatory approvals and bring our DNA medicine candidates and proprietary device technology to market will require a commitment of substantial funds in excess of our current capital. Our future capital requirements will depend on many factors, including, among others:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the progress of our current and new product development programs; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the progress, scope and results of our pre-clinical and clinical testing; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the time and cost involved in obtaining regulatory approvals; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost to commercialize any product that obtains regulatory approval;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of manufacturing our DNA medicine candidates;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of prosecuting, enforcing and defending against patent infringement claims and other intellectual property rights; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">debt service obligations;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">competing technological and market developments; and </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability and the related costs to establish and maintain collaborative and other arrangements with third parties to assist in potentially bringing our products to market. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional financing may not be available on acceptable terms, or at all. Domestic and international capital markets have from time to time experienced heightened volatility, particularly in light of geopolitical turmoil, inflation and rising interest rates, making it more difficult in many cases to raise capital through the issuance of equity securities. Volatility in the capital markets can also negatively impact the cost and availability of credit, creating illiquid credit markets and wider credit spreads. Concern about the stability of the markets generally and the strength of counterparties specifically has led many lenders and institutional investors to reduce, and in some cases cease to provide, funding to borrowers. In particular, biotech and small-cap companies tend to feel these difficulties acutely. To the extent we are able to raise additional capital through the sale of equity securities, or we issue securities in connection with another transaction in the future, the ownership position of existing stockholders could be substantially diluted. If additional funds are raised through the issuance of preferred stock or debt securities, these securities are likely to have rights, preferences and privileges senior to our common stock and may involve significant fees, interest expense, restrictive covenants and the granting of security interests in our assets. Rising interest rates could also increase the costs of any debt financing we may obtain. Raising capital through a licensing or other transaction </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">involving our intellectual property could require us to relinquish valuable intellectual property rights and thereby sacrifice long-term value for short-term liquidity.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our failure to successfully address ongoing liquidity requirements would have a substantially negative impact on our business. If we are unable to obtain additional capital on acceptable terms when needed, we may need to take actions that adversely affect our business, our stock price and our ability to achieve cash flow in the future, including possibly surrendering our rights to some technologies or product opportunities, delaying our clinical trials or curtailing or ceasing operations. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Product Development, Manufacturing and Regulatory Approval</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to obtain FDA approval of our proprietary devices and DNA medicine candidates, we will not be able to commercialize them in the United States. In particular, because our product candidates are drug-device combination products comprising an electroporation device for delivery of a biologic, additional time may be required to obtain regulatory approval for our product candidates because of the complexity involved with developing and manufacturing a drug-device combination product. In addition, if the FDA and similar regulatory authorities do not provide marketing authorization for our CELLECTRA delivery devices, then we will not be able to bring to market our DNA medicines that rely on delivery by such a device.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We need FDA approval prior to marketing our proprietary device and DNA medicine candidates as combination products in the United States. If we fail to obtain FDA approval to market our proprietary device and DNA medicine candidates as combination products, we will be unable to sell our products in the United States, which will significantly impair our ability to generate any revenues.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This regulatory review and approval process, which includes evaluation of preclinical studies and clinical trials of our combination products as well as the evaluation of our device design, manufacturing processes and our third-party contract manufacturers' facilities, is lengthy, expensive and uncertain. To receive approval, we must, among other things, demonstrate with substantial evidence from well-controlled clinical trials that our proprietary device and DNA medicine candidates are both safe and effective for each indication for which approval is sought. In determining what is needed to demonstrate the safety and effectiveness of a combination product, the FDA takes into account the questions and considerations, reflected in the statutory and regulatory provisions associated with each constituent part in the FDA&#8217;s review of the combination product as a whole and its constituent parts. This includes how the constituent parts may interact and interrelate and is a complex process. To the extent that our DNA medicine candidates are manufactured at multiple sites or using different processes, we will also need to demonstrate comparability across the manufacturing batches in order to obtain regulatory approval. Satisfaction of the approval requirements typically takes several years and the time needed to satisfy them may vary substantially, based on the type, complexity and novelty of the product. We do not know if or when we might receive regulatory approvals for our proprietary device and any of our DNA medicine candidates currently under development. Moreover, any approvals that we obtain may not cover all of the clinical indications for which we are seeking approval, or could contain significant limitations in the form of narrow indications, warnings, precautions or contra-indications with respect to conditions of use. In such event, our ability to generate revenues from such products would be greatly reduced and our business would be harmed.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA has substantial discretion in the approval process and may either refuse to consider our application for substantive review or may form the opinion after review of our data that our application is insufficient to allow approval of our proprietary device and DNA medicine candidates. If the FDA does not consider or approve our application, it may require that we conduct additional clinical, preclinical or manufacturing validation studies and submit that data before it will reconsider our application. Depending on the extent of these or any other studies, approval of any applications that we submit may be delayed by several years, or may require us to expend more resources than we have available. It is also possible that additional studies, if performed and completed, may not be successful or considered sufficient by the FDA for approval or even to make our applications approvable. If any of these outcomes occur, we may be forced to abandon one or more of our applications for approval, which might significantly harm our business and prospects.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is possible that none of our product candidates or any product we may seek to develop in the future will ever obtain the appropriate regulatory approvals necessary for us or our collaborators to commence product sales. Any delay in obtaining, or an inability to obtain, applicable regulatory approvals would prevent us from commercializing our products, generating revenues and achieving and sustaining profitability. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pursuing accelerated approval for INO-3107 or any of our other product candidates may not lead to a faster development or regulatory review or approval process and does not increase the likelihood that our product candidates will receive marketing approval. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We plan to pursue accelerated approval for INO-3107 for the treatment of RRP and may in the future decide to pursue accelerated approval for one or more of our other product candidates. Under the FDA&#8217;s accelerated approval program, the FDA may approve a drug or biologic for a serious or life-threatening disease or condition that provides a meaningful advantage over available therapies based upon a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality that is reasonably likely to predict an effect on irreversible </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">morbidity or mortality or other clinical benefit. For drugs or biologics granted accelerated approval, post-marketing confirmatory trials are required to verify and describe the anticipated effect on irreversible morbidity or mortality or other clinical benefit. These confirmatory trials must be completed with due diligence, and the FDA may require that the trial be designed, initiated, and/or fully enrolled prior to approval. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our pursuit of accelerated approval for INO-3107 and any future product candidates would be on the basis that there is no available therapy for a particular disease or condition and that our product candidate provides a benefit over available therapy. If standard of care were to evolve or if any of our competitors were to receive full approval on the basis of a confirmatory trial for a drug or biologic for a disease or condition for which we are seeking accelerated approval before we receive accelerated approval, the disease or condition would no longer qualify as one for which there is no available therapy, and accelerated approval of our product candidate would not occur without a showing of benefit over available therapy. The treatment landscape can change quickly as the FDA converts accelerated approvals to full approvals on the basis of successful confirmatory trials. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have received feedback from the FDA that data from our completed Phase 1/2 clinical trial of INO-3107 can be used to support the submission of our planned BLA for review under the accelerated approval program; however, whether this trial will be sufficient to receive FDA approval under the accelerated approval pathway will only be determined by the FDA upon review of the submitted BLA. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, the FDA may withdraw approval of INO-3107 or any future product candidate approved under the accelerated approval pathway if, for example:</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the trial or trials required to verify the predicted clinical benefit of our product candidate fail to verify such benefit or do not demonstrate sufficient clinical benefit to justify the risks associated with such product;</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.75pt">other evidence demonstrates that our product candidate is not shown to be safe or effective under the conditions of use;</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.75pt">we fail to conduct any required post-approval trial of our product candidate with due diligence; or</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.75pt">we disseminate false or misleading promotional materials relating to the relevant product candidate.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the FDA may terminate the accelerated approval program or change the standards under which accelerated approvals are considered and granted in response to public pressure or other concerns regarding the accelerated approval program. Changes to or termination of the accelerated approval program could prevent or limit our ability to obtain accelerated approval of any of our clinical development programs. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if our products receive regulatory approval in the United States, we may never receive approval or commercialize our products outside of the United States, and the same risk applies for products approved outside the United States, with respect to regulatory approval in the United States.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to market any proprietary device and DNA medicine candidates outside of the United States, we must establish and comply with numerous and varying regulatory requirements of other countries regarding safety and efficacy.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approval procedures vary among countries and can involve additional product testing and additional administrative review periods. The time required to obtain approval in other countries might differ from that required to obtain FDA approval, and the regulatory approval process in other countries may include all of the risks detailed above regarding FDA approval in the United States as well as other risks. Furthermore, regulatory approval in one country does not ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval in one country may have a negative effect on the regulatory process in others. Failure to obtain regulatory approval in other countries or any delay or setback in obtaining such approval could have the same adverse effects detailed above regarding FDA approval in the United States. Such effects include the risks that our DNA medicine candidates may not be approved for all indications requested, which could limit the uses of our DNA medicine candidates and have an adverse effect on their commercial potential or require costly, post-marketing follow-up studies. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical testing is expensive and can take many years to complete, and its outcome is uncertain, particularly when the clinical testing involves drug and device combination products such as ours. Failure can occur at any time during the clinical trial process. The results of preclinical studies and early clinical trials of our product candidates may not be predictive of the results of later-stage clinical trials. Results from one study may not be reflected or supported by the results of similar studies. Results of an animal study may not be indicative of results achievable in human studies. Human-use equipment and DNA medicine candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits despite having progressed through preclinical studies and initial clinical testing. The time required to obtain approval by the FDA and similar foreign authorities is unpredictable but typically takes many years following the commencement of clinical trials, depending upon numerous factors. In addition, approval policies, regulations, or the type and amount of clinical data necessary to gain approval may change. We have not obtained regulatory approval for any products for use in humans.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates could fail to complete the clinical trial process for many reasons, including the following:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that our proprietary device meets the standard of reasonable assurance of safety and effectiveness or that our product candidate is safe and effective for any indication; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the results of clinical trials may not meet the level of clinical or statistical significance required by the FDA or comparable foreign regulatory authorities for approval;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not be successful in enrolling a sufficient number of participants in clinical trials; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be unable to demonstrate that our proprietary device or DNA medicine candidates' clinical and other benefits outweigh their safety risks; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be unable to demonstrate that our proprietary device or product candidate presents an advantage over existing therapies, or over placebo in any indications for which the FDA requires a placebo-controlled trial; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the data collected from clinical trials of our DNA medicine candidates may not be sufficient to support the submission of a new drug application or other submission or to obtain regulatory approval in the United States or elsewhere; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA or comparable foreign regulatory authorities may fail to approve our manufacturing processes or facilities or that of third-party manufacturers with which we or our collaborators contract for clinical and commercial supplies; and </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the regulations or marketing authorization and approval policies of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for marketing authorization or approval. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Delays in the commencement, conduct or completion of clinical testing could result in increased costs to us and delay or limit our ability to generate revenues.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Delays in the commencement, conduct or completion of clinical testing could significantly affect our product development costs. We do not know whether planned clinical trials will begin on time or be completed on schedule, if at all. In addition, ongoing clinical trials may not be completed on schedule, or at all, and could be placed on a hold by the regulators for various reasons. The commencement and completion of clinical trials can be delayed for a number of reasons, including delays related to:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">obtaining regulatory approval to commence a clinical trial;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">adverse results from third-party clinical trials involving gene-based therapies and the regulatory response thereto;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">reaching agreement on acceptable terms with prospective CROs and trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">future bans or stricter standards imposed on clinical trials of gene-based therapy;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">manufacturing sufficient quantities of our proprietary device and DNA medicine candidates for use in clinical trials;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">obtaining Institutional Review Board, or IRB, approval to conduct a clinical trial at a prospective site;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">slower than expected recruitment and enrollment of patients to participate in clinical trials for a variety of reasons, including competition from other clinical trial programs for similar indications;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">conducting clinical trials with sites internationally due to regulatory approvals and meeting international standards;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">retaining patients who have initiated a clinical trial but may be prone to withdraw due to side effects from the therapy, lack of efficacy or personal issues, or who are lost to further follow-up;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">collecting, reviewing and analyzing our clinical trial data; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">global unrest, including geopolitical risks emanating from countries such as Russia and China, global pathogen outbreaks or pandemics, terrorist activities, the conflict between Israel and Hamas, bank failures and other economic and other external factors beyond our control.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">With respect to clinical trials of product candidates for rare diseases, such as our planned confirmatory trial of INO-3107 for the treatment of RRP, we may encounter difficulties in recruiting a sufficient number of patients to enroll in the trial due to the small number of patients with the disease. Because RRP is caused by specific HPV types, 6 and 11, and there is currently no standard protocol for diagnostic/screening of RRP patients unless there are symptoms of dysphonia, respiratory distress or other symptoms related to the presence of papillomas, it may be difficult to identify and diagnose patients for whom INO-3107 may be a potential treatment.  </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Clinical trials may also be delayed as a result of ambiguous or negative interim results. In addition, a clinical trial may be suspended or terminated by us, the FDA, the IRB overseeing the clinical trial at issue, any of our clinical trial sites with respect to that site, or other regulatory authorities due to a number of factors, including:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">inspection of the clinical trial operations or trial sites by the FDA or other regulatory authorities resulting in the imposition of a clinical hold;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">unforeseen safety issues; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">lack of adequate funding to continue the clinical trial.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If we experience delays in completion of, or if we terminate, any of our clinical trials, the commercial prospects for our proprietary device and our DNA medicine candidates may be harmed and our ability to generate product revenues will be delayed or eliminated altogether. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of a product candidate. Further, delays in the commencement, conduct or completion of clinical trials may adversely affect the trading price of our common stock.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">None of our DNA medicine candidates have been approved for sale, and we may never develop commercially successful DNA medicine products.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our DNA medicines programs are in various stages of research and development. There are limited data regarding the efficacy of DNA medicine candidates compared with conventional therapies, including vaccines, and we must conduct a substantial amount of additional research and development before the FDA or any comparable foreign regulatory authority will approve any of our DNA medicine candidates. The success of our efforts to develop and commercialize our DNA medicine candidates could be delayed or fail for a number of reasons. For example, we could experience delays in product development and clinical trials. Our DNA medicine candidates could be found to be ineffective or unsafe, or otherwise fail to receive necessary regulatory clearances to proceed with further clinical development or to be approved for marketing. Our products, even if they are deemed to be safe and effective by regulatory authorities, could be difficult to manufacture on a large scale, particularly given the complexity concerning the manufacturing of combination products, or uneconomical to market, or our competitors could develop superior products more quickly and efficiently or more effectively market their competing products. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, adverse events, or the perception of adverse events, relating to vaccine and immunotherapy candidates and delivery technologies may negatively impact our ability to develop commercially successful products. For example, pharmaceutical companies have been subject to claims that the use of some pediatric vaccines has caused personal injuries, including brain damage, central nervous system damage and autism. These and other claims may influence public perception of the use of vaccine and immunotherapy products and could result in greater governmental regulation, stricter labeling requirements and potential regulatory delays in the testing or approval of our potential products.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">There can be no assurance that our vaccine candidate for COVID-19 will ever receive regulatory approval as a primary vaccine or a booster in any country, whether by Emergency Use Authorization or otherwise.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in 2020, we expended significant resources on the clinical development of a COVID-19 vaccine candidate, INO-4800. We were previously conducting a Phase 2/3 clinical trial of INO-4800 called INNOVATE. Based on regulatory feedback and the competitive landscape for COVID-19 vaccines, in 2022 we discontinued the INNOVATE trial and pursued a strategy to develop our COVID-19 vaccine as a potential heterologous booster following administration of other primary vaccines. Following changes in regulatory timelines and requirements, diminishing government financial support, and the overall uncertainty related to opportunities for heterologous booster vaccines, in the fourth quarter of 2022 we discontinued our internally funded efforts to develop INO-4800 as a COVID-19 heterologous booster vaccine. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are no longer conducting any active clinical trials of INO-4800 and do not expect that it will ever receive regulatory approval in the United States. Our collaborator Advaccine has completed enrollment of its 200-participant homologous and 267-participant heterologous booster vaccine trials in China. They may seek an Emergency Use Authorization, or EUA, from regulatory authorities in China and other countries in Asia for the use of INO-4800 as a heterologous booster. However, any such decision would be made by Advaccine, and there is no guarantee that Advaccine will apply for an EUA or other similar authorization or, if it does apply, that Advaccine will be able to obtain such authorization. An EUA may not be available if countries are no longer in a state of public health emergency, in which case full approval would need to be sought. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We could also pursue a strategy of seeking EUA for a COVID-19 vaccine candidate in other countries outside of the United States. Even if an EUA or other authorization is ultimately granted, we will rely on the applicable regulatory authority policies and guidance governing vaccines authorized in this manner in connection with the marketing and sale of our vaccine candidate. If these policies and guidance change unexpectedly and/or materially or if we misinterpret them, potential sales of our product could be adversely impacted. Regulatory authorities may also terminate an EUA if safety issues or other concerns about our product arise or if we or Advaccine fail to comply with the conditions of authorization. If we or Advaccine apply for an EUA or similar authorization from regulatory authorities outside of the United States, the failure to obtain such authorization or the termination of such an authorization, if obtained, would adversely impact our and Advaccine&#8217;s ability to market and sell the COVID-19 vaccine.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">DNA medicines are a novel approach to treating and preventing disease, and our CELLECTRA delivery devices are a novel approach to administering medicines. Negative perception of the efficacy, safety, or tolerability of any investigational medicines we develop or our devices could adversely affect our ability to conduct our business, advance our investigational medicines, or obtain regulatory approvals.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No DNA medicines have been granted an EUA or have been approved to date by the FDA. Adverse events in clinical trials of our investigational medicines or in clinical trials of others developing similar products and the resulting publicity, as well as any other adverse events in the field of DNA medicine, or other products that are perceived to be similar to DNA medicines, such as those related to other nucleic acid based vaccines such as mRNA vaccines, gene therapy or gene editing, could result in a decrease in the perceived benefit of one or more of our programs, increased regulatory scrutiny, decreased confidence by patients and clinical trial collaborators in our investigational medicines, and less demand for any product that we may develop. Our pipeline of DNA medicine candidates could result in a greater quantity of reportable adverse events, including suspected unexpected serious adverse reactions, other reportable negative clinical outcomes, manufacturing reportable events or material clinical events that could lead to clinical delay or hold by the FDA or applicable regulatory authority or other clinical delays, any of which could negatively impact the perception of one or more of our programs, as well as our business as a whole. In addition, responses by U.S., state, or foreign governments to negative public perception may result in new legislation or regulations that could limit our ability to develop any investigational medicines or commercialize any approved products, obtain or maintain regulatory approval, or otherwise achieve profitability. More restrictive statutory regimes, government regulations, or negative public opinion would have an adverse effect on our business, financial condition, results of operations, and prospects and may delay or impair the development of our investigational medicines and commercialization of any approved products or demand for any products we may develop.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, even if our product candidates receive regulatory approval from the FDA and similar regulatory authorities, the novelty of our CELLECTRA delivery devices may make it difficult to demonstrate to physicians and third-party payors that this delivery system is an appropriate approach for DNA medicines and provides advantages compared to the current standards of care. Further, if we or our commercialization and collaboration partners are not successful in conveying to physicians, patients and third-party payors that our CELLECTRA delivery devices provide useful patient outcomes, we or our commercialization and collaboration partners may experience reluctance, or refusal, on the part of physicians to order and use, and third-party payors to cover and provide adequate reimbursement for, our DNA medicines. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we and the contract manufacturers upon whom we rely fail to produce our proprietary devices and DNA medicine candidates in the volumes that we require on a timely basis, or at all, or if these contractors fail to comply with their obligations to us or with stringent regulations, we may face delays in the development and commercialization of our proprietary device and DNA medicine candidates.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We manufacture some components of our proprietary devices and utilize the services of contract manufacturers to manufacture the remaining components of these devices. We also rely on third party contract manufacturers to produce our DNA medicine candidates for use in our clinical trials and potentially for commercial distribution, if any product candidate is approved by regulatory authorities. The manufacture of these devices and our DNA medicine candidates requires significant expertise and capital investment, including the development of advanced manufacturing techniques and process controls that meet the relevant current good manufacturing practice (cGMP) requirements for combination products. Manufacturers often encounter difficulties in production, particularly in scaling up for commercial production. These problems include difficulties with production costs and yields, quality control, including stability of the equipment and DNA medicine candidates and quality assurance testing, shortages of qualified personnel, as well as compliance with strictly enforced federal, state and foreign regulations. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or our manufacturers were to encounter any of these difficulties or our manufacturers otherwise fail to comply with their obligations to us, our ability to provide our proprietary device to our partners and to supply DNA medicine candidates for clinical trials or to commercially launch a product would be jeopardized. For example, as part of the testing process required for BLA submission for INO-3107, we identified a manufacturing issue in the single use administration component of our CELLECTRA 5PSP device, which delayed our ability to commence our confirmatory trial and submit our BLA for INO-3107. While we believe that we have rectified the issue, there can be no assurance that we will not identify additional issues with our device that could further delay our planned regulatory submission or impair our ability to receive regulatory approval. In addition, we will have to update our existing IND with the 5PSP device in conjunction with submitting our confirmatory trial protocol for INO-3107, which will be subject to further FDA review.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we previously relied on VGXI to manufacture DNA plasmids for our DNA medicine candidates before they became unable to produce the necessary plasmids due to a lack of manufacturing capacity. As a result, we had to engage several additional third-party contract manufacturers. However, there can be no assurance that we will be able to secure adequate additional manufacturing capacity for any of our DNA medicine candidates on commercially reasonable terms. Our inability to secure sufficient manufacturing capacity, or our inability to transfer necessary manufacturing know-how to third parties, would adversely affect our commercialization plans and could also harm our reputation.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, any delay or interruption in the supply of clinical trial supplies for our DNA medicine candidates could delay the completion of our clinical trials, increase the costs associated with maintaining our clinical trial program and, depending upon the period of delay, require us to commence new trials at significant additional expense or terminate the trials completely. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, all manufacturers of our products must comply with cGMP requirements enforced by the FDA through its facilities inspection program. These requirements include, among other things, quality control, quality assurance and the generation and maintenance of records and documentation. Manufacturers of our products may be unable to comply with these cGMP requirements and with other FDA, state and foreign regulatory requirements. We have little control over our manufacturers' compliance with these regulations and standards. A failure to comply with these requirements may result in fines and civil penalties, suspension of production, suspension or delay in product approval, product seizure or recall, or withdrawal of product approval. If the safety of any product is compromised due to our or our manufacturers' failure to adhere to applicable laws or for other reasons, we may not be able to pass preapproval inspection of our manufacturing facilities and obtain regulatory approval for or successfully commercialize our products, and we may be held liable for any injuries sustained as a result. Any of these factors could cause a delay of clinical trials, regulatory submissions, approvals or commercialization of our products, entail higher costs or result in our being unable to effectively commercialize our products. Furthermore, if our manufacturers fail to deliver the required commercial quantities on a timely basis, pursuant to provided specifications and at commercially reasonable prices, we may be unable to meet demand for our products and would lose potential revenues.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates are combination products regulated under both the biologic and device regulations of the Public Health Service Act and Federal Food, Drug, and Cosmetic Act. Third-party manufacturers may not be able to comply with cGMP regulations, regulations applicable to biologic/device combination products, including applicable provisions of the FDA&#8217;s drug cGMP regulations, device cGMP requirements embodied in the quality system regulations, and any amendments thereto, or similar regulatory requirements outside the United States. Our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us, including clinical holds, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates, operating restrictions and criminal prosecutions, any of which could significantly affect supplies of our product candidates. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We are dependent on single-source suppliers for some of the components and materials used in, and the processes required to develop, our proprietary device and DNA medicine candidates.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently depend on single-source suppliers for some of the components and materials used in, and manufacturing processes required to develop and commercialize, our proprietary device and DNA medicine candidates. We cannot ensure that these suppliers or service providers will remain in business, have sufficient capacity or supply to meet our needs, or that they will not be purchased by one of our competitors or another company that may not be interested in continuing to work with us. Our use of single-source suppliers of raw materials, components, key processes, and finished goods exposes us to several risks, including disruptions in supply, price increases, or late deliveries. There are, in general, relatively few alternative sources of supply for substitute components. These vendors may be unable or unwilling to meet our future demands for our clinical trials or commercial sale. Establishing additional or replacement suppliers for these components, materials, and processes could take a substantial amount of time and it may be difficult to establish replacement suppliers who meet regulatory requirements. Any disruption in supply from any single-source supplier or service provider could lead to supply delays or interruptions which would damage our business, financial condition, results of operations, and prospects.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we have to switch to a replacement supplier, the manufacture and delivery of our product candidates or investigational medicines could be interrupted for an extended period, which could adversely affect our business. Establishing additional or replacement suppliers for any of the components or processes used in our product candidates or investigational medicines, if required, may not be accomplished quickly. If we are able to find a replacement supplier, the replacement supplier would need to be qualified and may require additional regulatory authority approval, which could result in further delay. While we seek to maintain adequate inventory of the single-source components and materials used in our product candidates, any interruption or delay in the supply of components or materials, or our inability to obtain components or materials from alternate sources at acceptable prices in a timely manner, could impair our ability to supply our investigational medicines.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our reliance on these suppliers, service providers, and manufacturers subjects us to a number of risks that could harm our reputation, business, and financial condition, including, among other things:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">delays to the development timelines for our development candidates or investigational medicines;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">interruption of supply resulting from modifications to or discontinuation of a supplier&#8217;s operations;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">delays in product shipments resulting from uncorrected defects, reliability issues, or a supplier&#8217;s variation in a component;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">a lack of long-term supply arrangements for key components with our suppliers;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">inability to obtain adequate supply in a timely manner, or to obtain adequate supply on commercially reasonable terms;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">difficulty and cost associated with locating and qualifying alternative suppliers for our components in a timely manner;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">production delays related to the evaluation and testing of components from alternative suppliers, and corresponding regulatory qualifications;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">delay in delivery due to our suppliers&#8217; prioritizing other customer orders over ours;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">damage to our reputation caused by defective components produced by our suppliers; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">fluctuation in delivery by our suppliers due to changes in demand from us or their other customers.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If any of these risks materialize, costs could significantly increase and our ability to meet demand for our products could be impacted.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Even if our product candidates receive regulatory approval, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with any of our product candidates.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if FDA regulatory approval is obtained, regulators may still impose significant restrictions on a product's indicated uses or marketing or impose ongoing requirements for potentially costly post-approval studies. This governmental oversight may be particularly strict with respect to gene-based therapies. Our products will also be subject to ongoing FDA requirements governing the labeling, packaging, storage, advertising, promotion, record keeping and submission of safety and other post-market information. For example, the FDA strictly regulates the promotional claims that may be made about medical products. In particular, a product may not be promoted for uses that are not approved by the FDA as reflected in the product&#8217;s approved labeling. Physicians, on the other hand, may prescribe products for off-label uses. Although the FDA and other regulatory authorities do not regulate a physician&#8217;s choice of drug treatment made in the physician&#8217;s independent medical judgment, they do restrict promotional communications from companies or their sales force with respect to off-label uses of products for which marketing clearance has not been issued. However, companies may in certain circumstances share truthful and not misleading information that is otherwise consistent with the product&#8217;s FDA approved labeling. In addition, manufacturers of drug products and devices and their facilities are subject to continual review and periodic inspections by the FDA and other regulatory authorities for compliance with current good manufacturing practices, or cGMP, regulations. If we or a regulatory agency discover previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facility where the product is manufactured, a regulatory agency may impose restrictions on that product, the manufacturer or us, including requiring withdrawal of the product from the market or suspension of manufacturing. If we, our DNA medicine candidates, or the manufacturing facilities for our DNA medicine candidates fail to comply with applicable regulatory requirements, a regulatory agency may: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">issue Warning Letters or untitled letters; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">initiate injunction actions;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">impose civil or criminal penalties; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">suspend regulatory approvals; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">suspend any ongoing clinical trials; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refuse to approve pending applications or supplements to applications filed by us; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">impose restrictions on operations, including costly new manufacturing requirements; or </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seize or detain products or require us to initiate a product recall. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FDA and comparable foreign regulatory authorities&#8217; policies may also change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. For example, the U.S. Supreme Court&#8217;s June 2024 decision in Loper Bright Enterprises v. Raimondo overturned the longstanding Chevron doctrine, under which courts were required to give deference to regulatory agencies&#8217; reasonable interpretations of ambiguous federal statutes. The Loper Bright decision could result in additional legal challenges to regulations and decisions issued by federal agencies, including the FDA, on which we rely. Any such legal challenges, if successful, could have a material impact on our business. Additionally, the Loper Bright decision may result in increased regulatory uncertainty, inconsistent judicial interpretations, and other impacts to the agency rulemaking process, any of which could adversely impact our business and operations. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. Certain policies of any administration may impact our business and industry. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are developing some of our investigational DNA medicines using new endpoints or methodologies for the treatment of diseases in which there is little clinical experience. As a result, the FDA or other regulatory authorities may not consider the endpoints of our clinical trials to provide clinically meaningful results.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no pharmacologic therapies approved to treat the underlying causes of many diseases that we currently attempt to address or may address in the future. There has been limited clinical trial experience for the development of pharmaceuticals </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to treat these rare diseases in general, and we are not aware of a registrational trial that led to approval of a drug to treat these diseases. There have been some historical trials with other agents which may have utilized clinical endpoints that are less applicable to our efforts that address the underlying defect. As a result, the design and conduct of clinical trials of investigational medicines for the treatment of these disorders and other disorders may take longer, be more costly, or be less effective as part of the novelty of development in these diseases. For example, our product candidate INO-3107 is being developed for RRP, a rare condition for which there are no approved non-surgical treatments. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if the FDA does find our success criteria to be sufficiently validated and clinically meaningful, we may not achieve the pre-specified endpoint to a degree of statistical significance in any pivotal or other clinical trials we or our strategic collaborators may conduct for our programs. Further, even if we do achieve the pre-specified criteria, our trials may produce results that are unpredictable or inconsistent with the results of the more traditional efficacy endpoints in the trial. The FDA also could give overriding weight to other efficacy endpoints over a primary endpoint, even if we achieve statistically significant results on that endpoint, if we do not do so on our secondary efficacy endpoints. The FDA also weighs the benefits of a product against its risks and the FDA may view the efficacy results in the context of safety as not being supportive of licensure. Other regulatory authorities in Europe and other countries may make similar findings with respect to these endpoints.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">As part of our business strategy, we may seek Orphan Drug Designation for our DNA medicine candidates, and we may be unsuccessful in obtaining new designations or may be unable to obtain or maintain the benefits associated with Orphan Drug Designation, including the potential for orphan drug exclusivity.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have obtained Orphan Drug Designation from the FDA for INO-3107 for the treatment of RRP. We have sought and may continue to seek Orphan Drug Designation for one or more of our other DNA medicine candidates, although we may be unsuccessful in doing so. Regulatory authorities in some jurisdictions, including the United States and Europe, may designate drugs for relatively small patient populations as orphan drugs. Under the Orphan Drug Act, the FDA may designate a drug as an orphan drug if it is a drug intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals in the United States, or a patient population greater than 200,000 in the United States where there is no reasonable expectation that the cost of developing the drug will be recovered from sales in the United States. In the United States, Orphan Drug Designation entitles a party to financial incentives such as tax advantages and user fee waivers. Opportunities for grant funding toward clinical trial costs may also be available for clinical trials of drugs for rare diseases, regardless of whether the drugs are designated for the orphan use. In addition, if a product that has Orphan Drug Designation subsequently receives the first FDA approval for the disease for which it has such designation, the product is entitled to orphan drug exclusivity, which means that the FDA may not approve any other applications to market the same product for the same indication for seven years, except in limited circumstances. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we have obtained Orphan Drug Designation for INO-3107 for the treatment of RRP, and even if we obtain Orphan Drug Designation for our other DNA medicine candidates in specific indications, we may not be the first to obtain marketing approval of these DNA medicine candidates for the orphan-designated indication due to the uncertainties associated with developing pharmaceutical products. If a competitor with a product that is determined by the FDA to be the same as one of our DNA medicine candidates obtains marketing approval before us for the same indication we are pursuing and obtains orphan drug exclusivity, our product candidate may not be approved until the period of exclusivity ends unless we are able to demonstrate that our product candidate is clinically superior. Even after obtaining approval, we may be limited in our ability to market our product. In addition, exclusive marketing rights in the United States may be limited if we seek approval for an indication broader than the orphan-designated indication or may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition. Further, even if we obtain orphan drug exclusivity for a product, that exclusivity may not effectively protect the product from competition because different drugs with different principal molecular structural features can be approved for the same condition. Even after an orphan product is approved, the FDA can subsequently approve the same drug with the same principal molecular structural features for the same condition if the FDA concludes that the later drug is safer, more effective or makes a major contribution to patient care. Orphan Drug Designation neither shortens the development time or regulatory review time of a drug nor gives the drug any advantage in the regulatory review or approval process. In addition, while we may seek Orphan Drug Designation for some of our DNA medicine candidates, we may never receive such designations. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">A breakthrough therapy designation or fast track designation by the FDA for a drug may not lead to a faster development or regulatory review or approval process, and it would not increase the likelihood that the drug will receive marketing approval.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have received breakthrough therapy designation for INO-3107 and may seek this designation for one or more of our other investigational medicines. A breakthrough therapy is defined as a drug that is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For drugs that have been designated as breakthrough therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. Drugs designated </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">as breakthrough therapies by the FDA are also eligible for priority review if supported by clinical data at the time of the regulatory submission.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Designation as a breakthrough therapy is at the discretion of the FDA. Accordingly, even if we believe that one of our investigational medicines meets the criteria for designation as a breakthrough therapy, the FDA may disagree and instead determine not to make such designation. In any event, the receipt of a breakthrough therapy designation for a drug may not result in a faster development process, review, or approval compared to drugs considered for approval under conventional FDA procedures and it would not assure ultimate approval by the FDA. Even if we are successful in obtaining accelerated approval in the United States or under comparable pathways in other jurisdictions, we may face requirements and limitations that will adversely affect our prospects. For example, we may be approved only for a very limited indication, we may not successfully complete required post-approval trials, such trials may not confirm the clinical benefit of our drug, or approval of the drug may be withdrawn. In addition, even if one or more of our investigational medicines qualify as breakthrough therapies, the FDA may later decide that the investigational medicine no longer meets the conditions for qualification or it may decide that the time period for FDA review or approval will not be shortened.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Reliance on Third Parties</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we lose or are unable to secure collaborators or partners, or if our collaborators or partners do not apply adequate resources to their relationships with us, our product development and potential for profitability will suffer. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into, and may continue to enter into, distribution, co-promotion, partnership, sponsored research and other arrangements for development, manufacturing, sales, marketing and other commercialization activities relating to our products. For example, in the past we have entered into license and collaboration agreements to develop, obtain regulatory approval for and commercialize our DNA medicine candidates for specified indications, including in jurisdictions outside of the United States. The amount and timing of resources applied by our collaborators are largely outside of our control. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of our current or future collaborators breaches or terminates our agreements, or fails to conduct our collaborative activities in a timely manner, our commercialization of products could be diminished or blocked completely. We may not receive any event-based payments, milestone payments or royalty payments under our collaborative agreements if our collaborative partners fail to develop products in a timely manner or at all. It is possible that collaborators will change their strategic focus, pursue alternative technologies or develop alternative products, either on their own or in collaboration with others. Further, we may be forced to fund programs that were previously funded by our collaborators, and we may not have, or be able to access, the necessary funding. The effectiveness of our partners, if any, in marketing our products will also affect our revenues and earnings.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We desire to enter into new collaborative agreements. However, we may not be able to successfully negotiate any additional collaborative arrangements and, if established, these relationships may not be scientifically or commercially successful. Our success in the future depends in part on our ability to strategically enter into agreements with other organizations. This can be difficult due to internal and external constraints placed on these organizations. Some organizations may have insufficient administrative and related infrastructure to enable collaborations with many companies at once, which can extend the time it takes to develop, negotiate, implement and execute a collaboration. Once news of discussions regarding possible collaborations are known in the medical community, regardless of whether the news is accurate, failure to announce a collaborative agreement or the entity's announcement of a collaboration with another entity may result in adverse speculation about us, resulting in harm to our reputation and our business. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disputes could also arise between us and our existing or future collaborators, as to a variety of matters, including financial and intellectual property matters or other obligations under our agreements. These disputes could be both expensive and time-consuming and may result in delays in the development and commercialization of our products or could damage our relationship with a collaborator. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have agreements with government agencies that are subject to termination and uncertain future funding. Termination or cessation of funding could have a negative impact on our ability to develop some of the product candidates in our pipeline and/or require us to seek alternative funding sources to advance those candidates. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into agreements with government agencies, such as the National Institutes of Health&#8217;s National Institute of Allergy and Infectious Diseases (NIH NIAID), Defense Advanced Research Projects Agency (DARPA), Medical CBRN Defense Consortium (MCDC) and the Department of Defense (DoD) Joint Program Executive Office (JPEO) for Chemical, Biological, Radiological and Nuclear Defense (CBRN), and we intend to continue entering into these types of agreements with government agencies in the future. Our business is partially dependent on the continued performance by these government agencies of their responsibilities under these agreements, including adequate continued funding of the agencies and their programs. We have no control over the resources and funding that government agencies may devote to these agreements, which may be subject to annual renewal and which generally may be terminated by the government agencies at any time. For example, in 2021 the DoD discontinued funding for the planned Phase 3 trial of our COVID-19 product candidate, which resulted in increased expenditures by us.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government agencies may fail to perform their responsibilities under these agreements, which may cause them to be terminated by the government agencies. In addition, we may fail to perform our responsibilities under these agreements. Many of our government agreements are subject to audits, which may occur several years after the period to which the audit relates. If an audit identifies significant unallowable costs, we could incur a material charge to our earnings or reduction in our cash position. As a result, we may be unsuccessful entering, or ineligible to enter, into future government agreements. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We and our collaborators rely on third parties to conduct our clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we and our collaborators may not be able to obtain regulatory approval for or commercialize our DNA medicine candidates.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our collaborators have entered into agreements with CROs to provide monitors for and to manage data for our on-going clinical programs. We and the CROs conducting clinical trials for our proprietary device and DNA medicine candidates are required to comply with current good clinical practices, or GCPs, regulations and guidelines enforced by the FDA for all of our products in clinical development. The FDA enforces GCPs through periodic inspections of trial sponsors, principal investigators and trial sites. If we or the CROs conducting clinical trials of our DNA medicine candidates fail to comply with applicable GCPs, the clinical data generated in the clinical trials may be deemed unreliable and the FDA may require additional clinical trials before approving any marketing applications. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any relationships with CROs terminate, we or our collaborators may not be able to enter into arrangements with alternative CROs. In addition, these third-party CROs are not our employees, and we cannot control whether or not they devote sufficient time and resources to our on-going clinical programs or perform trials efficiently. These CROs may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical studies or other drug development activities, which could harm our competitive position. If CROs do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced, or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols, regulatory requirements, or for other reasons, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain regulatory approval for or successfully commercialize our DNA medicine candidates. As a result, our financial results and the commercial prospects for our DNA medicine candidates would be harmed, our costs could increase and our ability to generate revenues could be delayed. Cost overruns by or disputes with our CROs may significantly increase our expenses.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We enter into various contracts in the normal course of our business in which we</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">agree to indemnify the other party to the contract. In the event we have to perform under these indemnification provisions, it could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, we periodically enter into academic, commercial, service, collaboration, licensing, consulting and other agreements that contain indemnification provisions. With respect to our academic and other research agreements, we typically agree to indemnify the institution and related parties from losses arising from claims relating to the products, processes or services made, used, sold or performed pursuant to the agreements for which we have secured licenses, and from claims arising from our or our sub licensees&#8217; exercise of rights under the agreement. With respect to our commercial agreements, we have agreed to indemnify our vendors from any third-party product liability claims that could result from the production, use or consumption of the product, as well as for alleged infringements of any patent or other intellectual property right by a third party. With respect to consultants, we typically agree to indemnify them from claims arising from the good faith performance of their services.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Should our obligation under an indemnification provision exceed applicable insurance coverage or if we were denied insurance coverage or not covered by insurance, our business, financial condition and results of operations could be adversely affected. Similarly, if we are relying on a collaborator or other third party to indemnify us and the collaborator or other third party is denied insurance coverage or otherwise does not have assets available to indemnify us, our business, financial condition and results of operations could be adversely affected.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Commercialization of Our DNA Medicine Candidates</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We currently have only a small marketing organization and no sales organization. If we are unable to establish marketing and sales capabilities or enter into agreements with third parties to market and sell our products, if approved, we may not be able to generate product revenues.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have only a small commercial organization to support pre-commercial activities for our proprietary device and DNA medicine candidates, if approved, and we do not currently have a sales organization. In order to successfully commercialize INO-3107 or any other products that may receive regulatory approval, we must build our marketing, sales, distribution, managerial and other non-technical capabilities or make arrangements with third parties to perform these services. We contemplate establishing our own sales force or seeking third-party partners to sell our products. The establishment and development of a sales force, either on our own or in conjunction with third parties, will be expensive and time-consuming and could delay any product launch, and we may not be able to successfully develop or acquire this capability. We will also have to compete with other pharmaceutical and biotechnology companies to recruit, hire, train and retain marketing and sales personnel. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent we rely on third parties to commercialize our approved products, if any, we will receive lower revenues than if we commercialized these products ourselves. In the event we are unable to successfully develop our own marketing and sales force or collaborate with a third-party marketing and sales organization, we would not be able to commercialize our DNA medicine candidates which would negatively impact our ability to generate product revenues. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If products for which we receive regulatory approval do not achieve broad market acceptance, the revenues that we generate from their sales will be limited.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The commercial success of our proprietary device and DNA medicine candidates for which we obtain marketing approval from the FDA or other regulatory authorities will depend upon the acceptance of these products by both the medical community and patient population. Coverage and reimbursement of our DNA medicine candidates by third-party payors, including government payors, generally is also necessary for optimal commercial success. The degree of market acceptance of any of our approved products will depend on a number of factors, including: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to provide acceptable evidence of safety and efficacy; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the relative convenience and ease of administration, including the acceptance and usage of our proprietary device by the medical community; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the prevalence and severity of any actual or perceived adverse side effects; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limitations or warnings contained in a product's FDA-approved labeling, including, for example, potential &#8220;black box&#8221; warnings; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">availability of alternative treatments; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">pricing and cost effectiveness; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effectiveness of our or any future collaborators' sales and marketing strategies; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the potential public perception of new therapies and the reputational challenges that the industry is facing related to drug costs;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain sufficient third-party coverage and adequate reimbursement; and </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the willingness of patients to pay out of pocket in the absence of third-party coverage. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our proprietary device and DNA medicine candidates are approved but do not achieve an adequate level of acceptance by physicians, healthcare payors and patients, we may not generate sufficient revenue from these products, and we may not become or remain profitable. In addition, our efforts to educate the medical community and third-party payors on the benefits of our DNA medicine candidates may require significant resources and may never be successful. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to uncertainty relating to coverage and reimbursement policies which, if not favorable to our DNA medicine candidates, could hinder or prevent our products' commercial success. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patients in the United States and elsewhere generally rely on third-party payors to reimburse part or all of the costs associated with their prescription drugs and medical treatments. Accordingly, our ability to commercialize our proprietary device and DNA medicine candidates successfully will depend in part on the extent to which governmental authorities, including Medicare and Medicaid, private health insurers and other third-party payors establish appropriate coverage and reimbursement levels for our DNA medicine candidates and related treatments. As a threshold for coverage and reimbursement, third-party payors in the United States generally require that drug products and vaccines have been approved for marketing by the FDA. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant uncertainty exists as to the coverage and reimbursement status of any products for which we may obtain regulatory approval. Coverage decisions may not favor new products when more established or lower cost therapeutic alternatives are already available. Even if we obtain coverage for a given product, co-payments may be required that patients find unacceptably high. Patients are unlikely to use our products unless reimbursement is adequate to cover all or a significant portion of the cost of our drug products. Even if we obtain coverage for our products, the revenue generated may not be adequate to cover our costs, including research, development, intellectual property, manufacture, sale and distribution.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, some of our products, if approved, will be provided under the supervision of a physician. When used in connection with medical procedures, our DNA medicine candidates may not be reimbursed separately but their cost may instead be bundled as part of the payment received by the provider for the procedure only. Separate reimbursement for the product itself or the treatment or procedure in which our product is used may not be available. A decision by a third-party payor not to cover or separately reimburse for our DNA medicine candidates or procedures using our DNA medicine candidates, could reduce physician utilization of our products once approved.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Coverage and reimbursement policies for products can differ significantly from payor to payor as there is no uniform policy of coverage and reimbursement for products among third-party payors in the United States. There may be significant delays in obtaining coverage and reimbursement as the process of determining coverage and reimbursement is often time-consuming and costly which will require us to provide scientific and clinical support for the use of our products to each payor </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">separately, with no assurance that coverage or adequate reimbursement will be obtained. It is difficult to predict at this time what government authorities and third-party payors will decide with respect to coverage and reimbursement for our products.</span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">A significant trend in the U.S. healthcare industry and elsewhere is cost containment. Third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular products and services. Third-party payors are increasingly challenging the effectiveness of and prices charged for medical products and services. Moreover, the U.S. government, state legislatures and foreign governmental entities have shown significant interest in implementing cost containment programs to limit the growth of government-paid healthcare costs, including price controls, restrictions on reimbursement and coverage and requirements for substitution of generic products for branded prescription drugs. We may not be able to obtain third-party payor coverage or reimbursement for our products in whole or in part. Further, coverage policies and third-party payor reimbursement rates may change at any time. Therefore, even if favorable coverage and reimbursement status is attained for one or more products, less favorable coverage policies and reimbursement rates may be implemented in the future.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Employee and Operational Matters</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are currently subject to litigation and may become subject to additional litigation, which could harm our business, financial condition and reputation.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may have actions brought against us by stockholders relating to past transactions, changes in our stock price or other matters. For example, numerous purported shareholder class action and shareholder derivative complaints were filed against us beginning in 2020, naming us and our directors and executive officers as defendants, alleging that we made materially false and misleading statements in violation of federal securities laws. Although we have resolved these actions, there can be no guarantee that we will not become subject to similar claims in the future. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also become party to litigation with third parties as a result of our business activities. In 2020, we filed a lawsuit against one of our contract manufacturers, who then filed a counterclaim against us alleging that we had breached our contract with them, among other claims. There can be no assurance that we will ultimately prevail in the ongoing litigation matters described in this report or in future litigation matters. These and any potential future actions against us could give rise to substantial damages, which could have a material adverse effect on our financial position, liquidity or results of operations. Even if an action is not resolved against us, the uncertainty and expense associated with litigation could harm our business, financial condition and reputation, as litigation is often costly, time-consuming and disruptive to business operations. The defense of our existing and potential future lawsuits could also result in diversion of our management's time and attention away from business operations, which could harm our business.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We depend upon key personnel who may terminate their employment with us at any time and we may need to hire additional qualified personnel in order to obtain financing, pursue collaborations or develop or market our DNA medicine candidates. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The success of our business strategy will depend to a significant degree upon the continued services of key management, technical and scientific personnel and our ability to attract and retain additional qualified personnel and managers, including personnel with expertise in clinical trials, government regulation, manufacturing, marketing and other areas. Competition for qualified personnel is intense among companies, academic institutions and other organizations. If we are unable to attract and retain key personnel and advisors, it may negatively affect our ability to successfully develop, test, commercialize and market our products and DNA medicine candidates. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business could be adversely affected by the effects of health epidemics.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In response to the COVID-19 pandemic, in 2020 a number of governmental orders and other public health guidance measures were implemented across much of the United States, including in the locations of our offices, laboratories, clinical trial sites and third parties on whom we rely. As a result, our expected clinical development timelines were negatively impacted. Similar events could result in future business and manufacturing disruption, or in reduced operations, any of which would materially affect our business, financial condition and results of operations. The COVID-19 pandemic also caused supply chain disruptions and supply shortages globally. As a result, we experienced delays and disruptions in obtaining clinical supplies, manufacturing supplies and components, and had to secure new vendors for certain supplies and components at higher prices. There can be no assurance that we will not encounter similar difficulties in the future.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future health epidemics could adversely affect our clinical trial operations, including our ability to initiate and conduct our planned trials on their expected timelines and to recruit and retain participants and principal investigators and site staff who, as healthcare providers, may have heightened exposure if an outbreak occurs in their geography. Trial participants may not be able to or may not feel safe going into healthcare facilities, which is necessary for the collection and completion of data samples for our clinical trials. Further, future epidemics could also result in delays in our clinical trials due to prioritization of hospital resources toward the disease, restrictions in travel, potential unwillingness of participants to enroll in trials, participants withdrawing from trials following enrollment as a result of contracting disease or other health conditions. In addition, we rely on independent clinical investigators, contract research organizations and other third-party service providers to assist us in managing, monitoring and otherwise carrying out our preclinical studies and clinical trials, and the outbreak may affect their ability to devote sufficient time and resources to our programs or to travel to sites to perform work for us. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face intense and increasing competition and steps taken by our competitors such as the introduction of a new, disruptive technology may impede our ability to develop and commercialize our DNA medicines. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of our competitors develop products with efficacy or safety profiles significantly better than our product candidates and introduce new, disruptive technology, we may not be able to complete the development of or commercialize our product candidates, and sales of any commercialized products could be harmed. Some of our competitors and potential competitors have substantially greater product development capabilities and financial, scientific, marketing and human resources than we do. Competitors may develop products earlier, obtain FDA approvals for products more rapidly, or develop products that are more effective than those under development by us. We will seek to expand our technological capabilities to remain competitive; however, research and development by others may render our technologies or product candidates obsolete or non-competitive, or result in treatments or cures superior to ours.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our competitors and potential competitors include large pharmaceutical companies broadly engaged in vaccine/immunotherapy research and development, such as Janssen Pharmaceuticals (part of J&amp;J), Sanofi-Aventis, GlaxoSmithKline, Merck, Pfizer, Roche, AbbVie, Novartis, Bristol-Myers Squibb, and AstraZeneca, as well as various development-stage biotechnology companies involved in different vaccine and immunotherapy technologies, such as CureVac, Dynavax, Genexine, Hookipa, Iovance, Nektar, Nykode, Precigen, Zydus, and Vir Biotechnology. These companies have significantly greater financial and other resources and greater expertise than us in research and development, securing government contracts and grants to support research and development efforts, manufacturing, preclinical and clinical testing, obtaining regulatory approvals and marketing. This may make it easier for them to respond more quickly than us to new or changing opportunities, technologies or market needs. Many of these competitors operate large, well-funded research and development programs and have significant products approved or in development. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck and GlaxoSmithKline have commercialized preventive vaccines against HPV to protect against cervical cancer. Some companies are seeking to treat early HPV infections or low-grade cervical dysplasia. Loop Electrosurgical Excision Procedure, commonly known as LEEP, is a surgical procedure and is the current standard of care in the United States and other high income countries for treating high-grade cervical dysplasia. In RRP caused by HPV subtypes 6 and 11, Precigen is developing a potential treatment for RRP based on a gorilla adenovirus vector and announced in late 2024 that it has submitted a BLA based on a completed Phase 1/2 study. As a result, Precigen could receive marketing approval for its RRP product candidate before we can obtain regulatory approval for INO-3107, which could put us at a competitive disadvantage in this indication. Advaxis, Genexine, and Gilead Sciences have therapeutic cervical cancer product candidates under development. Many companies are pursuing different approaches to pre-cancers and cancers we are targeting.  </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also compete more specifically with companies seeking to utilize antigen-encoding DNA delivered with electroporation or other delivery technologies such as viral vectors or lipid vectors to induce in vivo generated antigen production and immune responses to prevent or treat various diseases. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Small biotechnology companies may also prove to be significant competitors, particularly through collaborative arrangements with large pharmaceutical companies or through acquisition or development of intellectual property rights. Our potential competitors also include academic institutions, governmental agencies and other public and private research organizations that conduct research, seek patent protection and establish collaborative arrangements for product and clinical development and marketing. Research and development by others may seek to render our technologies or products obsolete or noncompetitive. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our failure to successfully acquire, develop and market additional product candidates or approved products would impair our ability to grow.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may acquire, in-license, develop and/or market additional products and product candidates. The success of these actions depends partly upon our ability to identify, select and acquire promising product candidates and products. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process of proposing, negotiating and implementing a license or acquisition of a product candidate or approved product is lengthy and complex. Other companies, including some with substantially greater financial, marketing and sales resources, may compete with us for the license or acquisition of product candidates and approved products. We have limited resources to identify and execute the acquisition or in-licensing of third-party products, businesses and technologies and integrate them into our current infrastructure. Moreover, we may devote resources to potential acquisitions or in-licensing opportunities that are never completed, or we may fail to realize the anticipated benefits of such efforts. We may not be able to acquire the rights to additional product candidates on terms that we find acceptable, or at all. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, future acquisitions may entail numerous operational and financial risks, including: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">exposure to unknown liabilities; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disruption of our business and diversion of our management's time and attention to develop acquired products or technologies; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">incurrence of substantial debt or dilutive issuances of securities to pay for acquisitions; </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">higher than expected acquisition and integration costs; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increased amortization expenses; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulty and cost in combining the operations and personnel of any acquired businesses with our operations and personnel; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">impairment of relationships with key suppliers or customers of any acquired businesses due to changes in management and ownership; and </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inability to retain key employees of any acquired businesses. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, any product candidate that we acquire may require additional development efforts prior to commercial sale, including extensive clinical testing and approval by the FDA and applicable foreign regulatory authorities. All product candidates are prone to risks of failure typical of product development, including the possibility that a product candidate will not be shown to be sufficiently safe and effective for approval by regulatory authorities. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in funding for the FDA and other government agencies could prevent new products from being developed or commercialized in a timely manner, which could negatively impact our business.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, in recent years, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities. In 2025, widespread reductions in force among federal agencies have occurred and may adversely impact the ability of FDA to timely review applications, including our planned BLA. If a prolonged government shutdown occurs or personnel or funding levels are reduced, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our information technology systems, or those of third parties with whom we work, or our data, are or were to be compromised, we could experience material adverse consequences resulting from such compromise.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely to a large extent upon sophisticated information technology systems to operate our businesses, some of which are managed, hosted provided and/or used for third-parties or their vendors. We collect, store and transmit large amounts of confidential, proprietary or otherwise sensitive information (including personal information and pseudonymized information), and we deploy and operate an array of technical and procedural controls designed to maintain the confidentiality, availability and integrity of such information as appropriate. A significant breakdown, invasion, corruption, destruction, interruption, or unavailability of critical information technology systems or infrastructure, by our workforce, others with authorized access to our systems or unauthorized persons could negatively impact operations. Hardware, software, or applications we develop or obtain from third parties may contain defects in design or manufacture or other supply chain problems that could unexpectedly compromise our information and network security. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ever-increasing use and evolution of technology, including cloud-based computing, creates opportunities for the compromise of information stored in our or our third-party providers' systems, portable media or storage devices. Cyber-attacks, malicious internet-based activity, online and offline fraud and other similar activities threaten our information and information technology systems and those of third parties with whom we work. Such threats are prevalent and continue to rise, are increasingly difficult to detect and come from a variety of sources such as traditional computer &#8220;hackers,&#8221; threat actors, &#8220;hacktivists,&#8221; organized criminal threat actors, personnel (such as through error or malfeasance), sophisticated national states and nation-state support actors (for example, in conjunction with military conflicts). During times of war and other major conflicts, we and the third parties with whom we work may be vulnerable to a heightened risk of these attacks. We and they are subject to a variety of evolving threats, including but not limited to business interruption, loss of information, theft of information or reputational damage from industrial espionage attacks, malware or other cyber-attacks (including ransomware), social-engineering attacks (including through deep fakes and phishing attacks), malicious code (such as viruses and worms), denial-of-service attacks, credential stuffing attacks, credential harvesting, personnel misconduct or error, supply-chain attacks, software bugs, server malfunctions, software or hardware failures, telecommunications failures, natural disasters, attacks enhanced or facilitated by artificial intelligence, or AI, and other similar threats, any of which may compromise our system infrastructure or lead to data compromise. In particular, severe ransomware attacks are becoming increasingly prevalent and can lead to significant interruptions in our operations, loss of data, reputational harm, diversion of funds and the potential loss of income. Extortion payments may alleviate some of the negative impact of a ransomware attack but we may be unwilling or unable to make such payments. Remote work has also become more common and increased risks to our information technology systems and data. Future or past business transactions (such as acquisitions or integrations) could expose us to additional </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cybersecurity risks and vulnerabilities as our systems could be negatively affected by vulnerabilities resent in acquired or integrated entities&#8217; systems and technologies. Furthermore, we may discover security issues that were not found during diligence of such acquired or integrated entities and it may be difficult to integrate such entities into our information technology environment and security programs. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on third parties to operate critical business systems to process sensitive information in a variety of contexts, including without limitation, cloud-based infrastructure, personnel email, data hosting, and other functions. Our ability to monitor these third parties&#8217; information security practices is limited and they may not have adequate information security measures in place. If they were to experience a security incident or other interruption, we could also experience adverse consequences. While we may be entitled to damages if those third parties fail to satisfy their privacy or security-related obligations to us, any aware may be insufficient or we may be unable to recover such award.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we have implemented measures designed to protect our data and information technology systems, there can be no assurance that our efforts will be effective (including, without limitation prevent service interruptions or security incidents). We take steps designed to detect, mitigate and remediate vulnerabilities in our information systems, such as our hardware and software, including that of the third parties with whom we work. We may not, however, detect and remediate all such vulnerabilities on a timely or effective basis. Vulnerabilities could be exploited and result in a security incident. Any such interruption or breach of our systems could adversely affect our business operations and/or result in the loss of critical or sensitive confidential information or intellectual property, and could result in financial, legal, business and reputational harm to us. In addition, as the regulatory environment related to information security, data collection and use, and privacy becomes increasingly rigorous, with new and constantly changing requirements applicable to our business, compliance with those requirements could also result in additional costs. We may expend significant resources or modify our business activities (including our clinical trial activities) to try to protect against security incidents. Certain data privacy and security obligations may require us to implement and maintain specific or reasonable security measures.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to experiencing a security incident, third parties may gather, collect, or infer sensitive information about us from public sources, data brokers, or other means that reveals competitively sensitive details about our organization and could be used to undermine our competitive advantage or market position. Additionally, sensitive information of ours could be leaked, disclosed, or revealed as a result of or in connection with our personnel&#8217;s or vendors&#8217; use of AI technologies, including generative AI, and machine learning, or ML, technologies, referred to collectively as AI/ML technologies. Any sensitive information (including confidential, competitive, proprietary, or personal data) that we input into a third-party generative AI/ML platform could be leaked or disclosed to others, including if sensitive information is used to train the third parties&#8217; AI/ML model. Additionally, where an AI/ML model ingests personal data and makes connections using such data, those technologies may reveal other personal or sensitive information generated by the model.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Applicable data privacy and security obligations may require us to, or we may voluntarily elect to, notify relevant stakeholders, including affected individuals, regulators and other stakeholders, of security incidents or to take other actions, such as providing credit monitoring and identity theft protection services. Such disclosures are costly, and the disclosure or the failure to comply with such requirements could lead to adverse consequences. If we, or a third party with whom we work, were to experience a security incident or are perceived to have experienced a security incident, we may experience material adverse consequences, which could include government enforcement actions such as investigations, fines, penalties, audits, and inspections; additional reporting requirements and/or oversight; restrictions on processing sensitive information, including personal data; litigation, including class claims; indemnification obligations; negative publicity; reputational harm; monetary fund diversions; diversion of management attention; interruptions in our operations, including availability of data; financial losses; and other similar harms. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contracts may not contain limitations of liability, and even where they do, there can be no assurance that limitations of liability in our contracts are sufficient to protect us from liabilities, damages, or claims related to our data privacy and security obligations. We cannot be sure that our insurance coverage will be adequate or sufficient to protect us from or to mitigate liabilities arising out of our privacy and security practices, that such coverage will continue to be available on commercially reasonable terms or at all, or that such coverage will pay future claims.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face potential product liability exposure and, if successful claims are brought against us, we may incur substantial liability.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The use of our proprietary device and DNA medicine candidates in clinical trials and the sale of any products for which we obtain marketing approval expose us to the risk of product liability claims. Product liability claims might be brought against us by consumers, healthcare providers, pharmaceutical companies or others selling or otherwise coming into contact with our products. If we cannot successfully defend ourselves against product liability claims, we could incur substantial liabilities. In addition, regardless of merit or eventual outcome, product liability claims may result in: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">decreased demand for our DNA medicine candidates; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">impairment of our business reputation; </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">withdrawal of clinical trial participants; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs of related litigation; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">distraction of management's attention from our primary business; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">substantial monetary awards to patients or other claimants; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">loss of revenues; and </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inability to commercialize our products. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have obtained product liability insurance coverage for our clinical trials, but our insurance coverage may not be sufficient to reimburse us for any expenses or losses we may suffer. Moreover, insurance coverage is becoming increasingly expensive, and, in the future, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability. On occasion, large judgments have been awarded in class action lawsuits based on products that had unanticipated side effects. A successful product liability claim or series of claims brought against us could cause our stock price to decline and, if judgments exceed our insurance coverage, could adversely affect our business. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Healthcare reform measures could hinder or prevent our products' commercial success. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In both the United States and certain foreign jurisdictions there have been, and we anticipate there will continue to be, a number of legislative and regulatory changes to the healthcare system that could impact our ability to sell any of our products profitably. In the United States, the federal government enacted healthcare reform legislation, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively, the ACA. The ACA, among other things, increased the minimum level of Medicaid rebates payable by manufacturers of brand name drugs; required collection of rebates for drugs paid by Medicaid managed care organizations; required manufacturers to participate in a coverage gap discount program, under which they must agree to offer point-of-sale discounts (increased to 70 percent, effective as of January 1, 2019) off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs to be covered under Medicare Part D; imposed a non-deductible annual fee on pharmaceutical manufacturers or importers who sell certain &#8220;branded prescription drugs&#8221; to specified federal government programs, implemented a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted, or injected expanded the types of entities eligible for the 340B drug discount program; expanded eligibility criteria for Medicaid programs; created a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research; and established a Center for Medicare Innovation at the U.S. Centers for Medicare &amp; Medicaid Services, or CMS, to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been amendments to and executive, judicial, and Congressional challenges to certain aspects of the ACA. For example, on August 16, 2022, the Inflation Reduction Act of 2022, or IRA, was signed into law, which among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan year 2025. The IRA also eliminates the &#8220;donut hole&#8221; under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost and creating a new manufacturer discount program. It is unclear how such challenges, and the healthcare reform measures of the Biden administration will impact the ACA and our business. Additionally, on March 11, 2021, the American Rescue Plan Act of 2021 was signed into law, which eliminates the statutory Medicaid drug rebate cap, currently set at 100% of a drug&#8217;s average manufacturer price, for single source and innovator multiple source drugs, effective January 1, 2024. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, other legislative changes have been proposed and adopted since the ACA was enacted. The Budget Control Act of 2011 included reductions to Medicare payments to providers of 2% per fiscal year, which, due to subsequent legislative amendments to the statute will remain in effect until 2032, unless Congressional action is taken. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There has also been heightened governmental scrutiny in the United States of pharmaceutical pricing practices in light of the rising cost of prescription drugs and biologics. Such scrutiny has resulted in several recent Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for products. For example, at the federal level, the IRA, among other things (i) directs the U.S. Department of Health and Human Services, or HHS, to negotiate the price of certain high-expenditure, single-source biologics that have been on the market for at least 11 years covered under Medicare, known as the Medicare Drug Price Negotiation Program, and (ii) imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation. These provisions began to take effect progressively starting in fiscal year 2023. On August 15, 2024, HHS announced the agreed-upon prices of the first ten drugs that were subject to price negotiations, although the Medicare Drug Price Negotiation Program is currently subject to legal challenges. On January 17, 2025, HHS selected fifteen additional products covered under Part D for price negotiation in 2025. Each year thereafter more Part B and Part D products will become subject to the Medicare Drug Price Negotiation Program. Further, on December 7, 2023, an initiative to control the price of prescription drugs through the use of </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">march-in rights under the Bayh-Dole Act was announced. On December 8, 2023, the National Institute of Standards and Technology published for comment a Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights which for the first time includes the price of a product as one factor an agency can use when deciding to exercise march-in rights. While march-in rights have not previously been exercised, it is uncertain if that will continue under the new framework. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The current Trump administration is pursuing policies to reduce regulations and expenditures across the U.S. government, including at HHS, the FDA, CMS and related agencies. These actions, presently directed by executive orders or memoranda from the Office of Management and Budget, may propose policy changes that create additional uncertainty for our business. These actions, for example, include directives to reduce agency workforce, program cuts, rescinding a Biden administration executive order tasking the Center for Medicare and Medicaid Innovation, or CMMI, to consider new payment and healthcare models to limit drug spending, eliminating the Biden administration&#8217;s executive order that directed HHS to establish an AI task force, developing a strategic plan directing HHS and other agencies to lower prescription drug costs for Medicare through a variety of initiatives, including by improving upon the Medicare Drug Price Negotiation Program, and directing certain federal agencies to enforce existing law regarding hospital and price plan transparency and by standardizing prices across hospitals and health plans. Additionally, the U.S. Supreme Court&#8217;s recent Loper Bright decision described above could result in additional legal challenges to current regulations and guidance issued by federal agencies applicable to our operations, including those issued by the FDA. Congress may introduce and ultimately pass healthcare-related legislation that could impact the drug approval process and make changes to the Medicare Drug Price Negotiation Program.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to make and implement healthcare reforms may adversely affect: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to set a price we believe is fair for our products; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to generate revenues and achieve or maintain profitability; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the availability of capital; and </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain timely approval of our products. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with applicable healthcare regulations, we could face substantial penalties and our business, operations and financial condition could be adversely affected. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain federal, state, local and foreign healthcare laws and regulations pertaining to fraud and abuse, transparency, patients' rights, and privacy are applicable to our business. The laws that may affect our ability to operate include:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal healthcare program Anti-Kickback Statute, which prohibits, among other things, people from soliciting, receiving or providing remuneration, directly or indirectly, to induce or reward either the referral of an individual, or ordering, or leasing of an item, good, facility or service, for which payment may be made by a federal healthcare program such as Medicare or Medicaid. The intent standard under the federal healthcare program Anti-Kickback Statute was amended by the ACA to a stricter standard such that a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. Further, the ACA codified case law that a claim including items or services resulting from a violation of the federal healthcare program Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">federal civil and criminal false claims laws, including the civil False Claims Act, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other third-party payors that are false or fraudulent; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the Health Insurance Portability and Accountability Act (HIPAA), which prohibits, among other things, executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters. Similar to the federal healthcare program Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, and related regulations, which impose certain requirements relating to the privacy, security and transmission of individually identifiable health information on certain individuals and entities; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the Physician Payments Sunshine Act, created under the ACA, which requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program, with certain exceptions, to report annually to CMS, information related to payments or other transfers of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists, and chiropractors), other healthcare professionals (such as physicians assistants and nurse practitioners) and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the Federal Food, Drug and Cosmetic Act (FDCA), which among other things, strictly regulates drug product marketing, prohibits manufacturers from marketing drug products for off-label use and regulates the distribution of drug samples; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the U.S. Foreign Corrupt Practices Act, which, among other things, prohibits companies issuing stock in the U.S. from bribing foreign officials for government contracts and other business; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">state law equivalents of each of the above federal laws, such as anti-kickback and false claims laws which may apply to items or services reimbursed by any third-party payor, including commercial insurers, state and local laws requiring the registration of pharmaceutical sales and medical representatives, and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">additional state and local laws such as laws in California and Massachusetts, which mandate implementation of compliance programs, compliance with industry ethics codes, and spending limits, and other state and local laws, such as laws in Vermont, Maine, and Minnesota which require reporting to state governments of gifts, compensation, and other remuneration to physicians. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The shifting regulatory environment, along with the requirement to comply with multiple jurisdictions with different compliance and/or reporting requirements, increases the possibility that a company may run afoul of one or more laws.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will be required to spend substantial time and money to ensure that our business arrangements with third parties comply with applicable healthcare laws and regulations. Because of the breadth of these laws and the narrowness of the statutory exceptions and regulatory safe harbors available, which require strict compliance in order to offer protection, it is possible that governmental authorities may conclude that our business practices do not comply with current or future statutes, regulations, agency guidance or case law involving applicable healthcare laws. If our operations are found to be in violation of any of the laws described above or any other governmental regulations that apply to us, we may be subject to significant penalties, including administrative, civil and criminal penalties, damages, fines, disgorgement, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, imprisonment, integrity and/or other oversight obligations, contractual damages, reputational harm, and the curtailment or restructuring of our operations. Any such penalties could adversely affect our ability to operate our business and our financial results. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management's attention from the operation of our business. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business involves the use of hazardous materials and we and our third-party manufacturers must comply with environmental laws and regulations, which can be expensive and restrict how we do business. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our and our third-party manufacturers' activities involve the controlled storage, use and disposal of hazardous materials, including the components of our DNA medicine candidates and other hazardous compounds. We and our manufacturers are subject to federal, state and local laws and regulations governing the use, manufacture, storage, handling and disposal of these hazardous materials. In the event of an accident, state or federal authorities may curtail the use of these materials and interrupt our business operations. If we are subject to any liability as a result of our or our third-party manufacturers' activities involving hazardous materials, our business and financial condition may be adversely affected. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We have entered into collaborations with Chinese companies and may rely on clinical materials manufactured in China for our development efforts. Uncertainties regarding the interpretation and enforcement of Chinese laws, rules and regulations, a trade war, political unrest or unstable economic conditions in China could materially adversely affect our business, financial condition and results of operations.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are party to a license and collaboration agreement with a China-based company, ApolloBio, pursuant to which ApolloBio has the exclusive right to develop and commercialize VGX-3100 in China, Hong Kong, Macao and Taiwan. The Chinese legal system is a civil law system based on written statutes. Unlike the common law system, prior court decisions may be cited for reference but have limited precedential value. In addition, the Chinese legal system is based in part on government policies and internal rules, some of which are not published on a timely basis or at all, and which may have a retroactive effect. As a result, we may not be aware of our violation of these policies and rules until after the occurrence of the violation. Any administrative and court proceedings in China may be protracted, resulting in substantial costs and diversion of resources and management attention. Because Chinese administrative and court authorities have significant discretion in interpreting and implementing statutory and contractual terms, it may be more difficult to evaluate the outcome of administrative and court proceedings and the level of legal protection we enjoy than in more developed legal systems. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, we are exposed to the possibility of disruption of our research and development activities in the event of changes in the policies of the United States or Chinese governments, political unrest or unstable economic conditions in China. For example, China's "zero COVID" policy caused delays in Advaccine&#8217;s conduct of clinical trials for INO-4800 in China under our collaboration with them, which in turn resulted in delays in obtaining clinical data to evaluate the safety and potential efficacy of INO-4800. In addition, the biopharmaceutical industry in China is strictly regulated by the Chinese government. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes to Chinese regulations or government policies affecting biopharmaceutical companies are unpredictable and may have a material adverse effect on ApolloBio or Advaccine, which could have an adverse effect on our business, financial condition, results of operations and prospects. Evolving changes in China&#8217;s public health, economic, political, and social conditions and the uncertainty around China&#8217;s relationship with other governments, including the threat of a trade war between the United States and China, could lead to supply chain disruptions or increased costs for clinical materials manufactured in China that are necessary for our development efforts. Certain Chinese biotechnology companies and contract development and manufacturing organizations may become subject to trade restrictions, sanctions, other regulatory requirements, or proposed legislation by the U.S. government, which could potentially impact our ability to secure the materials we need for our product candidates.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, the recently proposed BIOSECURE Act that was passed by the U.S. House of Representatives in September 2024, as well as a substantially similar bill in the U.S. Senate, target U.S. government contracts, grants, and loans for entities that use equipment and services from certain named Chinese biotech companies, and authorize the U.S. government to name additional Chinese biotechnology companies of concern. If these bills become law, or similar laws are passed, they would have the potential to severely restrict the ability of companies to work with certain Chinese biotechnology companies of concern without losing the ability to contract with, or otherwise receive funding from, the U.S. government. We may also be exposed to fluctuations in the value of the local currency in China. These disruptions, failures or uncertainties may have adverse impacts on the development of our product candidates, our ability to commercialize our DNA medicine candidates, if approved, our business operations, our ability to enforce the contracts we have entered into and could materially and adversely affect our business, financial condition and results of operations.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">International trade policies, including tariffs, sanctions and trade barriers may adversely affect our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in a global economy, which includes utilizing third-party suppliers in several countries outside the United States. There is inherent risk, based on the complex relationships among the U.S. and the countries in which we conduct our business, that political, diplomatic, and national security factors can lead to global trade restrictions and changes in trade policies and export regulations that may adversely affect our business and operations. The current international trade and regulatory environment is subject to significant ongoing uncertainty. The U.S. government has recently announced substantial new tariffs affecting a wide range of products and jurisdictions and has indicated an intention to continue developing new trade policies, including with respect to the pharmaceutical industry. In response, certain foreign governments have announced or implemented retaliatory tariffs and other protectionist measures. These developments have created a dynamic and unpredictable trade landscape, which may adversely impact our business, results of operations, financial condition and prospects.  </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not own or operate, and currently have no plans to establish, any manufacturing facilities for the drug substance and drug product in our DNA medicine candidates. We currently rely, and expect to continue to rely, on third parties for the manufacture of our DNA medicine candidates for clinical testing, as well as for manufacture of any products that we may commercialize, if approved. Currently, several of our suppliers are located outside of the United States; our principal suppliers of critical raw materials and our manufacturer for the active pharmaceutical ingredients (APIs) for INO-3107 are located in Europe. We also rely on specialized laboratory equipment, supplies, materials, and precursor compounds, all or part of which we believe may be ultimately sourced from multiple countries outside the United States, to advance our research and development efforts.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current or future tariffs will result in increased research and development expenses, including with respect to increased costs associated with APIs, raw materials, laboratory equipment and research materials and components. In addition, such tariffs will increase our supply chain complexity and could also potentially disrupt our existing supply chain. Trade restrictions affecting the import of materials necessary for clinical trials could result in delays to our development timelines. Increased development costs and extended development timelines could place us at a competitive disadvantage compared to companies operating in regions with more favorable trade relationships and could reduce investor confidence, negatively impacting our ability to secure additional financing on favorable terms or at all. In addition, as we advance toward potential commercialization of INO-3107, tariffs and trade restrictions could hinder our ability to establish cost-effective production capabilities, negatively impacting our growth prospects.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The complexity of announced or future tariffs may also increase the risk that we or our customers or suppliers may be subject to civil or criminal enforcement actions in the United States or foreign jurisdictions related to compliance with trade regulations. Foreign governments may also adopt non-tariff measures, such as procurement preferences or informal disincentives to engage with, purchase from or invest in U.S. entities, which may limit our ability to compete internationally and attract non-U.S. investment, employees, customers and suppliers. Foreign governments may also take other retaliatory actions against U.S. entities, such as decreased intellectual property protection, increased enforcement actions, or delays in regulatory approvals, which may result in heightened international legal and operational risks. In addition, the United States and other governments have imposed and may continue to impose additional sanctions, such as trade restrictions or trade barriers, which could restrict us from doing business directly or indirectly in or with certain countries or parties and may impose additional costs and complexity to our business.  </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade disputes, tariffs, restrictions and other political tensions between the United States and other countries may also exacerbate unfavorable macroeconomic conditions including inflationary pressures, foreign exchange volatility, financial market instability, and economic recessions or downturns. The ultimate impact of current or future tariffs and trade restrictions remains uncertain and could materially and adversely affect our business, financial condition, and prospects. While we actively monitor these risks, any prolonged economic downturn, escalation in trade tensions, or deterioration in international perception of U.S.-based companies could materially and adversely affect our business, ability to access the capital markets or other financing sources, results of operations, financial condition and prospects. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our employees, principal investigators, and consultants may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the risk of fraud or other misconduct by our employees, principal investigators, and consultants. Misconduct by these parties could include intentional failures to comply with FDA regulations or the regulations applicable in the European Union, or EU, and other jurisdictions; provide accurate information to the FDA, the European Medicines Agency, or EMA, and other regulatory authorities; comply with healthcare fraud and abuse laws and regulations in the United States and abroad; or report financial information or data accurately or disclose unauthorized activities to us. Such misconduct also could involve the improper use of information obtained in the course of clinical trials or interactions with the FDA or other regulatory authorities, which could result in regulatory sanctions and cause serious harm to our reputation. Sales, marketing, and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing, and other abusive practices. These laws and regulations restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs, and other business arrangements. We have adopted a code of conduct applicable to all of our employees, but it is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from government investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, financial condition, results of operations, and prospects, including the imposition of significant fines or other sanctions.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee litigation and unfavorable publicity could negatively affect our future business.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our employees may, from time to time, bring lawsuits against us regarding injury, creating a hostile work place, discrimination, wage and hour disputes, sexual harassment, or other employment issues. In recent years there has been an increase in the number of discrimination and harassment claims generally. Coupled with the expansion of social media platforms and similar devices that allow individuals access to a broad audience, these claims have had a significant negative impact on some businesses. Certain companies that have faced employment- or harassment-related lawsuits have had to terminate management or other key personnel, and have suffered reputational harm that has negatively impacted their business. If we were to face any employment-related claims, our business could be negatively affected.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Intellectual Property</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">It is difficult and costly to generate and protect our intellectual property and our proprietary technologies, and we may not be able to ensure their protection. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success will depend in part on obtaining and maintaining patent, trademark, trade secret, and other intellectual property protection relating to our proprietary device and DNA medicine candidates, as well as successfully defending these intellectual property rights against third-party challenges. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent positions of pharmaceutical and biotechnology companies can be highly uncertain and involve complex legal and factual questions for which important legal principles remain unresolved. The laws and regulations regarding the breadth of claims allowed in biotechnology patents have evolved over recent years and continues to undergo review and revision, both in the United States and abroad. The biotechnology patent situation outside the United States can be even more uncertain depending on the country. Changes in either the patent laws or in interpretations of patent laws in the United States and other countries may diminish the value of our intellectual property. Accordingly, we cannot predict the breadth of claims that may be allowed or enforced in our licensed patents, our patents or in third-party patents, nor can we predict the likelihood of our patents surviving a patent validity challenge. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The degree of future protection for our intellectual property rights is uncertain, because legal decision-making can be unpredictable, thereby often times resulting in limited protection, which may not adequately protect our rights or permit us to gain or keep our competitive advantage, or resulting in an invalid or unenforceable patent. For example: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we, or the parties from whom we have acquired or licensed patent rights, may not have been the first to file the underlying patent applications or the first to make the inventions covered by such patents; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the named inventors or co-inventors of patents or patent applications that we have licensed or acquired may be incorrect, which may give rise to inventorship and ownership challenges; </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">others may develop similar or alternative technologies, or duplicate any of our products or technologies that may not be covered by our patents, including design-arounds; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">pending patent applications may not result in issued patents; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the issued patents covering our products and technologies may not provide us with any competitive advantages or have any commercial value; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the issued patents may be challenged and invalidated, or rendered unenforceable; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">governments in the United States or abroad may prevent us from enforcing patents on our vaccines, which could prevent us from excluding competitors from those markets;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the issued patents may be subject to reexamination, which could result in a narrowing of the scope of claims or cancellation of claims found unpatentable; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not develop or acquire additional proprietary technologies that are patentable; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our trademarks may be invalid or subject to a third party's prior use; or </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to enforce our patent rights will depend on our ability to detect infringement, and litigation to enforce patent rights may not be pursued due to significant financial costs, diversion of resources, and unpredictability of a favorable result or ruling. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We depend, in part, on our licensors and collaborators to protect a portion of our intellectual property rights. In such cases, our licensors and collaborators may be primarily or wholly responsible for the maintenance of patents and prosecution of patent applications relating to important areas of our business. If any of these parties fail to adequately protect these products with issued patents, our business and prospects would be harmed significantly. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also may rely on trade secrets to protect our technology, especially where we do not believe patent protection is appropriate or obtainable. However, trade secrets are difficult to protect. Although we use reasonable efforts to protect our trade secrets, our employees, consultants, contractors, outside scientific collaborators and other advisors may unintentionally or willfully disclose our trade secrets to competitors. Enforcing a claim that a third-party entity illegally obtained and is using any of our trade secrets is expensive and time consuming, and the outcome is unpredictable. In addition, courts outside the United States are sometimes less willing to protect trade secrets. Moreover, our competitors may independently develop equivalent knowledge, methods and know-how. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or our licensors fail to obtain or maintain patent protection or trade secret protection for our DNA medicine candidates or our technologies, third parties could use our proprietary information, which could impair our ability to compete in the market and adversely affect our ability to generate revenues and attain profitability. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, U.S. and other policymakers have proposed reforming the patent laws and regulations of their countries. In September 2011 the America Invents Act (the Act) was signed into law. The Act changed the current &#8220;first-to-invent&#8221; system to a system that awards a patent to the &#8220;first-inventor-to-file&#8221; for an application for a patentable invention. The Act also created a procedure to challenge newly issued patents in the patent office via post-grant proceedings and new inter parties reexamination proceedings. These changes may make it easier for competitors to challenge our patents, which could result in increased competition and have a material adverse effect on our product sales, business and results of operations. The changes may also make it harder to challenge third-party patents and place greater importance on being the first inventor to file a patent application on an invention. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are sued for infringing intellectual property rights of third parties, it will be costly and time-consuming, and an unfavorable outcome in that litigation would have a material adverse effect on our business. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other companies may have or may acquire intellectual property rights that could be enforced against us. If they do so, we may be required to alter our technologies, pay licensing fees or cease activities. If our products or technologies infringe the intellectual property rights of others, they could bring legal action against us or our licensors or collaborators claiming damages and seeking to enjoin any activities that they believe infringe their intellectual property rights. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because patent applications can take many years to issue, and there is a period when the application remains undisclosed to the public, there may be currently pending applications unknown to us or reissue applications that may later result in issued patents upon which our products or technologies may infringe. There could also be existing patents of which we are unaware that our products or technologies may infringe. In addition, if third parties file patent applications or obtain patents claiming products or technologies also claimed by us in pending applications or issued patents, we may have to participate in interference or derivation proceedings in the United States Patent and Trademark Office to determine priority or derivation of the invention. If third parties file oppositions in foreign countries, we may also have to participate in opposition proceedings in foreign tribunals to defend the patentability of our filed foreign patent applications. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a third party claims that we infringe its intellectual property rights, it could cause our business to suffer in a number of ways, including: </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may become involved in time-consuming and expensive litigation, even if the claim is without merit, the third party's patent is invalid or we have not infringed; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may become liable for substantial damages for past infringement if a court decides that our technologies infringe upon a third party's patent; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be enjoined by a court to stop making, selling or licensing our products or technologies without a license from a patent holder, which may not be available on commercially acceptable terms, if at all, or which may require us to pay substantial royalties or grant cross-licenses to our patents; and </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may have to redesign our products so that they do not infringe upon others' patent rights, which may not be possible or could require substantial investment or time. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of these events occur, our business could suffer and the market price of our common stock may decline. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have not yet registered our trademarks in all of our potential markets, and failure to secure those registrations could adversely affect our business.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our trademark applications may not be allowed for registration, and our registered trademarks may not be maintained or enforced. During trademark registration proceedings, we may receive rejections. Although we are given an opportunity to respond to those rejections, we may be unable to overcome such rejections. In addition, in the USPTO and in comparable agencies in many foreign jurisdictions, third parties are given an opportunity to oppose pending trademark applications and to seek to cancel registered trademarks. Opposition or cancellation proceedings may be filed against our trademarks, and our trademarks may not survive such proceedings. If we do not secure registrations for our trademarks, we may encounter more difficulty in enforcing them against third parties than we otherwise would.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to an Investment in Our Common Stock</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">An active trading market for our common stock may not be sustained.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although our common stock is listed on the Nasdaq Capital Market, we cannot be certain that an active trading market for our shares will continue to be sustained. If an active market for our common stock is not sustained, it may be difficult for investors in our common stock to sell shares without depressing the market price for the shares or to sell the shares at all.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The price of our common stock has been and may continue to be volatile, and an investment in our common stock could decline substantially in value. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In light of our small size and limited resources, as well as the uncertainties and risks that can affect our business and industry, our stock price has been and may continue to be highly volatile and has been and may in the future be subject to substantial drops, with or even in the absence of news affecting our business. Period to period comparisons are not indicative of future performance. The following factors, which are not exhaustive, in addition to the other risk factors described in this report, and the potentially low volume of trades in our common stock, may have a significant impact on the market price of our common stock, some of which are beyond our control: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developments concerning any research and development, clinical trials, manufacturing, and marketing efforts or collaborations;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fluctuating public or scientific interest in the potential for our vaccines or other DNA medicine candidates;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our announcement of significant acquisitions, strategic collaborations, joint ventures or capital commitments; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fluctuations in our operating results; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements of technological innovations; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">new products or services that we or our competitors offer; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the structure of healthcare payment systems;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the initiation, conduct and/or outcome of intellectual property and/or litigation matters; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in financial or other estimates by securities analysts or other reviewers or evaluators of our business; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">conditions or trends in bio-pharmaceutical or other healthcare industries; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory developments in the United States and other countries; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">perceptions of gene-based therapy; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the economic performance and/or market valuations of other biotechnology and medical device companies; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">additions or departures of key personnel; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sales or other transactions involving our common stock; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in our capital structure;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sales or other transactions by executive officers or directors involving our common stock; </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in accounting principles; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">global unrest including geopolitical risks emanating from countries such as Russia and China, terrorist activities, the conflict between Israel and Hamas, bank failures, and other economic and other external factors; and </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">catastrophic weather and/or global disease pandemics. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The stock market in general can experience relatively large price and volume fluctuations from time to time. In particular, the market prices of securities of smaller biotechnology and medical device companies have experienced dramatic fluctuations that often have been unrelated or disproportionate to the operating results of these companies. Continued market fluctuations could result in extreme volatility in the price of our common stock, which could cause a decline in the value of our common stock. In addition, price volatility may increase if the trading volume of our common stock remains limited or declines.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We have broad discretion in the use of our cash, cash equivalents, and investments, and may not use them effectively.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management has broad discretion in the application of our cash, cash equivalents, and investments, and could spend the proceeds in ways that do not improve our results of operations or enhance the value of our common stock. For example, our operating expenses increased significantly from 2020 to 2022 due to development and manufacturing activities for our COVID-19 vaccine program, which has since been discontinued internally. We may not deploy our current capital resources effectively. The failure by our management to apply our funds effectively could result in financial losses that could have a material adverse impact on our business, cause the price of our common stock to decline, and delay the development of our product candidates. Pending their use, we may invest our cash, cash equivalents, and investments in a manner that does not produce income or that loses value.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Anti-takeover provisions under our charter documents and Delaware law could delay or prevent a change of control which could limit the market price of our common stock. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our amended and restated certificate of incorporation contains provisions that could delay or prevent a change of control of our company or changes in our board of directors that our stockholders might consider favorable. Some of these provisions include: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the authority of our board of directors to issue shares of undesignated preferred stock and to determine the rights, preferences and privileges of these shares, without stockholder approval; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">all stockholder actions must be effected at a duly called meeting of stockholders and not by written consent; and </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the elimination of cumulative voting. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we are governed by the provisions of Section 203 of the Delaware General Corporate Law, which may prohibit certain business combinations with stockholders owning 15% or more of our outstanding voting stock. These and other provisions in our amended and restated certificate of incorporation, amended and restated bylaws and Delaware law could make it more difficult for stockholders or potential acquirers to obtain control of our board of directors or initiate actions that are opposed by the then-current board of directors, including to delay or impede a merger, tender offer or proxy contest involving our company. Any delay or prevention of a change of control transaction or changes in our board of directors could cause the market price of our common stock to decline. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have never paid cash dividends on our common stock and we do not anticipate paying dividends in the foreseeable future. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have paid no cash dividends on our common stock to date, and we currently intend to retain our future earnings, if any, to fund the development and growth of our business. In addition, the terms of any future debt or credit facility may preclude or limit our ability to pay any dividends. As a result, capital appreciation, if any, of our common stock will be the sole source of potential gain for the foreseeable future. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited.</span></div><div style="margin-top:5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Sections 382 and 383 of the revised Internal Revenue Code of 1986, as amended, or the Code, if a corporation undergoes an &#8220;ownership change&#8221; (generally defined as a greater than 50 percentage point change (by value) in the ownership of its equity by certain significant shareholders over a rolling three year period), the corporation&#8217;s ability to use its pre-change net operating loss carryforwards and certain other pre-change tax attributes to offset its post-change income and taxes may be limited. We may have experienced such ownership changes in the past, and we may experience ownership changes in the future as a result of shifts in our share ownership, some of which would be outside our control. If our ability to use our net operating losses and other tax attributes is limited by ownership changes, we may be unable to utilize a material portion of our net operating losses and other tax attributes to offset our future taxable income. In addition, there is also a risk that due to changes in laws and regulations, such as alternative minimum taxes or suspensions on the use of net operating losses, or other unforeseen reasons, our existing net operating losses could expire or otherwise become unavailable to offset future income tax liabilities.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Risk Factors</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our quarterly operating results may fluctuate significantly.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect our operating results to be subject to quarterly fluctuations. Our net loss and other operating results will be affected by numerous factors, including: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">variations in the level of expenses related to our proprietary device, DNA medicine candidates or future development programs; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenses related to corporate transactions, including ones not fully completed; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">addition or termination of clinical trials or funding support; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any intellectual property infringement lawsuit in which we may become involved; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any legal claims that may be asserted against us or any of our officers; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory developments affecting our proprietary device and DNA medicine candidates or those of our competitors; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">debt service obligations;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the fair value of our investments, including investments in affiliated entities;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our execution of any collaborative, licensing or similar arrangements, and the timing of payments we may make or receive under these arrangements; and </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">if any of our DNA medicine candidates receive regulatory approval, the levels of underlying demand for our products. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our quarterly operating results fall below the expectations of investors or securities analysts, the price of our common stock could decline substantially. Furthermore, any quarterly fluctuations in our operating results may, in turn, cause the price of our stock to fluctuate substantially. We believe that quarterly comparisons of our financial results are not necessarily meaningful and should not be relied upon as an indication of our future performance. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our results of operations and liquidity needs could be materially affected by market fluctuations and general economic conditions. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our results of operations could be materially affected by economic conditions generally, both in the United States and elsewhere around the world. Concerns due to reasons including, among other things, inflation, rising interest rates, energy costs, geopolitical issues, political changes and trends such as protectionism, economic nationalism resulting in government actions impacting international trade agreements or imposing trade restrictions such as tariffs and retaliatory counter measures, global pathogen outbreaks or pandemics, and the availability and cost of credit have in the past and may continue to contribute to increased volatility and diminished expectations for the economy and the markets going forward. Market upheavals may have an adverse effect on us. In the event of a market downturn, our results of operations could be adversely affected. Our future cost of equity or debt capital and access to the capital markets could be adversely affected, and our stock price could decline. There may be disruption or delay in the performance of our third-party contractors and suppliers. If our contractors, suppliers and partners are unable to satisfy their contractual commitments, our business could suffer. In addition, we maintain significant amounts of cash and cash equivalents at one or more financial institutions that are in excess of federally insured limits, and we may experience losses on these deposits. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Adverse developments affecting the financial services industry, such as actual events or concerns involving liquidity, could adversely impact our business, financial condition and results of operations.</span></div><div style="margin-top:5pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Actual events involving limited liquidity or other adverse developments that affect financial institutions or other companies in the financial services industry or the financial services industry generally, or concerns or rumors about any events of these kinds or other similar risks, have in the past and may in the future lead to market-wide liquidity problems. For example, in 2023, several banking institutions were closed or seized by the Federal Deposit Insurance Corporation, leading to significant liquidity concerns in the broader financial services industry. We maintain deposits at financial institutions as a part of doing business that could be at risk if another similar event were to occur. Our ongoing cash management strategy is to maintain the majority of our deposit accounts in large financial institutions, but there can be no assurance this strategy will be successful. Increasing concerns regarding the U.S. or international financial systems, including bank failures and bailouts, and their potential broader effects and potential systemic risk on the banking sector generally, may adversely affect our access to capital. Any decline in available funding or access to our cash and liquidity resources could, among other risks, limit our ability to meet our capital needs and fund future growth or fulfill our other obligations, or result in breaches of our financial and/or contractual obligations. Any of these impacts, or any other impacts resulting from the factors described above or other related or similar factors not described above, could have material adverse impacts on our business, financial condition and results of operations.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If equity research analysts do not publish research or reports, or publish unfavorable research or reports, about us, our business or our market, our stock price and trading volume could decline.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading market for our common stock is influenced by the research and reports that equity research analysts publish about us and our business, and we have limited research coverage by equity research analysts. Equity research analysts may elect not to initiate or continue to provide research coverage of our common stock, and such lack of research coverage may </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">adversely affect the market price of our common stock. Even if we have equity research analyst coverage, we will not have any control over the analysts or the content and opinions included in their reports. The price of our stock could decline if one or more equity research analysts downgrade our stock or issue other unfavorable commentary or research. If one or more equity research analysts ceases coverage of our company or fails to publish reports on us regularly, demand for our stock could decrease, which in turn could cause our stock price or trading volume to decline.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The issuance of additional stock in connection with financings, acquisitions, investments, our stock incentive plans or otherwise will dilute all other stockholders.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our certificate of incorporation authorizes us to issue up to 600,000,000 shares of common stock and up to 10,000,000 shares of preferred stock with such rights and preferences as may be determined by our board of directors. Subject to compliance with applicable rules and regulations, we may issue our shares of common stock or securities convertible into our common stock from time to time in connection with a financing, acquisition, investment, our stock incentive plans or otherwise. Any such issuance could result in substantial dilution to our existing stockholders and cause the trading price of our common stock to decline.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We incur significant costs and demands upon management as a result of being a public company.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a public company listed in the United States, we incur significant legal, accounting and other costs that could negatively affect our financial results. In addition, changing laws, regulations and standards relating to corporate governance and public disclosure, including regulations implemented by the SEC and stock exchanges, may increase legal and financial compliance costs and make some activities more time-consuming. These laws, regulations and standards are subject to varying interpretations and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. We intend to invest resources to comply with evolving laws, regulations and standards, and this investment may result in increased general and administrative expenses and a diversion of management's time and attention from revenue-generating activities to compliance activities. If notwithstanding our efforts to comply with new laws, regulations and standards, we fail to comply, regulatory authorities may initiate legal proceedings against us and our business may be harmed.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to comply with these rules might also make it more difficult for us to obtain some types of insurance, including director and officer liability insurance, and we might be forced to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. The impact of these events could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, on committees of our board of directors or as members of senior management.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in tax laws could adversely affect our business and financial condition.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tax regimes to which we are subject or under which we operate are unsettled and may be subject to significant change. In 2017, tax legislation commonly known as the Tax Cuts and Jobs Act, or Tax Act, was enacted, which significantly revised the Internal Revenue Code of 1986, as amended, or the Code. The Tax Act, among other things, resulted in significant changes to corporate taxation, including reduction of the corporate tax rate from a top marginal rate of 35 percent to a flat rate of 21 percent, limitation of the tax deduction for interest expense to 30 percent of adjusted earnings (except for certain small businesses), limitation of the deduction for net operating losses to 80 percent of current-year taxable income and elimination of net operating loss carrybacks, one time taxation of offshore earnings at reduced rates regardless of whether they are repatriated, immediate deductions for certain new investments instead of deductions for depreciation expense over time, and modifying or repealing many business deductions and credits (including reducing the business tax credit for certain clinical testing expenses incurred in the testing of certain drugs for rare diseases or conditions). It is uncertain if and to what extent various states will conform to the federal tax law. The issuance of additional regulatory or accounting guidance related to the Tax Act, or legislative changes proposed or implemented, could materially affect our tax obligations and effective tax rate.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The increasing use of social media platforms presents new risks and challenges.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Social media is increasingly being used to communicate about our research, development candidates, investigational medicines, and the diseases our development candidates and investigational medicines are being developed to treat. Social media practices in the biopharmaceutical industry continue to evolve and regulations relating to such use are not always clear. This evolution creates uncertainty and risk of noncompliance with regulations applicable to our business, resulting in potential regulatory actions against us. For example, participants may use social media channels to comment on their experience in an ongoing blinded clinical trial or to report an alleged adverse event. When such disclosures occur, there is a risk that we fail to monitor and comply with applicable adverse event reporting obligations or we may not be able to defend our business or the public&#8217;s legitimate interests in the face of the political and market pressures generated by social media due to restrictions on what we may say about our development candidates and investigational medicines. There is also a risk of inappropriate disclosure of sensitive information or negative or inaccurate posts or comments about us on any social networking website. If any of these events were to occur or we otherwise fail to comply with applicable regulations, we could incur liability, face regulatory actions, or incur other harm to our business.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to stringent and evolving U.S. and foreign laws, regulations, and rules, contractual obligations, industry standards, policies and other obligations related to data privacy and security. Our actual or perceived failure, or the failure of third parties with whom we work, to comply with such obligations could lead to material adverse business consequences.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, we collect, receive, store, process, generate, use, transfer, disclose, make accessible, protect, secure, dispose of, transmit, and share (collectively, process) personal data and other sensitive information, including proprietary and confidential business data, trade secrets, intellectual property, sensitive third-party data, business plans, transactions, and financial information (collectively, sensitive data).</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our data processing activities subject us to numerous data privacy and security obligations, such as various laws, regulations, guidance, industry standards, external and internal privacy and security policies, contractual requirements, and other obligations relating to data privacy and security. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, federal, state, and local governments have enacted numerous data privacy and security laws, including data breach notification laws, personal data privacy laws, consumer protection laws (e.g., Section 5 of the Federal Trade Commission Act), and other similar laws (e.g., wiretapping laws). Numerous U.S. states have enacted comprehensive privacy laws that impose certain obligations on covered businesses, including providing specific disclosures in privacy notices and affording residents with certain rights concerning their personal data. As applicable, such rights may include the right to access, correct, or delete certain personal data, and to opt-out of certain data processing activities, such as targeted advertising, profiling, and automated decision-making. The exercise of these rights may impact our business and ability to provide our products and services. Certain states also impose stricter requirements for processing certain personal data, including sensitive information, such as conducting data privacy impact assessments. These state laws allow for statutory fines for noncompliance. For example, the California Consumer Privacy Act of 2018,or CCPA, applies to personal data of consumers, business representatives, and employees who are California residents, and requires certain businesses to provide specific disclosures in privacy notices and honor requests of such individuals to exercise certain privacy rights. The CCPA provides for fines and allows private litigants affected by certain data breaches to recover significant statutory damages. Similar laws are being considered in several other states, as well as at the federal and local levels, and we expect more states to pass similar laws in the future. These developments may further complicate compliance efforts, and increase legal risk and compliance costs for us and the third parties with whom we work. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside the United States, an increasing number of laws, regulations, and industry standards may govern data privacy and security.  For example, the EU&#8217;s General Data Protection Regulation, or GDPR, the United Kingdom&#8217;s, or UK&#8217;s, GDPR, and similar laws adopted in Brazil and China impose strict requirements for processing personal data. In addition, companies may face temporary or definitive bans on data processing and other corrective actions; fines of up to 20 million Euros under the EU GDPR, 17.5 million pounds sterling under the UK GDPR or, in each case, 4% of annual global revenue, whichever is greater; or private litigation related to processing of personal data brought by classes of data subjects or consumer protection organizations authorized at law to represent their interests.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we may be unable to transfer personal data from Europe and other jurisdictions to the United States or other countries due to data localization requirements or limitations on cross-border data flows. Europe and other jurisdictions have enacted laws requiring data to be localized or limiting the transfer of personal data to other countries. In particular, the UK and the European Economic Area, or EEA, have significantly restricted the transfer of personal data to the United States and other countries whose privacy laws it generally believes are inadequate. Other jurisdictions may adopt similarly stringent interpretations of their data localization and cross-border data transfer laws. Although there are currently various mechanisms that may be used to transfer personal data from the EEA and UK to the United States in compliance with law, such as the EEA&#8217;s standard contractual clauses, the UK&#8217;s International Data Transfer Agreement / Addendum, and the EU-U.S. Data Privacy Framework and the UK extension thereto (which allows for transfers to relevant U.S.-based organizations who self-certify compliance and participate in the Framework), these mechanisms are subject to legal challenges, and there is no assurance that we can satisfy or rely on these measures to lawfully transfer personal data to the United States.  If there is no lawful manner for us to transfer personal data from the EEA, the UK, or other jurisdictions to the United States, or if the requirements for a legally-compliant transfer are too onerous, we could face significant adverse consequences, including the interruption or degradation of our operations, the need to relocate part of or all of our business or data processing activities to other jurisdictions (such as Europe) at significant expense, increased exposure to regulatory actions, substantial fines and penalties, the inability to transfer data and work with partners, vendors and other third parties, and injunctions against our processing or transferring of personal data necessary to operate our business. Additionally, companies that transfer personal data out of the EEA and UK to other jurisdictions, particularly to the United States, are subject to increased scrutiny from regulators, individual litigants, and activities groups. Some European regulators have ordered certain companies to suspend or permanently cease certain transfers of personal data out of Europe for allegedly violating the GDPR&#8217;s cross-border data transfer limitations. Other jurisdictions have adopted or may adopt stringent data localization and cross-border data transfer laws, such as the U.S. Department of Justice&#8217;s Rule on Preventing Access to U.S. Sensitive Personal Data and Government-Related Data by Countries of Concern or Covered Persons.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to data privacy and security laws, we may be contractually subject to certain industry standards adopted by industry groups. We are also bound by other contractual obligations related to data privacy and security, and our efforts to comply with such obligations may not be successful. We publish statements regarding data privacy and security. Regulators in the United States and elsewhere are increasingly scrutinizing these statements and if these policies, materials or statements are found to be deficient, lacking in transparency, deceptive, unfair, misleading, or misrepresentative of our practices, we may be subject to investigation, enforcement actions by regulators, or other adverse consequences. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our personnel and certain third parties with whom we work may use generative AI and/or automated decision-making technologies to perform their work, and the disclosure and use of personal data in AI technologies is subject to various privacy laws and other privacy obligations. Governments have passed and are likely to pass additional laws regulating AI and/or automated decision-making technologies. Our use of this technology could result in additional compliance costs, regulatory investigations and actions, and lawsuits. If we are unable to use AI and/or automated decision-making technologies, it could make our business less efficient and result in competitive disadvantages. Due to inaccuracies or flaws in the inputs, outputs, or logic of the AI/ML, AI models could be biased and could lead us to make decisions that could bias certain individuals (or classes of individuals), and adversely impact their rights, employment, and ability to obtain certain pricing, products, services, or benefits.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obligations related to data privacy and security (and consumers&#8217; data privacy expectations) are quickly changing, becoming increasingly stringent, and creating uncertainty. Additionally, these obligations may be subject to differing applications and interpretations, which has in the past and may in the future be inconsistent or conflict among jurisdictions. Preparing for and complying with these obligations requires us to devote significant resources and may necessitate changes to our services, information technologies, systems, and practices and to those of any third parties that process personal data on our behalf. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may at times fail, or be perceived to have failed, in our efforts to comply with our data privacy and security obligations. Moreover, despite our efforts, our personnel or those of third parties with whom we work may fail to comply with such obligations, which could negatively impact our business operations. If we or they fail, or are perceived to have failed, to address or comply with applicable data privacy and security obligations, we could face significant consequences, including but not limited to government enforcement actions that could result in investigations, fines, penalties, audits, inspections, and similar actions; litigation, including class action claims, and mass arbitration demands; additional reporting requirements and/or oversight; bans on processing personal data; and orders to destroy or not use personal data. In particular, plaintiffs have become increasingly more active in bringing privacy-related claims against companies, including class claims and mass arbitration demands. Some of these claims allow for the recovery of statutory damages on a per violation basis, and, if viable, carry the potential for monumental statutory damages, depending on the volume of data and the number of violations. Any of these events could have a material adverse effect on our reputation, business, or financial condition, including but not limited to: inability to process personal data or to operate in certain jurisdictions; limited ability to develop or commercialize our products; expenditure of time and resources to defend any claim or inquiry; adverse publicity; or substantial changes to our business model or operations.</span></div><div><span><br/></span></div><div id="icec13c599da34407bd5c5256baff0b0b_148"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> ITEM 5.&#160;&#160;&#160;&#160;OTHER INFORMATION</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2025, none of our directors and officers (as defined in Rule 16a-1(f) under the Securities Exchange Act of 1934, as amended) <ix:nonNumeric contextRef="c-1" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-653"><ix:nonNumeric contextRef="c-1" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-654">adopted</ix:nonNumeric></ix:nonNumeric> or <ix:nonNumeric contextRef="c-1" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-655"><ix:nonNumeric contextRef="c-1" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-656">terminated</ix:nonNumeric></ix:nonNumeric> any contracts, instructions or written plans for the purchase or sale of our securities.</span></div><div style="text-indent:27pt"><span><br/></span></div><div id="icec13c599da34407bd5c5256baff0b0b_151"></div><div style="margin-bottom:3pt"><span><br/></span></div><div style="-sec-extract:summary;margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> ITEM 6.&#160;&#160;&#160;&#160;EXHIBITS</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Exhibits</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#icec13c599da34407bd5c5256baff0b0b_7">Table of Contents</a></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:8.284%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:88.783%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Number</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Description of Document</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1055726/000119312514277137/d742468dex31.htm">3.1</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1055726/000119312514277137/d742468dex31.htm">Certificate of Incorporation with all amendments prior to December 31, 2023 (incorporated by reference to Exhibit 3.1 to the registrant&#8217;s registration statement on Form S-3, filed on July 23, 2014).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1055726/000119312524015380/d736726d8k.htm">3.2</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1055726/000119312524015380/d736726d8k.htm">Certificate of Amendment to Certificate of Incorporation, effective as of January 24, 2024 (incorporated by reference to Exhibit 3.1 to the registrant&#8217;s current report on Form 8-K filed on January 25, 2024).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1055726/000095012311076829/w84047exv3w2.htm">3.3</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1055726/000095012311076829/w84047exv3w2.htm">Amended and Restated Bylaws of Inovio Pharmaceuticals, Inc. dated August 10, 2011 (incorporated by reference to Exhibit 3.2 to the registrant&#8217;s current report on Form 8-K filed on August 12, 2011).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ino-33125x10qex311.htm">31.1</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ino-33125x10qex311.htm">Certification of Chief Executive Officer Pursuant to Item 601(b)(31) of Regulation S-K, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith)</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ino-3312510qex312.htm">31.2</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ino-3312510qex312.htm">Certification of Chief Financial Officer Pursuant to Item 601(b)(31) of Regulation S-K, as adopted pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002 (filed herewith).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ino-33125x10qex321.htm">32.1</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> *</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ino-33125x10qex321.htm">Certification of the Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C.&#160;Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002 (furnished herewith).*</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document).</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema with Embedded Linkbase Documents.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:4.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.906%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">This exhibit shall not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date hereof and irrespective of any general incorporation language in any filings. </span></div><div style="margin-top:7.5pt;padding-left:11.25pt;text-indent:-11.25pt"><span><br/></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><div id="icec13c599da34407bd5c5256baff0b0b_154"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. </span></div><div style="margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:4.325%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:38.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.419%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:49.927%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Inovio Pharmaceuticals, Inc.</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 13, 2025</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;JACQUELINE E. SHEA&#160;&#160;&#160;&#160;&#160;&#160;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Jacqueline E. Shea</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">President, Chief Executive Officer and Director                                                                                         (On Behalf of the Registrant)</span></div></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 13, 2025</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;PETER KIES&#160;&#160;&#160;&#160;&#160;&#160;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Peter Kies </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">Chief Financial Officer (Principal Financial and Accounting Officer)</span></div></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>ino-33125x10qex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="ice48ee217f7e46a59322b4fadd504a77_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;31.1 </font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification of CEO Pursuant to </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities Exchange Act Rules&#160;13a-15(e) and 15d-15(e) </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">as Adopted Pursuant to </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section&#160;302 of the Sarbanes-Oxley Act of 2002 </font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Jacqueline E. Shea, certify that&#58; </font></div><div style="margin-top:4.5pt;padding-left:24.75pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;I have reviewed this quarterly report on Form&#160;10-Q of Inovio Pharmaceuticals, Inc.&#59; </font></div><div style="margin-top:4.5pt;padding-left:24.75pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59; </font></div><div style="margin-top:4.5pt;padding-left:24.75pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59; </font></div><div style="margin-top:4.5pt;padding-left:24.75pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.&#160;&#160;&#160;&#160;The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e)&#160;and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f)&#160;and 15d-15(f)) for the registrant and have&#58; </font></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59; </font></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59; </font></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and </font></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and </font></div><div style="margin-top:4.5pt;padding-left:24.75pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.&#160;&#160;&#160;&#160;The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58; </font></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)&#160;&#160;&#160;&#160;all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and </font></div><div style="margin-bottom:5pt;margin-top:4.5pt;padding-left:47.25pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)&#160;&#160;&#160;&#160;any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. </font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:4.349%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.176%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 13, 2025</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;&#160;&#160;&#160;JACQUELINE E. SHEA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Jacqueline E. Shea</font></div><div style="margin-bottom:0.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">President, Chief Executive Officer and Director                       (Principal Executive Officer)</font></div></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>ino-3312510qex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i36b2a4f5660d484cb10f49cbd4dbb07e_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;31.2 </font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification of CFO Pursuant to </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities Exchange Act Rules&#160;13a-15(e) and 15d-15(e) </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">as Adopted Pursuant to </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section&#160;302 of the Sarbanes-Oxley Act of 2002 </font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Peter Kies, certify that&#58; </font></div><div style="margin-top:4.5pt;padding-left:24.75pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;I have reviewed this quarterly report on Form&#160;10-Q of Inovio Pharmaceuticals, Inc.&#59; </font></div><div style="margin-top:4.5pt;padding-left:24.75pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59; </font></div><div style="margin-top:4.5pt;padding-left:24.75pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59; </font></div><div style="margin-top:4.5pt;padding-left:24.75pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.&#160;&#160;&#160;&#160;The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e)&#160;and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f)&#160;and 15d-15(f)) for the registrant and have&#58; </font></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59; </font></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59; </font></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and </font></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and </font></div><div style="margin-top:4.5pt;padding-left:24.75pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.&#160;&#160;&#160;&#160;The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58; </font></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)&#160;&#160;&#160;&#160;all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and </font></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)&#160;&#160;&#160;&#160;any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. </font></div><div style="margin-top:9pt;padding-left:72pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.309%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.198%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.193%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 13, 2025</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;&#160;&#160;&#160;P</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">ETER</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> K</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">IES&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Peter Kies</font></div><div style="margin-bottom:0.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Chief Financial Officer                                                                    (Principal Financial and Accounting Officer)</font></div></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>ino-33125x10qex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="iaf1e9b815ae74de0861b80f836c31002_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;32.1 </font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification Pursuant to </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. Section&#160;1350, </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As Adopted Pursuant to </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section&#160;906 of the Sarbanes-Oxley Act of 2002 </font></div><div style="margin-top:9pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the quarterly report of Inovio Pharmaceuticals, Inc. (the &#8220;Company&#8221;) on Form&#160;10-Q for the quarter ending March&#160;31, 2025, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), each of the undersigned, in the capacities and on the date indicated below, hereby certifies, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that to his knowledge&#58; </font></div><div style="margin-top:4.5pt;padding-left:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) The Report fully complies with the requirements of Section&#160;13(a)&#160;or 15(d)&#160;of the Securities Exchange Act of 1934&#59; and </font></div><div style="margin-top:4.5pt;padding-left:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:4.349%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.176%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 13, 2025</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;&#160;&#160;&#160;JACQUELINE E. SHEA</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Jacqueline E. Shea</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">President, Chief Executive Officer and Director</font></div><div style="margin-bottom:0.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">(Principal Executive Officer)</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 13, 2025</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;&#160;&#160;&#160;P</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">ETER</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> K</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">IES&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Peter Kies</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Chief Financial Officer</font></div><div style="margin-bottom:0.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">(Principal Financial and Accounting Officer)</font></div></td></tr></table></div><div><font><br></font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The foregoing certification is being furnished solely pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002 and is not filed with the Securities and Exchange Commission as part of the Form&#160;10-Q or as a separate disclosure document and is not incorporated by reference into any filing of Inovio Pharmaceuticals, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, irrespective of any general incorporation language contained in such filing. A signed original of this written statement required by Section&#160;906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request. </font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>ino-20250331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:382d2453-c46c-4ade-9f50-1f9566f15edb,g:9bfa17de-2275-45c6-a4f6-49112bde99df-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ino="http://www.inovio.com/20250331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types1="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.inovio.com/20250331">
  <xs:import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ino-20250331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ino-20250331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ino-20250331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ino-20250331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.inovio.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://www.inovio.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>9952151 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofOperations" roleURI="http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations">
        <link:definition>9952152 - Statement - Condensed Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofComprehensiveLoss" roleURI="http://www.inovio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss">
        <link:definition>9952153 - Statement - Condensed Consolidated Statements of Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofStockholdersEquity" roleURI="http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity">
        <link:definition>9952154 - Statement - Condensed Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlows" roleURI="http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows">
        <link:definition>9952155 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandOperations" roleURI="http://www.inovio.com/role/OrganizationandOperations">
        <link:definition>9952156 - Disclosure - Organization and Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationLiquidityandRisksandUncertainties" roleURI="http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertainties">
        <link:definition>9952157 - Disclosure - Basis of Presentation, Liquidity and Risks and Uncertainties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CriticalAccountingPolicies" roleURI="http://www.inovio.com/role/CriticalAccountingPolicies">
        <link:definition>9952158 - Disclosure - Critical Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShorttermInvestmentsandFairValueMeasurements" roleURI="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurements">
        <link:definition>9952159 - Disclosure - Short-term Investments and Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CertainBalanceSheetItems" roleURI="http://www.inovio.com/role/CertainBalanceSheetItems">
        <link:definition>9952160 - Disclosure - Certain Balance Sheet Items</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleDebt" roleURI="http://www.inovio.com/role/ConvertibleDebt">
        <link:definition>9952161 - Disclosure - Convertible Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.inovio.com/role/StockholdersEquity">
        <link:definition>9952162 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShare" roleURI="http://www.inovio.com/role/NetLossPerShare">
        <link:definition>9952163 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://www.inovio.com/role/StockBasedCompensation">
        <link:definition>9952164 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactions" roleURI="http://www.inovio.com/role/RelatedPartyTransactions">
        <link:definition>9952165 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.inovio.com/role/CommitmentsandContingencies">
        <link:definition>9952166 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeAgreements" roleURI="http://www.inovio.com/role/CollaborativeAgreements">
        <link:definition>9952167 - Disclosure - Collaborative Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.inovio.com/role/IncomeTaxes">
        <link:definition>9952168 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GeneosTherapeuticsInc" roleURI="http://www.inovio.com/role/GeneosTherapeuticsInc">
        <link:definition>9952169 - Disclosure - Geneos Therapeutics, Inc.</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformation" roleURI="http://www.inovio.com/role/SegmentInformation">
        <link:definition>9952170 - Disclosure - Segment Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationLiquidityandRisksandUncertaintiesPolicies" roleURI="http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesPolicies">
        <link:definition>9955511 - Disclosure - Basis of Presentation, Liquidity and Risks and Uncertainties (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShorttermInvestmentsandFairValueMeasurementsTables" roleURI="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsTables">
        <link:definition>9955512 - Disclosure - Short-term Investments and Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CertainBalanceSheetItemsTables" roleURI="http://www.inovio.com/role/CertainBalanceSheetItemsTables">
        <link:definition>9955513 - Disclosure - Certain Balance Sheet Items (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityTables" roleURI="http://www.inovio.com/role/StockholdersEquityTables">
        <link:definition>9955514 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareTables" roleURI="http://www.inovio.com/role/NetLossPerShareTables">
        <link:definition>9955515 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://www.inovio.com/role/StockBasedCompensationTables">
        <link:definition>9955516 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesTables" roleURI="http://www.inovio.com/role/CommitmentsandContingenciesTables">
        <link:definition>9955517 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationTables" roleURI="http://www.inovio.com/role/SegmentInformationTables">
        <link:definition>9955518 - Disclosure - Segment Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationLiquidityandRisksandUncertaintiesDetails" roleURI="http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails">
        <link:definition>9955519 - Disclosure - Basis of Presentation, Liquidity and Risks and Uncertainties (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails" roleURI="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails">
        <link:definition>9955520 - Disclosure - Short-term Investments and Fair Value Measurements - Summary of Available-for-sale Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails" roleURI="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails">
        <link:definition>9955521 - Disclosure - Short-term Investments and Fair Value Measurements - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" roleURI="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails">
        <link:definition>9955522 - Disclosure - Short-term Investments and Fair Value Measurements - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShorttermInvestmentsandFairValueMeasurementsScheduleofAssumptionsUsedToEstimateTheFairValueOfWarrantsDetails" roleURI="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAssumptionsUsedToEstimateTheFairValueOfWarrantsDetails">
        <link:definition>9955523 - Disclosure - Short-term Investments and Fair Value Measurements - Schedule of Assumptions Used To Estimate The Fair Value Of Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShorttermInvestmentsandFairValueMeasurementsChangesInFairValueOfTheCompanysTotalLevel3FinancialLiabilitiesDetails" roleURI="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsChangesInFairValueOfTheCompanysTotalLevel3FinancialLiabilitiesDetails">
        <link:definition>9955524 - Disclosure - Short-term Investments and Fair Value Measurements - Changes In Fair Value Of The Company&#8217;s Total Level 3 Financial Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CertainBalanceSheetItemsPrepaidandOtherCurrentAssetsDetails" roleURI="http://www.inovio.com/role/CertainBalanceSheetItemsPrepaidandOtherCurrentAssetsDetails">
        <link:definition>9955525 - Disclosure - Certain Balance Sheet Items - Prepaid and Other Current Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CertainBalanceSheetItemsAccountsPayableandAccruedExpensesDetails" roleURI="http://www.inovio.com/role/CertainBalanceSheetItemsAccountsPayableandAccruedExpensesDetails">
        <link:definition>9955526 - Disclosure - Certain Balance Sheet Items - Accounts Payable and Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleDebtDetails" roleURI="http://www.inovio.com/role/ConvertibleDebtDetails">
        <link:definition>9955527 - Disclosure - Convertible Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails" roleURI="http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails">
        <link:definition>9955528 - Disclosure - Stockholders' Equity - Summary of Authorized and Issued Common and Preferred Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityOfferingofCommonStockWarrantsandPrefundedWarrantsDetails" roleURI="http://www.inovio.com/role/StockholdersEquityOfferingofCommonStockWarrantsandPrefundedWarrantsDetails">
        <link:definition>9955529 - Disclosure - Stockholders' Equity - Offering of Common Stock, Warrants, and Pre-funded Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityAtTheMarketSalesAgreementsDetails" roleURI="http://www.inovio.com/role/StockholdersEquityAtTheMarketSalesAgreementsDetails">
        <link:definition>9955530 - Disclosure - Stockholders' Equity - At-The-Market Sales Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityStockOptionsandRestrictedStockUnitsDetails" roleURI="http://www.inovio.com/role/StockholdersEquityStockOptionsandRestrictedStockUnitsDetails">
        <link:definition>9955531 - Disclosure - Stockholders' Equity - Stock Options and Restricted Stock Units (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareScheduleofBasicandDilutedNetLossPerShareDetails" roleURI="http://www.inovio.com/role/NetLossPerShareScheduleofBasicandDilutedNetLossPerShareDetails">
        <link:definition>9955532 - Disclosure - Net Loss Per Share - Schedule of Basic and Diluted Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareAntidilutiveDetails" roleURI="http://www.inovio.com/role/NetLossPerShareAntidilutiveDetails">
        <link:definition>9955533 - Disclosure - Net Loss Per Share - Anti-dilutive (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationWeightedAverageAssumptionsDetails" roleURI="http://www.inovio.com/role/StockBasedCompensationWeightedAverageAssumptionsDetails">
        <link:definition>9955534 - Disclosure - Stock-Based Compensation - Weighted Average Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationNarrativeDetails" roleURI="http://www.inovio.com/role/StockBasedCompensationNarrativeDetails">
        <link:definition>9955535 - Disclosure - Stock-Based Compensation - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationSignificantAssumptionUsedinMonteCarloSimulationMethodDetails" roleURI="http://www.inovio.com/role/StockBasedCompensationSignificantAssumptionUsedinMonteCarloSimulationMethodDetails">
        <link:definition>9955536 - Disclosure - Stock-Based Compensation - Significant Assumption Used in Monte Carlo Simulation Method (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsDetails" roleURI="http://www.inovio.com/role/RelatedPartyTransactionsDetails">
        <link:definition>9955537 - Disclosure - Related Party Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesNarrativeDetails" roleURI="http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails">
        <link:definition>9955538 - Disclosure - Commitments and Contingencies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesSummaryofFutureMinimumLeasePaymentsDetails" roleURI="http://www.inovio.com/role/CommitmentsandContingenciesSummaryofFutureMinimumLeasePaymentsDetails">
        <link:definition>9955539 - Disclosure - Commitments and Contingencies - Summary of Future Minimum Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesSummaryofFutureMinimumLeasePaymentsDetails_1" roleURI="http://www.inovio.com/role/CommitmentsandContingenciesSummaryofFutureMinimumLeasePaymentsDetails_1">
        <link:definition>9955539 - Disclosure - Commitments and Contingencies - Summary of Future Minimum Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeAgreementsDetails" roleURI="http://www.inovio.com/role/CollaborativeAgreementsDetails">
        <link:definition>9955540 - Disclosure - Collaborative Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GeneosTherapeuticsIncDetails" roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncDetails">
        <link:definition>9955541 - Disclosure - Geneos Therapeutics, Inc. (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationDetails" roleURI="http://www.inovio.com/role/SegmentInformationDetails">
        <link:definition>9955542 - Disclosure - Segment Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="ino_AccruedClinicalTrialExpenseCurrent" abstract="false" name="AccruedClinicalTrialExpenseCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_ChangeInValueOfInvestmentsInAffiliatedCompany" abstract="false" name="ChangeInValueOfInvestmentsInAffiliatedCompany" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_NonCashInterestIncomeExpense" abstract="false" name="NonCashInterestIncomeExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_IncreaseDecreaseInAccruedClinicalTrialExpense" abstract="false" name="IncreaseDecreaseInAccruedClinicalTrialExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet" abstract="false" name="IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_IncreaseDecreaseinDeferredGrantFundingCurrent" abstract="false" name="IncreaseDecreaseinDeferredGrantFundingCurrent" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_ProceedsFromPaymentsForStockOptionsExercisedAndExerciseOfWarrantsNetOfTaxWithholdings" abstract="false" name="ProceedsFromPaymentsForStockOptionsExercisedAndExerciseOfWarrantsNetOfTaxWithholdings" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_CertainBalanceSheetItemsAbstract" abstract="true" name="CertainBalanceSheetItemsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" abstract="false" name="ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="ino_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" abstract="false" name="ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="ino_December2024OfferingWarrantsMember" abstract="true" name="December2024OfferingWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_UnderwrittenRegisteredDirectOfferingMember" abstract="true" name="UnderwrittenRegisteredDirectOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_A2024SalesAgreementMember" abstract="true" name="A2024SalesAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_December2024OfferingMember" abstract="true" name="December2024OfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_WorkingCapital" abstract="false" name="WorkingCapital" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_MutualFundsMember" abstract="true" name="MutualFundsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ino_DebtSecuritiesAvailableforSaleContractualMaturity" abstract="false" name="DebtSecuritiesAvailableforSaleContractualMaturity" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ino_CommonStockWarrantLiabilityFairValue" abstract="false" name="CommonStockWarrantLiabilityFairValue" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_WarrantLiabilityMeasurementInput" abstract="false" name="WarrantLiabilityMeasurementInput" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:decimalItemType"/>
  <xs:element id="ino_PrepaidClinicalExpensesCurrent" abstract="false" name="PrepaidClinicalExpensesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_AccountsPayableAndAccruedExpensesTable" abstract="true" name="AccountsPayableAndAccruedExpensesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="ino_AccountsPayableAndAccruedExpensesLineItems" abstract="true" name="AccountsPayableAndAccruedExpensesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ino_A6.50ConvertibleSeniorNotesDue2024Member" abstract="true" name="A6.50ConvertibleSeniorNotesDue2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ino_ClassOfWarrantOrRightCommonStockOwnershipPercent" abstract="false" name="ClassOfWarrantOrRightCommonStockOwnershipPercent" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ino_ClassOfWarrantOrRightCommonStockOwnershipPriorToIssuancePercent" abstract="false" name="ClassOfWarrantOrRightCommonStockOwnershipPriorToIssuancePercent" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ino_ClassOfWarrantOrRightCommonStockOwnershipMaximumPercent" abstract="false" name="ClassOfWarrantOrRightCommonStockOwnershipMaximumPercent" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ino_A2021SalesAgreementMember" abstract="true" name="A2021SalesAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ino_StockSalesAgreementMaximumAuthorizedAmount" abstract="false" name="StockSalesAgreementMaximumAuthorizedAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage" abstract="false" name="SaleOfStockSalesProceedsOfAnyCommonStockPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="ino_StockSaleAgreementAggregateNumberofSharesIssued" abstract="false" name="StockSaleAgreementAggregateNumberofSharesIssued" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ino_StockSaleAgreementWeightedAveragePricePerShare" abstract="false" name="StockSaleAgreementWeightedAveragePricePerShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock" abstract="false" name="StockSaleAgreementAggregateProceedsFromIssuanceOfStock" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_StockSaleAgreementRemainingCapacityAmount" abstract="false" name="StockSaleAgreementRemainingCapacityAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_A2023IncentivePlanMember" abstract="true" name="A2023IncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ino_A2016IncentivePlanMember" abstract="true" name="A2016IncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ino_A2022InducementPlanMember" abstract="true" name="A2022InducementPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ino_A2007IncentivePlanMember" abstract="true" name="A2007IncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ino_WeightedAverageNumberOfSharesOutstanding" abstract="false" name="WeightedAverageNumberOfSharesOutstanding" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ino_IncrementalCommonSharesAttributableToBasicAndDilutiveEffectOfPreFundedWarrants" abstract="false" name="IncrementalCommonSharesAttributableToBasicAndDilutiveEffectOfPreFundedWarrants" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ino_EarningsPerShareBasicAndDilutedEPSAbstract" abstract="true" name="EarningsPerShareBasicAndDilutedEPSAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ino_ServiceBasedRestrictedStockUnitsMember" abstract="true" name="ServiceBasedRestrictedStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ino_EmployeesAndDirectorsMember" abstract="true" name="EmployeesAndDirectorsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ino_NonEmployeeMember" abstract="true" name="NonEmployeeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ino_RestrictedStockUnitsRSUsMilestoneBasedMember" abstract="true" name="RestrictedStockUnitsRSUsMilestoneBasedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_RestrictedStockUnitsRSUsMarketBasedMember" abstract="true" name="RestrictedStockUnitsRSUsMarketBasedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_RestrictedStockUnitsRSUsTotalShareholderReturnMember" abstract="true" name="RestrictedStockUnitsRSUsTotalShareholderReturnMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_RestrictedStockUnitsPerformanceBasedMember" abstract="true" name="RestrictedStockUnitsPerformanceBasedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_StockOptionsPerformanceBasedMember" abstract="true" name="StockOptionsPerformanceBasedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_December2024Member" abstract="true" name="December2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPercentage" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardUnderlyingCommonStock" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardUnderlyingCommonStock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsGrantDateFairValue" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsGrantDateFairValue" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantDateClosingSharePrice" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantDateClosingSharePrice" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="ino_PlumblineLifeSciencesMember" abstract="true" name="PlumblineLifeSciencesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ino_TheWistarInstituteMember" abstract="true" name="TheWistarInstituteMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ino_CollaborativeAgreementExpensesToReimburse" abstract="false" name="CollaborativeAgreementExpensesToReimburse" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_CollaborativeArrangementTerm" abstract="false" name="CollaborativeArrangementTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ino_CollaborativeAgreementAwardedAmount" abstract="false" name="CollaborativeAgreementAwardedAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_CollaborativeAgreementAmendedAmount" abstract="false" name="CollaborativeAgreementAmendedAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_CollaborativeAgreementAwardedOptionAmount" abstract="false" name="CollaborativeAgreementAwardedOptionAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_GrantProceedsReceived" abstract="false" name="GrantProceedsReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_SanDiegoOfficeMember" abstract="true" name="SanDiegoOfficeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ino_PlymouthMeetingPennsylvaniaMember" abstract="true" name="PlymouthMeetingPennsylvaniaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ino_SanDiegoCaliforniaMember" abstract="true" name="SanDiegoCaliforniaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ino_LesseeOperatingLeaseAreaofLandUnderLease" abstract="false" name="LesseeOperatingLeaseAreaofLandUnderLease" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:areaItemType"/>
  <xs:element id="ino_LesseeOperatingLeaseBaseRatePercentageIncreaseDecrease" abstract="false" name="LesseeOperatingLeaseBaseRatePercentageIncreaseDecrease" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ino_ApolloBioMember" abstract="true" name="ApolloBioMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ino_CoalitionforEpidemicPreparednessInnovationsMember" abstract="true" name="CoalitionforEpidemicPreparednessInnovationsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ino_BillAndMelindaGatesFoundationMember" abstract="true" name="BillAndMelindaGatesFoundationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ino_LassaFeverAndMERSVaccineMember" abstract="true" name="LassaFeverAndMERSVaccineMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ino_DNAEncodedMonoclonalAntibodyTechnologyMember" abstract="true" name="DNAEncodedMonoclonalAntibodyTechnologyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ino_CollaborationAgreementAdditionalRevenueToBeAchieved" abstract="false" name="CollaborationAgreementAdditionalRevenueToBeAchieved" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_CollaborationAgreementRoyaltyPeriod" abstract="false" name="CollaborationAgreementRoyaltyPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ino_CollaborativeAgreementFundingToBeReceived" abstract="false" name="CollaborativeAgreementFundingToBeReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment" abstract="false" name="CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ino_CollaborativeAgreementFundingReceived" abstract="false" name="CollaborativeAgreementFundingReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_GeneosTherapeuticsInc.Member" abstract="true" name="GeneosTherapeuticsInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ino_EquityMethodInvestmentsMinimum" abstract="false" name="EquityMethodInvestmentsMinimum" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_ReportableSegmentsMember" abstract="true" name="ReportableSegmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_ResearchAndDevelopmentCostAxis" abstract="true" name="ResearchAndDevelopmentCostAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="ino_ResearchAndDevelopmentCostDomain" abstract="true" name="ResearchAndDevelopmentCostDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_INO3107Member" abstract="true" name="INO3107Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_INO3112AndOtherImmunoOncologyMember" abstract="true" name="INO3112AndOtherImmunoOncologyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_OtherProgramsMember" abstract="true" name="OtherProgramsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_EngineeringAndDeviceRelatedMember" abstract="true" name="EngineeringAndDeviceRelatedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_StockBasedCompensationMember" abstract="true" name="StockBasedCompensationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_OtherUnallocatedExpensesMember" abstract="true" name="OtherUnallocatedExpensesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>ino-20250331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:382d2453-c46c-4ade-9f50-1f9566f15edb,g:9bfa17de-2275-45c6-a4f6-49112bde99df-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.inovio.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="ino-20250331.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_1dd4100f-556f-46ff-aadb-873d06e07545" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_0508fcee-27ad-4e7e-b657-3bfe22731344" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_1dd4100f-556f-46ff-aadb-873d06e07545" xlink:to="loc_us-gaap_AdditionalPaidInCapital_0508fcee-27ad-4e7e-b657-3bfe22731344" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_ab900977-fab3-4de0-944e-147b1f810af3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_1dd4100f-556f-46ff-aadb-873d06e07545" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_ab900977-fab3-4de0-944e-147b1f810af3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_b03f0806-d42c-4260-be65-017fafb409c6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_1dd4100f-556f-46ff-aadb-873d06e07545" xlink:to="loc_us-gaap_CommonStockValue_b03f0806-d42c-4260-be65-017fafb409c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ad104a48-93a4-4ef5-8831-7932d0df479f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_1dd4100f-556f-46ff-aadb-873d06e07545" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ad104a48-93a4-4ef5-8831-7932d0df479f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_3b0741ab-b75c-4a50-8d3b-d7c934be6164" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_1dd4100f-556f-46ff-aadb-873d06e07545" xlink:to="loc_us-gaap_PreferredStockValue_3b0741ab-b75c-4a50-8d3b-d7c934be6164" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_127849aa-512a-4cf5-a60f-92fbfe234d78" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_10d04e28-a088-44e5-ab62-3cacf4eced4e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_127849aa-512a-4cf5-a60f-92fbfe234d78" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_10d04e28-a088-44e5-ab62-3cacf4eced4e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_d8517156-14ee-4a86-abee-0d8aa22db53b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_127849aa-512a-4cf5-a60f-92fbfe234d78" xlink:to="loc_us-gaap_ShortTermInvestments_d8517156-14ee-4a86-abee-0d8aa22db53b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_8e03a0e3-12c2-411d-8275-7b7091fc064a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_127849aa-512a-4cf5-a60f-92fbfe234d78" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_8e03a0e3-12c2-411d-8275-7b7091fc064a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_d33ab18d-d0f8-4f2c-a9c4-1234330c6427" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_127849aa-512a-4cf5-a60f-92fbfe234d78" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_d33ab18d-d0f8-4f2c-a9c4-1234330c6427" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_0c31b15d-e9ea-4458-8f61-87859335a42e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_d4088494-122a-4032-802b-f685b2e3cbe7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_0c31b15d-e9ea-4458-8f61-87859335a42e" xlink:to="loc_us-gaap_LiabilitiesCurrent_d4088494-122a-4032-802b-f685b2e3cbe7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_6982f232-6c4d-414a-8337-819c0f170040" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_0c31b15d-e9ea-4458-8f61-87859335a42e" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_6982f232-6c4d-414a-8337-819c0f170040" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_6ea7e73b-9505-4c16-a581-091dccaa672c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_58e74f84-d012-4058-a54c-5806dc181175" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_6ea7e73b-9505-4c16-a581-091dccaa672c" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_58e74f84-d012-4058-a54c-5806dc181175" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_3668944f-fea5-4ee4-b0c2-864c56c0a755" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_6ea7e73b-9505-4c16-a581-091dccaa672c" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_3668944f-fea5-4ee4-b0c2-864c56c0a755" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AccruedClinicalTrialExpenseCurrent_4d9ab742-3df9-4817-8a09-b14243b27c37" xlink:href="ino-20250331.xsd#ino_AccruedClinicalTrialExpenseCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_6ea7e73b-9505-4c16-a581-091dccaa672c" xlink:to="loc_ino_AccruedClinicalTrialExpenseCurrent_4d9ab742-3df9-4817-8a09-b14243b27c37" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_10ad84b8-6be3-42ef-94a7-0316b513d201" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_6ea7e73b-9505-4c16-a581-091dccaa672c" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent_10ad84b8-6be3-42ef-94a7-0316b513d201" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_cf10762a-5623-4009-882d-373713bf8def" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_7ca1610f-80a4-4a23-adbe-d02629a74e26" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_cf10762a-5623-4009-882d-373713bf8def" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_7ca1610f-80a4-4a23-adbe-d02629a74e26" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_5198ec33-ce88-4165-b486-8cc75bed6e65" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_cf10762a-5623-4009-882d-373713bf8def" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_5198ec33-ce88-4165-b486-8cc75bed6e65" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_78e4ad12-23ac-4dd3-91f8-1419e106a44f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_cf10762a-5623-4009-882d-373713bf8def" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_78e4ad12-23ac-4dd3-91f8-1419e106a44f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_efae4fc6-22ac-4ac1-b244-cc9f127ec9f3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_cf10762a-5623-4009-882d-373713bf8def" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_efae4fc6-22ac-4ac1-b244-cc9f127ec9f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_aecc7a8f-b5b5-41a3-ab1e-30c8266468a7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_cf10762a-5623-4009-882d-373713bf8def" xlink:to="loc_us-gaap_AssetsCurrent_aecc7a8f-b5b5-41a3-ab1e-30c8266468a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_ebcc0f8e-ef22-4ab2-a138-7eb374663af1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_3afcc5b0-1aa2-4853-a052-ca12314c3302" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_ebcc0f8e-ef22-4ab2-a138-7eb374663af1" xlink:to="loc_us-gaap_Liabilities_3afcc5b0-1aa2-4853-a052-ca12314c3302" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_d33e2f61-7810-45a3-9880-87f2c728d60f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_ebcc0f8e-ef22-4ab2-a138-7eb374663af1" xlink:to="loc_us-gaap_StockholdersEquity_d33e2f61-7810-45a3-9880-87f2c728d60f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="ino-20250331.xsd#CondensedConsolidatedStatementsofOperations"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_7231804d-845a-4e78-9efb-a6921fb8044e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_3ae71fc1-3eb9-4e38-a07b-eeb161d2c2d3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_7231804d-845a-4e78-9efb-a6921fb8044e" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_3ae71fc1-3eb9-4e38-a07b-eeb161d2c2d3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_3ac35e43-0494-4159-a259-e8149db68ca9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_7231804d-845a-4e78-9efb-a6921fb8044e" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_3ac35e43-0494-4159-a259-e8149db68ca9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_061aa70c-96f1-43e9-9498-dca32a5b0fe2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_eee38c79-3698-4b9d-981d-b54b7fe65166" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_061aa70c-96f1-43e9-9498-dca32a5b0fe2" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_eee38c79-3698-4b9d-981d-b54b7fe65166" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_884b2eec-afc4-4e63-a958-240f38b771ef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_061aa70c-96f1-43e9-9498-dca32a5b0fe2" xlink:to="loc_us-gaap_OperatingExpenses_884b2eec-afc4-4e63-a958-240f38b771ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f9c5b8c9-3d02-4951-85da-0b3d039bfa5a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_80e8bad1-c617-4a6e-b8a0-f623f34e8432" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_f9c5b8c9-3d02-4951-85da-0b3d039bfa5a" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_80e8bad1-c617-4a6e-b8a0-f623f34e8432" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_a5011ff4-3097-4365-a342-f644d619aacf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_f9c5b8c9-3d02-4951-85da-0b3d039bfa5a" xlink:to="loc_us-gaap_InvestmentIncomeInterest_a5011ff4-3097-4365-a342-f644d619aacf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_44926700-b653-4e85-a84c-96940f6c0e16" xlink:href="ino-20250331.xsd#ino_ChangeInValueOfInvestmentsInAffiliatedCompany"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_f9c5b8c9-3d02-4951-85da-0b3d039bfa5a" xlink:to="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_44926700-b653-4e85-a84c-96940f6c0e16" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_57449239-8c70-4d68-a657-948549f55bc4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_f9c5b8c9-3d02-4951-85da-0b3d039bfa5a" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_57449239-8c70-4d68-a657-948549f55bc4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_46b3b6ad-8fe5-4301-804d-dd91bda9f86d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_f9c5b8c9-3d02-4951-85da-0b3d039bfa5a" xlink:to="loc_us-gaap_OperatingIncomeLoss_46b3b6ad-8fe5-4301-804d-dd91bda9f86d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating_4f26ca3f-5b0c-4c05-bba7-4f8ee95a91cb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_f9c5b8c9-3d02-4951-85da-0b3d039bfa5a" xlink:to="loc_us-gaap_InterestExpenseNonoperating_4f26ca3f-5b0c-4c05-bba7-4f8ee95a91cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_d3fb0b99-962d-40a6-95a1-f61aa53498f4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_f9c5b8c9-3d02-4951-85da-0b3d039bfa5a" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_d3fb0b99-962d-40a6-95a1-f61aa53498f4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" xlink:type="simple" xlink:href="ino-20250331.xsd#CondensedConsolidatedStatementsofComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_e600c5cb-8734-4c93-82bb-7d616418a26a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_8eaad30d-0839-4af0-a3f0-9028dc656378" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_e600c5cb-8734-4c93-82bb-7d616418a26a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_8eaad30d-0839-4af0-a3f0-9028dc656378" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ff19f8fa-0762-4410-ae0b-dba84902f623" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_e600c5cb-8734-4c93-82bb-7d616418a26a" xlink:to="loc_us-gaap_NetIncomeLoss_ff19f8fa-0762-4410-ae0b-dba84902f623" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_ea35b61c-04f7-4e5b-a013-d437bb209dea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_e600c5cb-8734-4c93-82bb-7d616418a26a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_ea35b61c-04f7-4e5b-a013-d437bb209dea" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="ino-20250331.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_25580667-b318-46bb-81de-e121741bca04" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments_a82ca9af-c4cd-4dd5-ad18-37142d4fdc44" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_25580667-b318-46bb-81de-e121741bca04" xlink:to="loc_us-gaap_PaymentsToAcquireShortTermInvestments_a82ca9af-c4cd-4dd5-ad18-37142d4fdc44" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_c7e8eb4d-1e1d-433c-8a96-4bc73eb5b8d4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_25580667-b318-46bb-81de-e121741bca04" xlink:to="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_c7e8eb4d-1e1d-433c-8a96-4bc73eb5b8d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_873ed868-80ee-439a-a564-2059b74ce54b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_25580667-b318-46bb-81de-e121741bca04" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_873ed868-80ee-439a-a564-2059b74ce54b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ac9decf1-0972-4819-8d01-ae45d6cd5cb3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_79fe42da-0e1f-47d4-ad70-c453141f82f3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ac9decf1-0972-4819-8d01-ae45d6cd5cb3" xlink:to="loc_us-gaap_Depreciation_79fe42da-0e1f-47d4-ad70-c453141f82f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseinDeferredGrantFundingCurrent_eb54b7fc-13e1-4603-98d2-1bfe9dc8d5ce" xlink:href="ino-20250331.xsd#ino_IncreaseDecreaseinDeferredGrantFundingCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ac9decf1-0972-4819-8d01-ae45d6cd5cb3" xlink:to="loc_ino_IncreaseDecreaseinDeferredGrantFundingCurrent_eb54b7fc-13e1-4603-98d2-1bfe9dc8d5ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet_ebfcb8b3-4eb2-49ab-bc0e-479ee6a79541" xlink:href="ino-20250331.xsd#ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ac9decf1-0972-4819-8d01-ae45d6cd5cb3" xlink:to="loc_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet_ebfcb8b3-4eb2-49ab-bc0e-479ee6a79541" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfOtherInvestments_a09c52cb-dabf-4750-a8dd-4f87f5fbff43" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfOtherInvestments"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ac9decf1-0972-4819-8d01-ae45d6cd5cb3" xlink:to="loc_us-gaap_GainLossOnSaleOfOtherInvestments_a09c52cb-dabf-4750-a8dd-4f87f5fbff43" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_06008c6d-482b-436c-8590-64058b391397" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ac9decf1-0972-4819-8d01-ae45d6cd5cb3" xlink:to="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_06008c6d-482b-436c-8590-64058b391397" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_c58abaa3-2110-4997-bf72-1b386d6efbbc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ac9decf1-0972-4819-8d01-ae45d6cd5cb3" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_c58abaa3-2110-4997-bf72-1b386d6efbbc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3e785af7-f629-4353-aad6-5c8b54943f86" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ac9decf1-0972-4819-8d01-ae45d6cd5cb3" xlink:to="loc_us-gaap_NetIncomeLoss_3e785af7-f629-4353-aad6-5c8b54943f86" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_fee3c319-c7a3-4079-95cf-84893b17564d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ac9decf1-0972-4819-8d01-ae45d6cd5cb3" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_fee3c319-c7a3-4079-95cf-84893b17564d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseInAccruedClinicalTrialExpense_197964e4-9fc8-45dc-95ca-63618c99dde3" xlink:href="ino-20250331.xsd#ino_IncreaseDecreaseInAccruedClinicalTrialExpense"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ac9decf1-0972-4819-8d01-ae45d6cd5cb3" xlink:to="loc_ino_IncreaseDecreaseInAccruedClinicalTrialExpense_197964e4-9fc8-45dc-95ca-63618c99dde3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_a9bd7dd3-f3dd-46df-803d-7d11e23cb54c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ac9decf1-0972-4819-8d01-ae45d6cd5cb3" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_a9bd7dd3-f3dd-46df-803d-7d11e23cb54c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_e4b1c302-0864-4df6-8a8d-ad1f0a6aab31" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ac9decf1-0972-4819-8d01-ae45d6cd5cb3" xlink:to="loc_us-gaap_ShareBasedCompensation_e4b1c302-0864-4df6-8a8d-ad1f0a6aab31" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_fd8fd279-927d-4092-bc8c-21717057556f" xlink:href="ino-20250331.xsd#ino_ChangeInValueOfInvestmentsInAffiliatedCompany"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ac9decf1-0972-4819-8d01-ae45d6cd5cb3" xlink:to="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_fd8fd279-927d-4092-bc8c-21717057556f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_8a44f226-f1ea-4664-828a-e66bb7dc19ff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ac9decf1-0972-4819-8d01-ae45d6cd5cb3" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_8a44f226-f1ea-4664-828a-e66bb7dc19ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_NonCashInterestIncomeExpense_0f9786f0-4924-486c-ae36-e913c9b8c8d6" xlink:href="ino-20250331.xsd#ino_NonCashInterestIncomeExpense"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ac9decf1-0972-4819-8d01-ae45d6cd5cb3" xlink:to="loc_ino_NonCashInterestIncomeExpense_0f9786f0-4924-486c-ae36-e913c9b8c8d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_85ef8451-21d3-421a-807c-0be118624ecc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ac9decf1-0972-4819-8d01-ae45d6cd5cb3" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_85ef8451-21d3-421a-807c-0be118624ecc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_391941c7-8250-4365-936a-454a9c2e161d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:calculationArc order="16" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ac9decf1-0972-4819-8d01-ae45d6cd5cb3" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_391941c7-8250-4365-936a-454a9c2e161d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_38174c50-925f-432c-bfac-23073c2ce2b1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2bede2c7-321c-4905-a723-e46b5cc2d0f5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_38174c50-925f-432c-bfac-23073c2ce2b1" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2bede2c7-321c-4905-a723-e46b5cc2d0f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_96c68b68-2828-4f47-b62d-73014817a5b0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_38174c50-925f-432c-bfac-23073c2ce2b1" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_96c68b68-2828-4f47-b62d-73014817a5b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a078f2c8-5591-42d4-bd98-4382340dc28f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_38174c50-925f-432c-bfac-23073c2ce2b1" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a078f2c8-5591-42d4-bd98-4382340dc28f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8a813799-3be1-406d-8cc5-6122e01bd6c7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_38174c50-925f-432c-bfac-23073c2ce2b1" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8a813799-3be1-406d-8cc5-6122e01bd6c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c5239901-a4b5-4e70-a6d2-355fb42af70a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfConvertibleDebt_5a1ae6ee-d801-40b5-8419-fee4a7f82f7f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfConvertibleDebt"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c5239901-a4b5-4e70-a6d2-355fb42af70a" xlink:to="loc_us-gaap_RepaymentsOfConvertibleDebt_5a1ae6ee-d801-40b5-8419-fee4a7f82f7f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ProceedsFromPaymentsForStockOptionsExercisedAndExerciseOfWarrantsNetOfTaxWithholdings_2a3aa3ea-01df-4e50-80b9-90c2425c28bc" xlink:href="ino-20250331.xsd#ino_ProceedsFromPaymentsForStockOptionsExercisedAndExerciseOfWarrantsNetOfTaxWithholdings"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c5239901-a4b5-4e70-a6d2-355fb42af70a" xlink:to="loc_ino_ProceedsFromPaymentsForStockOptionsExercisedAndExerciseOfWarrantsNetOfTaxWithholdings_2a3aa3ea-01df-4e50-80b9-90c2425c28bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_56a0342d-287e-4ea6-b088-85b335df91ff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c5239901-a4b5-4e70-a6d2-355fb42af70a" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_56a0342d-287e-4ea6-b088-85b335df91ff" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails" xlink:type="simple" xlink:href="ino-20250331.xsd#ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_d38ef415-26b0-48a6-ae84-08720c0e1fed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_b8779b71-4c02-4943-bef3-ec2b164ae5f7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_d38ef415-26b0-48a6-ae84-08720c0e1fed" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_b8779b71-4c02-4943-bef3-ec2b164ae5f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_34471336-dde0-4a8f-b586-214b9f676bc6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_d38ef415-26b0-48a6-ae84-08720c0e1fed" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_34471336-dde0-4a8f-b586-214b9f676bc6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_cc67fa09-4cf3-41f1-a110-0a483db80ac0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_d38ef415-26b0-48a6-ae84-08720c0e1fed" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_cc67fa09-4cf3-41f1-a110-0a483db80ac0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="ino-20250331.xsd#ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_7b638249-9a1f-4aa6-9a12-649cb3f41fbf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CommonStockWarrantLiabilityFairValue_ae55698a-c8a2-4151-a1e6-7dd15b54cbbd" xlink:href="ino-20250331.xsd#ino_CommonStockWarrantLiabilityFairValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_7b638249-9a1f-4aa6-9a12-649cb3f41fbf" xlink:to="loc_ino_CommonStockWarrantLiabilityFairValue_ae55698a-c8a2-4151-a1e6-7dd15b54cbbd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_a9319748-4672-47de-9d2c-db722056a8d3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_89e81d24-1560-4d58-b284-e125eb29d6fc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_a9319748-4672-47de-9d2c-db722056a8d3" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_89e81d24-1560-4d58-b284-e125eb29d6fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_db74d3f8-20b5-4ea2-b0c5-644e2ac01852" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_a9319748-4672-47de-9d2c-db722056a8d3" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_db74d3f8-20b5-4ea2-b0c5-644e2ac01852" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CertainBalanceSheetItemsPrepaidandOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="ino-20250331.xsd#CertainBalanceSheetItemsPrepaidandOtherCurrentAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/CertainBalanceSheetItemsPrepaidandOtherCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_8b053cc3-71a6-482d-96e8-fbbf16e5a808" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PrepaidClinicalExpensesCurrent_808aca0d-959d-444f-b3d2-927681b0c2a4" xlink:href="ino-20250331.xsd#ino_PrepaidClinicalExpensesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_8b053cc3-71a6-482d-96e8-fbbf16e5a808" xlink:to="loc_ino_PrepaidClinicalExpensesCurrent_808aca0d-959d-444f-b3d2-927681b0c2a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_41a073cc-04cd-4a14-930b-2cd660f9501f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_8b053cc3-71a6-482d-96e8-fbbf16e5a808" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_41a073cc-04cd-4a14-930b-2cd660f9501f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CertainBalanceSheetItemsAccountsPayableandAccruedExpensesDetails" xlink:type="simple" xlink:href="ino-20250331.xsd#CertainBalanceSheetItemsAccountsPayableandAccruedExpensesDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/CertainBalanceSheetItemsAccountsPayableandAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_3763ba0c-f57e-4e44-a0a7-85a436cd7929" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_5fd75a88-3b5f-41de-8b55-146220f4d7f4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_3763ba0c-f57e-4e44-a0a7-85a436cd7929" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_5fd75a88-3b5f-41de-8b55-146220f4d7f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableTradeCurrentAndNoncurrent_5cb147fb-f494-4d8a-a06c-d8b6e17873e4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableTradeCurrentAndNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_3763ba0c-f57e-4e44-a0a7-85a436cd7929" xlink:to="loc_us-gaap_AccountsPayableTradeCurrentAndNoncurrent_5cb147fb-f494-4d8a-a06c-d8b6e17873e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalariesCurrent_e8b98171-970a-45b2-b8a2-2ed84829343e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedSalariesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_3763ba0c-f57e-4e44-a0a7-85a436cd7929" xlink:to="loc_us-gaap_AccruedSalariesCurrent_e8b98171-970a-45b2-b8a2-2ed84829343e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/NetLossPerShareScheduleofBasicandDilutedNetLossPerShareDetails" xlink:type="simple" xlink:href="ino-20250331.xsd#NetLossPerShareScheduleofBasicandDilutedNetLossPerShareDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/NetLossPerShareScheduleofBasicandDilutedNetLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b579534e-d8a6-4a6b-87f1-e753876f702a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_WeightedAverageNumberOfSharesOutstanding_4065c602-2e26-4286-9864-4728ba0ac19a" xlink:href="ino-20250331.xsd#ino_WeightedAverageNumberOfSharesOutstanding"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b579534e-d8a6-4a6b-87f1-e753876f702a" xlink:to="loc_ino_WeightedAverageNumberOfSharesOutstanding_4065c602-2e26-4286-9864-4728ba0ac19a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncrementalCommonSharesAttributableToBasicAndDilutiveEffectOfPreFundedWarrants_4612ee8a-8fb4-4055-ab6a-c796ce5cb08a" xlink:href="ino-20250331.xsd#ino_IncrementalCommonSharesAttributableToBasicAndDilutiveEffectOfPreFundedWarrants"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b579534e-d8a6-4a6b-87f1-e753876f702a" xlink:to="loc_ino_IncrementalCommonSharesAttributableToBasicAndDilutiveEffectOfPreFundedWarrants_4612ee8a-8fb4-4055-ab6a-c796ce5cb08a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_32887d0a-2b95-4c3a-9fe5-5996d27303e7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_WeightedAverageNumberOfSharesOutstanding_14df1aa0-567b-42e2-92c4-6d080511adb2" xlink:href="ino-20250331.xsd#ino_WeightedAverageNumberOfSharesOutstanding"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_32887d0a-2b95-4c3a-9fe5-5996d27303e7" xlink:to="loc_ino_WeightedAverageNumberOfSharesOutstanding_14df1aa0-567b-42e2-92c4-6d080511adb2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncrementalCommonSharesAttributableToBasicAndDilutiveEffectOfPreFundedWarrants_e8cbfdc2-c0b7-40d9-93ac-f7c7e4acc455" xlink:href="ino-20250331.xsd#ino_IncrementalCommonSharesAttributableToBasicAndDilutiveEffectOfPreFundedWarrants"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_32887d0a-2b95-4c3a-9fe5-5996d27303e7" xlink:to="loc_ino_IncrementalCommonSharesAttributableToBasicAndDilutiveEffectOfPreFundedWarrants_e8cbfdc2-c0b7-40d9-93ac-f7c7e4acc455" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CommitmentsandContingenciesSummaryofFutureMinimumLeasePaymentsDetails" xlink:type="simple" xlink:href="ino-20250331.xsd#CommitmentsandContingenciesSummaryofFutureMinimumLeasePaymentsDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/CommitmentsandContingenciesSummaryofFutureMinimumLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_8736217a-3a7e-442c-b8cc-27f73569bc62" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_379f5d9e-f1d0-4235-8ba8-8aa88fae70a5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_8736217a-3a7e-442c-b8cc-27f73569bc62" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_379f5d9e-f1d0-4235-8ba8-8aa88fae70a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_83e272ec-5629-42dc-b936-a412422c71c1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_8736217a-3a7e-442c-b8cc-27f73569bc62" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_83e272ec-5629-42dc-b936-a412422c71c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3e80bed3-4837-4fdb-bc7b-f966fcd540ef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2e7a2c0a-4a26-4b7e-9c57-57048c20503d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3e80bed3-4837-4fdb-bc7b-f966fcd540ef" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2e7a2c0a-4a26-4b7e-9c57-57048c20503d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_197b412d-73f5-46de-9427-b0d4dbb47d00" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3e80bed3-4837-4fdb-bc7b-f966fcd540ef" xlink:to="loc_us-gaap_OperatingLeaseLiability_197b412d-73f5-46de-9427-b0d4dbb47d00" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CommitmentsandContingenciesSummaryofFutureMinimumLeasePaymentsDetails_1" xlink:type="simple" xlink:href="ino-20250331.xsd#CommitmentsandContingenciesSummaryofFutureMinimumLeasePaymentsDetails_1"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/CommitmentsandContingenciesSummaryofFutureMinimumLeasePaymentsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_7325a5de-cb3d-4ff6-9e28-ddac2da97e93" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_ae772743-128c-465e-8a05-cb5c76676e00" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_7325a5de-cb3d-4ff6-9e28-ddac2da97e93" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_ae772743-128c-465e-8a05-cb5c76676e00" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_0ec839d2-febf-4c8c-b33d-2949b1e3b955" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_7325a5de-cb3d-4ff6-9e28-ddac2da97e93" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_0ec839d2-febf-4c8c-b33d-2949b1e3b955" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_ce0b6cb7-a11b-4666-91d5-136b4b2e2e3b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_7325a5de-cb3d-4ff6-9e28-ddac2da97e93" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_ce0b6cb7-a11b-4666-91d5-136b4b2e2e3b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_3b02b16c-9d05-4807-b0ac-caea8ae3dec7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_7325a5de-cb3d-4ff6-9e28-ddac2da97e93" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_3b02b16c-9d05-4807-b0ac-caea8ae3dec7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_ec0ae290-3852-43aa-af0f-777dabf31793" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_7325a5de-cb3d-4ff6-9e28-ddac2da97e93" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_ec0ae290-3852-43aa-af0f-777dabf31793" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>ino-20250331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:382d2453-c46c-4ade-9f50-1f9566f15edb,g:9bfa17de-2275-45c6-a4f6-49112bde99df-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.inovio.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="ino-20250331.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_19201e08-9b56-4896-9930-81771fb994fe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_a32a3a85-2b81-4d13-80ae-dfc3a9ef6142" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_19201e08-9b56-4896-9930-81771fb994fe" xlink:to="loc_us-gaap_StatementTable_a32a3a85-2b81-4d13-80ae-dfc3a9ef6142" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2e456aa8-a1ad-427c-9713-dfa3fa7344c6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_a32a3a85-2b81-4d13-80ae-dfc3a9ef6142" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2e456aa8-a1ad-427c-9713-dfa3fa7344c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_2e456aa8-a1ad-427c-9713-dfa3fa7344c6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2e456aa8-a1ad-427c-9713-dfa3fa7344c6" xlink:to="loc_us-gaap_RelatedPartyDomain_2e456aa8-a1ad-427c-9713-dfa3fa7344c6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_9fe42960-39ad-46f9-8b57-27c66bcc1c92" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2e456aa8-a1ad-427c-9713-dfa3fa7344c6" xlink:to="loc_us-gaap_RelatedPartyDomain_9fe42960-39ad-46f9-8b57-27c66bcc1c92" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrelatedPartyMember_e3e04b9b-6de2-4fc7-8225-a8773d80de6a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonrelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_9fe42960-39ad-46f9-8b57-27c66bcc1c92" xlink:to="loc_us-gaap_NonrelatedPartyMember_e3e04b9b-6de2-4fc7-8225-a8773d80de6a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_7653db13-e810-48e3-b781-05d4a0786a47" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_9fe42960-39ad-46f9-8b57-27c66bcc1c92" xlink:to="loc_us-gaap_RelatedPartyMember_7653db13-e810-48e3-b781-05d4a0786a47" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_ed5f8539-576e-46b8-9947-e1e572bb884c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_19201e08-9b56-4896-9930-81771fb994fe" xlink:to="loc_us-gaap_AssetsAbstract_ed5f8539-576e-46b8-9947-e1e572bb884c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_1fbe3b02-d4f2-43b3-8244-3abd9a93043d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_ed5f8539-576e-46b8-9947-e1e572bb884c" xlink:to="loc_us-gaap_AssetsCurrentAbstract_1fbe3b02-d4f2-43b3-8244-3abd9a93043d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_23ce97c5-1e62-4bf1-9bde-36d88886ed49" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1fbe3b02-d4f2-43b3-8244-3abd9a93043d" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_23ce97c5-1e62-4bf1-9bde-36d88886ed49" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_d54d2df8-a844-4432-b012-4b23fd1747bd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1fbe3b02-d4f2-43b3-8244-3abd9a93043d" xlink:to="loc_us-gaap_ShortTermInvestments_d54d2df8-a844-4432-b012-4b23fd1747bd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_eb790240-d7fe-45b8-9e4f-6dfa1e5cc6ca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1fbe3b02-d4f2-43b3-8244-3abd9a93043d" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_eb790240-d7fe-45b8-9e4f-6dfa1e5cc6ca" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_da891b57-fb57-4254-a5b7-8b4d6616000f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1fbe3b02-d4f2-43b3-8244-3abd9a93043d" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_da891b57-fb57-4254-a5b7-8b4d6616000f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_ab49a91d-e0fc-49d9-a9da-8640ac613048" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1fbe3b02-d4f2-43b3-8244-3abd9a93043d" xlink:to="loc_us-gaap_AssetsCurrent_ab49a91d-e0fc-49d9-a9da-8640ac613048" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_3021c3e8-d420-46f7-94cb-d0510583f200" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_ed5f8539-576e-46b8-9947-e1e572bb884c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_3021c3e8-d420-46f7-94cb-d0510583f200" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_b5f637d5-f207-4d0b-8d29-1592f75daa95" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_ed5f8539-576e-46b8-9947-e1e572bb884c" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_b5f637d5-f207-4d0b-8d29-1592f75daa95" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_54716d75-622e-45fe-8a07-fec178124f36" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_ed5f8539-576e-46b8-9947-e1e572bb884c" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_54716d75-622e-45fe-8a07-fec178124f36" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_fbf31daa-3155-43c1-b6b7-a4717dbac902" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_ed5f8539-576e-46b8-9947-e1e572bb884c" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_fbf31daa-3155-43c1-b6b7-a4717dbac902" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_513270ca-ac93-4868-833a-6ee67b5bedb5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_ed5f8539-576e-46b8-9947-e1e572bb884c" xlink:to="loc_us-gaap_Assets_513270ca-ac93-4868-833a-6ee67b5bedb5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_beabc432-e790-4b27-9d63-5df75cfb90a0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_19201e08-9b56-4896-9930-81771fb994fe" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_beabc432-e790-4b27-9d63-5df75cfb90a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_cc87fc32-237e-48c5-b6d1-892e3d689cdf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_beabc432-e790-4b27-9d63-5df75cfb90a0" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_cc87fc32-237e-48c5-b6d1-892e3d689cdf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_74cf8855-e13c-4662-a441-0979f68c00f1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_cc87fc32-237e-48c5-b6d1-892e3d689cdf" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_74cf8855-e13c-4662-a441-0979f68c00f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AccruedClinicalTrialExpenseCurrent_9c5f50c5-03f6-42a7-b6e1-04d1cf5b57e6" xlink:href="ino-20250331.xsd#ino_AccruedClinicalTrialExpenseCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_cc87fc32-237e-48c5-b6d1-892e3d689cdf" xlink:to="loc_ino_AccruedClinicalTrialExpenseCurrent_9c5f50c5-03f6-42a7-b6e1-04d1cf5b57e6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_a012312b-af2c-401e-b68a-c51b63aa0537" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_cc87fc32-237e-48c5-b6d1-892e3d689cdf" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent_a012312b-af2c-401e-b68a-c51b63aa0537" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_4d6b74c2-fc10-47b4-8846-0b161b51fdb2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_cc87fc32-237e-48c5-b6d1-892e3d689cdf" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_4d6b74c2-fc10-47b4-8846-0b161b51fdb2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_fa21be95-db87-4ecd-88ad-02d95b5794ab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_cc87fc32-237e-48c5-b6d1-892e3d689cdf" xlink:to="loc_us-gaap_LiabilitiesCurrent_fa21be95-db87-4ecd-88ad-02d95b5794ab" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_0e0b8a13-15ef-4c36-8ad8-07836b833d9e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_beabc432-e790-4b27-9d63-5df75cfb90a0" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_0e0b8a13-15ef-4c36-8ad8-07836b833d9e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_0a667805-a97c-47ef-a90f-caa2e08af6c7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_beabc432-e790-4b27-9d63-5df75cfb90a0" xlink:to="loc_us-gaap_Liabilities_0a667805-a97c-47ef-a90f-caa2e08af6c7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_d9874ad3-f0df-4d86-84c5-6ca3a6afffb4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_beabc432-e790-4b27-9d63-5df75cfb90a0" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_d9874ad3-f0df-4d86-84c5-6ca3a6afffb4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_275b89f7-1724-4114-8ed1-2af2cf29d6e6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_d9874ad3-f0df-4d86-84c5-6ca3a6afffb4" xlink:to="loc_us-gaap_PreferredStockValue_275b89f7-1724-4114-8ed1-2af2cf29d6e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_d627a4f9-3a8c-4c02-a35a-c00f4380718d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_d9874ad3-f0df-4d86-84c5-6ca3a6afffb4" xlink:to="loc_us-gaap_CommonStockValue_d627a4f9-3a8c-4c02-a35a-c00f4380718d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_5d96b27b-ca47-4deb-9202-04202ce0e529" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_d9874ad3-f0df-4d86-84c5-6ca3a6afffb4" xlink:to="loc_us-gaap_AdditionalPaidInCapital_5d96b27b-ca47-4deb-9202-04202ce0e529" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_38b0ca04-532d-4cd8-992b-b096ff07213f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_d9874ad3-f0df-4d86-84c5-6ca3a6afffb4" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_38b0ca04-532d-4cd8-992b-b096ff07213f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_48323b98-b205-4e0b-8faa-809473a38cd4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_d9874ad3-f0df-4d86-84c5-6ca3a6afffb4" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_48323b98-b205-4e0b-8faa-809473a38cd4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_c6ff8cad-8d2a-4b7e-acbe-1bee03f754cb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_d9874ad3-f0df-4d86-84c5-6ca3a6afffb4" xlink:to="loc_us-gaap_StockholdersEquity_c6ff8cad-8d2a-4b7e-acbe-1bee03f754cb" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_43e45d4e-17a4-4453-9a99-07e51c4ba33f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_beabc432-e790-4b27-9d63-5df75cfb90a0" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_43e45d4e-17a4-4453-9a99-07e51c4ba33f" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="ino-20250331.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_d02aaa3c-eaca-49b0-b12f-78ca439133f0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_d716c5e8-45b1-45a5-941c-94b06615b57b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_d02aaa3c-eaca-49b0-b12f-78ca439133f0" xlink:to="loc_us-gaap_StatementTable_d716c5e8-45b1-45a5-941c-94b06615b57b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_eb84eb90-fc5a-45ed-8e8b-d80a5d396cc4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_d716c5e8-45b1-45a5-941c-94b06615b57b" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_eb84eb90-fc5a-45ed-8e8b-d80a5d396cc4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_eb84eb90-fc5a-45ed-8e8b-d80a5d396cc4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_eb84eb90-fc5a-45ed-8e8b-d80a5d396cc4" xlink:to="loc_us-gaap_EquityComponentDomain_eb84eb90-fc5a-45ed-8e8b-d80a5d396cc4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_d6d1f1b8-a12e-4d0a-97ee-5a7277caffdc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_eb84eb90-fc5a-45ed-8e8b-d80a5d396cc4" xlink:to="loc_us-gaap_EquityComponentDomain_d6d1f1b8-a12e-4d0a-97ee-5a7277caffdc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_73a23350-781a-46b1-80e0-2f5e34d3ae12" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_d6d1f1b8-a12e-4d0a-97ee-5a7277caffdc" xlink:to="loc_us-gaap_PreferredStockMember_73a23350-781a-46b1-80e0-2f5e34d3ae12" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_02789816-6e48-4122-b0d5-30f7101012f8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_d6d1f1b8-a12e-4d0a-97ee-5a7277caffdc" xlink:to="loc_us-gaap_CommonStockMember_02789816-6e48-4122-b0d5-30f7101012f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_f1b6dfe3-4d8b-4f3a-b30c-d573745bb5ae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_d6d1f1b8-a12e-4d0a-97ee-5a7277caffdc" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_f1b6dfe3-4d8b-4f3a-b30c-d573745bb5ae" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_df8d1695-5dbb-4f59-9db5-4319a39a744f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_d6d1f1b8-a12e-4d0a-97ee-5a7277caffdc" xlink:to="loc_us-gaap_RetainedEarningsMember_df8d1695-5dbb-4f59-9db5-4319a39a744f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e4f1663d-b957-4ab2-8074-899f8108cc03" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_d6d1f1b8-a12e-4d0a-97ee-5a7277caffdc" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e4f1663d-b957-4ab2-8074-899f8108cc03" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d6b24916-b167-487b-8036-92c9d0fd7f6d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d02aaa3c-eaca-49b0-b12f-78ca439133f0" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d6b24916-b167-487b-8036-92c9d0fd7f6d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_3d11f0e7-bcd3-4a87-a94e-d95c17030b02" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d6b24916-b167-487b-8036-92c9d0fd7f6d" xlink:to="loc_us-gaap_SharesIssued_3d11f0e7-bcd3-4a87-a94e-d95c17030b02" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_b7ffbcec-d1ba-4bc6-a310-32d4df25e45d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d6b24916-b167-487b-8036-92c9d0fd7f6d" xlink:to="loc_us-gaap_StockholdersEquity_b7ffbcec-d1ba-4bc6-a310-32d4df25e45d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_9b33628e-4e7f-45ef-bb81-6b5836562987" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d6b24916-b167-487b-8036-92c9d0fd7f6d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_9b33628e-4e7f-45ef-bb81-6b5836562987" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_6b807673-a373-4687-9910-35e25cffbb65" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d6b24916-b167-487b-8036-92c9d0fd7f6d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_6b807673-a373-4687-9910-35e25cffbb65" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_456b0e91-8988-43df-8ce8-61b6157237da" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d6b24916-b167-487b-8036-92c9d0fd7f6d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_456b0e91-8988-43df-8ce8-61b6157237da" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_98b2125b-0475-46ac-b562-79835e716e6f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d6b24916-b167-487b-8036-92c9d0fd7f6d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_98b2125b-0475-46ac-b562-79835e716e6f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_c80b4e55-acb3-4ba7-aefb-c96421d9a8cd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d6b24916-b167-487b-8036-92c9d0fd7f6d" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_c80b4e55-acb3-4ba7-aefb-c96421d9a8cd" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_cba9043a-cf7a-47bb-89b3-1db8171da15c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d6b24916-b167-487b-8036-92c9d0fd7f6d" xlink:to="loc_us-gaap_NetIncomeLoss_cba9043a-cf7a-47bb-89b3-1db8171da15c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_6583f1b9-2d0c-4afe-9b27-2db738c7a4ee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d6b24916-b167-487b-8036-92c9d0fd7f6d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_6583f1b9-2d0c-4afe-9b27-2db738c7a4ee" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_a503d4c3-f2bb-4568-8430-3878ef00fcad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d6b24916-b167-487b-8036-92c9d0fd7f6d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_a503d4c3-f2bb-4568-8430-3878ef00fcad" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_675b4e1e-9956-4601-8af3-cf58558862c4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssued"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_3b0b161b-9c41-48c9-b6a5-817a274751ce" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails" xlink:type="simple" xlink:href="ino-20250331.xsd#BasisofPresentationLiquidityandRisksandUncertaintiesDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_a9b83778-f722-4353-88a6-e8205c95d56d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_5bfcd8ac-dc6b-4f7f-9e83-5f6f4fb5e260" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_a9b83778-f722-4353-88a6-e8205c95d56d" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_5bfcd8ac-dc6b-4f7f-9e83-5f6f4fb5e260" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_2891ee38-eea4-4dab-8e65-ab4d268c8711" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_5bfcd8ac-dc6b-4f7f-9e83-5f6f4fb5e260" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_2891ee38-eea4-4dab-8e65-ab4d268c8711" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_2891ee38-eea4-4dab-8e65-ab4d268c8711_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_2891ee38-eea4-4dab-8e65-ab4d268c8711" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_2891ee38-eea4-4dab-8e65-ab4d268c8711_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_35f1215c-1b92-4b20-a39c-70ada4e34889" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_2891ee38-eea4-4dab-8e65-ab4d268c8711" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_35f1215c-1b92-4b20-a39c-70ada4e34889" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_December2024OfferingWarrantsMember_3aa4117b-8ff1-4d4c-9413-68a6189bff4e" xlink:href="ino-20250331.xsd#ino_December2024OfferingWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_35f1215c-1b92-4b20-a39c-70ada4e34889" xlink:to="loc_ino_December2024OfferingWarrantsMember_3aa4117b-8ff1-4d4c-9413-68a6189bff4e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_38ecb030-dc7c-4fe3-9f3f-5fc2f193de5c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_5bfcd8ac-dc6b-4f7f-9e83-5f6f4fb5e260" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_38ecb030-dc7c-4fe3-9f3f-5fc2f193de5c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_38ecb030-dc7c-4fe3-9f3f-5fc2f193de5c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_38ecb030-dc7c-4fe3-9f3f-5fc2f193de5c" xlink:to="loc_us-gaap_EquityComponentDomain_38ecb030-dc7c-4fe3-9f3f-5fc2f193de5c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_3dae38bb-0a1b-425d-ab91-1aeea161b3e5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_38ecb030-dc7c-4fe3-9f3f-5fc2f193de5c" xlink:to="loc_us-gaap_EquityComponentDomain_3dae38bb-0a1b-425d-ab91-1aeea161b3e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_45e7efb9-70ed-41db-ae57-aa01cb0fabbc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3dae38bb-0a1b-425d-ab91-1aeea161b3e5" xlink:to="loc_us-gaap_CommonStockMember_45e7efb9-70ed-41db-ae57-aa01cb0fabbc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_35349f01-ceda-425a-899c-f72e42c5e721" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3dae38bb-0a1b-425d-ab91-1aeea161b3e5" xlink:to="loc_us-gaap_WarrantMember_35349f01-ceda-425a-899c-f72e42c5e721" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_183747f2-60b4-41c8-a2ff-e68fb09ee918" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_5bfcd8ac-dc6b-4f7f-9e83-5f6f4fb5e260" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_183747f2-60b4-41c8-a2ff-e68fb09ee918" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_183747f2-60b4-41c8-a2ff-e68fb09ee918_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_183747f2-60b4-41c8-a2ff-e68fb09ee918" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_183747f2-60b4-41c8-a2ff-e68fb09ee918_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e175e6bf-b9f7-4fda-8f26-32202551270f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_183747f2-60b4-41c8-a2ff-e68fb09ee918" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e175e6bf-b9f7-4fda-8f26-32202551270f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_UnderwrittenRegisteredDirectOfferingMember_bec3136c-fce3-4887-b3be-ab24892caf16" xlink:href="ino-20250331.xsd#ino_UnderwrittenRegisteredDirectOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e175e6bf-b9f7-4fda-8f26-32202551270f" xlink:to="loc_ino_UnderwrittenRegisteredDirectOfferingMember_bec3136c-fce3-4887-b3be-ab24892caf16" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A2024SalesAgreementMember_02f94783-478f-480c-bc02-3a6323c7c329" xlink:href="ino-20250331.xsd#ino_A2024SalesAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e175e6bf-b9f7-4fda-8f26-32202551270f" xlink:to="loc_ino_A2024SalesAgreementMember_02f94783-478f-480c-bc02-3a6323c7c329" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_December2024OfferingMember_23a06167-2950-45ae-81bf-fcc5b692d380" xlink:href="ino-20250331.xsd#ino_December2024OfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e175e6bf-b9f7-4fda-8f26-32202551270f" xlink:to="loc_ino_December2024OfferingMember_23a06167-2950-45ae-81bf-fcc5b692d380" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_9386c1f6-1cc6-4cd8-a3c9-a26366a2ee46" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_5bfcd8ac-dc6b-4f7f-9e83-5f6f4fb5e260" xlink:to="loc_us-gaap_StatementClassOfStockAxis_9386c1f6-1cc6-4cd8-a3c9-a26366a2ee46" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_9386c1f6-1cc6-4cd8-a3c9-a26366a2ee46_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_9386c1f6-1cc6-4cd8-a3c9-a26366a2ee46" xlink:to="loc_us-gaap_ClassOfStockDomain_9386c1f6-1cc6-4cd8-a3c9-a26366a2ee46_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_adcab22c-d674-4d96-b803-53a7937b5a56" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_9386c1f6-1cc6-4cd8-a3c9-a26366a2ee46" xlink:to="loc_us-gaap_ClassOfStockDomain_adcab22c-d674-4d96-b803-53a7937b5a56" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_b83c8cac-baf2-44cb-9264-03c2c4f07d89" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_adcab22c-d674-4d96-b803-53a7937b5a56" xlink:to="loc_us-gaap_CommonStockMember_b83c8cac-baf2-44cb-9264-03c2c4f07d89" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_846ed9c9-b6aa-4e53-b1e1-02aeaaf9eb67" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_a9b83778-f722-4353-88a6-e8205c95d56d" xlink:to="loc_us-gaap_NetIncomeLoss_846ed9c9-b6aa-4e53-b1e1-02aeaaf9eb67" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_WorkingCapital_de70be5b-af3e-41f9-9355-ed59073fae97" xlink:href="ino-20250331.xsd#ino_WorkingCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_a9b83778-f722-4353-88a6-e8205c95d56d" xlink:to="loc_ino_WorkingCapital_de70be5b-af3e-41f9-9355-ed59073fae97" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_4d01abd4-8053-4938-ba94-687e34dd9631" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_a9b83778-f722-4353-88a6-e8205c95d56d" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_4d01abd4-8053-4938-ba94-687e34dd9631" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_96e4732a-a76e-4998-901b-d7956328c1a6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_a9b83778-f722-4353-88a6-e8205c95d56d" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_96e4732a-a76e-4998-901b-d7956328c1a6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_9439d9e3-3d1c-4722-9ebb-ef95cb5d6f63" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_a9b83778-f722-4353-88a6-e8205c95d56d" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_9439d9e3-3d1c-4722-9ebb-ef95cb5d6f63" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_4b273b1a-d07e-4bc0-bd35-6ac8714f54cf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_a9b83778-f722-4353-88a6-e8205c95d56d" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_4b273b1a-d07e-4bc0-bd35-6ac8714f54cf" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_6542fab1-0696-474f-a554-bc0eebe69681" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_a9b83778-f722-4353-88a6-e8205c95d56d" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_6542fab1-0696-474f-a554-bc0eebe69681" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_9bcd8269-bf73-4e93-bed6-59cd98b16052" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_a9b83778-f722-4353-88a6-e8205c95d56d" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_9bcd8269-bf73-4e93-bed6-59cd98b16052" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_5a8ac926-aa40-4b9c-b8e5-05c80fa621be" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_a9b83778-f722-4353-88a6-e8205c95d56d" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_5a8ac926-aa40-4b9c-b8e5-05c80fa621be" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_7686d792-4103-42c0-ab8b-4b1a0103759f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_a9b83778-f722-4353-88a6-e8205c95d56d" xlink:to="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_7686d792-4103-42c0-ab8b-4b1a0103759f" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_b3f20038-724a-4797-8818-f4d1fb238d2d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_a9b83778-f722-4353-88a6-e8205c95d56d" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_b3f20038-724a-4797-8818-f4d1fb238d2d" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_373eb15e-0c2b-4ffa-9ece-01318e70b3c3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_a9b83778-f722-4353-88a6-e8205c95d56d" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_373eb15e-0c2b-4ffa-9ece-01318e70b3c3" xlink:type="arc" order="11"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails" xlink:type="simple" xlink:href="ino-20250331.xsd#ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_891eae1d-898c-4863-99b4-8063d6489133" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_9bea7d72-020c-4967-bfbf-aadafef6785e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_891eae1d-898c-4863-99b4-8063d6489133" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_9bea7d72-020c-4967-bfbf-aadafef6785e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_97e40c67-682c-4728-b20e-63852b147707" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_9bea7d72-020c-4967-bfbf-aadafef6785e" xlink:to="loc_us-gaap_FinancialInstrumentAxis_97e40c67-682c-4728-b20e-63852b147707" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_97e40c67-682c-4728-b20e-63852b147707_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_97e40c67-682c-4728-b20e-63852b147707" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_97e40c67-682c-4728-b20e-63852b147707_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fbce33b4-c062-49ee-a350-1f8b66ad17e6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_97e40c67-682c-4728-b20e-63852b147707" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fbce33b4-c062-49ee-a350-1f8b66ad17e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_MutualFundsMember_88c4a43d-96a0-4723-9020-4e4fb7ad6cd6" xlink:href="ino-20250331.xsd#ino_MutualFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fbce33b4-c062-49ee-a350-1f8b66ad17e6" xlink:to="loc_ino_MutualFundsMember_88c4a43d-96a0-4723-9020-4e4fb7ad6cd6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_b0e4373d-9b06-40d2-9886-61c82d29acb0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fbce33b4-c062-49ee-a350-1f8b66ad17e6" xlink:to="loc_us-gaap_CertificatesOfDepositMember_b0e4373d-9b06-40d2-9886-61c82d29acb0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember_a271e815-c333-411c-989d-d47e021b63d2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fbce33b4-c062-49ee-a350-1f8b66ad17e6" xlink:to="loc_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember_a271e815-c333-411c-989d-d47e021b63d2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DebtSecuritiesAvailableforSaleContractualMaturity_b9e855e6-884c-44ec-a5dd-e6919e02f437" xlink:href="ino-20250331.xsd#ino_DebtSecuritiesAvailableforSaleContractualMaturity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_891eae1d-898c-4863-99b4-8063d6489133" xlink:to="loc_ino_DebtSecuritiesAvailableforSaleContractualMaturity_b9e855e6-884c-44ec-a5dd-e6919e02f437" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_f2c436c4-b605-402d-ad07-51c29161e833" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_891eae1d-898c-4863-99b4-8063d6489133" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAbstract_f2c436c4-b605-402d-ad07-51c29161e833" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_e2e210f9-279d-4848-9865-4019fd96cb97" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_f2c436c4-b605-402d-ad07-51c29161e833" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_e2e210f9-279d-4848-9865-4019fd96cb97" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_31f550ae-e389-40be-a5e0-e61c67257985" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_f2c436c4-b605-402d-ad07-51c29161e833" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_31f550ae-e389-40be-a5e0-e61c67257985" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_155dc9eb-2969-47b8-8f8e-db5e53d992ac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_f2c436c4-b605-402d-ad07-51c29161e833" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_155dc9eb-2969-47b8-8f8e-db5e53d992ac" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1fc5a55a-26f3-46cd-b5a9-3551a166cd48" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_f2c436c4-b605-402d-ad07-51c29161e833" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1fc5a55a-26f3-46cd-b5a9-3551a166cd48" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="ino-20250331.xsd#ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_545353ef-5028-49bb-988f-c04043f65106" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_f040e04a-928a-430b-b253-feb9df242aad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_545353ef-5028-49bb-988f-c04043f65106" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_f040e04a-928a-430b-b253-feb9df242aad" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1e832798-378b-4800-bb4a-f40f9479a814" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_f040e04a-928a-430b-b253-feb9df242aad" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1e832798-378b-4800-bb4a-f40f9479a814" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1e832798-378b-4800-bb4a-f40f9479a814_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1e832798-378b-4800-bb4a-f40f9479a814" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1e832798-378b-4800-bb4a-f40f9479a814_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_23cb5cd6-8854-4c59-a511-849a4726355b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1e832798-378b-4800-bb4a-f40f9479a814" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_23cb5cd6-8854-4c59-a511-849a4726355b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_db7c2da9-3c5b-4b15-a1b7-6a2422db5b6d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_23cb5cd6-8854-4c59-a511-849a4726355b" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_db7c2da9-3c5b-4b15-a1b7-6a2422db5b6d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_2995b0c6-29ff-44be-bb97-2056f6bcde95" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_545353ef-5028-49bb-988f-c04043f65106" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_2995b0c6-29ff-44be-bb97-2056f6bcde95" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_7bcdb28b-0bad-4558-806c-3257d275c21c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_545353ef-5028-49bb-988f-c04043f65106" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_7bcdb28b-0bad-4558-806c-3257d275c21c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_855cf18d-eadd-48a3-a127-4d4406b20633" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_545353ef-5028-49bb-988f-c04043f65106" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_855cf18d-eadd-48a3-a127-4d4406b20633" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_3e22e36e-9fc7-4a02-a209-f538f0fcbc06" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_545353ef-5028-49bb-988f-c04043f65106" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_3e22e36e-9fc7-4a02-a209-f538f0fcbc06" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_57bbd7ce-8960-4d38-bfc9-66d57b984bc6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_545353ef-5028-49bb-988f-c04043f65106" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_57bbd7ce-8960-4d38-bfc9-66d57b984bc6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares_47ca6e8e-a012-4696-a330-193699739bb2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_545353ef-5028-49bb-988f-c04043f65106" xlink:to="loc_us-gaap_InvestmentOwnedBalanceShares_47ca6e8e-a012-4696-a330-193699739bb2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_a61adca4-9d34-4207-ada0-b03d04577675" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_545353ef-5028-49bb-988f-c04043f65106" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_a61adca4-9d34-4207-ada0-b03d04577675" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="ino-20250331.xsd#ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_cba24271-1319-4a75-ba2a-f37f230bbe75" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_df2ed5d1-b78d-4e61-af46-3ce99930c0ae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_cba24271-1319-4a75-ba2a-f37f230bbe75" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_df2ed5d1-b78d-4e61-af46-3ce99930c0ae" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c9b8aa16-7523-4ad6-b97b-960a445d94fe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_df2ed5d1-b78d-4e61-af46-3ce99930c0ae" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c9b8aa16-7523-4ad6-b97b-960a445d94fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_c9b8aa16-7523-4ad6-b97b-960a445d94fe_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c9b8aa16-7523-4ad6-b97b-960a445d94fe" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_c9b8aa16-7523-4ad6-b97b-960a445d94fe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_003971d2-b231-4ad1-9d76-d842d53f6f7e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c9b8aa16-7523-4ad6-b97b-960a445d94fe" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_003971d2-b231-4ad1-9d76-d842d53f6f7e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_07085da1-cd5b-4691-b639-9b5ed0163114" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_003971d2-b231-4ad1-9d76-d842d53f6f7e" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_07085da1-cd5b-4691-b639-9b5ed0163114" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_23df905b-2a5b-46d7-b234-137d8b8f7f9a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_df2ed5d1-b78d-4e61-af46-3ce99930c0ae" xlink:to="loc_us-gaap_FinancialInstrumentAxis_23df905b-2a5b-46d7-b234-137d8b8f7f9a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_23df905b-2a5b-46d7-b234-137d8b8f7f9a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_23df905b-2a5b-46d7-b234-137d8b8f7f9a" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_23df905b-2a5b-46d7-b234-137d8b8f7f9a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a1dd48a0-3d22-497e-a681-59e94f166a13" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_23df905b-2a5b-46d7-b234-137d8b8f7f9a" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a1dd48a0-3d22-497e-a681-59e94f166a13" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_MutualFundsMember_a06a77a0-6966-43d8-a7f1-8cfcd54d9491" xlink:href="ino-20250331.xsd#ino_MutualFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a1dd48a0-3d22-497e-a681-59e94f166a13" xlink:to="loc_ino_MutualFundsMember_a06a77a0-6966-43d8-a7f1-8cfcd54d9491" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_29c4a84d-e075-49b2-a64e-d9304b0a67ac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a1dd48a0-3d22-497e-a681-59e94f166a13" xlink:to="loc_us-gaap_CertificatesOfDepositMember_29c4a84d-e075-49b2-a64e-d9304b0a67ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember_aa9edd97-9588-46dd-9fd1-ba24c3fab092" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a1dd48a0-3d22-497e-a681-59e94f166a13" xlink:to="loc_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember_aa9edd97-9588-46dd-9fd1-ba24c3fab092" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_843004e0-e85e-4c62-afc5-7e7a9eb95b3a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_df2ed5d1-b78d-4e61-af46-3ce99930c0ae" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_843004e0-e85e-4c62-afc5-7e7a9eb95b3a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_843004e0-e85e-4c62-afc5-7e7a9eb95b3a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_843004e0-e85e-4c62-afc5-7e7a9eb95b3a" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_843004e0-e85e-4c62-afc5-7e7a9eb95b3a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_16879f5f-4875-4e69-976e-71cf8147d590" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_843004e0-e85e-4c62-afc5-7e7a9eb95b3a" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_16879f5f-4875-4e69-976e-71cf8147d590" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_334610ee-8143-4e02-85de-91f0da1d4f8c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_16879f5f-4875-4e69-976e-71cf8147d590" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_334610ee-8143-4e02-85de-91f0da1d4f8c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_30e496a7-11e4-4241-9a43-7c7e22ba24a6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_16879f5f-4875-4e69-976e-71cf8147d590" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_30e496a7-11e4-4241-9a43-7c7e22ba24a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_72945aaa-8e76-481a-a9c5-c0c6ea48568e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_16879f5f-4875-4e69-976e-71cf8147d590" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_72945aaa-8e76-481a-a9c5-c0c6ea48568e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_a06d81f2-f6fd-4c66-95ec-8c0663d71b62" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_cba24271-1319-4a75-ba2a-f37f230bbe75" xlink:to="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_a06d81f2-f6fd-4c66-95ec-8c0663d71b62" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_10698cd8-9f7b-47c0-916d-213458a4b1a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_a06d81f2-f6fd-4c66-95ec-8c0663d71b62" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_10698cd8-9f7b-47c0-916d-213458a4b1a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7ece372b-64a9-4a18-b137-e8cd956f84dc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_10698cd8-9f7b-47c0-916d-213458a4b1a2" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7ece372b-64a9-4a18-b137-e8cd956f84dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_dac6fb87-f8d2-49ad-8cf4-0aa880c6760d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_10698cd8-9f7b-47c0-916d-213458a4b1a2" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_dac6fb87-f8d2-49ad-8cf4-0aa880c6760d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_b2721c04-1873-47e7-b04f-8f944717322d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_10698cd8-9f7b-47c0-916d-213458a4b1a2" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_b2721c04-1873-47e7-b04f-8f944717322d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_9a9c01d2-9cd5-4367-8d1e-9791d861b41a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_cba24271-1319-4a75-ba2a-f37f230bbe75" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_9a9c01d2-9cd5-4367-8d1e-9791d861b41a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CommonStockWarrantLiabilityFairValue_2985a961-a0a1-45c9-8ca2-067a3b42d71a" xlink:href="ino-20250331.xsd#ino_CommonStockWarrantLiabilityFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_9a9c01d2-9cd5-4367-8d1e-9791d861b41a" xlink:to="loc_ino_CommonStockWarrantLiabilityFairValue_2985a961-a0a1-45c9-8ca2-067a3b42d71a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_9bf629be-4167-427d-abdd-07f174d50ba9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_9a9c01d2-9cd5-4367-8d1e-9791d861b41a" xlink:to="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_9bf629be-4167-427d-abdd-07f174d50ba9" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAssumptionsUsedToEstimateTheFairValueOfWarrantsDetails" xlink:type="simple" xlink:href="ino-20250331.xsd#ShorttermInvestmentsandFairValueMeasurementsScheduleofAssumptionsUsedToEstimateTheFairValueOfWarrantsDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAssumptionsUsedToEstimateTheFairValueOfWarrantsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b23c905d-d26a-4d05-83d2-9cdc873966d9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_305dbd2a-bf14-460c-8b81-5fc2ecc0a570" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b23c905d-d26a-4d05-83d2-9cdc873966d9" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_305dbd2a-bf14-460c-8b81-5fc2ecc0a570" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_1cce8365-1b98-4e06-bd70-a40ad798a111" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_305dbd2a-bf14-460c-8b81-5fc2ecc0a570" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_1cce8365-1b98-4e06-bd70-a40ad798a111" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_1cce8365-1b98-4e06-bd70-a40ad798a111_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_1cce8365-1b98-4e06-bd70-a40ad798a111" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_1cce8365-1b98-4e06-bd70-a40ad798a111_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_b02e5751-6117-4dd3-a7b0-36abbb5cde81" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_1cce8365-1b98-4e06-bd70-a40ad798a111" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_b02e5751-6117-4dd3-a7b0-36abbb5cde81" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_8814a843-6da2-4699-aacb-2c4e70bc85cb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_b02e5751-6117-4dd3-a7b0-36abbb5cde81" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_8814a843-6da2-4699-aacb-2c4e70bc85cb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_8a9ad3ce-dc34-45b8-b292-2a6152f24c5e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_b02e5751-6117-4dd3-a7b0-36abbb5cde81" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_8a9ad3ce-dc34-45b8-b292-2a6152f24c5e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_41b84491-cbf6-4fbf-97ca-a45324c00271" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_b02e5751-6117-4dd3-a7b0-36abbb5cde81" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_41b84491-cbf6-4fbf-97ca-a45324c00271" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_44e630ad-1f29-43d2-b795-7174865ca53c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_b02e5751-6117-4dd3-a7b0-36abbb5cde81" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_44e630ad-1f29-43d2-b795-7174865ca53c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_WarrantLiabilityMeasurementInput_c078221b-dd01-4b97-9f14-981a87807099" xlink:href="ino-20250331.xsd#ino_WarrantLiabilityMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b23c905d-d26a-4d05-83d2-9cdc873966d9" xlink:to="loc_ino_WarrantLiabilityMeasurementInput_c078221b-dd01-4b97-9f14-981a87807099" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CertainBalanceSheetItemsAccountsPayableandAccruedExpensesDetails" xlink:type="simple" xlink:href="ino-20250331.xsd#CertainBalanceSheetItemsAccountsPayableandAccruedExpensesDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/CertainBalanceSheetItemsAccountsPayableandAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ino_AccountsPayableAndAccruedExpensesLineItems_e956f3a0-4ef6-4a26-80c9-298c9a1fa55f" xlink:href="ino-20250331.xsd#ino_AccountsPayableAndAccruedExpensesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AccountsPayableAndAccruedExpensesTable_695fb5e6-146d-43d2-85a4-e06c9f2323c2" xlink:href="ino-20250331.xsd#ino_AccountsPayableAndAccruedExpensesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ino_AccountsPayableAndAccruedExpensesLineItems_e956f3a0-4ef6-4a26-80c9-298c9a1fa55f" xlink:to="loc_ino_AccountsPayableAndAccruedExpensesTable_695fb5e6-146d-43d2-85a4-e06c9f2323c2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5c9a0e23-5c56-4b9a-be49-23f6b7919751" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ino_AccountsPayableAndAccruedExpensesTable_695fb5e6-146d-43d2-85a4-e06c9f2323c2" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5c9a0e23-5c56-4b9a-be49-23f6b7919751" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_5c9a0e23-5c56-4b9a-be49-23f6b7919751_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5c9a0e23-5c56-4b9a-be49-23f6b7919751" xlink:to="loc_us-gaap_RelatedPartyDomain_5c9a0e23-5c56-4b9a-be49-23f6b7919751_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_b0dec921-e94b-4926-a74a-6b79ad658032" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5c9a0e23-5c56-4b9a-be49-23f6b7919751" xlink:to="loc_us-gaap_RelatedPartyDomain_b0dec921-e94b-4926-a74a-6b79ad658032" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrelatedPartyMember_38386e21-d171-47e0-8add-83cd725061b3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonrelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_b0dec921-e94b-4926-a74a-6b79ad658032" xlink:to="loc_us-gaap_NonrelatedPartyMember_38386e21-d171-47e0-8add-83cd725061b3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableTradeCurrentAndNoncurrent_d7c0a30e-5da3-4ad0-a533-3de262083e47" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableTradeCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_AccountsPayableAndAccruedExpensesLineItems_e956f3a0-4ef6-4a26-80c9-298c9a1fa55f" xlink:to="loc_us-gaap_AccountsPayableTradeCurrentAndNoncurrent_d7c0a30e-5da3-4ad0-a533-3de262083e47" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalariesCurrent_14ee04bc-6624-4aef-9715-7d6a573a0964" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedSalariesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_AccountsPayableAndAccruedExpensesLineItems_e956f3a0-4ef6-4a26-80c9-298c9a1fa55f" xlink:to="loc_us-gaap_AccruedSalariesCurrent_14ee04bc-6624-4aef-9715-7d6a573a0964" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_54096148-8f2a-4a66-8529-32f1a0df31dd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_AccountsPayableAndAccruedExpensesLineItems_e956f3a0-4ef6-4a26-80c9-298c9a1fa55f" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_54096148-8f2a-4a66-8529-32f1a0df31dd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_703b4ab5-0d10-4ded-bbb3-9e74033b092b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_AccountsPayableAndAccruedExpensesLineItems_e956f3a0-4ef6-4a26-80c9-298c9a1fa55f" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_703b4ab5-0d10-4ded-bbb3-9e74033b092b" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebtDetails" xlink:type="simple" xlink:href="ino-20250331.xsd#ConvertibleDebtDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/ConvertibleDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_577ebeed-8cce-40a5-a9fe-7c9dcb73b46f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_9df3d186-dc56-488a-8c16-2b568deed61d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_577ebeed-8cce-40a5-a9fe-7c9dcb73b46f" xlink:to="loc_us-gaap_DebtInstrumentTable_9df3d186-dc56-488a-8c16-2b568deed61d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_d130540e-202e-4818-be8a-9c4d3ab32c63" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_9df3d186-dc56-488a-8c16-2b568deed61d" xlink:to="loc_us-gaap_DebtInstrumentAxis_d130540e-202e-4818-be8a-9c4d3ab32c63" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_d130540e-202e-4818-be8a-9c4d3ab32c63_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_d130540e-202e-4818-be8a-9c4d3ab32c63" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_d130540e-202e-4818-be8a-9c4d3ab32c63_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_44fb9b70-c909-4b65-8c19-cbf2ecf2dc4d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_d130540e-202e-4818-be8a-9c4d3ab32c63" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_44fb9b70-c909-4b65-8c19-cbf2ecf2dc4d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_1cc7d7a9-d21b-4ef1-8974-912ddb649251" xlink:href="ino-20250331.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_44fb9b70-c909-4b65-8c19-cbf2ecf2dc4d" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_1cc7d7a9-d21b-4ef1-8974-912ddb649251" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_11254860-d58a-49b1-9d57-cdae1d610ad3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_9df3d186-dc56-488a-8c16-2b568deed61d" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_11254860-d58a-49b1-9d57-cdae1d610ad3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_11254860-d58a-49b1-9d57-cdae1d610ad3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_11254860-d58a-49b1-9d57-cdae1d610ad3" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_11254860-d58a-49b1-9d57-cdae1d610ad3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_c6d7055d-beec-4269-8837-3be9848124d2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_11254860-d58a-49b1-9d57-cdae1d610ad3" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_c6d7055d-beec-4269-8837-3be9848124d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_70bd216f-7ab5-4ec6-a647-1f7106530f6f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_c6d7055d-beec-4269-8837-3be9848124d2" xlink:to="loc_us-gaap_ConvertibleDebtMember_70bd216f-7ab5-4ec6-a647-1f7106530f6f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_1184f6cd-42f8-4072-afdf-320d50b78475" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_577ebeed-8cce-40a5-a9fe-7c9dcb73b46f" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_1184f6cd-42f8-4072-afdf-320d50b78475" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_ae999a00-60ae-4eba-afbc-ec8f061ab546" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_577ebeed-8cce-40a5-a9fe-7c9dcb73b46f" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_ae999a00-60ae-4eba-afbc-ec8f061ab546" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_fcd9f840-6869-4e1c-96ac-3c2f5c0190bf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_577ebeed-8cce-40a5-a9fe-7c9dcb73b46f" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_fcd9f840-6869-4e1c-96ac-3c2f5c0190bf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfConvertibleDebt_2934589b-08de-47f0-8fcd-3aa063fdca2c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfConvertibleDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_577ebeed-8cce-40a5-a9fe-7c9dcb73b46f" xlink:to="loc_us-gaap_RepaymentsOfConvertibleDebt_2934589b-08de-47f0-8fcd-3aa063fdca2c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseOperating_1b27debd-5d41-44eb-b449-ac23b95bc4ce" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseOperating"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_577ebeed-8cce-40a5-a9fe-7c9dcb73b46f" xlink:to="loc_us-gaap_InterestExpenseOperating_1b27debd-5d41-44eb-b449-ac23b95bc4ce" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails" xlink:type="simple" xlink:href="ino-20250331.xsd#StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_6c398d53-8140-4f85-925a-afb7769e39c7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_f882d44e-f3cf-44e6-9fe5-9f8c1c43a427" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_6c398d53-8140-4f85-925a-afb7769e39c7" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_f882d44e-f3cf-44e6-9fe5-9f8c1c43a427" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_44358882-412b-4220-90dd-b71cb5179968" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_f882d44e-f3cf-44e6-9fe5-9f8c1c43a427" xlink:to="loc_us-gaap_StatementClassOfStockAxis_44358882-412b-4220-90dd-b71cb5179968" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_44358882-412b-4220-90dd-b71cb5179968_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_44358882-412b-4220-90dd-b71cb5179968" xlink:to="loc_us-gaap_ClassOfStockDomain_44358882-412b-4220-90dd-b71cb5179968_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_003680df-d774-421c-ae13-324330d67a46" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_44358882-412b-4220-90dd-b71cb5179968" xlink:to="loc_us-gaap_ClassOfStockDomain_003680df-d774-421c-ae13-324330d67a46" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_f8836969-0dcf-4725-b882-727e7dc1ac9f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesCPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_003680df-d774-421c-ae13-324330d67a46" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_f8836969-0dcf-4725-b882-727e7dc1ac9f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_3a1722bd-2094-459b-8657-eda2b9beafe1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6c398d53-8140-4f85-925a-afb7769e39c7" xlink:to="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_3a1722bd-2094-459b-8657-eda2b9beafe1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_9fb00077-d800-4ae5-b1e7-e12a67947347" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_3a1722bd-2094-459b-8657-eda2b9beafe1" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_9fb00077-d800-4ae5-b1e7-e12a67947347" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_7f09780f-0162-4abd-9860-2c1145797b11" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_3a1722bd-2094-459b-8657-eda2b9beafe1" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_7f09780f-0162-4abd-9860-2c1145797b11" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_00235c61-58a9-4ef6-b7d8-565e101f7329" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_3a1722bd-2094-459b-8657-eda2b9beafe1" xlink:to="loc_us-gaap_CommonStockSharesIssued_00235c61-58a9-4ef6-b7d8-565e101f7329" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_6e59a8de-abe2-4e93-b359-7aad8a4bcf49" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_3a1722bd-2094-459b-8657-eda2b9beafe1" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_6e59a8de-abe2-4e93-b359-7aad8a4bcf49" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_05777d18-9b51-4848-b480-882e2629168b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_3a1722bd-2094-459b-8657-eda2b9beafe1" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_05777d18-9b51-4848-b480-882e2629168b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_d785a648-24ee-4271-97d3-2fda9b9a1e81" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_3a1722bd-2094-459b-8657-eda2b9beafe1" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_d785a648-24ee-4271-97d3-2fda9b9a1e81" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_c0f5c3f0-bdce-441f-8a6f-02928d06e08d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_3a1722bd-2094-459b-8657-eda2b9beafe1" xlink:to="loc_us-gaap_PreferredStockSharesIssued_c0f5c3f0-bdce-441f-8a6f-02928d06e08d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_decea834-f2bd-4372-b297-e4c0c647caa7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_3a1722bd-2094-459b-8657-eda2b9beafe1" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_decea834-f2bd-4372-b297-e4c0c647caa7" xlink:type="arc" order="8"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquityOfferingofCommonStockWarrantsandPrefundedWarrantsDetails" xlink:type="simple" xlink:href="ino-20250331.xsd#StockholdersEquityOfferingofCommonStockWarrantsandPrefundedWarrantsDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/StockholdersEquityOfferingofCommonStockWarrantsandPrefundedWarrantsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_be5b1809-b8d8-4d6c-b89b-bbfec69f59d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_be023871-2141-4c82-9695-6ab3ae0bcd3d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_be5b1809-b8d8-4d6c-b89b-bbfec69f59d1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_be023871-2141-4c82-9695-6ab3ae0bcd3d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_ef9bda17-2a99-4f17-91ae-dba124246b28" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_be023871-2141-4c82-9695-6ab3ae0bcd3d" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_ef9bda17-2a99-4f17-91ae-dba124246b28" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_ef9bda17-2a99-4f17-91ae-dba124246b28_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_ef9bda17-2a99-4f17-91ae-dba124246b28" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_ef9bda17-2a99-4f17-91ae-dba124246b28_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_b2057189-1d61-4232-932f-8711e4d10ded" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_ef9bda17-2a99-4f17-91ae-dba124246b28" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_b2057189-1d61-4232-932f-8711e4d10ded" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_December2024OfferingWarrantsMember_53fa47f8-56f5-405b-adc8-e285e4881523" xlink:href="ino-20250331.xsd#ino_December2024OfferingWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_b2057189-1d61-4232-932f-8711e4d10ded" xlink:to="loc_ino_December2024OfferingWarrantsMember_53fa47f8-56f5-405b-adc8-e285e4881523" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_fa1b8124-a282-4498-a761-6a441f455c10" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_be023871-2141-4c82-9695-6ab3ae0bcd3d" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_fa1b8124-a282-4498-a761-6a441f455c10" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_fa1b8124-a282-4498-a761-6a441f455c10_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_fa1b8124-a282-4498-a761-6a441f455c10" xlink:to="loc_us-gaap_EquityComponentDomain_fa1b8124-a282-4498-a761-6a441f455c10_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_43de7e3c-82dd-4d55-84b6-a592eb457e60" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_fa1b8124-a282-4498-a761-6a441f455c10" xlink:to="loc_us-gaap_EquityComponentDomain_43de7e3c-82dd-4d55-84b6-a592eb457e60" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_95086894-9396-436c-8947-99c6e16e8a17" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_43de7e3c-82dd-4d55-84b6-a592eb457e60" xlink:to="loc_us-gaap_WarrantMember_95086894-9396-436c-8947-99c6e16e8a17" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_f4b91a3d-7598-4f0f-acdc-8c54c65ebcf1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_43de7e3c-82dd-4d55-84b6-a592eb457e60" xlink:to="loc_us-gaap_CommonStockMember_f4b91a3d-7598-4f0f-acdc-8c54c65ebcf1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_294d5e2c-a724-44e8-bc66-b8d7453e615a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_be023871-2141-4c82-9695-6ab3ae0bcd3d" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_294d5e2c-a724-44e8-bc66-b8d7453e615a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_294d5e2c-a724-44e8-bc66-b8d7453e615a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_294d5e2c-a724-44e8-bc66-b8d7453e615a" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_294d5e2c-a724-44e8-bc66-b8d7453e615a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_388e8bb4-6bde-44dc-85dd-768b8e28d2fb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_294d5e2c-a724-44e8-bc66-b8d7453e615a" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_388e8bb4-6bde-44dc-85dd-768b8e28d2fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_UnderwrittenRegisteredDirectOfferingMember_98f967b9-66d2-407a-82bc-36d98dcea19f" xlink:href="ino-20250331.xsd#ino_UnderwrittenRegisteredDirectOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_388e8bb4-6bde-44dc-85dd-768b8e28d2fb" xlink:to="loc_ino_UnderwrittenRegisteredDirectOfferingMember_98f967b9-66d2-407a-82bc-36d98dcea19f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_005e6bba-fd9e-423d-b1c4-87acb8604299" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_be5b1809-b8d8-4d6c-b89b-bbfec69f59d1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_005e6bba-fd9e-423d-b1c4-87acb8604299" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ClassOfWarrantOrRightCommonStockOwnershipPercent_0b4fc3f5-80cd-4c9c-b1b5-ef905d504b32" xlink:href="ino-20250331.xsd#ino_ClassOfWarrantOrRightCommonStockOwnershipPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_be5b1809-b8d8-4d6c-b89b-bbfec69f59d1" xlink:to="loc_ino_ClassOfWarrantOrRightCommonStockOwnershipPercent_0b4fc3f5-80cd-4c9c-b1b5-ef905d504b32" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ClassOfWarrantOrRightCommonStockOwnershipPriorToIssuancePercent_fcc23066-a0af-49f4-bba0-ab8a75a6cd95" xlink:href="ino-20250331.xsd#ino_ClassOfWarrantOrRightCommonStockOwnershipPriorToIssuancePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_be5b1809-b8d8-4d6c-b89b-bbfec69f59d1" xlink:to="loc_ino_ClassOfWarrantOrRightCommonStockOwnershipPriorToIssuancePercent_fcc23066-a0af-49f4-bba0-ab8a75a6cd95" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ClassOfWarrantOrRightCommonStockOwnershipMaximumPercent_736e9fe6-03e7-40d4-92e6-dc96e9d68f20" xlink:href="ino-20250331.xsd#ino_ClassOfWarrantOrRightCommonStockOwnershipMaximumPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_be5b1809-b8d8-4d6c-b89b-bbfec69f59d1" xlink:to="loc_ino_ClassOfWarrantOrRightCommonStockOwnershipMaximumPercent_736e9fe6-03e7-40d4-92e6-dc96e9d68f20" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquityAtTheMarketSalesAgreementsDetails" xlink:type="simple" xlink:href="ino-20250331.xsd#StockholdersEquityAtTheMarketSalesAgreementsDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/StockholdersEquityAtTheMarketSalesAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_b9a43c11-4eda-4595-9c10-9f4d593cc186" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_3031160a-dcba-4c5e-a0c3-3ebfc5ef19be" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_b9a43c11-4eda-4595-9c10-9f4d593cc186" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_3031160a-dcba-4c5e-a0c3-3ebfc5ef19be" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_7f56afb7-a098-415a-b779-8b88820ad11b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_3031160a-dcba-4c5e-a0c3-3ebfc5ef19be" xlink:to="loc_us-gaap_StatementClassOfStockAxis_7f56afb7-a098-415a-b779-8b88820ad11b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_7f56afb7-a098-415a-b779-8b88820ad11b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_7f56afb7-a098-415a-b779-8b88820ad11b" xlink:to="loc_us-gaap_ClassOfStockDomain_7f56afb7-a098-415a-b779-8b88820ad11b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_f6633396-e44f-4dd6-9b7c-6a9f8698eae6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_7f56afb7-a098-415a-b779-8b88820ad11b" xlink:to="loc_us-gaap_ClassOfStockDomain_f6633396-e44f-4dd6-9b7c-6a9f8698eae6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_190ebd3b-f34f-46f1-a9e4-d343cedbff16" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_f6633396-e44f-4dd6-9b7c-6a9f8698eae6" xlink:to="loc_us-gaap_CommonStockMember_190ebd3b-f34f-46f1-a9e4-d343cedbff16" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_fd4e6520-5a2a-4b8f-9224-f5ef3d83acc4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_3031160a-dcba-4c5e-a0c3-3ebfc5ef19be" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_fd4e6520-5a2a-4b8f-9224-f5ef3d83acc4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_fd4e6520-5a2a-4b8f-9224-f5ef3d83acc4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_fd4e6520-5a2a-4b8f-9224-f5ef3d83acc4" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_fd4e6520-5a2a-4b8f-9224-f5ef3d83acc4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3c2f1fa3-fd71-4f30-a235-9a90d32a5bfb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_fd4e6520-5a2a-4b8f-9224-f5ef3d83acc4" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3c2f1fa3-fd71-4f30-a235-9a90d32a5bfb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A2024SalesAgreementMember_0a9a26c9-ed37-4879-8523-3bb5fbce2930" xlink:href="ino-20250331.xsd#ino_A2024SalesAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3c2f1fa3-fd71-4f30-a235-9a90d32a5bfb" xlink:to="loc_ino_A2024SalesAgreementMember_0a9a26c9-ed37-4879-8523-3bb5fbce2930" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A2021SalesAgreementMember_ad1bab17-be48-4952-aeda-145ca4eb1c8f" xlink:href="ino-20250331.xsd#ino_A2021SalesAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3c2f1fa3-fd71-4f30-a235-9a90d32a5bfb" xlink:to="loc_ino_A2021SalesAgreementMember_ad1bab17-be48-4952-aeda-145ca4eb1c8f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSalesAgreementMaximumAuthorizedAmount_94e1a57d-0ff4-4236-868c-dee643473847" xlink:href="ino-20250331.xsd#ino_StockSalesAgreementMaximumAuthorizedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b9a43c11-4eda-4595-9c10-9f4d593cc186" xlink:to="loc_ino_StockSalesAgreementMaximumAuthorizedAmount_94e1a57d-0ff4-4236-868c-dee643473847" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage_14fb31dc-347c-41dc-be61-e6b41527fc52" xlink:href="ino-20250331.xsd#ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b9a43c11-4eda-4595-9c10-9f4d593cc186" xlink:to="loc_ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage_14fb31dc-347c-41dc-be61-e6b41527fc52" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSaleAgreementAggregateNumberofSharesIssued_113bf7cb-cbb0-403d-92e8-f512d945c020" xlink:href="ino-20250331.xsd#ino_StockSaleAgreementAggregateNumberofSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b9a43c11-4eda-4595-9c10-9f4d593cc186" xlink:to="loc_ino_StockSaleAgreementAggregateNumberofSharesIssued_113bf7cb-cbb0-403d-92e8-f512d945c020" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSaleAgreementWeightedAveragePricePerShare_0eedc66e-318e-479a-8d6b-82aede4c870c" xlink:href="ino-20250331.xsd#ino_StockSaleAgreementWeightedAveragePricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b9a43c11-4eda-4595-9c10-9f4d593cc186" xlink:to="loc_ino_StockSaleAgreementWeightedAveragePricePerShare_0eedc66e-318e-479a-8d6b-82aede4c870c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock_b3a110ca-b7d7-4c1b-8a0d-e1448fc16a84" xlink:href="ino-20250331.xsd#ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b9a43c11-4eda-4595-9c10-9f4d593cc186" xlink:to="loc_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock_b3a110ca-b7d7-4c1b-8a0d-e1448fc16a84" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSaleAgreementRemainingCapacityAmount_fdcf3775-074b-4e9e-b7e6-4bc684e8ed45" xlink:href="ino-20250331.xsd#ino_StockSaleAgreementRemainingCapacityAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b9a43c11-4eda-4595-9c10-9f4d593cc186" xlink:to="loc_ino_StockSaleAgreementRemainingCapacityAmount_fdcf3775-074b-4e9e-b7e6-4bc684e8ed45" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquityStockOptionsandRestrictedStockUnitsDetails" xlink:type="simple" xlink:href="ino-20250331.xsd#StockholdersEquityStockOptionsandRestrictedStockUnitsDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/StockholdersEquityStockOptionsandRestrictedStockUnitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_f1124d6d-abf6-421d-9870-1b8fc379645b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_26113fed-000e-49ad-8ef0-54d06fb3f59c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_f1124d6d-abf6-421d-9870-1b8fc379645b" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_26113fed-000e-49ad-8ef0-54d06fb3f59c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_4f3f2d47-b4c3-4bfc-8ec7-6d21b449be57" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_26113fed-000e-49ad-8ef0-54d06fb3f59c" xlink:to="loc_us-gaap_PlanNameAxis_4f3f2d47-b4c3-4bfc-8ec7-6d21b449be57" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_4f3f2d47-b4c3-4bfc-8ec7-6d21b449be57_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_4f3f2d47-b4c3-4bfc-8ec7-6d21b449be57" xlink:to="loc_us-gaap_PlanNameDomain_4f3f2d47-b4c3-4bfc-8ec7-6d21b449be57_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_0c46b533-63e6-4416-ad38-739fd4833a4a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_4f3f2d47-b4c3-4bfc-8ec7-6d21b449be57" xlink:to="loc_us-gaap_PlanNameDomain_0c46b533-63e6-4416-ad38-739fd4833a4a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A2023IncentivePlanMember_276488a4-9740-4280-aab0-ab65d42e5ddc" xlink:href="ino-20250331.xsd#ino_A2023IncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_0c46b533-63e6-4416-ad38-739fd4833a4a" xlink:to="loc_ino_A2023IncentivePlanMember_276488a4-9740-4280-aab0-ab65d42e5ddc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A2016IncentivePlanMember_96fbd95f-b260-456f-9b59-48fa090c5642" xlink:href="ino-20250331.xsd#ino_A2016IncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_0c46b533-63e6-4416-ad38-739fd4833a4a" xlink:to="loc_ino_A2016IncentivePlanMember_96fbd95f-b260-456f-9b59-48fa090c5642" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A2022InducementPlanMember_a0a22100-b637-453f-aeeb-dc396c5bdf83" xlink:href="ino-20250331.xsd#ino_A2022InducementPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_0c46b533-63e6-4416-ad38-739fd4833a4a" xlink:to="loc_ino_A2022InducementPlanMember_a0a22100-b637-453f-aeeb-dc396c5bdf83" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A2007IncentivePlanMember_d89ed93d-0cf1-4f9d-972a-9e4362758719" xlink:href="ino-20250331.xsd#ino_A2007IncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_0c46b533-63e6-4416-ad38-739fd4833a4a" xlink:to="loc_ino_A2007IncentivePlanMember_d89ed93d-0cf1-4f9d-972a-9e4362758719" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_e0241866-840b-4c74-ae31-ca4bf24c1489" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f1124d6d-abf6-421d-9870-1b8fc379645b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_e0241866-840b-4c74-ae31-ca4bf24c1489" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_8f8b9d1d-f245-4d78-851a-608e9fa39529" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f1124d6d-abf6-421d-9870-1b8fc379645b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_8f8b9d1d-f245-4d78-851a-608e9fa39529" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_02e7ba7a-2290-414b-89d6-adf8313894d4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f1124d6d-abf6-421d-9870-1b8fc379645b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_02e7ba7a-2290-414b-89d6-adf8313894d4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockOtherSharesOutstanding_c3c3ad31-bbcf-4ec9-92bd-e749d443f143" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockOtherSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f1124d6d-abf6-421d-9870-1b8fc379645b" xlink:to="loc_us-gaap_CommonStockOtherSharesOutstanding_c3c3ad31-bbcf-4ec9-92bd-e749d443f143" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_cb9875ce-f90c-4173-a494-2fa882f222c5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f1124d6d-abf6-421d-9870-1b8fc379645b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_cb9875ce-f90c-4173-a494-2fa882f222c5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm_f2bbfb56-c2b8-4a6d-8b46-c0ff5a197432" xlink:href="ino-20250331.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f1124d6d-abf6-421d-9870-1b8fc379645b" xlink:to="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm_f2bbfb56-c2b8-4a6d-8b46-c0ff5a197432" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/NetLossPerShareAntidilutiveDetails" xlink:type="simple" xlink:href="ino-20250331.xsd#NetLossPerShareAntidilutiveDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/NetLossPerShareAntidilutiveDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_3e54b59a-39d6-4a86-89a3-d12e03a820d3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_a202c91d-494e-447e-95b9-1ac62b84d65b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_3e54b59a-39d6-4a86-89a3-d12e03a820d3" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_a202c91d-494e-447e-95b9-1ac62b84d65b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_e20b3f7e-aebe-418d-b7c2-948eb61efa42" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_a202c91d-494e-447e-95b9-1ac62b84d65b" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_e20b3f7e-aebe-418d-b7c2-948eb61efa42" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_e20b3f7e-aebe-418d-b7c2-948eb61efa42_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_e20b3f7e-aebe-418d-b7c2-948eb61efa42" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_e20b3f7e-aebe-418d-b7c2-948eb61efa42_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1155fe7f-2cef-40b0-b1f4-1e884797505e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_e20b3f7e-aebe-418d-b7c2-948eb61efa42" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1155fe7f-2cef-40b0-b1f4-1e884797505e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_34c97f72-e916-4ecd-b075-9c550b510d25" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1155fe7f-2cef-40b0-b1f4-1e884797505e" xlink:to="loc_us-gaap_WarrantMember_34c97f72-e916-4ecd-b075-9c550b510d25" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_a145900b-2cf5-479c-9c31-811290d2dbbc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1155fe7f-2cef-40b0-b1f4-1e884797505e" xlink:to="loc_us-gaap_EmployeeStockOptionMember_a145900b-2cf5-479c-9c31-811290d2dbbc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ServiceBasedRestrictedStockUnitsMember_dbb782c2-e558-4506-98c5-efeea167859e" xlink:href="ino-20250331.xsd#ino_ServiceBasedRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1155fe7f-2cef-40b0-b1f4-1e884797505e" xlink:to="loc_ino_ServiceBasedRestrictedStockUnitsMember_dbb782c2-e558-4506-98c5-efeea167859e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_6b6d336d-041f-4871-9c00-378af365face" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1155fe7f-2cef-40b0-b1f4-1e884797505e" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_6b6d336d-041f-4871-9c00-378af365face" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_d5b35582-60a0-4968-ba9f-018b9f2f70d3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1155fe7f-2cef-40b0-b1f4-1e884797505e" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_d5b35582-60a0-4968-ba9f-018b9f2f70d3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_00b6eaec-94a3-4bb0-9c9b-5e9d2df9072d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_3e54b59a-39d6-4a86-89a3-d12e03a820d3" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_00b6eaec-94a3-4bb0-9c9b-5e9d2df9072d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockBasedCompensationWeightedAverageAssumptionsDetails" xlink:type="simple" xlink:href="ino-20250331.xsd#StockBasedCompensationWeightedAverageAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/StockBasedCompensationWeightedAverageAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5cf72984-665c-4158-be55-c1f9ceaa95b9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e97f5af0-7afd-460c-9b4e-0da43a1d6348" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5cf72984-665c-4158-be55-c1f9ceaa95b9" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e97f5af0-7afd-460c-9b4e-0da43a1d6348" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_969c4c3a-52a6-4a3d-b223-74aed99116f9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e97f5af0-7afd-460c-9b4e-0da43a1d6348" xlink:to="loc_us-gaap_AwardTypeAxis_969c4c3a-52a6-4a3d-b223-74aed99116f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_969c4c3a-52a6-4a3d-b223-74aed99116f9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_969c4c3a-52a6-4a3d-b223-74aed99116f9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_969c4c3a-52a6-4a3d-b223-74aed99116f9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_18be060c-0268-4fa0-a6df-5c9ea6bcfbea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_969c4c3a-52a6-4a3d-b223-74aed99116f9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_18be060c-0268-4fa0-a6df-5c9ea6bcfbea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_d90317d4-6d21-49cc-9109-1fd1d7933ff5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_18be060c-0268-4fa0-a6df-5c9ea6bcfbea" xlink:to="loc_us-gaap_EmployeeStockOptionMember_d90317d4-6d21-49cc-9109-1fd1d7933ff5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_2913e84f-3873-4217-8458-1e0f2e33ffe5" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e97f5af0-7afd-460c-9b4e-0da43a1d6348" xlink:to="loc_srt_TitleOfIndividualAxis_2913e84f-3873-4217-8458-1e0f2e33ffe5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_2913e84f-3873-4217-8458-1e0f2e33ffe5_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_2913e84f-3873-4217-8458-1e0f2e33ffe5" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_2913e84f-3873-4217-8458-1e0f2e33ffe5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_14ff0c02-44ba-4898-8df6-5a5b068a4503" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_2913e84f-3873-4217-8458-1e0f2e33ffe5" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_14ff0c02-44ba-4898-8df6-5a5b068a4503" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_EmployeesAndDirectorsMember_1ae68527-7700-4506-928e-15ca7d235b14" xlink:href="ino-20250331.xsd#ino_EmployeesAndDirectorsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_14ff0c02-44ba-4898-8df6-5a5b068a4503" xlink:to="loc_ino_EmployeesAndDirectorsMember_1ae68527-7700-4506-928e-15ca7d235b14" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_f8c95bc0-5585-477e-b406-293713dd7894" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5cf72984-665c-4158-be55-c1f9ceaa95b9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_f8c95bc0-5585-477e-b406-293713dd7894" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_87a20215-215b-48aa-af01-de83ce05bf7f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5cf72984-665c-4158-be55-c1f9ceaa95b9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_87a20215-215b-48aa-af01-de83ce05bf7f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_c719ed0c-d701-4aa8-befb-987abf52723c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5cf72984-665c-4158-be55-c1f9ceaa95b9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_c719ed0c-d701-4aa8-befb-987abf52723c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2f51ca7d-28d2-4a2e-88f6-1c3142442025" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5cf72984-665c-4158-be55-c1f9ceaa95b9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2f51ca7d-28d2-4a2e-88f6-1c3142442025" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="ino-20250331.xsd#StockBasedCompensationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cfc5fff8-4702-4d82-9472-bbc9ff4814e4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_202c6cdb-1aa5-4c41-82f8-ee814f213c3a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cfc5fff8-4702-4d82-9472-bbc9ff4814e4" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_202c6cdb-1aa5-4c41-82f8-ee814f213c3a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_e34b0dc1-52a6-442c-a9d7-e684f400399b" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_202c6cdb-1aa5-4c41-82f8-ee814f213c3a" xlink:to="loc_srt_TitleOfIndividualAxis_e34b0dc1-52a6-442c-a9d7-e684f400399b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_e34b0dc1-52a6-442c-a9d7-e684f400399b_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_e34b0dc1-52a6-442c-a9d7-e684f400399b" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_e34b0dc1-52a6-442c-a9d7-e684f400399b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_0ace15bb-65b5-4746-b3ce-27129bc09d06" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_e34b0dc1-52a6-442c-a9d7-e684f400399b" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_0ace15bb-65b5-4746-b3ce-27129bc09d06" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_EmployeesAndDirectorsMember_09bf3428-e50c-4d97-ad36-55ff455f3dd8" xlink:href="ino-20250331.xsd#ino_EmployeesAndDirectorsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_0ace15bb-65b5-4746-b3ce-27129bc09d06" xlink:to="loc_ino_EmployeesAndDirectorsMember_09bf3428-e50c-4d97-ad36-55ff455f3dd8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_NonEmployeeMember_8ce84522-04be-4384-b944-6c5bfb710ee7" xlink:href="ino-20250331.xsd#ino_NonEmployeeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_0ace15bb-65b5-4746-b3ce-27129bc09d06" xlink:to="loc_ino_NonEmployeeMember_8ce84522-04be-4384-b944-6c5bfb710ee7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_986302d7-5fd0-48bc-8348-b1d9b251f38a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_202c6cdb-1aa5-4c41-82f8-ee814f213c3a" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_986302d7-5fd0-48bc-8348-b1d9b251f38a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_986302d7-5fd0-48bc-8348-b1d9b251f38a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_986302d7-5fd0-48bc-8348-b1d9b251f38a" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_986302d7-5fd0-48bc-8348-b1d9b251f38a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_15635d7e-5ca0-44d6-b862-3645f75db749" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_986302d7-5fd0-48bc-8348-b1d9b251f38a" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_15635d7e-5ca0-44d6-b862-3645f75db749" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_2ac59b14-b991-4bbe-a65d-ec8b0ffc72bd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_15635d7e-5ca0-44d6-b862-3645f75db749" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_2ac59b14-b991-4bbe-a65d-ec8b0ffc72bd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_31cfd53d-ce3b-4ab8-97a9-7beedadfab62" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_15635d7e-5ca0-44d6-b862-3645f75db749" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_31cfd53d-ce3b-4ab8-97a9-7beedadfab62" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_f94edd9a-22ce-4ec6-bdd9-fb293f8ea584" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_202c6cdb-1aa5-4c41-82f8-ee814f213c3a" xlink:to="loc_us-gaap_AwardTypeAxis_f94edd9a-22ce-4ec6-bdd9-fb293f8ea584" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f94edd9a-22ce-4ec6-bdd9-fb293f8ea584_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_f94edd9a-22ce-4ec6-bdd9-fb293f8ea584" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f94edd9a-22ce-4ec6-bdd9-fb293f8ea584_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3554bb81-8fd8-4668-8fab-914e4bdbc9a3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_f94edd9a-22ce-4ec6-bdd9-fb293f8ea584" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3554bb81-8fd8-4668-8fab-914e4bdbc9a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ServiceBasedRestrictedStockUnitsMember_f58d09c3-5b78-456f-8f54-5dd8c4ab3579" xlink:href="ino-20250331.xsd#ino_ServiceBasedRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3554bb81-8fd8-4668-8fab-914e4bdbc9a3" xlink:to="loc_ino_ServiceBasedRestrictedStockUnitsMember_f58d09c3-5b78-456f-8f54-5dd8c4ab3579" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_66d9cbc3-928a-4dac-ab48-a2d9c19d542f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3554bb81-8fd8-4668-8fab-914e4bdbc9a3" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_66d9cbc3-928a-4dac-ab48-a2d9c19d542f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RestrictedStockUnitsRSUsMilestoneBasedMember_6a0ee5a1-463f-4f5b-bb33-e6a51369df6d" xlink:href="ino-20250331.xsd#ino_RestrictedStockUnitsRSUsMilestoneBasedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember_66d9cbc3-928a-4dac-ab48-a2d9c19d542f" xlink:to="loc_ino_RestrictedStockUnitsRSUsMilestoneBasedMember_6a0ee5a1-463f-4f5b-bb33-e6a51369df6d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RestrictedStockUnitsRSUsMarketBasedMember_01b7089c-a1ff-42e1-abd9-c96588898f74" xlink:href="ino-20250331.xsd#ino_RestrictedStockUnitsRSUsMarketBasedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember_66d9cbc3-928a-4dac-ab48-a2d9c19d542f" xlink:to="loc_ino_RestrictedStockUnitsRSUsMarketBasedMember_01b7089c-a1ff-42e1-abd9-c96588898f74" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RestrictedStockUnitsRSUsTotalShareholderReturnMember_7d17fb98-c770-46ce-b71d-558460327666" xlink:href="ino-20250331.xsd#ino_RestrictedStockUnitsRSUsTotalShareholderReturnMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember_66d9cbc3-928a-4dac-ab48-a2d9c19d542f" xlink:to="loc_ino_RestrictedStockUnitsRSUsTotalShareholderReturnMember_7d17fb98-c770-46ce-b71d-558460327666" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_23372688-ea75-4691-8d05-79124ee2c1f2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3554bb81-8fd8-4668-8fab-914e4bdbc9a3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_23372688-ea75-4691-8d05-79124ee2c1f2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RestrictedStockUnitsPerformanceBasedMember_e36a6395-be91-4652-b92a-d221200e73b8" xlink:href="ino-20250331.xsd#ino_RestrictedStockUnitsPerformanceBasedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3554bb81-8fd8-4668-8fab-914e4bdbc9a3" xlink:to="loc_ino_RestrictedStockUnitsPerformanceBasedMember_e36a6395-be91-4652-b92a-d221200e73b8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockOptionsPerformanceBasedMember_4c5cf221-d221-4ce6-884d-9225bad90eba" xlink:href="ino-20250331.xsd#ino_StockOptionsPerformanceBasedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3554bb81-8fd8-4668-8fab-914e4bdbc9a3" xlink:to="loc_ino_StockOptionsPerformanceBasedMember_4c5cf221-d221-4ce6-884d-9225bad90eba" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_a536a8ce-0e84-4542-be01-f2b0b12379d4" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_202c6cdb-1aa5-4c41-82f8-ee814f213c3a" xlink:to="loc_srt_RangeAxis_a536a8ce-0e84-4542-be01-f2b0b12379d4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a536a8ce-0e84-4542-be01-f2b0b12379d4_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_a536a8ce-0e84-4542-be01-f2b0b12379d4" xlink:to="loc_srt_RangeMember_a536a8ce-0e84-4542-be01-f2b0b12379d4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7db148ad-1c2e-415a-8e8b-2b0d753ce435" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_a536a8ce-0e84-4542-be01-f2b0b12379d4" xlink:to="loc_srt_RangeMember_7db148ad-1c2e-415a-8e8b-2b0d753ce435" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_89769224-0570-4025-9769-d875395becd8" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_7db148ad-1c2e-415a-8e8b-2b0d753ce435" xlink:to="loc_srt_MinimumMember_89769224-0570-4025-9769-d875395becd8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_aa213e31-da8f-4c5b-81e8-023b280f5fd6" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_7db148ad-1c2e-415a-8e8b-2b0d753ce435" xlink:to="loc_srt_MaximumMember_aa213e31-da8f-4c5b-81e8-023b280f5fd6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateAxis_d499b6cb-57e9-4825-93d9-b5e0add60e23" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardDateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_202c6cdb-1aa5-4c41-82f8-ee814f213c3a" xlink:to="loc_us-gaap_AwardDateAxis_d499b6cb-57e9-4825-93d9-b5e0add60e23" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateDomain_d499b6cb-57e9-4825-93d9-b5e0add60e23_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardDateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardDateAxis_d499b6cb-57e9-4825-93d9-b5e0add60e23" xlink:to="loc_us-gaap_AwardDateDomain_d499b6cb-57e9-4825-93d9-b5e0add60e23_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateDomain_fac9bd17-9d2b-47b1-8af8-886424038d31" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardDateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardDateAxis_d499b6cb-57e9-4825-93d9-b5e0add60e23" xlink:to="loc_us-gaap_AwardDateDomain_fac9bd17-9d2b-47b1-8af8-886424038d31" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_December2024Member_11dff507-bd47-4ec2-a84a-b58cdb5742fa" xlink:href="ino-20250331.xsd#ino_December2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AwardDateDomain_fac9bd17-9d2b-47b1-8af8-886424038d31" xlink:to="loc_ino_December2024Member_11dff507-bd47-4ec2-a84a-b58cdb5742fa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_fea634b2-1ff9-43d7-8de7-99ce0dbd057c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cfc5fff8-4702-4d82-9472-bbc9ff4814e4" xlink:to="loc_us-gaap_ShareBasedCompensation_fea634b2-1ff9-43d7-8de7-99ce0dbd057c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_a88f01aa-52c7-40f7-98a0-c44e3bdbb424" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cfc5fff8-4702-4d82-9472-bbc9ff4814e4" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_a88f01aa-52c7-40f7-98a0-c44e3bdbb424" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_a6c80d45-15fa-4534-8779-41e15e60eae5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cfc5fff8-4702-4d82-9472-bbc9ff4814e4" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_a6c80d45-15fa-4534-8779-41e15e60eae5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_d64bfb5c-8680-4df4-81d5-b8388f2540e3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cfc5fff8-4702-4d82-9472-bbc9ff4814e4" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_d64bfb5c-8680-4df4-81d5-b8388f2540e3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_fafec8c9-dba1-4576-9ef1-203acbc7c08d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cfc5fff8-4702-4d82-9472-bbc9ff4814e4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_fafec8c9-dba1-4576-9ef1-203acbc7c08d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_14a1df50-cf45-4322-8cbd-94426ba490cf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cfc5fff8-4702-4d82-9472-bbc9ff4814e4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_14a1df50-cf45-4322-8cbd-94426ba490cf" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ea55d7d6-8bbe-4a82-a928-84a23e161ce7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cfc5fff8-4702-4d82-9472-bbc9ff4814e4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ea55d7d6-8bbe-4a82-a928-84a23e161ce7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_57e7ce0d-6ec0-4f1e-9fdf-fb717cb8a120" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cfc5fff8-4702-4d82-9472-bbc9ff4814e4" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_57e7ce0d-6ec0-4f1e-9fdf-fb717cb8a120" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPercentage_d9e01e8e-acb9-4824-b0da-ab963cdcdb7a" xlink:href="ino-20250331.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cfc5fff8-4702-4d82-9472-bbc9ff4814e4" xlink:to="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPercentage_d9e01e8e-acb9-4824-b0da-ab963cdcdb7a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_3cf5cce1-cc4c-42ce-b763-4a7161f2ab9a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cfc5fff8-4702-4d82-9472-bbc9ff4814e4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_3cf5cce1-cc4c-42ce-b763-4a7161f2ab9a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue_3f98c8d2-33c5-4df9-befa-e18c72a40ecb" xlink:href="ino-20250331.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cfc5fff8-4702-4d82-9472-bbc9ff4814e4" xlink:to="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue_3f98c8d2-33c5-4df9-befa-e18c72a40ecb" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardUnderlyingCommonStock_cff7f3f6-f883-4bb1-9b23-f6bf14505fd5" xlink:href="ino-20250331.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardUnderlyingCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cfc5fff8-4702-4d82-9472-bbc9ff4814e4" xlink:to="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardUnderlyingCommonStock_cff7f3f6-f883-4bb1-9b23-f6bf14505fd5" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsGrantDateFairValue_81f49f5f-2272-49c5-94e0-621e2fe0c569" xlink:href="ino-20250331.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cfc5fff8-4702-4d82-9472-bbc9ff4814e4" xlink:to="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsGrantDateFairValue_81f49f5f-2272-49c5-94e0-621e2fe0c569" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantDateClosingSharePrice_86cbad2f-90bb-4b59-8439-d721dbeab267" xlink:href="ino-20250331.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantDateClosingSharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cfc5fff8-4702-4d82-9472-bbc9ff4814e4" xlink:to="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantDateClosingSharePrice_86cbad2f-90bb-4b59-8439-d721dbeab267" xlink:type="arc" order="13"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockBasedCompensationSignificantAssumptionUsedinMonteCarloSimulationMethodDetails" xlink:type="simple" xlink:href="ino-20250331.xsd#StockBasedCompensationSignificantAssumptionUsedinMonteCarloSimulationMethodDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/StockBasedCompensationSignificantAssumptionUsedinMonteCarloSimulationMethodDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3034666b-b16b-4e74-be9b-4543e6eacac3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c7afb94b-d6c2-4e9c-a149-2af7a188588a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3034666b-b16b-4e74-be9b-4543e6eacac3" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c7afb94b-d6c2-4e9c-a149-2af7a188588a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_521d3464-ea25-4e73-af35-a22a039d4797" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c7afb94b-d6c2-4e9c-a149-2af7a188588a" xlink:to="loc_us-gaap_AwardTypeAxis_521d3464-ea25-4e73-af35-a22a039d4797" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_521d3464-ea25-4e73-af35-a22a039d4797_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_521d3464-ea25-4e73-af35-a22a039d4797" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_521d3464-ea25-4e73-af35-a22a039d4797_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8f136039-5c13-49fe-86d8-fa920c86edde" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_521d3464-ea25-4e73-af35-a22a039d4797" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8f136039-5c13-49fe-86d8-fa920c86edde" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RestrictedStockUnitsRSUsMarketBasedMember_43c81e38-5737-42d5-9b70-6886c85de09f" xlink:href="ino-20250331.xsd#ino_RestrictedStockUnitsRSUsMarketBasedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8f136039-5c13-49fe-86d8-fa920c86edde" xlink:to="loc_ino_RestrictedStockUnitsRSUsMarketBasedMember_43c81e38-5737-42d5-9b70-6886c85de09f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2a85e230-8f00-4c07-aebb-5bda3a76a518" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3034666b-b16b-4e74-be9b-4543e6eacac3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2a85e230-8f00-4c07-aebb-5bda3a76a518" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_63662488-3f5b-44c6-aacc-e977344cff40" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3034666b-b16b-4e74-be9b-4543e6eacac3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_63662488-3f5b-44c6-aacc-e977344cff40" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_cd77d00a-f804-47af-a351-ef09b735f599" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3034666b-b16b-4e74-be9b-4543e6eacac3" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_cd77d00a-f804-47af-a351-ef09b735f599" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_5082277d-7664-461e-b219-f4faeaa13318" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3034666b-b16b-4e74-be9b-4543e6eacac3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_5082277d-7664-461e-b219-f4faeaa13318" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/RelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="ino-20250331.xsd#RelatedPartyTransactionsDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/RelatedPartyTransactionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_a03fa5ef-3da3-4d2d-a7ad-802a50aa8c4f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_cdf1ece2-f962-42f4-a7e8-cf5dd3e87a3a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_a03fa5ef-3da3-4d2d-a7ad-802a50aa8c4f" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_cdf1ece2-f962-42f4-a7e8-cf5dd3e87a3a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_53f71632-f2e0-4326-a7de-aff48cd0b7c1" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_cdf1ece2-f962-42f4-a7e8-cf5dd3e87a3a" xlink:to="loc_srt_CounterpartyNameAxis_53f71632-f2e0-4326-a7de-aff48cd0b7c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_53f71632-f2e0-4326-a7de-aff48cd0b7c1_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_53f71632-f2e0-4326-a7de-aff48cd0b7c1" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_53f71632-f2e0-4326-a7de-aff48cd0b7c1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_90c89535-f1a4-400a-beb6-9c2c963aca34" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_53f71632-f2e0-4326-a7de-aff48cd0b7c1" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_90c89535-f1a4-400a-beb6-9c2c963aca34" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PlumblineLifeSciencesMember_2f302a52-d113-4ece-84d0-ed587946d0f4" xlink:href="ino-20250331.xsd#ino_PlumblineLifeSciencesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_90c89535-f1a4-400a-beb6-9c2c963aca34" xlink:to="loc_ino_PlumblineLifeSciencesMember_2f302a52-d113-4ece-84d0-ed587946d0f4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TheWistarInstituteMember_f5038b22-a0c4-4983-a630-af6e15de4558" xlink:href="ino-20250331.xsd#ino_TheWistarInstituteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_90c89535-f1a4-400a-beb6-9c2c963aca34" xlink:to="loc_ino_TheWistarInstituteMember_f5038b22-a0c4-4983-a630-af6e15de4558" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_eb440b70-1e41-4329-95f8-43ca4ca6f890" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_cdf1ece2-f962-42f4-a7e8-cf5dd3e87a3a" xlink:to="loc_srt_OwnershipAxis_eb440b70-1e41-4329-95f8-43ca4ca6f890" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_eb440b70-1e41-4329-95f8-43ca4ca6f890_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_eb440b70-1e41-4329-95f8-43ca4ca6f890" xlink:to="loc_srt_OwnershipDomain_eb440b70-1e41-4329-95f8-43ca4ca6f890_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_e7bf6749-b38a-445d-af90-819a1a868603" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_eb440b70-1e41-4329-95f8-43ca4ca6f890" xlink:to="loc_srt_OwnershipDomain_e7bf6749-b38a-445d-af90-819a1a868603" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PlumblineLifeSciencesMember_a0a71e5b-4684-49f2-92ff-fb6e03baa877" xlink:href="ino-20250331.xsd#ino_PlumblineLifeSciencesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_e7bf6749-b38a-445d-af90-819a1a868603" xlink:to="loc_ino_PlumblineLifeSciencesMember_a0a71e5b-4684-49f2-92ff-fb6e03baa877" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_24c645a3-3240-4213-849d-c05672342d83" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_cdf1ece2-f962-42f4-a7e8-cf5dd3e87a3a" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_24c645a3-3240-4213-849d-c05672342d83" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_24c645a3-3240-4213-849d-c05672342d83_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_24c645a3-3240-4213-849d-c05672342d83" xlink:to="loc_us-gaap_RelatedPartyDomain_24c645a3-3240-4213-849d-c05672342d83_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_80f4c2bd-e08c-4f6d-80d5-1650e3cf1095" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_24c645a3-3240-4213-849d-c05672342d83" xlink:to="loc_us-gaap_RelatedPartyDomain_80f4c2bd-e08c-4f6d-80d5-1650e3cf1095" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_088e8ea6-e473-47c9-b4c2-cb905f1364ca" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_AffiliatedEntityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_80f4c2bd-e08c-4f6d-80d5-1650e3cf1095" xlink:to="loc_srt_AffiliatedEntityMember_088e8ea6-e473-47c9-b4c2-cb905f1364ca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares_83fdc61b-68bb-4e43-9a1c-021b51fe4257" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_a03fa5ef-3da3-4d2d-a7ad-802a50aa8c4f" xlink:to="loc_us-gaap_InvestmentOwnedBalanceShares_83fdc61b-68bb-4e43-9a1c-021b51fe4257" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_cc3406fc-0de0-4be6-b363-ad94d16f039a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_a03fa5ef-3da3-4d2d-a7ad-802a50aa8c4f" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_cc3406fc-0de0-4be6-b363-ad94d16f039a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_ada1148a-80ce-4505-a68b-3e35e15a7dd1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_a03fa5ef-3da3-4d2d-a7ad-802a50aa8c4f" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_ada1148a-80ce-4505-a68b-3e35e15a7dd1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementExpensesToReimburse_39373a34-7cf8-47f4-849b-715861edb6e2" xlink:href="ino-20250331.xsd#ino_CollaborativeAgreementExpensesToReimburse"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_a03fa5ef-3da3-4d2d-a7ad-802a50aa8c4f" xlink:to="loc_ino_CollaborativeAgreementExpensesToReimburse_39373a34-7cf8-47f4-849b-715861edb6e2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeArrangementTerm_ad7b70c8-968d-4e02-9a1b-0ab56f856695" xlink:href="ino-20250331.xsd#ino_CollaborativeArrangementTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_a03fa5ef-3da3-4d2d-a7ad-802a50aa8c4f" xlink:to="loc_ino_CollaborativeArrangementTerm_ad7b70c8-968d-4e02-9a1b-0ab56f856695" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementAwardedAmount_fb1a2320-e4d5-4bf6-9213-a1739aafbc60" xlink:href="ino-20250331.xsd#ino_CollaborativeAgreementAwardedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_a03fa5ef-3da3-4d2d-a7ad-802a50aa8c4f" xlink:to="loc_ino_CollaborativeAgreementAwardedAmount_fb1a2320-e4d5-4bf6-9213-a1739aafbc60" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementAmendedAmount_45b52525-1782-40ac-9fd5-0530ccc84cbb" xlink:href="ino-20250331.xsd#ino_CollaborativeAgreementAmendedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_a03fa5ef-3da3-4d2d-a7ad-802a50aa8c4f" xlink:to="loc_ino_CollaborativeAgreementAmendedAmount_45b52525-1782-40ac-9fd5-0530ccc84cbb" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementAwardedOptionAmount_473970e0-c9f4-495b-a971-80432c0f1583" xlink:href="ino-20250331.xsd#ino_CollaborativeAgreementAwardedOptionAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_a03fa5ef-3da3-4d2d-a7ad-802a50aa8c4f" xlink:to="loc_ino_CollaborativeAgreementAwardedOptionAmount_473970e0-c9f4-495b-a971-80432c0f1583" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GrantProceedsReceived_fd90e7cd-7d09-4eea-ab47-83d623669dd6" xlink:href="ino-20250331.xsd#ino_GrantProceedsReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_a03fa5ef-3da3-4d2d-a7ad-802a50aa8c4f" xlink:to="loc_ino_GrantProceedsReceived_fd90e7cd-7d09-4eea-ab47-83d623669dd6" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_e7ef450d-d824-4de3-ae60-739fdc045d49" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_a03fa5ef-3da3-4d2d-a7ad-802a50aa8c4f" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_e7ef450d-d824-4de3-ae60-739fdc045d49" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_57c3fff3-c975-457c-b4f8-7a96d24f1a88" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_a03fa5ef-3da3-4d2d-a7ad-802a50aa8c4f" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_57c3fff3-c975-457c-b4f8-7a96d24f1a88" xlink:type="arc" order="10"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="simple" xlink:href="ino-20250331.xsd#CommitmentsandContingenciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_9b15ae3f-2664-4bfc-84c7-abcad98e0495" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_aab228d9-6fd2-4854-8ab9-0c0941784e88" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_9b15ae3f-2664-4bfc-84c7-abcad98e0495" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_aab228d9-6fd2-4854-8ab9-0c0941784e88" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_5b08321f-4331-43e3-ad21-823fc41ac218" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_aab228d9-6fd2-4854-8ab9-0c0941784e88" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_5b08321f-4331-43e3-ad21-823fc41ac218" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_5b08321f-4331-43e3-ad21-823fc41ac218_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_5b08321f-4331-43e3-ad21-823fc41ac218" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_5b08321f-4331-43e3-ad21-823fc41ac218_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_9ad2292c-2cb0-4a3a-adfe-5ae75abe2fb3" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_5b08321f-4331-43e3-ad21-823fc41ac218" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_9ad2292c-2cb0-4a3a-adfe-5ae75abe2fb3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SanDiegoOfficeMember_add66f67-8085-4e61-885e-c49f8c774471" xlink:href="ino-20250331.xsd#ino_SanDiegoOfficeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_9ad2292c-2cb0-4a3a-adfe-5ae75abe2fb3" xlink:to="loc_ino_SanDiegoOfficeMember_add66f67-8085-4e61-885e-c49f8c774471" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PlymouthMeetingPennsylvaniaMember_1bc67074-f3f1-4c61-8696-5958ff0bb98f" xlink:href="ino-20250331.xsd#ino_PlymouthMeetingPennsylvaniaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_9ad2292c-2cb0-4a3a-adfe-5ae75abe2fb3" xlink:to="loc_ino_PlymouthMeetingPennsylvaniaMember_1bc67074-f3f1-4c61-8696-5958ff0bb98f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SanDiegoCaliforniaMember_bedefc98-087d-4ce2-89c1-f6cb521963ac" xlink:href="ino-20250331.xsd#ino_SanDiegoCaliforniaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_9ad2292c-2cb0-4a3a-adfe-5ae75abe2fb3" xlink:to="loc_ino_SanDiegoCaliforniaMember_bedefc98-087d-4ce2-89c1-f6cb521963ac" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_0643a07e-b68b-4f75-ab2d-e1db0616863f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_aab228d9-6fd2-4854-8ab9-0c0941784e88" xlink:to="loc_srt_RangeAxis_0643a07e-b68b-4f75-ab2d-e1db0616863f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0643a07e-b68b-4f75-ab2d-e1db0616863f_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_0643a07e-b68b-4f75-ab2d-e1db0616863f" xlink:to="loc_srt_RangeMember_0643a07e-b68b-4f75-ab2d-e1db0616863f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1eab84cc-98ec-4a4c-bea2-e95217efea10" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_0643a07e-b68b-4f75-ab2d-e1db0616863f" xlink:to="loc_srt_RangeMember_1eab84cc-98ec-4a4c-bea2-e95217efea10" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_3334040d-127a-4a61-88cc-364d812f0e2b" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1eab84cc-98ec-4a4c-bea2-e95217efea10" xlink:to="loc_srt_MinimumMember_3334040d-127a-4a61-88cc-364d812f0e2b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_c67b2536-9e0c-47dc-9fd5-a7993a79e9d2" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1eab84cc-98ec-4a4c-bea2-e95217efea10" xlink:to="loc_srt_MaximumMember_c67b2536-9e0c-47dc-9fd5-a7993a79e9d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LesseeOperatingLeaseAreaofLandUnderLease_bb6a8e3d-5a1f-43a3-9e17-7920ee06e7d2" xlink:href="ino-20250331.xsd#ino_LesseeOperatingLeaseAreaofLandUnderLease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_9b15ae3f-2664-4bfc-84c7-abcad98e0495" xlink:to="loc_ino_LesseeOperatingLeaseAreaofLandUnderLease_bb6a8e3d-5a1f-43a3-9e17-7920ee06e7d2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_cd463eb9-f8c7-41ee-bee6-e305478cc871" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_9b15ae3f-2664-4bfc-84c7-abcad98e0495" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_cd463eb9-f8c7-41ee-bee6-e305478cc871" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LesseeOperatingLeaseBaseRatePercentageIncreaseDecrease_d32638f6-5a4e-42c4-b7e7-e0648598d5d9" xlink:href="ino-20250331.xsd#ino_LesseeOperatingLeaseBaseRatePercentageIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_9b15ae3f-2664-4bfc-84c7-abcad98e0495" xlink:to="loc_ino_LesseeOperatingLeaseBaseRatePercentageIncreaseDecrease_d32638f6-5a4e-42c4-b7e7-e0648598d5d9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_b017bb0e-2881-4f80-b20b-065893d7faea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_9b15ae3f-2664-4bfc-84c7-abcad98e0495" xlink:to="loc_us-gaap_LeaseCost_b017bb0e-2881-4f80-b20b-065893d7faea" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CollaborativeAgreementsDetails" xlink:type="simple" xlink:href="ino-20250331.xsd#CollaborativeAgreementsDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/CollaborativeAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fb5f1534-9d3d-4f5e-9b78-bf18157cef00" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_60b79a2c-8778-480c-a021-9079b2fa15c2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fb5f1534-9d3d-4f5e-9b78-bf18157cef00" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_60b79a2c-8778-480c-a021-9079b2fa15c2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_0f2138bb-daee-45af-b479-0ee78da7b75b" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_60b79a2c-8778-480c-a021-9079b2fa15c2" xlink:to="loc_srt_CounterpartyNameAxis_0f2138bb-daee-45af-b479-0ee78da7b75b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0f2138bb-daee-45af-b479-0ee78da7b75b_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_0f2138bb-daee-45af-b479-0ee78da7b75b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0f2138bb-daee-45af-b479-0ee78da7b75b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_079fbde6-ef68-4bf8-8d6a-75594d619d75" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_0f2138bb-daee-45af-b479-0ee78da7b75b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_079fbde6-ef68-4bf8-8d6a-75594d619d75" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ApolloBioMember_6c389772-bea1-48f8-adc4-9b7281db66be" xlink:href="ino-20250331.xsd#ino_ApolloBioMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_079fbde6-ef68-4bf8-8d6a-75594d619d75" xlink:to="loc_ino_ApolloBioMember_6c389772-bea1-48f8-adc4-9b7281db66be" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CoalitionforEpidemicPreparednessInnovationsMember_7f87ff62-a8c7-4028-9815-069deb62b1ad" xlink:href="ino-20250331.xsd#ino_CoalitionforEpidemicPreparednessInnovationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_079fbde6-ef68-4bf8-8d6a-75594d619d75" xlink:to="loc_ino_CoalitionforEpidemicPreparednessInnovationsMember_7f87ff62-a8c7-4028-9815-069deb62b1ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_BillAndMelindaGatesFoundationMember_91043696-e71c-4115-9aeb-a4f37870c8ea" xlink:href="ino-20250331.xsd#ino_BillAndMelindaGatesFoundationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_079fbde6-ef68-4bf8-8d6a-75594d619d75" xlink:to="loc_ino_BillAndMelindaGatesFoundationMember_91043696-e71c-4115-9aeb-a4f37870c8ea" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_2931d1c9-7906-473f-b2e9-e5f858afb5f8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_60b79a2c-8778-480c-a021-9079b2fa15c2" xlink:to="loc_us-gaap_TypeOfArrangementAxis_2931d1c9-7906-473f-b2e9-e5f858afb5f8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2931d1c9-7906-473f-b2e9-e5f858afb5f8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_2931d1c9-7906-473f-b2e9-e5f858afb5f8" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2931d1c9-7906-473f-b2e9-e5f858afb5f8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fa2760d6-9969-4c02-838a-59368b873aad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_2931d1c9-7906-473f-b2e9-e5f858afb5f8" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fa2760d6-9969-4c02-838a-59368b873aad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_f8f3a869-abef-45de-a5d0-d01db84e67af" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fa2760d6-9969-4c02-838a-59368b873aad" xlink:to="loc_us-gaap_CollaborativeArrangementMember_f8f3a869-abef-45de-a5d0-d01db84e67af" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_c1d370bc-5cad-43a3-9409-ee7ba6573a31" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_60b79a2c-8778-480c-a021-9079b2fa15c2" xlink:to="loc_srt_ProductOrServiceAxis_c1d370bc-5cad-43a3-9409-ee7ba6573a31" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c1d370bc-5cad-43a3-9409-ee7ba6573a31_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_c1d370bc-5cad-43a3-9409-ee7ba6573a31" xlink:to="loc_srt_ProductsAndServicesDomain_c1d370bc-5cad-43a3-9409-ee7ba6573a31_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_14382682-8ac8-439c-b535-074a9c3106a5" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_c1d370bc-5cad-43a3-9409-ee7ba6573a31" xlink:to="loc_srt_ProductsAndServicesDomain_14382682-8ac8-439c-b535-074a9c3106a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LassaFeverAndMERSVaccineMember_4f295b7b-7983-45f3-8945-ebc7f26be4a3" xlink:href="ino-20250331.xsd#ino_LassaFeverAndMERSVaccineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_14382682-8ac8-439c-b535-074a9c3106a5" xlink:to="loc_ino_LassaFeverAndMERSVaccineMember_4f295b7b-7983-45f3-8945-ebc7f26be4a3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DNAEncodedMonoclonalAntibodyTechnologyMember_d259c2e2-7184-4498-b642-3c15118dffb2" xlink:href="ino-20250331.xsd#ino_DNAEncodedMonoclonalAntibodyTechnologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_14382682-8ac8-439c-b535-074a9c3106a5" xlink:to="loc_ino_DNAEncodedMonoclonalAntibodyTechnologyMember_d259c2e2-7184-4498-b642-3c15118dffb2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborationAgreementAdditionalRevenueToBeAchieved_f201424a-ab2a-4e63-b245-6e84b40dbb13" xlink:href="ino-20250331.xsd#ino_CollaborationAgreementAdditionalRevenueToBeAchieved"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fb5f1534-9d3d-4f5e-9b78-bf18157cef00" xlink:to="loc_ino_CollaborationAgreementAdditionalRevenueToBeAchieved_f201424a-ab2a-4e63-b245-6e84b40dbb13" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborationAgreementRoyaltyPeriod_60faae00-7fff-4e11-bdb8-bc2c0e5d050a" xlink:href="ino-20250331.xsd#ino_CollaborationAgreementRoyaltyPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fb5f1534-9d3d-4f5e-9b78-bf18157cef00" xlink:to="loc_ino_CollaborationAgreementRoyaltyPeriod_60faae00-7fff-4e11-bdb8-bc2c0e5d050a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_76550ca2-e7b3-4b24-b43f-59de71a0f358" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fb5f1534-9d3d-4f5e-9b78-bf18157cef00" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_76550ca2-e7b3-4b24-b43f-59de71a0f358" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementFundingToBeReceived_917a2812-7cb7-4e1e-9675-4eb21be2e126" xlink:href="ino-20250331.xsd#ino_CollaborativeAgreementFundingToBeReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fb5f1534-9d3d-4f5e-9b78-bf18157cef00" xlink:to="loc_ino_CollaborativeAgreementFundingToBeReceived_917a2812-7cb7-4e1e-9675-4eb21be2e126" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment_9f201af1-c5d4-4956-b047-cd8332baffe8" xlink:href="ino-20250331.xsd#ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fb5f1534-9d3d-4f5e-9b78-bf18157cef00" xlink:to="loc_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment_9f201af1-c5d4-4956-b047-cd8332baffe8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementFundingReceived_97222613-e558-466b-a0d0-048970e63bcc" xlink:href="ino-20250331.xsd#ino_CollaborativeAgreementFundingReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fb5f1534-9d3d-4f5e-9b78-bf18157cef00" xlink:to="loc_ino_CollaborativeAgreementFundingReceived_97222613-e558-466b-a0d0-048970e63bcc" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncDetails" xlink:type="simple" xlink:href="ino-20250331.xsd#GeneosTherapeuticsIncDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/GeneosTherapeuticsIncDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems_abc7eb1f-846c-4856-91d8-30e4f9e5a10c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable_283f48a5-8027-4162-9f92-ad6eb3c2e800" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterestTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_MinorityInterestLineItems_abc7eb1f-846c-4856-91d8-30e4f9e5a10c" xlink:to="loc_us-gaap_MinorityInterestTable_283f48a5-8027-4162-9f92-ad6eb3c2e800" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_57ff40a1-bd6a-4dae-8e8e-ddb78299d50a" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MinorityInterestTable_283f48a5-8027-4162-9f92-ad6eb3c2e800" xlink:to="loc_srt_OwnershipAxis_57ff40a1-bd6a-4dae-8e8e-ddb78299d50a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_57ff40a1-bd6a-4dae-8e8e-ddb78299d50a_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_57ff40a1-bd6a-4dae-8e8e-ddb78299d50a" xlink:to="loc_srt_OwnershipDomain_57ff40a1-bd6a-4dae-8e8e-ddb78299d50a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_8084fac4-7b79-48cd-8347-88828b33c5e0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_57ff40a1-bd6a-4dae-8e8e-ddb78299d50a" xlink:to="loc_srt_OwnershipDomain_8084fac4-7b79-48cd-8347-88828b33c5e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GeneosTherapeuticsInc.Member_359f3b01-8015-4aec-b4a8-936491cdbd75" xlink:href="ino-20250331.xsd#ino_GeneosTherapeuticsInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_8084fac4-7b79-48cd-8347-88828b33c5e0" xlink:to="loc_ino_GeneosTherapeuticsInc.Member_359f3b01-8015-4aec-b4a8-936491cdbd75" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_2a8539a5-701a-4fcc-a7a9-2539a0ef592d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_abc7eb1f-846c-4856-91d8-30e4f9e5a10c" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_2a8539a5-701a-4fcc-a7a9-2539a0ef592d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_a964ac0b-496a-4eb5-ace0-7cd036834503" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_abc7eb1f-846c-4856-91d8-30e4f9e5a10c" xlink:to="loc_us-gaap_EquityMethodInvestments_a964ac0b-496a-4eb5-ace0-7cd036834503" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_EquityMethodInvestmentsMinimum_500609de-1626-4391-9419-b21a8f661500" xlink:href="ino-20250331.xsd#ino_EquityMethodInvestmentsMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_abc7eb1f-846c-4856-91d8-30e4f9e5a10c" xlink:to="loc_ino_EquityMethodInvestmentsMinimum_500609de-1626-4391-9419-b21a8f661500" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/SegmentInformationDetails" xlink:type="simple" xlink:href="ino-20250331.xsd#SegmentInformationDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/SegmentInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_9728c8f2-bb11-427e-bb98-bb1620918c0b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_3152e2e9-99b8-4cdb-bd94-d1884b7599ad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_9728c8f2-bb11-427e-bb98-bb1620918c0b" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_3152e2e9-99b8-4cdb-bd94-d1884b7599ad" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_77190d2e-6b67-44d9-be4e-1b36785ee549" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_3152e2e9-99b8-4cdb-bd94-d1884b7599ad" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_77190d2e-6b67-44d9-be4e-1b36785ee549" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_77190d2e-6b67-44d9-be4e-1b36785ee549_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_77190d2e-6b67-44d9-be4e-1b36785ee549" xlink:to="loc_us-gaap_SegmentDomain_77190d2e-6b67-44d9-be4e-1b36785ee549_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_fd0b67e7-5a78-4996-98cb-b42cb36d82de" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_77190d2e-6b67-44d9-be4e-1b36785ee549" xlink:to="loc_us-gaap_SegmentDomain_fd0b67e7-5a78-4996-98cb-b42cb36d82de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ReportableSegmentsMember_8e363641-22dd-4fc8-a199-3da116443503" xlink:href="ino-20250331.xsd#ino_ReportableSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_fd0b67e7-5a78-4996-98cb-b42cb36d82de" xlink:to="loc_ino_ReportableSegmentsMember_8e363641-22dd-4fc8-a199-3da116443503" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ResearchAndDevelopmentCostAxis_16da8357-048f-4232-b511-1c0b283d8081" xlink:href="ino-20250331.xsd#ino_ResearchAndDevelopmentCostAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_3152e2e9-99b8-4cdb-bd94-d1884b7599ad" xlink:to="loc_ino_ResearchAndDevelopmentCostAxis_16da8357-048f-4232-b511-1c0b283d8081" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ResearchAndDevelopmentCostDomain_16da8357-048f-4232-b511-1c0b283d8081_default" xlink:href="ino-20250331.xsd#ino_ResearchAndDevelopmentCostDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ino_ResearchAndDevelopmentCostAxis_16da8357-048f-4232-b511-1c0b283d8081" xlink:to="loc_ino_ResearchAndDevelopmentCostDomain_16da8357-048f-4232-b511-1c0b283d8081_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ResearchAndDevelopmentCostDomain_7e82844a-0b37-4d26-bfc2-f3bf9f74d992" xlink:href="ino-20250331.xsd#ino_ResearchAndDevelopmentCostDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ino_ResearchAndDevelopmentCostAxis_16da8357-048f-4232-b511-1c0b283d8081" xlink:to="loc_ino_ResearchAndDevelopmentCostDomain_7e82844a-0b37-4d26-bfc2-f3bf9f74d992" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_INO3107Member_e57dd058-bb41-4c4f-af3f-3cb6798bf7af" xlink:href="ino-20250331.xsd#ino_INO3107Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_ResearchAndDevelopmentCostDomain_7e82844a-0b37-4d26-bfc2-f3bf9f74d992" xlink:to="loc_ino_INO3107Member_e57dd058-bb41-4c4f-af3f-3cb6798bf7af" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_INO3112AndOtherImmunoOncologyMember_bcbd16bf-0ae7-4e27-a3b3-2c86026ae301" xlink:href="ino-20250331.xsd#ino_INO3112AndOtherImmunoOncologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_ResearchAndDevelopmentCostDomain_7e82844a-0b37-4d26-bfc2-f3bf9f74d992" xlink:to="loc_ino_INO3112AndOtherImmunoOncologyMember_bcbd16bf-0ae7-4e27-a3b3-2c86026ae301" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OtherProgramsMember_81322de6-ee5f-4984-bc40-0b1f6477ab23" xlink:href="ino-20250331.xsd#ino_OtherProgramsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_ResearchAndDevelopmentCostDomain_7e82844a-0b37-4d26-bfc2-f3bf9f74d992" xlink:to="loc_ino_OtherProgramsMember_81322de6-ee5f-4984-bc40-0b1f6477ab23" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_EngineeringAndDeviceRelatedMember_2da86ca7-1cf3-4f0f-96bf-d302d3c07a27" xlink:href="ino-20250331.xsd#ino_EngineeringAndDeviceRelatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_ResearchAndDevelopmentCostDomain_7e82844a-0b37-4d26-bfc2-f3bf9f74d992" xlink:to="loc_ino_EngineeringAndDeviceRelatedMember_2da86ca7-1cf3-4f0f-96bf-d302d3c07a27" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockBasedCompensationMember_7478244e-e807-44f0-8df4-6b16bf4ae042" xlink:href="ino-20250331.xsd#ino_StockBasedCompensationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_ResearchAndDevelopmentCostDomain_7e82844a-0b37-4d26-bfc2-f3bf9f74d992" xlink:to="loc_ino_StockBasedCompensationMember_7478244e-e807-44f0-8df4-6b16bf4ae042" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OtherUnallocatedExpensesMember_967bd97b-08a0-4916-9fc1-8d7e1d0067e9" xlink:href="ino-20250331.xsd#ino_OtherUnallocatedExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_ResearchAndDevelopmentCostDomain_7e82844a-0b37-4d26-bfc2-f3bf9f74d992" xlink:to="loc_ino_OtherUnallocatedExpensesMember_967bd97b-08a0-4916-9fc1-8d7e1d0067e9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_bda9fbcc-20cd-4cde-ba34-5d33ac5c1e13" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_9728c8f2-bb11-427e-bb98-bb1620918c0b" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_bda9fbcc-20cd-4cde-ba34-5d33ac5c1e13" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_52043c22-cd5b-4234-a496-aab9dc302411" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_9728c8f2-bb11-427e-bb98-bb1620918c0b" xlink:to="loc_us-gaap_OperatingExpensesAbstract_52043c22-cd5b-4234-a496-aab9dc302411" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_0be25d8e-f586-4c95-b611-8b36f613a7c0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_52043c22-cd5b-4234-a496-aab9dc302411" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_0be25d8e-f586-4c95-b611-8b36f613a7c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_2ef73b4e-e9cb-4f82-9afe-2b82b6018932" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_52043c22-cd5b-4234-a496-aab9dc302411" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_2ef73b4e-e9cb-4f82-9afe-2b82b6018932" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_5e8396d0-a55d-4b14-a121-336a1a263511" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_9728c8f2-bb11-427e-bb98-bb1620918c0b" xlink:to="loc_us-gaap_OperatingExpenses_5e8396d0-a55d-4b14-a121-336a1a263511" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_28b2a7e6-246d-4480-bcf2-9efbafac232d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_9728c8f2-bb11-427e-bb98-bb1620918c0b" xlink:to="loc_us-gaap_InvestmentIncomeInterest_28b2a7e6-246d-4480-bcf2-9efbafac232d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating_2e57a805-d274-48fa-b4eb-d6f1a4fd57c5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_9728c8f2-bb11-427e-bb98-bb1620918c0b" xlink:to="loc_us-gaap_InterestExpenseNonoperating_2e57a805-d274-48fa-b4eb-d6f1a4fd57c5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_94112808-1a63-45d0-b2d9-2c778d47d762" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_9728c8f2-bb11-427e-bb98-bb1620918c0b" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_94112808-1a63-45d0-b2d9-2c778d47d762" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_fcc59408-359a-487d-9859-45b09b10df43" xlink:href="ino-20250331.xsd#ino_ChangeInValueOfInvestmentsInAffiliatedCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_9728c8f2-bb11-427e-bb98-bb1620918c0b" xlink:to="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_fcc59408-359a-487d-9859-45b09b10df43" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_c8f687af-022e-4ff2-8bd2-ff2edf05d9b9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_9728c8f2-bb11-427e-bb98-bb1620918c0b" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_c8f687af-022e-4ff2-8bd2-ff2edf05d9b9" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_35e6a6be-4734-4902-8492-62bcf6e3e0d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_9728c8f2-bb11-427e-bb98-bb1620918c0b" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_35e6a6be-4734-4902-8492-62bcf6e3e0d0" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_e5cb0593-36f6-43b3-b31e-4be6fc490f68" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_9728c8f2-bb11-427e-bb98-bb1620918c0b" xlink:to="loc_us-gaap_NetIncomeLoss_e5cb0593-36f6-43b3-b31e-4be6fc490f68" xlink:type="arc" order="9"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants" xlink:type="arc" order="691"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>ino-20250331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:382d2453-c46c-4ade-9f50-1f9566f15edb,g:9bfa17de-2275-45c6-a4f6-49112bde99df-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_116d0626-a79c-4ba3-94d3-18528a11287a_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_60557181-1fbb-4522-b9f1-bd3f92ca0730_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_b97fdb85-ede2-483d-a172-c2edbdb098d0_verboseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transactions</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_NonCashInterestIncomeExpense_aa86eaf8-a5ff-4b02-b445-dd273b2cee9c_negatedTerseLabel_en-US" xlink:label="lab_ino_NonCashInterestIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Non-cash interest on senior convertible notes</link:label>
    <link:label id="lab_ino_NonCashInterestIncomeExpense_label_en-US" xlink:label="lab_ino_NonCashInterestIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Cash Interest Income (Expense)</link:label>
    <link:label id="lab_ino_NonCashInterestIncomeExpense_documentation_en-US" xlink:label="lab_ino_NonCashInterestIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non-Cash Interest Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_NonCashInterestIncomeExpense" xlink:href="ino-20250331.xsd#ino_NonCashInterestIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_NonCashInterestIncomeExpense" xlink:to="lab_ino_NonCashInterestIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_b0331f2f-3c8f-4336-bbff-42b3d054e618_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Gross&#160;Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_6eb56042-202e-425d-9adf-50eedef445d2_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d6873a51-3a79-4fd3-bccd-70bc976465ce_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">(Decrease) Increase in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_59244996-f86c-4a88-9e12-1e6a2351d42f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Future Minimum Rental Payments for Operating Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_283e57bf-c56e-48be-8283-af24e58d8943_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_ababc41c-3c70-40e1-a4a3-a5b5c407183c_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllTradingArrangementsMember_terseLabel_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Trading Arrangements</link:label>
    <link:label id="lab_ecd_AllTradingArrangementsMember_label_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Trading Arrangements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllTradingArrangementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="lab_ecd_AllTradingArrangementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonNeosMember_terseLabel_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-NEOs</link:label>
    <link:label id="lab_ecd_NonNeosMember_label_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-NEOs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonNeosMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonNeosMember" xlink:to="lab_ecd_NonNeosMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_be8183c3-9fb4-410b-a9de-ab5a3d2126b9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award vesting period (in years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:to="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestments_8d2c4b86-4823-4a32-a6ca-39aaa2aacfd6_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment in Geneos</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestments" xlink:to="lab_us-gaap_EquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PayVsPerformanceDisclosureLineItems_label_en-US" xlink:label="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_OtherProgramsMember_784512ba-c233-4414-90b6-e3b3db7dcf75_terseLabel_en-US" xlink:label="lab_ino_OtherProgramsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other programs</link:label>
    <link:label id="lab_ino_OtherProgramsMember_label_en-US" xlink:label="lab_ino_OtherProgramsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Programs [Member]</link:label>
    <link:label id="lab_ino_OtherProgramsMember_documentation_en-US" xlink:label="lab_ino_OtherProgramsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Programs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OtherProgramsMember" xlink:href="ino-20250331.xsd#ino_OtherProgramsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_OtherProgramsMember" xlink:to="lab_ino_OtherProgramsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_A2007IncentivePlanMember_bbfc0959-1f15-42d2-8267-7fe1d5693854_terseLabel_en-US" xlink:label="lab_ino_A2007IncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2007 Incentive Plan</link:label>
    <link:label id="lab_ino_A2007IncentivePlanMember_label_en-US" xlink:label="lab_ino_A2007IncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2007 Incentive Plan [Member]</link:label>
    <link:label id="lab_ino_A2007IncentivePlanMember_documentation_en-US" xlink:label="lab_ino_A2007IncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2007 Incentive Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A2007IncentivePlanMember" xlink:href="ino-20250331.xsd#ino_A2007IncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_A2007IncentivePlanMember" xlink:to="lab_ino_A2007IncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_07df17f9-e127-45b6-98f5-d2fdd35cce08_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable from affiliated entity</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_INO3107Member_d5415a84-c766-4b27-9d25-c3f5428b55e4_terseLabel_en-US" xlink:label="lab_ino_INO3107Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">INO-3107</link:label>
    <link:label id="lab_ino_INO3107Member_label_en-US" xlink:label="lab_ino_INO3107Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">INO-3107 [Member]</link:label>
    <link:label id="lab_ino_INO3107Member_documentation_en-US" xlink:label="lab_ino_INO3107Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">INO-3107</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_INO3107Member" xlink:href="ino-20250331.xsd#ino_INO3107Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_INO3107Member" xlink:to="lab_ino_INO3107Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_488247cf-eb3c-40b3-bbee-93350c211dda_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_0f9aa7e4-5d28-4e96-b8ed-3ab210592798_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geneos Therapeutics, Inc.</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:to="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_96326b25-ae30-46ee-9b81-65d2dae743fe_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term Investments and Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_GrantProceedsReceived_3f7014dc-9d35-4936-8961-f54848c91ebe_terseLabel_en-US" xlink:label="lab_ino_GrantProceedsReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contra-research and development expense</link:label>
    <link:label id="lab_ino_GrantProceedsReceived_label_en-US" xlink:label="lab_ino_GrantProceedsReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Grant Proceeds Received</link:label>
    <link:label id="lab_ino_GrantProceedsReceived_documentation_en-US" xlink:label="lab_ino_GrantProceedsReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Grant Proceeds Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GrantProceedsReceived" xlink:href="ino-20250331.xsd#ino_GrantProceedsReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_GrantProceedsReceived" xlink:to="lab_ino_GrantProceedsReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_b1be85f7-ac21-4fa2-8301-478bded08d6b_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gain (loss) on short-term investments, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgDiscLineItems_label_en-US" xlink:label="lab_ecd_AwardTmgDiscLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Disclosures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="lab_ecd_AwardTmgDiscLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_cedacbc5-7d34-4295-a793-05cd8c207a1c_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of common and preferred stock authorized, issued and outstanding</link:label>
    <link:label id="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Number of Shares, Par Value and Other Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_label_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OtherPerfMeasureAmt" xlink:to="lab_ecd_OtherPerfMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_0c492200-0a92-4a77-a527-5277afe11e36_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares, outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_b6a5a3ca-4015-4802-baa6-fa1c7317e976_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_16c8dc4b-a587-460f-94aa-a71bacf8421d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares available for grant (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_9e0905fd-5bea-4dc1-8a5c-3cc14435cd5f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liability, net of current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_cef40ff3-15ed-416f-ad1d-801c40d32b9e_netLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Long-term operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_20f2d867-70fe-45ca-9208-009c4c7930e3_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_69d13ca4-facd-4f67-8ec1-43388f698b2a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Realized loss on investments</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Realized Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_0cb9f2c9-54fc-45ab-83d9-0aa4c2cdfa5a_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_df180d20-12c2-4e50-b5d4-54e711fe10a9_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock, price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_7a7e9842-25a9-42f9-826a-a0454f6d8381_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sale of stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance or Sale of Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_22af0df9-705a-4fb5-a68c-448be7a9464f_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_768406fb-2b24-46e3-bc1d-8d4bb0333ee4_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_1bbc5b1f-a223-4f65-93fb-052bcff25091_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_ced9634e-9887-49a8-be1e-a7624b8239f6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Amortization of discounts on investments</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Income, Net, Amortization of Discount and Premium</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:to="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_b85eb917-d866-4cf9-a3d2-a2b46cd29e25_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_07019e41-031c-4732-bdc4-ef8f9b02be8f_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consideration received on transaction</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e9c933c2-ae89-4b18-8733-4c134e6d183c_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_24e4a70b-781f-49b2-917f-884be29b11a7_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_0fb2a108-0a9c-4841-8e33-9bd4e18230ac_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Method</link:label>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMethodTextBlock" xlink:to="lab_ecd_AwardTmgMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_b57804aa-691e-420e-810b-c86c5200c90c_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Expenses - Clinical Trial Accruals</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrByIndTable_terseLabel_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual</link:label>
    <link:label id="lab_ecd_TradingArrByIndTable_label_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrByIndTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="lab_ecd_TradingArrByIndTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ad382c0d-1fed-4db9-9983-503ff9a3fa97_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair&#160;Market&#160;Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_43832f32-d69b-4b1b-aa16-c059c540ee87_netLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestLineItems_771cec7c-1b3c-4d8d-b9a8-03dd55e3559a_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest [Line Items]</link:label>
    <link:label id="lab_us-gaap_MinorityInterestLineItems_label_en-US" xlink:label="lab_us-gaap_MinorityInterestLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestLineItems" xlink:to="lab_us-gaap_MinorityInterestLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_8ccfa751-90ac-4ac8-a02f-0d8adaa9fbc4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_MutualFundsMember_042c4b1f-c95e-4987-9507-b679bf576ced_verboseLabel_en-US" xlink:label="lab_ino_MutualFundsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Mutual funds</link:label>
    <link:label id="lab_ino_MutualFundsMember_label_en-US" xlink:label="lab_ino_MutualFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Mutual Funds [Member]</link:label>
    <link:label id="lab_ino_MutualFundsMember_documentation_en-US" xlink:label="lab_ino_MutualFundsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Mutual funds.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_MutualFundsMember" xlink:href="ino-20250331.xsd#ino_MutualFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_MutualFundsMember" xlink:to="lab_ino_MutualFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_cbda46d3-0b54-4c8a-aaf1-1bb947204f5b_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingPoliciesProcLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
    <link:label id="lab_ecd_AdjToCompAmt_label_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAmt" xlink:to="lab_ecd_AdjToCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryCompAmt" xlink:to="lab_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_3e075d80-f652-4b0a-8b8c-b992ea958c31_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureAmt" xlink:to="lab_ecd_CoSelectedMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TabularListTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tabular List, Table</link:label>
    <link:label id="lab_ecd_TabularListTableTextBlock_label_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tabular List [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TabularListTableTextBlock" xlink:to="lab_ecd_TabularListTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_f5790c19-f015-4163-a54c-058c75006731_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Significant Unobservable Inputs (Level&#160;3)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8f70da7a-23df-4771-8bdb-bca86379f9ed_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardDateAxis_2f713111-7b2f-4550-9a22-df360eb6dc13_terseLabel_en-US" xlink:label="lab_us-gaap_AwardDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Date [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardDateAxis_label_en-US" xlink:label="lab_us-gaap_AwardDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardDateAxis" xlink:to="lab_us-gaap_AwardDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_0116c7c7-e530-4604-8bf8-372af53c80b8_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of securities called by warrants or rights (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_34ff84f6-f298-4a72-b127-ebeef97216fb_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a7ae1aa9-f382-45a7-93c5-d1c6c4ff9f72_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_ad8faa55-39e0-447d-b59b-1d2a0d9ecf07_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive securities excluded (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputExpectedDividendRateMember_7a8367ce-ac9f-4c74-8cd2-c1b66b8120e7_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividend yield</link:label>
    <link:label id="lab_us-gaap_MeasurementInputExpectedDividendRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Expected Dividend Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:to="lab_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_StockSaleAgreementRemainingCapacityAmount_1563ccf8-1812-41ab-8d83-6da0d8d64566_terseLabel_en-US" xlink:label="lab_ino_StockSaleAgreementRemainingCapacityAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock sale agreement, remaining capacity, amount</link:label>
    <link:label id="lab_ino_StockSaleAgreementRemainingCapacityAmount_label_en-US" xlink:label="lab_ino_StockSaleAgreementRemainingCapacityAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Sale Agreement, Remaining Capacity, Amount</link:label>
    <link:label id="lab_ino_StockSaleAgreementRemainingCapacityAmount_documentation_en-US" xlink:label="lab_ino_StockSaleAgreementRemainingCapacityAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Sale Agreement, Remaining Capacity, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSaleAgreementRemainingCapacityAmount" xlink:href="ino-20250331.xsd#ino_StockSaleAgreementRemainingCapacityAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_StockSaleAgreementRemainingCapacityAmount" xlink:to="lab_ino_StockSaleAgreementRemainingCapacityAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_b94a1a9f-1040-4a3a-b94a-5efaf599790c_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_358e7830-4778-476e-b20e-51e9f5676450_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents, beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8919c9f6-0e1f-42f8-a402-c9bdb9388590_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents, end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_2981cb6c-2c37-4a94-a294-c41ee70ceba7_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment in affiliated entity</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNi" xlink:to="lab_us-gaap_EquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_4f7cc51b-f45e-4b50-ac30-cdc0357f3673_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total unrecognized compensation cost related to unvested stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ServiceBasedRestrictedStockUnitsMember_ed2174a0-114c-4ae8-918a-60acd5896535_verboseLabel_en-US" xlink:label="lab_ino_ServiceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Service-based restricted stock units</link:label>
    <link:label id="lab_ino_ServiceBasedRestrictedStockUnitsMember_bfa4b7c7-1ce2-4a8b-a1b2-b3be45b8abae_terseLabel_en-US" xlink:label="lab_ino_ServiceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Service-Based Restricted Stock Units</link:label>
    <link:label id="lab_ino_ServiceBasedRestrictedStockUnitsMember_label_en-US" xlink:label="lab_ino_ServiceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Service-Based Restricted Stock Units [Member]</link:label>
    <link:label id="lab_ino_ServiceBasedRestrictedStockUnitsMember_documentation_en-US" xlink:label="lab_ino_ServiceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Service-Based Restricted Stock Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ServiceBasedRestrictedStockUnitsMember" xlink:href="ino-20250331.xsd#ino_ServiceBasedRestrictedStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ServiceBasedRestrictedStockUnitsMember" xlink:to="lab_ino_ServiceBasedRestrictedStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_6bec29e2-3ae2-4d65-9f0e-dc07eddc81cc_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_c769cb0c-369d-4c5e-bebd-32c70ff34f4c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive loss:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_BillAndMelindaGatesFoundationMember_e73eb054-cab0-4686-bbdf-5b7f8da3a9bf_terseLabel_en-US" xlink:label="lab_ino_BillAndMelindaGatesFoundationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Bill and Melinda Gates Foundation</link:label>
    <link:label id="lab_ino_BillAndMelindaGatesFoundationMember_label_en-US" xlink:label="lab_ino_BillAndMelindaGatesFoundationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bill And Melinda Gates Foundation [Member]</link:label>
    <link:label id="lab_ino_BillAndMelindaGatesFoundationMember_documentation_en-US" xlink:label="lab_ino_BillAndMelindaGatesFoundationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Bill And Melinda Gates Foundation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_BillAndMelindaGatesFoundationMember" xlink:href="ino-20250331.xsd#ino_BillAndMelindaGatesFoundationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_BillAndMelindaGatesFoundationMember" xlink:to="lab_ino_BillAndMelindaGatesFoundationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_55c463c3-db9e-457f-b294-e2694c501cc7_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_581694a4-13a7-44cf-aad3-465a193fb308_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Options to purchase common stock</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_8b0db549-7cb9-4100-9b8f-04d309d237fa_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_7761e161-c985-4eca-a895-3897ee14b8b3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_7c6828ef-c1b3-4144-a930-cccfaffbe8a8_verboseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_4d592e26-09db-4e4e-8282-471fde2950cb_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_StockSalesAgreementMaximumAuthorizedAmount_9ae48af0-1896-41c0-9647-243409708299_terseLabel_en-US" xlink:label="lab_ino_StockSalesAgreementMaximumAuthorizedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum authorized amount</link:label>
    <link:label id="lab_ino_StockSalesAgreementMaximumAuthorizedAmount_label_en-US" xlink:label="lab_ino_StockSalesAgreementMaximumAuthorizedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Sales Agreement, Maximum Authorized Amount</link:label>
    <link:label id="lab_ino_StockSalesAgreementMaximumAuthorizedAmount_documentation_en-US" xlink:label="lab_ino_StockSalesAgreementMaximumAuthorizedAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Sales Agreement, Maximum Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSalesAgreementMaximumAuthorizedAmount" xlink:href="ino-20250331.xsd#ino_StockSalesAgreementMaximumAuthorizedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_StockSalesAgreementMaximumAuthorizedAmount" xlink:to="lab_ino_StockSalesAgreementMaximumAuthorizedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_199caa54-414c-4cc0-98e0-3e22c76853d3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_6a9dd060-ef75-442e-b1ff-c5ef1c092dcf_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_6c86834b-fab8-4dc2-a239-06008d9da33f_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_b6abea06-5aba-4db2-82f8-6738e686c0a8_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants to purchase common stock</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_52958f02-bbf4-42d7-898b-da0444ef9e3a_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_556af9ca-4ec9-4076-b1dd-6db5ea4cba2b_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_A2021SalesAgreementMember_50cddd30-4e82-4b61-8fc3-0b14cf3985fb_terseLabel_en-US" xlink:label="lab_ino_A2021SalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2021 Sales Agreement</link:label>
    <link:label id="lab_ino_A2021SalesAgreementMember_label_en-US" xlink:label="lab_ino_A2021SalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2021 Sales Agreement [Member]</link:label>
    <link:label id="lab_ino_A2021SalesAgreementMember_documentation_en-US" xlink:label="lab_ino_A2021SalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2021 Sales Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A2021SalesAgreementMember" xlink:href="ino-20250331.xsd#ino_A2021SalesAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_A2021SalesAgreementMember" xlink:to="lab_ino_A2021SalesAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_d2f7b432-288a-4e17-a7b4-878a046b77e7_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Fixed assets, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_822f7d25-5138-46c6-b2af-865defce24d0_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_9a05bc7f-e749-4cc7-88e7-6af832b5ab31_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible Debt</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtMember" xlink:to="lab_us-gaap_ConvertibleDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_EarningsPerShareBasicAndDilutedEPSAbstract_b133d9d1-8415-4db4-a3e6-26cd8b18ee6b_terseLabel_en-US" xlink:label="lab_ino_EarningsPerShareBasicAndDilutedEPSAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share</link:label>
    <link:label id="lab_ino_EarningsPerShareBasicAndDilutedEPSAbstract_label_en-US" xlink:label="lab_ino_EarningsPerShareBasicAndDilutedEPSAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic and Diluted EPS [Abstract]</link:label>
    <link:label id="lab_ino_EarningsPerShareBasicAndDilutedEPSAbstract_documentation_en-US" xlink:label="lab_ino_EarningsPerShareBasicAndDilutedEPSAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic and Diluted EPS</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_EarningsPerShareBasicAndDilutedEPSAbstract" xlink:href="ino-20250331.xsd#ino_EarningsPerShareBasicAndDilutedEPSAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_EarningsPerShareBasicAndDilutedEPSAbstract" xlink:to="lab_ino_EarningsPerShareBasicAndDilutedEPSAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_ac43085f-fb74-41a6-a3c8-a0dcfec7d1c7_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_6e427ffe-ddaa-45e6-bdea-851aa0605bbb_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_24cac49a-3a62-4acf-b2ea-b327563f10ab_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_dc632d0f-239f-48f7-a117-f3508db49b50_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrExpirationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expiration Date</link:label>
    <link:label id="lab_ecd_TrdArrExpirationDate_label_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Expiration Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrExpirationDate" xlink:to="lab_ecd_TrdArrExpirationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f7695699-49b7-4ed9-ba98-4541da86cb17_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentOwnedBalanceShares_b55fc4f1-b88e-4bdc-a9a8-2574506260dd_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentOwnedBalanceShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment owned (in shares)</link:label>
    <link:label id="lab_us-gaap_InvestmentOwnedBalanceShares_label_en-US" xlink:label="lab_us-gaap_InvestmentOwnedBalanceShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Owned, Balance, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentOwnedBalanceShares" xlink:to="lab_us-gaap_InvestmentOwnedBalanceShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_116458e7-6bbd-4153-863f-72c66328a8f7_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_54d0f0a7-3b09-4ccc-b219-d139860e796e_negatedLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnAmt" xlink:to="lab_ecd_TotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_32bde272-b7af-4bca-a874-3c59b2c29598_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares, issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:to="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_73341d7d-b64f-4e2d-8d52-063e3aec703c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Realized gain on investments</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Realized Gain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_December2024Member_66b35c60-fe20-40ec-833a-b288e486e750_terseLabel_en-US" xlink:label="lab_ino_December2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">December 2024</link:label>
    <link:label id="lab_ino_December2024Member_label_en-US" xlink:label="lab_ino_December2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">December 2024 [Member]</link:label>
    <link:label id="lab_ino_December2024Member_documentation_en-US" xlink:label="lab_ino_December2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">December 2024</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_December2024Member" xlink:href="ino-20250331.xsd#ino_December2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_December2024Member" xlink:to="lab_ino_December2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember_a7510429-01f6-4a74-94d2-1ed57ef067ba_terseLabel_en-US" xlink:label="lab_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. agency mortgage-backed securities</link:label>
    <link:label id="lab_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember_label_en-US" xlink:label="lab_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Mortgage-Backed Security, Issued by US Government-Sponsored Enterprise [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember" xlink:to="lab_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock_9a47d1d9-4705-474f-8037-4766bfae228d_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Related Costs, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_EmployeesAndDirectorsMember_2910c4e3-8af4-4865-b452-8909e233a1b2_terseLabel_en-US" xlink:label="lab_ino_EmployeesAndDirectorsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employees and Directors</link:label>
    <link:label id="lab_ino_EmployeesAndDirectorsMember_label_en-US" xlink:label="lab_ino_EmployeesAndDirectorsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employees and Directors [Member]</link:label>
    <link:label id="lab_ino_EmployeesAndDirectorsMember_documentation_en-US" xlink:label="lab_ino_EmployeesAndDirectorsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employees and Directors [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_EmployeesAndDirectorsMember" xlink:href="ino-20250331.xsd#ino_EmployeesAndDirectorsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_EmployeesAndDirectorsMember" xlink:to="lab_ino_EmployeesAndDirectorsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_442cac70-00eb-4ae0-9601-74d83001150d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_label_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_dffdf371-aaa7-484d-b85a-642656350a51_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_a2e3683e-cb91-4d7b-94be-e29f62357605_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares, authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_5204bdb4-78d6-4bc1-ad54-8408707ad7b0_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:to="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_6acf93fe-64f8-49bc-974f-d236dd38e40c_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Presentation and Liquidity</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_01202f24-b133-4e66-b14f-7a5ceb499782_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1be48c3f-9e3d-4b6b-ace5-77ed263f703a_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Weighted-average common shares outstanding used to compute basic and diluted net loss per share, diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_terseLabel_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_label_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:to="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_5417d4dc-bb9b-4902-8c37-7a3d1b8b6603_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_0d53da14-386f-433a-9111-8ab4ead7b9cb_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Inovio Pharmaceuticals, Inc. stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_3b825bf1-3071-4edc-8d29-2078f443d62b_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_6df9ed95-a2e1-475d-b0ac-c151fa68e367_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfDebt_c3a6fea1-94d8-46e0-9a73-ed210dfa0467_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_5a25e6d4-407c-4456-8bf6-0144d2ae0d81_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyMember_2c63a948-259e-44f4-ad34-5199817d2741_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party</link:label>
    <link:label id="lab_us-gaap_RelatedPartyMember_label_en-US" xlink:label="lab_us-gaap_RelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyMember" xlink:to="lab_us-gaap_RelatedPartyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_0ad2f90f-1790-4139-a335-5761c31a9e5b_verboseLabel_en-US" xlink:label="lab_ino_ChangeInValueOfInvestmentsInAffiliatedCompany" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Gain (loss) on investment in affiliated entity</link:label>
    <link:label id="lab_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_3099e825-60b1-4e11-8def-3aaec3bc06a6_negatedLabel_en-US" xlink:label="lab_ino_ChangeInValueOfInvestmentsInAffiliatedCompany" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">(Gain) loss on equity investment in affiliated entity</link:label>
    <link:label id="lab_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_caae6968-14c6-49a1-bbcc-be4d19866bc4_terseLabel_en-US" xlink:label="lab_ino_ChangeInValueOfInvestmentsInAffiliatedCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain (loss) on investment in affiliated entity</link:label>
    <link:label id="lab_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_label_en-US" xlink:label="lab_ino_ChangeInValueOfInvestmentsInAffiliatedCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in Value of Investments in Affiliated Company</link:label>
    <link:label id="lab_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_documentation_en-US" xlink:label="lab_ino_ChangeInValueOfInvestmentsInAffiliatedCompany" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The net result for the period of the change in fair value of the investment in affiliated entity. This investment is measured at fair value on a recurring basis.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany" xlink:href="ino-20250331.xsd#ino_ChangeInValueOfInvestmentsInAffiliatedCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany" xlink:to="lab_ino_ChangeInValueOfInvestmentsInAffiliatedCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseNonoperating_9f36afbd-9d9b-4d6d-9578-58434e761606_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseNonoperating" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseNonoperating_label_en-US" xlink:label="lab_us-gaap_InterestExpenseNonoperating" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense, Nonoperating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseNonoperating" xlink:to="lab_us-gaap_InterestExpenseNonoperating" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedSalariesCurrent_a2c3a2b1-d95f-49e2-8eb0-e30efe6c9875_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedSalariesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_us-gaap_AccruedSalariesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedSalariesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Salaries, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalariesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedSalariesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedSalariesCurrent" xlink:to="lab_us-gaap_AccruedSalariesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_8b19d352-25d0-4001-8c80-77424bcda93f_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Table]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments_658011c0-21fe-4d31-865b-89eb35b5bec6_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sale or maturity of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale of Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfConvertibleDebt_c7370439-7353-41fd-af27-bd02c6b53e61_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfConvertibleDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Repayment of convertible senior notes</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfConvertibleDebt_89e6cf2f-9da4-45a0-a39d-4246ef8b1256_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Repayment of convertible senior notes</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfConvertibleDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfConvertibleDebt" xlink:to="lab_us-gaap_RepaymentsOfConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_StockSaleAgreementAggregateNumberofSharesIssued_630c4be0-0ea8-4fdb-8195-76b6c97449c6_terseLabel_en-US" xlink:label="lab_ino_StockSaleAgreementAggregateNumberofSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate number of shares issued (in shares)</link:label>
    <link:label id="lab_ino_StockSaleAgreementAggregateNumberofSharesIssued_label_en-US" xlink:label="lab_ino_StockSaleAgreementAggregateNumberofSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Sale Agreement, Aggregate Number of Shares Issued</link:label>
    <link:label id="lab_ino_StockSaleAgreementAggregateNumberofSharesIssued_documentation_en-US" xlink:label="lab_ino_StockSaleAgreementAggregateNumberofSharesIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Sale Agreement, Aggregate Number of Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSaleAgreementAggregateNumberofSharesIssued" xlink:href="ino-20250331.xsd#ino_StockSaleAgreementAggregateNumberofSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_StockSaleAgreementAggregateNumberofSharesIssued" xlink:to="lab_ino_StockSaleAgreementAggregateNumberofSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_de323906-8d04-4fe4-a7ae-32a70248154e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurements, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_62ec6de1-82d0-42f5-bcf9-c496a52dbd28_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable from affiliated entity</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_4f9a5fb6-4fe3-4829-8c56-c69d28046228_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_250abdb9-293c-4432-ba1b-98e8f4d39000_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncontrolling interest, ownership percentage by parent (in percent)</link:label>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_label_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsidiary, Ownership Percentage, Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:to="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_091abc9a-cf16-4430-b819-d2723ebcce57_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_df09343a-db1c-408d-aaab-f8e0742e1e75_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_96a29cd7-97da-4bbc-aeeb-74da5796645c_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:to="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_6e1e1630-b659-419f-936e-fafee57bebb4_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_terseLabel_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Executive Categories</link:label>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_label_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Executive Categories [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="lab_ecd_AllExecutiveCategoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage_030c2e4a-f271-4341-b944-9ddd6e579075_terseLabel_en-US" xlink:label="lab_ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock, sales proceeds of any common stock, percentage (in percent)</link:label>
    <link:label id="lab_ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage_label_en-US" xlink:label="lab_ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Sales Proceeds of Any Common Stock, Percentage</link:label>
    <link:label id="lab_ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage_documentation_en-US" xlink:label="lab_ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale of Stock, Sales Proceeds of Any Common Stock, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage" xlink:href="ino-20250331.xsd#ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage" xlink:to="lab_ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeAgreementAwardedOptionAmount_57b4bdc4-4ddd-4700-a364-79916db8ad9a_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementAwardedOptionAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awarded option amount</link:label>
    <link:label id="lab_ino_CollaborativeAgreementAwardedOptionAmount_label_en-US" xlink:label="lab_ino_CollaborativeAgreementAwardedOptionAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Agreement, Awarded Option Amount</link:label>
    <link:label id="lab_ino_CollaborativeAgreementAwardedOptionAmount_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementAwardedOptionAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Agreement, Awarded Option Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementAwardedOptionAmount" xlink:href="ino-20250331.xsd#ino_CollaborativeAgreementAwardedOptionAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementAwardedOptionAmount" xlink:to="lab_ino_CollaborativeAgreementAwardedOptionAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_label_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:to="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_c95b0af1-65cd-452a-aeec-c07c0f3eef90_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_72be2c7f-d812-43f8-93f5-1fb1d3a31f05_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dd29c084-9181-4e71-936a-3fcfb6999ec0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPercentage_29a4f87f-9358-4a4c-9f50-4338c38ae11e_terseLabel_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Threshold, percentage</link:label>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPercentage_label_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Threshold, Percentage</link:label>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPercentage_documentation_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Threshold, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPercentage" xlink:href="ino-20250331.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPercentage" xlink:to="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_1479f96b-81f7-4ef3-bcae-65207539d4de_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:to="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_1928225b-16cd-4e62-a28d-f370cb58c7ea_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CommonStockWarrantLiabilityFairValue_cd00c1f9-bab3-477f-aa76-a384ac7cec28_terseLabel_en-US" xlink:label="lab_ino_CommonStockWarrantLiabilityFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock warrant liability</link:label>
    <link:label id="lab_ino_CommonStockWarrantLiabilityFairValue_label_en-US" xlink:label="lab_ino_CommonStockWarrantLiabilityFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock Warrant Liability, Fair Value</link:label>
    <link:label id="lab_ino_CommonStockWarrantLiabilityFairValue_documentation_en-US" xlink:label="lab_ino_CommonStockWarrantLiabilityFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common Stock Warrant Liability, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CommonStockWarrantLiabilityFairValue" xlink:href="ino-20250331.xsd#ino_CommonStockWarrantLiabilityFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CommonStockWarrantLiabilityFairValue" xlink:to="lab_ino_CommonStockWarrantLiabilityFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_TheWistarInstituteMember_b5fc6392-3071-447a-83cc-d572ba0cd46f_terseLabel_en-US" xlink:label="lab_ino_TheWistarInstituteMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">The Wistar Institute</link:label>
    <link:label id="lab_ino_TheWistarInstituteMember_label_en-US" xlink:label="lab_ino_TheWistarInstituteMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">The Wistar Institute [Member]</link:label>
    <link:label id="lab_ino_TheWistarInstituteMember_documentation_en-US" xlink:label="lab_ino_TheWistarInstituteMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The Wistar Institute [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TheWistarInstituteMember" xlink:href="ino-20250331.xsd#ino_TheWistarInstituteMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_TheWistarInstituteMember" xlink:to="lab_ino_TheWistarInstituteMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonrelatedPartyMember_56e24663-cc58-4f74-bea3-be7a9f86ca56_terseLabel_en-US" xlink:label="lab_us-gaap_NonrelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Nonrelated Party</link:label>
    <link:label id="lab_us-gaap_NonrelatedPartyMember_label_en-US" xlink:label="lab_us-gaap_NonrelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonrelated Party [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonrelatedPartyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonrelatedPartyMember" xlink:to="lab_us-gaap_NonrelatedPartyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_796a5d70-dc60-4fd5-ae29-64c416777d40_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_92f9eb01-6750-4311-8c8f-bec0445610e6_terseLabel_en-US" xlink:label="lab_ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Prepaid Expenses And Other Current Assets</link:label>
    <link:label id="lab_ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_label_en-US" xlink:label="lab_ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Prepaid Expenses And Other Current Assets [Table Text Block]</link:label>
    <link:label id="lab_ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_documentation_en-US" xlink:label="lab_ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule Of Prepaid Expenses And Other Current Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:href="ino-20250331.xsd#ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:to="lab_ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_cea51cd8-55af-4b56-ad52-edb88c280f3f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_95cbcaf1-917d-4d0d-aaac-2043c655be43_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_fbd3596e-f7a1-4d55-a58b-fa09a6769b53_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale [Abstract]</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_label_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockMember_a2433e9b-d4be-423a-9584-074d756b0a7b_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible preferred stock</link:label>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockMember_label_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertiblePreferredStockMember" xlink:to="lab_us-gaap_ConvertiblePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_e81bca79-b5bc-491b-807f-b6858d4f8c13_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_A6.50ConvertibleSeniorNotesDue2024Member_ca4e8fec-3134-47ca-8f6b-92c0229d96bd_terseLabel_en-US" xlink:label="lab_ino_A6.50ConvertibleSeniorNotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">6.50% Convertible Senior Notes Due 2024</link:label>
    <link:label id="lab_ino_A6.50ConvertibleSeniorNotesDue2024Member_label_en-US" xlink:label="lab_ino_A6.50ConvertibleSeniorNotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">6.50% Convertible Senior Notes Due 2024 [Member]</link:label>
    <link:label id="lab_ino_A6.50ConvertibleSeniorNotesDue2024Member_documentation_en-US" xlink:label="lab_ino_A6.50ConvertibleSeniorNotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">6.50% Convertible Senior Notes Due 2024 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member" xlink:href="ino-20250331.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member" xlink:to="lab_ino_A6.50ConvertibleSeniorNotesDue2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_3746b11a-5863-4368-bf0e-78d94ee56d96_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_ae9f28e8-3b3b-4058-9360-6c5ed0511d27_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_e7ca9ee8-5ebc-435e-b854-b93f34015274_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Weighted Average Assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_9f42f8b7-75e1-4144-bd81-d3ffcbf5b27b_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_dccefdeb-dc00-4f65-8fd7-3f5849d55339_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less: present value adjustment</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_4d76391f-9f93-4328-9d78-2ed883e81e2b_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease cost</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_RestrictedStockUnitsRSUsMarketBasedMember_618a22f2-76ab-4685-be22-7b2420cb0e76_terseLabel_en-US" xlink:label="lab_ino_RestrictedStockUnitsRSUsMarketBasedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Market-Based RSUs</link:label>
    <link:label id="lab_ino_RestrictedStockUnitsRSUsMarketBasedMember_label_en-US" xlink:label="lab_ino_RestrictedStockUnitsRSUsMarketBasedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs), Market-Based [Member]</link:label>
    <link:label id="lab_ino_RestrictedStockUnitsRSUsMarketBasedMember_documentation_en-US" xlink:label="lab_ino_RestrictedStockUnitsRSUsMarketBasedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs), Market-Based</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RestrictedStockUnitsRSUsMarketBasedMember" xlink:href="ino-20250331.xsd#ino_RestrictedStockUnitsRSUsMarketBasedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_RestrictedStockUnitsRSUsMarketBasedMember" xlink:to="lab_ino_RestrictedStockUnitsRSUsMarketBasedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestments_c8ca2fd2-d716-4fea-8431-b2409a3a19da_verboseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestments" xlink:to="lab_us-gaap_ShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_b82e4cdf-ddac-43cf-9c42-f5068eaee29c_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoName_terseLabel_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:label id="lab_ecd_PeoName_label_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoName" xlink:to="lab_ecd_PeoName" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:to="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ec3541bd-3cf8-46af-931b-a0fae0479d57_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryIndName" xlink:to="lab_ecd_OutstandingRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_3711b749-fb2d-4cb5-bc3a-bbf4d273ed79_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting of RSUs, net of tax payments (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_c2d69566-a04e-4ef1-b647-7a69695107f1_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CoalitionforEpidemicPreparednessInnovationsMember_b73178ad-d3fa-4edf-bb48-3f07ebe39678_terseLabel_en-US" xlink:label="lab_ino_CoalitionforEpidemicPreparednessInnovationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Coalition for Epidemic Preparedness Innovations</link:label>
    <link:label id="lab_ino_CoalitionforEpidemicPreparednessInnovationsMember_label_en-US" xlink:label="lab_ino_CoalitionforEpidemicPreparednessInnovationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Coalition for Epidemic Preparedness Innovations [Member]</link:label>
    <link:label id="lab_ino_CoalitionforEpidemicPreparednessInnovationsMember_documentation_en-US" xlink:label="lab_ino_CoalitionforEpidemicPreparednessInnovationsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Coalition for Epidemic Preparedness Innovations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CoalitionforEpidemicPreparednessInnovationsMember" xlink:href="ino-20250331.xsd#ino_CoalitionforEpidemicPreparednessInnovationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CoalitionforEpidemicPreparednessInnovationsMember" xlink:to="lab_ino_CoalitionforEpidemicPreparednessInnovationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoMember_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO</link:label>
    <link:label id="lab_ecd_NonPeoNeoMember_label_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoMember" xlink:to="lab_ecd_NonPeoNeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_a926f99e-daed-4d25-98ea-0d2b2b1e8182_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title and Position [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_INO3112AndOtherImmunoOncologyMember_8155a993-8ae2-4a8f-b99c-f02513a47405_terseLabel_en-US" xlink:label="lab_ino_INO3112AndOtherImmunoOncologyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">INO-3112 And Other Immuno-oncology</link:label>
    <link:label id="lab_ino_INO3112AndOtherImmunoOncologyMember_label_en-US" xlink:label="lab_ino_INO3112AndOtherImmunoOncologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">INO-3112 And Other Immuno-oncology [Member]</link:label>
    <link:label id="lab_ino_INO3112AndOtherImmunoOncologyMember_documentation_en-US" xlink:label="lab_ino_INO3112AndOtherImmunoOncologyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">INO-3112 And Other Immuno-oncology</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_INO3112AndOtherImmunoOncologyMember" xlink:href="ino-20250331.xsd#ino_INO3112AndOtherImmunoOncologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_INO3112AndOtherImmunoOncologyMember" xlink:to="lab_ino_INO3112AndOtherImmunoOncologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_b39ec740-0878-472b-bba1-0c3ecb9cfce1_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined</link:label>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_label_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgPredtrmndFlag" xlink:to="lab_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_dfb072c9-109d-4161-b8df-0076a4cb674b_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Product</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementMember" xlink:to="lab_us-gaap_CollaborativeArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_622beaef-393e-4533-8c21-57af099d7786_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_645c0852-7cd2-40cf-ba37-dc43b52524cd_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_2346752a-d557-4f81-b46b-60eb85ff3daf_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_3f0d8baa-7c3f-4a09-864d-5cdbfa71e384_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of Individual with Relationship to Entity [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title and Position [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_3cfde285-176d-49dc-a2b7-bbf86fe95011_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_3a7c7e11-f1bb-403f-93a5-283275f80cde_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Periodic Reduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureName_terseLabel_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_MeasureName_label_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureName" xlink:to="lab_ecd_MeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_a7b12fa3-1d88-4848-8c7b-f7da5b3efee7_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableTradeCurrentAndNoncurrent_cf65edeb-58d5-41fe-8bc0-e06fa0594dcb_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableTradeCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trade accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableTradeCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableTradeCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Trade</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableTradeCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableTradeCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableTradeCurrentAndNoncurrent" xlink:to="lab_us-gaap_AccountsPayableTradeCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_terseLabel_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement does not require Recovery</link:label>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_label_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Does Not Require Recovery [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipAxis_26b70b48-dbbe-48b0-bcbf-bae6ac8df532_terseLabel_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:label id="lab_srt_OwnershipAxis_label_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipAxis" xlink:to="lab_srt_OwnershipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_7d980cf5-a0e0-472a-ac5e-c45e2d15709a_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents, and short-term investments</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, and Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_4bafe2ea-ed83-4880-98de-9bcf69e27a48_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting percentage</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeAgreementAwardedAmount_0da787e6-aa32-4b22-ba9b-afb9251c2cb3_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementAwardedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awarded amount</link:label>
    <link:label id="lab_ino_CollaborativeAgreementAwardedAmount_label_en-US" xlink:label="lab_ino_CollaborativeAgreementAwardedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Agreement, Awarded Amount</link:label>
    <link:label id="lab_ino_CollaborativeAgreementAwardedAmount_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementAwardedAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Agreement, Awarded Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementAwardedAmount" xlink:href="ino-20250331.xsd#ino_CollaborativeAgreementAwardedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementAwardedAmount" xlink:to="lab_ino_CollaborativeAgreementAwardedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_NonEmployeeMember_ee50845b-373d-436c-8ac3-501e5ba609a8_terseLabel_en-US" xlink:label="lab_ino_NonEmployeeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non Employee</link:label>
    <link:label id="lab_ino_NonEmployeeMember_label_en-US" xlink:label="lab_ino_NonEmployeeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non Employee [Member]</link:label>
    <link:label id="lab_ino_NonEmployeeMember_documentation_en-US" xlink:label="lab_ino_NonEmployeeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non employee.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_NonEmployeeMember" xlink:href="ino-20250331.xsd#ino_NonEmployeeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_NonEmployeeMember" xlink:to="lab_ino_NonEmployeeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_StockBasedCompensationMember_7c074dab-3d03-44d9-9294-bbc201c68d5c_terseLabel_en-US" xlink:label="lab_ino_StockBasedCompensationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_ino_StockBasedCompensationMember_label_en-US" xlink:label="lab_ino_StockBasedCompensationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock-Based Compensation [Member]</link:label>
    <link:label id="lab_ino_StockBasedCompensationMember_documentation_en-US" xlink:label="lab_ino_StockBasedCompensationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockBasedCompensationMember" xlink:href="ino-20250331.xsd#ino_StockBasedCompensationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_StockBasedCompensationMember" xlink:to="lab_ino_StockBasedCompensationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_96823ade-cb97-4d3a-ab1a-0e37e36e58ef_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of common stock warrant liability</link:label>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_4c983f36-cf73-4249-8349-44aaaf6409ce_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of common stock warrant liability</link:label>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_label_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Adjustment of Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAdjustmentOfWarrants" xlink:to="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_8765025e-2919-421c-8e5c-7dec641c5942_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_076f0366-43c5-4275-9981-a19da9c5344e_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_830739bd-75ad-4391-92f5-3ba9b1b06b35_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_3e2b4a0b-7f3a-4041-aca5-9121c4232fbd_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_DebtSecuritiesAvailableforSaleContractualMaturity_c19a35b4-c576-48df-b56a-b3893f67fe98_terseLabel_en-US" xlink:label="lab_ino_DebtSecuritiesAvailableforSaleContractualMaturity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contractual Maturity&#160;(in&#160;years)</link:label>
    <link:label id="lab_ino_DebtSecuritiesAvailableforSaleContractualMaturity_label_en-US" xlink:label="lab_ino_DebtSecuritiesAvailableforSaleContractualMaturity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale Contractual Maturity</link:label>
    <link:label id="lab_ino_DebtSecuritiesAvailableforSaleContractualMaturity_documentation_en-US" xlink:label="lab_ino_DebtSecuritiesAvailableforSaleContractualMaturity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale contractual maturity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DebtSecuritiesAvailableforSaleContractualMaturity" xlink:href="ino-20250331.xsd#ino_DebtSecuritiesAvailableforSaleContractualMaturity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DebtSecuritiesAvailableforSaleContractualMaturity" xlink:to="lab_ino_DebtSecuritiesAvailableforSaleContractualMaturity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_c9a5d4d1-07bd-445e-8d6f-3958ce966560_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfOtherInvestments_44b73e9d-5ebe-47de-8d3b-66d2c794408f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfOtherInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Loss on sales of short-term investments</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfOtherInvestments_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfOtherInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Sale of Other Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfOtherInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfOtherInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfOtherInvestments" xlink:to="lab_us-gaap_GainLossOnSaleOfOtherInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_December2024OfferingWarrantsMember_4eb2caae-d9d0-404c-9564-23f0c23885d0_terseLabel_en-US" xlink:label="lab_ino_December2024OfferingWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">December 2024 Offering Warrants</link:label>
    <link:label id="lab_ino_December2024OfferingWarrantsMember_label_en-US" xlink:label="lab_ino_December2024OfferingWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">December 2024 Offering Warrants [Member]</link:label>
    <link:label id="lab_ino_December2024OfferingWarrantsMember_documentation_en-US" xlink:label="lab_ino_December2024OfferingWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">December 2024 Offering Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_December2024OfferingWarrantsMember" xlink:href="ino-20250331.xsd#ino_December2024OfferingWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_December2024OfferingWarrantsMember" xlink:to="lab_ino_December2024OfferingWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_2cc3cb8e-f2ff-429c-9daa-f233a66399d9_verboseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense):</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_c91eda7a-12b3-44f8-8d5b-869685da705a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt interest based on the fixed rate (in percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_798c163e-7a15-49e3-9145-af63c4488e17_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental disclosures:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_StockOptionsPerformanceBasedMember_e4543bf3-7711-497f-9cd9-e79cb771c3a0_terseLabel_en-US" xlink:label="lab_ino_StockOptionsPerformanceBasedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Options, Performance-Based</link:label>
    <link:label id="lab_ino_StockOptionsPerformanceBasedMember_label_en-US" xlink:label="lab_ino_StockOptionsPerformanceBasedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Options, Performance-Based [Member]</link:label>
    <link:label id="lab_ino_StockOptionsPerformanceBasedMember_documentation_en-US" xlink:label="lab_ino_StockOptionsPerformanceBasedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Options, Performance-Based</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockOptionsPerformanceBasedMember" xlink:href="ino-20250331.xsd#ino_StockOptionsPerformanceBasedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_StockOptionsPerformanceBasedMember" xlink:to="lab_ino_StockOptionsPerformanceBasedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeriesCPreferredStockMember_8bd19d4b-613b-45cd-8fc5-dd24e4824373_verboseLabel_en-US" xlink:label="lab_us-gaap_SeriesCPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Series C Preferred Stock</link:label>
    <link:label id="lab_us-gaap_SeriesCPreferredStockMember_label_en-US" xlink:label="lab_us-gaap_SeriesCPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series C Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesCPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesCPreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesCPreferredStockMember" xlink:to="lab_us-gaap_SeriesCPreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_05117e79-8132-43a4-8a4b-0ec958a46b74_verboseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Investments in affiliated entity</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:to="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_a7853cb9-ad6c-4068-b582-78ffc47c253e_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Period over which total unrecognized compensation cost related to unvested stock options will be recognized (in years)</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_82109519-ffba-4864-a761-eaf04560ffc8_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revenue from collaborative arrangements</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_bd196f9c-d59c-4ea5-b848-c03f868b50cb_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from collaborative arrangements</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_38e80b7d-7713-45ed-96ca-e8f476fe45c1_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_83922928-0480-4f36-bff1-99e3b6d2c69c_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash (used in) provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_2160a9ee-9cfc-4276-8a6a-dca4d2ac192c_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_00707e51-b94f-4a35-b26a-31a7dd270bf3_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_245d3750-da52-4f70-8c85-c4888c91bd87_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:to="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllAdjToCompMember_terseLabel_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation</link:label>
    <link:label id="lab_ecd_AllAdjToCompMember_label_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllAdjToCompMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="lab_ecd_AllAdjToCompMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_236012b6-0350-498d-977b-5034240ecf49_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_b3c15652-e9f5-47da-908a-935e14c17c75_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_650dee22-1baa-4057-be9a-377b71718e09_verboseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesCurrent_e9289c75-64c4-4d1f-9951-5ef8409df550_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock warrant liability</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilitiesCurrent" xlink:to="lab_us-gaap_DerivativeLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_de8e4abe-793e-4d1a-8ddf-ff1ef41a13f7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestTable_3fef4cd1-525d-4f22-8e27-40e269e02b81_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest [Table]</link:label>
    <link:label id="lab_us-gaap_MinorityInterestTable_label_en-US" xlink:label="lab_us-gaap_MinorityInterestTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterestTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestTable" xlink:to="lab_us-gaap_MinorityInterestTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_71d75263-f8c1-4b39-b91d-38aa9cf747c5_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_EngineeringAndDeviceRelatedMember_3d6ee4c4-df75-4308-870c-a3742f5fadab_terseLabel_en-US" xlink:label="lab_ino_EngineeringAndDeviceRelatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Engineering and device-related</link:label>
    <link:label id="lab_ino_EngineeringAndDeviceRelatedMember_label_en-US" xlink:label="lab_ino_EngineeringAndDeviceRelatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Engineering And Device-Related [Member]</link:label>
    <link:label id="lab_ino_EngineeringAndDeviceRelatedMember_documentation_en-US" xlink:label="lab_ino_EngineeringAndDeviceRelatedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Engineering And Device-Related</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_EngineeringAndDeviceRelatedMember" xlink:href="ino-20250331.xsd#ino_EngineeringAndDeviceRelatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_EngineeringAndDeviceRelatedMember" xlink:to="lab_ino_EngineeringAndDeviceRelatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeAgreementExpensesToReimburse_b5b79936-c2cd-4319-ae56-43f78daae493_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementExpensesToReimburse" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expenses to reimburse</link:label>
    <link:label id="lab_ino_CollaborativeAgreementExpensesToReimburse_label_en-US" xlink:label="lab_ino_CollaborativeAgreementExpensesToReimburse" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Agreement, Expenses To Reimburse</link:label>
    <link:label id="lab_ino_CollaborativeAgreementExpensesToReimburse_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementExpensesToReimburse" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Agreement, Expenses To Reimburse</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementExpensesToReimburse" xlink:href="ino-20250331.xsd#ino_CollaborativeAgreementExpensesToReimburse"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementExpensesToReimburse" xlink:to="lab_ino_CollaborativeAgreementExpensesToReimburse" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_GeneosTherapeuticsInc.Member_6cb51f3a-e12f-4c17-b841-e357af073716_terseLabel_en-US" xlink:label="lab_ino_GeneosTherapeuticsInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geneos Therapeutics, Inc.</link:label>
    <link:label id="lab_ino_GeneosTherapeuticsInc.Member_label_en-US" xlink:label="lab_ino_GeneosTherapeuticsInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geneos Therapeutics, Inc. [Member]</link:label>
    <link:label id="lab_ino_GeneosTherapeuticsInc.Member_documentation_en-US" xlink:label="lab_ino_GeneosTherapeuticsInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Geneos Therapeutics, Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GeneosTherapeuticsInc.Member" xlink:href="ino-20250331.xsd#ino_GeneosTherapeuticsInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_GeneosTherapeuticsInc.Member" xlink:to="lab_ino_GeneosTherapeuticsInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_terseLabel_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change</link:label>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_label_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:to="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_28f08311-f0a1-4a88-af01-b6aa743cb546_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_IndividualAxis_terseLabel_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Individual:</link:label>
    <link:label id="lab_ecd_IndividualAxis_label_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_IndividualAxis" xlink:to="lab_ecd_IndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_c4171d6e-75cf-44dc-94cb-500552036982_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_32f8bc39-8d13-4459-8b5c-2e4979c8d4d3_terseLabel_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name of Property [Domain]</link:label>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_label_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Name of Property [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:to="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_db49cf97-65d8-467a-b0fe-893e842b1093_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected life in years</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_9fa7e6ab-5aa9-44f0-9749-2f4f8f01541f_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_9c95e9a5-9e79-4df5-b04a-404c9c496da8_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_fde34fc1-d397-488d-a9f9-8bb49dc25fb5_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ResearchAndDevelopmentCostDomain_466ad7aa-130a-4f8a-934f-3a556339722e_terseLabel_en-US" xlink:label="lab_ino_ResearchAndDevelopmentCostDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research And Development Cost [Domain]</link:label>
    <link:label id="lab_ino_ResearchAndDevelopmentCostDomain_label_en-US" xlink:label="lab_ino_ResearchAndDevelopmentCostDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research And Development Cost [Domain]</link:label>
    <link:label id="lab_ino_ResearchAndDevelopmentCostDomain_documentation_en-US" xlink:label="lab_ino_ResearchAndDevelopmentCostDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research And Development Cost [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ResearchAndDevelopmentCostDomain" xlink:href="ino-20250331.xsd#ino_ResearchAndDevelopmentCostDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ResearchAndDevelopmentCostDomain" xlink:to="lab_ino_ResearchAndDevelopmentCostDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_e84039e8-9ed9-459d-b9b3-dc2e61cde965_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeAgreementFundingToBeReceived_03eed633-a62a-46c7-8476-cd0a87b04c37_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementFundingToBeReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative agreement, funding to be received</link:label>
    <link:label id="lab_ino_CollaborativeAgreementFundingToBeReceived_label_en-US" xlink:label="lab_ino_CollaborativeAgreementFundingToBeReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Agreement, Funding To Be Received</link:label>
    <link:label id="lab_ino_CollaborativeAgreementFundingToBeReceived_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementFundingToBeReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Agreement, Funding Received for Research and Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementFundingToBeReceived" xlink:href="ino-20250331.xsd#ino_CollaborativeAgreementFundingToBeReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementFundingToBeReceived" xlink:to="lab_ino_CollaborativeAgreementFundingToBeReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_da9c9447-7241-4eec-8567-9d1185cbc664_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_label_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompAnalysisTextBlock" xlink:to="lab_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_75d4ba63-c5ed-4684-a326-8b112e3870fb_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_1b64dc82-2419-4d2d-a608-fb6e83ef0522_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Less:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8e4525f3-0279-493c-80ac-b109a5af5874_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instrument [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b91fc230-4eb9-4d99-b2a6-3695a6c4cc16_verboseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Financial Instrument [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a340fd8c-ed80-4038-82a1-e3e4d3d89b6e_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_8872c4da-2dc5-465d-8b91-33e3cc077c0d_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_0f1333ea-c37b-429a-92cb-b908eca2c055_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_AccruedClinicalTrialExpenseCurrent_d0b0e3ce-2253-4702-bde6-502e90b111ad_verboseLabel_en-US" xlink:label="lab_ino_AccruedClinicalTrialExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accrued clinical trial expenses</link:label>
    <link:label id="lab_ino_AccruedClinicalTrialExpenseCurrent_label_en-US" xlink:label="lab_ino_AccruedClinicalTrialExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Clinical Trial Expense, Current</link:label>
    <link:label id="lab_ino_AccruedClinicalTrialExpenseCurrent_documentation_en-US" xlink:label="lab_ino_AccruedClinicalTrialExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Clinical Trial Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AccruedClinicalTrialExpenseCurrent" xlink:href="ino-20250331.xsd#ino_AccruedClinicalTrialExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_AccruedClinicalTrialExpenseCurrent" xlink:to="lab_ino_AccruedClinicalTrialExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_7593690b-d518-4be0-a82b-9036d9f6eaf9_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDeterminationDate_terseLabel_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:label id="lab_ecd_RestatementDeterminationDate_label_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDeterminationDate" xlink:to="lab_ecd_RestatementDeterminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrAdoptionDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adoption Date</link:label>
    <link:label id="lab_ecd_TrdArrAdoptionDate_label_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Adoption Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrAdoptionDate" xlink:to="lab_ecd_TrdArrAdoptionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTable_terseLabel_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure</link:label>
    <link:label id="lab_ecd_PvpTable_label_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTable" xlink:to="lab_ecd_PvpTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_SanDiegoCaliforniaMember_ae84075f-1ea1-40c6-af07-04d05515df79_terseLabel_en-US" xlink:label="lab_ino_SanDiegoCaliforniaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">San Diego, California</link:label>
    <link:label id="lab_ino_SanDiegoCaliforniaMember_label_en-US" xlink:label="lab_ino_SanDiegoCaliforniaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">San Diego, California [Member]</link:label>
    <link:label id="lab_ino_SanDiegoCaliforniaMember_documentation_en-US" xlink:label="lab_ino_SanDiegoCaliforniaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">San Diego, California [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SanDiegoCaliforniaMember" xlink:href="ino-20250331.xsd#ino_SanDiegoCaliforniaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_SanDiegoCaliforniaMember" xlink:to="lab_ino_SanDiegoCaliforniaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_96b9f979-1425-47e4-b996-8918416d7a7a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Summary of Investments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_December2024OfferingMember_0ca719c3-078e-4b52-973e-4ea8fdeacec2_terseLabel_en-US" xlink:label="lab_ino_December2024OfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">December 2024 Offering</link:label>
    <link:label id="lab_ino_December2024OfferingMember_label_en-US" xlink:label="lab_ino_December2024OfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">December 2024 Offering [Member]</link:label>
    <link:label id="lab_ino_December2024OfferingMember_documentation_en-US" xlink:label="lab_ino_December2024OfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">December 2024 Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_December2024OfferingMember" xlink:href="ino-20250331.xsd#ino_December2024OfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_December2024OfferingMember" xlink:to="lab_ino_December2024OfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_e0b5141f-facb-48f5-9af8-db410a1e3e87_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompRecoveryTable_terseLabel_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery</link:label>
    <link:label id="lab_ecd_ErrCompRecoveryTable_label_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="lab_ecd_ErrCompRecoveryTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_WorkingCapital_49ab5090-add1-4ed9-ab78-6e676cd0c788_terseLabel_en-US" xlink:label="lab_ino_WorkingCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Working capital</link:label>
    <link:label id="lab_ino_WorkingCapital_label_en-US" xlink:label="lab_ino_WorkingCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Working Capital</link:label>
    <link:label id="lab_ino_WorkingCapital_documentation_en-US" xlink:label="lab_ino_WorkingCapital" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Working Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_WorkingCapital" xlink:href="ino-20250331.xsd#ino_WorkingCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_WorkingCapital" xlink:to="lab_ino_WorkingCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_A2022InducementPlanMember_a4bdb471-2157-4fb8-aad5-49dd2f7fe7f0_terseLabel_en-US" xlink:label="lab_ino_A2022InducementPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2022 Inducement Plan</link:label>
    <link:label id="lab_ino_A2022InducementPlanMember_label_en-US" xlink:label="lab_ino_A2022InducementPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2022 Inducement Plan [Member]</link:label>
    <link:label id="lab_ino_A2022InducementPlanMember_documentation_en-US" xlink:label="lab_ino_A2022InducementPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2022 Inducement Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A2022InducementPlanMember" xlink:href="ino-20250331.xsd#ino_A2022InducementPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_A2022InducementPlanMember" xlink:to="lab_ino_A2022InducementPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_e8ea7808-b90a-44eb-a93c-38ad7065e36f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year</link:label>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:to="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_IncreaseDecreaseinDeferredGrantFundingCurrent_fb3f155f-656b-4ba2-880e-f506bdb80e7d_terseLabel_en-US" xlink:label="lab_ino_IncreaseDecreaseinDeferredGrantFundingCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Grant funding liability, including from affiliated entity</link:label>
    <link:label id="lab_ino_IncreaseDecreaseinDeferredGrantFundingCurrent_label_en-US" xlink:label="lab_ino_IncreaseDecreaseinDeferredGrantFundingCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Deferred Grant Funding, Current</link:label>
    <link:label id="lab_ino_IncreaseDecreaseinDeferredGrantFundingCurrent_documentation_en-US" xlink:label="lab_ino_IncreaseDecreaseinDeferredGrantFundingCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Deferred Grant Funding, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseinDeferredGrantFundingCurrent" xlink:href="ino-20250331.xsd#ino_IncreaseDecreaseinDeferredGrantFundingCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_IncreaseDecreaseinDeferredGrantFundingCurrent" xlink:to="lab_ino_IncreaseDecreaseinDeferredGrantFundingCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardExrcPrice_terseLabel_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise Price</link:label>
    <link:label id="lab_ecd_AwardExrcPrice_label_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardExrcPrice" xlink:to="lab_ecd_AwardExrcPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ResearchAndDevelopmentCostAxis_45e2ec7e-089b-403c-9013-a0e8d40d0b6b_terseLabel_en-US" xlink:label="lab_ino_ResearchAndDevelopmentCostAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research And Development Cost [Axis]</link:label>
    <link:label id="lab_ino_ResearchAndDevelopmentCostAxis_label_en-US" xlink:label="lab_ino_ResearchAndDevelopmentCostAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research And Development Cost [Axis]</link:label>
    <link:label id="lab_ino_ResearchAndDevelopmentCostAxis_documentation_en-US" xlink:label="lab_ino_ResearchAndDevelopmentCostAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research And Development Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ResearchAndDevelopmentCostAxis" xlink:href="ino-20250331.xsd#ino_ResearchAndDevelopmentCostAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ResearchAndDevelopmentCostAxis" xlink:to="lab_ino_ResearchAndDevelopmentCostAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_PrepaidClinicalExpensesCurrent_30e17dc4-6dd3-4adf-99ac-7bae40d3684b_terseLabel_en-US" xlink:label="lab_ino_PrepaidClinicalExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid clinical expenses</link:label>
    <link:label id="lab_ino_PrepaidClinicalExpensesCurrent_label_en-US" xlink:label="lab_ino_PrepaidClinicalExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Clinical Expenses, Current</link:label>
    <link:label id="lab_ino_PrepaidClinicalExpensesCurrent_documentation_en-US" xlink:label="lab_ino_PrepaidClinicalExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Prepaid Clinical Expenses, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PrepaidClinicalExpensesCurrent" xlink:href="ino-20250331.xsd#ino_PrepaidClinicalExpensesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_PrepaidClinicalExpensesCurrent" xlink:to="lab_ino_PrepaidClinicalExpensesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_AccountsPayableAndAccruedExpensesTable_264fb9e8-dda7-443b-85e0-4155282245ac_terseLabel_en-US" xlink:label="lab_ino_AccountsPayableAndAccruedExpensesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts Payable and Accrued Expenses [Table]</link:label>
    <link:label id="lab_ino_AccountsPayableAndAccruedExpensesTable_label_en-US" xlink:label="lab_ino_AccountsPayableAndAccruedExpensesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable and Accrued Expenses [Table]</link:label>
    <link:label id="lab_ino_AccountsPayableAndAccruedExpensesTable_documentation_en-US" xlink:label="lab_ino_AccountsPayableAndAccruedExpensesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accounts Payable and Accrued Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AccountsPayableAndAccruedExpensesTable" xlink:href="ino-20250331.xsd#ino_AccountsPayableAndAccruedExpensesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_AccountsPayableAndAccruedExpensesTable" xlink:to="lab_ino_AccountsPayableAndAccruedExpensesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure_d2d273b8-5e61-413f-ac2f-b7abf36f7755_totalLabel_en-US" xlink:label="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Liabilities Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_658048b7-c800-43e4-81cd-a4801b4176b8_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other accrued expenses</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_99eb3611-809d-44c9-84ff-972261ca3d81_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrDuration_terseLabel_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arrangement Duration</link:label>
    <link:label id="lab_ecd_TrdArrDuration_label_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Duration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrDuration" xlink:to="lab_ecd_TrdArrDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c757fb73-58aa-4689-9c89-fe46380cc38b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average grant date fair value, restricted stock units (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_A2024SalesAgreementMember_7025885e-e974-47b4-b592-8a4f657f20ff_terseLabel_en-US" xlink:label="lab_ino_A2024SalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2024 Sales Agreement</link:label>
    <link:label id="lab_ino_A2024SalesAgreementMember_label_en-US" xlink:label="lab_ino_A2024SalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2024 Sales Agreement [Member]</link:label>
    <link:label id="lab_ino_A2024SalesAgreementMember_documentation_en-US" xlink:label="lab_ino_A2024SalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2024 Sales Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A2024SalesAgreementMember" xlink:href="ino-20250331.xsd#ino_A2024SalesAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_A2024SalesAgreementMember" xlink:to="lab_ino_A2024SalesAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_c9b8e17c-3c38-4462-84fe-11746d915728_terseLabel_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name of Property [Axis]</link:label>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_label_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Name of Property [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:to="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_SanDiegoOfficeMember_ae4f6049-1326-4666-b7a6-c556e39acde2_terseLabel_en-US" xlink:label="lab_ino_SanDiegoOfficeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">San Diego, California</link:label>
    <link:label id="lab_ino_SanDiegoOfficeMember_label_en-US" xlink:label="lab_ino_SanDiegoOfficeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">San Diego Office [Member]</link:label>
    <link:label id="lab_ino_SanDiegoOfficeMember_documentation_en-US" xlink:label="lab_ino_SanDiegoOfficeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">San Diego Office [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SanDiegoOfficeMember" xlink:href="ino-20250331.xsd#ino_SanDiegoOfficeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_SanDiegoOfficeMember" xlink:to="lab_ino_SanDiegoOfficeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_label_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:to="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_333df753-36a2-425a-a7e4-f82a100a12f1_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_terseLabel_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_label_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_LesseeOperatingLeaseAreaofLandUnderLease_d2ab15b7-830e-4dde-8ac0-6fe703d4cc57_terseLabel_en-US" xlink:label="lab_ino_LesseeOperatingLeaseAreaofLandUnderLease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Area leased (in square feet)</link:label>
    <link:label id="lab_ino_LesseeOperatingLeaseAreaofLandUnderLease_label_en-US" xlink:label="lab_ino_LesseeOperatingLeaseAreaofLandUnderLease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Area of Land Under Lease</link:label>
    <link:label id="lab_ino_LesseeOperatingLeaseAreaofLandUnderLease_documentation_en-US" xlink:label="lab_ino_LesseeOperatingLeaseAreaofLandUnderLease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Area of Land Under Lease</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LesseeOperatingLeaseAreaofLandUnderLease" xlink:href="ino-20250331.xsd#ino_LesseeOperatingLeaseAreaofLandUnderLease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_LesseeOperatingLeaseAreaofLandUnderLease" xlink:to="lab_ino_LesseeOperatingLeaseAreaofLandUnderLease" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllIndividualsMember_terseLabel_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Individuals</link:label>
    <link:label id="lab_ecd_AllIndividualsMember_label_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Individuals [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="lab_ecd_AllIndividualsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoMember_terseLabel_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO</link:label>
    <link:label id="lab_ecd_PeoMember_label_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoMember" xlink:to="lab_ecd_PeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_ba18f5ed-56b4-4741-a523-7d7dc4e0f158_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndName_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_TrdArrIndName_label_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndName" xlink:to="lab_ecd_TrdArrIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_fbc0d710-794b-4697-8a19-2278a79c977f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other expense, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_b4ddf8d5-d8ea-4c02-ae9a-70fe743238dc_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_8aea0ce9-d059-4ec0-b5da-a324bb0a5cd7_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Gross&#160;Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_55c036b0-c87f-4c5e-9b3e-a8a295d54d86_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease, remaining lease term (in years)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_IncreaseDecreaseInAccruedClinicalTrialExpense_11ac1962-83ff-40d4-9546-abab692ffb06_terseLabel_en-US" xlink:label="lab_ino_IncreaseDecreaseInAccruedClinicalTrialExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued clinical trial expenses</link:label>
    <link:label id="lab_ino_IncreaseDecreaseInAccruedClinicalTrialExpense_label_en-US" xlink:label="lab_ino_IncreaseDecreaseInAccruedClinicalTrialExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Accrued Clinical Trial Expense</link:label>
    <link:label id="lab_ino_IncreaseDecreaseInAccruedClinicalTrialExpense_documentation_en-US" xlink:label="lab_ino_IncreaseDecreaseInAccruedClinicalTrialExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Accrued Clinical Trial Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseInAccruedClinicalTrialExpense" xlink:href="ino-20250331.xsd#ino_IncreaseDecreaseInAccruedClinicalTrialExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_IncreaseDecreaseInAccruedClinicalTrialExpense" xlink:to="lab_ino_IncreaseDecreaseInAccruedClinicalTrialExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ReportableSegmentsMember_509f85c5-350f-4314-93b2-db9614179eff_terseLabel_en-US" xlink:label="lab_ino_ReportableSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reportable Segments</link:label>
    <link:label id="lab_ino_ReportableSegmentsMember_label_en-US" xlink:label="lab_ino_ReportableSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reportable Segments [Member]</link:label>
    <link:label id="lab_ino_ReportableSegmentsMember_documentation_en-US" xlink:label="lab_ino_ReportableSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ReportableSegmentsMember" xlink:href="ino-20250331.xsd#ino_ReportableSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ReportableSegmentsMember" xlink:to="lab_ino_ReportableSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_4ba29227-e567-484c-9eb6-2c6d397b0c51_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputPriceVolatilityMember_ef15d306-99b4-4251-8cc1-80fac9e237a9_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_MeasurementInputPriceVolatilityMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Price Volatility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year</link:label>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_label_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:to="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_193b6222-41d9-45c9-8238-961783a7878d_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related and Nonrelated Parties [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_641459c3-77e3-413a-bbcb-276b289f1db8_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_120c618a-7531-49a5-8c8b-b1f1e2becca0_totalLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_69184d41-c4cf-437a-bf3c-5f710baf9ded_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued liabilities, current</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_AggtErrCompAmt_label_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompAmt" xlink:to="lab_ecd_AggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_a9b9b138-009a-4249-b6b9-c535963dc6a9_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_label_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_7afafe43-18ce-40c5-9970-8b79ae2ce71e_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_64bdf6b4-60c0-49b6-950d-ac1314dfdb13_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_296443e1-26c7-4f8e-b698-540c7d3c77c4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Unrealized loss</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrealized Gain (Loss) on Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:to="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentAssetsTextBlock_7c15c95d-1820-46f7-b04b-99e972886a74_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Certain Balance Sheet Items</link:label>
    <link:label id="lab_us-gaap_OtherCurrentAssetsTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Current Assets [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCurrentAssetsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentAssetsTextBlock" xlink:to="lab_us-gaap_OtherCurrentAssetsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_8c34b2d4-6c94-48c7-a326-b594cfb13d64_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock_33897469-c70d-46ed-aa85-2f9ee3be3451_terseLabel_en-US" xlink:label="lab_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate proceeds</link:label>
    <link:label id="lab_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock_label_en-US" xlink:label="lab_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Sale Agreement, Aggregate Proceeds From Issuance Of Stock</link:label>
    <link:label id="lab_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock_documentation_en-US" xlink:label="lab_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Sale Agreement, Aggregate Proceeds From Issuance Of Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock" xlink:href="ino-20250331.xsd#ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock" xlink:to="lab_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_8f6893d4-f449-4481-8bd0-210c2213ca27_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of securities in a gross unrealized loss position</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue_ed7e4b25-c680-471a-b8b9-6ae268737275_terseLabel_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Grant date fair value</link:label>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue_label_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Grant Date Fair Value</link:label>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue_documentation_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xlink:href="ino-20250331.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xlink:to="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_390521c6-6163-4106-bf03-d0b85e856dbd_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoTotalCompAmt_label_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoTotalCompAmt" xlink:to="lab_ecd_PeoTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_66e2c14b-6f39-4045-9e64-636c82b6222a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock_6ad5e8df-ff11-4d3e-a10b-2da67bb3dff8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Basic and Diluted Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_9e33fe45-358f-4ae7-95d5-02798a1843d0_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs, by Report Line [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_8aa92659-cf2d-4024-8397-d705d76ff4a2_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_141a02d3-209e-46a2-9343-32f56591a98c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_22f2b5ba-e857-4d0d-85cc-1ecdd4e8a6dc_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureAxis_terseLabel_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measure:</link:label>
    <link:label id="lab_ecd_MeasureAxis_label_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureAxis" xlink:to="lab_ecd_MeasureAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock_f312205a-91f9-47ef-b04a-357fdb0e60af_terseLabel_en-US" xlink:label="lab_ino_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Significant Assumption Used in Monte Carlo Simulation Method</link:label>
    <link:label id="lab_ino_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_ino_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Share-Based Payment Award, Equity Instruments Other Than Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:label id="lab_ino_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock_documentation_en-US" xlink:label="lab_ino_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule Of Share-Based Payment Award, Equity Instruments Other Than Options, Valuation Assumptions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" xlink:href="ino-20250331.xsd#ino_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_ino_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_590bf5ba-eca2-4849-b606-52c30acf896f_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting of RSUs, net of tax payments</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_ba606bf6-d5aa-4044-9e3a-52ce3e893553_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_b1c0b445-b853-45b2-be8d-e70b30749464_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_563eee19-db01-4b48-b3d4-d52049a283a2_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock for cash, net of financing costs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_5c23ab0d-fd60-4f43-9eda-2907f47908fa_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList_dec28d34-0737-4f28-bd0a-ec84d2475560_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList_label_en-US" xlink:label="lab_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:to="lab_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_78734fd2-10ed-43fc-bfdf-b053ee96e926_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_85b6148b-6364-4d1c-afe7-ee982a69b8cc_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_76b80db2-9628-4ec6-ac6f-9e535be305cf_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description</link:label>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_label_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_a70b2b85-cae0-4ace-9644-ebf82916ca7c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_ab3dc0b2-8e6c-430f-b4e6-e93de938f05b_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_7b9b5b5d-992d-4e9f-a97a-4b40229a745a_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued expenses, including due to affiliated entity</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_f42c7b4d-93d2-43b2-a744-56fcdf55eca2_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_b5eca36c-9cab-4541-86ee-b915c058b2c2_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_a89f4d35-5d05-4b86-a00f-eeb0fe82ad09_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_7c1a45ba-95c3-4ff0-a268-e327e89913ce_verboseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_a798cd97-740b-47cf-91d8-6bf793dc9917_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_1cc92d4f-dceb-4f09-b82e-4fa235cf7db6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Decrease in fair value of liability</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_bb4b67cc-0bd0-4cba-acd9-c86bafc4fe87_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Decrease in fair value of liability</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_label_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Additional402vDisclosureTextBlock" xlink:to="lab_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_OtherUnallocatedExpensesMember_489eab7f-e618-44d2-8785-fabf7a2847a4_terseLabel_en-US" xlink:label="lab_ino_OtherUnallocatedExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other unallocated expenses</link:label>
    <link:label id="lab_ino_OtherUnallocatedExpensesMember_label_en-US" xlink:label="lab_ino_OtherUnallocatedExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Unallocated Expenses [Member]</link:label>
    <link:label id="lab_ino_OtherUnallocatedExpensesMember_documentation_en-US" xlink:label="lab_ino_OtherUnallocatedExpensesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Unallocated Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OtherUnallocatedExpensesMember" xlink:href="ino-20250331.xsd#ino_OtherUnallocatedExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_OtherUnallocatedExpensesMember" xlink:to="lab_ino_OtherUnallocatedExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_bfd39883-ad22-4a3e-b3eb-d8de3f49b620_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_bd687e13-7f38-437f-8644-0a285ce5f444_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_a608b049-6b95-4b0d-9e17-4280d3d4e63d_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_895749ef-6b3d-4255-a20c-9b21d24807db_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndTitle_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title</link:label>
    <link:label id="lab_ecd_TrdArrIndTitle_label_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Title</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndTitle" xlink:to="lab_ecd_TrdArrIndTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet_961b0ef9-b408-4e9a-aace-c98e2fc1a286_terseLabel_en-US" xlink:label="lab_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease right-of-use assets and liabilities, net</link:label>
    <link:label id="lab_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet_label_en-US" xlink:label="lab_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Operating Lease, Right-Of-Use Asset (Lease Liability), Net</link:label>
    <link:label id="lab_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet_documentation_en-US" xlink:label="lab_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Operating Lease, Right-Of-Use Asset (Lease Liability), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet" xlink:href="ino-20250331.xsd#ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet" xlink:to="lab_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_832a803d-7deb-4fe0-8dde-e346fd8edcbb_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_bae60734-cf29-468f-8b8f-4366d3b60ff2_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_b6b8e0ea-ae97-485e-ab8a-5b0df5568c6a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_c7f74208-8076-4a39-aedd-8130aa1138ac_verboseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Critical Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockOtherSharesOutstanding_e14e74e0-5cc2-4c25-b8c6-98ad3f30729b_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockOtherSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, other shares, outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockOtherSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockOtherSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Other Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockOtherSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockOtherSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockOtherSharesOutstanding" xlink:to="lab_us-gaap_CommonStockOtherSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_bed93d9e-0ced-462f-82e6-3562953d7937_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_DNAEncodedMonoclonalAntibodyTechnologyMember_0da1afb4-1c2a-4fad-ae81-2275b65169ff_terseLabel_en-US" xlink:label="lab_ino_DNAEncodedMonoclonalAntibodyTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">DNA-Encoded Monoclonal Antibody Technology</link:label>
    <link:label id="lab_ino_DNAEncodedMonoclonalAntibodyTechnologyMember_label_en-US" xlink:label="lab_ino_DNAEncodedMonoclonalAntibodyTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">DNA-Encoded Monoclonal Antibody Technology [Member]</link:label>
    <link:label id="lab_ino_DNAEncodedMonoclonalAntibodyTechnologyMember_documentation_en-US" xlink:label="lab_ino_DNAEncodedMonoclonalAntibodyTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">DNA-Encoded Monoclonal Antibody Technology [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DNAEncodedMonoclonalAntibodyTechnologyMember" xlink:href="ino-20250331.xsd#ino_DNAEncodedMonoclonalAntibodyTechnologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DNAEncodedMonoclonalAntibodyTechnologyMember" xlink:to="lab_ino_DNAEncodedMonoclonalAntibodyTechnologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_de576bf7-271d-4a42-9cb7-e2b2617cadc1_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_724c8f84-8800-4347-8d11-a4246c87bc5f_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_2122c53e-d37d-4d31-95eb-2014f76bb8bb_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest paid</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireShortTermInvestments_38c8a5fc-967d-419d-8330-9ae903372d1d_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_45f095da-e961-4324-8279-4cd25aa5063c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_5578fcda-bbcf-4106-a307-8edab0c05f9d_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Quoted Prices in Active Markets (Level&#160;1)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_e76fbdfb-7f24-4d60-b0ed-e4737c5a7553_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_d518ed31-a161-4c0b-a348-64ff9077cddd_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency translation</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ClassOfWarrantOrRightCommonStockOwnershipMaximumPercent_b419bd41-98c0-46bc-badb-781cbb2a35d5_terseLabel_en-US" xlink:label="lab_ino_ClassOfWarrantOrRightCommonStockOwnershipMaximumPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of warrant or right, common stock ownership, maximum percent</link:label>
    <link:label id="lab_ino_ClassOfWarrantOrRightCommonStockOwnershipMaximumPercent_label_en-US" xlink:label="lab_ino_ClassOfWarrantOrRightCommonStockOwnershipMaximumPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right, Common Stock Ownership, Maximum Percent</link:label>
    <link:label id="lab_ino_ClassOfWarrantOrRightCommonStockOwnershipMaximumPercent_documentation_en-US" xlink:label="lab_ino_ClassOfWarrantOrRightCommonStockOwnershipMaximumPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right, Common Stock Ownership, Maximum Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ClassOfWarrantOrRightCommonStockOwnershipMaximumPercent" xlink:href="ino-20250331.xsd#ino_ClassOfWarrantOrRightCommonStockOwnershipMaximumPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ClassOfWarrantOrRightCommonStockOwnershipMaximumPercent" xlink:to="lab_ino_ClassOfWarrantOrRightCommonStockOwnershipMaximumPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_7ee9ac69-1f5b-4fcc-986f-d1a89ac88f2f_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_e99769f9-cf9e-433a-9443-60e0a306c2c2_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockMember_a1d0fadb-00d0-4c95-982e-f06a15e9fd0c_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockMember_label_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockMember" xlink:to="lab_us-gaap_PreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_d6e28995-b887-410a-a0ca-1f78798cdb9a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_8c1c88bb-72f6-4559-9212-30eb837b8267_verboseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Financial assets and liabilities that are measured at fair value on recurring basis</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:to="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_6c84dd44-2870-456d-ae4c-ba4ef56537b2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_3abb8a9a-0aa0-47bd-98c1-a4478ee63135_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5985c3e7-75c4-4ae2-9471-792734a63afd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average grant date fair value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_RestrictedStockUnitsRSUsTotalShareholderReturnMember_0cf989dd-b57b-4ecc-9ae3-11addad21cec_terseLabel_en-US" xlink:label="lab_ino_RestrictedStockUnitsRSUsTotalShareholderReturnMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Stockholders Return</link:label>
    <link:label id="lab_ino_RestrictedStockUnitsRSUsTotalShareholderReturnMember_label_en-US" xlink:label="lab_ino_RestrictedStockUnitsRSUsTotalShareholderReturnMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs), Total Shareholder Return [Member]</link:label>
    <link:label id="lab_ino_RestrictedStockUnitsRSUsTotalShareholderReturnMember_documentation_en-US" xlink:label="lab_ino_RestrictedStockUnitsRSUsTotalShareholderReturnMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs), Total Shareholder Return</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RestrictedStockUnitsRSUsTotalShareholderReturnMember" xlink:href="ino-20250331.xsd#ino_RestrictedStockUnitsRSUsTotalShareholderReturnMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_RestrictedStockUnitsRSUsTotalShareholderReturnMember" xlink:to="lab_ino_RestrictedStockUnitsRSUsTotalShareholderReturnMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_WarrantLiabilityMeasurementInput_86c3873e-9869-478c-acd8-0bad3762ab8b_terseLabel_en-US" xlink:label="lab_ino_WarrantLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant liability, measurement input</link:label>
    <link:label id="lab_ino_WarrantLiabilityMeasurementInput_label_en-US" xlink:label="lab_ino_WarrantLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant Liability, Measurement Input</link:label>
    <link:label id="lab_ino_WarrantLiabilityMeasurementInput_documentation_en-US" xlink:label="lab_ino_WarrantLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrant Liability, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_WarrantLiabilityMeasurementInput" xlink:href="ino-20250331.xsd#ino_WarrantLiabilityMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_WarrantLiabilityMeasurementInput" xlink:to="lab_ino_WarrantLiabilityMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputExpectedTermMember_ea786fd4-bcb3-4699-ac8e-44773e3d51f5_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected life in years</link:label>
    <link:label id="lab_us-gaap_MeasurementInputExpectedTermMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Expected Term [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedTermMember" xlink:to="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_5233ecb2-8e50-4818-bd76-582bff856ca7_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_6ae64e12-8a55-45fd-94f2-8e4408e3a0fd_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2029</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_1051dcf5-5be7-4a83-acf4-f89c8dc98ecb_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_f86aa471-959b-43e5-b5ab-4744f0650205_netLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_22fdac44-e681-4f98-a446-9d71a550d288_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_EquityMethodInvestmentsMinimum_d5fceaf0-1ac6-4d42-960a-4d85f020e367_terseLabel_en-US" xlink:label="lab_ino_EquityMethodInvestmentsMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity method investments, minimum</link:label>
    <link:label id="lab_ino_EquityMethodInvestmentsMinimum_label_en-US" xlink:label="lab_ino_EquityMethodInvestmentsMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investments, Minimum</link:label>
    <link:label id="lab_ino_EquityMethodInvestmentsMinimum_documentation_en-US" xlink:label="lab_ino_EquityMethodInvestmentsMinimum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Method Investments, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_EquityMethodInvestmentsMinimum" xlink:href="ino-20250331.xsd#ino_EquityMethodInvestmentsMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_EquityMethodInvestmentsMinimum" xlink:to="lab_ino_EquityMethodInvestmentsMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ClassOfWarrantOrRightCommonStockOwnershipPercent_2461c39a-ebaf-43e1-9f50-29ffc47ed2c3_terseLabel_en-US" xlink:label="lab_ino_ClassOfWarrantOrRightCommonStockOwnershipPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of warrant or right, common stock ownership (in percent)</link:label>
    <link:label id="lab_ino_ClassOfWarrantOrRightCommonStockOwnershipPercent_label_en-US" xlink:label="lab_ino_ClassOfWarrantOrRightCommonStockOwnershipPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right, Common Stock Ownership, Percent</link:label>
    <link:label id="lab_ino_ClassOfWarrantOrRightCommonStockOwnershipPercent_documentation_en-US" xlink:label="lab_ino_ClassOfWarrantOrRightCommonStockOwnershipPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right, Common Stock Ownership, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ClassOfWarrantOrRightCommonStockOwnershipPercent" xlink:href="ino-20250331.xsd#ino_ClassOfWarrantOrRightCommonStockOwnershipPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ClassOfWarrantOrRightCommonStockOwnershipPercent" xlink:to="lab_ino_ClassOfWarrantOrRightCommonStockOwnershipPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_IncrementalCommonSharesAttributableToBasicAndDilutiveEffectOfPreFundedWarrants_6c770e81-4667-4e9e-9c39-e8b69e141616_terseLabel_en-US" xlink:label="lab_ino_IncrementalCommonSharesAttributableToBasicAndDilutiveEffectOfPreFundedWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average pre-funded warrants (in shares)</link:label>
    <link:label id="lab_ino_IncrementalCommonSharesAttributableToBasicAndDilutiveEffectOfPreFundedWarrants_label_en-US" xlink:label="lab_ino_IncrementalCommonSharesAttributableToBasicAndDilutiveEffectOfPreFundedWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Incremental Common Shares Attributable To Basic And Dilutive Effect Of PreFunded Warrants</link:label>
    <link:label id="lab_ino_IncrementalCommonSharesAttributableToBasicAndDilutiveEffectOfPreFundedWarrants_documentation_en-US" xlink:label="lab_ino_IncrementalCommonSharesAttributableToBasicAndDilutiveEffectOfPreFundedWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Incremental Common Shares Attributable To Basic And Dilutive Effect Of PreFunded Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncrementalCommonSharesAttributableToBasicAndDilutiveEffectOfPreFundedWarrants" xlink:href="ino-20250331.xsd#ino_IncrementalCommonSharesAttributableToBasicAndDilutiveEffectOfPreFundedWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_IncrementalCommonSharesAttributableToBasicAndDilutiveEffectOfPreFundedWarrants" xlink:to="lab_ino_IncrementalCommonSharesAttributableToBasicAndDilutiveEffectOfPreFundedWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_e48ee7b2-9baf-43de-9bc3-d85fec69dac8_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_3cbbb617-e0fa-484c-a3c8-4f59fb264f99_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_7187dfe3-3807-4bb4-b612-8786bd964cb7_verboseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_93a1e81e-6435-410a-bb38-386ad3efd068_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_98d95047-d16b-4985-95a0-b1db83ca00bc_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net unrealized gain on available-for-sale equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_e0a65d39-6222-4218-adf3-22d260915d77_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Net unrealized gain on available-for-sale equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_d4a34189-7e4d-4b69-bf57-6d0afba0096c_verboseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net unrealized gain (loss) on available-for-sale equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0924f9f6-9b5d-4ce2-8df0-706519737033_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_terseLabel_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Available</link:label>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_label_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Securities Aggregate Available Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:to="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="lab_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_370cb0d0-dde2-4f20-9b5e-512c89418ac0_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_5aace161-56a1-4410-a9d5-6f909a320635_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_5a49ce1d-57e0-437e-b1eb-af71bbe3cdce_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by (used in) financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_terseLabel_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Securities</link:label>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_label_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Underlying Securities Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:to="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_9fb6026f-50fa-46ca-aa41-4b9fc9915f3d_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Short-term Investments and Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_A2023IncentivePlanMember_db1950c0-5a43-4c0d-83d2-53fe6d3ebf76_terseLabel_en-US" xlink:label="lab_ino_A2023IncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2023 Incentive Plan</link:label>
    <link:label id="lab_ino_A2023IncentivePlanMember_label_en-US" xlink:label="lab_ino_A2023IncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2023 Incentive Plan [Member]</link:label>
    <link:label id="lab_ino_A2023IncentivePlanMember_documentation_en-US" xlink:label="lab_ino_A2023IncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2023 Incentive Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A2023IncentivePlanMember" xlink:href="ino-20250331.xsd#ino_A2023IncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_A2023IncentivePlanMember" xlink:to="lab_ino_A2023IncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_932c5919-c231-4364-a839-5b31a9c294f0_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_89883ce3-34cb-465b-a86d-8ea55fe298d8_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeAgreementAmendedAmount_26a3aebf-cfe9-41cf-a647-8d26e8124fe5_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementAmendedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative agreement, amended amount</link:label>
    <link:label id="lab_ino_CollaborativeAgreementAmendedAmount_label_en-US" xlink:label="lab_ino_CollaborativeAgreementAmendedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Agreement, Amended Amount</link:label>
    <link:label id="lab_ino_CollaborativeAgreementAmendedAmount_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementAmendedAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Agreement, Amended Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementAmendedAmount" xlink:href="ino-20250331.xsd#ino_CollaborativeAgreementAmendedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementAmendedAmount" xlink:to="lab_ino_CollaborativeAgreementAmendedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_terseLabel_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs)</link:label>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_label_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:to="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeAgreementFundingReceived_de20adf0-eb40-4b8b-bef5-927262bf1fbd_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementFundingReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative agreement, funding received</link:label>
    <link:label id="lab_ino_CollaborativeAgreementFundingReceived_label_en-US" xlink:label="lab_ino_CollaborativeAgreementFundingReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Agreement, Funding Received</link:label>
    <link:label id="lab_ino_CollaborativeAgreementFundingReceived_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementFundingReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Agreement, Funding Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementFundingReceived" xlink:href="ino-20250331.xsd#ino_CollaborativeAgreementFundingReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementFundingReceived" xlink:to="lab_ino_CollaborativeAgreementFundingReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardGrantDateFairValue_terseLabel_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value as of Grant Date</link:label>
    <link:label id="lab_ecd_AwardGrantDateFairValue_label_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardGrantDateFairValue" xlink:to="lab_ecd_AwardGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_AffiliatedEntityMember_0aa23bb4-6aa1-4cc5-a8bc-2457aefc4993_terseLabel_en-US" xlink:label="lab_srt_AffiliatedEntityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Affiliated Entity</link:label>
    <link:label id="lab_srt_AffiliatedEntityMember_label_en-US" xlink:label="lab_srt_AffiliatedEntityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Affiliated Entity [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_AffiliatedEntityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_AffiliatedEntityMember" xlink:to="lab_srt_AffiliatedEntityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_b8f44748-e050-443f-ac22-951358363d7c_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Significant Other Unobservable Inputs (Level&#160;2)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_9e0d9864-420a-4ea4-81f4-dcdcea676f0f_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares issued in transaction (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_4da280e7-e05c-4944-a580-11e994adb7e0_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible Debt</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b5f6f1ff-7c91-413c-a211-2f91208a5199_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurements, Fair Value Hierarchy [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_6c1ecf4e-4f50-4ccf-83df-c2348a844d9d_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RecoveryOfErrCompDisclosureLineItems_label_en-US" xlink:label="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Recovery of Erroneously Awarded Compensation Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_684b93ec-950a-4cb9-b425-057fb2953f61_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, face amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_UnderwrittenRegisteredDirectOfferingMember_68a25df4-5b7a-4bf9-aa69-c35d860c01de_terseLabel_en-US" xlink:label="lab_ino_UnderwrittenRegisteredDirectOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underwritten Registered Direct Offering</link:label>
    <link:label id="lab_ino_UnderwrittenRegisteredDirectOfferingMember_label_en-US" xlink:label="lab_ino_UnderwrittenRegisteredDirectOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Underwritten Registered Direct Offering [Member]</link:label>
    <link:label id="lab_ino_UnderwrittenRegisteredDirectOfferingMember_documentation_en-US" xlink:label="lab_ino_UnderwrittenRegisteredDirectOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Underwritten Registered Direct Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_UnderwrittenRegisteredDirectOfferingMember" xlink:href="ino-20250331.xsd#ino_UnderwrittenRegisteredDirectOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_UnderwrittenRegisteredDirectOfferingMember" xlink:to="lab_ino_UnderwrittenRegisteredDirectOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_e6254702-6cec-4446-93cc-be3e7f084662_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock for cash, net of financing costs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementAccountingPolicy_f0ef8651-c4c5-4885-95d2-b65351ceb1c4_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration Agreements and Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementAccountingPolicy_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Accounting Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementAccountingPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:to="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_c74ac4da-cbe6-4968-8a34-75f047b73104_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_5f8f4823-2e2d-45c7-9c09-4ab873ec5471_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDateAxis_terseLabel_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date:</link:label>
    <link:label id="lab_ecd_RestatementDateAxis_label_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDateAxis" xlink:to="lab_ecd_RestatementDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_acd06da6-c7b4-462c-92f5-3ef837fd02c4_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_f3b1a4a7-031c-4f01-964f-41cbb0ccd41b_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_13d7271c-bb89-493a-9c9d-3f8cbe0876b3_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeArrangementTerm_db43b60d-47da-4523-974d-1adc0351de7a_terseLabel_en-US" xlink:label="lab_ino_CollaborativeArrangementTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative arrangement, term (in years)</link:label>
    <link:label id="lab_ino_CollaborativeArrangementTerm_label_en-US" xlink:label="lab_ino_CollaborativeArrangementTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Term</link:label>
    <link:label id="lab_ino_CollaborativeArrangementTerm_documentation_en-US" xlink:label="lab_ino_CollaborativeArrangementTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeArrangementTerm" xlink:href="ino-20250331.xsd#ino_CollaborativeArrangementTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeArrangementTerm" xlink:to="lab_ino_CollaborativeArrangementTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_58715885-d5b5-4a6e-906f-ce8cdfa6f197_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_7c5aec0f-8b90-428a-8d61-082a3456366e_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ProceedsFromPaymentsForStockOptionsExercisedAndExerciseOfWarrantsNetOfTaxWithholdings_fe9aaa3a-50b7-45ca-b741-277bff08a433_terseLabel_en-US" xlink:label="lab_ino_ProceedsFromPaymentsForStockOptionsExercisedAndExerciseOfWarrantsNetOfTaxWithholdings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Taxes paid related to net share settlement of equity awards</link:label>
    <link:label id="lab_ino_ProceedsFromPaymentsForStockOptionsExercisedAndExerciseOfWarrantsNetOfTaxWithholdings_label_en-US" xlink:label="lab_ino_ProceedsFromPaymentsForStockOptionsExercisedAndExerciseOfWarrantsNetOfTaxWithholdings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds From (Payments For) Stock Options Exercised and Exercise Of Warrants, Net Of Tax Withholdings</link:label>
    <link:label id="lab_ino_ProceedsFromPaymentsForStockOptionsExercisedAndExerciseOfWarrantsNetOfTaxWithholdings_documentation_en-US" xlink:label="lab_ino_ProceedsFromPaymentsForStockOptionsExercisedAndExerciseOfWarrantsNetOfTaxWithholdings" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds From (Payments For) Stock Options Exercised and Exercise Of Warrants, Net Of Tax Withholdings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ProceedsFromPaymentsForStockOptionsExercisedAndExerciseOfWarrantsNetOfTaxWithholdings" xlink:href="ino-20250331.xsd#ino_ProceedsFromPaymentsForStockOptionsExercisedAndExerciseOfWarrantsNetOfTaxWithholdings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ProceedsFromPaymentsForStockOptionsExercisedAndExerciseOfWarrantsNetOfTaxWithholdings" xlink:to="lab_ino_ProceedsFromPaymentsForStockOptionsExercisedAndExerciseOfWarrantsNetOfTaxWithholdings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_5a15065f-6641-482e-8f73-f3b3f1df15c9_terseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Certificates of deposit</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_label_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Certificates of Deposit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CertificatesOfDepositMember" xlink:to="lab_us-gaap_CertificatesOfDepositMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_label_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:to="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_59a2677e-71c0-4996-8ccd-f835859a6e62_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_terseLabel_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_label_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:to="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_abc40777-a7c2-4efd-b062-57a3caef418e_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_e5749098-7693-4ee2-b214-77cf7125e34a_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_b9e642fd-222e-478f-9ff2-5741a124e0f2_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of common stock, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_32227265-b455-4b2e-bda1-f5468ed42230_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToPeoCompFnTextBlock" xlink:to="lab_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:to="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherPrepaidExpenseCurrent_c5aa3604-b69c-4772-8149-ccc1e3120a79_terseLabel_en-US" xlink:label="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other prepaid expenses</link:label>
    <link:label id="lab_us-gaap_OtherPrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPrepaidExpenseCurrent" xlink:to="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm_be2e7b0c-029b-4813-bf55-55ab0f147d38_terseLabel_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum contractual term (in years)</link:label>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm_label_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share based Compensation Arrangement By Share based Payment Award Maximum Contractual Term</link:label>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm_documentation_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share based compensation arrangement by share based payment award maximum contractual term.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm" xlink:href="ino-20250331.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm" xlink:to="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipDomain_510efdc1-f0bc-47c8-9c1c-606cdaa45104_terseLabel_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:label id="lab_srt_OwnershipDomain_label_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipDomain" xlink:to="lab_srt_OwnershipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_8a9340ab-6e77-42cd-a5a8-b21e77407f75_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amounts accrued for purchases of fixed assets</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment_fbadc10a-2d47-4005-8ef6-3dc6065688ca_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative agreement, period to receive funding for research and development (in years)</link:label>
    <link:label id="lab_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment_label_en-US" xlink:label="lab_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Agreement, Period to Receive Funding for Research and Development</link:label>
    <link:label id="lab_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Agreement, Period to Receive Funding for Research and Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment" xlink:href="ino-20250331.xsd#ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment" xlink:to="lab_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_10a82f2a-81fa-49cd-b77e-f1d210c753b3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock, Class of Stock [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_e5741653-c34d-4144-9b86-2784ff58c897_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year</link:label>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:to="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_fd694e87-fc87-40a2-b678-285438519e06_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_PlymouthMeetingPennsylvaniaMember_4b9898db-a8e3-445d-bf27-bd6d386e0d42_terseLabel_en-US" xlink:label="lab_ino_PlymouthMeetingPennsylvaniaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plymouth Meeting, Pennsylvania</link:label>
    <link:label id="lab_ino_PlymouthMeetingPennsylvaniaMember_label_en-US" xlink:label="lab_ino_PlymouthMeetingPennsylvaniaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plymouth Meeting, Pennsylvania [Member]</link:label>
    <link:label id="lab_ino_PlymouthMeetingPennsylvaniaMember_documentation_en-US" xlink:label="lab_ino_PlymouthMeetingPennsylvaniaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Plymouth Meeting, Pennsylvania [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PlymouthMeetingPennsylvaniaMember" xlink:href="ino-20250331.xsd#ino_PlymouthMeetingPennsylvaniaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_PlymouthMeetingPennsylvaniaMember" xlink:to="lab_ino_PlymouthMeetingPennsylvaniaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0125842a-fe41-44ae-b485-d885079851da_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of capital assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardUnderlyingCommonStock_77376d54-83ac-4239-9334-ea0aa58548d3_terseLabel_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardUnderlyingCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying common stock (in shares)</link:label>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardUnderlyingCommonStock_label_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardUnderlyingCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Underlying Common Stock</link:label>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardUnderlyingCommonStock_documentation_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardUnderlyingCommonStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Underlying Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardUnderlyingCommonStock" xlink:href="ino-20250331.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardUnderlyingCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardUnderlyingCommonStock" xlink:to="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardUnderlyingCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_AccountsPayableAndAccruedExpensesLineItems_0bb541c1-d0b8-479f-bd6d-46fbe350fb3f_terseLabel_en-US" xlink:label="lab_ino_AccountsPayableAndAccruedExpensesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts Payable and Accrued Expenses [Line Items]</link:label>
    <link:label id="lab_ino_AccountsPayableAndAccruedExpensesLineItems_label_en-US" xlink:label="lab_ino_AccountsPayableAndAccruedExpensesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable and Accrued Expenses [Line Items]</link:label>
    <link:label id="lab_ino_AccountsPayableAndAccruedExpensesLineItems_documentation_en-US" xlink:label="lab_ino_AccountsPayableAndAccruedExpensesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accounts Payable and Accrued Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AccountsPayableAndAccruedExpensesLineItems" xlink:href="ino-20250331.xsd#ino_AccountsPayableAndAccruedExpensesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_AccountsPayableAndAccruedExpensesLineItems" xlink:to="lab_ino_AccountsPayableAndAccruedExpensesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrTerminationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Termination Date</link:label>
    <link:label id="lab_ecd_TrdArrTerminationDate_label_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Termination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrTerminationDate" xlink:to="lab_ecd_TrdArrTerminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_15c106c2-f42b-49e2-9e28-fcba3275077f_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_a8bb995b-803d-49f0-8f82-e6362055028e_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Presentation, Liquidity and Risks and Uncertainties</link:label>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NatureOfOperations_8f41780b-fe94-4721-aefd-6d413e1eb321_terseLabel_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization and Operations</link:label>
    <link:label id="lab_us-gaap_NatureOfOperations_label_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NatureOfOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations" xlink:to="lab_us-gaap_NatureOfOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_5a7bf016-d50e-4d7c-a99c-d84cde24bc88_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_964e8d08-2c60-4c9a-9601-c14300966d60_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_c9b55bcd-a3ab-4862-89fd-b024b825b3dc_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_da72eb90-4838-44e7-a04c-38882ab0ffe6_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_1bcf20e1-c3ea-43a4-9c6e-f76ef3b4a206_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_cac34b9e-37e3-441d-8537-136df422e5d9_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestAbstract_143e0710-c74d-4035-866a-6db0359cdc14_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest [Abstract]</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract" xlink:to="lab_us-gaap_NoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborationAgreementAdditionalRevenueToBeAchieved_77afe061-7a84-45d5-bec8-c40f52cc03c1_terseLabel_en-US" xlink:label="lab_ino_CollaborationAgreementAdditionalRevenueToBeAchieved" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional revenue to be achieved</link:label>
    <link:label id="lab_ino_CollaborationAgreementAdditionalRevenueToBeAchieved_label_en-US" xlink:label="lab_ino_CollaborationAgreementAdditionalRevenueToBeAchieved" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Agreement, Additional Revenue To Be Achieved</link:label>
    <link:label id="lab_ino_CollaborationAgreementAdditionalRevenueToBeAchieved_documentation_en-US" xlink:label="lab_ino_CollaborationAgreementAdditionalRevenueToBeAchieved" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Agreement, Additional Revenue To Be Achieved</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborationAgreementAdditionalRevenueToBeAchieved" xlink:href="ino-20250331.xsd#ino_CollaborationAgreementAdditionalRevenueToBeAchieved"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborationAgreementAdditionalRevenueToBeAchieved" xlink:to="lab_ino_CollaborationAgreementAdditionalRevenueToBeAchieved" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_3c3bc722-9d49-402c-9345-4b99b709fbd1_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Allocated share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_f3da6b1a-ad00-4e4c-80b9-cbc087e42813_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_42f7f3eb-3939-496e-80e3-1dffbc5962da_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_113f76a7-baff-4271-b6a7-07f05f11b832_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_fbfdc62b-e24a-43e4-9eca-e0afb953c295_negatedLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrAxis_terseLabel_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangement:</link:label>
    <link:label id="lab_ecd_TradingArrAxis_label_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrAxis" xlink:to="lab_ecd_TradingArrAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_WeightedAverageNumberOfSharesOutstanding_05e4cbce-6150-4a00-b2ac-5f55ba5f4ed7_terseLabel_en-US" xlink:label="lab_ino_WeightedAverageNumberOfSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average common shares outstanding (in shares)</link:label>
    <link:label id="lab_ino_WeightedAverageNumberOfSharesOutstanding_label_en-US" xlink:label="lab_ino_WeightedAverageNumberOfSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number Of Shares Outstanding</link:label>
    <link:label id="lab_ino_WeightedAverageNumberOfSharesOutstanding_documentation_en-US" xlink:label="lab_ino_WeightedAverageNumberOfSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Weighted Average Number Of Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_WeightedAverageNumberOfSharesOutstanding" xlink:href="ino-20250331.xsd#ino_WeightedAverageNumberOfSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_WeightedAverageNumberOfSharesOutstanding" xlink:to="lab_ino_WeightedAverageNumberOfSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_e91c1513-13a4-47a1-971e-281f7b97c1f5_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
    <link:label id="lab_ecd_PvpTableTextBlock_label_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTableTextBlock" xlink:to="lab_ecd_PvpTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CertainBalanceSheetItemsAbstract_label_en-US" xlink:label="lab_ino_CertainBalanceSheetItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Certain Balance Sheet Items [Abstract]</link:label>
    <link:label id="lab_ino_CertainBalanceSheetItemsAbstract_documentation_en-US" xlink:label="lab_ino_CertainBalanceSheetItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Certain Balance Sheet Items</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CertainBalanceSheetItemsAbstract" xlink:href="ino-20250331.xsd#ino_CertainBalanceSheetItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CertainBalanceSheetItemsAbstract" xlink:to="lab_ino_CertainBalanceSheetItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_RestrictedStockUnitsRSUsMilestoneBasedMember_cb92134b-adae-496b-96d8-788c93fbcf36_terseLabel_en-US" xlink:label="lab_ino_RestrictedStockUnitsRSUsMilestoneBasedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone-Based RSUs</link:label>
    <link:label id="lab_ino_RestrictedStockUnitsRSUsMilestoneBasedMember_label_en-US" xlink:label="lab_ino_RestrictedStockUnitsRSUsMilestoneBasedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs), Milestone-Based [Member]</link:label>
    <link:label id="lab_ino_RestrictedStockUnitsRSUsMilestoneBasedMember_documentation_en-US" xlink:label="lab_ino_RestrictedStockUnitsRSUsMilestoneBasedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs), Milestone-Based</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RestrictedStockUnitsRSUsMilestoneBasedMember" xlink:href="ino-20250331.xsd#ino_RestrictedStockUnitsRSUsMilestoneBasedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_RestrictedStockUnitsRSUsMilestoneBasedMember" xlink:to="lab_ino_RestrictedStockUnitsRSUsMilestoneBasedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year</link:label>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_label_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:to="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_fd6dbbb6-56c1-4a00-a6d2-9031064c3c7a_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantDateClosingSharePrice_9425ad57-0629-49d9-be92-f829749142a4_terseLabel_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantDateClosingSharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Grant date closing share price (in dollars per share)</link:label>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantDateClosingSharePrice_label_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantDateClosingSharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grant Date Closing Share Price</link:label>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantDateClosingSharePrice_documentation_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantDateClosingSharePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grant Date Closing Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantDateClosingSharePrice" xlink:href="ino-20250331.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantDateClosingSharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantDateClosingSharePrice" xlink:to="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantDateClosingSharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_195ab626-f497-46cf-8a9d-33c0d7a049ab_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_1549313e-0015-4c93-97f1-388e58367376_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_9476d36e-12bb-42e6-ba3c-53604974debf_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_95dcdb40-2fa6-4379-bfd7-745c5d5bfec3_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_0438b2f3-7db4-4b4a-9227-083cd03c2ca3_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_A2016IncentivePlanMember_dd1eeac8-64ca-4e2e-840c-06f3c325d0fe_terseLabel_en-US" xlink:label="lab_ino_A2016IncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2016 Incentive Plan</link:label>
    <link:label id="lab_ino_A2016IncentivePlanMember_label_en-US" xlink:label="lab_ino_A2016IncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2016 Incentive Plan [Member]</link:label>
    <link:label id="lab_ino_A2016IncentivePlanMember_documentation_en-US" xlink:label="lab_ino_A2016IncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2016 Incentive Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A2016IncentivePlanMember" xlink:href="ino-20250331.xsd#ino_A2016IncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_A2016IncentivePlanMember" xlink:to="lab_ino_A2016IncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_77b15e5a-d3ad-42eb-bfce-f9007a62b860_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_eac0a3ce-df1c-4905-9bf6-31b639cdfd76_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9efa0069-2ad6-4322-a6a1-181b20705c6d_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_c8ca6a72-1129-4c1f-b43e-4bead54c5477_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average number of common shares used to compute net loss per share</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborationAgreementRoyaltyPeriod_0bc577ab-d626-4ccc-9c8c-c51b4b64f6e1_terseLabel_en-US" xlink:label="lab_ino_CollaborationAgreementRoyaltyPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty period (in years)</link:label>
    <link:label id="lab_ino_CollaborationAgreementRoyaltyPeriod_label_en-US" xlink:label="lab_ino_CollaborationAgreementRoyaltyPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Agreement, Royalty Period</link:label>
    <link:label id="lab_ino_CollaborationAgreementRoyaltyPeriod_documentation_en-US" xlink:label="lab_ino_CollaborationAgreementRoyaltyPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Agreement, Royalty Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborationAgreementRoyaltyPeriod" xlink:href="ino-20250331.xsd#ino_CollaborationAgreementRoyaltyPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborationAgreementRoyaltyPeriod" xlink:to="lab_ino_CollaborationAgreementRoyaltyPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_1b9b9067-abf1-46f8-8246-f70e97b70eb2_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets measured at fair value</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryIndName" xlink:to="lab_ecd_ForgoneRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_d5df33ba-20ae-4d06-9893-3daef5f31323_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Remainder of 2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_cd4d5dd9-2b95-41fb-8670-c6ac1ac7ceb9_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average remaining lease term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardDateDomain_e26a92a6-f5cd-485d-a29e-3ed4440a5ed0_terseLabel_en-US" xlink:label="lab_us-gaap_AwardDateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Date [Domain]</link:label>
    <link:label id="lab_us-gaap_AwardDateDomain_label_en-US" xlink:label="lab_us-gaap_AwardDateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Date [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardDateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardDateDomain" xlink:to="lab_us-gaap_AwardDateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_RestrictedStockUnitsPerformanceBasedMember_9bede53b-1f24-4336-b5a3-cc2ddc4e4529_terseLabel_en-US" xlink:label="lab_ino_RestrictedStockUnitsPerformanceBasedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Stock Units, Performance-Based</link:label>
    <link:label id="lab_ino_RestrictedStockUnitsPerformanceBasedMember_label_en-US" xlink:label="lab_ino_RestrictedStockUnitsPerformanceBasedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units, Performance-Based [Member]</link:label>
    <link:label id="lab_ino_RestrictedStockUnitsPerformanceBasedMember_documentation_en-US" xlink:label="lab_ino_RestrictedStockUnitsPerformanceBasedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restricted Stock Units, Performance-Based</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RestrictedStockUnitsPerformanceBasedMember" xlink:href="ino-20250331.xsd#ino_RestrictedStockUnitsPerformanceBasedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_RestrictedStockUnitsPerformanceBasedMember" xlink:to="lab_ino_RestrictedStockUnitsPerformanceBasedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_4b90c5ec-32b7-4e1e-bfca-2ee787bea68d_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ClassOfWarrantOrRightCommonStockOwnershipPriorToIssuancePercent_d9c5f69c-c230-4e53-99f6-35ad12d15a73_terseLabel_en-US" xlink:label="lab_ino_ClassOfWarrantOrRightCommonStockOwnershipPriorToIssuancePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of warrant or right, common stock, prior to issuance (percent)</link:label>
    <link:label id="lab_ino_ClassOfWarrantOrRightCommonStockOwnershipPriorToIssuancePercent_label_en-US" xlink:label="lab_ino_ClassOfWarrantOrRightCommonStockOwnershipPriorToIssuancePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right, Common Stock Ownership, Prior To Issuance, Percent</link:label>
    <link:label id="lab_ino_ClassOfWarrantOrRightCommonStockOwnershipPriorToIssuancePercent_documentation_en-US" xlink:label="lab_ino_ClassOfWarrantOrRightCommonStockOwnershipPriorToIssuancePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right, Common Stock Ownership, Prior To Issuance, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ClassOfWarrantOrRightCommonStockOwnershipPriorToIssuancePercent" xlink:href="ino-20250331.xsd#ino_ClassOfWarrantOrRightCommonStockOwnershipPriorToIssuancePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ClassOfWarrantOrRightCommonStockOwnershipPriorToIssuancePercent" xlink:to="lab_ino_ClassOfWarrantOrRightCommonStockOwnershipPriorToIssuancePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_dce1c2a0-e55e-4ec1-ad02-dbaad7352fa6_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_PlumblineLifeSciencesMember_8c5de5b2-c947-45d6-a1f1-60ced9f7bc76_terseLabel_en-US" xlink:label="lab_ino_PlumblineLifeSciencesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plumbline Life Sciences</link:label>
    <link:label id="lab_ino_PlumblineLifeSciencesMember_label_en-US" xlink:label="lab_ino_PlumblineLifeSciencesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plumbline Life Sciences [Member]</link:label>
    <link:label id="lab_ino_PlumblineLifeSciencesMember_documentation_en-US" xlink:label="lab_ino_PlumblineLifeSciencesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Plumbline Life Sciences [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PlumblineLifeSciencesMember" xlink:href="ino-20250331.xsd#ino_PlumblineLifeSciencesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_PlumblineLifeSciencesMember" xlink:to="lab_ino_PlumblineLifeSciencesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_390e5c39-c353-4f74-87f6-f9aff1e00332_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total remaining lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_54b19968-0aab-4526-a4f8-e50855111f34_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares of unvested restricted stock units and options outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c70e33e4-1762-49e2-b3fc-5ad3d9441899_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Number of shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingArrLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingArrLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="lab_ecd_InsiderTradingArrLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_StockSaleAgreementWeightedAveragePricePerShare_6bf6bbf5-b9ea-446b-a367-e7e946315d99_terseLabel_en-US" xlink:label="lab_ino_StockSaleAgreementWeightedAveragePricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock sale agreement weighted average price (in dollars per share)</link:label>
    <link:label id="lab_ino_StockSaleAgreementWeightedAveragePricePerShare_label_en-US" xlink:label="lab_ino_StockSaleAgreementWeightedAveragePricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Sale Agreement, Weighted Average Price Per Share</link:label>
    <link:label id="lab_ino_StockSaleAgreementWeightedAveragePricePerShare_documentation_en-US" xlink:label="lab_ino_StockSaleAgreementWeightedAveragePricePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Sale Agreement Weighted Average Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSaleAgreementWeightedAveragePricePerShare" xlink:href="ino-20250331.xsd#ino_StockSaleAgreementWeightedAveragePricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_StockSaleAgreementWeightedAveragePricePerShare" xlink:to="lab_ino_StockSaleAgreementWeightedAveragePricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ApolloBioMember_3e10fdf5-b25b-4be3-9111-0b39779b2542_terseLabel_en-US" xlink:label="lab_ino_ApolloBioMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ApolloBio</link:label>
    <link:label id="lab_ino_ApolloBioMember_label_en-US" xlink:label="lab_ino_ApolloBioMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ApolloBio [Member]</link:label>
    <link:label id="lab_ino_ApolloBioMember_documentation_en-US" xlink:label="lab_ino_ApolloBioMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">ApolloBio [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ApolloBioMember" xlink:href="ino-20250331.xsd#ino_ApolloBioMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ApolloBioMember" xlink:to="lab_ino_ApolloBioMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingAggtErrCompAmt" xlink:to="lab_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTextBlock_c6ad0672-f096-440e-bd7b-3a8ac903140f_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Summary of Common and Preferred Stock Authorized, Issued and Outstanding</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_a5ade26e-3c13-4c61-9292-fac8e602bd6e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_07710f3b-e6f8-4a55-880d-fc197ca4d85a_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_LesseeOperatingLeaseBaseRatePercentageIncreaseDecrease_eea5553a-f99c-47fe-8780-fdd57d4de693_terseLabel_en-US" xlink:label="lab_ino_LesseeOperatingLeaseBaseRatePercentageIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, operating lease, base rate percentage (in percent)</link:label>
    <link:label id="lab_ino_LesseeOperatingLeaseBaseRatePercentageIncreaseDecrease_label_en-US" xlink:label="lab_ino_LesseeOperatingLeaseBaseRatePercentageIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Base Rate Percentage, Increase (Decrease)</link:label>
    <link:label id="lab_ino_LesseeOperatingLeaseBaseRatePercentageIncreaseDecrease_documentation_en-US" xlink:label="lab_ino_LesseeOperatingLeaseBaseRatePercentageIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Base Rate Percentage, Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LesseeOperatingLeaseBaseRatePercentageIncreaseDecrease" xlink:href="ino-20250331.xsd#ino_LesseeOperatingLeaseBaseRatePercentageIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_LesseeOperatingLeaseBaseRatePercentageIncreaseDecrease" xlink:to="lab_ino_LesseeOperatingLeaseBaseRatePercentageIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_label_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoActuallyPaidCompAmt" xlink:to="lab_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAxis_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation:</link:label>
    <link:label id="lab_ecd_AdjToCompAxis_label_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="lab_ecd_AdjToCompAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_9be43db6-3352-4380-b087-34be8e5ecdf0_verboseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_d93bd9fd-5b35-45a9-920a-8fb97e5ea4b3_totalLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Prepaid expense and other assets, current</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_9dfb85fb-d0ef-4350-89a9-abbc5e0d09f0_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsGrantDateFairValue_e3f78e80-6723-4752-b73d-8d119ed66969_terseLabel_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Grant date fair value</link:label>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsGrantDateFairValue_label_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments, Grant Date Fair Value</link:label>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsGrantDateFairValue_documentation_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments, Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsGrantDateFairValue" xlink:href="ino-20250331.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsGrantDateFairValue" xlink:to="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_dd7266ee-c27e-4093-8655-167db300ab55_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseOperating_14431b43-19d4-471d-b7b8-3c17c55e806f_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseOperating" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseOperating_label_en-US" xlink:label="lab_us-gaap_InterestExpenseOperating" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense, Operating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseOperating" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseOperating"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseOperating" xlink:to="lab_us-gaap_InterestExpenseOperating" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_b922535b-e282-4a98-878a-ecf7743fe40b_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_321d8640-6e9d-4dd6-a458-18eb02e8c9ba_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_f06068b4-e564-49a4-b3f7-40a204543281_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_57b0d1dc-9a5d-42d6-bbb4-c49b773bde1b_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-controlling interest (in percent)</link:label>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_label_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsidiary, Ownership Percentage, Noncontrolling Owner</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:to="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsSvcCstMember" xlink:to="lab_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_adbb4138-871a-44e9-a781-0464436f262b_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_374747d9-1fda-4454-8d31-8a9604e24be2_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Weighted-average common shares outstanding used to compute basic and diluted net loss per share, basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_6d87aa23-216a-4781-bcdf-77d2d51cec34_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related and Nonrelated Parties [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_label_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_3b6c9bb1-2961-4557-bcde-1dceb3d80a35_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance-and market-based restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_65036579-b006-4b0d-a045-2c01b17f2129_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_terseLabel_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Executive Category:</link:label>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_label_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Executive Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="lab_ecd_ExecutiveCategoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:to="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_LassaFeverAndMERSVaccineMember_d1977913-2a52-473e-a3e9-a666961f46e0_terseLabel_en-US" xlink:label="lab_ino_LassaFeverAndMERSVaccineMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lassa Fever and MERS Vaccine</link:label>
    <link:label id="lab_ino_LassaFeverAndMERSVaccineMember_label_en-US" xlink:label="lab_ino_LassaFeverAndMERSVaccineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lassa Fever And MERS Vaccine [Member]</link:label>
    <link:label id="lab_ino_LassaFeverAndMERSVaccineMember_documentation_en-US" xlink:label="lab_ino_LassaFeverAndMERSVaccineMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lassa Fever And MERS Vaccine [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LassaFeverAndMERSVaccineMember" xlink:href="ino-20250331.xsd#ino_LassaFeverAndMERSVaccineMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_LassaFeverAndMERSVaccineMember" xlink:to="lab_ino_LassaFeverAndMERSVaccineMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_dda9d8d0-d7d5-4391-9d5c-516640eb1378_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssued_f7de1960-a9ea-432c-afee-e1e43b53c1ac_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_18e1e15b-564a-4dbf-9066-58229dff37ed_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_label_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued" xlink:to="lab_us-gaap_SharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_a3aa0a9f-cdc3-4914-9e41-3764c5acf949_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Allocation of Recognized Period Costs, Report Line [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureName_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureName_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureName" xlink:to="lab_ecd_CoSelectedMeasureName" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>ino-20250331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:382d2453-c46c-4ade-9f50-1f9566f15edb,g:9bfa17de-2275-45c6-a4f6-49112bde99df-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.inovio.com/role/Cover" xlink:type="simple" xlink:href="ino-20250331.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_8a43be3d-0158-4275-82a8-3c1276878d4f" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_1aefa8a3-0d07-495f-bc64-a257ef204661" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8a43be3d-0158-4275-82a8-3c1276878d4f" xlink:to="loc_dei_DocumentType_1aefa8a3-0d07-495f-bc64-a257ef204661" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_44f5b9a2-0ce0-40f5-8cc4-0734e79565b3" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8a43be3d-0158-4275-82a8-3c1276878d4f" xlink:to="loc_dei_DocumentQuarterlyReport_44f5b9a2-0ce0-40f5-8cc4-0734e79565b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_4327c3e2-e8a1-45e2-a7bb-5f80c45c77b6" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8a43be3d-0158-4275-82a8-3c1276878d4f" xlink:to="loc_dei_DocumentPeriodEndDate_4327c3e2-e8a1-45e2-a7bb-5f80c45c77b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_3d2ce898-a659-4713-9d2c-ffb2d929daf1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8a43be3d-0158-4275-82a8-3c1276878d4f" xlink:to="loc_dei_DocumentTransitionReport_3d2ce898-a659-4713-9d2c-ffb2d929daf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_14d1a2b4-a31f-4442-9e9e-11d957fce07c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8a43be3d-0158-4275-82a8-3c1276878d4f" xlink:to="loc_dei_EntityFileNumber_14d1a2b4-a31f-4442-9e9e-11d957fce07c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_8b9ecdaa-61af-4737-a844-9f4bcee4ec1a" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8a43be3d-0158-4275-82a8-3c1276878d4f" xlink:to="loc_dei_EntityRegistrantName_8b9ecdaa-61af-4737-a844-9f4bcee4ec1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_bdf27b67-2912-4581-8950-cc06e3616f34" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8a43be3d-0158-4275-82a8-3c1276878d4f" xlink:to="loc_dei_EntityIncorporationStateCountryCode_bdf27b67-2912-4581-8950-cc06e3616f34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_4e8e2771-c3ec-4399-a2a3-500ff5f60977" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8a43be3d-0158-4275-82a8-3c1276878d4f" xlink:to="loc_dei_EntityTaxIdentificationNumber_4e8e2771-c3ec-4399-a2a3-500ff5f60977" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_a918da02-2770-4aa7-8886-a8659d54e50f" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8a43be3d-0158-4275-82a8-3c1276878d4f" xlink:to="loc_dei_EntityAddressAddressLine1_a918da02-2770-4aa7-8886-a8659d54e50f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_424960de-58f3-4f9c-88d7-e877e636c0cc" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8a43be3d-0158-4275-82a8-3c1276878d4f" xlink:to="loc_dei_EntityAddressAddressLine2_424960de-58f3-4f9c-88d7-e877e636c0cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_914c4fd0-9188-47a6-b820-ff8f4300bc30" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8a43be3d-0158-4275-82a8-3c1276878d4f" xlink:to="loc_dei_EntityAddressCityOrTown_914c4fd0-9188-47a6-b820-ff8f4300bc30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_366a356c-4694-407b-9c27-904c0ee80130" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8a43be3d-0158-4275-82a8-3c1276878d4f" xlink:to="loc_dei_EntityAddressStateOrProvince_366a356c-4694-407b-9c27-904c0ee80130" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_de8087d2-e1af-4842-88e4-a937f37f2de1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8a43be3d-0158-4275-82a8-3c1276878d4f" xlink:to="loc_dei_EntityAddressPostalZipCode_de8087d2-e1af-4842-88e4-a937f37f2de1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_f31b5ac6-13bd-4c2c-8036-9a0176016d92" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8a43be3d-0158-4275-82a8-3c1276878d4f" xlink:to="loc_dei_CityAreaCode_f31b5ac6-13bd-4c2c-8036-9a0176016d92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_0e2076c1-1657-4c35-b0b4-93ffa2d930ef" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8a43be3d-0158-4275-82a8-3c1276878d4f" xlink:to="loc_dei_LocalPhoneNumber_0e2076c1-1657-4c35-b0b4-93ffa2d930ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_40dc9595-d685-4e65-b6db-b60fa5221bb8" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8a43be3d-0158-4275-82a8-3c1276878d4f" xlink:to="loc_dei_Security12bTitle_40dc9595-d685-4e65-b6db-b60fa5221bb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_66a086c1-c3f6-4a87-808b-1394bec4f01b" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8a43be3d-0158-4275-82a8-3c1276878d4f" xlink:to="loc_dei_TradingSymbol_66a086c1-c3f6-4a87-808b-1394bec4f01b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_197bd6a7-c1ba-4a5b-96d0-ee2c9f0c49ea" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8a43be3d-0158-4275-82a8-3c1276878d4f" xlink:to="loc_dei_SecurityExchangeName_197bd6a7-c1ba-4a5b-96d0-ee2c9f0c49ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_64c20a92-862b-436b-b555-b073cae41dd8" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8a43be3d-0158-4275-82a8-3c1276878d4f" xlink:to="loc_dei_EntityCurrentReportingStatus_64c20a92-862b-436b-b555-b073cae41dd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_6d2e48f8-9aad-473d-83ac-4472acfa1b41" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8a43be3d-0158-4275-82a8-3c1276878d4f" xlink:to="loc_dei_EntityInteractiveDataCurrent_6d2e48f8-9aad-473d-83ac-4472acfa1b41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_1538331e-82c3-4d93-b3b2-764b66420136" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8a43be3d-0158-4275-82a8-3c1276878d4f" xlink:to="loc_dei_EntityFilerCategory_1538331e-82c3-4d93-b3b2-764b66420136" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_f87f2c6c-3258-41ec-bc70-e1236d22085f" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8a43be3d-0158-4275-82a8-3c1276878d4f" xlink:to="loc_dei_EntitySmallBusiness_f87f2c6c-3258-41ec-bc70-e1236d22085f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_bbcd94e3-8fe5-482e-b372-511f36a8340e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8a43be3d-0158-4275-82a8-3c1276878d4f" xlink:to="loc_dei_EntityEmergingGrowthCompany_bbcd94e3-8fe5-482e-b372-511f36a8340e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_64cf51b3-120a-46d6-95ff-f7cda01c640e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8a43be3d-0158-4275-82a8-3c1276878d4f" xlink:to="loc_dei_EntityShellCompany_64cf51b3-120a-46d6-95ff-f7cda01c640e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_4a316f7e-1280-4628-b3fc-dc9a17593860" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8a43be3d-0158-4275-82a8-3c1276878d4f" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_4a316f7e-1280-4628-b3fc-dc9a17593860" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_1e11d3bc-4d80-475d-a8f2-5c53934050a7" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8a43be3d-0158-4275-82a8-3c1276878d4f" xlink:to="loc_dei_AmendmentFlag_1e11d3bc-4d80-475d-a8f2-5c53934050a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_d22e6016-4bdf-48be-a95a-90d956750b66" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8a43be3d-0158-4275-82a8-3c1276878d4f" xlink:to="loc_dei_DocumentFiscalYearFocus_d22e6016-4bdf-48be-a95a-90d956750b66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_1afa9a86-d296-4726-b6e1-8c39ad303a83" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8a43be3d-0158-4275-82a8-3c1276878d4f" xlink:to="loc_dei_DocumentFiscalPeriodFocus_1afa9a86-d296-4726-b6e1-8c39ad303a83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_681bab57-a0e7-4458-a9c0-df92a6437fc8" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8a43be3d-0158-4275-82a8-3c1276878d4f" xlink:to="loc_dei_EntityCentralIndexKey_681bab57-a0e7-4458-a9c0-df92a6437fc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_a0352ea4-896f-4267-a8d7-20d4d77882a5" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8a43be3d-0158-4275-82a8-3c1276878d4f" xlink:to="loc_dei_CurrentFiscalYearEndDate_a0352ea4-896f-4267-a8d7-20d4d77882a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="ino-20250331.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_0f479e81-87ac-40ee-bd54-250518dec544" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_a32a3a85-2b81-4d13-80ae-dfc3a9ef6142" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0f479e81-87ac-40ee-bd54-250518dec544" xlink:to="loc_us-gaap_StatementTable_a32a3a85-2b81-4d13-80ae-dfc3a9ef6142" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2e456aa8-a1ad-427c-9713-dfa3fa7344c6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_a32a3a85-2b81-4d13-80ae-dfc3a9ef6142" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2e456aa8-a1ad-427c-9713-dfa3fa7344c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_9fe42960-39ad-46f9-8b57-27c66bcc1c92" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2e456aa8-a1ad-427c-9713-dfa3fa7344c6" xlink:to="loc_us-gaap_RelatedPartyDomain_9fe42960-39ad-46f9-8b57-27c66bcc1c92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrelatedPartyMember_e3e04b9b-6de2-4fc7-8225-a8773d80de6a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonrelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_9fe42960-39ad-46f9-8b57-27c66bcc1c92" xlink:to="loc_us-gaap_NonrelatedPartyMember_e3e04b9b-6de2-4fc7-8225-a8773d80de6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_7653db13-e810-48e3-b781-05d4a0786a47" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_9fe42960-39ad-46f9-8b57-27c66bcc1c92" xlink:to="loc_us-gaap_RelatedPartyMember_7653db13-e810-48e3-b781-05d4a0786a47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_19201e08-9b56-4896-9930-81771fb994fe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_a32a3a85-2b81-4d13-80ae-dfc3a9ef6142" xlink:to="loc_us-gaap_StatementLineItems_19201e08-9b56-4896-9930-81771fb994fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_ed5f8539-576e-46b8-9947-e1e572bb884c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_19201e08-9b56-4896-9930-81771fb994fe" xlink:to="loc_us-gaap_AssetsAbstract_ed5f8539-576e-46b8-9947-e1e572bb884c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_1fbe3b02-d4f2-43b3-8244-3abd9a93043d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ed5f8539-576e-46b8-9947-e1e572bb884c" xlink:to="loc_us-gaap_AssetsCurrentAbstract_1fbe3b02-d4f2-43b3-8244-3abd9a93043d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_23ce97c5-1e62-4bf1-9bde-36d88886ed49" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1fbe3b02-d4f2-43b3-8244-3abd9a93043d" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_23ce97c5-1e62-4bf1-9bde-36d88886ed49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_d54d2df8-a844-4432-b012-4b23fd1747bd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1fbe3b02-d4f2-43b3-8244-3abd9a93043d" xlink:to="loc_us-gaap_ShortTermInvestments_d54d2df8-a844-4432-b012-4b23fd1747bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_eb790240-d7fe-45b8-9e4f-6dfa1e5cc6ca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1fbe3b02-d4f2-43b3-8244-3abd9a93043d" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_eb790240-d7fe-45b8-9e4f-6dfa1e5cc6ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_da891b57-fb57-4254-a5b7-8b4d6616000f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1fbe3b02-d4f2-43b3-8244-3abd9a93043d" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_da891b57-fb57-4254-a5b7-8b4d6616000f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_ab49a91d-e0fc-49d9-a9da-8640ac613048" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1fbe3b02-d4f2-43b3-8244-3abd9a93043d" xlink:to="loc_us-gaap_AssetsCurrent_ab49a91d-e0fc-49d9-a9da-8640ac613048" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_3021c3e8-d420-46f7-94cb-d0510583f200" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ed5f8539-576e-46b8-9947-e1e572bb884c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_3021c3e8-d420-46f7-94cb-d0510583f200" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_b5f637d5-f207-4d0b-8d29-1592f75daa95" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ed5f8539-576e-46b8-9947-e1e572bb884c" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_b5f637d5-f207-4d0b-8d29-1592f75daa95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_54716d75-622e-45fe-8a07-fec178124f36" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ed5f8539-576e-46b8-9947-e1e572bb884c" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_54716d75-622e-45fe-8a07-fec178124f36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_fbf31daa-3155-43c1-b6b7-a4717dbac902" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ed5f8539-576e-46b8-9947-e1e572bb884c" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_fbf31daa-3155-43c1-b6b7-a4717dbac902" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_513270ca-ac93-4868-833a-6ee67b5bedb5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ed5f8539-576e-46b8-9947-e1e572bb884c" xlink:to="loc_us-gaap_Assets_513270ca-ac93-4868-833a-6ee67b5bedb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_beabc432-e790-4b27-9d63-5df75cfb90a0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_19201e08-9b56-4896-9930-81771fb994fe" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_beabc432-e790-4b27-9d63-5df75cfb90a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_cc87fc32-237e-48c5-b6d1-892e3d689cdf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_beabc432-e790-4b27-9d63-5df75cfb90a0" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_cc87fc32-237e-48c5-b6d1-892e3d689cdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_74cf8855-e13c-4662-a441-0979f68c00f1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_cc87fc32-237e-48c5-b6d1-892e3d689cdf" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_74cf8855-e13c-4662-a441-0979f68c00f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AccruedClinicalTrialExpenseCurrent_9c5f50c5-03f6-42a7-b6e1-04d1cf5b57e6" xlink:href="ino-20250331.xsd#ino_AccruedClinicalTrialExpenseCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_cc87fc32-237e-48c5-b6d1-892e3d689cdf" xlink:to="loc_ino_AccruedClinicalTrialExpenseCurrent_9c5f50c5-03f6-42a7-b6e1-04d1cf5b57e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_a012312b-af2c-401e-b68a-c51b63aa0537" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_cc87fc32-237e-48c5-b6d1-892e3d689cdf" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent_a012312b-af2c-401e-b68a-c51b63aa0537" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_4d6b74c2-fc10-47b4-8846-0b161b51fdb2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_cc87fc32-237e-48c5-b6d1-892e3d689cdf" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_4d6b74c2-fc10-47b4-8846-0b161b51fdb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_fa21be95-db87-4ecd-88ad-02d95b5794ab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_cc87fc32-237e-48c5-b6d1-892e3d689cdf" xlink:to="loc_us-gaap_LiabilitiesCurrent_fa21be95-db87-4ecd-88ad-02d95b5794ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_0e0b8a13-15ef-4c36-8ad8-07836b833d9e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_beabc432-e790-4b27-9d63-5df75cfb90a0" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_0e0b8a13-15ef-4c36-8ad8-07836b833d9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_0a667805-a97c-47ef-a90f-caa2e08af6c7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_beabc432-e790-4b27-9d63-5df75cfb90a0" xlink:to="loc_us-gaap_Liabilities_0a667805-a97c-47ef-a90f-caa2e08af6c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_d9874ad3-f0df-4d86-84c5-6ca3a6afffb4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_beabc432-e790-4b27-9d63-5df75cfb90a0" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_d9874ad3-f0df-4d86-84c5-6ca3a6afffb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_275b89f7-1724-4114-8ed1-2af2cf29d6e6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_d9874ad3-f0df-4d86-84c5-6ca3a6afffb4" xlink:to="loc_us-gaap_PreferredStockValue_275b89f7-1724-4114-8ed1-2af2cf29d6e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_d627a4f9-3a8c-4c02-a35a-c00f4380718d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_d9874ad3-f0df-4d86-84c5-6ca3a6afffb4" xlink:to="loc_us-gaap_CommonStockValue_d627a4f9-3a8c-4c02-a35a-c00f4380718d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_5d96b27b-ca47-4deb-9202-04202ce0e529" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_d9874ad3-f0df-4d86-84c5-6ca3a6afffb4" xlink:to="loc_us-gaap_AdditionalPaidInCapital_5d96b27b-ca47-4deb-9202-04202ce0e529" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_38b0ca04-532d-4cd8-992b-b096ff07213f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_d9874ad3-f0df-4d86-84c5-6ca3a6afffb4" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_38b0ca04-532d-4cd8-992b-b096ff07213f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_48323b98-b205-4e0b-8faa-809473a38cd4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_d9874ad3-f0df-4d86-84c5-6ca3a6afffb4" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_48323b98-b205-4e0b-8faa-809473a38cd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_c6ff8cad-8d2a-4b7e-acbe-1bee03f754cb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_d9874ad3-f0df-4d86-84c5-6ca3a6afffb4" xlink:to="loc_us-gaap_StockholdersEquity_c6ff8cad-8d2a-4b7e-acbe-1bee03f754cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_43e45d4e-17a4-4453-9a99-07e51c4ba33f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_beabc432-e790-4b27-9d63-5df75cfb90a0" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_43e45d4e-17a4-4453-9a99-07e51c4ba33f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="ino-20250331.xsd#CondensedConsolidatedStatementsofOperations"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_925349bf-df55-4255-8ada-9a792284b819" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_65c5deeb-ccdf-4143-a01b-f75701bc67d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_925349bf-df55-4255-8ada-9a792284b819" xlink:to="loc_us-gaap_RevenuesAbstract_65c5deeb-ccdf-4143-a01b-f75701bc67d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_81301e83-ad3c-43f9-8b76-92e28e0c63e3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_65c5deeb-ccdf-4143-a01b-f75701bc67d6" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_81301e83-ad3c-43f9-8b76-92e28e0c63e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_d2b9a836-b0aa-4d08-ae66-d1fcb574abe8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_925349bf-df55-4255-8ada-9a792284b819" xlink:to="loc_us-gaap_OperatingExpensesAbstract_d2b9a836-b0aa-4d08-ae66-d1fcb574abe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_85ad8af2-9fab-4e51-841d-1af178dd6f11" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d2b9a836-b0aa-4d08-ae66-d1fcb574abe8" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_85ad8af2-9fab-4e51-841d-1af178dd6f11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_52597bd8-0bec-49a0-bf43-eda98ab2eb7e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d2b9a836-b0aa-4d08-ae66-d1fcb574abe8" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_52597bd8-0bec-49a0-bf43-eda98ab2eb7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_4f0d5d6a-42fe-49d2-9d61-81ce0220f7cf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d2b9a836-b0aa-4d08-ae66-d1fcb574abe8" xlink:to="loc_us-gaap_OperatingExpenses_4f0d5d6a-42fe-49d2-9d61-81ce0220f7cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_019d23b8-e885-420d-a79e-cdc42f07be8d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_925349bf-df55-4255-8ada-9a792284b819" xlink:to="loc_us-gaap_OperatingIncomeLoss_019d23b8-e885-420d-a79e-cdc42f07be8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_f6abaf9b-63b2-4b0c-9854-c629abf1bf6e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_925349bf-df55-4255-8ada-9a792284b819" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_f6abaf9b-63b2-4b0c-9854-c629abf1bf6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_959a0dd3-79f8-4fea-9c58-edeeac4de8f1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_f6abaf9b-63b2-4b0c-9854-c629abf1bf6e" xlink:to="loc_us-gaap_InvestmentIncomeInterest_959a0dd3-79f8-4fea-9c58-edeeac4de8f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating_7fe93c38-ba8b-4c2d-ab81-89ed6886fc5b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_f6abaf9b-63b2-4b0c-9854-c629abf1bf6e" xlink:to="loc_us-gaap_InterestExpenseNonoperating_7fe93c38-ba8b-4c2d-ab81-89ed6886fc5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_1d8c565b-de3e-411b-ac2d-6f0605d0bff4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_f6abaf9b-63b2-4b0c-9854-c629abf1bf6e" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_1d8c565b-de3e-411b-ac2d-6f0605d0bff4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_93bbb4d7-65fc-4acf-87c7-4c66dbba26ce" xlink:href="ino-20250331.xsd#ino_ChangeInValueOfInvestmentsInAffiliatedCompany"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_f6abaf9b-63b2-4b0c-9854-c629abf1bf6e" xlink:to="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_93bbb4d7-65fc-4acf-87c7-4c66dbba26ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_255772b8-74d1-407b-a6be-17c6353545fe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_f6abaf9b-63b2-4b0c-9854-c629abf1bf6e" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_255772b8-74d1-407b-a6be-17c6353545fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_76d874aa-738a-4195-9d27-79e646996c97" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_f6abaf9b-63b2-4b0c-9854-c629abf1bf6e" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_76d874aa-738a-4195-9d27-79e646996c97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_15a91860-1cec-4e97-93f5-c14708548d14" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_f6abaf9b-63b2-4b0c-9854-c629abf1bf6e" xlink:to="loc_us-gaap_NetIncomeLoss_15a91860-1cec-4e97-93f5-c14708548d14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_0bb2be72-e777-48a1-99ae-1c718d1e3f32" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_925349bf-df55-4255-8ada-9a792284b819" xlink:to="loc_us-gaap_EarningsPerShareAbstract_0bb2be72-e777-48a1-99ae-1c718d1e3f32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_29fe4a14-10f5-4ee3-a150-7dec98c9fa25" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0bb2be72-e777-48a1-99ae-1c718d1e3f32" xlink:to="loc_us-gaap_EarningsPerShareBasic_29fe4a14-10f5-4ee3-a150-7dec98c9fa25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_83010f62-76be-4b98-81ff-ada256ac0908" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0bb2be72-e777-48a1-99ae-1c718d1e3f32" xlink:to="loc_us-gaap_EarningsPerShareDiluted_83010f62-76be-4b98-81ff-ada256ac0908" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_f7d6f803-4d1d-430c-bbc8-d106672b26b9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_925349bf-df55-4255-8ada-9a792284b819" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_f7d6f803-4d1d-430c-bbc8-d106672b26b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_9d72ef99-b1b3-4adb-910d-eaba464f167a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_f7d6f803-4d1d-430c-bbc8-d106672b26b9" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_9d72ef99-b1b3-4adb-910d-eaba464f167a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_6044b113-feee-4c93-ad07-8f9a497bf595" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_f7d6f803-4d1d-430c-bbc8-d106672b26b9" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_6044b113-feee-4c93-ad07-8f9a497bf595" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" xlink:type="simple" xlink:href="ino-20250331.xsd#CondensedConsolidatedStatementsofComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_b851425a-6a8b-4eab-bb16-ec6b92d29b79" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ac127964-f71a-4a6e-94f2-d1a5173de6ef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_b851425a-6a8b-4eab-bb16-ec6b92d29b79" xlink:to="loc_us-gaap_NetIncomeLoss_ac127964-f71a-4a6e-94f2-d1a5173de6ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_54e28616-cb2e-47fa-b82a-feaa15660ec3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_b851425a-6a8b-4eab-bb16-ec6b92d29b79" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_54e28616-cb2e-47fa-b82a-feaa15660ec3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_30b397d3-55bf-44c9-b45e-04a83d831942" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_54e28616-cb2e-47fa-b82a-feaa15660ec3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_30b397d3-55bf-44c9-b45e-04a83d831942" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_77745103-dcee-4ea5-b001-9b408764efc3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_54e28616-cb2e-47fa-b82a-feaa15660ec3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_77745103-dcee-4ea5-b001-9b408764efc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_13ad688b-6d8e-471f-97bb-10fc26bbe6d5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_b851425a-6a8b-4eab-bb16-ec6b92d29b79" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_13ad688b-6d8e-471f-97bb-10fc26bbe6d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="ino-20250331.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_92c0aa7c-fdac-4000-84d8-d21ce1bda7d7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_d716c5e8-45b1-45a5-941c-94b06615b57b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_92c0aa7c-fdac-4000-84d8-d21ce1bda7d7" xlink:to="loc_us-gaap_StatementTable_d716c5e8-45b1-45a5-941c-94b06615b57b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_eb84eb90-fc5a-45ed-8e8b-d80a5d396cc4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_d716c5e8-45b1-45a5-941c-94b06615b57b" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_eb84eb90-fc5a-45ed-8e8b-d80a5d396cc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_d6d1f1b8-a12e-4d0a-97ee-5a7277caffdc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_eb84eb90-fc5a-45ed-8e8b-d80a5d396cc4" xlink:to="loc_us-gaap_EquityComponentDomain_d6d1f1b8-a12e-4d0a-97ee-5a7277caffdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_73a23350-781a-46b1-80e0-2f5e34d3ae12" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_d6d1f1b8-a12e-4d0a-97ee-5a7277caffdc" xlink:to="loc_us-gaap_PreferredStockMember_73a23350-781a-46b1-80e0-2f5e34d3ae12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_02789816-6e48-4122-b0d5-30f7101012f8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_d6d1f1b8-a12e-4d0a-97ee-5a7277caffdc" xlink:to="loc_us-gaap_CommonStockMember_02789816-6e48-4122-b0d5-30f7101012f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_f1b6dfe3-4d8b-4f3a-b30c-d573745bb5ae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_d6d1f1b8-a12e-4d0a-97ee-5a7277caffdc" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_f1b6dfe3-4d8b-4f3a-b30c-d573745bb5ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_df8d1695-5dbb-4f59-9db5-4319a39a744f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_d6d1f1b8-a12e-4d0a-97ee-5a7277caffdc" xlink:to="loc_us-gaap_RetainedEarningsMember_df8d1695-5dbb-4f59-9db5-4319a39a744f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e4f1663d-b957-4ab2-8074-899f8108cc03" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_d6d1f1b8-a12e-4d0a-97ee-5a7277caffdc" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e4f1663d-b957-4ab2-8074-899f8108cc03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_d02aaa3c-eaca-49b0-b12f-78ca439133f0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_d716c5e8-45b1-45a5-941c-94b06615b57b" xlink:to="loc_us-gaap_StatementLineItems_d02aaa3c-eaca-49b0-b12f-78ca439133f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d6b24916-b167-487b-8036-92c9d0fd7f6d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d02aaa3c-eaca-49b0-b12f-78ca439133f0" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d6b24916-b167-487b-8036-92c9d0fd7f6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_3d11f0e7-bcd3-4a87-a94e-d95c17030b02" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d6b24916-b167-487b-8036-92c9d0fd7f6d" xlink:to="loc_us-gaap_SharesIssued_3d11f0e7-bcd3-4a87-a94e-d95c17030b02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_b7ffbcec-d1ba-4bc6-a310-32d4df25e45d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d6b24916-b167-487b-8036-92c9d0fd7f6d" xlink:to="loc_us-gaap_StockholdersEquity_b7ffbcec-d1ba-4bc6-a310-32d4df25e45d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_9b33628e-4e7f-45ef-bb81-6b5836562987" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d6b24916-b167-487b-8036-92c9d0fd7f6d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_9b33628e-4e7f-45ef-bb81-6b5836562987" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_6b807673-a373-4687-9910-35e25cffbb65" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d6b24916-b167-487b-8036-92c9d0fd7f6d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_6b807673-a373-4687-9910-35e25cffbb65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_456b0e91-8988-43df-8ce8-61b6157237da" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d6b24916-b167-487b-8036-92c9d0fd7f6d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_456b0e91-8988-43df-8ce8-61b6157237da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_98b2125b-0475-46ac-b562-79835e716e6f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d6b24916-b167-487b-8036-92c9d0fd7f6d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_98b2125b-0475-46ac-b562-79835e716e6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_c80b4e55-acb3-4ba7-aefb-c96421d9a8cd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d6b24916-b167-487b-8036-92c9d0fd7f6d" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_c80b4e55-acb3-4ba7-aefb-c96421d9a8cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_cba9043a-cf7a-47bb-89b3-1db8171da15c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d6b24916-b167-487b-8036-92c9d0fd7f6d" xlink:to="loc_us-gaap_NetIncomeLoss_cba9043a-cf7a-47bb-89b3-1db8171da15c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_6583f1b9-2d0c-4afe-9b27-2db738c7a4ee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d6b24916-b167-487b-8036-92c9d0fd7f6d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_6583f1b9-2d0c-4afe-9b27-2db738c7a4ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_a503d4c3-f2bb-4568-8430-3878ef00fcad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d6b24916-b167-487b-8036-92c9d0fd7f6d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_a503d4c3-f2bb-4568-8430-3878ef00fcad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_675b4e1e-9956-4601-8af3-cf58558862c4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d6b24916-b167-487b-8036-92c9d0fd7f6d" xlink:to="loc_us-gaap_SharesIssued_675b4e1e-9956-4601-8af3-cf58558862c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_3b0b161b-9c41-48c9-b6a5-817a274751ce" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d6b24916-b167-487b-8036-92c9d0fd7f6d" xlink:to="loc_us-gaap_StockholdersEquity_3b0b161b-9c41-48c9-b6a5-817a274751ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="ino-20250331.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_b145beeb-a8ef-4dde-bcb3-323b4b07635d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_86c1df85-74e7-4cd9-ad87-68ed910fe740" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b145beeb-a8ef-4dde-bcb3-323b4b07635d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_86c1df85-74e7-4cd9-ad87-68ed910fe740" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3e7a2543-7630-4845-9b04-fa137dce6db0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_86c1df85-74e7-4cd9-ad87-68ed910fe740" xlink:to="loc_us-gaap_NetIncomeLoss_3e7a2543-7630-4845-9b04-fa137dce6db0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_76d6a695-d84f-4bf4-ab69-29368c42c95f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_86c1df85-74e7-4cd9-ad87-68ed910fe740" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_76d6a695-d84f-4bf4-ab69-29368c42c95f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_46147f78-f6be-4d1d-a918-5f10a71db34a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_76d6a695-d84f-4bf4-ab69-29368c42c95f" xlink:to="loc_us-gaap_Depreciation_46147f78-f6be-4d1d-a918-5f10a71db34a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_40ac9d1b-a917-4ff5-9d18-f51e58885585" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_76d6a695-d84f-4bf4-ab69-29368c42c95f" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_40ac9d1b-a917-4ff5-9d18-f51e58885585" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_f0648469-9807-4d5d-8e52-6e0518f62966" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_76d6a695-d84f-4bf4-ab69-29368c42c95f" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_f0648469-9807-4d5d-8e52-6e0518f62966" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_a5c76128-aa32-44bb-900e-b86f6f95b703" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_76d6a695-d84f-4bf4-ab69-29368c42c95f" xlink:to="loc_us-gaap_ShareBasedCompensation_a5c76128-aa32-44bb-900e-b86f6f95b703" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_NonCashInterestIncomeExpense_1abf86e3-c50e-436f-acfb-435df7d06845" xlink:href="ino-20250331.xsd#ino_NonCashInterestIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_76d6a695-d84f-4bf4-ab69-29368c42c95f" xlink:to="loc_ino_NonCashInterestIncomeExpense_1abf86e3-c50e-436f-acfb-435df7d06845" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_949e4ffd-6cd6-4c0a-a2d1-3ec2f5099200" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_76d6a695-d84f-4bf4-ab69-29368c42c95f" xlink:to="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_949e4ffd-6cd6-4c0a-a2d1-3ec2f5099200" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfOtherInvestments_184b780b-7729-4500-af63-8766f634bb65" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfOtherInvestments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_76d6a695-d84f-4bf4-ab69-29368c42c95f" xlink:to="loc_us-gaap_GainLossOnSaleOfOtherInvestments_184b780b-7729-4500-af63-8766f634bb65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_bf159c60-63cf-4064-b5f2-2b6ccd997fc5" xlink:href="ino-20250331.xsd#ino_ChangeInValueOfInvestmentsInAffiliatedCompany"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_76d6a695-d84f-4bf4-ab69-29368c42c95f" xlink:to="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_bf159c60-63cf-4064-b5f2-2b6ccd997fc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_0fc70b90-f58b-42ce-ba3f-9a049de81392" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_76d6a695-d84f-4bf4-ab69-29368c42c95f" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_0fc70b90-f58b-42ce-ba3f-9a049de81392" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_485571a1-1587-46e2-b696-0a225b393c8e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_76d6a695-d84f-4bf4-ab69-29368c42c95f" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_485571a1-1587-46e2-b696-0a225b393c8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_79e55df4-848b-4200-a262-45eb34ee781f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_485571a1-1587-46e2-b696-0a225b393c8e" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_79e55df4-848b-4200-a262-45eb34ee781f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_00ae6460-6c27-4fed-9022-5420319300ff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_485571a1-1587-46e2-b696-0a225b393c8e" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_00ae6460-6c27-4fed-9022-5420319300ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_016b6885-e279-4511-a8a3-b4710068b192" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_485571a1-1587-46e2-b696-0a225b393c8e" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_016b6885-e279-4511-a8a3-b4710068b192" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseInAccruedClinicalTrialExpense_1b3e305a-5752-4927-8947-0955d15e80d7" xlink:href="ino-20250331.xsd#ino_IncreaseDecreaseInAccruedClinicalTrialExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_485571a1-1587-46e2-b696-0a225b393c8e" xlink:to="loc_ino_IncreaseDecreaseInAccruedClinicalTrialExpense_1b3e305a-5752-4927-8947-0955d15e80d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet_aa0a88ec-2984-41b2-849c-1d6dcabac192" xlink:href="ino-20250331.xsd#ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_485571a1-1587-46e2-b696-0a225b393c8e" xlink:to="loc_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet_aa0a88ec-2984-41b2-849c-1d6dcabac192" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseinDeferredGrantFundingCurrent_5d530528-0cb1-448d-84d5-2e6fe6164d39" xlink:href="ino-20250331.xsd#ino_IncreaseDecreaseinDeferredGrantFundingCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_485571a1-1587-46e2-b696-0a225b393c8e" xlink:to="loc_ino_IncreaseDecreaseinDeferredGrantFundingCurrent_5d530528-0cb1-448d-84d5-2e6fe6164d39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c8a07906-b4ba-4002-bf9d-e7ad06d67ee5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_86c1df85-74e7-4cd9-ad87-68ed910fe740" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c8a07906-b4ba-4002-bf9d-e7ad06d67ee5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_e89011fe-aa7e-460e-985f-c2cd323a8dae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b145beeb-a8ef-4dde-bcb3-323b4b07635d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_e89011fe-aa7e-460e-985f-c2cd323a8dae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments_456e6fd1-e511-4f02-b1be-7da6e9352d11" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_e89011fe-aa7e-460e-985f-c2cd323a8dae" xlink:to="loc_us-gaap_PaymentsToAcquireShortTermInvestments_456e6fd1-e511-4f02-b1be-7da6e9352d11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_88c80f69-8c9a-41f0-af68-42ceb8b58fb3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_e89011fe-aa7e-460e-985f-c2cd323a8dae" xlink:to="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_88c80f69-8c9a-41f0-af68-42ceb8b58fb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_4a5f9610-6c78-40f1-8f51-3356b0a312db" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_e89011fe-aa7e-460e-985f-c2cd323a8dae" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_4a5f9610-6c78-40f1-8f51-3356b0a312db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f9286e8c-a7f9-47a6-9cda-ba523e54f323" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_e89011fe-aa7e-460e-985f-c2cd323a8dae" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f9286e8c-a7f9-47a6-9cda-ba523e54f323" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_79054005-e31c-4925-b96a-802d743cab24" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b145beeb-a8ef-4dde-bcb3-323b4b07635d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_79054005-e31c-4925-b96a-802d743cab24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfConvertibleDebt_f7e67a04-0c6d-4446-bcdc-fd97f352ef59" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfConvertibleDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_79054005-e31c-4925-b96a-802d743cab24" xlink:to="loc_us-gaap_RepaymentsOfConvertibleDebt_f7e67a04-0c6d-4446-bcdc-fd97f352ef59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_741e31d7-ef95-4058-92cc-7ae22f70c238" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_79054005-e31c-4925-b96a-802d743cab24" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_741e31d7-ef95-4058-92cc-7ae22f70c238" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ProceedsFromPaymentsForStockOptionsExercisedAndExerciseOfWarrantsNetOfTaxWithholdings_7e91ff79-f678-4017-8692-2b498111f58d" xlink:href="ino-20250331.xsd#ino_ProceedsFromPaymentsForStockOptionsExercisedAndExerciseOfWarrantsNetOfTaxWithholdings"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_79054005-e31c-4925-b96a-802d743cab24" xlink:to="loc_ino_ProceedsFromPaymentsForStockOptionsExercisedAndExerciseOfWarrantsNetOfTaxWithholdings_7e91ff79-f678-4017-8692-2b498111f58d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b7febf74-515b-4181-b180-6ce7e9ab3c36" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_79054005-e31c-4925-b96a-802d743cab24" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b7febf74-515b-4181-b180-6ce7e9ab3c36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6a56bf8a-1950-4355-a428-4041fc0d04cf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b145beeb-a8ef-4dde-bcb3-323b4b07635d" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6a56bf8a-1950-4355-a428-4041fc0d04cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_846e7ec8-a8d1-4026-bcf9-cfa66968b5eb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b145beeb-a8ef-4dde-bcb3-323b4b07635d" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_846e7ec8-a8d1-4026-bcf9-cfa66968b5eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8a839576-9fdc-467a-8201-f877e29f8695" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b145beeb-a8ef-4dde-bcb3-323b4b07635d" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8a839576-9fdc-467a-8201-f877e29f8695" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e7275843-dd44-4537-a1d7-dc57163a194d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b145beeb-a8ef-4dde-bcb3-323b4b07635d" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e7275843-dd44-4537-a1d7-dc57163a194d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_7f20243c-88c8-4827-8413-25079de66b05" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b145beeb-a8ef-4dde-bcb3-323b4b07635d" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_7f20243c-88c8-4827-8413-25079de66b05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_58349144-ba99-494f-856e-0672362d56de" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_7f20243c-88c8-4827-8413-25079de66b05" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_58349144-ba99-494f-856e-0672362d56de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_7a9932d9-b18a-4479-be2b-2a35b47e9c9a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_7f20243c-88c8-4827-8413-25079de66b05" xlink:to="loc_us-gaap_InterestPaidNet_7a9932d9-b18a-4479-be2b-2a35b47e9c9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/OrganizationandOperations" xlink:type="simple" xlink:href="ino-20250331.xsd#OrganizationandOperations"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/OrganizationandOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e2a65406-e1f5-4d50-998f-e7b7ecfb0009" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations_82be1247-d7eb-4345-a444-d6a0f5a03b51" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NatureOfOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e2a65406-e1f5-4d50-998f-e7b7ecfb0009" xlink:to="loc_us-gaap_NatureOfOperations_82be1247-d7eb-4345-a444-d6a0f5a03b51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertainties" xlink:type="simple" xlink:href="ino-20250331.xsd#BasisofPresentationLiquidityandRisksandUncertainties"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertainties" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_27db1f0f-3824-4626-af44-3c7fd1e2465b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_c39a413c-c2e1-4362-b2b0-421b4e7f9580" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_27db1f0f-3824-4626-af44-3c7fd1e2465b" xlink:to="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_c39a413c-c2e1-4362-b2b0-421b4e7f9580" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CriticalAccountingPolicies" xlink:type="simple" xlink:href="ino-20250331.xsd#CriticalAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CriticalAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_da684102-95fd-453b-b7da-1cbccba3ebed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_efa1e2a4-4bdf-46d3-a0fe-eec89bcc9829" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_da684102-95fd-453b-b7da-1cbccba3ebed" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_efa1e2a4-4bdf-46d3-a0fe-eec89bcc9829" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurements" xlink:type="simple" xlink:href="ino-20250331.xsd#ShorttermInvestmentsandFairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_f67ac24a-7402-4dca-b53c-79a1637e40d8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_5bf9f858-36f8-4464-a38d-101b6709ae3f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_f67ac24a-7402-4dca-b53c-79a1637e40d8" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_5bf9f858-36f8-4464-a38d-101b6709ae3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_3e767064-18cd-4fdb-9dac-67fdb4113c72" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_f67ac24a-7402-4dca-b53c-79a1637e40d8" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_3e767064-18cd-4fdb-9dac-67fdb4113c72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CertainBalanceSheetItems" xlink:type="simple" xlink:href="ino-20250331.xsd#CertainBalanceSheetItems"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CertainBalanceSheetItems" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ino_CertainBalanceSheetItemsAbstract_a34852b8-67f4-4d06-a03a-ec028f7cf683" xlink:href="ino-20250331.xsd#ino_CertainBalanceSheetItemsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsTextBlock_925a0945-4ece-45a8-ac46-bf9ad3512cb6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCurrentAssetsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_CertainBalanceSheetItemsAbstract_a34852b8-67f4-4d06-a03a-ec028f7cf683" xlink:to="loc_us-gaap_OtherCurrentAssetsTextBlock_925a0945-4ece-45a8-ac46-bf9ad3512cb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebt" xlink:type="simple" xlink:href="ino-20250331.xsd#ConvertibleDebt"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ConvertibleDebt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_48f369ca-f393-4b59-8ea2-f26a9a2a41a6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_17ec5471-5bf9-46cd-ab45-4b9ea4645049" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_48f369ca-f393-4b59-8ea2-f26a9a2a41a6" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_17ec5471-5bf9-46cd-ab45-4b9ea4645049" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquity" xlink:type="simple" xlink:href="ino-20250331.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_8fa6bd5a-f133-499d-aaf0-b9394565c287" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_cf696881-c03b-4513-bc27-9277e4f09abe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_8fa6bd5a-f133-499d-aaf0-b9394565c287" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_cf696881-c03b-4513-bc27-9277e4f09abe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/NetLossPerShare" xlink:type="simple" xlink:href="ino-20250331.xsd#NetLossPerShare"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/NetLossPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_13ef0ab8-9073-4329-bf9a-753e33140c99" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_bbe69cea-34cd-4d66-a6a0-a89b65157510" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_13ef0ab8-9073-4329-bf9a-753e33140c99" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_bbe69cea-34cd-4d66-a6a0-a89b65157510" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="ino-20250331.xsd#StockBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_af2a4ab8-f8c4-4a37-9253-ffa6c78ac435" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_6e4e9400-30e3-4649-b902-59a5641a3118" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_af2a4ab8-f8c4-4a37-9253-ffa6c78ac435" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_6e4e9400-30e3-4649-b902-59a5641a3118" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="ino-20250331.xsd#RelatedPartyTransactions"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/RelatedPartyTransactions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_6da8242a-46fe-44eb-8b44-24d5c49f21ca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_8542647c-4d17-4fc8-852c-a48b2d56c43d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_6da8242a-46fe-44eb-8b44-24d5c49f21ca" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_8542647c-4d17-4fc8-852c-a48b2d56c43d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="ino-20250331.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_7f87919b-ecc8-477c-b69b-1a7f3657e08e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_69959380-980b-449c-8685-975150fcc5fb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_7f87919b-ecc8-477c-b69b-1a7f3657e08e" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_69959380-980b-449c-8685-975150fcc5fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CollaborativeAgreements" xlink:type="simple" xlink:href="ino-20250331.xsd#CollaborativeAgreements"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CollaborativeAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8b1ac375-0c67-45d4-b74f-f58f22bce9c2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_c1b7c804-425e-4acf-b2aa-290a43c6b666" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8b1ac375-0c67-45d4-b74f-f58f22bce9c2" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_c1b7c804-425e-4acf-b2aa-290a43c6b666" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/IncomeTaxes" xlink:type="simple" xlink:href="ino-20250331.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_66eb0490-1ab6-494b-a7c3-4e6998a1ee56" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_e26ed706-bc08-41dd-98fe-80cbde41b146" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_66eb0490-1ab6-494b-a7c3-4e6998a1ee56" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_e26ed706-bc08-41dd-98fe-80cbde41b146" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GeneosTherapeuticsInc" xlink:type="simple" xlink:href="ino-20250331.xsd#GeneosTherapeuticsInc"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/GeneosTherapeuticsInc" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_c971a47c-e601-4d12-b72d-29a785c5523d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_8ff90eb6-298e-48dd-9835-40f71852dbbd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_c971a47c-e601-4d12-b72d-29a785c5523d" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_8ff90eb6-298e-48dd-9835-40f71852dbbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/SegmentInformation" xlink:type="simple" xlink:href="ino-20250331.xsd#SegmentInformation"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/SegmentInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_be5fd6b3-e935-46d2-bd55-92386c205dc4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_8cfe5e72-b085-4c32-a7c0-73246302ec48" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_be5fd6b3-e935-46d2-bd55-92386c205dc4" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_8cfe5e72-b085-4c32-a7c0-73246302ec48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesPolicies" xlink:type="simple" xlink:href="ino-20250331.xsd#BasisofPresentationLiquidityandRisksandUncertaintiesPolicies"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_39fce3ed-1552-4b60-8820-da486104cb1a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_3fc124ad-84f7-450a-8d70-048bb0e5e732" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_39fce3ed-1552-4b60-8820-da486104cb1a" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_3fc124ad-84f7-450a-8d70-048bb0e5e732" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementAccountingPolicy_9ddca88f-041e-4506-805e-261e3bbc8214" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementAccountingPolicy"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_39fce3ed-1552-4b60-8820-da486104cb1a" xlink:to="loc_us-gaap_CollaborativeArrangementAccountingPolicy_9ddca88f-041e-4506-805e-261e3bbc8214" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_2284f462-e411-4686-9cd4-0579935ce1f6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_39fce3ed-1552-4b60-8820-da486104cb1a" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_2284f462-e411-4686-9cd4-0579935ce1f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_afd254cd-ef36-4ae5-ac02-217369ff36e4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_39fce3ed-1552-4b60-8820-da486104cb1a" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_afd254cd-ef36-4ae5-ac02-217369ff36e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_faf47823-b4d7-481a-b224-ee5416ffa0e3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_39fce3ed-1552-4b60-8820-da486104cb1a" xlink:to="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_faf47823-b4d7-481a-b224-ee5416ffa0e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsTables" xlink:type="simple" xlink:href="ino-20250331.xsd#ShorttermInvestmentsandFairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_adc3748e-2815-48bc-bba0-76073f3782a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_c1cdea17-cca7-433a-abdb-8c3730a5cb55" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_adc3748e-2815-48bc-bba0-76073f3782a2" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_c1cdea17-cca7-433a-abdb-8c3730a5cb55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_0c8fe91e-d683-4034-9951-fea11bd3f30a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_adc3748e-2815-48bc-bba0-76073f3782a2" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_0c8fe91e-d683-4034-9951-fea11bd3f30a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_74211aa1-b263-4025-a81c-4c574816999a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_adc3748e-2815-48bc-bba0-76073f3782a2" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_74211aa1-b263-4025-a81c-4c574816999a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_18033363-5e81-4713-ba96-6fb8acf28309" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_adc3748e-2815-48bc-bba0-76073f3782a2" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_18033363-5e81-4713-ba96-6fb8acf28309" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CertainBalanceSheetItemsTables" xlink:type="simple" xlink:href="ino-20250331.xsd#CertainBalanceSheetItemsTables"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CertainBalanceSheetItemsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ino_CertainBalanceSheetItemsAbstract_1cbbcb12-50a5-4053-88b7-036bdf522347" xlink:href="ino-20250331.xsd#ino_CertainBalanceSheetItemsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_79372492-cfaa-4361-b468-c075399ccd62" xlink:href="ino-20250331.xsd#ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_CertainBalanceSheetItemsAbstract_1cbbcb12-50a5-4053-88b7-036bdf522347" xlink:to="loc_ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_79372492-cfaa-4361-b468-c075399ccd62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_37389a08-c586-4614-aa14-ebe871210c00" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_CertainBalanceSheetItemsAbstract_1cbbcb12-50a5-4053-88b7-036bdf522347" xlink:to="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_37389a08-c586-4614-aa14-ebe871210c00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="ino-20250331.xsd#StockholdersEquityTables"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/StockholdersEquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_f935d831-4518-4169-b13c-5d950d111787" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTextBlock_7257463d-d129-4515-a113-85376a4ef307" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_f935d831-4518-4169-b13c-5d950d111787" xlink:to="loc_us-gaap_ScheduleOfStockByClassTextBlock_7257463d-d129-4515-a113-85376a4ef307" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/NetLossPerShareTables" xlink:type="simple" xlink:href="ino-20250331.xsd#NetLossPerShareTables"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/NetLossPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_a816b555-41da-40e3-88f0-e2b1869168d9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock_caa13738-04b6-4bfc-be11-1e6259fc73b7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_a816b555-41da-40e3-88f0-e2b1869168d9" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock_caa13738-04b6-4bfc-be11-1e6259fc73b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_70bc3685-70c6-401b-a027-2d58dd4919f6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_a816b555-41da-40e3-88f0-e2b1869168d9" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_70bc3685-70c6-401b-a027-2d58dd4919f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="ino-20250331.xsd#StockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ee70741b-3ae3-45b5-a335-082361516804" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_c953297e-8d79-46ab-9fa3-0b9d8f38638b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ee70741b-3ae3-45b5-a335-082361516804" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_c953297e-8d79-46ab-9fa3-0b9d8f38638b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock_05938490-8129-47b8-bdea-6b71bbaa51eb" xlink:href="ino-20250331.xsd#ino_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ee70741b-3ae3-45b5-a335-082361516804" xlink:to="loc_ino_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock_05938490-8129-47b8-bdea-6b71bbaa51eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CommitmentsandContingenciesTables" xlink:type="simple" xlink:href="ino-20250331.xsd#CommitmentsandContingenciesTables"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CommitmentsandContingenciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_a75038ee-b9b2-4ce7-9c71-6ade66110083" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_ffd297b2-e1a7-4316-957a-192a48398890" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_a75038ee-b9b2-4ce7-9c71-6ade66110083" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_ffd297b2-e1a7-4316-957a-192a48398890" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/SegmentInformationTables" xlink:type="simple" xlink:href="ino-20250331.xsd#SegmentInformationTables"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/SegmentInformationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_eab74c23-cbba-4965-9809-637b7442cc55" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_db790acb-a317-4746-9b9b-56d8a5cd5e10" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_eab74c23-cbba-4965-9809-637b7442cc55" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_db790acb-a317-4746-9b9b-56d8a5cd5e10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails" xlink:type="simple" xlink:href="ino-20250331.xsd#BasisofPresentationLiquidityandRisksandUncertaintiesDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_a52d08bb-6c43-4575-8b48-8be018c9fb22" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_5bfcd8ac-dc6b-4f7f-9e83-5f6f4fb5e260" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a52d08bb-6c43-4575-8b48-8be018c9fb22" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_5bfcd8ac-dc6b-4f7f-9e83-5f6f4fb5e260" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_2891ee38-eea4-4dab-8e65-ab4d268c8711" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_5bfcd8ac-dc6b-4f7f-9e83-5f6f4fb5e260" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_2891ee38-eea4-4dab-8e65-ab4d268c8711" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_35f1215c-1b92-4b20-a39c-70ada4e34889" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_2891ee38-eea4-4dab-8e65-ab4d268c8711" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_35f1215c-1b92-4b20-a39c-70ada4e34889" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_December2024OfferingWarrantsMember_3aa4117b-8ff1-4d4c-9413-68a6189bff4e" xlink:href="ino-20250331.xsd#ino_December2024OfferingWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_35f1215c-1b92-4b20-a39c-70ada4e34889" xlink:to="loc_ino_December2024OfferingWarrantsMember_3aa4117b-8ff1-4d4c-9413-68a6189bff4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_38ecb030-dc7c-4fe3-9f3f-5fc2f193de5c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_5bfcd8ac-dc6b-4f7f-9e83-5f6f4fb5e260" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_38ecb030-dc7c-4fe3-9f3f-5fc2f193de5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_3dae38bb-0a1b-425d-ab91-1aeea161b3e5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_38ecb030-dc7c-4fe3-9f3f-5fc2f193de5c" xlink:to="loc_us-gaap_EquityComponentDomain_3dae38bb-0a1b-425d-ab91-1aeea161b3e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_45e7efb9-70ed-41db-ae57-aa01cb0fabbc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3dae38bb-0a1b-425d-ab91-1aeea161b3e5" xlink:to="loc_us-gaap_CommonStockMember_45e7efb9-70ed-41db-ae57-aa01cb0fabbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_35349f01-ceda-425a-899c-f72e42c5e721" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3dae38bb-0a1b-425d-ab91-1aeea161b3e5" xlink:to="loc_us-gaap_WarrantMember_35349f01-ceda-425a-899c-f72e42c5e721" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_183747f2-60b4-41c8-a2ff-e68fb09ee918" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_5bfcd8ac-dc6b-4f7f-9e83-5f6f4fb5e260" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_183747f2-60b4-41c8-a2ff-e68fb09ee918" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e175e6bf-b9f7-4fda-8f26-32202551270f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_183747f2-60b4-41c8-a2ff-e68fb09ee918" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e175e6bf-b9f7-4fda-8f26-32202551270f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_UnderwrittenRegisteredDirectOfferingMember_bec3136c-fce3-4887-b3be-ab24892caf16" xlink:href="ino-20250331.xsd#ino_UnderwrittenRegisteredDirectOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e175e6bf-b9f7-4fda-8f26-32202551270f" xlink:to="loc_ino_UnderwrittenRegisteredDirectOfferingMember_bec3136c-fce3-4887-b3be-ab24892caf16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A2024SalesAgreementMember_02f94783-478f-480c-bc02-3a6323c7c329" xlink:href="ino-20250331.xsd#ino_A2024SalesAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e175e6bf-b9f7-4fda-8f26-32202551270f" xlink:to="loc_ino_A2024SalesAgreementMember_02f94783-478f-480c-bc02-3a6323c7c329" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_December2024OfferingMember_23a06167-2950-45ae-81bf-fcc5b692d380" xlink:href="ino-20250331.xsd#ino_December2024OfferingMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e175e6bf-b9f7-4fda-8f26-32202551270f" xlink:to="loc_ino_December2024OfferingMember_23a06167-2950-45ae-81bf-fcc5b692d380" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_9386c1f6-1cc6-4cd8-a3c9-a26366a2ee46" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_5bfcd8ac-dc6b-4f7f-9e83-5f6f4fb5e260" xlink:to="loc_us-gaap_StatementClassOfStockAxis_9386c1f6-1cc6-4cd8-a3c9-a26366a2ee46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_adcab22c-d674-4d96-b803-53a7937b5a56" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_9386c1f6-1cc6-4cd8-a3c9-a26366a2ee46" xlink:to="loc_us-gaap_ClassOfStockDomain_adcab22c-d674-4d96-b803-53a7937b5a56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_b83c8cac-baf2-44cb-9264-03c2c4f07d89" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_adcab22c-d674-4d96-b803-53a7937b5a56" xlink:to="loc_us-gaap_CommonStockMember_b83c8cac-baf2-44cb-9264-03c2c4f07d89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_a9b83778-f722-4353-88a6-e8205c95d56d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_5bfcd8ac-dc6b-4f7f-9e83-5f6f4fb5e260" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_a9b83778-f722-4353-88a6-e8205c95d56d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_846ed9c9-b6aa-4e53-b1e1-02aeaaf9eb67" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_a9b83778-f722-4353-88a6-e8205c95d56d" xlink:to="loc_us-gaap_NetIncomeLoss_846ed9c9-b6aa-4e53-b1e1-02aeaaf9eb67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_WorkingCapital_de70be5b-af3e-41f9-9355-ed59073fae97" xlink:href="ino-20250331.xsd#ino_WorkingCapital"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_a9b83778-f722-4353-88a6-e8205c95d56d" xlink:to="loc_ino_WorkingCapital_de70be5b-af3e-41f9-9355-ed59073fae97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_4d01abd4-8053-4938-ba94-687e34dd9631" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_a9b83778-f722-4353-88a6-e8205c95d56d" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_4d01abd4-8053-4938-ba94-687e34dd9631" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_96e4732a-a76e-4998-901b-d7956328c1a6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_a9b83778-f722-4353-88a6-e8205c95d56d" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_96e4732a-a76e-4998-901b-d7956328c1a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_9439d9e3-3d1c-4722-9ebb-ef95cb5d6f63" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_a9b83778-f722-4353-88a6-e8205c95d56d" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_9439d9e3-3d1c-4722-9ebb-ef95cb5d6f63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_4b273b1a-d07e-4bc0-bd35-6ac8714f54cf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_a9b83778-f722-4353-88a6-e8205c95d56d" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_4b273b1a-d07e-4bc0-bd35-6ac8714f54cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_6542fab1-0696-474f-a554-bc0eebe69681" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_a9b83778-f722-4353-88a6-e8205c95d56d" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_6542fab1-0696-474f-a554-bc0eebe69681" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_9bcd8269-bf73-4e93-bed6-59cd98b16052" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_a9b83778-f722-4353-88a6-e8205c95d56d" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_9bcd8269-bf73-4e93-bed6-59cd98b16052" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_5a8ac926-aa40-4b9c-b8e5-05c80fa621be" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_a9b83778-f722-4353-88a6-e8205c95d56d" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_5a8ac926-aa40-4b9c-b8e5-05c80fa621be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_7686d792-4103-42c0-ab8b-4b1a0103759f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_a9b83778-f722-4353-88a6-e8205c95d56d" xlink:to="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_7686d792-4103-42c0-ab8b-4b1a0103759f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_b3f20038-724a-4797-8818-f4d1fb238d2d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_a9b83778-f722-4353-88a6-e8205c95d56d" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_b3f20038-724a-4797-8818-f4d1fb238d2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_373eb15e-0c2b-4ffa-9ece-01318e70b3c3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_a9b83778-f722-4353-88a6-e8205c95d56d" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_373eb15e-0c2b-4ffa-9ece-01318e70b3c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails" xlink:type="simple" xlink:href="ino-20250331.xsd#ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_5cee46fe-fd3d-4fff-9df2-4a8c09562ee9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_9bea7d72-020c-4967-bfbf-aadafef6785e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_5cee46fe-fd3d-4fff-9df2-4a8c09562ee9" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_9bea7d72-020c-4967-bfbf-aadafef6785e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_97e40c67-682c-4728-b20e-63852b147707" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_9bea7d72-020c-4967-bfbf-aadafef6785e" xlink:to="loc_us-gaap_FinancialInstrumentAxis_97e40c67-682c-4728-b20e-63852b147707" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fbce33b4-c062-49ee-a350-1f8b66ad17e6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_97e40c67-682c-4728-b20e-63852b147707" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fbce33b4-c062-49ee-a350-1f8b66ad17e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_MutualFundsMember_88c4a43d-96a0-4723-9020-4e4fb7ad6cd6" xlink:href="ino-20250331.xsd#ino_MutualFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fbce33b4-c062-49ee-a350-1f8b66ad17e6" xlink:to="loc_ino_MutualFundsMember_88c4a43d-96a0-4723-9020-4e4fb7ad6cd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_b0e4373d-9b06-40d2-9886-61c82d29acb0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fbce33b4-c062-49ee-a350-1f8b66ad17e6" xlink:to="loc_us-gaap_CertificatesOfDepositMember_b0e4373d-9b06-40d2-9886-61c82d29acb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember_a271e815-c333-411c-989d-d47e021b63d2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fbce33b4-c062-49ee-a350-1f8b66ad17e6" xlink:to="loc_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember_a271e815-c333-411c-989d-d47e021b63d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_891eae1d-898c-4863-99b4-8063d6489133" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_9bea7d72-020c-4967-bfbf-aadafef6785e" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_891eae1d-898c-4863-99b4-8063d6489133" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DebtSecuritiesAvailableforSaleContractualMaturity_b9e855e6-884c-44ec-a5dd-e6919e02f437" xlink:href="ino-20250331.xsd#ino_DebtSecuritiesAvailableforSaleContractualMaturity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_891eae1d-898c-4863-99b4-8063d6489133" xlink:to="loc_ino_DebtSecuritiesAvailableforSaleContractualMaturity_b9e855e6-884c-44ec-a5dd-e6919e02f437" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_f2c436c4-b605-402d-ad07-51c29161e833" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_891eae1d-898c-4863-99b4-8063d6489133" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAbstract_f2c436c4-b605-402d-ad07-51c29161e833" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_e2e210f9-279d-4848-9865-4019fd96cb97" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_f2c436c4-b605-402d-ad07-51c29161e833" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_e2e210f9-279d-4848-9865-4019fd96cb97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_31f550ae-e389-40be-a5e0-e61c67257985" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_f2c436c4-b605-402d-ad07-51c29161e833" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_31f550ae-e389-40be-a5e0-e61c67257985" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_155dc9eb-2969-47b8-8f8e-db5e53d992ac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_f2c436c4-b605-402d-ad07-51c29161e833" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_155dc9eb-2969-47b8-8f8e-db5e53d992ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1fc5a55a-26f3-46cd-b5a9-3551a166cd48" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_f2c436c4-b605-402d-ad07-51c29161e833" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1fc5a55a-26f3-46cd-b5a9-3551a166cd48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="ino-20250331.xsd#ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_6563a892-8c30-4d52-8969-61c52f0eba03" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_f040e04a-928a-430b-b253-feb9df242aad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_6563a892-8c30-4d52-8969-61c52f0eba03" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_f040e04a-928a-430b-b253-feb9df242aad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1e832798-378b-4800-bb4a-f40f9479a814" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_f040e04a-928a-430b-b253-feb9df242aad" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1e832798-378b-4800-bb4a-f40f9479a814" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_23cb5cd6-8854-4c59-a511-849a4726355b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1e832798-378b-4800-bb4a-f40f9479a814" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_23cb5cd6-8854-4c59-a511-849a4726355b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_db7c2da9-3c5b-4b15-a1b7-6a2422db5b6d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_23cb5cd6-8854-4c59-a511-849a4726355b" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_db7c2da9-3c5b-4b15-a1b7-6a2422db5b6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_545353ef-5028-49bb-988f-c04043f65106" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_f040e04a-928a-430b-b253-feb9df242aad" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_545353ef-5028-49bb-988f-c04043f65106" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_2995b0c6-29ff-44be-bb97-2056f6bcde95" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_545353ef-5028-49bb-988f-c04043f65106" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_2995b0c6-29ff-44be-bb97-2056f6bcde95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_7bcdb28b-0bad-4558-806c-3257d275c21c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_545353ef-5028-49bb-988f-c04043f65106" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_7bcdb28b-0bad-4558-806c-3257d275c21c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_855cf18d-eadd-48a3-a127-4d4406b20633" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_545353ef-5028-49bb-988f-c04043f65106" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_855cf18d-eadd-48a3-a127-4d4406b20633" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_3e22e36e-9fc7-4a02-a209-f538f0fcbc06" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_545353ef-5028-49bb-988f-c04043f65106" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_3e22e36e-9fc7-4a02-a209-f538f0fcbc06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_57bbd7ce-8960-4d38-bfc9-66d57b984bc6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_545353ef-5028-49bb-988f-c04043f65106" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_57bbd7ce-8960-4d38-bfc9-66d57b984bc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares_47ca6e8e-a012-4696-a330-193699739bb2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_545353ef-5028-49bb-988f-c04043f65106" xlink:to="loc_us-gaap_InvestmentOwnedBalanceShares_47ca6e8e-a012-4696-a330-193699739bb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_a61adca4-9d34-4207-ada0-b03d04577675" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_545353ef-5028-49bb-988f-c04043f65106" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_a61adca4-9d34-4207-ada0-b03d04577675" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="ino-20250331.xsd#ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_25494f14-4647-4d91-bc42-9a727a7973f2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_df2ed5d1-b78d-4e61-af46-3ce99930c0ae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_25494f14-4647-4d91-bc42-9a727a7973f2" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_df2ed5d1-b78d-4e61-af46-3ce99930c0ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c9b8aa16-7523-4ad6-b97b-960a445d94fe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_df2ed5d1-b78d-4e61-af46-3ce99930c0ae" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c9b8aa16-7523-4ad6-b97b-960a445d94fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_003971d2-b231-4ad1-9d76-d842d53f6f7e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c9b8aa16-7523-4ad6-b97b-960a445d94fe" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_003971d2-b231-4ad1-9d76-d842d53f6f7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_07085da1-cd5b-4691-b639-9b5ed0163114" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_003971d2-b231-4ad1-9d76-d842d53f6f7e" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_07085da1-cd5b-4691-b639-9b5ed0163114" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_23df905b-2a5b-46d7-b234-137d8b8f7f9a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_df2ed5d1-b78d-4e61-af46-3ce99930c0ae" xlink:to="loc_us-gaap_FinancialInstrumentAxis_23df905b-2a5b-46d7-b234-137d8b8f7f9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a1dd48a0-3d22-497e-a681-59e94f166a13" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_23df905b-2a5b-46d7-b234-137d8b8f7f9a" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a1dd48a0-3d22-497e-a681-59e94f166a13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_MutualFundsMember_a06a77a0-6966-43d8-a7f1-8cfcd54d9491" xlink:href="ino-20250331.xsd#ino_MutualFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a1dd48a0-3d22-497e-a681-59e94f166a13" xlink:to="loc_ino_MutualFundsMember_a06a77a0-6966-43d8-a7f1-8cfcd54d9491" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_29c4a84d-e075-49b2-a64e-d9304b0a67ac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a1dd48a0-3d22-497e-a681-59e94f166a13" xlink:to="loc_us-gaap_CertificatesOfDepositMember_29c4a84d-e075-49b2-a64e-d9304b0a67ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember_aa9edd97-9588-46dd-9fd1-ba24c3fab092" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a1dd48a0-3d22-497e-a681-59e94f166a13" xlink:to="loc_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember_aa9edd97-9588-46dd-9fd1-ba24c3fab092" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_843004e0-e85e-4c62-afc5-7e7a9eb95b3a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_df2ed5d1-b78d-4e61-af46-3ce99930c0ae" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_843004e0-e85e-4c62-afc5-7e7a9eb95b3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_16879f5f-4875-4e69-976e-71cf8147d590" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_843004e0-e85e-4c62-afc5-7e7a9eb95b3a" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_16879f5f-4875-4e69-976e-71cf8147d590" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_334610ee-8143-4e02-85de-91f0da1d4f8c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_16879f5f-4875-4e69-976e-71cf8147d590" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_334610ee-8143-4e02-85de-91f0da1d4f8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_30e496a7-11e4-4241-9a43-7c7e22ba24a6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_16879f5f-4875-4e69-976e-71cf8147d590" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_30e496a7-11e4-4241-9a43-7c7e22ba24a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_72945aaa-8e76-481a-a9c5-c0c6ea48568e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_16879f5f-4875-4e69-976e-71cf8147d590" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_72945aaa-8e76-481a-a9c5-c0c6ea48568e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_cba24271-1319-4a75-ba2a-f37f230bbe75" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_df2ed5d1-b78d-4e61-af46-3ce99930c0ae" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_cba24271-1319-4a75-ba2a-f37f230bbe75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_a06d81f2-f6fd-4c66-95ec-8c0663d71b62" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_cba24271-1319-4a75-ba2a-f37f230bbe75" xlink:to="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_a06d81f2-f6fd-4c66-95ec-8c0663d71b62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_10698cd8-9f7b-47c0-916d-213458a4b1a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_a06d81f2-f6fd-4c66-95ec-8c0663d71b62" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_10698cd8-9f7b-47c0-916d-213458a4b1a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7ece372b-64a9-4a18-b137-e8cd956f84dc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_10698cd8-9f7b-47c0-916d-213458a4b1a2" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7ece372b-64a9-4a18-b137-e8cd956f84dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_dac6fb87-f8d2-49ad-8cf4-0aa880c6760d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_10698cd8-9f7b-47c0-916d-213458a4b1a2" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_dac6fb87-f8d2-49ad-8cf4-0aa880c6760d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_b2721c04-1873-47e7-b04f-8f944717322d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_10698cd8-9f7b-47c0-916d-213458a4b1a2" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_b2721c04-1873-47e7-b04f-8f944717322d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_9a9c01d2-9cd5-4367-8d1e-9791d861b41a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_cba24271-1319-4a75-ba2a-f37f230bbe75" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_9a9c01d2-9cd5-4367-8d1e-9791d861b41a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CommonStockWarrantLiabilityFairValue_2985a961-a0a1-45c9-8ca2-067a3b42d71a" xlink:href="ino-20250331.xsd#ino_CommonStockWarrantLiabilityFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_9a9c01d2-9cd5-4367-8d1e-9791d861b41a" xlink:to="loc_ino_CommonStockWarrantLiabilityFairValue_2985a961-a0a1-45c9-8ca2-067a3b42d71a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_9bf629be-4167-427d-abdd-07f174d50ba9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_9a9c01d2-9cd5-4367-8d1e-9791d861b41a" xlink:to="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_9bf629be-4167-427d-abdd-07f174d50ba9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAssumptionsUsedToEstimateTheFairValueOfWarrantsDetails" xlink:type="simple" xlink:href="ino-20250331.xsd#ShorttermInvestmentsandFairValueMeasurementsScheduleofAssumptionsUsedToEstimateTheFairValueOfWarrantsDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAssumptionsUsedToEstimateTheFairValueOfWarrantsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_d8d704d9-8c2e-496f-956f-6acc79060826" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_305dbd2a-bf14-460c-8b81-5fc2ecc0a570" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_d8d704d9-8c2e-496f-956f-6acc79060826" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_305dbd2a-bf14-460c-8b81-5fc2ecc0a570" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_1cce8365-1b98-4e06-bd70-a40ad798a111" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_305dbd2a-bf14-460c-8b81-5fc2ecc0a570" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_1cce8365-1b98-4e06-bd70-a40ad798a111" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_b02e5751-6117-4dd3-a7b0-36abbb5cde81" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_1cce8365-1b98-4e06-bd70-a40ad798a111" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_b02e5751-6117-4dd3-a7b0-36abbb5cde81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_8814a843-6da2-4699-aacb-2c4e70bc85cb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_b02e5751-6117-4dd3-a7b0-36abbb5cde81" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_8814a843-6da2-4699-aacb-2c4e70bc85cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_8a9ad3ce-dc34-45b8-b292-2a6152f24c5e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_b02e5751-6117-4dd3-a7b0-36abbb5cde81" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_8a9ad3ce-dc34-45b8-b292-2a6152f24c5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_41b84491-cbf6-4fbf-97ca-a45324c00271" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_b02e5751-6117-4dd3-a7b0-36abbb5cde81" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_41b84491-cbf6-4fbf-97ca-a45324c00271" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_44e630ad-1f29-43d2-b795-7174865ca53c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_b02e5751-6117-4dd3-a7b0-36abbb5cde81" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_44e630ad-1f29-43d2-b795-7174865ca53c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b23c905d-d26a-4d05-83d2-9cdc873966d9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_305dbd2a-bf14-460c-8b81-5fc2ecc0a570" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b23c905d-d26a-4d05-83d2-9cdc873966d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_WarrantLiabilityMeasurementInput_c078221b-dd01-4b97-9f14-981a87807099" xlink:href="ino-20250331.xsd#ino_WarrantLiabilityMeasurementInput"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b23c905d-d26a-4d05-83d2-9cdc873966d9" xlink:to="loc_ino_WarrantLiabilityMeasurementInput_c078221b-dd01-4b97-9f14-981a87807099" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsChangesInFairValueOfTheCompanysTotalLevel3FinancialLiabilitiesDetails" xlink:type="simple" xlink:href="ino-20250331.xsd#ShorttermInvestmentsandFairValueMeasurementsChangesInFairValueOfTheCompanysTotalLevel3FinancialLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsChangesInFairValueOfTheCompanysTotalLevel3FinancialLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_ffb0cc9d-48d7-4511-a5d1-5f5ca60c20a6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList_8c79757e-713b-4ae5-9f4a-34b12626fc55" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_ffb0cc9d-48d7-4511-a5d1-5f5ca60c20a6" xlink:to="loc_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList_8c79757e-713b-4ae5-9f4a-34b12626fc55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_0e7dd0e4-bf69-4edb-bed4-b8a5ee52f6e3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_ffb0cc9d-48d7-4511-a5d1-5f5ca60c20a6" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_0e7dd0e4-bf69-4edb-bed4-b8a5ee52f6e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_c2eec885-45bd-4f04-803e-2581f622f5d4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_0e7dd0e4-bf69-4edb-bed4-b8a5ee52f6e3" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_c2eec885-45bd-4f04-803e-2581f622f5d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_00a42431-a636-4b06-9514-d4cba23bd8cc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_0e7dd0e4-bf69-4edb-bed4-b8a5ee52f6e3" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_00a42431-a636-4b06-9514-d4cba23bd8cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_b1079f52-8eb9-4365-af03-e516d06b1317" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_0e7dd0e4-bf69-4edb-bed4-b8a5ee52f6e3" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_b1079f52-8eb9-4365-af03-e516d06b1317" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CertainBalanceSheetItemsPrepaidandOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="ino-20250331.xsd#CertainBalanceSheetItemsPrepaidandOtherCurrentAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CertainBalanceSheetItemsPrepaidandOtherCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ino_CertainBalanceSheetItemsAbstract_3ab21868-30b4-41b2-aa28-5e89950ca665" xlink:href="ino-20250331.xsd#ino_CertainBalanceSheetItemsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PrepaidClinicalExpensesCurrent_030c416e-9729-4057-8bd6-c03531723582" xlink:href="ino-20250331.xsd#ino_PrepaidClinicalExpensesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_CertainBalanceSheetItemsAbstract_3ab21868-30b4-41b2-aa28-5e89950ca665" xlink:to="loc_ino_PrepaidClinicalExpensesCurrent_030c416e-9729-4057-8bd6-c03531723582" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_b665bfb7-25ba-4202-a3aa-97a7fc8bf834" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_CertainBalanceSheetItemsAbstract_3ab21868-30b4-41b2-aa28-5e89950ca665" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_b665bfb7-25ba-4202-a3aa-97a7fc8bf834" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_cd893997-b687-4113-91ef-9d9adfe24f3b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_CertainBalanceSheetItemsAbstract_3ab21868-30b4-41b2-aa28-5e89950ca665" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_cd893997-b687-4113-91ef-9d9adfe24f3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CertainBalanceSheetItemsAccountsPayableandAccruedExpensesDetails" xlink:type="simple" xlink:href="ino-20250331.xsd#CertainBalanceSheetItemsAccountsPayableandAccruedExpensesDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CertainBalanceSheetItemsAccountsPayableandAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ino_CertainBalanceSheetItemsAbstract_3fa9e9fd-0fd9-43da-b647-26b97cf7779b" xlink:href="ino-20250331.xsd#ino_CertainBalanceSheetItemsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AccountsPayableAndAccruedExpensesTable_695fb5e6-146d-43d2-85a4-e06c9f2323c2" xlink:href="ino-20250331.xsd#ino_AccountsPayableAndAccruedExpensesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_CertainBalanceSheetItemsAbstract_3fa9e9fd-0fd9-43da-b647-26b97cf7779b" xlink:to="loc_ino_AccountsPayableAndAccruedExpensesTable_695fb5e6-146d-43d2-85a4-e06c9f2323c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5c9a0e23-5c56-4b9a-be49-23f6b7919751" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_AccountsPayableAndAccruedExpensesTable_695fb5e6-146d-43d2-85a4-e06c9f2323c2" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5c9a0e23-5c56-4b9a-be49-23f6b7919751" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_b0dec921-e94b-4926-a74a-6b79ad658032" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5c9a0e23-5c56-4b9a-be49-23f6b7919751" xlink:to="loc_us-gaap_RelatedPartyDomain_b0dec921-e94b-4926-a74a-6b79ad658032" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrelatedPartyMember_38386e21-d171-47e0-8add-83cd725061b3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonrelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_b0dec921-e94b-4926-a74a-6b79ad658032" xlink:to="loc_us-gaap_NonrelatedPartyMember_38386e21-d171-47e0-8add-83cd725061b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AccountsPayableAndAccruedExpensesLineItems_e956f3a0-4ef6-4a26-80c9-298c9a1fa55f" xlink:href="ino-20250331.xsd#ino_AccountsPayableAndAccruedExpensesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_AccountsPayableAndAccruedExpensesTable_695fb5e6-146d-43d2-85a4-e06c9f2323c2" xlink:to="loc_ino_AccountsPayableAndAccruedExpensesLineItems_e956f3a0-4ef6-4a26-80c9-298c9a1fa55f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableTradeCurrentAndNoncurrent_d7c0a30e-5da3-4ad0-a533-3de262083e47" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableTradeCurrentAndNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_AccountsPayableAndAccruedExpensesLineItems_e956f3a0-4ef6-4a26-80c9-298c9a1fa55f" xlink:to="loc_us-gaap_AccountsPayableTradeCurrentAndNoncurrent_d7c0a30e-5da3-4ad0-a533-3de262083e47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalariesCurrent_14ee04bc-6624-4aef-9715-7d6a573a0964" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedSalariesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_AccountsPayableAndAccruedExpensesLineItems_e956f3a0-4ef6-4a26-80c9-298c9a1fa55f" xlink:to="loc_us-gaap_AccruedSalariesCurrent_14ee04bc-6624-4aef-9715-7d6a573a0964" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_54096148-8f2a-4a66-8529-32f1a0df31dd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_AccountsPayableAndAccruedExpensesLineItems_e956f3a0-4ef6-4a26-80c9-298c9a1fa55f" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_54096148-8f2a-4a66-8529-32f1a0df31dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_703b4ab5-0d10-4ded-bbb3-9e74033b092b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_AccountsPayableAndAccruedExpensesLineItems_e956f3a0-4ef6-4a26-80c9-298c9a1fa55f" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_703b4ab5-0d10-4ded-bbb3-9e74033b092b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebtDetails" xlink:type="simple" xlink:href="ino-20250331.xsd#ConvertibleDebtDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ConvertibleDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_f175bd0b-853f-433b-8086-b37935bd7c69" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_9df3d186-dc56-488a-8c16-2b568deed61d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_f175bd0b-853f-433b-8086-b37935bd7c69" xlink:to="loc_us-gaap_DebtInstrumentTable_9df3d186-dc56-488a-8c16-2b568deed61d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_d130540e-202e-4818-be8a-9c4d3ab32c63" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_9df3d186-dc56-488a-8c16-2b568deed61d" xlink:to="loc_us-gaap_DebtInstrumentAxis_d130540e-202e-4818-be8a-9c4d3ab32c63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_44fb9b70-c909-4b65-8c19-cbf2ecf2dc4d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_d130540e-202e-4818-be8a-9c4d3ab32c63" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_44fb9b70-c909-4b65-8c19-cbf2ecf2dc4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_1cc7d7a9-d21b-4ef1-8974-912ddb649251" xlink:href="ino-20250331.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_44fb9b70-c909-4b65-8c19-cbf2ecf2dc4d" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_1cc7d7a9-d21b-4ef1-8974-912ddb649251" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_11254860-d58a-49b1-9d57-cdae1d610ad3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_9df3d186-dc56-488a-8c16-2b568deed61d" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_11254860-d58a-49b1-9d57-cdae1d610ad3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_c6d7055d-beec-4269-8837-3be9848124d2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_11254860-d58a-49b1-9d57-cdae1d610ad3" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_c6d7055d-beec-4269-8837-3be9848124d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_70bd216f-7ab5-4ec6-a647-1f7106530f6f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_c6d7055d-beec-4269-8837-3be9848124d2" xlink:to="loc_us-gaap_ConvertibleDebtMember_70bd216f-7ab5-4ec6-a647-1f7106530f6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_577ebeed-8cce-40a5-a9fe-7c9dcb73b46f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_9df3d186-dc56-488a-8c16-2b568deed61d" xlink:to="loc_us-gaap_DebtInstrumentLineItems_577ebeed-8cce-40a5-a9fe-7c9dcb73b46f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_1184f6cd-42f8-4072-afdf-320d50b78475" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_577ebeed-8cce-40a5-a9fe-7c9dcb73b46f" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_1184f6cd-42f8-4072-afdf-320d50b78475" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_ae999a00-60ae-4eba-afbc-ec8f061ab546" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_577ebeed-8cce-40a5-a9fe-7c9dcb73b46f" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_ae999a00-60ae-4eba-afbc-ec8f061ab546" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_fcd9f840-6869-4e1c-96ac-3c2f5c0190bf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_577ebeed-8cce-40a5-a9fe-7c9dcb73b46f" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_fcd9f840-6869-4e1c-96ac-3c2f5c0190bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfConvertibleDebt_2934589b-08de-47f0-8fcd-3aa063fdca2c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfConvertibleDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_577ebeed-8cce-40a5-a9fe-7c9dcb73b46f" xlink:to="loc_us-gaap_RepaymentsOfConvertibleDebt_2934589b-08de-47f0-8fcd-3aa063fdca2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseOperating_1b27debd-5d41-44eb-b449-ac23b95bc4ce" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseOperating"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_577ebeed-8cce-40a5-a9fe-7c9dcb73b46f" xlink:to="loc_us-gaap_InterestExpenseOperating_1b27debd-5d41-44eb-b449-ac23b95bc4ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails" xlink:type="simple" xlink:href="ino-20250331.xsd#StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_aec0fddf-679b-4ae9-bf0e-17be282d7696" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_f882d44e-f3cf-44e6-9fe5-9f8c1c43a427" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_aec0fddf-679b-4ae9-bf0e-17be282d7696" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_f882d44e-f3cf-44e6-9fe5-9f8c1c43a427" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_44358882-412b-4220-90dd-b71cb5179968" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_f882d44e-f3cf-44e6-9fe5-9f8c1c43a427" xlink:to="loc_us-gaap_StatementClassOfStockAxis_44358882-412b-4220-90dd-b71cb5179968" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_003680df-d774-421c-ae13-324330d67a46" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_44358882-412b-4220-90dd-b71cb5179968" xlink:to="loc_us-gaap_ClassOfStockDomain_003680df-d774-421c-ae13-324330d67a46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_f8836969-0dcf-4725-b882-727e7dc1ac9f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesCPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_003680df-d774-421c-ae13-324330d67a46" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_f8836969-0dcf-4725-b882-727e7dc1ac9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_6c398d53-8140-4f85-925a-afb7769e39c7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_f882d44e-f3cf-44e6-9fe5-9f8c1c43a427" xlink:to="loc_us-gaap_ClassOfStockLineItems_6c398d53-8140-4f85-925a-afb7769e39c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_3a1722bd-2094-459b-8657-eda2b9beafe1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6c398d53-8140-4f85-925a-afb7769e39c7" xlink:to="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_3a1722bd-2094-459b-8657-eda2b9beafe1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_9fb00077-d800-4ae5-b1e7-e12a67947347" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_3a1722bd-2094-459b-8657-eda2b9beafe1" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_9fb00077-d800-4ae5-b1e7-e12a67947347" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_7f09780f-0162-4abd-9860-2c1145797b11" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_3a1722bd-2094-459b-8657-eda2b9beafe1" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_7f09780f-0162-4abd-9860-2c1145797b11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_00235c61-58a9-4ef6-b7d8-565e101f7329" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_3a1722bd-2094-459b-8657-eda2b9beafe1" xlink:to="loc_us-gaap_CommonStockSharesIssued_00235c61-58a9-4ef6-b7d8-565e101f7329" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_6e59a8de-abe2-4e93-b359-7aad8a4bcf49" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_3a1722bd-2094-459b-8657-eda2b9beafe1" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_6e59a8de-abe2-4e93-b359-7aad8a4bcf49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_05777d18-9b51-4848-b480-882e2629168b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_3a1722bd-2094-459b-8657-eda2b9beafe1" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_05777d18-9b51-4848-b480-882e2629168b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_d785a648-24ee-4271-97d3-2fda9b9a1e81" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_3a1722bd-2094-459b-8657-eda2b9beafe1" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_d785a648-24ee-4271-97d3-2fda9b9a1e81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_c0f5c3f0-bdce-441f-8a6f-02928d06e08d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_3a1722bd-2094-459b-8657-eda2b9beafe1" xlink:to="loc_us-gaap_PreferredStockSharesIssued_c0f5c3f0-bdce-441f-8a6f-02928d06e08d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_decea834-f2bd-4372-b297-e4c0c647caa7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_3a1722bd-2094-459b-8657-eda2b9beafe1" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_decea834-f2bd-4372-b297-e4c0c647caa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquityOfferingofCommonStockWarrantsandPrefundedWarrantsDetails" xlink:type="simple" xlink:href="ino-20250331.xsd#StockholdersEquityOfferingofCommonStockWarrantsandPrefundedWarrantsDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/StockholdersEquityOfferingofCommonStockWarrantsandPrefundedWarrantsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_a178e29a-9f1c-4d02-b1db-392862830d7d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_be023871-2141-4c82-9695-6ab3ae0bcd3d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_a178e29a-9f1c-4d02-b1db-392862830d7d" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_be023871-2141-4c82-9695-6ab3ae0bcd3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_ef9bda17-2a99-4f17-91ae-dba124246b28" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_be023871-2141-4c82-9695-6ab3ae0bcd3d" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_ef9bda17-2a99-4f17-91ae-dba124246b28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_b2057189-1d61-4232-932f-8711e4d10ded" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_ef9bda17-2a99-4f17-91ae-dba124246b28" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_b2057189-1d61-4232-932f-8711e4d10ded" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_December2024OfferingWarrantsMember_53fa47f8-56f5-405b-adc8-e285e4881523" xlink:href="ino-20250331.xsd#ino_December2024OfferingWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_b2057189-1d61-4232-932f-8711e4d10ded" xlink:to="loc_ino_December2024OfferingWarrantsMember_53fa47f8-56f5-405b-adc8-e285e4881523" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_fa1b8124-a282-4498-a761-6a441f455c10" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_be023871-2141-4c82-9695-6ab3ae0bcd3d" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_fa1b8124-a282-4498-a761-6a441f455c10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_43de7e3c-82dd-4d55-84b6-a592eb457e60" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_fa1b8124-a282-4498-a761-6a441f455c10" xlink:to="loc_us-gaap_EquityComponentDomain_43de7e3c-82dd-4d55-84b6-a592eb457e60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_95086894-9396-436c-8947-99c6e16e8a17" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_43de7e3c-82dd-4d55-84b6-a592eb457e60" xlink:to="loc_us-gaap_WarrantMember_95086894-9396-436c-8947-99c6e16e8a17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_f4b91a3d-7598-4f0f-acdc-8c54c65ebcf1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_43de7e3c-82dd-4d55-84b6-a592eb457e60" xlink:to="loc_us-gaap_CommonStockMember_f4b91a3d-7598-4f0f-acdc-8c54c65ebcf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_294d5e2c-a724-44e8-bc66-b8d7453e615a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_be023871-2141-4c82-9695-6ab3ae0bcd3d" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_294d5e2c-a724-44e8-bc66-b8d7453e615a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_388e8bb4-6bde-44dc-85dd-768b8e28d2fb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_294d5e2c-a724-44e8-bc66-b8d7453e615a" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_388e8bb4-6bde-44dc-85dd-768b8e28d2fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_UnderwrittenRegisteredDirectOfferingMember_98f967b9-66d2-407a-82bc-36d98dcea19f" xlink:href="ino-20250331.xsd#ino_UnderwrittenRegisteredDirectOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_388e8bb4-6bde-44dc-85dd-768b8e28d2fb" xlink:to="loc_ino_UnderwrittenRegisteredDirectOfferingMember_98f967b9-66d2-407a-82bc-36d98dcea19f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_be5b1809-b8d8-4d6c-b89b-bbfec69f59d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_be023871-2141-4c82-9695-6ab3ae0bcd3d" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_be5b1809-b8d8-4d6c-b89b-bbfec69f59d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_005e6bba-fd9e-423d-b1c4-87acb8604299" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_be5b1809-b8d8-4d6c-b89b-bbfec69f59d1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_005e6bba-fd9e-423d-b1c4-87acb8604299" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ClassOfWarrantOrRightCommonStockOwnershipPercent_0b4fc3f5-80cd-4c9c-b1b5-ef905d504b32" xlink:href="ino-20250331.xsd#ino_ClassOfWarrantOrRightCommonStockOwnershipPercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_be5b1809-b8d8-4d6c-b89b-bbfec69f59d1" xlink:to="loc_ino_ClassOfWarrantOrRightCommonStockOwnershipPercent_0b4fc3f5-80cd-4c9c-b1b5-ef905d504b32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ClassOfWarrantOrRightCommonStockOwnershipPriorToIssuancePercent_fcc23066-a0af-49f4-bba0-ab8a75a6cd95" xlink:href="ino-20250331.xsd#ino_ClassOfWarrantOrRightCommonStockOwnershipPriorToIssuancePercent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_be5b1809-b8d8-4d6c-b89b-bbfec69f59d1" xlink:to="loc_ino_ClassOfWarrantOrRightCommonStockOwnershipPriorToIssuancePercent_fcc23066-a0af-49f4-bba0-ab8a75a6cd95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ClassOfWarrantOrRightCommonStockOwnershipMaximumPercent_736e9fe6-03e7-40d4-92e6-dc96e9d68f20" xlink:href="ino-20250331.xsd#ino_ClassOfWarrantOrRightCommonStockOwnershipMaximumPercent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_be5b1809-b8d8-4d6c-b89b-bbfec69f59d1" xlink:to="loc_ino_ClassOfWarrantOrRightCommonStockOwnershipMaximumPercent_736e9fe6-03e7-40d4-92e6-dc96e9d68f20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquityAtTheMarketSalesAgreementsDetails" xlink:type="simple" xlink:href="ino-20250331.xsd#StockholdersEquityAtTheMarketSalesAgreementsDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/StockholdersEquityAtTheMarketSalesAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_d848115b-65cd-4b1a-8d3b-5b09783fb0ce" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_3031160a-dcba-4c5e-a0c3-3ebfc5ef19be" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_d848115b-65cd-4b1a-8d3b-5b09783fb0ce" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_3031160a-dcba-4c5e-a0c3-3ebfc5ef19be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_7f56afb7-a098-415a-b779-8b88820ad11b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_3031160a-dcba-4c5e-a0c3-3ebfc5ef19be" xlink:to="loc_us-gaap_StatementClassOfStockAxis_7f56afb7-a098-415a-b779-8b88820ad11b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_f6633396-e44f-4dd6-9b7c-6a9f8698eae6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_7f56afb7-a098-415a-b779-8b88820ad11b" xlink:to="loc_us-gaap_ClassOfStockDomain_f6633396-e44f-4dd6-9b7c-6a9f8698eae6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_190ebd3b-f34f-46f1-a9e4-d343cedbff16" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_f6633396-e44f-4dd6-9b7c-6a9f8698eae6" xlink:to="loc_us-gaap_CommonStockMember_190ebd3b-f34f-46f1-a9e4-d343cedbff16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_fd4e6520-5a2a-4b8f-9224-f5ef3d83acc4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_3031160a-dcba-4c5e-a0c3-3ebfc5ef19be" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_fd4e6520-5a2a-4b8f-9224-f5ef3d83acc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3c2f1fa3-fd71-4f30-a235-9a90d32a5bfb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_fd4e6520-5a2a-4b8f-9224-f5ef3d83acc4" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3c2f1fa3-fd71-4f30-a235-9a90d32a5bfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A2024SalesAgreementMember_0a9a26c9-ed37-4879-8523-3bb5fbce2930" xlink:href="ino-20250331.xsd#ino_A2024SalesAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3c2f1fa3-fd71-4f30-a235-9a90d32a5bfb" xlink:to="loc_ino_A2024SalesAgreementMember_0a9a26c9-ed37-4879-8523-3bb5fbce2930" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A2021SalesAgreementMember_ad1bab17-be48-4952-aeda-145ca4eb1c8f" xlink:href="ino-20250331.xsd#ino_A2021SalesAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3c2f1fa3-fd71-4f30-a235-9a90d32a5bfb" xlink:to="loc_ino_A2021SalesAgreementMember_ad1bab17-be48-4952-aeda-145ca4eb1c8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_b9a43c11-4eda-4595-9c10-9f4d593cc186" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_3031160a-dcba-4c5e-a0c3-3ebfc5ef19be" xlink:to="loc_us-gaap_ClassOfStockLineItems_b9a43c11-4eda-4595-9c10-9f4d593cc186" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSalesAgreementMaximumAuthorizedAmount_94e1a57d-0ff4-4236-868c-dee643473847" xlink:href="ino-20250331.xsd#ino_StockSalesAgreementMaximumAuthorizedAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b9a43c11-4eda-4595-9c10-9f4d593cc186" xlink:to="loc_ino_StockSalesAgreementMaximumAuthorizedAmount_94e1a57d-0ff4-4236-868c-dee643473847" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage_14fb31dc-347c-41dc-be61-e6b41527fc52" xlink:href="ino-20250331.xsd#ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b9a43c11-4eda-4595-9c10-9f4d593cc186" xlink:to="loc_ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage_14fb31dc-347c-41dc-be61-e6b41527fc52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSaleAgreementAggregateNumberofSharesIssued_113bf7cb-cbb0-403d-92e8-f512d945c020" xlink:href="ino-20250331.xsd#ino_StockSaleAgreementAggregateNumberofSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b9a43c11-4eda-4595-9c10-9f4d593cc186" xlink:to="loc_ino_StockSaleAgreementAggregateNumberofSharesIssued_113bf7cb-cbb0-403d-92e8-f512d945c020" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSaleAgreementWeightedAveragePricePerShare_0eedc66e-318e-479a-8d6b-82aede4c870c" xlink:href="ino-20250331.xsd#ino_StockSaleAgreementWeightedAveragePricePerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b9a43c11-4eda-4595-9c10-9f4d593cc186" xlink:to="loc_ino_StockSaleAgreementWeightedAveragePricePerShare_0eedc66e-318e-479a-8d6b-82aede4c870c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock_b3a110ca-b7d7-4c1b-8a0d-e1448fc16a84" xlink:href="ino-20250331.xsd#ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b9a43c11-4eda-4595-9c10-9f4d593cc186" xlink:to="loc_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock_b3a110ca-b7d7-4c1b-8a0d-e1448fc16a84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSaleAgreementRemainingCapacityAmount_fdcf3775-074b-4e9e-b7e6-4bc684e8ed45" xlink:href="ino-20250331.xsd#ino_StockSaleAgreementRemainingCapacityAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b9a43c11-4eda-4595-9c10-9f4d593cc186" xlink:to="loc_ino_StockSaleAgreementRemainingCapacityAmount_fdcf3775-074b-4e9e-b7e6-4bc684e8ed45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquityStockOptionsandRestrictedStockUnitsDetails" xlink:type="simple" xlink:href="ino-20250331.xsd#StockholdersEquityStockOptionsandRestrictedStockUnitsDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/StockholdersEquityStockOptionsandRestrictedStockUnitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_5791163c-a997-4d26-96d0-d96a50fc5d2c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_26113fed-000e-49ad-8ef0-54d06fb3f59c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_5791163c-a997-4d26-96d0-d96a50fc5d2c" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_26113fed-000e-49ad-8ef0-54d06fb3f59c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_4f3f2d47-b4c3-4bfc-8ec7-6d21b449be57" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_26113fed-000e-49ad-8ef0-54d06fb3f59c" xlink:to="loc_us-gaap_PlanNameAxis_4f3f2d47-b4c3-4bfc-8ec7-6d21b449be57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_0c46b533-63e6-4416-ad38-739fd4833a4a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_4f3f2d47-b4c3-4bfc-8ec7-6d21b449be57" xlink:to="loc_us-gaap_PlanNameDomain_0c46b533-63e6-4416-ad38-739fd4833a4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A2023IncentivePlanMember_276488a4-9740-4280-aab0-ab65d42e5ddc" xlink:href="ino-20250331.xsd#ino_A2023IncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_0c46b533-63e6-4416-ad38-739fd4833a4a" xlink:to="loc_ino_A2023IncentivePlanMember_276488a4-9740-4280-aab0-ab65d42e5ddc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A2016IncentivePlanMember_96fbd95f-b260-456f-9b59-48fa090c5642" xlink:href="ino-20250331.xsd#ino_A2016IncentivePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_0c46b533-63e6-4416-ad38-739fd4833a4a" xlink:to="loc_ino_A2016IncentivePlanMember_96fbd95f-b260-456f-9b59-48fa090c5642" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A2022InducementPlanMember_a0a22100-b637-453f-aeeb-dc396c5bdf83" xlink:href="ino-20250331.xsd#ino_A2022InducementPlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_0c46b533-63e6-4416-ad38-739fd4833a4a" xlink:to="loc_ino_A2022InducementPlanMember_a0a22100-b637-453f-aeeb-dc396c5bdf83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A2007IncentivePlanMember_d89ed93d-0cf1-4f9d-972a-9e4362758719" xlink:href="ino-20250331.xsd#ino_A2007IncentivePlanMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_0c46b533-63e6-4416-ad38-739fd4833a4a" xlink:to="loc_ino_A2007IncentivePlanMember_d89ed93d-0cf1-4f9d-972a-9e4362758719" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_f1124d6d-abf6-421d-9870-1b8fc379645b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_26113fed-000e-49ad-8ef0-54d06fb3f59c" xlink:to="loc_us-gaap_ClassOfStockLineItems_f1124d6d-abf6-421d-9870-1b8fc379645b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_e0241866-840b-4c74-ae31-ca4bf24c1489" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f1124d6d-abf6-421d-9870-1b8fc379645b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_e0241866-840b-4c74-ae31-ca4bf24c1489" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_8f8b9d1d-f245-4d78-851a-608e9fa39529" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f1124d6d-abf6-421d-9870-1b8fc379645b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_8f8b9d1d-f245-4d78-851a-608e9fa39529" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_02e7ba7a-2290-414b-89d6-adf8313894d4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f1124d6d-abf6-421d-9870-1b8fc379645b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_02e7ba7a-2290-414b-89d6-adf8313894d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockOtherSharesOutstanding_c3c3ad31-bbcf-4ec9-92bd-e749d443f143" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockOtherSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f1124d6d-abf6-421d-9870-1b8fc379645b" xlink:to="loc_us-gaap_CommonStockOtherSharesOutstanding_c3c3ad31-bbcf-4ec9-92bd-e749d443f143" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_cb9875ce-f90c-4173-a494-2fa882f222c5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f1124d6d-abf6-421d-9870-1b8fc379645b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_cb9875ce-f90c-4173-a494-2fa882f222c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm_f2bbfb56-c2b8-4a6d-8b46-c0ff5a197432" xlink:href="ino-20250331.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f1124d6d-abf6-421d-9870-1b8fc379645b" xlink:to="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm_f2bbfb56-c2b8-4a6d-8b46-c0ff5a197432" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/NetLossPerShareScheduleofBasicandDilutedNetLossPerShareDetails" xlink:type="simple" xlink:href="ino-20250331.xsd#NetLossPerShareScheduleofBasicandDilutedNetLossPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/NetLossPerShareScheduleofBasicandDilutedNetLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_782bc349-75e1-431c-b626-79ab562155d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_d5a304e3-6d4a-45e8-90db-c4c65b830400" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_782bc349-75e1-431c-b626-79ab562155d6" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_d5a304e3-6d4a-45e8-90db-c4c65b830400" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d53de5bf-d15e-4b56-8138-51e89c52e3d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_d5a304e3-6d4a-45e8-90db-c4c65b830400" xlink:to="loc_us-gaap_NetIncomeLoss_d53de5bf-d15e-4b56-8138-51e89c52e3d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_52432d45-6d18-4ac0-b2d8-e669752128c6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_782bc349-75e1-431c-b626-79ab562155d6" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_52432d45-6d18-4ac0-b2d8-e669752128c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_WeightedAverageNumberOfSharesOutstanding_57448ea6-f3fe-4f0e-8999-9fd45c2660f1" xlink:href="ino-20250331.xsd#ino_WeightedAverageNumberOfSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_52432d45-6d18-4ac0-b2d8-e669752128c6" xlink:to="loc_ino_WeightedAverageNumberOfSharesOutstanding_57448ea6-f3fe-4f0e-8999-9fd45c2660f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncrementalCommonSharesAttributableToBasicAndDilutiveEffectOfPreFundedWarrants_acfa8901-52a3-49a6-8b0a-5884aef7f2b8" xlink:href="ino-20250331.xsd#ino_IncrementalCommonSharesAttributableToBasicAndDilutiveEffectOfPreFundedWarrants"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_52432d45-6d18-4ac0-b2d8-e669752128c6" xlink:to="loc_ino_IncrementalCommonSharesAttributableToBasicAndDilutiveEffectOfPreFundedWarrants_acfa8901-52a3-49a6-8b0a-5884aef7f2b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e9548c1b-88e8-4c4f-8bed-a2e757cc6305" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_52432d45-6d18-4ac0-b2d8-e669752128c6" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e9548c1b-88e8-4c4f-8bed-a2e757cc6305" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5065f96e-9c84-453f-a845-85997ef4a5ae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_52432d45-6d18-4ac0-b2d8-e669752128c6" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5065f96e-9c84-453f-a845-85997ef4a5ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_EarningsPerShareBasicAndDilutedEPSAbstract_ffe87c1c-7c78-475d-83d7-7bb48f677b8d" xlink:href="ino-20250331.xsd#ino_EarningsPerShareBasicAndDilutedEPSAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_52432d45-6d18-4ac0-b2d8-e669752128c6" xlink:to="loc_ino_EarningsPerShareBasicAndDilutedEPSAbstract_ffe87c1c-7c78-475d-83d7-7bb48f677b8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_c9ab76ce-c3dc-4c4a-8891-18e22026c721" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_EarningsPerShareBasicAndDilutedEPSAbstract_ffe87c1c-7c78-475d-83d7-7bb48f677b8d" xlink:to="loc_us-gaap_EarningsPerShareBasic_c9ab76ce-c3dc-4c4a-8891-18e22026c721" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_259b33cd-c2a0-4d62-8082-c952f29098cf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_EarningsPerShareBasicAndDilutedEPSAbstract_ffe87c1c-7c78-475d-83d7-7bb48f677b8d" xlink:to="loc_us-gaap_EarningsPerShareDiluted_259b33cd-c2a0-4d62-8082-c952f29098cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/NetLossPerShareAntidilutiveDetails" xlink:type="simple" xlink:href="ino-20250331.xsd#NetLossPerShareAntidilutiveDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/NetLossPerShareAntidilutiveDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_826383d0-4d1a-438e-a7b0-1c3dec91538e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_a202c91d-494e-447e-95b9-1ac62b84d65b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_826383d0-4d1a-438e-a7b0-1c3dec91538e" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_a202c91d-494e-447e-95b9-1ac62b84d65b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_e20b3f7e-aebe-418d-b7c2-948eb61efa42" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_a202c91d-494e-447e-95b9-1ac62b84d65b" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_e20b3f7e-aebe-418d-b7c2-948eb61efa42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1155fe7f-2cef-40b0-b1f4-1e884797505e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_e20b3f7e-aebe-418d-b7c2-948eb61efa42" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1155fe7f-2cef-40b0-b1f4-1e884797505e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_34c97f72-e916-4ecd-b075-9c550b510d25" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1155fe7f-2cef-40b0-b1f4-1e884797505e" xlink:to="loc_us-gaap_WarrantMember_34c97f72-e916-4ecd-b075-9c550b510d25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_a145900b-2cf5-479c-9c31-811290d2dbbc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1155fe7f-2cef-40b0-b1f4-1e884797505e" xlink:to="loc_us-gaap_EmployeeStockOptionMember_a145900b-2cf5-479c-9c31-811290d2dbbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ServiceBasedRestrictedStockUnitsMember_dbb782c2-e558-4506-98c5-efeea167859e" xlink:href="ino-20250331.xsd#ino_ServiceBasedRestrictedStockUnitsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1155fe7f-2cef-40b0-b1f4-1e884797505e" xlink:to="loc_ino_ServiceBasedRestrictedStockUnitsMember_dbb782c2-e558-4506-98c5-efeea167859e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_6b6d336d-041f-4871-9c00-378af365face" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1155fe7f-2cef-40b0-b1f4-1e884797505e" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_6b6d336d-041f-4871-9c00-378af365face" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_d5b35582-60a0-4968-ba9f-018b9f2f70d3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1155fe7f-2cef-40b0-b1f4-1e884797505e" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_d5b35582-60a0-4968-ba9f-018b9f2f70d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_3e54b59a-39d6-4a86-89a3-d12e03a820d3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_a202c91d-494e-447e-95b9-1ac62b84d65b" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_3e54b59a-39d6-4a86-89a3-d12e03a820d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_00b6eaec-94a3-4bb0-9c9b-5e9d2df9072d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_3e54b59a-39d6-4a86-89a3-d12e03a820d3" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_00b6eaec-94a3-4bb0-9c9b-5e9d2df9072d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockBasedCompensationWeightedAverageAssumptionsDetails" xlink:type="simple" xlink:href="ino-20250331.xsd#StockBasedCompensationWeightedAverageAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/StockBasedCompensationWeightedAverageAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6e9c6292-a092-4018-9213-039abc65600e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e97f5af0-7afd-460c-9b4e-0da43a1d6348" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6e9c6292-a092-4018-9213-039abc65600e" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e97f5af0-7afd-460c-9b4e-0da43a1d6348" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_969c4c3a-52a6-4a3d-b223-74aed99116f9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e97f5af0-7afd-460c-9b4e-0da43a1d6348" xlink:to="loc_us-gaap_AwardTypeAxis_969c4c3a-52a6-4a3d-b223-74aed99116f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_18be060c-0268-4fa0-a6df-5c9ea6bcfbea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_969c4c3a-52a6-4a3d-b223-74aed99116f9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_18be060c-0268-4fa0-a6df-5c9ea6bcfbea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_d90317d4-6d21-49cc-9109-1fd1d7933ff5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_18be060c-0268-4fa0-a6df-5c9ea6bcfbea" xlink:to="loc_us-gaap_EmployeeStockOptionMember_d90317d4-6d21-49cc-9109-1fd1d7933ff5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_2913e84f-3873-4217-8458-1e0f2e33ffe5" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e97f5af0-7afd-460c-9b4e-0da43a1d6348" xlink:to="loc_srt_TitleOfIndividualAxis_2913e84f-3873-4217-8458-1e0f2e33ffe5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_14ff0c02-44ba-4898-8df6-5a5b068a4503" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_2913e84f-3873-4217-8458-1e0f2e33ffe5" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_14ff0c02-44ba-4898-8df6-5a5b068a4503" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_EmployeesAndDirectorsMember_1ae68527-7700-4506-928e-15ca7d235b14" xlink:href="ino-20250331.xsd#ino_EmployeesAndDirectorsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_14ff0c02-44ba-4898-8df6-5a5b068a4503" xlink:to="loc_ino_EmployeesAndDirectorsMember_1ae68527-7700-4506-928e-15ca7d235b14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5cf72984-665c-4158-be55-c1f9ceaa95b9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e97f5af0-7afd-460c-9b4e-0da43a1d6348" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5cf72984-665c-4158-be55-c1f9ceaa95b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_f8c95bc0-5585-477e-b406-293713dd7894" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5cf72984-665c-4158-be55-c1f9ceaa95b9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_f8c95bc0-5585-477e-b406-293713dd7894" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_87a20215-215b-48aa-af01-de83ce05bf7f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5cf72984-665c-4158-be55-c1f9ceaa95b9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_87a20215-215b-48aa-af01-de83ce05bf7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_c719ed0c-d701-4aa8-befb-987abf52723c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5cf72984-665c-4158-be55-c1f9ceaa95b9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_c719ed0c-d701-4aa8-befb-987abf52723c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2f51ca7d-28d2-4a2e-88f6-1c3142442025" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5cf72984-665c-4158-be55-c1f9ceaa95b9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2f51ca7d-28d2-4a2e-88f6-1c3142442025" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="ino-20250331.xsd#StockBasedCompensationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f36f7155-58fd-47e7-89a3-2cf6b070fd5b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_202c6cdb-1aa5-4c41-82f8-ee814f213c3a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f36f7155-58fd-47e7-89a3-2cf6b070fd5b" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_202c6cdb-1aa5-4c41-82f8-ee814f213c3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_e34b0dc1-52a6-442c-a9d7-e684f400399b" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_202c6cdb-1aa5-4c41-82f8-ee814f213c3a" xlink:to="loc_srt_TitleOfIndividualAxis_e34b0dc1-52a6-442c-a9d7-e684f400399b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_0ace15bb-65b5-4746-b3ce-27129bc09d06" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_e34b0dc1-52a6-442c-a9d7-e684f400399b" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_0ace15bb-65b5-4746-b3ce-27129bc09d06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_EmployeesAndDirectorsMember_09bf3428-e50c-4d97-ad36-55ff455f3dd8" xlink:href="ino-20250331.xsd#ino_EmployeesAndDirectorsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_0ace15bb-65b5-4746-b3ce-27129bc09d06" xlink:to="loc_ino_EmployeesAndDirectorsMember_09bf3428-e50c-4d97-ad36-55ff455f3dd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_NonEmployeeMember_8ce84522-04be-4384-b944-6c5bfb710ee7" xlink:href="ino-20250331.xsd#ino_NonEmployeeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_0ace15bb-65b5-4746-b3ce-27129bc09d06" xlink:to="loc_ino_NonEmployeeMember_8ce84522-04be-4384-b944-6c5bfb710ee7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_986302d7-5fd0-48bc-8348-b1d9b251f38a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_202c6cdb-1aa5-4c41-82f8-ee814f213c3a" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_986302d7-5fd0-48bc-8348-b1d9b251f38a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_15635d7e-5ca0-44d6-b862-3645f75db749" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_986302d7-5fd0-48bc-8348-b1d9b251f38a" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_15635d7e-5ca0-44d6-b862-3645f75db749" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_2ac59b14-b991-4bbe-a65d-ec8b0ffc72bd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_15635d7e-5ca0-44d6-b862-3645f75db749" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_2ac59b14-b991-4bbe-a65d-ec8b0ffc72bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_31cfd53d-ce3b-4ab8-97a9-7beedadfab62" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_15635d7e-5ca0-44d6-b862-3645f75db749" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_31cfd53d-ce3b-4ab8-97a9-7beedadfab62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_f94edd9a-22ce-4ec6-bdd9-fb293f8ea584" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_202c6cdb-1aa5-4c41-82f8-ee814f213c3a" xlink:to="loc_us-gaap_AwardTypeAxis_f94edd9a-22ce-4ec6-bdd9-fb293f8ea584" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3554bb81-8fd8-4668-8fab-914e4bdbc9a3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_f94edd9a-22ce-4ec6-bdd9-fb293f8ea584" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3554bb81-8fd8-4668-8fab-914e4bdbc9a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ServiceBasedRestrictedStockUnitsMember_f58d09c3-5b78-456f-8f54-5dd8c4ab3579" xlink:href="ino-20250331.xsd#ino_ServiceBasedRestrictedStockUnitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3554bb81-8fd8-4668-8fab-914e4bdbc9a3" xlink:to="loc_ino_ServiceBasedRestrictedStockUnitsMember_f58d09c3-5b78-456f-8f54-5dd8c4ab3579" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_66d9cbc3-928a-4dac-ab48-a2d9c19d542f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3554bb81-8fd8-4668-8fab-914e4bdbc9a3" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_66d9cbc3-928a-4dac-ab48-a2d9c19d542f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RestrictedStockUnitsRSUsMilestoneBasedMember_6a0ee5a1-463f-4f5b-bb33-e6a51369df6d" xlink:href="ino-20250331.xsd#ino_RestrictedStockUnitsRSUsMilestoneBasedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember_66d9cbc3-928a-4dac-ab48-a2d9c19d542f" xlink:to="loc_ino_RestrictedStockUnitsRSUsMilestoneBasedMember_6a0ee5a1-463f-4f5b-bb33-e6a51369df6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RestrictedStockUnitsRSUsMarketBasedMember_01b7089c-a1ff-42e1-abd9-c96588898f74" xlink:href="ino-20250331.xsd#ino_RestrictedStockUnitsRSUsMarketBasedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember_66d9cbc3-928a-4dac-ab48-a2d9c19d542f" xlink:to="loc_ino_RestrictedStockUnitsRSUsMarketBasedMember_01b7089c-a1ff-42e1-abd9-c96588898f74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RestrictedStockUnitsRSUsTotalShareholderReturnMember_7d17fb98-c770-46ce-b71d-558460327666" xlink:href="ino-20250331.xsd#ino_RestrictedStockUnitsRSUsTotalShareholderReturnMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember_66d9cbc3-928a-4dac-ab48-a2d9c19d542f" xlink:to="loc_ino_RestrictedStockUnitsRSUsTotalShareholderReturnMember_7d17fb98-c770-46ce-b71d-558460327666" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_23372688-ea75-4691-8d05-79124ee2c1f2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3554bb81-8fd8-4668-8fab-914e4bdbc9a3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_23372688-ea75-4691-8d05-79124ee2c1f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RestrictedStockUnitsPerformanceBasedMember_e36a6395-be91-4652-b92a-d221200e73b8" xlink:href="ino-20250331.xsd#ino_RestrictedStockUnitsPerformanceBasedMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3554bb81-8fd8-4668-8fab-914e4bdbc9a3" xlink:to="loc_ino_RestrictedStockUnitsPerformanceBasedMember_e36a6395-be91-4652-b92a-d221200e73b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockOptionsPerformanceBasedMember_4c5cf221-d221-4ce6-884d-9225bad90eba" xlink:href="ino-20250331.xsd#ino_StockOptionsPerformanceBasedMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3554bb81-8fd8-4668-8fab-914e4bdbc9a3" xlink:to="loc_ino_StockOptionsPerformanceBasedMember_4c5cf221-d221-4ce6-884d-9225bad90eba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_a536a8ce-0e84-4542-be01-f2b0b12379d4" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_202c6cdb-1aa5-4c41-82f8-ee814f213c3a" xlink:to="loc_srt_RangeAxis_a536a8ce-0e84-4542-be01-f2b0b12379d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7db148ad-1c2e-415a-8e8b-2b0d753ce435" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_a536a8ce-0e84-4542-be01-f2b0b12379d4" xlink:to="loc_srt_RangeMember_7db148ad-1c2e-415a-8e8b-2b0d753ce435" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_89769224-0570-4025-9769-d875395becd8" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_7db148ad-1c2e-415a-8e8b-2b0d753ce435" xlink:to="loc_srt_MinimumMember_89769224-0570-4025-9769-d875395becd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_aa213e31-da8f-4c5b-81e8-023b280f5fd6" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_7db148ad-1c2e-415a-8e8b-2b0d753ce435" xlink:to="loc_srt_MaximumMember_aa213e31-da8f-4c5b-81e8-023b280f5fd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateAxis_d499b6cb-57e9-4825-93d9-b5e0add60e23" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardDateAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_202c6cdb-1aa5-4c41-82f8-ee814f213c3a" xlink:to="loc_us-gaap_AwardDateAxis_d499b6cb-57e9-4825-93d9-b5e0add60e23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateDomain_fac9bd17-9d2b-47b1-8af8-886424038d31" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardDateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardDateAxis_d499b6cb-57e9-4825-93d9-b5e0add60e23" xlink:to="loc_us-gaap_AwardDateDomain_fac9bd17-9d2b-47b1-8af8-886424038d31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_December2024Member_11dff507-bd47-4ec2-a84a-b58cdb5742fa" xlink:href="ino-20250331.xsd#ino_December2024Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardDateDomain_fac9bd17-9d2b-47b1-8af8-886424038d31" xlink:to="loc_ino_December2024Member_11dff507-bd47-4ec2-a84a-b58cdb5742fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cfc5fff8-4702-4d82-9472-bbc9ff4814e4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_202c6cdb-1aa5-4c41-82f8-ee814f213c3a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cfc5fff8-4702-4d82-9472-bbc9ff4814e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_fea634b2-1ff9-43d7-8de7-99ce0dbd057c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cfc5fff8-4702-4d82-9472-bbc9ff4814e4" xlink:to="loc_us-gaap_ShareBasedCompensation_fea634b2-1ff9-43d7-8de7-99ce0dbd057c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_a88f01aa-52c7-40f7-98a0-c44e3bdbb424" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cfc5fff8-4702-4d82-9472-bbc9ff4814e4" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_a88f01aa-52c7-40f7-98a0-c44e3bdbb424" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_a6c80d45-15fa-4534-8779-41e15e60eae5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cfc5fff8-4702-4d82-9472-bbc9ff4814e4" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_a6c80d45-15fa-4534-8779-41e15e60eae5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_d64bfb5c-8680-4df4-81d5-b8388f2540e3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cfc5fff8-4702-4d82-9472-bbc9ff4814e4" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_d64bfb5c-8680-4df4-81d5-b8388f2540e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_fafec8c9-dba1-4576-9ef1-203acbc7c08d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cfc5fff8-4702-4d82-9472-bbc9ff4814e4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_fafec8c9-dba1-4576-9ef1-203acbc7c08d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_14a1df50-cf45-4322-8cbd-94426ba490cf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cfc5fff8-4702-4d82-9472-bbc9ff4814e4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_14a1df50-cf45-4322-8cbd-94426ba490cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ea55d7d6-8bbe-4a82-a928-84a23e161ce7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cfc5fff8-4702-4d82-9472-bbc9ff4814e4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ea55d7d6-8bbe-4a82-a928-84a23e161ce7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_57e7ce0d-6ec0-4f1e-9fdf-fb717cb8a120" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cfc5fff8-4702-4d82-9472-bbc9ff4814e4" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_57e7ce0d-6ec0-4f1e-9fdf-fb717cb8a120" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPercentage_d9e01e8e-acb9-4824-b0da-ab963cdcdb7a" xlink:href="ino-20250331.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPercentage"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cfc5fff8-4702-4d82-9472-bbc9ff4814e4" xlink:to="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPercentage_d9e01e8e-acb9-4824-b0da-ab963cdcdb7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_3cf5cce1-cc4c-42ce-b763-4a7161f2ab9a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cfc5fff8-4702-4d82-9472-bbc9ff4814e4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_3cf5cce1-cc4c-42ce-b763-4a7161f2ab9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue_3f98c8d2-33c5-4df9-befa-e18c72a40ecb" xlink:href="ino-20250331.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cfc5fff8-4702-4d82-9472-bbc9ff4814e4" xlink:to="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue_3f98c8d2-33c5-4df9-befa-e18c72a40ecb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardUnderlyingCommonStock_cff7f3f6-f883-4bb1-9b23-f6bf14505fd5" xlink:href="ino-20250331.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardUnderlyingCommonStock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cfc5fff8-4702-4d82-9472-bbc9ff4814e4" xlink:to="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardUnderlyingCommonStock_cff7f3f6-f883-4bb1-9b23-f6bf14505fd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsGrantDateFairValue_81f49f5f-2272-49c5-94e0-621e2fe0c569" xlink:href="ino-20250331.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsGrantDateFairValue"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cfc5fff8-4702-4d82-9472-bbc9ff4814e4" xlink:to="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsGrantDateFairValue_81f49f5f-2272-49c5-94e0-621e2fe0c569" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantDateClosingSharePrice_86cbad2f-90bb-4b59-8439-d721dbeab267" xlink:href="ino-20250331.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantDateClosingSharePrice"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cfc5fff8-4702-4d82-9472-bbc9ff4814e4" xlink:to="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantDateClosingSharePrice_86cbad2f-90bb-4b59-8439-d721dbeab267" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockBasedCompensationSignificantAssumptionUsedinMonteCarloSimulationMethodDetails" xlink:type="simple" xlink:href="ino-20250331.xsd#StockBasedCompensationSignificantAssumptionUsedinMonteCarloSimulationMethodDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/StockBasedCompensationSignificantAssumptionUsedinMonteCarloSimulationMethodDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_52ed2388-cc14-40ca-a240-74aa6b5cd16b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c7afb94b-d6c2-4e9c-a149-2af7a188588a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_52ed2388-cc14-40ca-a240-74aa6b5cd16b" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c7afb94b-d6c2-4e9c-a149-2af7a188588a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_521d3464-ea25-4e73-af35-a22a039d4797" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c7afb94b-d6c2-4e9c-a149-2af7a188588a" xlink:to="loc_us-gaap_AwardTypeAxis_521d3464-ea25-4e73-af35-a22a039d4797" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8f136039-5c13-49fe-86d8-fa920c86edde" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_521d3464-ea25-4e73-af35-a22a039d4797" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8f136039-5c13-49fe-86d8-fa920c86edde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RestrictedStockUnitsRSUsMarketBasedMember_43c81e38-5737-42d5-9b70-6886c85de09f" xlink:href="ino-20250331.xsd#ino_RestrictedStockUnitsRSUsMarketBasedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8f136039-5c13-49fe-86d8-fa920c86edde" xlink:to="loc_ino_RestrictedStockUnitsRSUsMarketBasedMember_43c81e38-5737-42d5-9b70-6886c85de09f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3034666b-b16b-4e74-be9b-4543e6eacac3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c7afb94b-d6c2-4e9c-a149-2af7a188588a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3034666b-b16b-4e74-be9b-4543e6eacac3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2a85e230-8f00-4c07-aebb-5bda3a76a518" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3034666b-b16b-4e74-be9b-4543e6eacac3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2a85e230-8f00-4c07-aebb-5bda3a76a518" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_63662488-3f5b-44c6-aacc-e977344cff40" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3034666b-b16b-4e74-be9b-4543e6eacac3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_63662488-3f5b-44c6-aacc-e977344cff40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_cd77d00a-f804-47af-a351-ef09b735f599" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3034666b-b16b-4e74-be9b-4543e6eacac3" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_cd77d00a-f804-47af-a351-ef09b735f599" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_5082277d-7664-461e-b219-f4faeaa13318" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3034666b-b16b-4e74-be9b-4543e6eacac3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_5082277d-7664-461e-b219-f4faeaa13318" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/RelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="ino-20250331.xsd#RelatedPartyTransactionsDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/RelatedPartyTransactionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_77857e53-0db2-4041-835e-496ba5f4f3df" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_cdf1ece2-f962-42f4-a7e8-cf5dd3e87a3a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_77857e53-0db2-4041-835e-496ba5f4f3df" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_cdf1ece2-f962-42f4-a7e8-cf5dd3e87a3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_53f71632-f2e0-4326-a7de-aff48cd0b7c1" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_cdf1ece2-f962-42f4-a7e8-cf5dd3e87a3a" xlink:to="loc_srt_CounterpartyNameAxis_53f71632-f2e0-4326-a7de-aff48cd0b7c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_90c89535-f1a4-400a-beb6-9c2c963aca34" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_53f71632-f2e0-4326-a7de-aff48cd0b7c1" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_90c89535-f1a4-400a-beb6-9c2c963aca34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PlumblineLifeSciencesMember_2f302a52-d113-4ece-84d0-ed587946d0f4" xlink:href="ino-20250331.xsd#ino_PlumblineLifeSciencesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_90c89535-f1a4-400a-beb6-9c2c963aca34" xlink:to="loc_ino_PlumblineLifeSciencesMember_2f302a52-d113-4ece-84d0-ed587946d0f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TheWistarInstituteMember_f5038b22-a0c4-4983-a630-af6e15de4558" xlink:href="ino-20250331.xsd#ino_TheWistarInstituteMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_90c89535-f1a4-400a-beb6-9c2c963aca34" xlink:to="loc_ino_TheWistarInstituteMember_f5038b22-a0c4-4983-a630-af6e15de4558" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_eb440b70-1e41-4329-95f8-43ca4ca6f890" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_cdf1ece2-f962-42f4-a7e8-cf5dd3e87a3a" xlink:to="loc_srt_OwnershipAxis_eb440b70-1e41-4329-95f8-43ca4ca6f890" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_e7bf6749-b38a-445d-af90-819a1a868603" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_eb440b70-1e41-4329-95f8-43ca4ca6f890" xlink:to="loc_srt_OwnershipDomain_e7bf6749-b38a-445d-af90-819a1a868603" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PlumblineLifeSciencesMember_a0a71e5b-4684-49f2-92ff-fb6e03baa877" xlink:href="ino-20250331.xsd#ino_PlumblineLifeSciencesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_e7bf6749-b38a-445d-af90-819a1a868603" xlink:to="loc_ino_PlumblineLifeSciencesMember_a0a71e5b-4684-49f2-92ff-fb6e03baa877" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_24c645a3-3240-4213-849d-c05672342d83" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_cdf1ece2-f962-42f4-a7e8-cf5dd3e87a3a" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_24c645a3-3240-4213-849d-c05672342d83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_80f4c2bd-e08c-4f6d-80d5-1650e3cf1095" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_24c645a3-3240-4213-849d-c05672342d83" xlink:to="loc_us-gaap_RelatedPartyDomain_80f4c2bd-e08c-4f6d-80d5-1650e3cf1095" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_088e8ea6-e473-47c9-b4c2-cb905f1364ca" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_AffiliatedEntityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_80f4c2bd-e08c-4f6d-80d5-1650e3cf1095" xlink:to="loc_srt_AffiliatedEntityMember_088e8ea6-e473-47c9-b4c2-cb905f1364ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_a03fa5ef-3da3-4d2d-a7ad-802a50aa8c4f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_cdf1ece2-f962-42f4-a7e8-cf5dd3e87a3a" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_a03fa5ef-3da3-4d2d-a7ad-802a50aa8c4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares_83fdc61b-68bb-4e43-9a1c-021b51fe4257" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_a03fa5ef-3da3-4d2d-a7ad-802a50aa8c4f" xlink:to="loc_us-gaap_InvestmentOwnedBalanceShares_83fdc61b-68bb-4e43-9a1c-021b51fe4257" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_cc3406fc-0de0-4be6-b363-ad94d16f039a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_a03fa5ef-3da3-4d2d-a7ad-802a50aa8c4f" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_cc3406fc-0de0-4be6-b363-ad94d16f039a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_ada1148a-80ce-4505-a68b-3e35e15a7dd1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_a03fa5ef-3da3-4d2d-a7ad-802a50aa8c4f" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_ada1148a-80ce-4505-a68b-3e35e15a7dd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementExpensesToReimburse_39373a34-7cf8-47f4-849b-715861edb6e2" xlink:href="ino-20250331.xsd#ino_CollaborativeAgreementExpensesToReimburse"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_a03fa5ef-3da3-4d2d-a7ad-802a50aa8c4f" xlink:to="loc_ino_CollaborativeAgreementExpensesToReimburse_39373a34-7cf8-47f4-849b-715861edb6e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeArrangementTerm_ad7b70c8-968d-4e02-9a1b-0ab56f856695" xlink:href="ino-20250331.xsd#ino_CollaborativeArrangementTerm"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_a03fa5ef-3da3-4d2d-a7ad-802a50aa8c4f" xlink:to="loc_ino_CollaborativeArrangementTerm_ad7b70c8-968d-4e02-9a1b-0ab56f856695" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementAwardedAmount_fb1a2320-e4d5-4bf6-9213-a1739aafbc60" xlink:href="ino-20250331.xsd#ino_CollaborativeAgreementAwardedAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_a03fa5ef-3da3-4d2d-a7ad-802a50aa8c4f" xlink:to="loc_ino_CollaborativeAgreementAwardedAmount_fb1a2320-e4d5-4bf6-9213-a1739aafbc60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementAmendedAmount_45b52525-1782-40ac-9fd5-0530ccc84cbb" xlink:href="ino-20250331.xsd#ino_CollaborativeAgreementAmendedAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_a03fa5ef-3da3-4d2d-a7ad-802a50aa8c4f" xlink:to="loc_ino_CollaborativeAgreementAmendedAmount_45b52525-1782-40ac-9fd5-0530ccc84cbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementAwardedOptionAmount_473970e0-c9f4-495b-a971-80432c0f1583" xlink:href="ino-20250331.xsd#ino_CollaborativeAgreementAwardedOptionAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_a03fa5ef-3da3-4d2d-a7ad-802a50aa8c4f" xlink:to="loc_ino_CollaborativeAgreementAwardedOptionAmount_473970e0-c9f4-495b-a971-80432c0f1583" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GrantProceedsReceived_fd90e7cd-7d09-4eea-ab47-83d623669dd6" xlink:href="ino-20250331.xsd#ino_GrantProceedsReceived"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_a03fa5ef-3da3-4d2d-a7ad-802a50aa8c4f" xlink:to="loc_ino_GrantProceedsReceived_fd90e7cd-7d09-4eea-ab47-83d623669dd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_e7ef450d-d824-4de3-ae60-739fdc045d49" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_a03fa5ef-3da3-4d2d-a7ad-802a50aa8c4f" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_e7ef450d-d824-4de3-ae60-739fdc045d49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_57c3fff3-c975-457c-b4f8-7a96d24f1a88" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_a03fa5ef-3da3-4d2d-a7ad-802a50aa8c4f" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_57c3fff3-c975-457c-b4f8-7a96d24f1a88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="simple" xlink:href="ino-20250331.xsd#CommitmentsandContingenciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3125fd5d-64cc-4387-b107-e64ed2370c30" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_aab228d9-6fd2-4854-8ab9-0c0941784e88" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3125fd5d-64cc-4387-b107-e64ed2370c30" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_aab228d9-6fd2-4854-8ab9-0c0941784e88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_5b08321f-4331-43e3-ad21-823fc41ac218" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_aab228d9-6fd2-4854-8ab9-0c0941784e88" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_5b08321f-4331-43e3-ad21-823fc41ac218" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_9ad2292c-2cb0-4a3a-adfe-5ae75abe2fb3" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_5b08321f-4331-43e3-ad21-823fc41ac218" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_9ad2292c-2cb0-4a3a-adfe-5ae75abe2fb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SanDiegoOfficeMember_add66f67-8085-4e61-885e-c49f8c774471" xlink:href="ino-20250331.xsd#ino_SanDiegoOfficeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_9ad2292c-2cb0-4a3a-adfe-5ae75abe2fb3" xlink:to="loc_ino_SanDiegoOfficeMember_add66f67-8085-4e61-885e-c49f8c774471" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PlymouthMeetingPennsylvaniaMember_1bc67074-f3f1-4c61-8696-5958ff0bb98f" xlink:href="ino-20250331.xsd#ino_PlymouthMeetingPennsylvaniaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_9ad2292c-2cb0-4a3a-adfe-5ae75abe2fb3" xlink:to="loc_ino_PlymouthMeetingPennsylvaniaMember_1bc67074-f3f1-4c61-8696-5958ff0bb98f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SanDiegoCaliforniaMember_bedefc98-087d-4ce2-89c1-f6cb521963ac" xlink:href="ino-20250331.xsd#ino_SanDiegoCaliforniaMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_9ad2292c-2cb0-4a3a-adfe-5ae75abe2fb3" xlink:to="loc_ino_SanDiegoCaliforniaMember_bedefc98-087d-4ce2-89c1-f6cb521963ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_0643a07e-b68b-4f75-ab2d-e1db0616863f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_aab228d9-6fd2-4854-8ab9-0c0941784e88" xlink:to="loc_srt_RangeAxis_0643a07e-b68b-4f75-ab2d-e1db0616863f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1eab84cc-98ec-4a4c-bea2-e95217efea10" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_0643a07e-b68b-4f75-ab2d-e1db0616863f" xlink:to="loc_srt_RangeMember_1eab84cc-98ec-4a4c-bea2-e95217efea10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_3334040d-127a-4a61-88cc-364d812f0e2b" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1eab84cc-98ec-4a4c-bea2-e95217efea10" xlink:to="loc_srt_MinimumMember_3334040d-127a-4a61-88cc-364d812f0e2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_c67b2536-9e0c-47dc-9fd5-a7993a79e9d2" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1eab84cc-98ec-4a4c-bea2-e95217efea10" xlink:to="loc_srt_MaximumMember_c67b2536-9e0c-47dc-9fd5-a7993a79e9d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_9b15ae3f-2664-4bfc-84c7-abcad98e0495" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_aab228d9-6fd2-4854-8ab9-0c0941784e88" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_9b15ae3f-2664-4bfc-84c7-abcad98e0495" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LesseeOperatingLeaseAreaofLandUnderLease_bb6a8e3d-5a1f-43a3-9e17-7920ee06e7d2" xlink:href="ino-20250331.xsd#ino_LesseeOperatingLeaseAreaofLandUnderLease"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_9b15ae3f-2664-4bfc-84c7-abcad98e0495" xlink:to="loc_ino_LesseeOperatingLeaseAreaofLandUnderLease_bb6a8e3d-5a1f-43a3-9e17-7920ee06e7d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_cd463eb9-f8c7-41ee-bee6-e305478cc871" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_9b15ae3f-2664-4bfc-84c7-abcad98e0495" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_cd463eb9-f8c7-41ee-bee6-e305478cc871" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LesseeOperatingLeaseBaseRatePercentageIncreaseDecrease_d32638f6-5a4e-42c4-b7e7-e0648598d5d9" xlink:href="ino-20250331.xsd#ino_LesseeOperatingLeaseBaseRatePercentageIncreaseDecrease"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_9b15ae3f-2664-4bfc-84c7-abcad98e0495" xlink:to="loc_ino_LesseeOperatingLeaseBaseRatePercentageIncreaseDecrease_d32638f6-5a4e-42c4-b7e7-e0648598d5d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_b017bb0e-2881-4f80-b20b-065893d7faea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_9b15ae3f-2664-4bfc-84c7-abcad98e0495" xlink:to="loc_us-gaap_LeaseCost_b017bb0e-2881-4f80-b20b-065893d7faea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CommitmentsandContingenciesSummaryofFutureMinimumLeasePaymentsDetails" xlink:type="simple" xlink:href="ino-20250331.xsd#CommitmentsandContingenciesSummaryofFutureMinimumLeasePaymentsDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CommitmentsandContingenciesSummaryofFutureMinimumLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_7a092a0d-1d8b-4aa9-a6c4-454b2c827d45" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_1bab9b98-513b-437f-864f-d75db3b46ab4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_7a092a0d-1d8b-4aa9-a6c4-454b2c827d45" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_1bab9b98-513b-437f-864f-d75db3b46ab4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_4417a3d8-761f-4477-809b-b4c4b778d6fb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_7a092a0d-1d8b-4aa9-a6c4-454b2c827d45" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_4417a3d8-761f-4477-809b-b4c4b778d6fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_9dba4c9c-1daf-473c-9bf8-b81e215c123a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_7a092a0d-1d8b-4aa9-a6c4-454b2c827d45" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_9dba4c9c-1daf-473c-9bf8-b81e215c123a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_b419c5f9-430a-443b-9196-d71aa1757698" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_7a092a0d-1d8b-4aa9-a6c4-454b2c827d45" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_b419c5f9-430a-443b-9196-d71aa1757698" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_366c1a22-f6e3-44e5-8e62-dce3b323f9a6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_7a092a0d-1d8b-4aa9-a6c4-454b2c827d45" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_366c1a22-f6e3-44e5-8e62-dce3b323f9a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f3a5f022-62b2-4344-992a-37496b895db1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_7a092a0d-1d8b-4aa9-a6c4-454b2c827d45" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f3a5f022-62b2-4344-992a-37496b895db1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_e72f078b-3270-4a54-9266-eb178ddf243f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_7a092a0d-1d8b-4aa9-a6c4-454b2c827d45" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_e72f078b-3270-4a54-9266-eb178ddf243f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_2945952f-1bd4-4b49-ae23-6ee4c4d9da8c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_7a092a0d-1d8b-4aa9-a6c4-454b2c827d45" xlink:to="loc_us-gaap_OperatingLeaseLiability_2945952f-1bd4-4b49-ae23-6ee4c4d9da8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_f48d67d7-18cf-40a9-adb8-22732ebafed8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_7a092a0d-1d8b-4aa9-a6c4-454b2c827d45" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_f48d67d7-18cf-40a9-adb8-22732ebafed8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_94339098-9830-46f3-959f-1d99417ca58c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_7a092a0d-1d8b-4aa9-a6c4-454b2c827d45" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_94339098-9830-46f3-959f-1d99417ca58c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_4975b4ae-4d95-4157-8ef2-ac333c08aacf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_7a092a0d-1d8b-4aa9-a6c4-454b2c827d45" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_4975b4ae-4d95-4157-8ef2-ac333c08aacf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_4ea6ccc7-2a9e-41ce-9272-e1904643fef2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_7a092a0d-1d8b-4aa9-a6c4-454b2c827d45" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_4ea6ccc7-2a9e-41ce-9272-e1904643fef2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CollaborativeAgreementsDetails" xlink:type="simple" xlink:href="ino-20250331.xsd#CollaborativeAgreementsDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CollaborativeAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_52353b30-9d91-4c01-ac23-bcc66865c240" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_60b79a2c-8778-480c-a021-9079b2fa15c2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_52353b30-9d91-4c01-ac23-bcc66865c240" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_60b79a2c-8778-480c-a021-9079b2fa15c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_0f2138bb-daee-45af-b479-0ee78da7b75b" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_60b79a2c-8778-480c-a021-9079b2fa15c2" xlink:to="loc_srt_CounterpartyNameAxis_0f2138bb-daee-45af-b479-0ee78da7b75b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_079fbde6-ef68-4bf8-8d6a-75594d619d75" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_0f2138bb-daee-45af-b479-0ee78da7b75b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_079fbde6-ef68-4bf8-8d6a-75594d619d75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ApolloBioMember_6c389772-bea1-48f8-adc4-9b7281db66be" xlink:href="ino-20250331.xsd#ino_ApolloBioMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_079fbde6-ef68-4bf8-8d6a-75594d619d75" xlink:to="loc_ino_ApolloBioMember_6c389772-bea1-48f8-adc4-9b7281db66be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CoalitionforEpidemicPreparednessInnovationsMember_7f87ff62-a8c7-4028-9815-069deb62b1ad" xlink:href="ino-20250331.xsd#ino_CoalitionforEpidemicPreparednessInnovationsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_079fbde6-ef68-4bf8-8d6a-75594d619d75" xlink:to="loc_ino_CoalitionforEpidemicPreparednessInnovationsMember_7f87ff62-a8c7-4028-9815-069deb62b1ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_BillAndMelindaGatesFoundationMember_91043696-e71c-4115-9aeb-a4f37870c8ea" xlink:href="ino-20250331.xsd#ino_BillAndMelindaGatesFoundationMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_079fbde6-ef68-4bf8-8d6a-75594d619d75" xlink:to="loc_ino_BillAndMelindaGatesFoundationMember_91043696-e71c-4115-9aeb-a4f37870c8ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_2931d1c9-7906-473f-b2e9-e5f858afb5f8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_60b79a2c-8778-480c-a021-9079b2fa15c2" xlink:to="loc_us-gaap_TypeOfArrangementAxis_2931d1c9-7906-473f-b2e9-e5f858afb5f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fa2760d6-9969-4c02-838a-59368b873aad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_2931d1c9-7906-473f-b2e9-e5f858afb5f8" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fa2760d6-9969-4c02-838a-59368b873aad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_f8f3a869-abef-45de-a5d0-d01db84e67af" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fa2760d6-9969-4c02-838a-59368b873aad" xlink:to="loc_us-gaap_CollaborativeArrangementMember_f8f3a869-abef-45de-a5d0-d01db84e67af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_c1d370bc-5cad-43a3-9409-ee7ba6573a31" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_60b79a2c-8778-480c-a021-9079b2fa15c2" xlink:to="loc_srt_ProductOrServiceAxis_c1d370bc-5cad-43a3-9409-ee7ba6573a31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_14382682-8ac8-439c-b535-074a9c3106a5" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_c1d370bc-5cad-43a3-9409-ee7ba6573a31" xlink:to="loc_srt_ProductsAndServicesDomain_14382682-8ac8-439c-b535-074a9c3106a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LassaFeverAndMERSVaccineMember_4f295b7b-7983-45f3-8945-ebc7f26be4a3" xlink:href="ino-20250331.xsd#ino_LassaFeverAndMERSVaccineMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_14382682-8ac8-439c-b535-074a9c3106a5" xlink:to="loc_ino_LassaFeverAndMERSVaccineMember_4f295b7b-7983-45f3-8945-ebc7f26be4a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DNAEncodedMonoclonalAntibodyTechnologyMember_d259c2e2-7184-4498-b642-3c15118dffb2" xlink:href="ino-20250331.xsd#ino_DNAEncodedMonoclonalAntibodyTechnologyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_14382682-8ac8-439c-b535-074a9c3106a5" xlink:to="loc_ino_DNAEncodedMonoclonalAntibodyTechnologyMember_d259c2e2-7184-4498-b642-3c15118dffb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fb5f1534-9d3d-4f5e-9b78-bf18157cef00" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_60b79a2c-8778-480c-a021-9079b2fa15c2" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fb5f1534-9d3d-4f5e-9b78-bf18157cef00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborationAgreementAdditionalRevenueToBeAchieved_f201424a-ab2a-4e63-b245-6e84b40dbb13" xlink:href="ino-20250331.xsd#ino_CollaborationAgreementAdditionalRevenueToBeAchieved"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fb5f1534-9d3d-4f5e-9b78-bf18157cef00" xlink:to="loc_ino_CollaborationAgreementAdditionalRevenueToBeAchieved_f201424a-ab2a-4e63-b245-6e84b40dbb13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborationAgreementRoyaltyPeriod_60faae00-7fff-4e11-bdb8-bc2c0e5d050a" xlink:href="ino-20250331.xsd#ino_CollaborationAgreementRoyaltyPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fb5f1534-9d3d-4f5e-9b78-bf18157cef00" xlink:to="loc_ino_CollaborationAgreementRoyaltyPeriod_60faae00-7fff-4e11-bdb8-bc2c0e5d050a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_76550ca2-e7b3-4b24-b43f-59de71a0f358" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fb5f1534-9d3d-4f5e-9b78-bf18157cef00" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_76550ca2-e7b3-4b24-b43f-59de71a0f358" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementFundingToBeReceived_917a2812-7cb7-4e1e-9675-4eb21be2e126" xlink:href="ino-20250331.xsd#ino_CollaborativeAgreementFundingToBeReceived"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fb5f1534-9d3d-4f5e-9b78-bf18157cef00" xlink:to="loc_ino_CollaborativeAgreementFundingToBeReceived_917a2812-7cb7-4e1e-9675-4eb21be2e126" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment_9f201af1-c5d4-4956-b047-cd8332baffe8" xlink:href="ino-20250331.xsd#ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fb5f1534-9d3d-4f5e-9b78-bf18157cef00" xlink:to="loc_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment_9f201af1-c5d4-4956-b047-cd8332baffe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementFundingReceived_97222613-e558-466b-a0d0-048970e63bcc" xlink:href="ino-20250331.xsd#ino_CollaborativeAgreementFundingReceived"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fb5f1534-9d3d-4f5e-9b78-bf18157cef00" xlink:to="loc_ino_CollaborativeAgreementFundingReceived_97222613-e558-466b-a0d0-048970e63bcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncDetails" xlink:type="simple" xlink:href="ino-20250331.xsd#GeneosTherapeuticsIncDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/GeneosTherapeuticsIncDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_47b3a289-49df-423f-9d1a-4df4c312872f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable_283f48a5-8027-4162-9f92-ad6eb3c2e800" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterestTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_47b3a289-49df-423f-9d1a-4df4c312872f" xlink:to="loc_us-gaap_MinorityInterestTable_283f48a5-8027-4162-9f92-ad6eb3c2e800" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_57ff40a1-bd6a-4dae-8e8e-ddb78299d50a" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_283f48a5-8027-4162-9f92-ad6eb3c2e800" xlink:to="loc_srt_OwnershipAxis_57ff40a1-bd6a-4dae-8e8e-ddb78299d50a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_8084fac4-7b79-48cd-8347-88828b33c5e0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_57ff40a1-bd6a-4dae-8e8e-ddb78299d50a" xlink:to="loc_srt_OwnershipDomain_8084fac4-7b79-48cd-8347-88828b33c5e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GeneosTherapeuticsInc.Member_359f3b01-8015-4aec-b4a8-936491cdbd75" xlink:href="ino-20250331.xsd#ino_GeneosTherapeuticsInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_8084fac4-7b79-48cd-8347-88828b33c5e0" xlink:to="loc_ino_GeneosTherapeuticsInc.Member_359f3b01-8015-4aec-b4a8-936491cdbd75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems_abc7eb1f-846c-4856-91d8-30e4f9e5a10c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_283f48a5-8027-4162-9f92-ad6eb3c2e800" xlink:to="loc_us-gaap_MinorityInterestLineItems_abc7eb1f-846c-4856-91d8-30e4f9e5a10c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_2a8539a5-701a-4fcc-a7a9-2539a0ef592d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_abc7eb1f-846c-4856-91d8-30e4f9e5a10c" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_2a8539a5-701a-4fcc-a7a9-2539a0ef592d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_a964ac0b-496a-4eb5-ace0-7cd036834503" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_abc7eb1f-846c-4856-91d8-30e4f9e5a10c" xlink:to="loc_us-gaap_EquityMethodInvestments_a964ac0b-496a-4eb5-ace0-7cd036834503" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_EquityMethodInvestmentsMinimum_500609de-1626-4391-9419-b21a8f661500" xlink:href="ino-20250331.xsd#ino_EquityMethodInvestmentsMinimum"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_abc7eb1f-846c-4856-91d8-30e4f9e5a10c" xlink:to="loc_ino_EquityMethodInvestmentsMinimum_500609de-1626-4391-9419-b21a8f661500" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/SegmentInformationDetails" xlink:type="simple" xlink:href="ino-20250331.xsd#SegmentInformationDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/SegmentInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_60caec25-a057-4471-b228-140889cdd186" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_dc7620cb-f696-417b-ad12-d247b4d06d08" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_60caec25-a057-4471-b228-140889cdd186" xlink:to="loc_us-gaap_NumberOfReportableSegments_dc7620cb-f696-417b-ad12-d247b4d06d08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_3152e2e9-99b8-4cdb-bd94-d1884b7599ad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_60caec25-a057-4471-b228-140889cdd186" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_3152e2e9-99b8-4cdb-bd94-d1884b7599ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_77190d2e-6b67-44d9-be4e-1b36785ee549" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_3152e2e9-99b8-4cdb-bd94-d1884b7599ad" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_77190d2e-6b67-44d9-be4e-1b36785ee549" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_fd0b67e7-5a78-4996-98cb-b42cb36d82de" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_77190d2e-6b67-44d9-be4e-1b36785ee549" xlink:to="loc_us-gaap_SegmentDomain_fd0b67e7-5a78-4996-98cb-b42cb36d82de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ReportableSegmentsMember_8e363641-22dd-4fc8-a199-3da116443503" xlink:href="ino-20250331.xsd#ino_ReportableSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_fd0b67e7-5a78-4996-98cb-b42cb36d82de" xlink:to="loc_ino_ReportableSegmentsMember_8e363641-22dd-4fc8-a199-3da116443503" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ResearchAndDevelopmentCostAxis_16da8357-048f-4232-b511-1c0b283d8081" xlink:href="ino-20250331.xsd#ino_ResearchAndDevelopmentCostAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_3152e2e9-99b8-4cdb-bd94-d1884b7599ad" xlink:to="loc_ino_ResearchAndDevelopmentCostAxis_16da8357-048f-4232-b511-1c0b283d8081" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ResearchAndDevelopmentCostDomain_7e82844a-0b37-4d26-bfc2-f3bf9f74d992" xlink:href="ino-20250331.xsd#ino_ResearchAndDevelopmentCostDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_ResearchAndDevelopmentCostAxis_16da8357-048f-4232-b511-1c0b283d8081" xlink:to="loc_ino_ResearchAndDevelopmentCostDomain_7e82844a-0b37-4d26-bfc2-f3bf9f74d992" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_INO3107Member_e57dd058-bb41-4c4f-af3f-3cb6798bf7af" xlink:href="ino-20250331.xsd#ino_INO3107Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_ResearchAndDevelopmentCostDomain_7e82844a-0b37-4d26-bfc2-f3bf9f74d992" xlink:to="loc_ino_INO3107Member_e57dd058-bb41-4c4f-af3f-3cb6798bf7af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_INO3112AndOtherImmunoOncologyMember_bcbd16bf-0ae7-4e27-a3b3-2c86026ae301" xlink:href="ino-20250331.xsd#ino_INO3112AndOtherImmunoOncologyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_ResearchAndDevelopmentCostDomain_7e82844a-0b37-4d26-bfc2-f3bf9f74d992" xlink:to="loc_ino_INO3112AndOtherImmunoOncologyMember_bcbd16bf-0ae7-4e27-a3b3-2c86026ae301" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OtherProgramsMember_81322de6-ee5f-4984-bc40-0b1f6477ab23" xlink:href="ino-20250331.xsd#ino_OtherProgramsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_ResearchAndDevelopmentCostDomain_7e82844a-0b37-4d26-bfc2-f3bf9f74d992" xlink:to="loc_ino_OtherProgramsMember_81322de6-ee5f-4984-bc40-0b1f6477ab23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_EngineeringAndDeviceRelatedMember_2da86ca7-1cf3-4f0f-96bf-d302d3c07a27" xlink:href="ino-20250331.xsd#ino_EngineeringAndDeviceRelatedMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_ResearchAndDevelopmentCostDomain_7e82844a-0b37-4d26-bfc2-f3bf9f74d992" xlink:to="loc_ino_EngineeringAndDeviceRelatedMember_2da86ca7-1cf3-4f0f-96bf-d302d3c07a27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockBasedCompensationMember_7478244e-e807-44f0-8df4-6b16bf4ae042" xlink:href="ino-20250331.xsd#ino_StockBasedCompensationMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_ResearchAndDevelopmentCostDomain_7e82844a-0b37-4d26-bfc2-f3bf9f74d992" xlink:to="loc_ino_StockBasedCompensationMember_7478244e-e807-44f0-8df4-6b16bf4ae042" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OtherUnallocatedExpensesMember_967bd97b-08a0-4916-9fc1-8d7e1d0067e9" xlink:href="ino-20250331.xsd#ino_OtherUnallocatedExpensesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_ResearchAndDevelopmentCostDomain_7e82844a-0b37-4d26-bfc2-f3bf9f74d992" xlink:to="loc_ino_OtherUnallocatedExpensesMember_967bd97b-08a0-4916-9fc1-8d7e1d0067e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_9728c8f2-bb11-427e-bb98-bb1620918c0b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_3152e2e9-99b8-4cdb-bd94-d1884b7599ad" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_9728c8f2-bb11-427e-bb98-bb1620918c0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_bda9fbcc-20cd-4cde-ba34-5d33ac5c1e13" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_9728c8f2-bb11-427e-bb98-bb1620918c0b" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_bda9fbcc-20cd-4cde-ba34-5d33ac5c1e13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_52043c22-cd5b-4234-a496-aab9dc302411" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_9728c8f2-bb11-427e-bb98-bb1620918c0b" xlink:to="loc_us-gaap_OperatingExpensesAbstract_52043c22-cd5b-4234-a496-aab9dc302411" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_0be25d8e-f586-4c95-b611-8b36f613a7c0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_52043c22-cd5b-4234-a496-aab9dc302411" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_0be25d8e-f586-4c95-b611-8b36f613a7c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_2ef73b4e-e9cb-4f82-9afe-2b82b6018932" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_52043c22-cd5b-4234-a496-aab9dc302411" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_2ef73b4e-e9cb-4f82-9afe-2b82b6018932" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_5e8396d0-a55d-4b14-a121-336a1a263511" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_9728c8f2-bb11-427e-bb98-bb1620918c0b" xlink:to="loc_us-gaap_OperatingExpenses_5e8396d0-a55d-4b14-a121-336a1a263511" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_28b2a7e6-246d-4480-bcf2-9efbafac232d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_9728c8f2-bb11-427e-bb98-bb1620918c0b" xlink:to="loc_us-gaap_InvestmentIncomeInterest_28b2a7e6-246d-4480-bcf2-9efbafac232d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating_2e57a805-d274-48fa-b4eb-d6f1a4fd57c5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_9728c8f2-bb11-427e-bb98-bb1620918c0b" xlink:to="loc_us-gaap_InterestExpenseNonoperating_2e57a805-d274-48fa-b4eb-d6f1a4fd57c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_94112808-1a63-45d0-b2d9-2c778d47d762" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_9728c8f2-bb11-427e-bb98-bb1620918c0b" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_94112808-1a63-45d0-b2d9-2c778d47d762" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_fcc59408-359a-487d-9859-45b09b10df43" xlink:href="ino-20250331.xsd#ino_ChangeInValueOfInvestmentsInAffiliatedCompany"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_9728c8f2-bb11-427e-bb98-bb1620918c0b" xlink:to="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_fcc59408-359a-487d-9859-45b09b10df43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_c8f687af-022e-4ff2-8bd2-ff2edf05d9b9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_9728c8f2-bb11-427e-bb98-bb1620918c0b" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_c8f687af-022e-4ff2-8bd2-ff2edf05d9b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_35e6a6be-4734-4902-8492-62bcf6e3e0d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_9728c8f2-bb11-427e-bb98-bb1620918c0b" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_35e6a6be-4734-4902-8492-62bcf6e3e0d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_e5cb0593-36f6-43b3-b31e-4be6fc490f68" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_9728c8f2-bb11-427e-bb98-bb1620918c0b" xlink:to="loc_us-gaap_NetIncomeLoss_e5cb0593-36f6-43b3-b31e-4be6fc490f68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardTimingDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaap_AwardTypeAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_EmployeeStockOptionMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardExrcPrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ErrCompDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompRecoveryTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_RestatementDateAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonNeosMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_ecd_NonNeosMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDeterminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_ExecutiveCategoryAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="loc_ecd_AllExecutiveCategoriesMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_PeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_NonPeoNeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_AdjToCompAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllAdjToCompMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="loc_ecd_AllAdjToCompMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_MeasureAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TabularListTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_us-gaap_NetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_OtherPerfMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_MeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangements"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrByIndTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TradingArrByIndTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_TradingArrAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllTradingArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrAxis" xlink:to="loc_ecd_AllTradingArrangementsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndTitle" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrAdoptionDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrTerminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrExpirationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrDuration" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingPoliciesProc"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>ino-20250331_g1.jpg
<TEXT>
begin 644 ino-20250331_g1.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_X@Q824-#7U!23T9)3$4  0$   Q(3&EN
M;P(0  !M;G1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@
M<U)'0@                  ]M8  0    #3+4A0("
M                                             !%C<')T   !4
M #-D97-C   !A    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "
M&    !1G6%E:   "+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D
M   "Q    (AV=65D   #3    (9V:65W   #U    "1L=6UI   #^    !1M
M96%S   $#    "1T96-H   $,     QR5%)#   $/   " QG5%)#   $/
M" QB5%)#   $/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L
M971T+5!A8VMA<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV
M-BTR+C$              !)S4D="($E%0S8Q.38V+3(N,0
M                                                    6%E:(
M     /-1  $    !%LQ865H@                     %A96B        !O
MH@  ./4   .06%E:(        &*9  "WA0  &-I865H@        )*    ^$
M  "VSV1E<V,         %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M    %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M                                  !D97-C         "Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M     "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M
M('-21T(                             9&5S8P         L4F5F97)E
M;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M    +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR
M+C$                                  '9I97<      !.D_@ 47RX
M$,\4  /MS  $$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P
M       !                         H\    "<VEG(     !#4E0@8W5R
M=@        0     !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4
M %D 7@!C &@ ;0!R '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$
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M])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SWG62=TIY
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MX5.2T_$F1&."E:+"18,H1F2EQ"='9H2C_\0 '@$!  (# 0 # 0
M  <(!08)! $" PK_Q !=$0 " @$"! ,$!@4%"P@'!0D  0(#! 41!A(A,0<3
M00@B46$4(S)"<8$54F*1H3-RDK'!"20U0U-C<W2"L_ T@Y.BH[+"T18E-D2D
MQ.%59'64M,/Q%U32TQ@FA/_:  P# 0 "$0,1 #\ O\(B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (G*\,Z \
MHB\<H#RB\<KR@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(O'* \HB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M20"N8;*1@+W,5>$/)IZTA<#(S-'9@**U!S#-&ZR#0!$1 $1$ 1$0!$1 $1$
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M_AM'>QMH'<2*-I!Z@(2%PGKR-T2,SA(/RM#CNAM)D]*9.3'9*+D7<CIVP9_
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M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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MG*OX#Q* P41$0!$1 %(KW2OTQ>V?]OU=_![JY1U*17NE?IB]L_[?J[^#W5R
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M#K/_ .(9/^\98W@C_ ^F?ZEC?[J(1%X6BFTE [M%9-KV\VZMEG%V_FA:O@Y
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MO$W#&>.MWL+9=N?,^9@R]<B9O-@&")BXX<AY<FVW1O;AX'R6ED6:IIN_=Y>
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M!+)XNU1LV:-ZO+4NTK$U2Y5F'IFJVZTA0V*\H_H9(9@.,Q^0A=O/WN!Z*(B
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MBO=*_3%[9_V_5W\'NKE'4I%>Z5^F+VS_ +?J[^#W5R N]HB( B(@"(B (B(
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MFFLSJ;(NXB5;#T9K?@N3.XO:F 6KTXW82+Q;<T$3"+DYLS.[3;=G;T>+<S4
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M2]R(JV3B;R8J]Z$V$&+I8#,I$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M2JXIJQ31'[<-N>U&7F+NI,$ 1$0!$1 $1$ 6!7>@?$'N9]@X?PKCUGJL"N]
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MB(B (B( I%>Z5^F+VS_M^KOX/=7*.I2*]TK],7MG_;]7?P>ZN0%WM$1 $1$
M1$0!$1 $1$ 1$0!$1 $1$!%1WT7Q ZD^S.DOQDQRIC*YSWT7Q ZD^S.DOQDQ
MRIC( B(@"(B (B( B(@"(B +GFV.YN<T=G\7J;3E^;&YG$6H[=.U"1-[0/\
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M-F$;T?/W?R_S+^'I+F94_P"7\F7Y%2^L_P#+^\JUK*^9RDAJ_IN^WR,-MS<
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M'4R2 (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M4TDAU9"DZ:&0=H6C]7NE)4M1H#RB(@"(B (B( B(@"(B (B( B(@"(B (B(
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M$1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1
M$0!5W._?[2HU<9I_:O'3\V,J4>IM2"#O\[QM2<XL)4EX\G>YD(;-UXW=RC;&
MUY#C9IH#>P=G,W4QE*YD;\X5:-"K8NW+,KNT5>K5B*>Q/([,[L$40&9<,[\"
M_#/Y*@#VHM^KFYNOM2ZVMM+&&9R$AXZK,3$='#U^*^)HD[$0L=>C'$TW03@]
M@IB#V29F Z"1$0!$1 $1$!W?V;=C[VY&N=-Z*H/($F=R,5>S8B9G.EC8F>QD
M[S<LXL]2A%8F!R9Q>00%V?JX6P#TMIFCA<9C\/C*X5,=BJ57'4*T;<!7ITX0
MKUX1^7B.*,!9WY=^.7=W=W5>3N'NS6,=;4.ZV0KB4EIYM*Z;.0.>BM#+#/G;
ML'5Y,\UF.MCAF%NH6J78!-ADG K'* (B( B(@"(B (B( L"N] ^(/<S[!P_A
M7'K/58%=Z!\0>YGV#A_"N/0%&1$1 $1$ 1$0%O[N,?B4L?;OJ#]Z8=3)*&WN
M,?B4L?;OJ#]Z8=3)( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (O7M6HH(I)YY(X888SEFFE,8XHHHQ<Y)))#=@", 9R,R=A$6<B=
MF9U6=[Q;O?Y;SW]#;1WI*],2DJ9G7-8Q&6Z/'3+4TQ(/)PUW=RCES7L33<.V
M,\.+HNR@9M=X%WL6"VT:[I71)4M1Z\%O!LR.7CX33,AMYED)(28;V3B'Z'$P
MS#X,CB^0EB8?5IJFVX^Y6>U?FKVH=396YF<SD97EM7KLKR2%R[N,,0^4=>K"
MS]%>I7"*O7CXCAB 6X7"Y)",B,R(S,B,S(G(C,W<C,B)W(B,G<B(G<B)W<G=
MW=?P@"(B (B( B(@"(N6:&T'F]3Y6I@].XF_F\O>D:.KCL;6EM6I7=^'+PXA
M?PX8V]N:Q*\=>"-BEGECB C8#B:[>V;V#UGN%DAQ.C-.9+/W',0E]3A9JE1B
MX^>9#(SE%0Q\3,[.\ERS /FS"Y$0B\\'9'[C0Y&KYK=[(] D+2!H[!V7:1O/
MR',YN)VZ7=F]JIB?H6=G?)]77$%A7;?:W3FC\5!A-+83&X#%5F9HJ.+J15(>
M>/.61HA8IYS?VI;$Y23S&[G+(9DY.! UV6NXJQM3U;+;KY@LI8%AD^97 3'7
MQ@'RS^'DLPXC<O WN*"@&/C=V]JS8B)XU/+MQM=IS1^+APNE\)C<#BX/,*6,
MJ1587/AF>67PQ8IYS9F\2Q.4D\G')R$_FN>H@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( OEYO!TLE4
ML4,C3JWZ-N-X;5*[7BMU+,)?116*TX20S1E^B"0"%_E9?41 0I=J'N3= :L>
MSE-"VI="9N3KD:E$'KFEK4I<OP>.+BSC7(N&:3&V1KQ"Y/\ !\I.+C7*[2G8
MGW(VGLF&KM/SQ8QY.BKJ+'OZ_@+G/T'1?A;\R2EP[>JY&.G:Y9W&$HW"0[\2
M^=E\/4R%::G?JUKM.P#Q6*EN"*S6GC+Z*.:"83BE OE Q(7^5D!K@$5KOM:]
MR/I+48V<OMC8AT9FG8Y?@*=IYM+7I'Y)XXF%Y;6"<R^A*F%JC$W$88X Z2CK
M7;Z=G?6>VN8+":TP-S#6^3]6FE#Q,?D8P=N9\9D8NJI?B9G'K>"4I(7(0GCB
M-W!@.E41$ 1$0!$1 %[%2Y-7FBL5YIJ]BO+'/7L5Y9(+%>>(F.*>":(@EAFB
M,1.*6,QDC,6("8F9V]=$!9/[OOODO%*EHW>&W&!DX5L7KLV\.,O98(JVJ %G
M$)"-ND<Y$T<+]8-D88NB;(26.:EN*Q%%/!+'-!-&$L,T1C)%+%(+''+%(#N$
MD<@.Q 8.XD+L0N[.SK6[<*6_N^.]+SVU4U33.JCN:AV^.2*".!R\;)Z5C.3@
M[.'(WZK&/C8_$GPTDG2(@Y8UX)7."R!<B1<*V\W%PFK,-0U#IS)5,OALG"T]
M*_3E:6&4.7$A?CVHYH9!**>"00FKS <,P!(!"W-4 1$0!$1 $1$ 1$0!$1 $
M1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 5%KO-OC[W-^SE
M7\!XE7I51:[S;X^]S?LY5_ >)0&"B(B (B( I%>Z5^F+VS_M^KOX/=7*.I2*
M]TK],7MG_;]7?P>ZN0%WM$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$!%1WT7Q ZD^
MS.DOQDQRIC*YSWT7Q ZD^S.DOQDQRIC( B(@"(B *[3W1_Q!Z*_NQ^&;RI+*
M[3W1WQ":*_NQ^&;R CD[X?N[G/U[=_1-%RE_H^N\16%N"C"-A?5%.$1Y>0&
M1S<4?]$#C*,#F%^22MBSK9%SP!*!QR ,D<@D$D9BQ 8&SB0&),XD)"[B0NSL
M[.[.SLJ>?>I=WH6UN;+5^E*9?S/L[99GKPQ_.]*Y>P9<XLNGD8\5;+@\1([
M,).>,=N8JTE@"(!$1 $1$ 1$0'\D+$SL[,[.SL[/[G9_>S_6=6P>Z/[Q3YM,
M?!MKK6_U:PQ<#CI[)63?Q-2XBK"Q/7FE/^B9O&1 ;R\NYWZ(-:]J>"X3U0%]
MO3>I,AALA1RV)N6,=D\;:ANT+]20H;-2W7-I(9X)1=G P-F?Y6)N0)B B9P-
MCHO*CD[N3MVX_>;2K!>.M4US@8*\.IL7&0AZRS_.HL]CX'X+X/OF#O+&#&./
MN.520W$JTL\C: (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@(GN^J^(3.?9[2GX<JJF@KE_?5?$)G/L]I3\.55300!$1 $1$
M5X;NI_I?MN/L?E_QDS*H\J\-W4_TOVW'V/R_XR9E 2%(B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B\.@(/>_;[9TFVNU;:3PEOU?56Y$EC"P
MG&7$U#344;/J+(!P[$,L\4L&'K$W#B>1EL@7748#I-[>:6/*WH:PL[0#Q)9,
M?T$(^3LS_P!,;\ #?5?GAV%UFYWNG:BDW3WVU;?@M>-I_2TWS&Z<C&1S@"E@
MCDBR-J/R$'/(YLLC:*1AZG@*K7(Y JQFNO=J-.1XG&0-89X[>3%YI'?V3 &
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MTK$5FK,<-B NN.4/HA+W.W'T+B[<B0DSB0NXDSB_#Y[[-[Q4]11M4L=%7+Q
MY20?0Q61'R>>HY._/U9('=SB^3KCX-1F%-]=>:V1FKRQSP2R031&TD4T,A1R
MQF/F)QR [&!L_FQ"[.WNY7%75^&ZLROE?N6I/R[$NJ?PDOO0;[K=;=TUZPKX
MX^SII/&VG>3?MAZICPE^CM5K@I6T2>\O)OC[OGX<Y/WZ7).+;LIE">[E-J(,
MR\]3+A79=J:OU[H[/:GBPLUREI.W5H9C(4V\1R]:@*P-IZ48O*(5XA$K\D8G
M# ,@3EX<3R-%RYB;W\^7U6\_[RAG6]#R]/G"&7193YT';1.4)*O(J4Y5>;1-
MI*VM60G6Y1WY9PE7+EG&45Q,X[\']:X6U.>F:WB3Q[UO.FU)RQLW'4Y5QRL.
M_90OHG*$H\RVG"<9TW0KNA97'^W)<1UMHRAGJ$N/R$77%*W(2"[#-!*+/X<\
M!NS]$D;OY>3B3.X2"<9&!<H(_J+\G?ZJ_'0>(L[2L[$U/3<N_ U# R*LK#S,
M6R561C9%,E.JVFR+4HSC)?@UNI)Q;1Z.&,;*P<G'S<*VW&RL6V%^/D4RE7;3
M;6U*$ZYQ:<91:_L?1M')^P]WC6J>S]E:^A];O<U%ME*?1CY(Q*;(Z>@>0?S5
MA.H^9:$0GQ>P!._@FPR8R2%G>*]:1U[J_!ZZVLU%EM.92IF,+F](YN6AD:4O
M7!8B+&VF\B<>N*0#%XYH9HPF@E$XIHXY0(1J+:UT;1SU$Z-Z)B!_;BE9A\:M
M,S.P3P$[/T&/+L[>8F+N!L0$0OUOV<>UCKWL_9?(XJ(CS&D,[#8ARFG[$TL6
M,R4-F ZIY+%R/XXXO-0B0^)+$!^-X<<%T)X/ D#OS[-WC_I7C%I=N!D2Q=+\
M1\+#F\[!7)CX7%-%=;5FJ:='W:Z<UKWL_%CM&NR3NC'Z+-V8_>WV5_:NCQ'I
MRTC6W&O5J<=UV+;ECE5J'(\K%CV:VV>3B1]ZAMV4)T?5U]JZ%/KQI?+S #_+
M_2L_N_E_YSA]S1D_^1]?TN?.+/8RVP^UY#8QSPOQ^@9G*J_N?GGGEN.'4#NT
M.I*F3H2R4Y6,6!QDC=V\6$G;EHY1;S$N/<_'2;>T+NSLZFC[FG(].:W)HN_O
MIZ9MQCR7M<3YN&8N/H&Z?S.SOY$74WO$?*K?A)IV5I?&UNGYN/=BY54\JB_'
MOKE5;59'%MDXSA-)Q?N)KIM)---IHFWPZFX:MIR:V;636T^G7Z-=+K^<>A/2
MB(KUEI3$_MU_$YN3]J.7_>Q*J?I__FL_^[_X.K6';J^)S<G[4<O^]B54_3W_
M #6?_=_\'5-/:B_Y5IG^B7^_D5^\6/\ "6+_ *C+_>VD_/<]SF^WF=C<G<(]
M6W>@?+@>NCCR+C_O/YJ6=1)]SQ\7^H/MMM?@['J6Q62\-/\  &E?ZG7_ &DI
M\!O_ -3X'^@7_>D%$]WQN2>':W#PLY<7M=86L[,S.SM'BL_>X)W\V'FFSLX^
M?6PM]"[NTL*AJ[Y^^S:-T53]GF;6+V>'=V+BK@\I$[LWN<6]=9B=_-G<./>Z
M^?$F[DT+5)?_ '64?Z<HP_\ $?7C^SET;/?QIY/Z<X0V_/FV(.<A[.*#_P"^
M_P!5E:7[O_'>K;-;?!QQXF"&UQT]'+7;=JZS\?*SM8YZ_P#K&?K?Z)59,^73
MC8V_[!/_ "_O*SCM=O5I3;+93;C(:KRU;&Q#H32[15O$::]D+98*E--!C:8O
MZQ=E>0S+B('"('ZY2BC9R:KGLWYN/B6ZQG9=]6-C48TG=D7V0JIJ@\B#<IV3
M<8Q7N=VTO3N1+X:95&-E9N5DVUT448"\VZZ<:ZZXRMK;<YS:C%>YW;Z^AG5+
M((B1D0B(LY$1.PB(BW)$1/PS,S,[N[NS,WO4&G;S[T[%8^KE=$[=209C*6X;
M.*RVI79Y,5BXYP>M:BQ3^0Y/(B!R -ENJA5E;JYN&)0C@1VR.\AU5N2UG#8C
MUC2VCR?H+'5K+MD\M&+OYYF[ X,\$OD18NN[U&9F">6YQUO&$(,\L8LW#=3-
M]1O\RUGQ/]JZ6?DUZ/POS5X]^15CY&K60<+KH661KE#!JFE*B$E+;Z3;%7--
M^554U&UZ'Q[[0WTRW]': W&B<U5=J,XN-EL92Y91Q*Y)2J@T]O/L2M>[\N%3
M4;)9,:(B:/'F[-PS1,+,W[3-_>X6*N[,W5=C'^EC-_\ YBX__(\OVUEK@!Z,
M4;^[EA;_ #%[EAIN1,QY$^'YZ(P!^'Y\^9"?]O@FY5?^+;O[UU![_P KDT5K
M_9FK=O\ LS3.(7RXM4?BXK;\]_[#J.W\O[7^E<8M_+^NZY/;^7Z_#<+E^WVT
M&9U1E:.)Q6/N9#(Y&<:]'&4H7ENW)2_0B/+-#&PLYRS2N,<43'+*<<8/(WE\
M+?"?7^+]06FZ!I]N9<MIY%W2K#P:-_>R<[,LY:,6B"3;E;-2GLX4PLM<8/&Z
M31.R<8PBYM[)))O=M]%T3ZOLEW;Z(RPV>M-=TWBY?>\<#U2?Y>JJ90<?6\HV
M;ZG''"['>E];C^7\OD636Z78ER&S&"TE4R=V&Y=S]?(7+\56-O4\9?KG3\3'
M03N[G;:.&S"4EJ1A\>SZR4(-"(\=%/$+_)_>4%^+W!=O#'$NKZ#=D4Y=FG9*
M@\G&5JQKXWTU94+*/.C79*IUWQY)RA%S7O<JWV.%7M)<*Y/#G'?$^DWU.F5.
MIVY,*WM[E&HPAJ6-'IT26/EU;)=NW38XJ]'ZW^;S_P!"X)J:R.*R.!RQM[ W
MWQ-@N/9"OF0&"(G_ +IPXUG=_9$',G\F7<;PCS[EU/OAACL:4S;0L[SUJ1WX
M&%GZO&Q[M<CZ>GSZ^J'@6'DN7;I]KA93P'U&F'&'#U65/R\3/U&O1\NU_P")
MP]=A9HN9?W[T8N?=:GZ.">TMMGY_9ZXUEI/&_#&:VX06K8V-=+?;EQ\^3T_(
M;VVZ*C*LW]-M]U+LY;>ZT[/YZFU=<U_DX7+$:5(JN(8Q^=V]16(FZIFZOH@Q
M5*1S\F_/5RL3$/JY@=BAEB#V!<?I^'9W;Z?37MXS)Z;H9@IRZ/'M9#*Q-=RD
M]MP\FM/?FL!+$[\UGC:HPQA7&,,OUVZX%X(_]'M/KTV<5')JE+Z;MU_OO[-L
M4]EO&IQ54'LMXP4FDVS^KS@K0XX&GTU])66I7WS3W4K;8IO9^L81Y:XOUC%2
M[MGAU7@[\SMB/0Q539C 6^,EJ*&OD]9' []=73K3.='$G(W]#DS5FOXMJ-G\
M1\96>*86KY$6EG(WOW@Q6@]*YG568+BGB:9SC#U"$MVT_L4Z%?J\GL7;)1UX
MFX?ASZR;H G:G#GL:.MM2YK6VIX MYC.79<C>E*29P9SX""K$Q2-TUJ=<(JE
M6-F9@@AC%F;AUL=7C/PWP;J.+G<04Y^8JHRR,;#TZG'NMG?"2C3.U9.3BUQA
M&7-.OWVY6UQW7*I;ZKXI\2RQ\5X&-)++S*Y)MMI58_6,I2:3:=KWA'H]XJSL
MTC!KF/&T?D$R#E^>/(6;ZO\ +_.ZM3]RWV.2T9HZ7<;/5"AU5KVK&5..<7:Q
MB](M*,^.KN!,SP2YHXX<Q:!O:*#X+CG8)ZQ110S]BWL8R[J;P08JW ;Z)TV=
M?4>HY.'*&>@TY/CL!UOPW5EKD!U91Y>3X-KWI0]L&)KHM:M'" 11 $448#'%
M%&(A''& L(  "S"( +,(B+,PBS,S,S<*UGB_XPXFK:1IE&CW^9BZMAXNIW6+
MI)8N17&[&QK$FU"V3:LR*V^:MPA%])21'/@3P).N5VKYD4[7.RO'WZISW<;+
M8M]=HK>N#[-N;[Q1^Z(BK"6<"Z?W[WOP.W&D<YK/4MGU?$X.F=F41=GL6YWX
M"ICJ<;NSS7LA9**I4A;Z.:4.IQ!B(>WW?R\_+Z_U/K_M*FQWK?;?/=S6@Z0T
MS<>70&CKDL,<U:;KJZFU!$1P6\PY1\!8Q]%NJEAWZI8I6]9R,9D-NOX,A>&O
M ENOZC#&7-'%JY;<VY?XNG?[$7V\VYIPJ77;WK-G&N1I_''%M.C8%F58X^8T
MXT0;^W9MW:W3<(?:GMZ;1W3DC!;>7>7/;KZWS>O=3'Q:RDWYEIB3E6P^)KNX
M8[$U!=WX@IU^&(OHK-D[%J5RFL2._,.S?V>LUO#KO$Z'P;20UYB]9SF5 .J+
M!X*N0^NY"1R9X_&)G:O0B-G]8OSP1=+Q^(0='VAF'U;%XZO-;O6YH:E6I4B*
M>U;MV#&&O5KP1"4DT\TT@10Q1B1R2D("SD0JYSW:_8CK[-:(CBR 0S:UU$\6
M1U7>%@-X)G#FK@JLHN?-+$1D\;D!D%J\=RXW 311Q7'\3.-,?AC2(4XD:X9-
ME?T;3J(I<M<:X*+N<>OU>/%Q:3W4['7![J4VJF^'7"U_$^KV9^9SRQ:I^;;*
M6^\^:3:@GZ3N:?;;DK4FMGLGFOM3M?A=%:<PVE=.U!HX7!4(,?0KL_4310 S
M/+-(_M3V;!]4]JP?,D]B26:1W,W==@HBY]773LG.RR4IV62E.<Y-RE.<FY2E
M)OJVVVVWU;ZLN_77&$8PA%1C"*C&,4E&,8K91271))))+HD$1>'=?F?<@V[W
MW:@0ETSK:"/@I6/3F1,6?@G!I[^,(W]S$POD 9_HB;I%WZ8Q952NVSI/YYA<
MU&+>V$^-LOPWFX/ZS4=^/^R]L7=_D:-O)F5@3O/N\2IZJU=2VITA)5O:>P>5
M:356=B>.Q%>SD$-FO%B<9*S$+5\1-*[W[<1<SY ?5(W\&M.\\//:@P;7='WS
MZ>3HS5;8OQR[,,X0R<?6Z)GZO^R+_(WERB]K[PXR^#_$_1=4MH^C8_%VG8VH
MPC]GW[K+M*R(V0Z<MDG1CYTUMU^DPG+ZQS2Y[^.\,5ZUGV8DE.,X5VVN'V5D
MUQY;E%KONZDY2[.<Y]UU>$W8J[5N7V1W+T_N!BFEFAH2O2U!C8W9OAG35TXF
MR^-X(A!Y2CBBMT7,A"/(U*<IDP@2V5^A=:XO4F%Q6H,+;BOXC-8^IE,;<A?F
M.S2NP!8KRC\HN<1BY 3,<9=0&S$+LVJ[MU??_+^^KBGHY?:X/.Z-S^T>8NO+
MDM%SEF=---*SS'I3*2"UBC$QOUR1X;,E,X.SDT%7*5*K###7@8K*^SKQNZLF
MS1[I/RLKFNQ=WTAD0CO9!?!6UK?^?6MEO.3-M]FKCWRLNS1KI[TYN]V+N^E>
M57#>R"W]+Z8;_!3IBDN:R3++:(BN07;"(B (B( B(@"(B (B( B(@"(B (B(
M NN]VMLL9K/3&=TIF <\;G\9;QEOIXZXPM1$ SQ<^RTU>1PL0N3.+2Q@Y,[<
ML_8B(#74;F[<Y72&H<UI;-QM%EL!DK6+O,'5X1S59'C\>!R9B>M:#HLUB)A(
MJ\T9$(N[LW!E/YWZ_9I?%ZDP>Y^-@<:.HJ\>!U T<3M'%F\>$LF.O2F/+=>2
MQKO3/J8!8L3"0O))9DZ8 T 1$0!$1 %;*[CKM)-J'0=[;V_8Z\IH:<I<<)E\
M]ETWE;$L]<6Y\Y QV0.U49_-H*LE"!F$!CYJ:K,;L$=H]]J]T=.ZHFF>'$22
MEA=1^VX1O@,J<(7)9N/(HZ$T57*])<MUT )FY9G8"^4B_.*43$3 A,#%B A=
MB$A)N1(2;EB%V=G9V=V=G9V\E^B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B+^3-A9R)V869W=W?AF9O-W=W\F
M9F\W=_)F0$,/?9=I-])[;P:,QTXQYC7UHJ5EA?B6OIJBS3Y:4>'Y$KL[TL8/
M4'25>U>(3&6$.:AZSL[Q_M'EN;NUJ3+U[+S8+$RMIS38B?5".,Q3E%-:CZ>
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M-F5PDK9+5KA(_P ]O,1#)5PIL('6Q11Q3S,[RY3ERCI5(=T1 $1$ 1$0!$1
M%_)&PL[D[,S-R[N_#,S>]W=_)F7;6S&QVJ]PLY6T[I#"W,SD[!!UC7C=JU*
MBX*YDKA<5L?3C\W.Q9DC%W;PXFDF*.([5/8?[H326W?JFH=:^IZRUD'1-$$]
M=CT[@IV=C#X.I6&+U^["3,XY.\'(&S'3JU#%I" AG[%_=(:YW+]6S>I1GT5H
MV3ID&W<A9L]EHG\_^2<7,/,$),[<9')#%"[.SU:UUF/HM-]G/LHZ%VJQ0XO1
MF#@H=<<87LG-^:LSE3#AWFR61D;QIB,^9/!#P:<)/TU:L$0A&.1;,O* (B(
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MV[CK836A-+9O8=GAK874\SLYF3\L$>+S,Q>37>L*-HR_-\<9D5T*I>KM(Y7
M9.[A<WCK>)RV.G*M?QUZ$H+=2<>'>.6,O=R+B8&+E'+&02Q&<9B3@<=1$0!$
M1 $1$!DGV5^U1JG:+5,&IM,6.6+PX,QB)R+X.SN-8^LZ-T&YZ2;DCJ7(V:Q2
MG?Q(G<"EAENX=ESM1:7W;TI5U5IB<_",O5LEC+/0.1PN2  .?'7X@(A:0&,3
MAFC<H+4!QSP&XGP.O\64G9&[6>I=GM5U]28"4IJLKQU\[A))"&EG,:Q.YUIQ
M\VCLP]12T+C"\E6QP_MP23PR@7[$72/9Y[06F]S=*X[5NE[C6<?>C89H#<6N
M8R\  ]O%Y&%G?P+M,RZ) Y<)!Z)X#EKRQ2GW<@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B *BUWFWQ][F_9RK^ \2KTJHM
M=YM\?>YOV<J_@/$H#!1$1 $1$ 4BO=*_3%[9_P!OU=_![JY1U*17NE?IB]L_
M[?J[^#W5R N]HB( B(@"(B (B( B(@"(B (B( B(@(J.^B^('4GV9TE^,F.5
M,97.>^B^('4GV9TE^,F.5,9 $1$ 1$0!7:>Z.^(317]V/PS>5)97:>Z.^(31
M7]V/PS>0$DZ(B *.KO&.PE0WHTJWJ35J6ML$$L^F\K( #X[.SG-@K\W#'\'9
M F9P-R=J5QHK8LX-8BFD51 :XG4>F\AA\A>Q.5IV,=D\;;GHY"A;C>*S4MUI
M'BG@FC?S$XS%V^42;@P<@(2?XJMA=[CW=_S:XZQN7HRESJ[#4^<]C*PLQZEQ
M%4>?6(8A9O$S6,AZBC\VDOT0>HWBV(*415/?Y?K?K_7^1V^1 $1$ 1$0!$1
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MC=@?R<H9QXZ@+CD)8RZ989&\XY0 V\Q95$MR=L,GMUK#-:+S/)OC[)-3M.W
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MK@W)S6)GBKPQB4LTL<8$33H]GKN/[DG@7MS=0QUH_(SP&F)'FFZ?)_"MYJS
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M;S$XS$3 F\Q)F=O-E?'[!G:-#=':[3&IY) ++-3'%:AC N7BSN,8:M\^GEW
M+I .1@!W=QKVXA(B(2=4,U.7W&_:2?3^N,KM[D+#MB]:UVN8H"=NB#4F*AD-
MQC]SC\)XII@E]_5+CJ;,P\F1 6Q41$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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MFL:!U!.9X&V[G*6*M.Q2S:>OR%R7BUQ8I<?.9%ZY2;S)[->RS1G( B(@"(B
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MMVY AP)LF4 P4*$,UJY9DCKP5JL1SV;5F8ACAK5H(1*6::60PCBAB$CDD(0
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M?4'[TPZF24-O<8_$I8^W?4'[TPZF20!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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MTM!.3%)A")V<;!GC!<VFH11V9UK=:]B2&2.:&22&:(PEBEB,HY8I8R8XY8I
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M?\9,RJ/*O#=U/]+]MQ]C\O\ C)F4!(4B(@"(B (B( B(@"(B (B( B(@"(B
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MEM"S@]!I#YDL::R9R25' 2?J=L9>&U2D86Z(8),<W5U3=(@3?(B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@/E9W-U<91N9*],
M%:ECZMB[<L2.PQP5:L)SV)C)_)@BBC,R=_)F%U0)[5V^]K<S</5.M+)$\>7R
M4GP9$74WJN%IB-+#U1 O,'CQ\$!3-P'7:DGF(!.4F5G/OK>TFVDMM T;1L>'
MF=P99<?(,4G3-%IRB\$N;D<1=B:&YXM7%&S^S-#=LQ\$S'TU!T 1$0!$1 $1
M<IT1HO):CS.*T_AX'LY7-9"IC,? S$[':N3#!%U] D0Q 1^),;"71")GQP/"
M L5=PYV;""#4>ZF1KN/K#EI?3#FS<E!"03YZ^'D[]$EAJF.A+J9^NID!('%X
MC>QZNH=@]GL=M_HW3FCL7P533^*JT/'Z&C.Y9CC9[E^4&(F&:];*:W*+$0B<
MSB+](BR[>0!$1 $1$ 1$0!$1 $1$ 1$0!8%=Z!\0>YGV#A_"N/6>JP*[T#X@
M]S/L'#^%<>@*,B(B (B( B(@+?W<8_$I8^W?4'[TPZF24-O<8_$I8^W?4'[T
MPZF20!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 ?$U)J.CA\?>RV4M0T<
M;C:EB]?N6#8(*M2K$4UB>4G]T<40$9.W+\-Y,[^2HX=X!VR;^\VN;.68Y(=+
M8<[&.TACB$@>'&=8^+D;,9/Y9#+G$%JSY#X$+5:7!>J>+)*7WUO;C]8F+9S3
M-MW@@>"UKF[6G;IEG9QGI::?P_-VAXBOY43)A\0J55P(@LB-<Y $1$ 1$0!$
M7AR9O>@/IX;#6\C<JX_'UI[M^]9AJ4JE:,I;%JU8D&*O7@B%G*2664A",6]Y
M.WN;W7)^[,[O"GM%@QS^H((;6XF<J V2G=XYXM/4Y.)&P>-D%G%I&=Q^%;D9
MDURQ&,<1^J01=>./=&=W0VDZ57=#6^/;YJ<E TNF,3<K<2Z:QMB)Q?(SQSCU
MPYS(PR$ CT1RXZ@90N3S6[ 0SRH B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"Q+[9/9#T[O)I&?3N:%JU^OXMK3N
M<CC8K>$RCQ](3Q^YY:ECI"'(TW(0MUVZ>0GC@FBRT1 :\7>W974.WFI\GI'5
M-)Z.7Q<K#(+.YU[5>1NNK?HS<,UBC<BXEKS,S<MU1R#'-'+$'5*N\]XMV#L=
MO1I?FDU>AK?!QR3:<RT@"PV!^CFP>1D9Q)\??=N(Y7)WQ]SPK@"<;6(+%*+4
MVF<CA<C>Q&7I6<;E,9:GHY"A<B*&U4MUC>.:":,F9Q,#9VY;D3'I,"("$G ^
M&B(@"(B +MG8W>G.[>:JP^L--V/5\IA[(S )]3U[E<O9MXZZ D+RT[T#G7L
MQ"3";21&$T<<@]3(@-@UV;.T'@=T-'8C66GI'>GDHB&Q5D?\TXS(UW\*_C+8
M\"[6*=AB#JZ6">)XK4/5!/$9=[*EUW6';?+:?6@XG-V^C0VK9H:F8>>4A@PN
M1?B*AJ .7\...-^FGE'?I%Z$C63/JH1@=T*.02%B$F(29B$A=B$A)N6)G;R=
MG;S9V\G;W(#^T1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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MPG%[QE%]FG_6NZ?1[-%?3O(^Q86F[=K<W1U3IPUF5IM5XFJ#\8RU*;L6<J1
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M;V2R-R4I9I781=R,S)V".(1CAB$8HHXX8P 9U-8T:&3C. @\2*>,HYP(&Z"
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MC",4DDDDD6WQ<6JBN%--<*JJHJ%==<5"$(16RC&*22279)!$1>X] 1$0!$1
M$1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!=7[Q;1X;7.G<EIG/5VG
MH9&!PZQX&Q3LBSO6OTY'9_"MU)>F6$G9P)Q>*8)8))8C[01>/4=.HR\>[%RJ
M:\C&R:K*+Z+8J=5U-L7"RNR$MU*$X-QDGT:9^.1CUW5SJMA&RNR,H60FDXSA
M);2C)/HTTVFBF3VDM@\[MCJ:SIW-1N8><^*R8 0U,MCB+B*U7=VX8P_H5NOR
MYUK#%&7(%%))B;N#CO7\;(P#U35W:S%[^7Z&=I ;AO-RC<NEO<Y,S?+RKM7:
M.[.6G=S=.3:>U!"0^93XW)P,#7\1>Z'".Y3D)G;Y>FQ7/YS:AYBE;Z @J/\
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M"VEQ5:_9]8U!HTFTSEW(W*:>"H'.%O2=7).5G%/7BFD<B\6Y5M2\BQL R=H
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B*.WO0^TO_
M #--I<W:J3M%G]2/\R^GQ$F\4+.2BE:]>%N'(1QV+CN61DXZ&M-4@<P.Q&[@
M5=.\F[2G\T_=C4&5J3O/@L*;Z9TZ0NSQ28W$SSA+=A<7=BCR60DN7HI.7<Z\
MT#OTLP@&!B\,W#<?47E $1$ 1$0!3H=QMV:FS^MLIN+D8.O&Z,KE1Q'6/(2Z
MDRL#@4[,_LG\&8HYW9G$NBQD*LXN$M>-W@T@@DE,(H@*664PBBB!NHY)9"8(
MXP%O,C,W$1%O-R=F97SNPGV<HMK-L--:4>-@R8UGRFH)/9ZY\]E':UD',A;@
MFJD4>.K^9.%2E7BZS:-C<#+U$1 $1$ 1$0!$1 $1$ 1$0!$1 %@5WH'Q![F?
M8.'\*X]9ZK KO0/B#W,^P</X5QZ HR(B( B(@"(B M_=QC\2EC[=]0?O3#J9
M)0V]QC\2EC[=]0?O3#J9) $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 %@[W@
M7:\J[.;?W<Z#QRZBR9%B-*428)/'R\T)FUN:(G;FCBX1*[;)V<2Z(:O#RVHA
M+-7(Y""I!/:M2QUZU:&6Q8GE-HXH((0*26:4RX$(XXQ(S)W9A%G=^&94:^\1
M[7D^\&XE_+5IC^97#=>(TE6?EA^#HB'UC)R"_OLYBT!W'?I%XJ?J=1V(JY2R
M@819G-7,E<M9#(6IKM^]9GN7;EDWEL6K=F4IK%B:0N2.6:4R,R=_-W7S41 $
M1$ 1$0!3H=T%W?0ZTR,&Y^KZ8R:3PUN1M.8ZP)>'J#-4YG KTH.W3+B<18C,
M.EW<+F3B>(V>&G8CFP2[ ?8SR.]&MX,1Q/6TQB"K9#5V5BX%ZV-*5_#Q]:0V
M<!R>7>&:M2Y"7P!"Q>.&6*H<9WC-):3QN!QE#"X>G!C\7BZD%''T:P-'!5J5
MHQBAAC%O<( +-R[N1/R1.Y.[N!R!>41 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$
M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M%FM/&[C)#/!*(2Q2 [.Q 8B3?473FJMO&-RLXX>#=^J2KRS"3^;N4+_H2_\
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MI8^W?4'[TPZF24-O<8_$I8^W?4'[TPZF20!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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MNP+.5I8X':)A<F;Z)V;RX^5F_P#-OD6(>Z/:BITRDKT'^$+;.X\1DWJL1?\
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M&9+=_2<2,8QG)^M^/TJM6_64HJNZ3;WM[(V[#U>VK9-\\.GNRZ[+Y/NOXI?
MW&**@9W;?I$>NMLGI:5W=?)[C:%C]7JU<N#UY=;Z:K"_ANX6K$E<-3X^"-P-
MJV3L!EHHXY KY&T/J]&.\?L-V@=&[G:9H:PT)J"AJ33V18F@OX^7J:.:/CQJ
M=R V"Q1O5G)ALTK<4-F%W'Q(A8A<J;\<>'&I:#;MEUJS'G+EIS*=Y8]O3=1;
M:3JLVWWJL49/:3ASP7.]NP]0KO7N/:2[P?22_P#-?-?GL=R(B+0CVA$1 $1$
M 1$0!$1 $1$ 1$0!?R3<MP_#L_D[/YL[/\G"_I$!1C[R?LU/MCNOJ#&5H7BP
M6=FDU-IWB-PBCQ^5GFEFH0_H7CQ5YK-&)A=^*T5;JX,G98%JWSWUG9J'5VVL
M>LJ4#%F=O)+&1,Q;VY=.76@#.1$[-R057KT\FSERT,=.PXN(RRN]09 $1$ 1
M$0!3H=QMVEAT_K7)[<Y&=H\=K6,KV(\0^F./4F*JF<D0\^R)Y+$02@S\B\LN
M.JP-UR'""@O7+-!ZVR.FLWB-0XB9Z^4PF1IY2A,S\=%JE.$\74[?H"</#D9O
M?&1C\J V,B+J+8/=_'Z_T9IK66+=VIZAQ%/(M$7'B59Y8V:Y1FZ7(6L4+@ST
MIV$B!IH#Z#,>"?MU $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M7A>5UOO!N?C=%:6S^K,O(T6.T_B[>3LNY,+F-:)RC@CY]\UF7PZ\ -R4DTL<
M8,1$S.!6Q[]CM)?"NI,#MECK/-/347PYJ".(^1ES61@8,96G9G?SQV+.6PP%
MQ[65$R'F*$F@%7.MT-Q,CJ[4F>U3EI"ER6H<M>R]PB?GIENV#F:$.&81AK1D
M%:O&+,$5>&**,1 !9N"H B(@"(B +-#N_NSB>Z&ZNF=.RPE)AJUGX<U))T\Q
MQX3$N-B:"3Y&?)6?5<4#/SP5WQ7 XXI&6%ZMI=Q[V;/F;T!?U[D8&'*ZYM,V
M.<A=I(-,8UWBJ>;LSL^1R'KMTNEW ZHX]_(QD9 3<PPA& QQB(1@(@ "S"(
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M1R%'&4</B&T;.@.^41$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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MM(=HPB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"^%J;4%?$XZ_E
M+9=-7'4[-ZP3<<M#5A.>3CJ=F<G$'86=VY?AOE7W5@OWC.X/S/[59T0D:.SG
M9J6GJO//)O?D*2V(NWFQCC:UZ47_ /N?'RNM2X]XHAHFB:MJ]FW+INGY>8DV
MDISHHG.NOKZV6*-<5ZRDDNK-:XSX@CI6D:GJ4MG]!P<K*C%_?G33.==?S=EB
MC!+NW))=65JM2:IM9K)Y',WBZKN6O6\G:=G?I\>].=F00YYXCC*5PC#R8(Q$
M!9F%F;YT9?YU\V,F7M@2_G-GE3MG.VV<K+;9RLLLD]Y3LFW*<Y-]Y2DW*3]6
MWN?S8\::+999;;8Y3LLE.=EDNLISFW*<Y/UE*3<I/XML^B!?R==-;LQY?,S8
MO1NF\==S.>U%8Z(,9C83L7)X(.#(1C#S%I"'DI#<88Z\-F24XXXB)=M^(PLY
M$[,(L[N[OPS,S<N[N_N9FYY^19[]R/MP6I]::_W4M0%ZEB(H-':;E,?8>6PP
MW<H43\\M)'2#&R2\CQ_RMT"3]!LW0#^YX^&,-5XPNXIS<>-^E\"X].KRKL7U
M61KF1:\?A_%D^Z<,N-NJ;QW?+I<HO;GW4A>QAX$_^DW'6+D9$/[PT+;/NER\
MR>7[_P! AUZ*==D+,R&Z:Y\2,)+WSU>R5W&EFXU?-[T7RBA)FDCT3I^](,O1
MRW3'G,]5<#C(A;B2IA)NH!)NC+,?4 6*]O-ML!I+%5L'IG#X[!8BH/%?'XRK
M%4K1^0BY]$0CURDPCXDTG5+(XLYF3KFR+L?Q;QYJ>MV^9GY$IPB]Z\>&\,:G
MT^KI3:WVZ>9-SMDME*;/Z#>'.$L#2J_+PZ(UMI*=KVE=9M^O8UNUOUY5M!/M
M%!$7P]1:FQN'ISY'+9"EB\?5 I+-[(6H*5.O&+<D<]FR<<,0LS.[D9BS,S^:
MU&,7)J,4W)O9)+=MOHDDNK;^"-C<DDVVDEU;?1)?,^XO7M6HH(I)YI(X888S
MEEFE,8XHHHQ<Y)))#=@",!9R,R=A$6=R=F9U!KVH._/T!IMK.-VWI2;AYIF.
M./(B4V.TG6F9V#Q"R$D/K>6C!^3%L77>K:81&+)1!(TXU_.T-VP-V=XI9!UA
MJ2Q'A2E>4-,8=Y,5IR)G=G$9:,4I%D?"X'PY,M/>D A>0"$R(GFGA#P)UG4^
M6S(A^C<:77S,F+\^2_S>+O&S\'<Z8M=8N78C#BGQ;TG3(R7FK*N7W*9+D3^$
MK>L?Z"L>_1I%E;M1=\]M5H([.*T[-/N%J2+KC]4T_)'\"5)A\F;(:ADYINS%
MSU18H,G8%Q<98X&(3>O;VC>\;WEW;.S4OYPM,:9L>( Z8TL\F/K%7D\GBR63
M9_A7+$\;,$K3V8:)^T\6/@:21BPQK8C'X\&ZW B%O(!X9F^MRWR?)PS+M#:?
M:O7&XN0;$: TME-06&,(II*$#!CZ763 TF1RM@H<;0B'GDI+EN)N&X;J)Q%[
M/<-^%'#^@5_2;8UVVU)2GG:A*MJMK[T%/EHH2?V9*/F)=':^K=<]<\5]=URS
MZ-I]5E==CY8UX\9IR3]'R[VV].ZWY'WY5V75-#2]"@#>)T,XM] #-Y?K\,S-
M[ER_16&SNJLI%@-'8/(YW+3^4=#$U);<["[\>+,\;.%:!G;@K%DX8!?R<V=V
M9Y\^S5W#P&]?*;NZDDLDS-(^E-*S/!5\3J;YUD\_-%ZU8BZ6?KAQE>A(YN)#
MD' 3CDGNVCV/TCH+%AAM':>Q6GL</2YPXVI% =DQ;AIKMAA>Q=L<>7CVI9IN
MG@>OI9F;5>+_ &A],P^:G2ZWJ-ZW7F[NK$C+^?*/F7;/KM7&,)+[-R,[PQX!
M9N7*-^L7NF+VDZND[6OAR)^77^,Y3DGWK*WO9J[C#5.<\#*;L9V/3E _#E;3
M6G9H[V=.-_,XLAE)83QF-EX]GPJ09=_-B*Q%()1/,K-W6FP4^B[&@;>VF!OX
M"YX<EH[P6+6;FMQ@0Q9'YHY)WSD&1A<B*O;JY" ZI.S5?!C$ &0%EY58N)/%
M+7-4M5E^=;3&$U.JG$G/&IJE%[PE%5R4I3@^L;+9V61?:2+(\.\#:7I<%'%Q
M:U/;9W615ETEZ^^U[J?K&M0B_P!4HE]XQZ-WJ[1(7=5[(V+>N-+0C/8N:0O&
M+ZTQ$(EU#\%2A''7U/5"-W$XOS'F8VB$HX<J4TCUX).R%VL]9;$[A8W7>D9#
MJYC#SRX_,8>X,D$&9Q?K,;9?369@(?&A"<ZS 77'ZSCLA7@LB'CU>A]L<Z@F
M[UGN1-';]5;FK-*-2T;NO"!SCF(8 BQ.KBCA<(\?JV"&)S.8^F(*V>KM\(U'
M  L->IL]5I=X$\=5;#]&<2QCDXM\'0\UPW?)-<KCF5Q6UD'%\OG5I60^U.-C
M;LCZ\W1MGYF.W&47OR;_  _4;[/Y/H_3;;9RB]D?M4Z4WHT#@=P]'6GGQ.;@
M?Q*TA ]W$Y*N_AY'#9*.,B:&_CK+%#,#\=8^'/'U031$62JU]7<^]K[5O94W
MRO;1[J4;>FM-:LRT&&U9B\JX@VF=3F U\!JJM+&<E6SCKKM7QEVY5DDJW<99
MIY.&R88L8I]@F),[,[/RS^;.WFSM\CL_RL_R/]11%XE<$/1-0\NJ7G8&5!9.
MGY"DIQLQY]H^9'W9SJW4923]^+KM24;8HRFGYGG5[M;3B^6R/;:2^7=)]_EU
M7H?TB(H]/>$1$ 1$0!$1 $1$ 1$0!=;;P;78S6VE\]I/,!UX[/XRUC;/#<E$
MUB)QCL1^8_/JTOAV(?:9O$B'E^/)=DH@-=+N5MYD](Z@S6E\U%X.6P&2MXJ^
M#<N#SU)2B>6%W87.O8%AL5I'9O%KRQ2<,Q+A*GT[]3LU/B=3X3<S'0,-#4L
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M16)A;\]Y&P9V\I==^D'=[F0GLV.7%G9I&'AN&9N^$ 1$0!$1 $1$ 1$0!$1
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M#JG?C6?P1I^QX9]-F^[4H7YX<!-G*S+_ /HZXFPNWND.-W\N5;%[LK8QMO\
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M=.34E&#PL)N%'/FXF'^AQ9ZN\,>H(1\FX>Q--6RA-R7SW(R]+B+" @1&(B(
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MR$W/46-JO6QSNQ$#G5,XWZ39 9UHB( B(@"(B (B( B(@"(B (B( B(@"(B
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M>;Z:]:P7OZ6I95L?;,^ER]7BL1CQXKJ\N@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( J+7>;?'WN;]G*OX#Q*O2JBUWFWQ][F_9RK^ \2@,%$1$
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M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M1$0'AU4_[P;,O:WGUR7+N,5O$519_+I:IIW#UR9N>>&*2*0_J.1.3,S$S*V
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M>@*,B(B (B( B(@+?W<8_$I8^W?4'[TPZF24-O<8_$I8^W?4'[TPZF20!$1
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M;A8;&I,G\!X@R;VO@?"</;G'^E&UEY[%=Q?VO^2V-O8D%3]( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@*G??H=GUL'KW#Z]HP]%'6>/:GDW"/IC'/X
M4!B\8B;V>N_B2J-T](NYX^:5W,I2<8,U=_[TO85M?;,ZGK5X?%RVG0CU7AG9
MB<VLX5CEN0@P,[D]S#R9*F(DSQM+/%*7#Q"8T?Q=G9G;W/YM^LZ \HB( B(@
M/[CE,"&2(RBDC(9(Y ?I..0"8@D F\Q,"9B%V\V=F=O<K]/8JWM'<3:S16JR
M,2N7\+6@RPB3%X>:QO..RX.W+D(E?JSRPL?!E7DAD=N#9WH)JS7W!N]SV,7K
M3;RU*[GB[%75.(C)Q\Z>0?U#+A&+>UTUKL-"8R?EG+)"S.W#L@+$J(B (B(
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M>,V?GV"8?[W#^3J^GOAV/]L]QXW'66B\%F;'0X1Y0Z85<W7;EWXK9JGZOE(
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M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MNO=V=R\;HW3.=U5F)/#QN Q=S*6W;CK..K"4@P0L3BQ3V9&"O7!R;Q)Y8PY;
MJ782KZ=^WVE7QV!P&V&,L,-K4$S9[4?A2,QQX?'R=&-HR"/FPY+)=5H^IQ?P
M\4T;C)'9+I K<;I[E9/6.I,YJK,$Q9/4&3MY2XPN[QQ26I7,:\3OY^#5BZ*T
M//M>%$'5R7+OP%$0!$1 $1$ 5L[N/.S;\SF@K^O[]=PRFNIV#'E((]<6G,5-
M-#5*-O,P'(WGM6G=^&L01T96%XVBD.LQV=MF+VX>N-,:+Q[%XV?RL%2641)_
M5* =5C)WCZ6=VCI8Z&U:)^/^J819R(1?8"Z.TG0P.(QF#Q=<*N-P]"IC*%:,
M6&."G1@CK5H@$69F8(HP'AF;W(#DB(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B + KO0/B#W,^P</X5QZSU6!7>@?$'N9]@X?PKCT!1D1$0!$1 $1$!;^[
MC'XE+'V[Z@_>F'4R2AM[C'XE+'V[Z@_>F'4R2 (B( B(@"(B (B( B(@"(B
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M^MT..!PM*C/)&W SW0B8[]EO)GXL73GF;JY)A-F=W=N7[J1$ 1$0!$1 $1$
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MMU/YL+.7[3-S^UY?*L"]O,]5JZOPV4O^=&MJG&9*][/B.].OF8+5OV'X8^8
ME]E_HOH7?S69H6?G4OG_ -5)_J%Q_G4=E6/Q&,?>Y]0\?5<O+_.[_P"=?;^X
MU:+#D\1<F7VK/_1O$36W-&&VN62Y7MTYG*._7JX1W70JSP!+;Z3/]7R=M_\
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MY<!HXCJTF?WE#/G;U4+U@'XZ3*KC\;)TD0Q2QD(RJQQ#"$8#'& A& L(  L
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M'6+,0B[M\\("9Q(1)K_^E]24LSC,=E\;.%K'96C4R5"S&_,=BE>KQVJLX/\
M*$T$H2"_RB3+7&*W%W(W:5;5.WEO0U^?JR^@9HH:HF7)SZ;R93RXTX^KAR&A
M9BN8^00<FKPQT6/H:Q"+@37(B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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MXG;G_E7-''A<5RWO<6R&0KN?'F,;&?+,+NU"-FX9FY=_KN_+O]=W^5W][O\
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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MP.0 >2LUA'(,W+6_#FH6N3T=K#)Z?RN/SF%NSX[+8JW#>Q]ZL?1/5M0$QQR
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M+HO*AY-'X.ZY1E^#A39'Y]M\[I'@'J^8U/4LI8\'U<'/GGU^%=3Y7_M6Q?\
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M1$1 $1$ 4BO=*_3%[9_V_5W\'NKE'4I%>Z5^F+VS_M^KOX/=7("[VB(@"(B
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M(=FJ&<Q(R/QSX>0Q7-IX1;E_%M8NF[\.S1^;<UA-:T\QIBVV.U?I[*Z>ND1
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MNY.7#F%Y.-%M;3M]^7QV?V%_1Z[>CDT$1%#9G@B(@"(B (B( B(@"(B (B(
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M:G ?<-C,VQGR<H=7)^$5IX1,B((Q<G62J(H@S<^_)L=N1=;?;+[5EUD[9O\
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MFM-9G'UP?GA[5BA.%1WX9W]FUX1>3/[O<ZUYM:5CC V]Q@)-^L0L[(#]D1$
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MQ1P0011PP0Q ,<4,,0,$<48"S"$<8"(  LPB+,S,S,O91%S_ &R80B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( O3OT8;4$U:S#%8K6(
MI(+$$T8RPS0S \<L4L9L021R 1!(!,XF!.),[.Z]Q>'9 T4!>\7['LFSNYF8
MTU!!,VF,J/PUI&S(W(2X:X9,5)I&\GGPMQIL;(!\3^#%5M2#T6X3DQ#V[P=6
MRT\,YA'8K2.Y"3LSG$3^S(#>\FYY$N/,>1YXZF5Y?O.NQ3'O-M[/4QT<(:QT
MX<F8TI9-F9YIPCXNX64_)QK9BN+PL7N@NQTK+L00R1R41<_B[5*8S>.>G<IR
MR5;D,@'#8KS0R/#-%/$3"<<L,HE#/$;,0DS@;-TNRO\ ^$?'<=7TRMVR4LW#
M4,?+BW[T]H[59'X7QBW)_P"5A:DE'E*P^)7"EE,[*J9RHKO?FX]D5NH;/>=3
M7PCOR[=U&4);M]#OU@QE-OD-V_69N?\ /_X+V,#DKN8R5'":?Q\V1RV3L!3Q
MV.HQ/-;N6I7XC@KQC[1RGQY-[N.7?AFY6,,F7L2_1RO]?CR^I]1?K3LRQ21S
M122131&$L4T1E'+%+&3''+%(#B<<D9LQ@8$) 3,0NSLSJ3\K4VHR5<4I;/E<
MEO%2^ZW&+3DD]MTI1;71-=U#6-P14I*67;9?[R<ES;;KN]MTXI[=GR/;X,GO
MV:[EG>?5/A6=53X;0%"40/PK]N/-9I@/VO/'XB:2E"?0[.T<^4"8"=PGAB,7
M%I9MDNX[VBTV\-K4TN<U_D0X>1LU9CH83K]SO!AL4,!/&0^3Q9+(93A^2$A\
MF'%[NO.^#AS88[;O=O)!!G!\"EI[6MZ:,(,XY%X4&-S\A#''5RS?.HZV4DD>
M'+$3C;>"\+29"QRSJE7B/X@\64Y5F'F9#PH/?RUI\713=7V4ZLC>61*+7249
M7;Q;<)QC+H6GX&X*X<>/"_#QH7R6RF\K:RVN>W6-E72J,EWBXU[27O0DUU."
M;?;7:;TG1'&:8P6)T_CQX?U3$4*U"$R$>EI)1K1Q^-+QY/++UR%[R)W\USM>
M44%6W3LE*<Y2G.3WE.<G*4G\92;;;^;9+,(1BE&,5&*6RC%))+X)+HE^ 1%T
MGNWVD= Z#B\;6.L=.Z<9P*6.'*92I7N3QC]$5:@\CW;7'N=JU>5V^LOOC8MM
MTU7379;9+[-=<)3G+\(Q3D_R1\6W0KBY62C"*[RG)1BOQ;:2.[$4'>\??R[5
M81Y:^D<1J37=T'<0EK5X\#A'(??XF3RG-UQ?R<)*>&N@7+\D/'G%]NUWW&]6
MI6D@TM1P&A*LC.(S5:C9W+ SER)#;R\94!DZ?9)_@@A?WBP/YJ4="\$^(L[E
M?T+Z)7+;ZS-FJ-M_C3M/)_[$T/6/$_1<)/S,R%LH_<H7F?NGTJ_[0M[9'*5J
M<)V+=B"K7C;DY[,T<$(-YOR<LA" MPW/+DS*/O>7O6=B=$G+7N:YHYO(PNXE
MC-)QS:DLL;?11RV,:,N,JRCY=45V_6D;Y!?A^*=&X>O->:WE.QK766I-1D;D
M[QYC,6[%,>I^2"#'O*./K1<^Z"M5BA'EV",66/FN,G0PL/JU1XY<@8LS,(L\
M=4'_ .L/W>V[?T*/Z[&7L\,<RZ)[,]$-IZEJ-EG;>K#A&J._P\ZY62DOPIK>
MWJB+,OQ^^D7+&TK"\RR3V4[I.<8KUG-5\L81BNK;LE\$FVDYJN\&[]^UK'2^
M7T-MM@<KIF'-P24,KJC)7XH<P.,F;HM5,52Q_BM1EOP$4,E\\AZS6KG(,%<)
MY0L05A;HL(\,S,S#PS,W#,S-Y,S-Y,S?(S+FMZ1RZB)W(B=R(G?EW=WY=W=_
M-W=_-UPR_P"Y_P!93[PMPCI^C8[Q]/H5-<Y>99)RE.RV>R7-99-N3V2VC%;0
MCUY8K=[^F[5<G+G&S)L\R:7+TBH02[[0BNB6_P =Y/IS-G"+WR_KO_XK(OL+
M=ER[O+N[HC;^K$9TLKFJMK4<X,SM2TIC)H[NHK3N[.+2%C8IJ=/J$@+(6Z82
M#X9&XXZ7OE_7?_Q5T;T;[L0EI?1F7WDSM7IS&X 18_2P31\24='X^>4I+L+O
MYB6I,CQ.1>;'C\9C#B<1GF\3#^)G%T=%T?*RU)+(G'Z/AQ?>63<FH22]?)BI
MWR3Z-5./=I/:>'L)WWQAM[J?--_L1VW7YO:/Y[]DRR[B\;!2K5Z=6(8*M2"*
MM6@!N AKUXQBAB!O/@(XP$1;E_)F7OHBYO-[]7U;[LF$(B+X 1$0!$1 $1$
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MVMR\CK/5&H-69:0I,CJ++WLM9Y)R:%[<Y20U(N7=QKTJ[Q4ZL?+M%6KQ1,_
M,NO4 1$0!$1 %F1V!>SD>Z.ZFF-,RP'+AXK)9G4DC,SQPX+$LUFR$KD)-QD;
M+5,1&W0?SW( 1!X02D&&ZME=QUV;"TYH3):_R59H\IK>TT>*(A=I8M+XQWBK
M&_4S=+Y+)/=M<#U =.+'2L3$1B($X4,0Q@,8"P@ B "+<"(BS,(LS>3,S,S,
MWR,OT1D0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 6!7>@?$'N9]
M@X?PKCUGJL"N] ^(/<S[!P_A7'H"C(B(@"(B (B("W]W&/Q*6/MWU!^],.ID
ME#;W&/Q*6/MWU!^],.IDD 1$0!$1 $1$ 1$0!$1 % EW_6L? T%H; "3B64U
MC-E387?VX,)A+]8@)N.'!Y\Y7D\W9^N('%BX+IGM56SO^M7>-J_06#$^6H:?
MR>2D#R]F3(WXZ\9,W+^^.@;/RS<\>7/#H" )$1 $1$ 7\2&PB1/[A%W?]9FY
M?_0O[7--M],?#>H]/X;IZVRV<Q&,(>.6<+V0KU9.6X?V6"4G+R?V6?AG?R<"
M^GV1M#%IK:S;K!2 T=C&:*TW6N"S<-Z^V)JGD"XX;CKNG.;\MSR7GR_*R)7K
MU*[0Q11#]#%&$8_K +"W^9E[" (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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MG49Q1<E\&W)I9</=L&+?T*KDI)*/47NDRE<6\G\@*R*(B (B( B(@+,_</\
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M$5JO7Y NJHOG8G+5;]6O>I6(+E.Y!%9J6JTH35[-><!DAG@FC(HY8I8R$XY
M)P,28A=V?E?10!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M $1$ 1$0!$1 $1$!$]WU7Q"9S[/:4_#E54T%<O[ZKXA,Y]GM*?ARJJ:" (B(
M B(@"O#=U/\ 2_;<?8_+_C)F51Y5X;NI_I?MN/L?E_QDS* D*1$0!$1 $1$
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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MLJPW)^5"QIV./H[''IWZJ"<N5;)RG)<QZ9_+^VO2/WKW3^7]M>D?O60K]/\
MCT,?3_Q^\]$_<O0D]S?R^JO?/W+B&HM34\;'U69/;XY" /:F/]8?T(\^\CX%
MOJKWTQ;V26[^1E\2J4Y*,(N4GMLDMW_Q_4?7&"24PCBC.660QCCBB I)))#=
M@"..,&<SD,B80 6<B)V$6=W93W]@[N.M0:N>CJC=KUS2NFS$;-?28"=;5&7C
M)V>-LD1=):=J&/M'"<<F6,7:,HL<?)JKKG-R\E-/%+5L38[U>6.>L5.:2"Q%
M-";'#,-J)PE&:(Q$XSC(/#-F(/;9B5A'N]?2%=6Z1]3TOO %K6V!CZ8:NHH?
M '5E*/J9FCL2S2UJF<C 7?PVO25;WETED)A\*$-8\0,/7_H#_0;J5SYO.6^V
M5Y>R6V(Y?4JSOS.35BZ>2_,V)5X5T+$KL5FI*4HK;EA'K5%[_P"/Y?>DET]V
M.\/U]X[ESC;3:[3NC<-2T[I7#8_ 83'Q^'4QN,K!6K1,_P!&;B#=4L\K^W/9
MF*2Q/(Y2S222$1/SU=+;%=H;1FY>$BU#HC/TL_BS<0EDJD06*<Y QO5R%*<(
MKE"T+/[5>W!#*W#^R[-RNZ50C.KOA=9')C;'(4Y><KU)7*S?>7F*?O\ /OUE
MS==^Y87'E6X0=3@Z^5<CKVY.7;IR\ON\NW;;H$1%Y3]@B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B _"Q5CFCD
MAFC"6*4"BEBD 3CDC,7 XS F<3 Q=Q("9Q)G=G9V=V5;3O'^YFAOQ6]6;4T.
M.EI+%_1M.(?$KNPD9V-, SMUQD[?/-/LWF3C\%D+\5'LI*&7M]][OIO;)[FE
M]&-4U7KN-BAL>T4FG].2D+MSE+$$@%=OQ/P38FG(Q!_]NV:C] 2[_P"'.HZQ
M1J$5I$9663V\^F6[QK*D^^3U480CO[MN\9P;VA+FEM+4.-:]->'*6I3C77'?
MRK%_+1L:Z*A;.4Y/;K!)QDEO-<JW5)'4FALG1NR4+%:2.:,C9W,#C%N@G$NO
MK$2C,"9QDB,1EC)NDP8E[N*TI7JNTALTT[>?60^R#N__ %8OY,__ &W]KZG3
MSPN\]T=S,[K'.Y+4NI<@>4S>6L%:OW3AKU_&F/WN->I%!6@ 69A"*"&.,!9F
M86X76I^Y7EKRK)1CSJ,)-1YXPDYQ4MO>49N,'**>ZBW"#:V;BGT55,C4I3<H
MUN2JW>S:49SCOT<TI246UMO&,FEVYI=WZ<GR_M_Z%Z$WO?\ ;_\ %>_)\O[?
M^AEZ$WO?]O\ \5Z:N_[CYI_X_<?,E^7]K_P7SI?Y?WW7T9?E_:_\%QC/YRKC
MX"LVYAAB#Y7\R)_/@(Q;VC,OD$6=_J\-YK*4K?HO^.IE<6+DXQBG)M[));MO
M?LDN[/JX_%6K]JM1HU;-V[;FBK5*=."6U;MV9W\.&O6K0@<T\\IDP1PQ <AD
M["(N[\*W3W5O<U5]%%C]Q=UZ=:]K!NBW@-*3!'9I:4+Z*&]DGZI(+VH.'8XH
MF JV&)A*(Y[S>+5JZ=W#WGF,V3W/CU3G-$4-3:<M0!C+$_@A)JK3M<I7>;,:
M:EFF"B-PXS<+E*80*Y6C"O7R-)WE*QL3]@]_M([G:5Q>M-#9JIG].YB)Y*MZ
MJ3\A('E/3N0&PSTK]23F&W2LQQV*\K.)@WD[U^\>>*-8P:H8>/19C8&3'EMS
MX2W=\I1WEBJ4>N.MD^=2:LOCNHM5*Q3FW@GA6J+5^3M.^+WA0^U?PG+TG+]5
M+>,'UZSV<>Y&9>414_)7"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@,5^VIV>X=T-L]4Z1(0:];H';P<YAU^JY['L]O%3-^B8#LQC6L='!E4L6
M %V<^50BOT)ZD\]6U"=>U5FEK6:\K.,D%B RBFAD%^'$XI!(#;Y"%V^1;(54
MU^^-[-+:'W4L:@H5_!P6OXY<Y78>?"@S<7A1:@KCY<-XUF2+*,/4_261D &"
M&.,6 B71$0!$1 %X(6=G9VY9V=G;ZS^3KRB NW]U?VEOYH^TN&*Y9>?/Z48-
M+9SQ9.NS*>/KQ?!U^;GVS>_C2KR'.?4\UF.WU&4H2\20,ZIL=SEVDVT/NK7P
M%ZP\.$W C@P,_4[>%'FXCEDT].?+MP\MF:?%@3<OXF2#J;HZB&Y0@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
MP$[RWM)OMEM-J')U)QAS^:B?3>G?;$90R.5C.&2]$S\N1XNCZUD09A(7GKPA
M(S1F1CGVJ?W?4]I)]7[F1:1H67DPV@*\E"2,';PI=1WO#ER\SN/T9588Z6.'
MJ<O5Y8;HAT//,S@0X?MN_P!5W=W=_KN[^;N_O=W\W][HB( B(@"(B _N*(Y"
M&..,Y99"$(XH@*2660W88XHHP9SDDD-Q  %G(R=A%G)V97Q>P3V<0VNVNTUI
MF6((\N=4<MJ(@9N3SN3$+%X"-G?Q&I<QX^,^78H:D;BP@[ -7GNC^S7_ #0-
MVL=>NUVEP&B(QU+DW,>8IKT4GAX*CY\LYRY#B\8NSB];'3@3B4D;O=.0!$1
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M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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MC&^/79617O1_\2^3_@^GP;[,1$46&3"(B (B( B(@"(B (B( B(@"(B (B(
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M8Z[?@>+4&M9&U-E&,>F6O5L1C'A,>_N=AKXT8[,@ORXW+UMF)P:/IE%7XUX
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MU1$0!$1 %9R]'W_YBW.^S.F_WADE6-5G+T?C_F+<W[,Z;_>&20%AY$1 $1$
M1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$
M1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 %&9WQ'TNFX']OT3_"%I
M129J,7OC; AV=]= _/,UO1<8<-Y=0Z[TS._5YMPW1"?FW/M<-QP_+ 4J41$
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M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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M<>>\+O'7(GE/#UZ]60R;%Y&;*%52HMELE5<JH5UJB;^S9RKR9/WVZFW5O$^
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M_20]RS]\HMKY,(B+3#.!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M B(@"D5[I7Z8O;/^WZN_@]U<HZE(KW2OTQ>V?]OU=_![JY 7>T1$ 1$0!$1
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M9RED(M)Y.T8C'I_)VI'9\59GD(>C#Y&<Q>J9OTX^\9"Y#5M?F8"U:B(@"(B
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M=*_3%[9_V_5W\'NKE'4I%>Z5^F+VS_M^KOX/=7("[VB(@"(B (B( B(@"(B
M(B( B(@"(B BH[Z+X@=2?9G27XR8Y4QE<Y[Z+X@=2?9G27XR8Y4QD 1$0!$1
M %=I[H[XA-%?W8_#-Y4EE=I[H[XA-%?W8_#-Y 23HB( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"KB=\-W
M=KSC?W?T31YFC"2UKS$50!O&AC%B/5%6(&%RFA%B?. +&<T3#D6%CBN'+8[7
MY3P!*!QR ,D<@$$D9BQ@8$SB0&!,XD)"[B0DSL3.[.W" UNB*8?O6.[T/;'-
M'K32E,OF U!=83IUH"\+265G%R?'F\?4,>(O2C))BYC&**M+(V)?VAI%9AX0
M!$1 $1$ 1_J(B M:]T5WB+:PH5ML-:7NK5F*JDVG,G9=V/46(J WYBGF)^F3
M-8N'R\^B3(8^-I^F6Q5O3R3MK7#8#4%_$WJ>3Q=RSCLEC[,-RA?IRE#:IVZY
MC)!8@E'S"2,Q$F?S9^.DF(7<7NM=W#V\:.\^EGCR#UJ6N,!'##J+&QD(#<!V
M8(<]CX7=B]1NDSM/&+$U"YU5C+PSK',!(^B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B(")[OJOB$SGV>TI^'*JIH*Y?WU7Q"9S[/:4_#E54T$ 1
M$0!$1 %>&[J?Z7[;C['Y?\9,RJ/*O#=U/]+]MQ]C\O\ C)F4!(4B(@"(B (B
M( B(@"(O#H"M3Z2.#_,KM47#NS:HSPN7'LL18>%V%R]S.3"3LS^;L).WT+JJ
M-<EX"*-OT3N;M^LW#?6^7_,K=_I'>'(]K]OLBW4XUMRHJ)\<=+>OZ3U/.Q&W
M3RW#XWI$N6%NOI+DC#BG_,?,O'R"(LW[7+_Z7?W*_7@/8GPSB+]6[,B_Q>39
M+^J2( X]A_ZUFW^I7+_LXK^LLU^CH;)-9S&O]Q+4+/'BZF-TEAI2!G9[=]SR
MF<(2?V@DKU(<+&SC]%'?F%_H>%:V41_<B[<!@.SYIBWX;#/J>_F]0S%T=!R#
M/D9J-5SY9G)FJ4(?"-_)XG!Q=Q<5+@JE^+.LO-XAU*S?>%5[Q*UZ*&(E0]OE
M*<)V/YS?X$N\*8:HT_&CMUG#S9?%NWW^OX1:C^"01$4<FQ!$1 $1?$U!J7'8
MFI-D,K?I8RA6C*6S=R%J"E4KQ W)R36;,D4,48-YD<AB(MYN[+[1BY-**;;>
MR26[;?9)+JV?#:2W?1+NWT2/MKQRHHM\N^;V0T=XT&.SEC761BZQ&IHV&/(U
M3D%W;I^&YI:V%('?AVE@NV!('YC\1VZ7ATWG[]7=74?C5M$Z=PNA*A\@%N>0
MM3YIAXX\09[52ABX9'XZQC^"[#1<N#RV&9C4F</>#VOZCRRKP9XU+V^NS7]&
MAL^S4)KSYQ_:KIFOF:5K7B)I& GYV97.:_Q='ULOPWC]7%_*4XLMH9_4>/Q5
M66]E+U3'4H6ZIK=ZS#4K1,S._)SSG'&/DSOYDW/#\*+S>_OFMC=(%/4H9^UK
M7+0.0O0TC1GOU&-AY;KS\XUL 0]3>&;5,C;L0GRTE<>'XJ3:_P!:ZYUU8/(Z
MVU9J+4TYD?1\-9:W:J5^LNN4*>/.5L=CX.2;BM1K5:S=;L$3>;+B<&G\?4'F
M0X^6;W#Q\GU^?_-3OP[[-.+#:>IYUN1+HW5BQ5%2?JI66*RVR/\ -C1+YHA+
MB#VB8INO3\9.7;FLWMG\MH0Y8P?\Z5B)@M[>_9W1U 4M306GL)HK'GR(W[X'
MJ+4+MSRQQ%*5;"TG<7<3B/&Y,F^CBM1OPS16;G;@:ZW#L-:USJK.ZF()/%BA
MRM^66A7DYYZZN.9PQ]4F;RZX*L9](BSD["W'RL"]K*6@QVG<-D<WD#=ABHX?
M'6\M>D-V\ACIT()[!D[-Y"$3N_G\G"D9V<[I7?36HQ6<CC*6A,;,P$TVJ;)!
MD&B+SZAPE ;%V.1AY_,]]Z$S'TA*,7)&,K5:;POPS!3Y=/T]Q7NV62C+*GTZ
M\L['9E6;[]H.6WP2V(XLUGBSB*3A37DSKD^J2<:8K?IO&/+3#\9-?CON1EU]
M.4*C-XA@W'Z$?/ZGN\N&_O\ _@OI8JV]RW'CL+CK63R$O]!IT*D]^Y+P[#S'
M5JQR2DW+MR31\-SYNRM#;(=Q/MUAFBL:YSV:UW?'I*2 .K3>"ZF?GI"A2M6L
MB8\<B?K&9F8VX,8XG\FEMVHV!T1H6GZCHW2> TU6?I>5L/BZE*:R8CT--<LQ
M1-9NV'%NDK%N:><V^BD=1[Q#[2&E8_-#3L:_.FNBLE_>M#_:3LC*]K]ET5[]
MMUW-NT7V>L_(<;-4S54GLY50?FS7QBU!QJ7X^9-+X/L5$]G>ZOWYUR\<\^GJ
M^BL3(S$V0U;<CIS&#\<^!A*;W,QXC,3&/KM3'P2#RX67+R7L=M3L"P;&UM*1
M3ZJL:ES>I!RDEUFH14,;4@QKTQ'U.)YK%J0BDM^W)/,S<,(C$S\D5T#A58N^
MZUNU_<[ 8.,V./3^D:\DK,_/A7LUD;L\\3M[F)Z-+&2\LS.0RCSY"RU/@?Q9
MUK7];IQ[94X^%&N^ZW&QZME*,*I1KY[;79:]K9UM\LX1;^YMT-ZUWPST?1-,
MLMQZI3RG.JNN^V6\DY33GRQ@H06]<;%UBVEZ^I6I[7,XO4PE?Y3L7K'U^((J
M\?/UN?6?V_/R?A6;_1?-X'O;>;A:%EFZI-+ZJJ9RI#YOX=#5%%Q(N?T(R9##
M778&=VZF,^&<R<JLO:?R'K&9K5F?D:5$6=F]S26)"E/]9^AHF=O^RWUE+=Z-
M3N'+B-^\_IXCZ*>J]N<LSQ\NWBY7 9G!W\>_#/TEX6-LY_CJ'EFD=P(6ZQ.6
M/%S2%E<+Y\=O?HA#,AOZ.BV,YO\ Z!VI?SO@93@"WR7BQ?W^:+^?FN3C_%P9
M>Q1$7/HFX(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( NN-X-<CI
MC2FIM2&X\8' 9?+\'] 18ZA8M@!>;<]9Q,''+<N[-RW*['4>7>NZO^!>SUNC
M:8N@[&GGQ41=3"[2YBY5Q@<.[MR[O:X$6Y<G=F9G]SY;0<'Z5G86-MNLC+QZ
M'^%MT(/^$CR9]_E476_Y.JR?]"#E_8:_AYY9@!I#*223Y]8D-W*224_:(S)_
M-R,W(R=_>3\NN5Z9S4&.M#*;\2B/SOEGX%R\G=WX]DNGR;GW<\\KX=2!A%S+
MW"W+\_49O_9<?,GD(C?Y2YX^HWR-^LS<<+J%*?7=>GP_AL52R,6%E,Z)[\DX
MN,]GLWS=))OX->ZUZKH98T-?UIF%I?#/J]W/')=/'/#MYOT\LY?4Y;GCEE]:
M2GC+C>3L+O[^>';S_:_E_>5CWN.^SUI'56P.6BU?I;!:DI9;7^<F"#.8BGD8
M_#IXW"T(I('N5Y'CE@GAM/#9K$TD$CEX4D<P'QW;O=W%NU>?&:?1^1S6@,B;
MF4;5)2SN$$R^A:3$9*P%EX0]KIBIY>@3\MS([-P\-Y7CSI6+J.5IV=3D4?1K
MYT?2815],N39.4HPVNAL]TXPKM?3OUV7@L\!,JS&JS--R8[VUJQ4N7E26^[4
M5S;U2].LI5]_EUK#;::LUAH2V>0T)JC,Z;L&3'+\#9"6M7LDW#=5RBSO3MNS
M-PSVZ\SBWD/#.I1]F._&W<TY)'6UMA<#KG&B[,=J&$M.Z@ >&'EK5/Q<19$&
M'D8CP]>:0R)Y+_''3P3>'N<-\=(--8P<6*U[0A?D3P-IJ.5./S?K?#Y4X?;8
M6Y*&M>N&SNP1/.3MS&MJ1\O@;98W5.!R^!R .P24<_BKV'O 7GQS6R->M.W4
MW+B_1P0MU"[CYK9YXG"_$T'+;3]0DX[2G!QCEP6W3>4/+RZOES./;;;NC7(Y
MG%W#DDI+(C5%[J+W=4NO79/GHF^O7;X_'8ML[)]]7LEJLX*F8RF0T)DYN@6@
MU51DBQOB$_!"V?H^N8F$ ?CF7)6,<)<^PQ,SNTJ&F-78K-U([^'R5#*T9A$H
MK>.MP7:QB3,0N,U>22-^6?GZ+E:\,H<9<;RZ0=_^Z3>?]YV_]^%R+0^:U1I&
MV.1T7JG.Z;M@7/C:?R][&/(W/4\=B*I/%%:A)_.2O:CF@E]TD9L[LHMXA]FG
M"LWGIF;=C2ZOR<F*R*M_11G'R[81^<O/EZ_(W_0_:,E%JO4\-)]%SU[U2_%J
M7/7-_P UUHV':*H%L[WVN\NEO!@U9C<)N!2BZ ,[,?S.9F0!YZG^$L95GH-*
M?+<D>#D'R9N@7?J4N>R/?=;.:G&&#4,N5T!D#X"6+457Q\8,O#<M'F<;ZS7:
M%RY:*:Y%1(A9SDBA8288*XA\&.(-.WE+">74O\;@R^D+\?*2CD16W7>5*C\R
M;="\3=&U!+RLR%<VE]7?]4^OIS-NIOY*QOY$Q2+AVB=PL#J6C#E-.9O$9_&S
ML[PY#"Y*GE*4K"_#O%:HS3P&S/Y%TF_#^3\/[N8J+K*Y0DXSC*$HMJ49)QE%
MKNFGLTUZIF^0FI)2BU*+6Z::::^*:Z-!$1?0^P1$0'A8U;M]CC:W73R'JK0F
MF\M8E<G.])C8:^1<R;AY/A&HT%WQ&]XR>/U"_N=9+(O5AYU^/-68]UM%B[64
MV3JFOPE!QDOWGX9&-7;%PMKA9!]XV1C.+_%23132[[WL.:3V TGIO7VW53+Q
MTLGJ@<!FL/DLM-D,;3CM8ZY;HSXZQ9@FR<,\EBH<<@6\A<@.)V:&* @=RJ0:
MVUA:SV2LY.YTM+.XL,8<N$,,8L$40N_F70+>T3\=9N1,(L_2VPK])(TW'<[*
M.KL@;,Y:?U3MWDHW=F=QDOZUPNE^1=WY%WCU"8NXL3])$+LPN1#KJ%?;P-U_
M*U'05=EW69%U.;D8KNMDYV35<*+HJ<Y;RDXQR(K=MO9+=MD;YW#F#AYDK<;%
MJHG.I)NN/*N64GNHQ7NQ3E!-J*7;X$M_<5YSU#M4;4GXC1^LWLW0Y<7+K:YI
MO+1/&S,S]+G[F-^&'Y79O-;,E:R;N/,.5WM3[2"+2/ZOE\K==H@<W8:NGLM(
M3GPS],;-_1#\F ?-W9;-E0/[2BC^FL/;O^C*^;_\UE;&X\/?R,O](_\ NQ"(
MBKN9X(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"_B0&)G$F8A)G8A
M=F<29VX=B9_)V=O)V?R=E_:("BGWB_9N/;#=;4>&@B>/"92<M1:<+A^CX*RT
MLDSU!?C_ /-EWUK'-R[D\->"4WZI>&P;5NCOM>S5\U>W5;6V/@ZLQH&>2S9>
M.)CELZ:R#QQ9.(R'@W:A8"IDHR?Q AABO,P#ZS)(-1= $1$ 1$0!3Y]Q3VDV
MQ&I\YMED+##3U2!9O A(Y=(YW&U>G(UXGYZ1._B( G(7;VGQ(]+B9$TL!BYQ
MMGN%D=):BP>I\3(462P&4I9:F0FX=4M.<)O!,FY^=60$Z\XNQ#)!+)&8&!$+
M@;%A%UGLUNEC=;:4T]JW$2#)C]0XFGE*_!,11>LPB<M67I=V&Q3G\6K9C?VX
MK$,L1LQB3-V8@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(N
M$[DZ_P =I73^9U+EYF@QF"QMS*792=AX@IPG,8L[^76?0T<;?HC(6^5 5O\
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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M0G<=+Y:?I <M$Q/P&.LD(1Y>,'%HQZ<B E)!-'8B+3A ;(JO8CFC"6(PEBE
M9(Y(R$XY(S9B P,7<3 Q=B$A=Q)G9V=V\U^RK7=SOWB'AO0V?UM=]EWAIZ!R
ML[OY>3B&EK4K\LS>0M@C)V;WXOGJ]1 K** (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B(")[OJOB$SGV>TI^'*JIH*Y?WU7Q"9S[/:4_#E54T$ 1$0!$1
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MYV<W,>&KB-50XC-R]+%IW4\?P%E6D)OZ'7>T7P?DG9_)RQ5^\(NXB;@9,"D
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M=G;EG;S9V?W.WUG7E $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1%X=
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M B(@"O#=U/\ 2_;<?8_+_C)F51Y5X;NI_I?MN/L?E_QDS* D*1$0!$1 $1$
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M:PQV=>X>QT/@9#=G4TF<L=3')IS2\UJAAQ;_ .#8S<L=;+W6=_,SJ08AV9W
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M4I3KR8^I8?.2D[ACZU_DW?(]]_B=F:V0VXVVL5\UNQ;JS0W<A&T%O$[?#,#
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M=XL-N'%6PAL3LT4>?K'-)IZ5^2;I.Q+8MXH..IY)LC #@7 G'<90!$1 $1$
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MT>"I>YV>2?)]-SI+@2K8VWY]72)76$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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MMG0.]&#^%]'949+=80',Z?NMZKG<'9(6ZH+U(^".'JY&#(57GQ]KA_ LF0R
M&6ZUI&CM<:BTEEZFI](YG):?SN/-C@R&)M25;+"W#$!/&_38KR#R%FG8&:K;
MA(HK$$L9$!3V[4^D&ZU@TJ]+4&@<9J#5<0!%3S\&4DQ&+MM[0G9RF'BHV9&G
MC=A=X\?;KP6^HF;U#H9Y?RXP]G[-INYM&:S,>R72BVRNO(QTWZSL<*[:X_KI
MQL2Z.N6SF_STGQ,Q?*_]8-8\X1ZVQC*55FWPC%2G";V^SLXOTDND2V-+*("1
MF0@ "Y&1$PB(BW)$1.[,(LS.[N[\,S.[J,CM*][?LYMQ)9QWPX6K]15V,2P6
MDA')/#,/EX-_+B0X:A)U>102W3N@W!O4<'8E5KW^[;6\6[4L@:GU7>JX:3R'
M3.GRFPN 8.KJ$;-6I*TV4<>!=CRMBZT9#U0C#U$SXT4M*4J8MXKQCT_H69N6
MX^3CW-_+R6V<)^S7!<MNL9;D^C^BX;Y8?':S)LCS27I*-=4/V;=MFXZXJ]H.
MBERJTZGS)]E9:N9OYQJA+I\4YR:^,"3?M"]\GO)KT[%+3/JFW> D=QBCPK';
MU'+$XN!>N9ZTW0'7RY .+QV..!WZ7LV7 )GC";2LMFS8R65M6+=ZY*\]R_?L
M2V[MR8N'.>U:L')9LRD[>U++(9EY<EY<OS71^)R^H<A'A=(Z?RNH<K-PT='"
MX^UD[?3R(O(<=6*5X(0<A\6Q-X<$(^U+* <DTP79][C_ %_J4J^0W(SU?16-
M)VDEPN,\'-:CG#AG\$[0S-A\4?+^<S%F';I(/5?;&<)EMS.&>%*.1O$T].*V
MK@N?*O2[;QBK,J_K]^?-%-^].*(HA'BGBBW>$;W5O]NQ\M5>[Z[;N-%?3[L?
M>V72+[$+7K]&J4<, ///(8Q0QB#R22RF["$<40,YR2&3LP +$1$_##SPRD&[
M/W=B;T[E%!:+"?,3IV7@FS6JF*G+)&_F[T,"!/F;!<.)#)9K4*9B_P [MR$)
M K0_9S[O_:G:X8IM,Z5HGF CZ#U)EP'+:@/GS/P\C<&0Z02/P\D&.&G ;B#G
M&3@+MF8H+XK]I2V?-5HV(JH]4LK,2E9_.KQX2\N+7H[9VIKO4B6N%_9YQ:G&
M[5,B65:MFZJFU7OWVE9)*37Q5<:VMNDV1#]F[N8]J=$G!D=11V]PL[&\<OK&
MHAA'"U9@=B_,&GZPC5<.IA+G*S969B%WCEBC)XE+7C<=7J5X:M2"&K5KQA#7
MK5XHX(((8Q88XH88A".*,!9A",!$0%F9F9F7O(JY:[Q+GZG;YV?EW94_3S)[
MPAOZ5UK:NM?LUQBOD3]I.B8F#7Y6)CU8\/55Q2<OG.7VIOYR;81>.5'[VJ.\
MRVGVG&S4S&>#-:DKL8MI331P93-M,(\C#>$)@J8AR]G_ )ULU"Z28Q V7ETK
M1\K.NCCX>/;DW2[5TPE.6W;F>RVC%>LI-1CW;2/3FY]&-6[<BVNFN/>=DE%?
M@M^[^"6[?HC)+M)[RUMOM#:EU?:<'^!L9--5CDY<;&1F<:V,JNS.+EZS?FKP
M]+.//7]$/T3:]'=S5UG+Y6U-9G*Q-):LV[DYNY'9R5R8[%VQ(3_12'-(74[^
M?6\COYDZE"[:?>EZQW@Q-C'38FEI72,%^&SCL+6GDO9*[=@"<*T^6RA!7"<8
M!G*<:5:G!5CF".0WL2UX9FAWE9W=W=W=R=W=W?EW)_-W=_E=W?E^?>ZN1X4<
M"WZ)BW?3(PAFY5D960C*-GE4UQ^JJE.+<7/FG;*?)*4>L5NW$KCQ[Q95J614
ML:3GC40DH2:<599-^_-)[/EVC",>9)^[)^J/BRA^TO0D!?9E!>A*'\O\ZF.J
M9IU4_P#CY'/-D-I;FN]::4T7CP,K>I]08O"BX,[O#!=M1QW+A=+.XPX^CZS>
MLFS/X=>M+)P_1PME1I33-3"XO&XBA'X5'%4:F.IQ,PMX=:E!'6@'@1$>6BC%
MGX%FYY=F95&_1]>SE\.:^U'N-=KN]'1./CQ6)EDCYCDU!GXIQL% ;LXO-C</
M#(T_#L<89FMY.,S\7!%4'V@N(UD:E1@0>\,"KFL_UC)4+)+X>[3&G\)2FNA8
M'PST[R\2>3)>]DSVC_HZFXI_G-S^6RBT$1% !)(1$0!$1 $1$ 1$0!$1 $1$
M 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!
M$1 $1$ 1$0!$1 $1$ 1$0!1X=ZAMF^I]D=71QQ]=K"#1U)4X;DQ/#VHYK+@W
M#\D>..["_N]F4N'9U(>N/ZKTU5S.+R.(O!XE+*T;>.MQ^7)UKM>2M.+<L[,[
MQR%P_#\/PZRV@ZF\+-Q,N.^^-DTW[+U5=D9./^TDTUZI['AU/#61C7T/M=39
M7U]'.#BG^3:?Y&L_R%7PK-B/Y FD9F_[/6_3_FX=?W5J'*;11MR9,3LWEY,+
M<O\ Z%V=OAM_<TKJK.8#(CTWL1D+>.M>RXB<]"Q+2EDC8N7\*62N4L3\EU1F
M),[L[._6> SHTK\%@V9P8G&1G;EO#D9Q?GR=O9Y8OJ\,NC5$H6.#4N:N;C)2
MB^DH2V::^3333^!3'.\V,;5&&]M<9[5OHW.">T'\'S+8^-EL;8C8F.-W;AV?
MY>6?R]WO]W/^=7Y.ZIWQ;7NQ.@\E)-XU_#XP=*91W?F0;VFN,6SS<NY^+/3A
MJ6B*3@I?':;S&07>EFXXZ^/N",B;ZSL__C^M[UVQLKO=N+M;=+(;?ZKR>%CD
MF&Q<QD4WK6"R1@+!SDL+9\7'V9'B;P6LO -V*-W&O:A?@FU?Q1\,GKF#"G&M
MKJR*+O-IE;S.MIPE"=4I14IP4]X/F49[."W6W5>GP^\6*-.RI?3*;:XVU^79
M%;=U).,X\S49<NTEMS+I)O==GL!$5;OLZ=_=#UP8S=G2<M N!C+5.E6.W3<_
M)G._@+#^N50X8G*7'W,B1&[ -*(&*1IW]F>T+HC<+'_">B]3XC4-5NGQFQ]R
M.2U4(QZQCOT2<;M"4@X,8K=>$RC<9 $HR$GI1Q/P#JVCR:SL*VNO?97P2MQY
M;]MKJ^:";_4FXV+U@F6QT+BS3]2@I8>57:]MW7ORVK\:Y;2V7ZR3C\&SN5?G
M+&)B0$+$),XD)-U"0NW!"3.SL[.WDXOY.W++^^5Y6G&Q$9_:,[IC9O<3QK18
M$](9N3J(<WHTJV(F>5W<NJUCBK6,/=$B_HOCX]YW!R:*Q!([2#!YO]W)^[&D
M?'O:'NT=PL7$Y&-2$X,+J2.$6=^7I7K XZZ0BSN05,B-F1^D*U.:0NAK>:*3
M>%_%[7=*Y8U9;R*(_P#NV9OD5<OZL9.2NKC\(U6PC\C1>(O#C2-34O/Q80LE
MWNH2JLW^+23KF_BYPDW^1KN=3AE]/WSP^J<+D<)DX^>NAF:%G'VV$7Z7(8K4
M<1F#$SMX@,<?4SLQ.[.R^+8Q.-OB_#B+DWF)<.S\_)SQ[OUVX6P-W6V0T?KK
M'EBM8Z9PFI:!?0P9C'5KO@&WF,M66:,IJE@']J.Q5DAGB+VHY!+S4*?:"[A?
M2F2\>_MGJ:]I"Z_688;,C+G,!*3N[C#'8\:++XP?/I:=Y<J$8,S-2,N35C>%
M_:-TS)Y:]3ILT^Q]';%/(QF_CO"*OKW?HZK(Q];-NI '$/L^9=#E;I.3YB75
M5-JJSUZ<LGY,_P >:#?I'T((-B^U/NSM1X46A]79"KBH6XCT_><<MIUA=^7&
M+%7'D@IB3]3O\'E4-R(CZNM^IIK.S[W^>.E:&CNOI&;"V.KIES^D1L9#$NW'
M]&EPEN:;+TQ8GX>*M;S)] ];$1$T+1!;\=AK>;:TI9=0Z1OY##1%P^H=.1S9
MW#,'F[26Y*<)6L9&[,S/+DZE2%C(8AE*0Q%\ M=[Y:<Q%<WO-ZQ=Z7>.A5Z7
ML&7R>+S[%<'=O,Y>GR^A _H7WG5.">&N)*GDJO%O=G7Z;A60A=S/UG;2VIS7
MZN1"S9]X[KIKFB\4<6Z+D0PW3D7]5&./97*46ETWY+-N2'9N=<X12Z\VV[-A
M#MGVN-LM88.SJ/3FN-.Y'#4*LEW)6WR$-,\55B!Y)I<O4O\ JMW$M#&SG,.1
MK53B;SD$551[U;TBT[P7] =G>\\=0_&IYS=%X9HY90Y**2MH:*;PCB$B9^K4
MUJ$PDA?JPD!>)!E8ZLFYF[N4SLTS=3T*,C%%\'TY9 BD@=V?PKACT/=9^D7<
M9A\'J;J"$'Y765+%22MU/S''_3E\O_=;Y?U_=]=:GPQ[/^E:?F2RK[;-0A!I
MXV/D5P5=;_6O4?=R9)[<B<*ZUWE5-[<MF:.(\NW%K>177C72C]:JK'-)_JQ?
MW7^LHRGUZ1FUU?I-XD\LAD1S3SRRV)YI#*266>>0IIY[$LA$<LLTLAS332$<
MDLIG)(1F;N_TN@*X.3NW+,[D;\,S,S<O^L+>]_J_Z/IF(0CT@S-]5_+EW^J[
M_P#A[F^HI\.XB[KD]Y]9AN)K7%M+M;HF\$@5KU?Q*>L]453CEKX9HI1\*YA<
M8_YJSSNTM>>4:V'DCE"S>&O+O$O$6-I6%?GY<^6FB.^RVY[)OI736GWLLEM&
M*[+K*348R:\F-3*^<807?^I=W+X)?\=2P!Z/AW=D^T^W4VX6JZ+U]>;E0UK@
M5IP<;& T< C/AL7(Q"QQWLD9EF<FWDP--0HN#'0DEGL,KPS>[CRX^1O=^TO*
MYL\3\19&JYV1GY+^MR)\W*M^6N"2C75#?KR55J,([]6EO+>3;<CXV/&J$:X]
MHK;\7ZM_-OJ$1%@3]PB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B *-CO5NS3_-(VFRS4X'ES^DC?5.#\-F>64J%>8,E0;RZC"[C)++#
M$+MU6X:<G!%" O).O#MS[_-G^1 :V\29V9V\V=F=G^L_FR\K-_O$>S:.UNZN
MH-/U(/ PE]PU#IP1C\.$,-EI9W"K![A>/'7(+F-$0X8 J W''#OA @"(B (B
M(#W<9DK%*S6NU)2@MT[$%NK.#\'#9K2A/7F!_D**6,#%VX=G%N'97YNQQV@Z
MVZ&V^E]90N#6<C1\#+P#PSU,WCY#HY:N0?1 +7()):_4PO+3EKV!;PY@=Z!B
MG[[BGM+/B]29O;')3]-'44$F>P#R2\!%F\>$<>0HQ@7+=>2QO%L.EP9BQ,HN
MTASAT@6E41$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$!T%VHM]:6VN@M3:T
MN^$387'224X)7=AN92=QJXNEPQ"1>MWYJ\+L)"709.SMQRU '.YRYE+U[)Y"
M<[60R=RUD+]J1^9+-V]/):MV)'^4YK$LDA/_ $Q.K!G?O]I4;>2T_M7CK'5'
MB_"U/J08I/)KUF":'"49V']%#2FL9$HC=FZ;E&=P=_!,:[R (B( B(@"\._'
MF_DS>;_6;Y77E9>]A/LY2;I;H:9TN<9EBAMAEM12"Q<!@,7)'9OQ.8\>&60X
MCQD4G+.$MP9!8G#I<"T)W0W9K+0&T]#(Y"N4.?UO*VI,B,@LTE:C*'AX*D_D
MSMT8UH[LH%[<=J_8B?D8QXE/7XUJT<,<<,,8111 $<448B$<<8"PA& "S"
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M?K M-:4EMXZM9KR<MX&5R'C/D<J)1^Q/%+-#0L<F[X\!<8PPTP^F*F.=I)7
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M?VOR5CJLX.<]0:=:0W<WP]\XX\G1C9W\XZ&3=K8<<NS960'Z8X8V5A! $1$
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MF/TYA<1I_%0#6QF$QM'$X^N#<##2Q]:.K6C;_NPQ SN_+N_+N[N[N@.5(B(
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MKAR27:U%I?=_ODMK\"4E73<&6UM>!W%CQL0X[#,3.[.QY7(],IL[<.!T<=>
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M$OSW?4(B+0S(!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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MW=+F;(72;@7ZKEZ6Q9?J;J;Q."=W9W?NQ $1$ 1$0!$1 $1$ 1$0!$1 $1$
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MR[.SNQ,0DSNQ"0N)"[/PXD+\.),_DXOYL_+/[EX0!$1 %X=N?)>40%S'N?\
MM/OK_:ZMALE9\;4>A9 P-WK)GFM8E@Z\%D';ER+FFSXZ4W\RLX^60N&F#F5]
M48>[@[4;[4;HXC+V[/@:<S7_ -C^J1)W\$<9=D#P+YMSTB6)OC7N>*[.XU1N
MQ,X#8,FO-12B8B8$)@8L0&+L0D)-R)"[<LXDSL[.SNSL_+(#]$1$ 1$0!$1
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M!$1 $1$ 1$0!$1 $1$!$]WU7Q"9S[/:4_#E54T%<O[ZKXA,Y]GM*?ARJJ:"
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MR(>T-&I;F=Q"(C'*14Z>^#[7_P#-!U^6D\18\32N@YYZ,1QD)09/49"T>6R
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M;7] ;B[$+D)"[$)"3B0D+\B0D+L0D+LSB0NSB[,[.SL@-D<BAG[J/O#FW*Q
M:(U=<9]>8*HWJURQ*WBZKQ%<!'U_DN"DR](68,J')G8#HR?412VAKS,( B(@
M"(B (B( B(@"(B B>[ZKXA,Y]GM*?ARJJ:"N7]]5\0F<^SVE/PY55-! $1$
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MV?VM<%LSH?(:MS#C8M<^HZ?PS2,%C.9N>,RJT(/>0Q"P'8NV&%QJTX9IB\V
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MDW][]1_>^R]Y;;V8T1%5DWD(B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M$$D4L9$$D9BXF!.),[.[+VT0%+OO.>[^GV@U$V9T_7EEV]U!8+X+EZCF+ Y
MW.67 6S)G-H1!GDQ%B4S*Q6&2O*96*IR319K8D[N;3X'7.G,MI74M&/(8;,U
MGK6ZY\,3<$,D%FO)P[P6ZE@(K52P'MP688I0]H&5&OMG]D?.[-ZSMZ;RC26L
M78>6WIK-O&X0YG$];,$GER 7ZG6%?)5A)_ GZ3'FO/ 9@8E(B( B(@"(B Y3
MH?6V5TUF,9J#!79L=F,/<BOXV] 73+6LPN_23?(0&+G#/$3/'/!)+!*)12&+
MW>.P'VVL3O1I".^)04]5X@(*NJ\*#NWJMPQ)HK]02?JDQ>2\.26J?M/#(,U2
M5WEKN1T7EW]V9^T?J+:K5^.U?IN;\T5'\"_CY)) IYK%R&!V\5>8/HH)VC H
MSX(JMF."W$+R0CR!L$D71W9T[0>G=S])8S5^F;+3T;X.%BN1"]O%Y")A]<Q>
M0C%^8;E0R9B$F9I83AM0]5>Q#(?>* (B( B(@"(B (B(")[OJOB$SGV>TI^'
M*JIH*Y?WU7Q"9S[/:4_#E54T$ 1$0!$1 %>&[J?Z7[;C['Y?\9,RJ/*O#=U/
M]+]MQ]C\O^,F90$A2(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M*JW>Z99I-Z)X7D<O5M*:?KN+L_$?5)DK70/+-[/YI:7D>6ZI';GJ8F:*O,X]
MG9W9N6?E_+^7\G4D7>]D4&^.1ZN&:?3>FY@X?]!X-F#S;Y':2"3R^IP_RJ/6
MM(,T?2_OX\OU_P"7"Z0^'=,9</:0E_\ 9^,_S=46_P".YS4\3U*OB'5K.NSU
M#);[]O-EM_ Z0RU#AW\OJ_R_66/^-J-;U"$3LW!7#'W/PS0B;O\ M-X;N[^7
MU5EWF<:_+^2QAVJTGF-1:JQF(T_0L93-9?(24\;1JAUSV;-H9@%AX\@ !(II
MYCXB@@CEFF((HS)L]BUQIG;98XPA".\Y2:C&,%[TI2;Z))1W;;226[-BX*E.
M^C.\K>5OT5UU)+=NRV-B@DEU;<HI)+K\%N9(Z)T+G-69O&:.T=C9LMG<M.->
MI5@X9G?WR6+,Q<1U:54.9K5J8@A@B$I#+W,]S3L%]A/ [):9>E 464U7E6"?
M4^I'CXDN3LS.%"@QBTE;#47;IJ5_(II/$N66>>8A#A?=T]WWB=EL ]N]ZMD]
M?YRL#:BS@#U!6A(QG;!8@S;KBQE:08GL2-T%D[<(VYQ$8ZD%:254Z\8O%J6L
M6RT_ FX:73/WIK>+SK(/I.79_1X-;TUO[3VMFN95QKM%X4>%U>C4K*RHJS4;
MH[R<MI?1U)=8Q?\ E6GM9)=E]7#W>9S\LB+!KMY]N' ;(:1/,76BR.H\GXM3
M2NG&D<9LKD!'EY['0_B08G'L039*W[+,+QU83>W:K@4*Z5I>1FY%.)BU2NOO
MFJZZXKK*3^/I&,5O*<I-1A%.4FHILEW-S:L>JR^Z:KJJBY3G+LDOXMOLDMVV
MTDFVD=-=YKWB%'9?3S8K"E6O[CZ@JF^ QLHO-#BJA&\$NH<K&! [5:Y#(%"L
M1@>1NQO$/%>"W+%3RJ-;RES(Y[.W9KV4R=NQE,CD;LAR6;UZU(<UN:4F!V*>
MS*;&Y/T +"PCT@PBWT]4ZOU!KC464UAJ[(2Y/-Y>R5N]<F]D1;W0U:T7+A6I
M5(V&O3K1\1P0@(-U%U$7=?9K[-^H]Y-85-&:7!X*L;!9SV:.-SIX'$-(P37;
M'#BTEB7VHJ%-B$[EEV!NF$)Y8K^\"<%8/"FEVW9-E:N\OSL_,ETC[BW\NMM<
MRIKWVKCMSVS?,X\TXPC2GCSC+,XFU&&GX$9NKG\NJN/HI/9SEL^7S)KJVWRU
MQ2Z[)R?9_8B[%^;WUU8-")YL=HG#R!)JK/0N G!%Y%'B,=U,;%E\BSOX/5&\
M52LTUV;GH@@LW5]O-OL-I3"8S3FGL?!B\+AZD5''4*S.T5>O"/2+<DY222&_
M,DTTIG-/*1S32'(9$_".S[L%IO;/2N,T?I6FU3%XT'<C+H>WD+LO!6\GD9@
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M5VE;TN,SF%M1WL?=KEP<$X,XD!LW#25[$125[,$G,=FM+-!*)!(3/='C'A;
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M7*4;3 [^V 9/)C9EZ>!:6M4I6!<PDC=@)T:U>.&..*(!CBB 8XXP%A (P%A
M %N&$1%F$19F9F9F7[(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( L"N] ^(/<S[!P_A7'K/58%=Z!\0>Y
MGV#A_"N/0%&1$1 $1$ 1$0%O[N,?B4L?;OJ#]Z8=3)*&WN,?B4L?;OJ#]Z8=
M3)( B(@"(B (B( B(@"(B (B( B(@"(B (B("F9WN79$;;;<23.XFL\6E=>2
MW<O1:,>*^/S?B#-F\4W2S#"!2V!R-*'R#U>U+#79XZ1A%%$K\?;2[,5#=O;[
M-Z1L^%#D)(2NZ?R$H,7P;GZD<A8ZR[\=30'([U;H@[')2L6 %V)Q=J'FK-*Y
M'!93(X7+U):.4Q-VQC\A3F%QDK7*DI0SQ$SLW/28OTDWLF#B8\B3.@./HB(
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MR>\-UM=>?R'G[K_WW:1O]#+VQ]F_.VZZEA)^OU=[7[^7^Q'DGXJXR[8F0_\
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M8RUB_A&2S&%$(G*P4S]/@.#?/(Y1?S:0?-F9N>M^/"ZF,>J*77NHFR^8RN3
M2$;UVQ/$!-[;1&;M ),WEUM$P,3,_#%RS>2NH^O5>OH0[X2U:A1=G863&?D8
MZARRFFDK92:Y.OWN2,G+;TY&^Z+M'HX\Q0OEJG#L,NW.CIS8N6(9(2;V7'R;
MWW)&]INH.&%G\R5J=5<^X!Q_JFHM35/ZET)@ZWUOG%R"+ZK_ -)]5U:,7/CQ
MOV_](\Q[=Z\5_P#P]:_J2+#^'UG-IL)>CORFOP>18_[0B(HD-V"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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MF\@))T1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M7!?/E@HK=]V]MVVVV13J6M])WY-SZ)N=ELI2>WXO=OX)+\$CX99TF^AB%O\
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MW'V/R_XR9E4>5>&[J?Z7[;C['Y?\9,R@)"D1$ 1$0!$1 $1$ 1$0!$1 $1$
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M#5RH^'#GZ3.WL\G=XR@"SCTAD_! &C@9W BF1$0!$1 %X)N6=OJ_R\G;W/\
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MSE!CZY=#/U3W3ACM7;/.;: (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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MZ%E\7(PC]1C+];RZ>?\ \;]I9VT/G>*-V?WB+?\ XK_RX6PZ?6DI/U_LV_\
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MRW1$5'B>@B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M2Q]N^H/WIAU,DH;>XQ^)2Q]N^H/WIAU,D@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( L->V_V.,)O/HZ? WW"GFJ+3W-,9OHZI,5E#B86:1F]N7'
M77CBAR5879YH0"0.+%> PS*1 :[+=?:K.Z(U%E=*ZEH28[-8>R5:Y6/@@?R8
MX;-:4?8LT[4)!/5LQ.\<T)B0OSRS=>*Z]WCO=\XW>; ->Q;5L=K["P&6%R9
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MCD=R#-VH96:K5DCBDP\764S/?GZ:$_C,@/*(B (B( B(@"(B (B( B(@"(B
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M5[>Q^YE[3@^(>F,N\V9T=;D<B\7"RV'$L=+*3,TMW"2F-"T_M$<7J=N3I]=
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M+%7LZ=+R;AWKYJ<1+@2=G=F>0/1G;6V?U#$,V%W/T%D8RXZ7KZKPK]74XLW
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M;OWIHZU2K$ ,Y$<L\H1LW'DY=3\,W+7>^PAV2Z.SFWN+TO'X-C-6.K*:HR@
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M1'KXE\S,UC2[I;SCD^2HR?7=U0KIY7^W%*'-\=TWUW+^>.I!6KP5H_H*\,4
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MQCX9G/3SV2=@<.7MY"[9Y=G\W?B5O:_1<=3>3LL^53_C:[S-9U:?ZVI9K_\
MB;-BU/#5?)IV!']7#QE_V, H3._IY_F+XUF^77>!Y=WXX_,F5=OU^7X;]OS\
ME-FH3._J^)?&_;U@/WKE%E?"[_VAT?\ UVK^MGAXW_P1J/\ JMO_ '2JJ;/\
M$NWN?E_?\G ^?/U./KJ[[W:_Q#[6_:I1_P!>7S_;]ZI!RF[XCA_JNWUW\O+G
MZO''E_\ 5Q=\[M?XA]K?M3H_ZTJLI[3/^"]/_P!?_P#EKBN7LX_\MU3^8_\
M?0,X$1%2XML0S=^QAO6-BSM=/46.U?IFPWT7(M/9EI$7L^7##:\W-NGCGW%P
MJG0OUXIV]_'_ ).KC??(X3UWL^:U-AZO4)<!D/<;]+09['@Y>Q[N&E\W/D&;
MWM[E3BQ#]>,D;W\,S\?W_P#S_E\MY/9OOYM!OAW=>H9"_!2IQI)+\VW^93WV
MBJN74<*S;O51^]76QW_=LBZMW5&8]<[/^VQ>_P!6P\]%_+CSI9&[7^J_/'0S
M<MPS\>3-[E(4HGNY2RCV.S_IR,F=CI9K5E,VZ>EN!U!>GBZ?-^IO L1<EY<G
MU-QPW+RPJH_'E'E:WJ]?I'4\Y+\/I-FW\"TG"UWF:9I\_P!;"Q7^^F!\C4&'
MBR-"[CY_Z#>J6:<WES\ZM0G!)Y<MS[)OY<MS[N6]ZUV.GL7)C<CD\3./1-CK
M]_&3 [_02TK4U24'][>P<1#^U\JV,CJA+VPM(?,WOMNKBF#PXWUSFLK$/GTM
M#J&Q\T,;!S^@$,JP"S>R+#T#Y!PT[^S%G\N7JN+O_*48]Z7^ALG5)_\ Q$/X
M$,>T3I_F:9CW)?R=EL-_G.$9Q_W4B3?N$]8O3W(W#TVY/QF-)4,W&/+]#'IW
M,A1D=AYX8S'4T?4[-R81#R_3&*[(])L[20:>VET]MO7L,-_<34$5N[7&1AD/
M3^D)JF6F(X_)S@?.'@A?Y.L!Y\N5@[W3.JVPO:)TV)&X19S%:AP9LW_6//0]
M?@!_K/:QL!/]3I43'?I=K*+=/M$ZJEQ]I[."T-!#M[AN@V*N3X"W?FS=J)@9
MA([&H+V2B*<F>66"G5B<RAKP<;IJ7!GTKQ AE2B_)HPL?4[);='=3S8F-'?L
MI*VFNQ+UC3+\3W>%NK>;PO3!-<RMMQU\HRVNE^35C7^TB//2N\5R@T=:VY7*
M0.PBTC\V*\?/T,,CO[48>;C!([BWT,91LZR6Q&?JWX!L5)@FB+Y1XY$OE"0?
M>!M\HDS.W/+>3L[QUG8+]9?:TYJN]BI_'IS/&[\,<9-U12CS]#)&_D7U&)N#
M'WB3.I]MQ$^L>C_@S\]4X6KNWG7M7;W?3:$W^TDNC?ZR7QW3[J0DI5^3RKB&
MV&=M:J@NR8_&7YI<76>WDQJUIK4=6J '));,X0-PK11QR2S2RB(UX@DEE<8A
M*1ON>*SLSL_+/\OR.WU>?E7B4-FUTYEMNM^JW[;_  W]#0[<&=4Y0LCRRB]F
MGL_3?OV?1I[K=--'O/+_ "_ERO3G 3;S;ZS/_+W_ *WU/J+\7E_DR_(I?Y<^
M:_6$'W6Z?R/M"O;KV/OX35%[&2,=>9^EGYZ";JC?]<'?V?UQ=OUW7=6FM^;.
M/RN+SV/.7#Y["WJN2QN0JDYC#>IRC-!,S-T2 W6##)'R8G&Y@1=)N*QP>5?D
M\GRM_F7K:4HRA9%2A*+C*+2<91:V:::V::;33Z-/9GER-%QKK89$J_+R*VG"
M^INNU-/=-N+2EL]MN=2V]-F;&WL3]LS3&\>BL+J#%Y+%CG9<?!\T>G(<A7FR
M.#RT?SB[#/48AM#4DL@<F-M2UXAMTI()A$"(HQS*Y6K;PV?M8ZU#>H6[./O5
MRZJ]VE8FJ6X"_IH+58XYX2\F]J.07;C]921[-=[QO_HQH8:>O)\Y1BZ>,=JR
ME4U!7,0^A K<XQ9F.-OE&KEJ[E\KN[#Q4[B;V;KO-MMTK-I\J<Y3AC94;*W5
M%MM51O@KO,Y5[L7.%;Z+FDWO)S?IGB)!0A#*IL<HQC&5U?++G:23G*#Y.5ON
MU%M;]DET-@$JJG?:]C+YF,_#O'INHX8C4ER"CK.O6BXAH9\X^BGG#"-F&"#-
M!"U:],[,!9AH992*UE2*3UMJ_2.\K&,46M=MZ-MV86EN:7R\U-Y"_1&&.RL=
ML8F9^':-\E+U>;/(S^:S O=]7V;]R-.Y72FN*NK<%BL]CYL;DX,MIZ7(5BBL
MBX$]>SIJ?-6@D@)QF@LE3@."8 E!F(&=:QPEPEQ1PSJE.:M,R,BA/RLJO#E7
MD^?C3:YU&%,YSYH[*RO>":LA'FZ<R/VXER=)UK MQ+,FJ$I+FJE<G7Y5J3Y)
M-S2CL]W&6SZQD]NNS*R^1A'(U&EC=QFC9G8P)QD$A=B"0#!V(3$F9V(79Q=F
M(79V97#.ZA[:G\U?0(8K-VVEUUHJ*GBM1>*8^LY6KX918O4?2S#U/DHZ\D=\
M@%@')U[+\1QS0"].7)7</@L]E,3C-05-18:K=FBQ>=A">M%E<:[\U+9U[4-:
M>K8. @:U7EA!X+0S1CU (&7??9C[35S:'<+"ZZPM@+-.*4:FH<;#-&_PMIVW
M+%\)4NGEV]9CC$;= WX:._6KN3^$\HG9+Q2X*KXATEJJ/]^4Q^DX,I1<)\SB
MG*B:FE*"R()0E&2CR6JN4]O+:*U>&NO9'#FK2Q<B,_H5\G78TG*M+F>TXR6\
M7Y4O>BXM\U;E&._,MK]Z+JO1V]VDL]B<;F\7J'#V,=E:5;(4IOA&F+G7M1#+
M&Y \W5&;"3#)&7!QR,49LQ"[+[MG<O3D(]<V?PD0<LW7)E:$8<O[FZCL,W+_
M "-RN>\\.Z,G"55BE%N+BX234D]FFMMTT^C1=J-\&DU.+32::DMFGU33WZIK
ML<W6'7;B[(.'WGT)?TM?>*IE87?(:9S91,<V&S< OX$S.W!O2MCS3R=<"9IZ
M<INS-/'!)'V1J/M5[9X@'/):_P!'5!'GGQ=1XGEN.KGD0M$3<=)?)\CLL4]?
M][MV?L !]6OJV9F%N0KZ<QV5SA2OS]"%FC3/'@[-R[E8N0Q^7'7U.(OL/#^E
M:Q#)HR=.P\Z6119&RJRC&NGRSB^C]V#CR^DE+W7'=2WBVC&:IE8,J;*<N['5
M5D'"R%EL(J49+9KK)/?X;=4]FNNQ3BR6GLKIK,YC2>I:4N/S.$OV,7DZ5@2$
MX;58W!S#K$?%KS#T6*=D.8;=2:&S <D$T9EEUV"NV'>V+U\&1LG:L:(S[14-
M6XR'KE$(.L7JY^I6;GKR.(?K=F#@[5">W5=CE*J4/T^\U[7^VN\&I,1J71&G
M=0X?-TX),?F,ME@Q]6'/8Z-F*@\N/J6KT@VZ$GB!7MG8CDDI6'@LQ.4%0:\;
M-S/V+(B$I\QC]"(LS-^V_'47[;NS/SPS+H#1MK.C1IU;"G1/+H\O*Q)[;US3
MV<H23ER[3BKJ)?;A[G,E.+13A<.9&DZX\K2LJN6/"SF5F\MIQVWVY%'WGLW7
M8FXPFN;:336_;W>2=NW7G:KU+7KC5OZ'VDT_;F^ M/W)">_E[ 2''\T6;JAX
M<<^3E@X"C4=SHX6(YA@LW;$DUB3'C0VA,7I^KZMCJXQ]3,\]DN"LVB']'/+Q
MR_'GT@W$<;<L(MR_/:^V&VVH-9YRCIO2^*MYK.9 G:KCZ0,<K@) ,EB8R<8:
MM.!Y \>[9DBJP=8-+,#F'-F#L5]R)C,,534.[TU7.Y(/"LU](8^:0\'3E;ID
M <S<88BS,L;\--2A8,4YL44AY.L_5)K6K\3Z+PM@U8N\**ZH?WO@T^_D7;M[
MS<6^9N<MW.^Z48.6ZYM]HDLJ&IZY:^6+56_O2>\*(;?K2V?/)=-H1YFNC4(]
M61@]@+NTM2[P7*^:RK6M/;?03<VLS+"06\YX1<24-/1RL+2=3L\5C+.Q4Z;M
M(,;6K43UAN([8[88+1N"QVF]-8VOBL-BX!KU*=8.D1%OHY93\SGLSGS+9LS$
M<]B8SEF,C)W?F-#'5ZD$-6K!%6K5XPA@KP1A#!!#&+!'%#%&PA'& LP@ "PB
MS,S,S+W53GCSQ$S=>N4K?J<6MMX^)"3<*_3GLELG;<UT<VDDMU",$VG+_#7"
MV/IM;4/?NFOK;Y+:4OV8KKR5I]HIO?O)R>VQ$11^;.$1$ 1$0!$1 $1$ 1$0
M!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $
M1$ 1$0!$1 $1$ 1$0!$1 %7)[^'LV/+5TYNGC:[.=0FTSJ<HX^2>M.138*_*
M8^Z."SZUCY2/GDKM$1<6 NJQLNI=]MHL=KW1VH]'Y1OS'J#%6\>4G')59Y8W
M>I=B;R^?4K30VXN>1>2$6-B!R%P->2BY9KS1&2TSF\MIW,0^KY7"9"WB\A#Y
M\#:IS%#*X._OB-Q\2$O+KB(#X]I<30!$1 $1$!DSV.^T!8VPW(TMK*(S:IC[
MXU\U"!$PV\#D&>IEH)!;R/HK2/<KL3$(7:M6?H(HA97Z<7DX+M:O<JRA/5MP
M16:T\;L4<U>>,9890)O(@DC,3%V]XNSK6^JXGW,?:3^;/:V/3%ZP\V:V\D@P
MDG6[/+)@9QFDT[,_M<O'!6@GQ0%TB_3C!ZNH^J0P)=K5J."*2:8PBAAC.666
M0F"...,7,Y#(N!$ %G(B=V9A9W?R94+>W-VBYMT=SM3ZI8S?%O</%Z>B,G=H
ML!C))*V.-A]T9WA8\E. \]$UPX^N3H8WM!=[_P!I0M![47<5C['@Y_7$KZ=H
M$)<2U\<8M)GK@LSL3=..8Z,1L[/'9OPRMSX3L],9F9O)O)F]S?60!$1 $1$
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M*..IQ5&C.'PVE>>/I<9S/VI)G(>6?J=WXX?@181;R9F;[>^>YM?!8R:;J%R
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M--B\"B6\7<]GESB^G1K>%&Z_5=DT]G&V.Q*NG\)2>T\^Y7/O]'I3KQE\IO\
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M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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M:G,[,[^!:CBF9F?D&X797* (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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M=C\,WD!).B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M$]?6^E6ADY%B?H:UDJT[=+NX%XD$?M"71U!TF6Q,X7E;A1[1?$$%M*&G6O\
M6LQK4W\_JLBN/[DE\CR?^BV+Z>8ODIK^V+?\370AZ/WVK3,0?0.(B8B87DDU
MQI#H!G?Z,_"RTLG2/O?PXY#X;V0)^&?M72GHU':5R!AZ_/MM@87=O$>]JO)7
M+0LY.WSNOBM.7H)"9FZG$KT+=)ATFY=8AL"47VN]HS7Y+:-6FUO]:&/<W^/U
MF39'^&WR/TAPUC+_ "C_ !DO[(HIA[;>BHYV4XSUEO!CJT3^<M?3.F;%B8..
M?9"WE<A%'([^7M/3!AY^@+CSDSV0]&L[.>EY(+>H8]7[AW(B&3HU-GO4L2,H
MMP_3B=,5<''8KDW/55R]C+1.[N[\\ P6"46H:GXP\292E&>J751DMFL6-6+T
M^"GCPKLV:Z/W^J[[[L]U6D8T-MJHO;];>?\ WFU_ Z:V<[.V@]O:38[0VC].
MZ3IL#1O#@L32QSR Q=3#-+7A":=F+S;QI).'X=O<R[D7E%'%^1.V<K+9SLG)
M[RG.3G.3^,I2;;?S;,BDDMDDDNR71!$1?D?(1$0!$1 $1$ 1$0!$1 $1$ 1$
M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M4D?1-%BGAZ-/TGY]KPXZ4AWQ9_=-D[#\-U*5Y $1$ 1$0!$1 $1$ 1$0!$1
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M 1$0!$1 %@5WH'Q![F?8.'\*X]9ZK KO0/B#W,^P</X5QZ HR(B( B(@"(B
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M/4FDX9JV;&U@;///#MX>7KU.>'\G<2(?<[$XNSO1>7AV9_?YH#8YZ>U5B\O
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M_"N/0%&1$1 $1$ 1$0%O[N,?B4L?;OJ#]Z8=3)*&WN,?B4L?;OJ#]Z8=3)(
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M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B +P[<KRB ZPW8V6TGKO$R8+66G<1J3$R%XGJ67I0VXXI6 HQL5BD%Y
M:EL ,QCMU3ALQL9-'(/4_-?#M.>CR8>X=G)[3:KFP4I,YCIC4XR9+%N?!.\=
M#-P.V2H@3LS#%>K99NLG=K->(1C:R\BVWACCK5='EO@9EE,&]Y4RVLQY_'FI
ML4J^9]N>*C8EVFC$ZGH6)F+;(IC-^D_LV+\)QVEM^RVX_%,UWN^_8#WIVREF
M^:G0>;^#X7?C/86 L_@) 9^&D+)8H; TA-_H(\I%0LFPD30=+<K$VAJ(@)^D
MN'$G$P?]"3/P0F+^XF=G9V=F)N';R6SR(6)G9V9V=G9V=N6=G\G9V?R=G;R=
MEB/O-V"MF]P'.35FW.F<G:DX8LE#1^"<OPS<=+9G#'C\J _+TC<87=F=V<F9
MVG_0O:6>T8:IIW-Z2NPI[;_/Z/?+;=_ZPEOV2711MJ?A5"3<L7(Y7Z0NCV_Y
MR"W7_1M_,H!X[4\$G R.T;\>_EW#]?GY/V_+ZZY?$XFW+=)"[<<MP[.WD_O;
MEG;_ -O)6L-P/1^=F<DYG@<GK'2YERXA6RL.6K1\^Y@CR]6S.XM\OB6C(F_1
M,_FL3=1^CL96N1GIK=R%AY+PZV9TH;D3<NX-);HYL09_)F-VQQ,[NY"(\,!2
M+B>-W#5Z3>9=B-_=R,6_I^=$+XK^GM\S4<KPZU2OI&JN]?&NVOM^%CK;_=^!
M N]@RA>N[_.B^3AN6Y^H_'^9=GV>UEVBJ6$H:8TGO;F=+Z:Q=,<?C\1C,'A*
M\E6F#/T1-F0JGEG(>HG::.>&9O+VWX;B4ZUW#6\4),U;5FVU\.IV8[-W4V,-
MP9O(NB'363'K=_)P8NEFX)C?GI7KW^XTWE@A\0,IM[<D9_SO4SN>:1_KB5W2
MM*'^_(+_ "<+VY?B!PSEJN.3G:;E1A+FKCE5PMC">W+S*.14^26S:YMHM?$\
M&E<+ZMIUEMN'A6X\[5M:Z:X>^MT^JCO&3W2;:ZLKD;F[7[IZTG*?6&ZFH=7$
M9D?5J?4FJ,XT;GSU#7@R=VW!7B9G<0@KC#!&'SN...-NE=>8[L43^0SY^M$#
M<>S6QTDO#?4%CM5Q]W][R]_RV.['<X;[1ETC@L',W2S]<6IL8P\_*/$Q1'U-
M\K]/3YMP7OXY?@^Y4WKMDPSMH_&-Y>W>U!8D%O+SY;&8K('Y<\/T@_G[N6X=
M\I'Q)T2FO:&JZ=""72-=U&R7RA#?;\HF4D^()=/HV1O\7BQ7\90V_P#WE>/!
M=CG3D#B5VYD\B7DY!UQ4X'X]_ 0 4[,_RL]DO+AOJN_?^D]K-.X3I+&XBE7E
M%G_-+PC+:^O^:9NN9N?E83%G\O)62-NNX:O.4<FK=P:L0<MXM/3>)EF/CY?#
MR64FA;S^A;JQ/E]%R_T*DBV;[J?9C2)Q63TX6I\C#PXW-4V9,I$Q>7)!BOG6
M&Y8A8HSDH2S1/_0YAY?G3=<\=]$H3\J_(SI_JX]4HP;_ &IW^3#;]J"G\4F>
MBG@O7,S_ )1/R:WW5URV:^55'.M_E)1^>Q5CV*[*.X6Y%@(=(Z8R.0KD;!+E
MI8GI8.HS^?58R]IHJ;.P^UX$,DUJ06=X:\GN5@+LK=S+IC3A5\QN-<BU=E1Z
M) P=>,X--TY&]IQL,;M:S1B_3_1VJ4WX(2I3-Q(\UM#'UZL,=>K!#6KQ#TQ0
M5X@AAC'^ECBC$0 ?K"+,O<4"<5^-FJ:@I58VVG8\MTU3)RR)KX2R&HN/_,PJ
M>VZDY(WW0_#?"Q6K+M\NU;->9%*J+7PJ3:E_SDIKLTDST<;C*].O#5IP0U:M
M>,(:]:M%'!7@AC9ACBAAB$(XHP%F$  1$69F9F9F7O(BAMMM[OJWU;?=LD)+
M;HNB01$7P?(1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$
M1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 74._NSV-W T9J/1
MN6 2I:@Q<]$C(6+U:QY34;T;.Q<38^]%6O5S9NJ.>O&8<$+.W;R(#7+ZXT=?
MT[FLQI_*Q/!D\%E+^'R$1-T]%S&VI:=AF]_(/+"11D+D!QN)@1 0D_%U=ZWT
M[K3:/</4^1U?J#&Y8,SE6K/?DQF8GH5[,M:O'5"P=>,"#QR@AB"61G;Q/#%R
M;JY=^H_R$K8O^H=3_?):_P#HD!3A17'OR$K8O^H=3_?):_\ HD_(2MB_ZAU/
M]\EK_P"B0%.%%<>_(2MB_P"H=3_?):_^B3\A*V+_ *AU/]\EK_Z) 4X5]S3&
MFKV:R6/P^,@*UD<K=JXZA7!G<IK=R8*]>-N&=V8I9!9WX]D>2?R9U<"_(2MB
M_P"H=3_?):_^B79NS7=1[/Z%U/B-787&YB3+X*>2UCOA+,SWJD5DZT]4;!U)
M &.66N,Y2UB/GP+(1609I88R$#*[LR;(4=N-!:7T71Z2'!XJM6M6&$1*]DS'
MQLI?D8?+KN9"2Q8X\VC&08A?H 6;O=$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1
M$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0
M!8%=Z!\0>YGV#A_"N/6>JZPWEVDP^O-,9C2.H L28;.5AJ7PJ3E5L%",\5AF
MBL SE$7B0AR3-SQRWR^0&N^17'OR$K8O^H=3_?):_P#HD_(2MB_ZAU/]\EK_
M .B0%.%%<>_(2MB_ZAU/]\EK_P"B3\A*V+_J'4_WR6O_ *) 4X45Q[\A*V+_
M *AU/]\EK_Z)/R$K8O\ J'4_WR6O_HD!Q_N,?B4L?;OJ#]Z8=3)+'_LV=FK2
M^U.G3TOI&*[#BCR-K*D%^X=Z?UNX$$<SM/((ET.-:+ICXX%^>/>L@$ 1$0!$
M1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M 1$0!$1 $1$ 70>]'9=V^W#@>'6.DL+FS8/#BO6*<892L/F[-5RL#19"N+$_
M5X<5D8R)F>0#X9=^(@*]N^?<)8"X4MO;O5UW"2/UD.&U)#\+XYR=VZ(Z^3K/
M6R-.,6Y8GM19>0W<>#C87ZH>=[>[(WIT*\TM[1MW-XV+S^%M*_\ +]7H\W<Y
M:M,7RU8 %N99;..BKQ^YYW]ZO,(@-;M:K2P2G!8BE@GC=VD@GC.*:-V]XR12
M,,@$S_(0LOP6P8W<[+^WFO(2AU?H[ 9UR8F:S;H1#?B<OHBKY*!H<A6D?E_G
ME>U%)YO[7FHM-W.XEVTRS2RZ2S>?TA8+K**"24=08P"?Z 7AOE'D7B'ZGPH\
MA?+*@*F2*9'=/N/=X,&4LF"LZ:UA4#EX_4;TN)R9@S>;RX_*1!5C)W\ACKY6
MX[_59_)1N[I=FC<+1+R/JS1FH\'#%SUW;F+LOC6X?C_G2 )L:_/D[,UKGAV?
MCS9 =((OY$Q+W.S_ *SL_P#H7]( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"+PY,WO=F_7\EV%MYM-JG5T[UM+:;SFHIA?I-L-B[F0"%
M_+\\35H9(:[>8^U/)&/M#Y^;(#KY%*MM9W-.]^H_#DNXK#Z2K&[=4NI<J(3"
M/D[\4<3!E;3R</[ RA"!%[)2Q\$0R;[1=P=I:FT4VM]9Y?.S<,\M+!58<'1Z
MN&=X_6)RR5Z41?V/%$JKRC[?A0N3" %7+GS9OE=V86^5W?R9F;Y7=_)F;S=_
M)98;+]AG=G7YQ?,UH;-RTY7'_E?)5BPN% 7]YMDLIZK!88/)SCHO;L")"7@N
MQ#S<IV:[".T>@O#DTUH3!UK@-Q\*7H3S.6=WXZG;)YB2]<B$R;J>*":* 2_H
M<0,PBV6HBS,S,S,S,S,S-PS,WDS,S>3,S>YD!6AV1[@RY*\%K<36H58_9*7#
M:3JC-.7GRX'F\F#PQ-Y=)M%B)W,2Y">$AY>9O8CL#;3;<O#/IO1^-;)P>U'F
M\K'\,9D#XZ7DAR&0\>6J3L[L_J?J[.Q./'2_"S%1 >&9>41 $1$ 1$0!$1 $
M1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$
M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M$1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1
M$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$
M1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!
M$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1
M$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0
M!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $
M1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$
M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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MB (B( B(@"(B (B( B(@"(B (B( B(@"(O#(#RB(@"(B (B( B(@"(B (B(
MB(@"+PO* (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (O'*\H
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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MOT^]ERG">EP=D.V3#/;W,QC.Y,YWMOKT@BS-RSNV-N9 ^"?V1Z1)^?HF$?-
M6=44'^W'I'_8LU//'5J[X8G$V9./8U7IS6ND*X.3DS,62U+IO%XEWX'J)X[Y
MB#./6XN3,I/MH>UEM?N!7AM:'W$T5JV"P[#7DT[J;#Y9IW+Z%HFI7)BDZOT/
M0S]7R<H#()$1 $1$ 1$0!$1 $1$ 1%XY0'E$1 $1$ 1$0!$1 $1$ 1$0!$1
M$1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1
M$0!$1 $1$ 1$0!$1 $18[[P=KK:O;Z&6QKK<;1&D(8'XG/46J,-B/!=G$7:4
M;MR$H^"(6?K9N')F][H#(A%!MN)Z23V+--335I][<=E[,75\[TKI?7&JX)"!
MQ9QCR> TSD,/R_5U"YY$!,6=P(N%BCFO2XNR)5)Q@L[FY)F<68Z6W]R,79QZ
MG)FR-Z@? O[!<@Q=7F(D'M("SNBJPEZ7[V4?&$&QV[CPN!.4_P P]5NF1G9A
MC\%\_P"(3$/)>(WLB[,+^;^7W<5Z75V1K!]$Q;I41Z@;Q;6@)C!F)^'+BCD[
MDG3&WM'Q'U.W]#$W\D!:!10(:$])P[%6<*&(MWI<%8G+I&+4FA=PL1#'Y#P\
M^4ETN>%@%W+H9Y<F')"_Z'I)Y*]EN\)V*W&'JT+N_MSJEV:/KBP^K\):L1%*
M(&$4U4;C68)W&0.JO-$$X.3"<8EY(#,1%_(&)"Q"[$),Q"0NSL0NW+.SMY.S
MMYL[>3M[E_2 (B( B(@"(B (B( B(@"+PG* \HB( B(@"+PSKR@"(B (B( B
M(@"(B (B( M39VG>_$[7&'W-W*PV*WYUG0Q6&W#UQB,71A@TV4-/&XO5.5H4
M*L93X&:8@KU:\40E++(;L#.1.ZVR:TB_; ^-_=S[JNY'XZ9Q 9R_D\W;'_5"
M:W_Q;2W\74_)YNV/^J$UO_BVEOXNJ))$!+;^3S=L?]4)K?\ Q;2W\74_)YNV
M/^J$UO\ XMI;^+JB21 2V_D\W;'_ %0FM_\ %M+?Q=3\GF[8_P"J$UO_ (MI
M;^+JB21 2V_D\W;'_5":W_Q;2W\74_)YNV/^J$UO_BVEOXNJ))$!+;^3S=L?
M]4)K?_%M+?Q=3\GF[8_ZH36_^+:6_BZHDD0$MOY/-VQ_U0FN/\6TM_%U<NQ'
MI#G;2I1Q11[]Z@FCA)G8;FF-O;AR-U=;C-8L:/.W*)>8OU6.M@]D#%F'B&1$
M!8^VO]*N[7V *(<GGM$ZPK@8/*&>T;6K6I@ >'#UO!7,4$3R/YF8TR9GYZ '
MRXE][-WIH(':K4]W]DRIU)#<;&H=NM2/D#KL_#"1:4U#2I221 _4<\L&J);#
M!Y08^>1F$Z(B(#<I=BKO:^S[V@6"OMIN1@LEGWKO:FT;DIQP>M*\ N RREIG
M*/7R<\$!20C8MT8;=. YH(Y; '-&)2/+1/XC+W,=<JY''7+F.R-"<+5#(X^U
M8HY"C:B?F*S2NU)(;56Q&_G'-!+'(+^XF5Q3N?\ TI_56C+>,T!VE[UO5^C9
M9(J>.W.:O#)JK2X$(10#JB"K' .H\'"8L\^6&(M04HI))[+Y>*(1C V)B+BV
MB-;X?4N'QFH-/Y.EF<)F:5;)8K*XVQ';H9"A;B&:M:J682*.:&:,A(# G9V?
MCR=G9N4H B(@"(B (B( OX.1A9R)V$19R(B=F$19N7<G?R9F;S=W\F91>]Y=
MWN^SW9;P W]>Y:3(:GR->:336@, \%O56?DCZ0&0:TDL4.*Q(3'&-K-926O3
MA%S:#UNT(5)-<_WE?I N_7:+L9##_#<^W.VE@WCKZ"TA:.H=VJW#,^J=2Q##
MF,[--TL4U.*6AA %V@;&3.TEJP!?$[=OI&79GV.*[BGU8.Y6L:9%#)I+;>6E
MGYZUL"Z"K9;.-:CT]B)8CZFLP6LD]^OX4L;TCL,$$E23M7>EU]H36@V:6VVG
MM*[0XZ7Q BN1?_9OJB.(G;H,<CF:%#"0V8V;EB;3LT/).)1R,S$]4B.,0%A
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M6TM<8MN=UN@ +1.>N5Y*N?D&+KFLZ+S(D$6:@$F-CQ]F&AG*[MR>.DK/#;F
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M 3"K1M3W].R122028N&3U2[1 VSZ+!_L!]X5MGVD]"5]>[9Y<[=-I IYS"9
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MP<6+P0V]0:2M/I+5$,+$ 36VQ-J/(8#+V A9Y&I^M:>"Q.1/Z]6CZ0:G+RB
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M!]SS;[][91 85_D\W;'_ %0FM_\ %M+?Q=3\GF[8_P"J$UO_ (MI;^+JB21
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M(R>=RDT4NAIY8L=B*4^0NR10AIWKFD"M7E((@]J0F8!\W96;UB]VW_B6W?\
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M$0!$1 $1$ 1$0!$1 %I%^V!\;^[GW5=R/QTSBW="TB_; ^-_=S[JNY'XZ9Q
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M,?G2U^QY_P!R)?17SLQ^=+7['G_<B0&][K_T./\ [@_ZK+]E^-?^AQ_]P?\
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M;9F>"/$#-)U2WMO\]/;GPIP\@)$.!R,60P4T?7.]6H&'<CCCN5X([:: (B(
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M):[W4R7@3V\%B98-,XN>5H6SFKLBST]-8<2Z9"8+>4E@>W($<IUZ$=NUX9M
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M1 $1$ 7!-SMS=/:,T]F-5ZLS%#3^F]/T+&4S6:REB.I0QU"J#R3V;$\CL(B
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MV5LN4VK]/T:S&VD[]J<G.SJ?3]:&8\?++*4^:P40CTR7L5:GN70T 1$0!$1
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M=K7.TVI/$EOZ/S4E2K?.)X1S6"M1A>T]GH!X87ARV(L5+).#,$=I[-;@3KF
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M)W:4KV/!ADLX#,2@ !%J/ D?@V1<6')4/5<M [O/:@J7R/16OI-=$?;/K_\
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M_MP#\#T5/$L#^P-V)6V.T]FL"VIGU1\+YALMZV^&;"^K\4X*GJ_@-E<KXO\
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M-6"'X1TKJ6M&#WL7;!B+Q*\G4-S%7HR."_CIX)A,9FL002$H B(@"(B (B(
MH8O2&_I+NT!]I];\8L(IG5#%Z0W])=V@/M/K?C%A$!J+%X?W.O*\/[G0&YR[
MIWZ5CLT_< V;_@ZTXL_U@!W3OTK'9I^X!LW_  =:<6?Z (B( B(@"(B \.M6
MCZ4#V]I=WNT9?T7BK92Z+V7A/2>-".0"K9#5EH(;>L,PS1\B;P6'JZ=K$9&4
M0XB[)'X8WY0?8!=[SVYH.SOV?MPMR(YJX:BK8B;"Z'@L@4L5O6^=C/'::"2
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M]5JPW;,T76;POFJ4U#4$0NXB4&5B., C(1:7% $1$ 1$0!$1 $1$ 1$0!$1
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M4,OBK<-_&92G6R&/NUS:2O;I7(0L5;,)M]%%-#($@/Y<B3<LSH#[B(B (B(
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M- ;./T0OZ4J;[K&O?]7"*T:JN7HA?TI4WW6->_ZN$5HU $1$ 1$0!$1 $1$
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M;6Z8C%L5H_!U,9ZPT;1R9*^PO-E<O9'DG>UE<E):OSN9R%XEAQ>0^GE90(B
M(B( B(@"(B (B( B(@"(B (B("M[Z4KV/Z^Y?9<S^JZ],9M1;.W(=?XRP(.5
MF/#0]-'5]:-Q'EX)<%-+>LQF8P<XR"R;%-4KN.K16\FWFVXHZQT?JO2.4KC;
MQFJM-9W3>1JFPN%FCG,7:QENN;&Q!TS5[4D9,8D/!/U,[<LM2Q>]'][8U*>>
MG'L/J^_'4FEJQWX;NE1BNQUY"BCN1C+J1I1"R -.(R-UBQLQ<NSN@(>K$(R
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M\O>WD_N?S;Y?-?J@-JKZ+KOU3UKV0-#XZ*;Q,CMWEM1[?YB'@!>M-C,@^5Q
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MD+&[>\G#@0+FB(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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MDJ]RO7N5)XK52U#%9JV:\@306*\\8RPSP2QN02PRQD,D<@$X&!,0NXNSKW4
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M,MD];S\OYNS-+J A$'\X@$8O+HX8"85$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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MI *3PP .KI$68#>3(M(1_/6;K?V5=SO\H6L/]\I_/6;K?V5=SO\ *%K#_?*
MW>Z+2$?SUFZW]E7<[_*%K#_?*?SUFZW]E7<[_*%K#_?* W>Z+2$?SUFZW]E7
M<[_*%K#_ 'RG\]9NM_95W._RA:P_WR@-WNBTA'\]9NM_95W._P H6L/]\I_/
M6;K?V5=SO\H6L/\ ?* W>ZXYF-8XC'"19#*8ZB(,[F5R]5JB+#SU.3SR@PL/
M#\N_''#\^Y:22QVHMTI1Z9=T-RY0Y8NF37^KC'J;EF?@LR[<MR[,_'/#O]5=
M9:GUMG,XQ-G,[G,XQ%UD.;S63RXN?4Y];CD;5D>KK=SZN.KJ?JYY\T!MZ>TM
MWY/93VI"R&I=Z-'WLI5ZQ/3VD+XZUU TP ,GJ\N,TNV4DH2D!"8?"A48S9QX
MD?J'FH]WD7I<NL=85+^E.SQIZSM_B+(2UK&X>HWAL:SGB-S!RT[A87DQNG7*
M/IDBR.1L93(,1<!C\=+$TLM,Z&$(Q8(P$ ;W" L(MSYOPPLS-R_+^[Y5^B ]
M[*Y2U?MV\A?MVK^0R%J>]D,A>LS7+]^]:D*:U=O7+,DMFW;LS&<UBS8EDGFE
M(I)9#(G=>BBEC[K;N;]VNU9G #2E,]-[?U)SBU#NAF*4TFGL=X/0\U#"Q,4+
MZFS_  8M'C:,PUJI.TF6O4(NEI0/R[G7NN]0=J?=K':5AAM5= 8"Q1RNYNHX
MA(8L;I_Q7D;"U+'#A\/:E&"7'XV-G<JL)6<K(+Q4ACGV].B-%XK3>&Q.GL'1
MKXS"X+&TL1B<=4C&&K0QN.K1U*5.O$#,,<->O#'%&(MPPBS+%SL(=@[;OLZ;
M?8W;K;C$M0QE5_6\IDK#M-F=2YJ:,!NYW.779CM7[9 +,/LUJ5<(:-&&O3@A
MA#,Q %C?VQ]4E@]H=U<T+F)8?;?7&4$HQ$C8L?IC*6V<!/V"-GAY$2]EWX9_
M+E9(+#[O#/B!WQ^X_N9^)>;0&E!Q0NU6LS^]J\+/^NT8LO?7J8]_G$']JC_U
M&7MH"_MZ%;I@ TCO]F^1>6YJ[1F(=O:ZVAQ6!R%Z)G_0=/B9N=QX;JZG/J=Q
MZ&:[TJ:'H7UFL^S^\T(L/K@;K4Y9R8.#>M+HK3XU6*7CVQ:6&XXQ]3^&Y&7#
M>)R]R] $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!5V?2HM+A?[%VX-LNGJP>I=L
M\I'U=7/7+N#IW"OX?3Y=7AY<W=C]GHZ_T?0K$R@7])LFA#L2[RO.+$)'MY&#
M.#'Q8EW1T7'6+A_<X6"B(3_ZMV8VX<>4!J=T1$!MAO1E<Z>0[%6STDG/-5]<
M8L.6%N(L3N#JG&0BW3[Q:*J#"[^TXLSG[3NIZE7W]%T^DFVI^RVZ'\*FLU8(
M0!$1 4<_3,>R<=G [4;W8ZJ1/A<G?VZU/-%&[O'1SL19C3=RP01^Q##DL9D<
M:\\Y]'K.6Q]>/I.5A.@VMRSWM/9._FV]G3=?;N"K':R^6TI?NZ;C.+Q2'5&#
M%LSIXH!ZP8;!92C6AAD<F\(Y6D\^GA:9ZI8:6*.5FX:2,#9OE;J%BX?CY6YX
M= <JT?K'(:<S.&U'B3>++:=R^+U!BI!)P>/)82_7RE F-G9QXMU(7<A<29O-
MB9^';=D]DO?_ !FZNV.@=R,/*$V.UMI/!ZC@>-VXC+)X^"Q8K&+.[Q35+)35
M;$!\2UYX9()1"6,Q;2*+91^B#]JJ'579]SNU]FT\F6VEU9?&"M)*)2QZ9UM:
MNZCQ<D<7'7'4;+GJ*K"1D['+6GCC80A86 MFHB( B(@/0RF3K4JUB[<GBJU*
MD$UJU9G,8H*]:O&4L\\TANP1Q11 4DAD[" "Y$[,SK2M]OSM56-[MZ-R=U)C
ME*OJ_5%^[AHYNL3KZ;JDV/TW7>,W<H''"5*4DL'EX5F6=N&?EFV;7I'?:_?:
M#LJ:[FI7'J:BW!]7VSTX\<OAV7M:HBM#EIX.!)W]1TS4S=Z1G%@(8&A<P*8"
M6IECC$!$!;@1%A%F]S,S<,S?69O)OK(#^U>_]#2['S!%NCOSDJA>):>';'2=
MB0'8/4J\M+/:NGKGUN!O9R$6 I2<QC)"6*D$3<+,@M1 8)#<0AB.>:0ACA@B
M%REGFD)@A@B%F=SEFD(8XP%G(C(19G=V9;E+NCNR!%L5V=-K=M^@6R>,T['E
M-23,/!VM4ZEL3ZBU%,;N 2.(97)V:M49&<Z]&M4J,_AUP9@)'D1$ 1$0&O.]
M,<['P837^W.^&.J]%?6V,ET)J:>*+@#SVFX9LEI^Q.8 P^LV\%)D:@G+(4LM
M?"PQ1LT5-^*8"V\'?W]C9M[NR[N/IVK6:QJ'3=(-P-).P"<T>H-(1SWQC@<N
M7 LEB2RV$F>-BE*GE+,4+>+(+MJ&H)AD )!\QD$3%^./9)F)O+Y/)_<@.=;:
M;CY31NIM-:QP<A0YO2&HL%JO#2@[,<>6TWE:F:QQ@3L3"0W*4+L_2_'OX=;M
M3LY[UXO<C0.C-?X66.;%:RTSA=249(G=X_ R]""Z("Y>U\[>5XGZO:Y!V?S6
MCV6RQ]$2[67S8=GK+;97[;S97:/5-^E2BEE$IFTIJJ:?46(Z <BF]5J9*SG,
M?7(^(XXJT=. 0AK # 6OT1$ 1$0'HY/)5Z=:Q<MSQ5JM2&6S9L3F,4->O!&4
MLTTTANP1Q11B4DAD[" "Y$[,W*TJ_;Y[4\V]N].YFZLCR-6UEJS)7\-%()1G
M7TU6-L=IF XC,WAF' T\>=N-G$?79+)M''U] [0+TA?M@-LWV5=Q,I5MO4U!
MK.&';72S@3#,>9U?%9KV9(&)G8SQVGJV=S!QNSL=?&S,_DM2!%$("("W @+"
M+?4$6X9OVF9D!_:O&>AH]D<;&8W5WSR%9R;'5JVV.F)I ?H&6X5'4>J[$!$+
M@<KQPZ<I]8.$M8&LQ<E'=D%J-TTO0!'TD70+ET@W)%PW/2+?*1>X6^5W9EN&
M>Y'['P;']F3:[1DU>.#.6L(VK=6&'2Y6-3ZND?.9+Q#80>1J(VZ^'JD8#*-#
M&U(I&8XW0$KB(B (B( M*WWCWTQG:$^[OO'_  CZE6ZD6E;[Q[Z8SM"?=WWC
M_A'U*@,,UZMBC#*[/+#'(X^3.8";LS^]FZF?A>TO5GNPQ.S2S11N[<LTD@ [
MM]5F)VY;]9 >O\#5/ZEK_P"!C_V4^!JG]2U_\#'_ +*\_#%3^JJ_^'B_VD^&
M*G]55_\ #Q?[2 \? U3^I:_^!C_V4^!JG]2U_P# Q_[*\_#%3^JJ_P#AXO\
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M?*Z?U-B,=GL)DZDL<U:_BLK4BO4;<$L1'')'/6GCD$@,A=G\G= <X1$0!$1
M$1$ 4/O?C=XM!V;-@M2ZKI6XHM<:CYT?MW4<N9Y=49>M8Z<D,0DQ^JZ=Q\5O
M.6YWZ8@]3@K]3V+=6">8):J[TEKO%2WR[061TS@KS6-OMG3MZ0T^\$_B5<MJ
M,FKOK+/N -X74&5A+3M$F*9_4L,=H90^$Y*M<"N[&+L+,1'(7Z*20NJ20W\S
MDD)_,I)"=SD)^7(W<G?EUYD-A%R)V$19R(G?AA%FY=W?ZC-YO]1E_2EW[C_N
M[Y>TEV@-,:4NQ$6BM+R5];;A2L)N$NG,-?K%'@7,';PY-47_  <.YN0O'1DR
M,\;O+  D!>?]%_[N0MF-AH-=:BQ\E/<#>7U35&4AM0-%<P^DXQF;1F"E8XQL
M12OCISSU^M,3/6R&:FJ%%')5D*2RTO7J5(J\44$$4<$$$80PPP@,<4,48L$<
M448,(1QQ@+   S"(LPBS,S,O80!$1 :.??[XP-P/M]UK^,^574Z[8W^^,#<#
M[?=:_C/E5U.@-DKZ&K]+1N-]W_4G\&>TRMMJI)Z&K]+1N-]W_4G\&>TRMMH
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MP-4_J6O_ (&/_97GX8J?U57_ ,/%_M)\,5/ZJK_X>+_:0'CX&J?U+7_P,?\
MLI\#5/ZEK_X&/_97GX8J?U57_P /%_M)\,5/ZJK_ .'B_P!I >/@:I_4M?\
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M=G;F/+$WEY^8EDW$F^JSL[/[G9V7:6CNY=[)>"D&6AV<]GRD NH"R>AL%G'
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M/&X'_P F"_WTMPLB T]/Y!=VP_U/&X'_ ,F"_P!])^07=L/]3QN!_P#)@O\
M?2W"R(#3FY/N4>US3&4Y^SON6P0MU2%#BZ5D6;AGY%ZV1E\3CGS\/JX\V?W/
MQB]N/V)-Y]'C*>J-H]RL'%!U>/8O:*U#ZG XD0%XU^"A/1CZ2$O,K#,[-U,[
MC[2W::_B2(3%Q,1,7]XDS$+_ *[/RSH#1%06XI6=XI(Y&;R?PS$^'^H_2[\/
M]9U[#K<X]J;NL>SUO.,Y[B[2:*SN2G P^:(,+4QNJ(NL.ABBU)C(ZF99X_(H
MP.X<0F('X;D+.U*CO4_1/]4;?8W,:\[/.4RVX&G*+'=N;:Y2 +&N<;28W*P>
MF\I7*&+5L%.)^L,38I5M0E7A(:UK4&0.."0"H=MYKG-Z0S%746D\SE=,9^B?
MB5,UI_(6L/E*Y<L[L%W'RP6/#-Q'Q(2,H9F9AFC,/95LCNQ_2P-RM"WJ.F>T
M,$VY6B#<(&UACZ-:#<# "Y</9NQUSJ8[5="-G(I(7JT\W&WG%<OMT50J)SP2
M1220S1R030RR03P3QG#/!/"91303PRB$L,\,H'%-#( R12B4<@B8NR_) ;Q_
M9?>O2FXNE\+K70^=Q^I=*ZAI19##9K&2O+4NU96?@AZA"6&6,F**Q6LQ0VJL
MX25[,,4\9QCVBM7_ .C.]['>V1W4H[3:JR;MM/NKF(:/3<LN-31^N[P#5Q&>
MJ#(7@UJFH; 4\%GA%X@.0\9DI'=Z$WB[/]OY?R_E_P"0'E$1 %67]+7^E R?
MW1MO?PM*K-"K+^EK_2@9/[HVWOX6E0&KW7SLQ^=+7['G_<B7T5\[,?G2U^QY
M_P!R) ;WNO\ T./_ +@_ZK+]E^-?^AQ_]P?]5E^R (B(#7Q>FF?&%L%]INOO
MPWIA4K%=3]-,^,+8+[3=??AO3"I6(";#T=#Z<_9#[)ZH_$?4JVX"U'_HZ'TY
M^R'V3U1^(^I5MP$ 1$0!$1 %Q/7FA,-JC"9;3FHL;3S.!SN/MXK,8G(0C8I9
M''7H3KVZEF$V<9(9X9#C-O?P_(NQ,SMRQ$!J3>_([G[,=E3<=WQ,-R_M!K*W
M:GV^STY-/)CY!%[5K1>9G9F=\IB(G(L?9D$2R^(B:U[5JK?Z805NSNV5V0-$
M[[;=:CVRU_CAOX#4-0HO& 8FR&'R,;.6.SN&L2QRM3S&)L]%JC:$"Z) >.09
M())8CU!_>%]@'7/9JW-R^V6N8GL351:_IW4D-4ZN,UEIN:0XZ6H,6!23C&TA
M@=;)4&L3R8G)PV*,TDC!%-,!ACB,O;Q]RGD<?:L4,ACK=6_C[U24H;=&_2GC
MM4[M68?:ALU;,45BO*/M1RQ@8^;+:5^CY=]/3[2^AVT9K>_5@WPT/C@^:. 8
MFIQZRP44S5:>M,3#UG&4A"=6KJ>G 0^H9HWLQUJN,RF-C;5B+NOLY=HG6.TN
MMM/;B: S$N#U9IBZ-W&W8^2AE'R&UC<E78@&]B,E!U5,E0E)H[%8R9BCF"*:
M,#>"HHT^ZJ[S#1_:DVLQVN].G!0SU-XL7KK23S^+=TIJ88 EL4Y!-@EFQEP2
M>WA<DP/!?I$[!(]FM<B@DL0!$1 8[=K[XI=T?N=ZV_%K)K2#X?\ .E7]CP?N
M0K=\=K[XI=T?N=ZV_%K)K2#X?\Z5?V/!^Y"@/HK;!^C$_2/[+?LC=/\ AFW#
M6I\6V#]&)^D?V6_9&Z?\,VX: GM1$0$-GI!VDGS78RW_ *@Q^(5;1D6:%G*4
M.E].9[#Z@:7F%G)_ ^#/&8";P9'C\.P[0%([:B);J;O$ML7UKL+O+I-N>=0[
M9:UQ3=).)/ZWI^_'PQ-YB3\\"[>;.[<+2GT)WE@AD=N'DBC-V;Y'(!)V_:=T
M![2V=WHBVKAR/9(]19XW/3NZ>O,1*( 8D!67Q&HP&4B(ADD*#/0R,<3 #121
M1D/BQRD6L16PS]"\W%:QM1O3I%Y ZL1N=CM2!$Y"QN.H]'X;%R2L//6X=6E8
MP<NGH8F9N>IW9 7/41$ 1$0!$1 $1$ 53/TQ/Z6O2'W7-/\ X U,K9BQJ[47
M8]VSWJP-72^ZFC\7K73]+)19BKB\N]KU6+)P06*T-QFJV:QE+'!;L1BQD0,T
MI/T\LSL!I)$6WD_*_'8R_4^:&_\ ER_^]$_*_'8R_4^:&_\ ER_^]$!J&T6W
MD_*_'8R_4^:&_P#ER_\ O1/ROQV,OU/FAO\ Y<O_ +T0&H;1;>3\K\=C+]3Y
MH;_Y<O\ [T3\K\=C+]3YH;_Y<O\ [T0&H;1;>3\K\=C+]3YH;_Y<O_O113=]
MYW5/9+V3[+F[6X&F=C=&XK55/#8_!Z6R-0LE'=Q^H-6Y[%:6QV3I/-E'![&&
MDR[YEFZ)':+'RFT4O0\9 :W1?.S'YTM?L>?]R)?17SLQ^=+7['G_ '(D!O@4
M1$ 1$0!$1 $1$ 1$0!$1 8W=LGXH-U?N;ZY_%C*+2'X?\Z5?V/!^Y"MWAVR?
MB@W5^YOKG\6,HM(?A_SI5_8\'[D* ^BMLQZ-)])-LG^Q]<?PD:P6IG6V8]&D
M^DFV3_8^N/X2-8("=A$1 $1$ 1$0!$1 $1$ 1$0!$1 >'6G3[[/4T>7[7':#
MO1=/0^XENJW1U./..Q6*QQ^9B+]774+K\N&/J8>19G6XL6D8[7VY46L]W-UM
M75Y?&J:FW+UWG*,OB-,)X[(ZIRMG&]$S"#2Q#CSK!#*PBTD0@3,S.R QW5C'
MT5'3Y7>V7I2R(=38G0FX>0,NHF\,9,74Q3'P/D7)Y,(^D^!^>=3>V(*N<K<'
MH;NW,U_M$;C:H>-BIZ9V>MXHC=G^=Y'5>L-,S4B$F-N']1TOF(W$@)B:7J9Q
M(&Y V2"(B +5R>EE?3A9+[F6@/W34"VC:U<GI97TX62^YEH#]TU @*U2M6>A
M]?30ZF^X[J/\9]'JJFK5GH?7TT.ION.ZC_&?1Z V8B(B (B( B(@.@NU!V9=
M&;Q:$U'MQK_$QYG2VIZ$E'(52=H[$!/[=;(8^STD=+*8ZP,=S'W8V<ZUJ&,^
M"%B M0YWGW=P:R[+VZ62V]U2TM[%V!ERNB-5^"T535FF"L%#!>'HZHH<I2-A
MIYS'B773N=$K"-2[2.3<P*,_O6>[-TEVI=JLIH+//%B\_68\IH;5XU([5W2F
MI80_,ML!)PDGQ=[AJ&>QT<\'PABYIHHYJ]H*MJN!IOUV3LYO#J?;W5>G]<Z+
MR]C :LTMDX<O@LQ68#EI786(.2BD$HK%:Q!)-4NU9A*&W3GGK2BX2DRY+VD>
MSIK#:376I-N->XB;"ZKTKD)*&2IRL3PS!SU4\ICIW$1NXC+57COXN_%S%:J3
M ;=)M( =(H#< =SGWKFE^U9M?6U)3]6Q6O=/!3Q6Y&DHW,7PV>.NQ^OXT)CD
MEL::SG1+<P=OQ9W")IL;;F^$L?=C"7!:6[N\^WWKCLV[G87<K1%@I"JR14]2
MZ>EF./&:OTS),)Y' Y(&)@8SCZIL5>=GEQ63&"Y'U1-9KV-O?V-.U_HG?;;K
M3NYN@,F&1T_J"KUO&[L-[$9*!_"R>"R]9^)*>5Q5L3K6J\HBY=(687DJ6*\T
MH&42(B *&+TAOZ2[M ?:?6_&+"*9U0Q>D-_27=H#[3ZWXQ81 :BQ>']SKRO#
M^YT!N<NZ=^E8[-/W -F_X.M.+/\ 6 '=._2L=FG[@&S?\'6G%G^@"(B (B^7
MG,W4QM*YD;]B*I1H5;%V[:G,8X*U2K"<]BQ-(;L$<4,,9R2&3L(@+D3LS.@*
M>_I?';V+2FV>F=AL#?>'-[G76S6K1@D(9HM!:>F\1J!E&8E$VH-1?!T,HR.X
M6L5CLK2.*2*W(4>NK4A/>J=MFUVA=_-P]T"GGDPV3R@XC1U:660X\?HO3\;8
MS 05@,G&".]'%/GK,<0Q!)D\S?LE$$L\C*/9 <[VLVQS6MM4::T7INJ=W4.K
ML_A],X.J L1397.7X,;2%V(@%HPGL#).9& 10!)+(81@1-NF.Q?V7<'LKM5H
M7:S3D8AB]%Z?IXD9!9N;E[VK67R<KL$;G8RN6L7LE9E(!.6Q:DDD]LB=:MON
M%>TWL9LOO<6ZF^&1R]2#2>G[0Z&JXK361U&\^I\PYX^WDIAQT,ST3Q&'>U'6
MEEZ'F/*FT75X,O3=U_+8/8X_3/KC_)SJC_TB LF(JV?Y;![''Z9]<?Y.=4?^
MC3\M@]CC],^N/\G.J/\ T: LF(JV?Y;![''Z9]<?Y.=4?^C3\M@]CC],^N/\
MG.J/_1H"R8BK9_EL'L<?IGUQ_DYU1_Z-/RV#V./TSZX_R<ZH_P#1H"R8H^N]
M+[$U#M"[$;@;76HX_A#,XE[VF+9](EC=7X64,KIJ]'(3CT"&4JP5[8]<86<?
M8N4YC:O9EYBX_+8/8X_3/KC_ "<ZH_\ 1I^6P>QQ^F?7'^3G5'_HT!JZ\MA[
MF.N7,=DJTE+)8VW:QV1I3,XS4\A0L25+U2479G:6M:AE@D9V;@XW7SU*+WQN
M[FS&X>_>K=Q-C+N0L:4UT\.I<Q4R.GKNFY*&L[QS?-(\-2[%"4\66L@&<GLQ
MQLTF1R-\Y#DF.0E%T@-@!Z'AV\_A/3&M>SOGL@\E_2UN;7>@HK!!UOI?,25Z
M^I,13]MCD@P^HC'+.#Q$4'S4&/K!5VK5ZMW!:5ON\^V!D=A-ZMO=V<>\Y1Z4
MS@'FJE=RZLEI?)PRXK4N.*,?SQXV'N69:\!>3WZ].4'CFABECW.^@==8C5&"
MPNIL!?K97 ZBQ&-SN$RE*:.Q3R6(R].'(8V_4L0D<,]:Y3L0V()HC..6*0#
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MM3^=,VK_ +&>W_WF:<_W:L@40&/W\Z9M7_8SV_\ O,TY_NU/YTS:O^QGM_\
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MQQ&XXNO6D:1JD<A 0.+YV8_.EK]CS_N1+Z*^=F/SI:_8\_[D2 WP*(B (B(
MB(@"(B (B( B(@,;NV3\4&ZOW-]<_BQE%I#\/^=*O['@_<A6[P[9/Q0;J_<W
MUS^+&46D/P_YTJ_L>#]R% ?16V8]&D^DFV3_ &/KC^$C6"U,ZVS'HTGTDVR?
M['UQ_"1K! 3L(B( B(@"(B (B( B(@"(B (B(#%_ML[WQ[:[/[FZ^DL>JOI+
M0VILY!8]GYU=I8FU)0+VG86;UWU=G=WX;GGSXX?21XZ)XZ\$9?1!#$!?KB L
M_P#G9;._TM7M4CH?LS1:&IV&CS.[VK<;IEHQ<FE'3.&"34FIK(\?.RBD:AB\
M'.!\N\>=ZXQ8H_%BUCB +8,>AA;)O2V_WEW#EA(2U)K#"Z6IV/T$]+2N).[+
M&S^YWKY#4-IG;S=O$?E^'9FU\DD@@)&3L(BSD1/[A86Y=W^LS-RMNAZ/AV8)
MMJ.R5M/A;\'J^;U#C;VO<\#@\<@7];9&SGJU6<"Y=K&,PMK$XB8N>)),>4@\
M";,P$T:(B +5R>EE?3A9+[F6@/W34"VC:U<GI97TX62^YEH#]TU @*U2M6>A
M]?30ZF^X[J/\9]'JJFK5GH?7TT.ION.ZC_&?1Z V8B(B (B( B(@"(B KK^D
M"=RQ2[3>B8M6:.K5Z>].A:-HM-V2-J\&KL,_YIN:-RY]+@YV)(FFT_D)>'QF
M3=XC,:%^\+ZL3)XNW0M6Z%^I9H9"A:LT,A0NPG7NT+].8ZURC<KR,TE>W4LQ
M2U[,$C,<4T9@3,XNM[&J3?I/'<?GJFME>TMM-B))M3XZK%-NII;&P 1ZAP]&
M'POFTQE2&)II]08BJ,09V&,SDR>%JA9A@._0(;H&OS4X'<;]\)F>RKN.WPS9
MR.1V=U=)'5U[IRN/K3XR?JA"IKC"5>/&^%L-$!PWZ560!S.(GL1'7M9&GB'@
M@] V)F(78A)F<29V=G9VY9V=O)V=O-G;R=E_2 WI6C-9XG46(QF>P.1IY?"Y
MFC5R6*RF/GCLTLA0NPC/5MU9XG*.6">$QDC,7X<7^3S7)EKA?1F^^X+:W.X[
ML^;I94(]M=3Y%XM!:AR,SM%H74M\WZ<#<LR&XPZ6U%<((Z3F(PX3-V'(Y8L=
M?E>EL>6?EF=O-G\V=O-G_6= >5#%Z0W])=V@/M/K?C%A%,ZH8O2&_I+NT!]I
M];\8L(@-18O#^YUY7A_<Z W.7=._2L=FG[@&S?\ !UIQ9_K #NG?I6.S3]P#
M9O\ @ZTXL_T 1$0!5D?2H.WK%M5V>+6WF+M^%JW?![^CJT41#XT&C(88"UU>
MD;Q!,*T^-N5].N;!*QS9^*/HZ/$EALVN_'F_DS>]_J+4:]_QV^&[0':1U=E\
M7;]:T7H62?;S1) 3O7M8_ WK$>8S==NHF\/.YWUVS7D;I\?&08R4XXI'*, (
M66;CR7E%DKV<>QMNQO!8RM7:S;W4^O9\%#5GS(:<I!:^#8KIRQTRMG+-  /9
M.O.T0"1&[1&3BPLSN!C4BE _(3NUW^IUW.__  34_P!X)^0G=KO]3KN=_P#@
MFI_O! 1?HI0/R$[M=_J==SO_ ,$U/]X)^0G=KO\ 4Z[G?_@FI_O! 1?HI0/R
M$[M=_J==SO\ \$U/]X)^0G=KO]3KN=_^":G^\$!%^BE _(3NUW^IUW.__!-3
M_>"?D)W:[_4Z[G?_ ()J?[P0$7Z*4#\A.[7?ZG7<[_\ !-3_ '@GY"=VN_U.
MNYW_ .":G^\$!%^BE _(3NUW^IUW._\ P34_W@L.>T-V6=R-I,O4P&Y^B-0Z
M$S5^@V4HXW45-JEBYCGFDK>N5G"2:*:$;$4D,G1(YQ2"S2 #'&Y ="K9:>B9
M]OP=Q=DK^SV9M$>J=E)*5''C,0]5W;_-G<DTW+ 3OXDWP+:IY'!6@X/U.O!A
MR.00OUH@UI:E:[E3MX3=GCM$Z&UI8G./2F:N0Z)U[$Q2^&^E-27*M:;)E#&_
M$TFG;XTLX#&$A/7IW((1&6R,@@;A9%^-:S'-''-%($L4H#)%+&0G')&8L021
MF+N)@8NQ"0NXD+L[.[.OV0!$1 $1$ 1$0!$1 $1$ 5?STH?Z23=G[)[7_P +
M&B58#5?STH?Z23=G[)[7_P +&B4!JDE\W,_G2U^QYOW,E])?-S/YTM?L>;]S
M) ;QKLW_ !=Z"^TO2WX#HKNA=+]F_P"+O07VEZ6_ =%=T( B(@"BC[Z/N]ZW
M:3V"U;H2"&+YK<> :JV_NR.0%3UA@@EFHP.8!(_JN;JG=T_?!P,7IY260&CL
MPU[$,KB(#1*6*TT$DL%F&2M9KRRU[-:8>B:M9@D*&Q7F!_,)H)@.*4'\PD A
M?W+\E9X]*=[O =H]]8MRM/XTJ^BMZVOYN4Z\ C1QVX-(XSU32)X0&*M)G(K-
M74=>.1@DO69<]/"\Y5+A15AT!L#_ $03O$?AK2NI>SAJ7)%)E='26-6[=#:D
MC8I='9&6$<Y@*9.32SMI[.RR9*.)P,J]'4 01R-3I0P5KL*TD_8R[4><V3W6
MT%NQIP7DRNAL_#E6JL71\(XRQ7L8K/X@C8@Z1R^ R&3QCNY,#/:8I&*-C MS
MUL#OCIS<S1&E-P=(WAR6F=98#&:BPEP1.,I*&4JQVH0GAD$)JUN!I'KW*EB.
M.S4MQ35;$4<\,D8@=O(B( H)_2&^\5?L^=GG/RX.\U7<+<-ST/H;PWA>Q1L9
M*$_AS4;1S,8N&GL&URW [QR">6DQ<$@>#-+)'.N[LS.[^3-YN[^3,S?*ZU*O
MI!W>)!VA^T/F[F$R W=OMNH9M":%> C>G<"I9>34^HHG?I"8L[G **&T$8A-
MA\3A_"*:,6L3 0<BW#>\B?Y2,B,R?Y2,R=R(B?S(B=R)W<G=W=W7\32C&!&3
M\" D1/\ 4$6=W?CW^3,OT4W/H_?=X!VB.T1@,=F\>5W0&W\,>O-=-+"TE"Y!
MC[D4>GM-W'D%X#;4.:Z'EI'UE=P^+S0/"< 3E&!>I]&V[N@]A>S[CLGGZ;U]
MP-UIJVN=4C,/%C%4;5&"+3&F7]D>@<3BF:W;!^LWS.5RK^*5=JL4%@Y$0!$1
M $1$!HY]_OC W ^WW6OXSY5=3KMC?[XP-P/M]UK^,^574Z V2OH:OTM&XWW?
M]2?P9[3*VVJDGH:OTM&XWW?]2?P9[3*VV@"(B Q?[;WQ+;O?<OU_^*F66D>P
M_P"=*O['@_<A6[A[;WQ+;O?<OU_^*F66D>P_YTJ_L>#]R% ?16VA]&K^DEV.
M_8>M_P"$S6:U+RVT/HU?TDNQW[#UO_"9K- 3GHB( B(@"(B (B( B(@"(B (
MB( B(@"(B T/F%_.=7^T1?Z@KZ:^9A?SG5_M$7^H*^F@-G'Z(7]*5-]UC7O^
MKA%:-57+T0OZ4J;[K&O?]7"*T:@"(B (B( B(@"(B (B( B(@"XMKC6-#3N%
MS&H,I+X&,P6+R&8R,W#/X-#&5)KMN5NHA%_#KP2'YD+>7F3-YKE*@F](_P"U
M9%M5V3=PI(K0ULWK\:NVFG19S:::_JH; Y$H&!V]JCIRGG,F?B?.GBI&!]3F
M($!JD==;@W]79[.ZMRA=63U7G,QJC)$S\L^0U#DK.8N\/P/+>LW9&%^EN69G
MX9<67\B+"S"S<,S,S-]1F]R_I 78O0OMC'LZVWLW-FKET8C3.G]O\;:X?I\7
M.9/YI<]79^..?#P6F9?>_//Z'H]K8'*M3Z*7V;3T/V4,+J6Y6]7R>Z>I=0ZU
MDZ@<)BQ$5T].Z=.5G;VAM8K"QY2L;._52R-?GI=G +*R (B("HIZ9+]+SMY]
MV'%_BCJY:WI;(7TR7Z7G;S[L.+_%'5RUO2 [\[)_QK[5?=/V\_''"K=Z+2%]
MD_XU]JONG[>?CCA5N]$ 1$0$<_>Y[%ON3V9][=(1Q#-:R&WFHK- '$B+X0Q%
M&3+TO"$!(GG>Q1C"!NEV>4@8O9=W;30UIVECCD;GB2,#;GW\&+$W^E;W*6(3
M$@,1,#%Q,"9B$A)N"$A?EB$F=V=G9V=GX?R6E?[Q#LLR[)[X[G[7E#+#2TKJ
MS)08)I>IW/3%^1LIIHQD,0>=APMVE7.=A899X)B9F]S 89K82>AF]HR/([=;
ML;4V)W>WI+5E#6&.K./ MA]847JV) -R?Q";,8*WXP@S-",M=S87G$I->VIU
M/1Q>U_!L_P!JW1$^3MC3T_N)4O[7YN20NBN):DL4+>GYIR=B$7CU/BL37B/H
M<_S;)")Q!8E)P-LXB(@"(B (B( B(@"(B (B( B(@"(B \.3-YN[,S-R_/R-
M]7]9:@WO-.\8W.U1VAMZ,SIO=#</$:=FW#U!0P6-Q.LM0XO'4\7@;#8"K%5H
M8_)0TX <,7XI/!&(S22E.[D<I&6SZ[T;M4P[*]GW=G<@CB&]I_1N7; 12NW3
M:U1DZQ8K357HY8I0ES=VCXXQ,4C51GD87:-UIAQ<W;F662>4N2EGE)SEFE)W
M*6:4R=R.64W*20R=R,R(B=W=W0&3?\^QO1_9AW4_RA:M_P![JZ-Z'CK7<#6F
M6W[U+K'6>L=4X_#T=O=/X@-2ZDS&>JPW\E-JS)YAZ<>4OVAK6(:M'">.<<8/
M+';A'K/PR$:#ZV@7HG'9ZDT;V5:FI;-<H;FY^L=0:QZC87>;&UWKZ9PTH$SD
M7@R4<$,P1OTL,DLTC Q2F1 6;D1$ 6H%[^_Z<?M ?;E4_%C +;]+4"]_?]./
MV@/MRJ?BQ@$!$2KP?H4W_2/M(?87:7]_;DJCXKP?H4W_ $C[2'V%VE_?VY*
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M;!?:;K[\-Z85*Q 38>CH?3G[(?9/5'XCZE6W 6H_]'0^G/V0^R>J/Q'U*MN
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M<=D:L]'(XVY;QV1H60\.S1R%"Q+4O4[ /]!/5M0RP2CYLQQOP[MYK>P+6/\
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M5</N!IWUK*;=:ME$V^"LP<+C)B\H<,<LUC3>;88ZV7JC',<3A7R5./UZC6=
M:@I9#=E+M2ZTV5W TWN7M_E),5J;35V.S [&;4\I1(P^$<!F(0?BYA<S6!Z>
M1JFS_.R&S7>*[6JV(>NMV-IM3:#U-G=%ZTPMO3NJ],Y&;$Y["7O#>QC\A7XZ
MXGDA.2"Q#(!1SU;=:66M<JRPV:\LD,H$_7R W,_=E]XOHOM.;6XG<724L=6X
M[_!NK=,26(Y<GI'4T$8E=Q%\1X)XC8@N8NYT#%DL9/6MQ?1F$<A*TX_=.]YY
MJOLJ[I5=<80+&6TOE8X,1N#I )!:/4NGAF>5I*C3$,%?4.'D([>$O$4?ME8Q
MUB5J&0M,MNMV?]^]*;H:,T[K_0^6@SFE=4XROE</DJ_+-+6G'EXYHBXDK6ZT
MC'6N5)A&>K:BEKS",D9,P%#/TTCXS=A_M%UK^'\&J7JNA>FD?&;L/]HNM?P_
M@U2]0$V/HY/T[.POV5UQ_!5KQ;;]:D#T<GZ=G87[*ZX_@JUXMM^@"(B +5H>
ME=?3CZ@^YYM]^]LHMI>M6AZ5U]./J#[GFWW[VRB K?*UYZ'?],YK'[C&?_&_
M12JAJUYZ'?\ 3.:Q^XQG_P ;]%(#9:(B( B(@"(B (B( B(@"(B (B( B(@"
MTS7>U;4GHCM.[\:;("$:^YFI,E"Y 8>+#J.RVI8Y0:1W?PC^%W\-V=P<6]CI
M%ND=S*M9EZ73V:)])]I3$[@00.V(W5T/B[!SL_LMJ;1IO@,M X,+#&)8,M+6
M(B<G*Q,=XND?!<C JN*Z=Z&-VAXZ&X&\FU-J<Q;4FE\+K["P&?$'K6F,C\S^
MH/#9WX*U8J:AT\;1CP95\;8D%B&&8@I8J0KNI^V@W9^W_P!NMT;)RA@\3EO@
MK5S0B4DA:/SXMC=02!$/G*="M(&5CA%NN>3'C #B4K$P&YF1>GC\A!;@@M59
MHK-:S#'8K6() F@L03 ,D,T,L;E'+%+&0G'(!$!@0D+NSLZ]Q $1$ 1$0!$1
M $1$ 1$0!?G+$)B0&(F!BXF!,Q"0DW!"0NSL0DSNSL[.SL[LZ_1=,=HW=BCH
M/;_6VM<G:"EC])Z4S^HK=N1V$*\&(Q=J\<I.[LS,#0<N[NS-\KL@-)]O15@@
MUMK:"L3'6@UKJZ&N0CTB5>+4>3CA<1X;I%XQ'I%F9A;AF9N%UNO=R>:FR5NY
MD[ N%C*7;F3L [N3A8R-F6[./4[,[],LYMR[-S]1O<WI("YWZ%S$3[H[Z2=/
ML#H'2 $7EPQGJ++$(_5?D0)_=Y<>?O;G8:JCEZ%GM3(&G]^-=2UB&*WJ#26C
MJ%OA^B0L3B;6=RM=G^A<X6SV(D)F\P:87=^#9FO&H B(@"(B (B( B(@"(B
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M6PF]"U^+#?'[I.#_ !2I+7LK83>A:_%AOC]TG!_BE20%TI$1 $1$ 1$0!$1
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M!2<*,>GLZ^4RDT0OE-4:BRF+EAR>H<P8ES/?OR-& 1^+X5.E#4QM1XZE.N
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MG5@$YK-NU.<<%:M"!S3S&$48$9,+@=X]ESLU:KWBW#TEMCHBGZ]J?6.5CQM
M"$GKU(!C.UDLM><?./&X;&06LG?E<A$:U4QZQ,A6Y&[#O9#TUL/M5HO:K2@=
M6,TEAJU&:^<4<-K.98A\;,Z@R Q^R]_-Y.2SD;/#N,9S^!%Q#%&(PH>CM]R>
MW9PTA-N!N+CJ,N]FM:;1VV'IM/H32TSPV*^DJ=DFZ6R=J2**[JFW5XCGNA6Q
MD4MFGBH+-FR\@"(B (B("HIZ9+]+SMY]V'%_BCJY:WI;(7TR7Z7G;S[L.+_%
M'5RUO2 [\[)_QK[5?=/V\_''"K=Z+2%]D_XU]JONG[>?CCA5N]$ 1$0!$1 4
M9?2O^Z/L9(/YZ';_ !;2V,;0CH;PXVE!\^L8ND,,.'UTP1#\\/#50/&:BD/V
MO@D,;<<FCQ<[24*5O6\[@Z64HW,;D:M>]C\C5L4;]*W$$]6Y2MPG7M5;,$C%
M'-7L02'#-%()!)&9 3.+NRU;??\ G<?97LT:JM;@:(J%<V*U9EPCQ#Q>++8V
M^S-\))7TIF'+K?X'GFBG/3&7*1HWBDCP-L8[M6G/E0*Y"M]^CL^D!0[0OCMB
M][<LT6U\\W@Z'UM?FE)MOK5F?GX!S<I^(,>C+,LQ2T\@101:7E:2.SU8B<9,
M54$7AV9VX=N6?R=G]SM]1 ;V7'Y&O;@AM59X;-6S%'/7LUY0F@L03 TD4T$T
M;E'+#+&0G')&1 8$Q"[L[.O<6K#[GKTBO<7LV#1T3K.');E;.1GT08(K4):K
MT=%)RYEH_(Y&:*"SC@+@FTQE;E?'1\R/C;V+>209-CKV,>WYM)V@--AJ;:K6
M6,U+5".$LECHY6KY_ S3@Q#4SV#G<,CBK(OU1\686BDDCD:":9@<D!F.B(@"
M(B (B( B(@"(H_\ M]]YSLYV:].GGMT-4P4+<U<IL+I3'>'D-8:D-C*,(<)@
M@E"Q,!S"41Y"R57%5>B22Y>K10RF(&7^ZNZVF]#:<S6K]7YK'Z=TSI['V,IF
MLUE; 5J./HU0<YIYY2^LS#%%&QS3RE'!!')-)'&6JE[\_OELMVK=>0U,&-W#
M[/:,M3-HG"66DKW,U=*,Z]G66H*[D[1Y"[&<L.*Q[BWP1BI!CF8LA8MFW&>]
MU[\/<WM69;X-M-+HS:G%WCLX#;VA<>5K<L9\5<QK&]",39S+A&('7J.+XC#2
ME*^.BEL')>EA00!=]]EWLS:PWDU_IC;30>.?(ZGU7D8J-,28FJ8^MRQ9#-Y6
M86?U;$8:IXE_(3\.30Q>! ,MN:O!+TYIW3V0S&2QN&Q%&WE<QF<A3Q.(Q6/@
M.S?RF4R-B.K0QU&M&SR6+=RS+'#!$#<D9M[FY)MI!Z/MW)M3LRZ//6FN*M&[
MO=K7'!'G;43^M0Z,P$TL=N#1>(M'''\\(XJEO5%R$!'(9>O%5CELX[$XZ8P)
M@NPOV.-+;!;6:2VJT?&[XK3&.&&>_)%'%;S>7L$]G,9V^T;<%=RV0DGMS<G(
M\;2! TAA$+K+9$0!$1 %J!>_O^G'[0'VY5/Q8P"V_2U O?W_ $X_: ^W*I^+
M& 0$1*O!^A3?](^TA]A=I?W]N2J/BO!^A3?](^TA]A=I?W]N2@+]J(B +ANX
MO_1[._8;*?O&=<R7#=Q?^CV=^PV4_>,Z T6&'_.E7]CP?N0KZ*^=A_SI5_8\
M'[D*^B@-J%Z*U])KHC[9]?\ XUY%6+E71]%:^DUT1]L^O_QKR*L7( B(@"(B
M (B( B(@"(B JX>D;]R0&_NEY=V-M<7%_-GT;BQ";'UAAKEN'IFD12R82P?
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M#1P4Z5</G5'&T*XQU<?1@9H:M:,(QZCZY# Z=7\22" D9/P("Y$_U!%N7?\
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MWXI:66N$6Q[]#7^(#<C[KM[\4M+("WJB(@"(B (B( B(@"(B (B( B(@"(B
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M,3F)*[-7''Y.]&T]X"HLLS>QMWA>\W9_R,M_:37F7TI%:L!;R.$#P<AIC+V
M8!:7*:=OQSXRQ*0111RVHX8+TD,80E:\( !L4=5:4RV!R-K#9[$Y3!9FD;QW
M<1F\==Q&5IFSN+A;QN1@K7*Q=0DS--"#NXOQ[E\! 7D^R'Z9=E( KX[?;:NK
M<,7$)-5;8V)*C&'7QXMO26HKULHY B]J:2AJ*<+,SF4&/HQ]$+6#=@_21>QS
MKYHXHMW:.CL@8/(>/W&Q68T3X(LWT)9G,4XM,2R>]O"J9VS(W#.0,Q Y:E]$
M!O ]#=I7;O4]>&UIW7>C\Y7L</!+BM28>\,O+<MT>KW)'+EO-N&\UW1%,$@B
M<9"8$W(F!,0DWU6(7=G;Z[.M$E0#U25IZCO4G;W3U2>M,W/F[M- \<C/SY\L
M2[%QN\&LJ;L]/6>LJCL+@WJNK-0U^ )V=P'P<D' N[,[BW#.[,_'D@-Y9RNM
MM3[S:/P@229G56G,2$0]<I9'-XRDT8,+'U%ZS9CX;H=B;ZHNSMY.RTDM_>S7
M%IA:UKG6]EAZF%I]8:DF8>MF8^EI,F3-U,S,7'T3,W//#+KK+6YL@3'D+%C(
MFWN/(6)KQMPS"W!VCF)N!9A;S\A9A;R9F0&WGW[[_/LA[<L89S>_2F3O TC-
MBM&?".N\GXT?5S7FKZ0I9D<?*3CTL64EHPLY YR@)@3P+=JOTRW1U&*S3V4V
MNS6I;KB0UL]K^<-.82,W'@9GPN-FNYNX(2=3O6.?$^-'TNUR$B=AU_  (LPB
M(B+,S,(LS,S-[F9FX9F^LWDOZ0$H?;H[Y7M$=HF.QC]Q->3PZ6L2,9Z&TE >
MF=(&(F4D4-S'U[-B]F88G=NF+/9/*@11PRR"<\,<HQ=  BS"(L(BS,PBS,+,
MWN9F;R9F^1F]R_I>8Q(Y(88P.6>Q+'!7@B Y9[$\I,$4%>&,2EGGE-V"*&(3
MED-V$ (G9G \+LO9[9K5FX6IL5HW0VGLKJK56<G]7Q>#PU9[-VT?EUF_+A!5
MJP,3':OW)J]&I'\\M6(H_:4[W=O>C1[];Z^I9_5=2QLQM]8?Q/AK6&&MCJW*
M5F,6Z\#HFV6-O#!8!R.GE<Y-C:<T;1W*E?)4Y83FV%G=Z]U7LQV9L$>+VSTQ
M##EKL,4>>UIE_"R.L=1%$W+?">:.&.4*@R.<D&*H!3Q-4C)Z]*,G)W AS[CC
MT<; ["GBMT]W1H:JWE&".QB<9&45W3.VTLHN1/BBZ.C+:I #:O9U";G6I.,D
M6!"$))KURU,R\H@"(B (B( B(@"(B *-GO>NR*V^/9RW3V\A@]8R]_3=C*Z:
M%@ZY!U1ITPSNGWA%A(BDDR5""NT8N'C#,4!R!'*;J29$!HB*MAI8HY69V:2,
M)&9_>S&+$S/[_-N?JK]U*/WTO9)CV3[3>ZNB:58*>"L9Q]7Z7KQ1-!!!IW6#
M%FJM2M&/SH*N-N39#%U8XB(8JU&*,^F49(PBX0!<_P!I]K\KKC56F-%8&,I,
MWJ_4.%TQB1"-YB^$,[D:^,K2-$SL\C0R66F,&<7((RX=O>N *S9Z*3V/@W$[
M2X:YR-7Q\)LU@I]3#XD325I-59V*Y@=-B;G&<3R4HI,OEX!8@L17:%"U"_$!
MNP&R<[.6R&(VTT!HO;W 0M!A=%:7PFF,;'U/(_JN%QU>A&<DI")S33-!XLT\
MC-)/*9RR?/#)W[H1$ 1$0!$1 $1$ 1$0!=$]I_87%;I;=:VVYS8B6*UKIG,:
M<N.3.31ADZ4M8)^&X=WK2G'8'I=BZHVZ79^';O9$!HN=>:!RVE,]G=*9^N=7
M.Z7S66TWFZTC"TE?+X+(6,5DH28"(.8[E28>0(@=F9Q(A=G?BJLJ>E3]D-MM
M^T]:U=0I/7P6\6!KZOAE"-QKGJ;%/%@]5P@3 $36/G>%R5F./DN<L%B9RELF
M95JT 7\EU<?.XY)9'X:.*(7.660GX"*(&Y(Y)#=@C 6=R,A%FY=E_2E)[E?L
MD'O7VG=IM&RP//A:&HZFM]5L43S0_,SHFQ7SUVM8%G%Q@S%ROCM/%)U<Q/F&
ME%GZ'0&SW[G?LBCL=V;=J=O98Q#+TM.AFM3&WAD4VJ=4V9]29]WDC$?%CK9'
M*34*9%R88^I4@=^(F9I,$1 $1$ 1$0!$1 %I6^\>^F,[0GW=]X_X1]2K=2+2
MM]X]],9VA/N[[Q_PCZE0&&:L!]S/W[EGLA:8UOIR#;.'7K:SU)1U"]R751:>
M?'>I8F'%>J-"."R_K/B>$T[3>)!T=3Q^&7'6J_B("\W^75<C^IVJ_P"4N3^)
M:?EU7(_J=JO^4N3^):HR(@+S?Y=5R/ZG:K_E+D_B6GY=5R/ZG:K_ )2Y/XEJ
MC(B O-_EU7(_J=JO^4N3^):?EU7(_J=JO^4N3^):HR(@+S?Y=5R/ZG:K_E+D
M_B6GY=5R/ZG:K_E+D_B6J,B("\W^75<C^IVJ_P"4N3^):?EU7(_J=JO^4N3^
M):HR(@+S?Y=5R/ZG:K_E+D_B6GY=5R/ZG:K_ )2Y/XEJC(B O-_EU7(_J=JO
M^4N3^):?EU7(_J=JO^4N3^):HR(@+S?Y=5R/ZG:K_E+D_B6K@_=Z=K*3?39C
M;_=J7!AIJ37&##,E@X\@^4#'=<\\+5QR!5*!6F%H>KQ7J5^7)_G;<+2NK;P^
MC[_2;;!?:17_ '[=0$QZ(B IV>F=?$;M']V,/Q#UDM=$MB[Z9U\1NT?W8P_$
M/62UT2 RC[#?QV[-_=5V\_&W$+=FK29=AOX[=F_NJ[>?C;B%NS4 1$0!$1 $
M1$ 1$0!$1 $1$ 6O&]-!TF,&Z6R&;$&ZLAH35F-E-@X=WQF>Q-B("/J]KV<C
M*X#PW3P;\ESPVPY5*#TT?;%YMO\ 9#6H1/TXW7F:TI:L</PWP]IJYF*4#O[F
MZRTU=D9O>7A^7D+H#7W+.'NR-QOF1[2&PFHWF:O#CMW]OX[DQ.3#%C<KJ2AA
M<J;]+L[L.,R5PNGG@G9F+D7=E@\O:H9F;&V*V2K];6<9:K9*L\;N)M8Q\\=R
M!P(?,3:6$'$F\V)F=O<@-[,BZDV#W5IZZT/I#6=":&>GJK36$S\$M<F. @RN
M.KW>(C;R(!*9P9V_I5VV@"K+^EK_ $H&3^Z-M[^%I59H59?TM?Z4#)_=&V]_
M"TJ U>Z^=F/SI:_8\_[D2^BOG9C\Z6OV//\ N1(#>]U_Z''_ -P?]5E^R_&O
M_0X_^X/^JR_9 $1$!KXO33/C"V"^TW7WX;TPJ5BNI^FF?&%L%]INOOPWIA4K
M$!-AZ.A].?LA]D]4?B/J5;<!:C_T=#Z<_9#[)ZH_$?4JVX" (B( B(@"(B (
MB( B(@"(B @S[]'N>L1VJMN'+$#5QF[FC(+-W;_/2O'!%=<F>2WH_.V"C,GP
M6<Z>(Y.H"Q66&IDP/P([M:WJA-<Z'S6F,WE]-:DQ=S":AP&1MXC-X?(1>#>Q
MF3H2E!;IV8N79I(I!=F(".*8'":"22&2.0MZ.JA'I,'<B#NE@;^_NU>&(]S=
M*8J2766GL54\2QN%IG'1/+ZS5JUP>:SJ[ 5@F*B,(2V,[C^O$O'+;BQ;Q@:X
M9%X9_P!?WNSL[.SL[.[.Q,_FQ"[.Q"[,[.SL[,[<+R@"VP?HQ/TC^RW[(W3_
M (9MPUJ?%M@_1B?I']EOV1NG_#-N&@)[41$ 1$0!?"U/IC'9K'7\/EZ-3)XK
M*4[&/R6.O01VJ5ZC;B."U4MUYA.*>O8@D.*6*02 P,A)G9^%]U$!K;N_,]&V
MS^TUK,;J["XC(:DVLFFMY+/Z+I\W,]MS&;O/++BJW#6\YHV GD&((&MYK P>
M#'8BOX^.;(U*CP2"0L0NQ"3,XD+L[.S^;.SMY.SM[G9;W Q8F<29G%V=G9V9
MV=G;AV=G\G9V\G9_)V557O8_1>-N=YK&0UQL[8Q>TVX]F:6[DL?#C6^8/5]F
M5Y9)SR&+H%7+3^9M3R-/+G<3%-'9E$_A'$VYK#W:X&L[7;NQ6_\ KC;#4<&K
MMNM69W16IJP/$&8T]>.E9EKD0F=2[&S'5R-(R #.CD:]JH4@1RO#XL49CW%V
MP^P/N_L'G9L!NOH3-Z6D:Q+#0S4E:2YI3.A'+X0V<#J>L!XC(Q3>Q(%?UB')
MP!+$-_'TYS\%L0$!<=[&OIAVY^G!KXO>[0F&W#QT0B#ZET?TZ6U9TLS^U=Q=
MN>QIO*RN73\\J'IQA!G<HK$GM/9"[/GI0'8_UTU>OD-?W]O<I.T0O1U_IO-8
M>H$ILWBB^HJM3(:8CCAD?H\6WF*CRB[2QQN#2/'JH$0&[?VS[8^TFLZD=_26
MYN@M24Y79HK.&U;@LA#)U,SCX9UKTC'U,[.SCRSL[<+(6CD:]J-I:T\-B)^.
M)()0FC?D1-N#C(A?D"$FX?S$A+W.SK1*1U8PE:<(PCG%^H9XQ8)A+CCJ&4&8
MQ+CRY8F?A<_QVZ&JJ?1ZGJO55-HR$XVIZFSE48S!A8" 8+\8@0L L)"S.+"+
M,[,(LP&\X7P\SJ;&XX>O(9"C0#AGZKEN"J/#]7#]4\@-P_0?#\^?07]*_&D
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ML,3-&#%6*$V !%@8NCI#IZ6P@S'YTM?L>?\ <B0&^!1$0!$1 $1$ 1$0!$1
M$1$!C=VR?B@W5^YOKG\6,HM(?A_SI5_8\'[D*W>';)^*#=7[F^N?Q8RBTA^'
M_.E7]CP?N0H#Z*M;]VWZ4%=[/&RVB]GH=F*^JX]'QYN,<^>N3PY7_AG4>7U
M[OCFTQD6KO7?+/5X:Y+XC0-+['B= U2$0%YO\NJY']3M5_RER?Q+3\NJY']3
MM5_RER?Q+5&1$!>;_+JN1_4[5?\ *7)_$M/RZKD?U.U7_*7)_$M49$0%YO\
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MD\K%TSX31E2UTR6-/Z1:6&.8C?@(,OJ"9AM98HNBM#0Q_%4K&2(@"(B (B(
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MM49$0%YO\NJY']3M5_RER?Q+3\NJY']3M5_RER?Q+5&1$!>;_+JN1_4[5?\
M*7)_$M/RZKD?U.U7_*7)_$M49$0%YO\ +JN1_4[5?\I<G\2T_+JN1_4[5?\
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MJ[4<1='E[/,>3%^GR;V?=Y-Y>2]RUOMKR<'BGU[KJ:,N'>.76>II =Q=G%W
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M_P"N>R_W[ZF_B GY4,[6?]<]E_OWU-_$!;.9$!K&?RH9VL_ZY[+_ '[ZF_B
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M4TUJ;6M[.31Y'3>8Q$'J%7*;<86A,8VK\!2C8RE01KM-(!G( 0RWID1 $1$
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M  \C3HO=S]KPV-@DR&I<M)?U#DYV8S9[&0R=F<F)V*1V6:2( B(@"(B (B(
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MDN8;3V%Q-N2J<DE8[..QM:G.=>26*"4X"EA-XCD@AD*-Q<XHR=P;L)$0!$1
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MGLO]^^IOX@+9S(@-8S^5#.UG_7/9?[]]3?Q 3\J&=K/^N>R_W[ZF_B MG,B
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MS'Z'J8<-#9C4F6.L>F;&K)KQ9+X?TAI<81F'/U6J>JO<<WBL>,T##&\MGM$
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M 681%F869F9E["( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
J (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>May 09, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-14888<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">INOVIO PHARMACEUTICALS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">33-0969592<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">660 W. Germantown Pike<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Plymouth Meeting<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">PA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">19462<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">440-4200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">COMMON STOCK, $0.001 PAR VALUE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">INO<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,674,436<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001055726<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 39,915,447<span></span>
</td>
<td class="nump">$ 65,813,297<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">28,447,097<span></span>
</td>
<td class="nump">28,300,232<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable from affiliated entity</a></td>
<td class="nump">1,310,237<span></span>
</td>
<td class="nump">1,199,056<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">2,221,668<span></span>
</td>
<td class="nump">2,517,465<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">71,894,449<span></span>
</td>
<td class="nump">97,830,050<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Fixed assets, net</a></td>
<td class="nump">3,347,824<span></span>
</td>
<td class="nump">3,659,818<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent', window );">Investments in affiliated entity</a></td>
<td class="nump">2,308,975<span></span>
</td>
<td class="nump">1,613,844<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">7,741,757<span></span>
</td>
<td class="nump">8,113,840<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">1,979,654<span></span>
</td>
<td class="nump">1,979,654<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">87,272,659<span></span>
</td>
<td class="nump">113,197,206<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_AccruedClinicalTrialExpenseCurrent', window );">Accrued clinical trial expenses</a></td>
<td class="nump">1,819,237<span></span>
</td>
<td class="nump">2,021,860<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Common stock warrant liability</a></td>
<td class="nump">9,542,316<span></span>
</td>
<td class="nump">13,255,188<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability</a></td>
<td class="nump">2,575,902<span></span>
</td>
<td class="nump">2,497,360<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">27,326,880<span></span>
</td>
<td class="nump">35,325,584<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, net of current portion</a></td>
<td class="nump">8,695,055<span></span>
</td>
<td class="nump">9,367,827<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">36,021,935<span></span>
</td>
<td class="nump">44,693,411<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock</a></td>
<td class="nump">36,674<span></span>
</td>
<td class="nump">36,099<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">1,801,789,329<span></span>
</td>
<td class="nump">1,799,362,625<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(1,749,913,959)<span></span>
</td>
<td class="num">(1,730,219,262)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(661,320)<span></span>
</td>
<td class="num">(675,667)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Inovio Pharmaceuticals, Inc. stockholders&#8217; equity</a></td>
<td class="nump">51,250,724<span></span>
</td>
<td class="nump">68,503,795<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">87,272,659<span></span>
</td>
<td class="nump">113,197,206<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember', window );">Nonrelated Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">12,919,788<span></span>
</td>
<td class="nump">16,200,013<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">$ 469,637<span></span>
</td>
<td class="nump">$ 1,351,163<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_AccruedClinicalTrialExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Clinical Trial Expense, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_AccruedClinicalTrialExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 80<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480078/944-80-55-14<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 80<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480078/944-80-55-9<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482736/825-10-45-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from collaborative arrangements</a></td>
<td class="nump">$ 65,343<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">16,090,902<span></span>
</td>
<td class="nump">20,913,790<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">9,024,970<span></span>
</td>
<td class="nump">10,571,179<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">25,115,872<span></span>
</td>
<td class="nump">31,484,969<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(25,050,529)<span></span>
</td>
<td class="num">(31,484,969)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">808,077<span></span>
</td>
<td class="nump">1,500,290<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(177,833)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of common stock warrant liability</a></td>
<td class="nump">3,712,872<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_ChangeInValueOfInvestmentsInAffiliatedCompany', window );">Gain (loss) on investment in affiliated entity</a></td>
<td class="nump">695,131<span></span>
</td>
<td class="num">(126,018)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Net unrealized gain on available-for-sale equity securities</a></td>
<td class="nump">140,234<span></span>
</td>
<td class="nump">500,877<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense, net</a></td>
<td class="num">(482)<span></span>
</td>
<td class="num">(682,218)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (19,694,697)<span></span>
</td>
<td class="num">$ (30,469,871)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net loss per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in dollars per share)</a></td>
<td class="num">$ (0.51)<span></span>
</td>
<td class="num">$ (1.31)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in dollars per share)</a></td>
<td class="num">$ (0.51)<span></span>
</td>
<td class="num">$ (1.31)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract', window );"><strong>Weighted average number of common shares used to compute net loss per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">38,613,653<span></span>
</td>
<td class="nump">23,291,512<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">38,613,653<span></span>
</td>
<td class="nump">23,291,512<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ChangeInValueOfInvestmentsInAffiliatedCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of the change in fair value of the investment in affiliated entity. This investment is measured at fair value on a recurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ChangeInValueOfInvestmentsInAffiliatedCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479536/321-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Loss - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (19,694,697)<span></span>
</td>
<td class="num">$ (30,469,871)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">32,403<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on short-term investments, net of tax</a></td>
<td class="nump">14,347<span></span>
</td>
<td class="num">(46,016)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (19,680,350)<span></span>
</td>
<td class="num">$ (30,483,484)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders' Equity - USD ($)<br></strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Preferred stock</div></th>
<th class="th"><div>Common stock</div></th>
<th class="th"><div>Additional paid-in capital</div></th>
<th class="th"><div>Accumulated deficit</div></th>
<th class="th"><div>Accumulated other comprehensive loss</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">22,793,075<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2023</a></td>
<td class="nump">$ 117,349,129<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 22,792<span></span>
</td>
<td class="nump">$ 1,740,954,074<span></span>
</td>
<td class="num">$ (1,622,965,136)<span></span>
</td>
<td class="num">$ (662,601)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock for cash, net of financing costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">543,620<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock for cash, net of financing costs</a></td>
<td class="nump">5,225,133<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 544<span></span>
</td>
<td class="nump">5,224,589<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Vesting of RSUs, net of tax payments (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,558<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Vesting of RSUs, net of tax payments</a></td>
<td class="num">(174,248)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34<span></span>
</td>
<td class="num">(174,282)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">2,525,433<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,525,433<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(30,469,871)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(30,469,871)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on short-term investments, net of tax</a></td>
<td class="num">(46,016)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(46,016)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation</a></td>
<td class="nump">32,403<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,403<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Mar. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">23,371,253<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2024</a></td>
<td class="nump">94,441,963<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 23,370<span></span>
</td>
<td class="nump">1,748,529,814<span></span>
</td>
<td class="num">(1,653,435,007)<span></span>
</td>
<td class="num">(676,214)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">36,099,991<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2024</a></td>
<td class="nump">68,503,795<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 36,099<span></span>
</td>
<td class="nump">1,799,362,625<span></span>
</td>
<td class="num">(1,730,219,262)<span></span>
</td>
<td class="num">(675,667)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock for cash, net of financing costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">518,670<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock for cash, net of financing costs</a></td>
<td class="nump">1,102,149<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 519<span></span>
</td>
<td class="nump">1,101,630<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Vesting of RSUs, net of tax payments (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,694<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Vesting of RSUs, net of tax payments</a></td>
<td class="num">(74,219)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56<span></span>
</td>
<td class="num">(74,275)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">1,399,349<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,399,349<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(19,694,697)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19,694,697)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on short-term investments, net of tax</a></td>
<td class="nump">14,347<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,347<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Mar. 31, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">36,674,355<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2025</a></td>
<td class="nump">$ 51,250,724<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 36,674<span></span>
</td>
<td class="nump">$ 1,801,789,329<span></span>
</td>
<td class="num">$ (1,749,913,959)<span></span>
</td>
<td class="num">$ (661,320)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (19,694,697)<span></span>
</td>
<td class="num">$ (30,469,871)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">371,367<span></span>
</td>
<td class="nump">424,473<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of operating lease right-of-use assets</a></td>
<td class="nump">372,083<span></span>
</td>
<td class="nump">335,257<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of common stock warrant liability</a></td>
<td class="num">(3,712,872)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Non-cash stock-based compensation</a></td>
<td class="nump">1,399,349<span></span>
</td>
<td class="nump">2,525,433<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_NonCashInterestIncomeExpense', window );">Non-cash interest on senior convertible notes</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(355,654)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium', window );">Amortization of discounts on investments</a></td>
<td class="num">(386)<span></span>
</td>
<td class="num">(684,651)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfOtherInvestments', window );">Loss on sales of short-term investments</a></td>
<td class="nump">482<span></span>
</td>
<td class="nump">691,168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_ChangeInValueOfInvestmentsInAffiliatedCompany', window );">(Gain) loss on equity investment in affiliated entity</a></td>
<td class="num">(695,131)<span></span>
</td>
<td class="nump">126,018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Net unrealized gain on available-for-sale equity securities</a></td>
<td class="num">(140,234)<span></span>
</td>
<td class="num">(500,877)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable from affiliated entity</a></td>
<td class="num">(111,181)<span></span>
</td>
<td class="num">(145,854)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">295,797<span></span>
</td>
<td class="nump">1,897,016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses, including due to affiliated entity</a></td>
<td class="num">(4,161,751)<span></span>
</td>
<td class="num">(3,160,238)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_IncreaseDecreaseInAccruedClinicalTrialExpense', window );">Accrued clinical trial expenses</a></td>
<td class="num">(202,623)<span></span>
</td>
<td class="nump">657,104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet', window );">Operating lease right-of-use assets and liabilities, net</a></td>
<td class="num">(594,230)<span></span>
</td>
<td class="num">(11,791)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_IncreaseDecreaseinDeferredGrantFundingCurrent', window );">Grant funding liability, including from affiliated entity</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(87,489)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(26,874,027)<span></span>
</td>
<td class="num">(28,759,956)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireShortTermInvestments', window );">Purchases of investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(9,751,047)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfShortTermInvestments', window );">Proceeds from sale or maturity of investments</a></td>
<td class="nump">7,620<span></span>
</td>
<td class="nump">55,169,260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of capital assets</a></td>
<td class="num">(59,373)<span></span>
</td>
<td class="num">(35,578)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash (used in) provided by investing activities</a></td>
<td class="num">(51,753)<span></span>
</td>
<td class="nump">45,382,635<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfConvertibleDebt', window );">Repayment of convertible senior notes</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(16,415,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of issuance costs</a></td>
<td class="nump">1,102,149<span></span>
</td>
<td class="nump">5,225,133<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_ProceedsFromPaymentsForStockOptionsExercisedAndExerciseOfWarrantsNetOfTaxWithholdings', window );">Taxes paid related to net share settlement of equity awards</a></td>
<td class="num">(74,219)<span></span>
</td>
<td class="num">(174,248)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="nump">1,027,930<span></span>
</td>
<td class="num">(11,364,115)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">32,403<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">(Decrease) Increase in cash and cash equivalents</a></td>
<td class="num">(25,897,850)<span></span>
</td>
<td class="nump">5,290,967<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, beginning of period</a></td>
<td class="nump">65,813,297<span></span>
</td>
<td class="nump">14,310,862<span></span>
</td>
<td class="nump">$ 14,310,862<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, end of period</a></td>
<td class="nump">39,915,447<span></span>
</td>
<td class="nump">19,601,829<span></span>
</td>
<td class="nump">$ 65,813,297<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosures:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Amounts accrued for purchases of fixed assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">442,976<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 533,487<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ChangeInValueOfInvestmentsInAffiliatedCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of the change in fair value of the investment in affiliated entity. This investment is measured at fair value on a recurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ChangeInValueOfInvestmentsInAffiliatedCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_IncreaseDecreaseInAccruedClinicalTrialExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Accrued Clinical Trial Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_IncreaseDecreaseInAccruedClinicalTrialExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Operating Lease, Right-Of-Use Asset (Lease Liability), Net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_IncreaseDecreaseinDeferredGrantFundingCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Deferred Grant Funding, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_IncreaseDecreaseinDeferredGrantFundingCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_NonCashInterestIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-Cash Interest Income (Expense)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_NonCashInterestIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ProceedsFromPaymentsForStockOptionsExercisedAndExerciseOfWarrantsNetOfTaxWithholdings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From (Payments For) Stock Options Exercised and Exercise Of Warrants, Net Of Tax Withholdings</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ProceedsFromPaymentsForStockOptionsExercisedAndExerciseOfWarrantsNetOfTaxWithholdings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479536/321-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfOtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) included in earnings for investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfOtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Operations<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Organization and Operations</a></td>
<td class="text">Organization and Operations<div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Inovio Pharmaceuticals, Inc. (the &#8220;Company&#8221; or &#8220;INOVIO&#8221;) is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer and infectious diseases. INOVIO's platform harnesses the power of in vivo protein production, featuring optimized design and delivery of DNA medicines that teach the body to manufacture its own disease-fighting tools. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">INOVIO uses proprietary technology to design DNA plasmids, which are small circular DNA molecules that work like software the body&#8217;s cells can download to produce specific proteins to target and fight disease. The Company's proprietary investigational CELLECTRA devices are designed to deliver the plasmids into the body's cells for optimal effect, without the use of chemical adjuvants, lipid nanoparticles or viral vectors. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INOVIO's lead candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease of the respiratory tract caused by HPV infection. In its completed Phase 1/2 clinical trial of INO-3107 for the treatment of HPV-6 and HPV-11-associated RRP, 81.3% of patients experienced a reduction in the number of surgical interventions in the year following administration of INO-3107, when compared with the year prior to treatment. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to its development efforts with INO-3107, INOVIO is actively developing or planning to develop DNA medicines for other indications, including HPV-related oropharyngeal squamous cell carcinoma (OPSCC) and anal dysplasia; glioblastoma multiforme (GBM), a deadly form of brain cancer; and a potential vaccine booster to protect against the Ebola virus. The Company was previously conducting clinical trials of a DNA medicine candidate for the treatment of HPV-related cervical high-grade squamous intraepithelial lesions (HSIL) but announced in 2023 that it was ceasing development for this indication in the United States. However, its collaborator ApolloBio Corporation continues to conduct a Phase 3 clinical trial of this candidate in China and plans to seek regulatory approval for and potentially commercialize the candidate in that jurisdiction. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, Coherus Biosciences, Defense Advanced Research Projects Agency (DARPA), HIV Vaccines Trial Network, International Vaccine Institute (IVI), Kaneka Eurogentec, National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID), Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter BioLogics, the University of Pennsylvania and The Wistar Institute.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INOVIO was incorporated in Delaware in June 2001 and has its principal executive offices in Plymouth Meeting, Pennsylvania.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/275/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation, Liquidity and Risks and Uncertainties<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Basis of Presentation, Liquidity and Risks and Uncertainties</a></td>
<td class="text">Basis of Presentation, Liquidity and Risks and Uncertainties<div style="margin-bottom:3pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation</span></div><div style="margin-top:4.5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements of Inovio have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) as contained in the Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") for interim financial information and with instructions to Form&#160;10-Q and Article&#160;10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The condensed consolidated balance sheet as of March&#160;31, 2025, the condensed consolidated statements of operations, the condensed consolidated statements of comprehensive loss, the condensed consolidated statements of stockholders' equity and the condensed consolidated statements of cash flows for the three months ended March 31, 2025 and 2024 are unaudited, but include all adjustments (consisting of normal recurring adjustments) that the Company considers necessary for a fair presentation of the financial position, results of operations, cash flows and changes in stockholders' equity for the periods presented. </span></div><div style="margin-top:4.5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of operations for the three months ended March 31, 2025 shown herein are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2025, or for any other period. These unaudited financial statements, and notes thereto, should be read in conjunction with the audited consolidated financial statements for the year ended December&#160;31, 2024, included in the Company's Annual Report on Form&#160;10-K filed with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) on March&#160;18, 2025. The balance sheet at December&#160;31, 2024 has been derived from the audited financial statements at that date, but does not include all of the information and footnotes required by U.S. GAAP for complete financial statements. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These unaudited condensed consolidated financial statements include the accounts of Inovio Pharmaceuticals, Inc. and its subsidiary. As of March&#160;31, 2025 and December 31, 2024, the Company consolidated its wholly-owned subsidiary Inovio Asia LLC. All intercompany accounts and transactions were eliminated upon consolidation. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Liquidity </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurred a net loss of $19.7 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the three months ended March 31, 2025. The Company had working capital of $44.6 million and an accumulated deficit of $1.7 billion as of March&#160;31, 2025. The Company has incurred losses in each year since its inception and expects to continue to incur significant expenses and operating losses for the foreseeable future in connection with the research and preclinical and clinical development of its product candidates. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 16, 2024, the Company closed an underwritten public offering (the "December 2024 Offering"), relating to the issuance and sale of 10,000,000 shares of its common stock, par value $0.001 per share, and warrants to purchase 10,000,000 shares of common stock (the &#8220;Warrants&#8221;), at an offering price of $3.00 per share and accompanying Warrant. The exercise price of the Warrants is $3.76 per share. The net proceeds from the December 2024 Offering were $27.6&#160;million, after deducting the underwriting discounts and commissions and offering expenses paid by the Company. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 18, 2024, the Company closed an underwritten registered direct offering (the &#8220;April 2024 Offering&#8221;) relating to the issuance and sale of 2,536,258 shares (the &#8220;Shares&#8221;) of its common stock, par value $0.001 per share, at a price of $7.693 per share and pre-funded warrants to purchase up to 2,135,477 shares of common stock (the &#8220;Pre-Funded Warrants&#8221;) at a price of $7.692 per Pre-Funded Warrant, which represents the per share price for the Shares less the $0.001 per share exercise price for each Pre-Funded Warrant. The net proceeds from the April 2024 Offering were $33.2&#160;million, after deducting the underwriting discounts and commissions and offering expenses paid by the Company. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Going Concern </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s cash, cash equivalents and short-term investments of $68.4 million as of March&#160;31, 2025 are expected to be sufficient to support the Company's planned operations into the first quarter of 2026. The Company's current financial resources may not be sufficient to support its planned operations beyond this date without securing additional financing.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to continue to fund future research and development activities, the Company will need to seek additional capital. This may occur through strategic alliance and licensing arrangements, grant agreements and/or future public or private debt or equity financings including At-the-Market Equity Offering Sales Agreements (&#8220;Sales Agreements&#8221;). The Company has a history of conducting debt and equity financings, including the receipt of net proceeds of $60.8&#160;million from equity offerings during the year ending December 31, 2024, and the receipt of net proceeds of $1.1&#160;million and $6.1&#160;million under Sales Agreements during the three months ended March 31, 2025 and year ended December 31, 2024, respectively. However, sufficient funding may not be available in the future, or if available, may be on terms that significantly dilute or otherwise adversely affect the rights of existing stockholders. If adequate funds are not available, the Company may need to delay, reduce the scope of or put on hold one or more of its clinical and/or preclinical programs.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s ability to continue its operations is dependent upon its ability to obtain additional capital in the future and achieve profitable operations. The Company expects to continue to rely on outside sources of financing to meet its capital needs and may never achieve positive cash flow. In light of these factors, management believes that there is substantial doubt about the Company's ability to continue as a going concern beyond the first quarter of 2026. The Company's condensed consolidated financial statements as of and for the three months ended March 31, 2025 do not include any adjustments that might result from the outcome of this uncertainty. The Company has evaluated subsequent events after the balance sheet date through the date it issued these condensed consolidated financial statements.</span></div>The Company is, and from time to time&#160;may in the future be, subject to various legal proceedings and claims arising in the ordinary course of business. The Company assesses contingencies to determine the degree of probability and range of possible loss for potential accrual in its consolidated financial statements. An estimated loss contingency is accrued in the consolidated financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Legal proceedings, including litigation, government investigations and enforcement actions, could result in material costs, occupy significant management resources and entail civil and criminal penalties, even if the Company ultimately prevails.&#160;Any of the foregoing consequences could result in serious harm to the Company&#8217;s business, results of operations and financial condition.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/275/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Critical Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Critical Accounting Policies</a></td>
<td class="text">Critical Accounting Policies<div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaboration Agreements and Revenue Recognition</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company assesses whether its collaboration agreements are subject to Accounting Standards Codification ("ASC") Topic 808: Collaborative Arrangements (&#8220;Topic 808&#8221;) based on whether they involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within the scope of Topic 808 and the Company concludes that its collaboration partner is not a customer, the </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Company presents such payments as a reduction of research and development expense. If payments from the collaboration partner to the Company represent consideration from a customer, then the Company accounts for those payments within the scope of Accounting Standards Update (&#8220;ASU&#8221;) 2014-09, Revenue from Contracts with Customers (&#8220;Topic 606&#8221;). </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses - Clinical Trial Accruals</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company's activities have largely consisted of research and development efforts related to developing its proprietary device technology and DNA medicine candidates. For clinical trial expenses, judgements used in estimating accruals rely on estimates of total costs incurred based on participant enrollment, completion of studies and other events. Accrued clinical trial costs are subject to revisions as trials progress. Revisions are charged to expense in the period in which the facts that give rise to the revision become known. Historically, revisions have not resulted in material changes to research and development expense; however, a modification in the protocol of a clinical trial or cancellation of a trial could result in a charge to the Company's results of operations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-term Investments and Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Short-term Investments and Fair Value Measurements</a></td>
<td class="text">Short-term Investments and Fair Value Measurements<div style="margin-bottom:3pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of available-for-sale securities as of March&#160;31, 2025 and December&#160;31, 2024:</span></div><div style="margin-bottom:3pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:25.839%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.812%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2025</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Maturity&#160;(in&#160;years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Market&#160;Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">---</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,926,415&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,305,472)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,620,943&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 1</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,980,607&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,268&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(276)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,989,599&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency mortgage-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,243,914&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(407,359)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">836,555&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,150,936&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,268&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,713,107)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,447,097&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:25.839%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.812%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2024</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Maturity&#160;(in&#160;years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Market&#160;Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">---</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,926,415&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,445,706)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,480,709&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 1</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,980,273&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(281)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,989,742&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency mortgage-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,260,745&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(430,964)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">829,781&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,167,433&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,750&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,876,951)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,300,232&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*No single maturity date.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During the three months ended March 31, 2025 and 2024, the Company recorded gross realized gains on investments of $200 and $200, respectively, and gross realized losses on investments of $700 and $691,000, respectively. During the three months ended March 31, 2025 and 2024, the Company recorded net unrealized gains on available-for-sale equity securities of $140,000 and $501,000, respectively. No&#160;material balances were&#160;reclassified out of accumulated&#160;other comprehensive loss for the three months ended March 31, 2025 and 2024. Interest and dividends on investments classified as available-for-sale are included in interest income in the condensed consolidated statements of operations. As of March&#160;31, 2025, the Company had 19 available-for-sale securities with an aggregate total unrealized loss of $1.7 million. All of these securities had been in a loss position for longer than 12 months as of March&#160;31, 2025.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company periodically reviews its portfolio of available-for-sale debt securities to determine if any investment is impaired due to credit loss or other potential valuation concerns. For the debt securities where the fair value of the investment is less than the amortized cost basis, the Company has assessed at the individual security level for various quantitative factors including, but not limited to, the nature of the investments, changes in credit ratings, interest rate fluctuations, industry analyst reports, and the severity of impairment. Unrealized losses on available-for-sale debt securities as of&#160;March&#160;31, 2025&#160;were primarily due to changes in interest rates</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">and not due to increased credit risks associated with specific securities. Based on the credit quality of the available-for-sale debt securities that are in an unrealized loss position, and the Company&#8217;s estimates of future cash flows to be collected from those securities, the Company believes the unrealized losses are not credit losses. Accordingly, at March&#160;31, 2025, the Company has not recorded an allowance for credit losses related to its available-for-sale debt securities.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following table presents the Company&#8217;s assets that were measured at fair value on a recurring basis, determined using the following inputs as of March&#160;31, 2025:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:35.796%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.541%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.541%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.737%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.689%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2025</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices<br/>in Active Markets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other Unobservable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Mutual funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,620,943&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,620,943&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,989,599&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,989,599&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">836,555&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">836,555&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,447,097&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,620,943&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,826,154&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in affiliated entity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,308,975&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,308,975&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,756,072&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,929,918&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,826,154&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock warrant liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,542,316&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,542,316&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,542,316&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,542,316&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s assets that were measured at fair value on a recurring basis, determined using the following inputs as of December&#160;31, 2024:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:35.796%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.541%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.541%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.737%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.689%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices<br/>in Active Markets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other Unobservable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Mutual funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,480,709&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,480,709&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,989,742&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,989,742&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">829,781&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">829,781&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,300,232&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,480,709&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,819,523&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in affiliated entity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,613,844&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,613,844&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,914,076&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,094,553&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,819,523&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock warrant liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,255,188&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,255,188&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,255,188&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,255,188&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Level 1 assets at March&#160;31, 2025 consisted of mutual funds and the Company&#8217;s investment in its affiliated entity, Plumbline Life Sciences, Inc. (PLS). See Note 10 for additional information. The Company accounts for its investment in 597,808 common shares of PLS based on the closing price of the shares on the Korea New Exchange Market on the applicable balance sheet date. Unrealized gains and losses on the Company's equity securities are reported in the consolidated statement of ope</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">rations as unrealized gain or loss on available-for-sale equity securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">or as a gain or loss on investment in affiliated entity.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 assets at March&#160;31, 2025 consisted of certificates of deposit and U.S. agency mortgage-backed securities held by the Company that are initially valued at the transaction price and subsequently valued, at the end of each reporting period, typically utilizing market observable data. The Company obtains the fair value of its Level 2 assets from a professional pricing service, which may use quoted market prices for identical or comparable instruments, or inputs other than quoted prices that are observable either directly or indirectly. The professional pricing service gathers quoted market prices and observable inputs from a variety of industry data providers. The valuation techniques used to measure the fair value of the Company's Level 2 financial instruments were derived from non-binding market consensus prices that are corroborated by observable market data, </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">quoted market prices for similar instruments, or pricing models such as discounted cash flow techniques. The Company validates the quoted market prices provided by the primary pricing service by comparing the service's assessment of the fair values of the Company's investment portfolio balance against the fair values of the Company's investment portfolio balance obtained from an independent source.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no Level 3 assets held as of March&#160;31, 2025 or December 31, 2024.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 liabilities held as of March&#160;31, 2025 and December 31, 2024 consisted of liabilities associated with the Warrants to purchase common stock issued in the Company's underwritten public offering that closed in December 2024. See Note 7 for additional information about the liability-classified warrants.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reassesses the fair value of the common stock warrant liability at each reporting date utilizing a Black-Scholes pricing model. The following assumptions were used to estimate the fair value of the warrant liability:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.016%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.905%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.198%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">March 31, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">4.0%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">4.4%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Expected volatility</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">94%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">111%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Expected life in years</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">4.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">5</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Dividend yield</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8212;</span></td></tr></table></div><div><span><br/></span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in these assumptions as well as fluctuations in the Company's stock price between the valuation dates can have a </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">significant impact on the fair value of the common stock warrant liability. Expected volatility was based on historical volatility. Historical volatility was computed using daily pricing observations for recent periods. The Company believes this method produced an estimate that was representative of the Company&#8217;s expectations of future volatility over the expected term. Expected term is calculated based on the remaining contractual term of the Warrants. The risk-free rate was based on the U.S. Treasury rate that corresponds to the expected term of the Warrants. As a result of these calculations, the Company recorded a decrease in fair value of the liability of $3.7&#160;million on the condensed consolidated statement of operations for the three months ended March&#160;31, 2025. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the change in fair value of the Company&#8217;s total Level 3 financial liabilities for the three months ended March&#160;31, 2025:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:83.110%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock Warrant Liability</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,255,188&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-394">Decrease in fair value of liability</span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,712,872)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2025</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,542,316&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Short-term Investments and Fair Value Measurements</a></td>
<td class="text">Short-term Investments and Fair Value Measurements<div style="margin-bottom:3pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of available-for-sale securities as of March&#160;31, 2025 and December&#160;31, 2024:</span></div><div style="margin-bottom:3pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:25.839%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.812%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2025</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Maturity&#160;(in&#160;years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Market&#160;Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">---</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,926,415&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,305,472)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,620,943&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 1</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,980,607&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,268&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(276)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,989,599&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency mortgage-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,243,914&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(407,359)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">836,555&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,150,936&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,268&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,713,107)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,447,097&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:25.839%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.812%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2024</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Maturity&#160;(in&#160;years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Market&#160;Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">---</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,926,415&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,445,706)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,480,709&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 1</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,980,273&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(281)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,989,742&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency mortgage-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,260,745&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(430,964)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">829,781&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,167,433&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,750&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,876,951)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,300,232&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*No single maturity date.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During the three months ended March 31, 2025 and 2024, the Company recorded gross realized gains on investments of $200 and $200, respectively, and gross realized losses on investments of $700 and $691,000, respectively. During the three months ended March 31, 2025 and 2024, the Company recorded net unrealized gains on available-for-sale equity securities of $140,000 and $501,000, respectively. No&#160;material balances were&#160;reclassified out of accumulated&#160;other comprehensive loss for the three months ended March 31, 2025 and 2024. Interest and dividends on investments classified as available-for-sale are included in interest income in the condensed consolidated statements of operations. As of March&#160;31, 2025, the Company had 19 available-for-sale securities with an aggregate total unrealized loss of $1.7 million. All of these securities had been in a loss position for longer than 12 months as of March&#160;31, 2025.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company periodically reviews its portfolio of available-for-sale debt securities to determine if any investment is impaired due to credit loss or other potential valuation concerns. For the debt securities where the fair value of the investment is less than the amortized cost basis, the Company has assessed at the individual security level for various quantitative factors including, but not limited to, the nature of the investments, changes in credit ratings, interest rate fluctuations, industry analyst reports, and the severity of impairment. Unrealized losses on available-for-sale debt securities as of&#160;March&#160;31, 2025&#160;were primarily due to changes in interest rates</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">and not due to increased credit risks associated with specific securities. Based on the credit quality of the available-for-sale debt securities that are in an unrealized loss position, and the Company&#8217;s estimates of future cash flows to be collected from those securities, the Company believes the unrealized losses are not credit losses. Accordingly, at March&#160;31, 2025, the Company has not recorded an allowance for credit losses related to its available-for-sale debt securities.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following table presents the Company&#8217;s assets that were measured at fair value on a recurring basis, determined using the following inputs as of March&#160;31, 2025:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:35.796%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.541%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.541%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.737%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.689%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2025</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices<br/>in Active Markets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other Unobservable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Mutual funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,620,943&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,620,943&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,989,599&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,989,599&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">836,555&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">836,555&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,447,097&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,620,943&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,826,154&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in affiliated entity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,308,975&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,308,975&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,756,072&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,929,918&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,826,154&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock warrant liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,542,316&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,542,316&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,542,316&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,542,316&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s assets that were measured at fair value on a recurring basis, determined using the following inputs as of December&#160;31, 2024:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:35.796%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.541%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.541%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.737%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.689%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices<br/>in Active Markets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other Unobservable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Mutual funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,480,709&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,480,709&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,989,742&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,989,742&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">829,781&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">829,781&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,300,232&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,480,709&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,819,523&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in affiliated entity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,613,844&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,613,844&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,914,076&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,094,553&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,819,523&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock warrant liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,255,188&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,255,188&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,255,188&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,255,188&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Level 1 assets at March&#160;31, 2025 consisted of mutual funds and the Company&#8217;s investment in its affiliated entity, Plumbline Life Sciences, Inc. (PLS). See Note 10 for additional information. The Company accounts for its investment in 597,808 common shares of PLS based on the closing price of the shares on the Korea New Exchange Market on the applicable balance sheet date. Unrealized gains and losses on the Company's equity securities are reported in the consolidated statement of ope</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">rations as unrealized gain or loss on available-for-sale equity securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">or as a gain or loss on investment in affiliated entity.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 assets at March&#160;31, 2025 consisted of certificates of deposit and U.S. agency mortgage-backed securities held by the Company that are initially valued at the transaction price and subsequently valued, at the end of each reporting period, typically utilizing market observable data. The Company obtains the fair value of its Level 2 assets from a professional pricing service, which may use quoted market prices for identical or comparable instruments, or inputs other than quoted prices that are observable either directly or indirectly. The professional pricing service gathers quoted market prices and observable inputs from a variety of industry data providers. The valuation techniques used to measure the fair value of the Company's Level 2 financial instruments were derived from non-binding market consensus prices that are corroborated by observable market data, </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">quoted market prices for similar instruments, or pricing models such as discounted cash flow techniques. The Company validates the quoted market prices provided by the primary pricing service by comparing the service's assessment of the fair values of the Company's investment portfolio balance against the fair values of the Company's investment portfolio balance obtained from an independent source.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no Level 3 assets held as of March&#160;31, 2025 or December 31, 2024.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 liabilities held as of March&#160;31, 2025 and December 31, 2024 consisted of liabilities associated with the Warrants to purchase common stock issued in the Company's underwritten public offering that closed in December 2024. See Note 7 for additional information about the liability-classified warrants.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reassesses the fair value of the common stock warrant liability at each reporting date utilizing a Black-Scholes pricing model. The following assumptions were used to estimate the fair value of the warrant liability:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.016%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.905%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.198%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">March 31, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">4.0%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">4.4%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Expected volatility</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">94%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">111%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Expected life in years</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">4.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">5</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Dividend yield</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8212;</span></td></tr></table></div><div><span><br/></span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in these assumptions as well as fluctuations in the Company's stock price between the valuation dates can have a </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">significant impact on the fair value of the common stock warrant liability. Expected volatility was based on historical volatility. Historical volatility was computed using daily pricing observations for recent periods. The Company believes this method produced an estimate that was representative of the Company&#8217;s expectations of future volatility over the expected term. Expected term is calculated based on the remaining contractual term of the Warrants. The risk-free rate was based on the U.S. Treasury rate that corresponds to the expected term of the Warrants. As a result of these calculations, the Company recorded a decrease in fair value of the liability of $3.7&#160;million on the condensed consolidated statement of operations for the three months ended March&#160;31, 2025. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the change in fair value of the Company&#8217;s total Level 3 financial liabilities for the three months ended March&#160;31, 2025:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:83.110%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock Warrant Liability</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,255,188&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-394">Decrease in fair value of liability</span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,712,872)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2025</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,542,316&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 940<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/940-320/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph b<br> -Publisher SEC<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/320/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6B<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/942-320/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Certain Balance Sheet Items<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CertainBalanceSheetItemsAbstract', window );"><strong>Certain Balance Sheet Items [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCurrentAssetsTextBlock', window );">Certain Balance Sheet Items</a></td>
<td class="text">Certain Balance Sheet Items<div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid and other current assets consisted of the following:</span></div><div style="text-indent:-4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.289%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.291%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid clinical expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,013,742&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">627,962&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other prepaid expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,207,926&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,889,503&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,221,668&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,517,465&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-indent:-4.5pt"><span><br/></span></div><div style="padding-left:27pt;text-indent:-31.5pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable and accrued expenses consisted of the following:</span></div><div style="text-indent:-4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.289%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.291%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade accounts payable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,054,582&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,091,503&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,322,421&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,007,180&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,542,785&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,101,330&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,919,788&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,200,013&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CertainBalanceSheetItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Certain Balance Sheet Items</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CertainBalanceSheetItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCurrentAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Debt<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Convertible Debt</a></td>
<td class="text">Convertible Debt<div style="margin-bottom:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Convertible Senior Notes </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In 2019, the Company completed a private placement of $78.5&#160;million aggregate principal amount of its 6.50% convertible senior notes due 2024 (the &#8220;Notes&#8221;). The Notes were sold in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. Net proceeds from the offering were $75.7&#160;million.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Notes were senior unsecured obligations of the Company and accrued interest payable in cash semi-annually in arrears on March 1 and September 1 of each year at a rate of 6.50% per annum. The Notes matured on March 1, 2024 and the Company paid the then remaining $16.9&#160;million obligation in full, including accrued interest.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">For the three months ended March 31, 2024,&#160;the Company recognized $178,000 of interest expense related to the Notes, all of which related to the contractual interes</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">t coupon.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/470/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">Stockholders&#8217; Equity<div style="margin-bottom:10pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the Company's authorized and issued common and preferred stock as of March&#160;31, 2025 and December&#160;31, 2024: </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"></td><td style="width:42.095%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.473%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.473%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.136%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.106%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outstanding as of</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Authorized</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Issued</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common Stock, par value $0.001 per share</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">600,000,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,674,355&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,674,355&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,099,991&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series&#160;C Preferred Stock, par value $0.001 per share</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,091&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,091&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:5pt;text-indent:27pt"><span><br/></span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Offering of Common Stock and Warrants</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 16, 2024, the Company closed the December 2024 Offering (see &#8220;Liquidity&#8221; in Note 2 above). </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each Warrant issued in the December 2024 Offering has an initial exercise price per share of $3.76, subject to certain adjustments. The Warrants may be exercised at any time, in whole or in part, until expiration on December 16, 2029. In the event there is no effective registration statement covering the shares of common stock underlying a Warrant exercise, the Warrants may be exercised via cashless exercise. A holder (together with its affiliates and other attribution parties) may not exercise any portion of a Warrant to the extent that immediately prior to or after giving effect to such exercise the holder would own more than 4.99% (or, for certain holders who so elected prior to the issuance of the Warrants, 9.99%) of the Company&#8217;s outstanding Common Stock immediately after exercise, which percentage may be changed at the holder&#8217;s election to a lower or higher percentage not in excess of 19.99% upon 61 days&#8217; notice to the Company subject to the terms of the Warrants. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the Warrants are not indexed to the Company&#8217;s common stock, the Company recorded a liability for the Warrants at fair value upon issuance on the Company's condensed consolidated balance sheet. The common stock warrant liability is remeasured to fair value at the end of each reporting period. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2025 and December 31, 2024, no Warrants issued in the December 2024 Offering had been exercised.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 18, 2024, the Company closed the April 2024 Offering (see &#8220;Liquidity&#8221; in Note 2 above). </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each Pre-Funded Warrant issued in the April 2024 Offering has an initial exercise price per share of $0.001, subject to certain adjustments. The Pre-Funded Warrants may be exercised at any time until exercised in full. A holder (together with its affiliates and other attribution parties) may not exercise any portion of a Pre-Funded Warrant to the extent that immediately prior to or after giving effect to such exercise the holder would own more than 9.99% of the Company&#8217;s outstanding Common Stock immediately after exercise, which percentage may be changed at the holder&#8217;s election to a lower or higher percentage not in excess of 19.99% upon 61 days&#8217; notice to the Company subject to the terms of the Pre-Funded Warrants. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the Pre-Funded Warrants issued in the April 2024 Offering are indexed to the Company's own shares of common stock (and otherwise meet the requirements to be classified in equity), the Company recorded the consideration received from the issuance of the Pre-Funded Warrants as additional paid-in capital on the Company's condensed consolidated balance sheet as of March 31, 2025 and December 31, 2024.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2025 and December 31, 2024, no Pre-Funded Warrants had been exercised.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">At-The-Market Sales Agreements</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 13, 2024, the Company entered into an Equity Distribution Agreement (the "2024 Sales Agreement") with an outside sales agent (the "Sales Agent") for the offer and sale of its common stock for an aggregate offering price of up to $60.0&#160;million. The 2024 Sales Agreement provides that the Sales Agent is entitled to compensation in an amount equal to up to 3.0% of the gross sales proceeds of any common stock sold through the Sales Agent under the 2024 Sales Agreement, and the Company has provided the Sales Agent with certain indemnification rights. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2025, the Company sold 518,670 shares of its common stock under the 2024 Sales Agreement. The sales were made at a weighted average price of $2.16 per share, resulting in aggregate net proceeds of $1.1 million. As of March&#160;31, 2025, there was $57.9&#160;million of remaining capacity under the 2024 Sales Agreement.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 9, 2021, the Company entered into an ATM Equity Offering</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">SM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Sales Agreement (the &#8220;2021 Sales Agreement&#8221;) with outside sales agents (collectively, the &#8220;Sales Agents&#8221;) for the offer and sale of its common stock for an aggregate offering price of up to $300.0&#160;million. The 2021 Sales Agreement provides that the Sales Agents were entitled to compensation in an amount equal to up to 3.0% of the gross sales proceeds of any common stock sold through the Sales Agents under the 2021 Sales Agreement. During the three months ended March 31, 2024, the Company sold 543,620 shares of its common stock under the 2021 Sales Agreement at a weighted average price of $9.76 per share, resulting in aggregate net proceeds of $5.2&#160;million. The 2021 Sales Agreement was terminated in August 2024 in connection with the entry into the 2024 Sales Agreement described above.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Options and Restricted Stock Units</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Board of Directors adopted the 2023 Omnibus Incentive Plan (the &#8220;2023 Plan&#8221;) on March 24, 2023, pursuant to which the Company may grant stock options, restricted stock awards, restricted stock units ("RSUs") and other stock-based awards or short-term cash incentive awards to employees, directors and consultants. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2023 Plan was approved by stockholders on May 16, 2023. The aggregate number of shares of the Company&#8217;s common stock that may be issued under the 2023 Plan will not exceed the sum of 1,166,666 shares plus any shares that may return from time to time from the 2016 Omnibus Incentive Plan (as amended, the &#8220;2016 Plan&#8221;) as a result of expirations, terminations or forfeitures of awards outstanding under the 2016 Plan as of May 16, 2023. At March&#160;31, 2025, the Company had 24,460 shares of common stock available for future grant under the 2023 Plan, 464,887 shares underlying outstanding RSUs and 732,165 shares underlying options outstanding to purchase common stock under the 2023 Plan. The awards granted and available for future grant under the 2023 Plan generally vest over three years and have a maximum contractual term of ten years. The 2023 Plan terminates by its terms on March&#160;24, 2033. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following adoption of the 2023 Plan, no further awards may be made under the 2016 Plan, but outstanding awards continue to be governed by their existing terms. At March&#160;31, 2025, the Company had 90,642 shares underlying outstanding but unvested RSUs and options outstanding to purchase 902,123 shares of common stock under the 2016 Plan. The outstanding awards granted under the 2016 Plan generally vest over three years and have a maximum contractual term of ten years. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 24, 2022, the Company's board of directors adopted a stock-based incentive plan (the "2022 Inducement Plan"), which provides for the discretionary grant of nonstatutory stock options, stock appreciation rights, restricted stock awards, RSU awards, performance awards, and other awards to individuals as a material inducement to entering into employment with the Company. The aggregate number of shares of the Company&#8217;s common stock that may be issued under the 2022 Inducement Plan will not exceed 166,666 shares. At March&#160;31, 2025, the Company had 85,378 shares of common stock available for future grant under the 2022 Inducement Plan, 18,191 shares underlying outstanding but unvested RSUs and options outstanding to purchase 52,634 shares of common stock under the 2022 Inducement Plan. The 2022 Inducement Plan can be terminated by the Company's board of directors at any time.</span></div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Amended and Restated 2007 Omnibus Incentive Plan (the "2007 Incentive Plan") was adopted on M</span>arch&#160;31, 2007 and terminated by its terms on March&#160;31, 2017. At March&#160;31, 2025, the Company had options outstanding to purchase 61,262 shares of common stock under the 2007 Incentive Plan. The outstanding awards granted under the 2007 Incentive Plan are fully vested and generally have a maximum contractual term of ten years.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text">Net Loss Per Share <div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is computed by dividing the net loss for the period by the weighted average number of shares of common stock outstanding during the period. The outstanding Pre-Funded Warrants (see Note 7) are included in the weighted-average common shares outstanding in the basic net loss per share calculation for the three months ended March 31, 2025 given their nominal exercise price.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Diluted net loss per share is calculated in accordance with the treasury stock method for the outstanding Warrants, stock options and RSUs and refle</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cts the potential dilution that would occur if securities or other con</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">tracts to issue common stock were exercised or converted to common stock. The calculation of diluted net loss per share requires that, to the extent the average market price of the underlying shares for the reporting period exceeds the exercise price of the options or other securities and the presumed exercise of such securities are dilutive to net loss per share for the period, an adjustment to the net loss used in the calculation is required to remove the change in fair value of such securities from the numerator for the period. Likewise, an adjustment to the denominator is required to reflect the related dilutive shares, if any. For the three months ended March 31, 2025 and 2024, basic and diluted net loss per share were the same, as the assumed exercise or settlement of common stock warrants, stock options, service-based RSUs and performance-and market-based RSUs would have been anti-dilutive.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted net loss per share for the three months ended March 31, 2025 and 2024 are calculated as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.128%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.960%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,694,697)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,469,871)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Shares used to compute net loss per share, basic and diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Weighted-average common shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,478,176&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,291,512&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Weighted-average shares underlying pre-funded warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,135,477&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Weighted-average common shares outstanding used to compute basic and diluted net loss per share</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,613,653&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,291,512&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Basic and diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.51)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.31)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span><br/></span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.128%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.960%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">          The following table summarizes potential shares of common stock that were excluded from the diluted net loss per share calculation because of their anti-dilutive effect: </span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.128%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.960%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,000,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,748,184&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,355,178&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service-based restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">573,720&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">392,120&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance-and market-based restricted stock units</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible preferred stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,450,979&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,747,573&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">Stock-Based Compensation<div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurs stock-based compensation expense related to service-based RSUs, performance-based RSUs and stock options. The fair value of restricted stock is determined by the closing price of the Company's common stock reported on the Nasdaq Capital Market on the date of grant. The Company estimates the fair value of stock options granted using the Black-Scholes option pricing model. The Black-Scholes option pricing model was developed for use in estimating the fair value of traded options, which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of subjective assumptions, including the expected stock price volatility and expected option life. The Company amortizes the fair value of the awards on a straight-line basis over the requisite vesting period of the awards. Expected volatility is based on historical volatility. The expected life of options granted is based on historical expected life. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant. The dividend yield is based on the fact that no dividends have been paid historically and none are currently expected to be paid in the foreseeable future. The Company recognizes forfeitures as they occur.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average assumptions used in the Black-Scholes model for option grants to employees and directors are presented below:</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.07%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.21%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life in years</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total employee and director stock-based compensation expense recognized in the condensed consolidated statements of operations for the three months ended March 31, 2025 and 2024 was $1.4 million and $2.4 million, respectively, of which $547,000 and $1.0 million, respectively, was included in research and development expenses, and $821,000 and $1.4 million, respectively, was included in general and administrative expenses. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2025, there was $1.9 million of total unrecognized compensation expense related to unvested stock options, which is expected to be recognized over a weighted-average period of 1.5 years.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average grant date fair value per share, calculated using the Black-Scholes option pricing model, was $1.60 and $6.77 for employee and director stock options granted during the three months ended March 31, 2025 and 2024, respectively.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2025, there was $2.2 million of total unrecognized compensation expense related to unvested service-based RSUs, which is expected to be recognized over a weighted-average period of 2.0 years.  </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average grant date fair value per share was $1.95 and $8.39 for service-based RSUs granted during the three months ended March 31, 2025 and 2024, respectively.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of stock options granted to non-employees was estimated using the Black-Scholes pricing model. Total stock-based compensation expense for stock options and RSUs granted to non-employees for the three months ended March 31, 2025 and 2024 was $32,000 and $103,000, respectively. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Performance-and Market-Based RSUs </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2024, the Company granted performance-and market-based RSUs (such performance-based grants, the "PSU Awards") to key employees under the 2023 Plan. Each PSU was expressed as a target number of RSUs. With respect to the PSU Awards, the Company's Board of Directors established specified performance goals and corresponding performance periods over which the goals must be attained, the satisfaction of which are conditions to earning the PSU Awards and vesting of the underlying RSUs. As of March&#160;31, 2025, 83,800 performance-and market-based RSU's were outstanding.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Of the target number of RSUs underlying each PSU Award, up to 70% (the "Milestone-based RSUs") will vest based on the achievement of specified milestones relating to the development, regulatory status and commercialization of the Company&#8217;s lead product candidate INO-3107 (each, a "Milestone," and collectively, the "Milestones"). Each Milestone has a specified deadline for achievement ranging between the end of 2025 and the end of 2027.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The remaining 30% of the target number of RSUs underlying each PSU Award (the "Market-based RSUs") will be eligible to vest based on the Company&#8217;s achievement of total stockholder return relative to a peer group consisting of companies in the Russell 2000 Biotechnology Subsector index (the &#8220;Relative TSR&#8221;) over the period beginning on June 1, 2024 and ending on December 31, 2027 (the &#8220;Performance Period&#8221;), expressed as a percentile ranking.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of Market-based RSUs, if any, actually earned based on the achievement of the Relative TSR goal may range from 50% of the target number of RSUs for performance at a specified threshold percentile, to 100% of the target number of RSUs for performance at the target percentile, and up to 150% of the target number of RSUs for performance at or above a specified maximum percentile. In the event that actual Relative TSR performance is between the threshold and target levels or between the target and maximum levels, the number of RSUs earned based on Relative TSR will be determined based on linear interpolation between the specified percentiles. If the Company&#8217;s actual Relative TSR performance is below the threshold percentile, then no RSUs would be earned based on Relative TSR. The number of RSUs earned based on Relative TSR may not exceed the target number of RSUs eligible to vest based on Relative TSR if the Company&#8217;s total stockholder return is negative for the Performance Period.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company values the Milestone-based RSUs based on the grant date closing price per share. The Company recognizes stock-based compensation expense over the performance period, if it is probable that the performance condition will be achieved. Adjustments to stock-based compensation expense are made, as needed, each reporting period based on changes in the Company's estimate of the number of units that are probable of vesting. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company values the Market-based RSUs on the grant date using the Monte Carlo simulation method, a generally accepted statistical technique used to simulate a range of possible future stock prices for the Company and the peer group. The determination of fair value is affected by the Company's stock price and a number of assumptions including the expected volatility and the risk-free interest rate. The Company will recognize stock-based compensation expense ratably over the performance period of the award. The market-based RSUs will cliff-vest at the end of the three-year period ranging from zero percent to 150 percent of the target number of awards granted. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The significant assumptions used in the Monte Carlo simulation method were as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:80.040%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.760%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.60%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life in years</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.61</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The grant date fair value of the Milestone-based RSUs was $643,000 based on the grant date closing price per share of $10.96. As of March&#160;31, 2025, the underlying performance milestones of the Milestone-based RSUs were determined to be not probable of achievement, and no stock-based compensation expense was recognized for the three months then ended.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The grant date fair value of the Market-based RSUs was $269,000 based on the fair value of $10.69 per share as determined using the Monte Carlo simulation method. For the three months ended March 31, 2025, the Company recognized $19,000 in stock-based compensation for the Market-based RSUs.  </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">December 2024 Performance-Based Awards</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2024, the Company granted performance-based stock options and RSUs (such performance-based grants, the "December 2024 Awards") to key employees under the 2023 Plan. Each award was expressed as a target number of stock options and RSUs. With respect to the December 2024 Awards, the Company's Board of Directors established specified performance goals and a corresponding performance period over which the goals must be attained, the satisfaction of which are conditions to earning the December 2024 Awards and vesting of the underlying stock options and RSUs. As of March&#160;31, 2025, December 2024 Awards were outstanding covering 25,686 shares of common stock underlying stock options and 19,314 shares of common stock underlying RSUs.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The grant date fair value of the performance-based RSUs was $34,000 based on the grant date closing price per share of $1.78. The grant date fair value of the performance-based stock options was $38,000 based on the Black-Scholes per share value of $1.46. As of March&#160;31, 2025, the underlying performance milestones of the December 2024 Awards were determined to be not probable of achievement, and no stock-based compensation expense was recognized for the three months then ended.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text">Related Party Transactions<div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Plumbline Life Sciences, Inc.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company owned 597,808 shares of common stock in PLS as of March&#160;31, 2025, representing an ownership interest of 16.7%. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's investment in PLS is recorded as investment in affiliated entity on the condensed consolidated balance sheet as of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2025 and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and was valued at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$2.3 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$1.6 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, respectively, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">based on the closing price of the shares on the Korea New Exchange Market at the applicable balance sheet date</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. O</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ne of the Company's directors, Dr.&#160;David B. Weiner, acts as a consultant to PLS.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Wistar Institute</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dr. Weiner is a director of the Vaccine Center of The Wistar Institute ("Wistar") and an Executive Vice President of Wistar.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, the Company entered into collaborative research agreements with Wistar&#160;for preventive and therapeutic DNA-based immunotherapy applications and products developed by&#160;Dr. Weiner and Wistar for the treatment of cancers and infectious diseases. Under the terms of the agreement, the Company reimbursed Wistar for all direct and indirect costs incurred in the conduct of the collaborative research, not to exceed $3.1 million during the five-year term of the agreements. In 2021, upon expiration of the 2016 agreements, the Company entered into new collaborative research agreements with Wistar&#160;with the same terms. The Company has the exclusive right to in-license new intellectual property developed under this agreement.  </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, the Company received a $10.7&#160;million sub-grant through Wistar, which was amended in 2021 to $13.6&#160;million, for the preclinical development and translational studies of DNA-Encoded Monoclonal Antibodies (DMAbs) as countermeasures for COVID-19. In August 2024, the sub-grant was amended to a total of $12.5&#160;million in funding through September 2025.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, the Company received a $1.2&#160;million sub-grant through Wistar, which was amended in 2024 to $2.4&#160;million with funding through November 2024, with an option for an additional $4.2&#160;million in funding that extends the sub-grant through November 2027. The Company will support the Wistar lead consortium in the research and development of synthetic DNA-launched nanoparticles (DLNPs) for vaccination against HIV infection.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred grant funding recognized from Wistar and recorded as contra-research and development expense is related to work performed by the Company on the research sub-contract agreements. For the three months ended March 31, 2025 and 2024, the Company recorded $286,000 and $140,000, respectively. </span></div>Research and development expenses recorded from Wistar relate primarily to collaborative research agreements. Research and development expenses recorded from Wistar for the three months ended March 31, 2025 and 2024 were $0 and $475,000, respectively. At March&#160;31, 2025 and December&#160;31, 2024, the Company had an accounts receivable balance of $1.3 million and $1.2 million, respectively, and an accounts payable and accrued liability balance of $470,000 and $1.4 million, respectively, related to Wistar.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies                                                  <div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases approximately 56,600 square feet of office, laboratory, and manufacturing space in San Diego, California and approximately 57,400 square feet of office space in Plymouth Meeting, Pennsylvania under various non-cancellable operating lease agreements with remaining lease terms as of March&#160;31, 2025</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of 2.2 to 4.8 ye</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ars, which represent the non-cancellable periods of the leases. The Company has excluded the extension options from its lease terms in the calculation of future lease payments as they are not reasonably certain to be exercised. The Company's lease payments consist primarily of fixed rental payments for the right to use the underlying leased assets over the lease terms as well as payments for common area maintenance and administrative services. The Company has received customary incentives from its landlords, such as reimbursements for tenant improvements and rent abatement periods, which effectively reduce the total lease payments owed for these leases.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The base rent adjusts periodically throughout the term of the lease. Rent payments under the lease will include base rent with an annual increase of approximately two to three percent, and additional monthly fees to cover the Company's share of certain facility expenses, including utilities, property taxes, insurance and maintenance. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company performed an evaluation of its contracts with customers and suppliers in accordance with ASC Topic 842 and determined that, except for the real estate leases described above and various copier leases, none of its other contracts contain a right-of-use asset. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease right-of-use assets and liabilities on the condensed consolidated balance sheet represents the present value of the remaining lease payments over the remaining lease terms. Payments for additional monthly fees to cover the Company's share of certain facility expenses are not included in operating lease right-of-use assets and liabilities. The Company uses its incremental borrowing rate to calculate the present value of its lease payments, as the implicit rates in the leases are not readily determinable.</span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">As of March&#160;31, 2025, the maturities of the Company's operating lease liabilities were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.449%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.351%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2025</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,637,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,592,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,992,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,319,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,132,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total remaining lease payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,672,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: present value adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,401,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,271,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,576,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,695,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.0%</span></td></tr></table></div><div style="margin-top:3pt;text-indent:27pt"><span><br/></span></div><div style="margin-top:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease costs included in operating expenses in the condensed consolidated statements of operations for the three months ended March 31, 2025 and 2024 were $515,000 and $837,000, respectively. Operating lease costs consisting of the fixed lease payments included in operating lease liabilities are recorded on a straight-line basis over the lease terms. Variable lease costs are recorded as incurred.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2023, the Company entered into agreements to sublease a total of approximately 11,400 square feet in its Plymouth Meeting headquarters with sublease terms through December 31, 2026.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2024, the Company amended the sublease agreements for its Plymouth Meeting headquarters to extend one sublease term through December 31, 2027 and the other through December 31, 2029.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company is a party to a variety of agreements pursuant to which it may be obligated to indemnify the other party. It is not possible to predict the maximum potential amount of future payments under these types of agreements due to the conditional nature of the Company's obligations and the unique facts and circumstances involved in each particular agreement. Historically, payments made by the Company under these types of agreements have not had a material effect on its business, consolidated results of operations or financial condition.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">VGXI Litigation</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, the Company filed a complaint in the Court of Common Pleas of Montgomery County, Pennsylvania against VGXI, Inc. and GeneOne Life Science, Inc., or GeneOne, and together with VGXI, Inc. collectively referred to as VGXI, alleging that VGXI had materially breached the Company&#8217;s supply agreement with them. The complaint seeks declaratory judgments, specific performance of the agreement, injunctive relief, an accounting, damages, attorneys&#8217; fees, interest, costs and other relief from VGXI. In June 2020, the Company filed a petition for preliminary injunction, which was denied.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following an appeal by the Company, in July 2020, VGXI filed counterclaims against the Company, alleging that the Company had breached the supply agreement, as well as misappropriation of trade secrets and unjust enrichment. The counterclaims seek injunctive relief, damages, attorneys&#8217; fees, interest, costs and other relief from the Company. VGXI also filed a third-party complaint against Ology Bioservices, Inc., a contract manufacturing organization that the Company had engaged to provide services similar to those that were being provided by VGXI, but VGXI later discontinued its third-party claims. The Company filed an answer to VGXI&#8217;s counterclaims, disputing the allegations and the claims raised in VGXI&#8217;s filing. In October 2020, the Company filed a notice of discontinuance of appeal with the Pennsylvania Superior Court. A trial date for the litigation has not been set.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company intends to aggressively prosecute the claims set forth in its complaint against VGXI and to vigorously defend itself against VGXI&#8217;s counterclaims.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">GeneOne Litigation</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, GeneOne filed a complaint in the Court of Common Pleas of Montgomery County, Pennsylvania against the Company, alleging that the Company had breached the CELLECTRA Device License Agreement, or the Agreement, between the Company and GeneOne. The Company terminated the Agreement in October 2020. The complaint asserts claims for breach of contract, declaratory judgment, unfair competition, and unjust enrichment. The complaint seeks injunctive relief, an accounting, damages, disgorgement of profits, attorneys&#8217; fees, interest, and other relief from the Company. The Company filed preliminary objections to the complaint, which were overruled by the court. In September 2021, the Company filed an answer to the complaint, new matter, and counterclaims. The Company&#8217;s counterclaims allege that GeneOne breached the Agreement and assert claims for breach of contract and declaratory judgment.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The counterclaims seek damages, interest, expenses, attorney&#8217;s fees, and costs. In October 2021, GeneOne filed its answer to the Company&#8217;s counterclaims and new matter. On February 29, 2024, the Company filed a motion for summary judgment. On April 1, 2024, GeneOne filed an opposition to the Company&#8217;s motion for summary judgment. On June 28, 2024, the court denied the motion for summary judgment. The court has set a trial date of August 19, 2025.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company intends to aggressively prosecute the claims set forth in its counterclaims against GeneOne and to vigorously defend itself against the claims in GeneOne&#8217;s complaint. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Matters</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company may be involved in disputes, including litigation, relating to claims arising out of operations in the normal course of its business. Any of these claims could subject the Company to costly legal expenses and, while the Company generally believes that it has adequate insurance to cover many different types of liabilities, its insurance carriers may deny coverage or its policy limits may be inadequate to fully satisfy any damage awards or settlements. If this were to happen, the payment of any such awards could have a material adverse effect on the Company's consolidated results of operations and financial position. Additionally, any such claims, whether or not successful, could damage the Company's reputation and business. Except as described above, the Company is not a party to any legal proceedings, the adverse outcome of which, in management&#8217;s opinion, individually or in the aggregate, would be reasonably expected to have a material adverse effect on the Company&#8217;s consolidated results of operations or financial position.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative Agreements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaborative Agreements</a></td>
<td class="text">Collaborative Agreements<div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Advaccine Biopharmaceuticals Suzhou Co., Ltd. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, the Company entered into a Collaboration and License Agreement with Advaccine Biopharmaceuticals Suzhou Co., Ltd. (&#8220;Advaccine&#8221;), which was amended and restated in 2021 (as amended and restated, the &#8220;Advaccine Agreement&#8221;). Under the terms of the Advaccine Agreement, the Company granted to Advaccine the exclusive right to develop, manufacture and commercialize the Company&#8217;s vaccine candidate INO-4800 within the territories of China, Taiwan, Hong Kong and Macau (referred to collectively as &#8220;Greater China&#8221;) and 33 additional countries in Asia. The 2021 amendment related to a collaboration between the Company and Advaccine to jointly conduct a global Phase 3 segment of the Company&#8217;s clinical trial of INO-4800 that was planned. The parties were jointly participating in the trial and were to equally share the global development costs for the trial, including the Company&#8217;s manufacturing costs to supply INO-4800. Advaccine agreed to be fully responsible for conducting the trial in Greater China, including its costs and expenses incurred. The Company has discontinued its internally funded efforts to develop INO-4800 as a COVID-19 heterologous booster vaccine. Advaccine continues to develop INO-4800 with its own resources under the terms of the Advaccine Agreement.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the 2021 amendment, the Company determined that the global Phase 3 trial component of the agreement was a collaboration and not a contract with a customer and therefore accounted for the 2021 amendment under ASC Topic 808. Reimbursements from Advaccine were recognized as contra-research development expense on the condensed consolidated statement of operations once earned and collectibility was assured. No funding was received from Advaccine during the three months ended March 31, 2024 or 2025.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ApolloBio Corporation </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, the Company entered into an Amended and Restated License and Collaboration Agreement (the "ApolloBio Agreement"),</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with ApolloBio Corporation ("ApolloBio"), which was amended in June 2023. Under the terms of the ApolloBio Agreement, the Company granted to ApolloBio the exclusive right to develop and commercialize&#160;VGX-3100, its DNA immunotherapy product candidate designed to treat&#160;pre-cancers&#160;caused by HPV, within the agreed upon territories.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is entitled to receive up to an aggregate of $20.0 million, less required income, withholding or other taxes, upon the achievement of specified milestones related to the regulatory approval of&#160;VGX-3100&#160;in accordance with the ApolloBio Agreement. In the event that&#160;VGX-3100 is approved for marketing, the Company will be entitled to receive royalty payments based on a tiered percentage of annual net sales, with such percentage being in the&#160;low-&#160;to&#160;mid-teens,&#160;subject to reduction in the event of generic competition in a particular territory. ApolloBio&#8217;s obligation to pay royalties will continue for 10 years after the first commercial sale in a particular territory or, if later, until the expiration of the&#160;last-to-expire&#160;patent covering the licensed products in the specified territory.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> During the three months ended March 31, 2025 and 2024, the Company received $65,000 and $0, respectively, from the ApolloBio Agreement that was recorded as revenue.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Coalition for Epidemic Preparedness Innovations </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company previously entered into agreements with the Coalition for Epidemic Preparedness Innovations (CEPI), pursuant to which the Company intended to develop vaccine candidates against Lassa fever and MERS. As part of the arrangement between the parties, CEPI agreed to fund up to an aggregate of $56&#160;million of costs over a five-year period for preclinical studies, as well as planned Phase 1 and Phase 2 clinical trials, to be conducted by the Company and collaborators, with funding from CEPI based on the achievement of identified milestones. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, the Company announced that it and CEPI would discontinue the development of these product candidates targeting Lassa fever and MERS, following the initial analysis of data from the studies conducted by the Company and funded by CEPI. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2025 and 2024, no amounts were recorded as contra-research and development expense related to the CEPI grants. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the third quarter of 2024</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company received funding of $1.6&#160;million in connection with the final close-out of these grants.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bill &amp; Melinda Gates Foundation</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, Gates awarded and funded the Company a grant of $2.2 million to advance the development of DMAbs to address issues in infectious disease prevention and therapy. This technology has high relevance for the control of influenza and HIV. This next-generation approach to the delivery of monoclonal antibodies would make the technology accessible to low and middle-income countries. In 2019, Gates funded an additional $1.1 million for the project. During the three months ended March 31, 2025 and 2024, the Company recorded $0 and $39,000, respectively, as contra-research and development expense related to the grant.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/808/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes <div style="margin-bottom:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses an estimated annual effective tax rate, which is based on expected annual income, statutory tax rates and tax planning opportunities available in the various jurisdictions in which the Company operates, to determine its quarterly provision for income taxes. Certain significant or unusual items are separately recognized in the quarter in which they occur and </span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">can be a source of variability in the effective tax rates from quarter to quarter.&#160;Due to the adoption of ASU 2019-12 which removes the exception under ASC 740-20-45-7 to consider all sources of income in order to determine the tax benefit resulting from a loss from continuing operations, ASC 740-20-45-7 no longer applies.</span></div>&#160;For the three months ended March 31, 2025 and 2024, the Company did not record any income tax provision/(benefit) due to the Company&#8217;s history of net operating losses generated and the maintenance of a full valuation allowance against its net deferred tax assets.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Geneos Therapeutics, Inc.<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestAbstract', window );"><strong>Noncontrolling Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Geneos Therapeutics, Inc.</a></td>
<td class="text">Geneos Therapeutics, Inc. <div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, the Company formed Geneos Therapeutics ("Geneos") to develop and commercialize neoantigen-based personalized cancer therapies. The Company's Chief Scientific Officer Dr. Laurent Humeau is on the Board of Directors of Geneos. The Company's director Dr.&#160;David B. Weiner is the Chairman of the Scientific Advisory Board of Geneos.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2025, the Company held 23% of the outstanding equity of Geneos on an as-converted to common stock basis. The Company accounts for its common stock investment in Geneos as an equity method investment under ASC 323. Due to continuing net losses of Geneos, the Company&#8217;s investment had been reduced to $0 as of each of March 31, 2025 and December 31, 2024. The Company has not made any further investment in Geneos. The Company will not reduce its investment below $0 and will not record its share of further net losses of Geneos, as the Company has no obligation to fund Geneos.</span></div>The Company continues to exclusively license its immunotherapy platform and CELLECTRA&#160;technology to Geneos to be used in the field of personalized, neoantigen-based therapy for cancer. The license agreement provides for potential royalty payments to the Company in the event that Geneos commercializes any products using the licensed technology. The Company is not obligated to use any of its assets to fund the future operations of Geneos.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Information</a></td>
<td class="text">Segment Information<div style="margin-bottom:5pt;margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates as one reportable segment in the United States, which includes all activities related to the development and commercialization of its DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's Chief Executive Officer (CEO) is its Chief Operating Decision Maker (CODM), responsible for allocating resources and assessing Company performance using aggregated financial information. Utilizing aggregated financial information enables the CODM to determine the most appropriate resource allocation across the organization, research and development projects or other initiatives consistent with the Company's corporate objectives. The CODM primarily uses total net loss as reported on the statements of operations and comprehensive loss to measure segment loss, supplemented by certain additional significant expense details reflected in the table below. The measure of segment assets is reported on the consolidated balance sheet as total assets.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Detailed information regarding the Company's single operating segment's revenues, expenses and operating loss are as follows:  </span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.075%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue from collaborative arrangements </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,343&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Less: </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;INO-3107</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,507,342&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,645,664&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;INO-3112 and other Immuno-oncology</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,315,084&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,020,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other programs (a)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,425&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">623,666&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Engineering and device-related</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,061,810&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,751,261&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">553,394&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,060,487&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other unallocated expenses </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,545,847&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,811,962&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,024,970&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,571,179&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,115,872&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,484,969&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">808,077&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500,290&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(177,833)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of common stock warrant liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,712,872&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) on investment in affiliated entity</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">695,131&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(126,018)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized gain on available-for-sale equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140,234&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500,877&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(482)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(682,218)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,694,697)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,469,871)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:24.75pt"><span><br/></span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Net of contributions received from grant agreements and recorded as contra-research and development expense.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (19,694,697)<span></span>
</td>
<td class="num">$ (30,469,871)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation, Liquidity and Risks and Uncertainties (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation and Liquidity</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation</span></div><div style="margin-top:4.5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements of Inovio have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) as contained in the Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") for interim financial information and with instructions to Form&#160;10-Q and Article&#160;10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The condensed consolidated balance sheet as of March&#160;31, 2025, the condensed consolidated statements of operations, the condensed consolidated statements of comprehensive loss, the condensed consolidated statements of stockholders' equity and the condensed consolidated statements of cash flows for the three months ended March 31, 2025 and 2024 are unaudited, but include all adjustments (consisting of normal recurring adjustments) that the Company considers necessary for a fair presentation of the financial position, results of operations, cash flows and changes in stockholders' equity for the periods presented. </span></div><div style="margin-top:4.5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of operations for the three months ended March 31, 2025 shown herein are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2025, or for any other period. These unaudited financial statements, and notes thereto, should be read in conjunction with the audited consolidated financial statements for the year ended December&#160;31, 2024, included in the Company's Annual Report on Form&#160;10-K filed with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) on March&#160;18, 2025. The balance sheet at December&#160;31, 2024 has been derived from the audited financial statements at that date, but does not include all of the information and footnotes required by U.S. GAAP for complete financial statements. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These unaudited condensed consolidated financial statements include the accounts of Inovio Pharmaceuticals, Inc. and its subsidiary. As of March&#160;31, 2025 and December 31, 2024, the Company consolidated its wholly-owned subsidiary Inovio Asia LLC. All intercompany accounts and transactions were eliminated upon consolidation. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Liquidity </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurred a net loss of $19.7 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the three months ended March 31, 2025. The Company had working capital of $44.6 million and an accumulated deficit of $1.7 billion as of March&#160;31, 2025. The Company has incurred losses in each year since its inception and expects to continue to incur significant expenses and operating losses for the foreseeable future in connection with the research and preclinical and clinical development of its product candidates. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 16, 2024, the Company closed an underwritten public offering (the "December 2024 Offering"), relating to the issuance and sale of 10,000,000 shares of its common stock, par value $0.001 per share, and warrants to purchase 10,000,000 shares of common stock (the &#8220;Warrants&#8221;), at an offering price of $3.00 per share and accompanying Warrant. The exercise price of the Warrants is $3.76 per share. The net proceeds from the December 2024 Offering were $27.6&#160;million, after deducting the underwriting discounts and commissions and offering expenses paid by the Company. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 18, 2024, the Company closed an underwritten registered direct offering (the &#8220;April 2024 Offering&#8221;) relating to the issuance and sale of 2,536,258 shares (the &#8220;Shares&#8221;) of its common stock, par value $0.001 per share, at a price of $7.693 per share and pre-funded warrants to purchase up to 2,135,477 shares of common stock (the &#8220;Pre-Funded Warrants&#8221;) at a price of $7.692 per Pre-Funded Warrant, which represents the per share price for the Shares less the $0.001 per share exercise price for each Pre-Funded Warrant. The net proceeds from the April 2024 Offering were $33.2&#160;million, after deducting the underwriting discounts and commissions and offering expenses paid by the Company. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Going Concern </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s cash, cash equivalents and short-term investments of $68.4 million as of March&#160;31, 2025 are expected to be sufficient to support the Company's planned operations into the first quarter of 2026. The Company's current financial resources may not be sufficient to support its planned operations beyond this date without securing additional financing.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to continue to fund future research and development activities, the Company will need to seek additional capital. This may occur through strategic alliance and licensing arrangements, grant agreements and/or future public or private debt or equity financings including At-the-Market Equity Offering Sales Agreements (&#8220;Sales Agreements&#8221;). The Company has a history of conducting debt and equity financings, including the receipt of net proceeds of $60.8&#160;million from equity offerings during the year ending December 31, 2024, and the receipt of net proceeds of $1.1&#160;million and $6.1&#160;million under Sales Agreements during the three months ended March 31, 2025 and year ended December 31, 2024, respectively. However, sufficient funding may not be available in the future, or if available, may be on terms that significantly dilute or otherwise adversely affect the rights of existing stockholders. If adequate funds are not available, the Company may need to delay, reduce the scope of or put on hold one or more of its clinical and/or preclinical programs.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s ability to continue its operations is dependent upon its ability to obtain additional capital in the future and achieve profitable operations. The Company expects to continue to rely on outside sources of financing to meet its capital needs and may never achieve positive cash flow. In light of these factors, management believes that there is substantial doubt about the Company's ability to continue as a going concern beyond the first quarter of 2026. The Company's condensed consolidated financial statements as of and for the three months ended March 31, 2025 do not include any adjustments that might result from the outcome of this uncertainty. The Company has evaluated subsequent events after the balance sheet date through the date it issued these condensed consolidated financial statements.</span></div>The Company is, and from time to time&#160;may in the future be, subject to various legal proceedings and claims arising in the ordinary course of business. The Company assesses contingencies to determine the degree of probability and range of possible loss for potential accrual in its consolidated financial statements. An estimated loss contingency is accrued in the consolidated financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Legal proceedings, including litigation, government investigations and enforcement actions, could result in material costs, occupy significant management resources and entail civil and criminal penalties, even if the Company ultimately prevails.&#160;Any of the foregoing consequences could result in serious harm to the Company&#8217;s business, results of operations and financial condition.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementAccountingPolicy', window );">Collaboration Agreements and Revenue Recognition</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaboration Agreements and Revenue Recognition</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company assesses whether its collaboration agreements are subject to Accounting Standards Codification ("ASC") Topic 808: Collaborative Arrangements (&#8220;Topic 808&#8221;) based on whether they involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within the scope of Topic 808 and the Company concludes that its collaboration partner is not a customer, the </span></div>Company presents such payments as a reduction of research and development expense. If payments from the collaboration partner to the Company represent consideration from a customer, then the Company accounts for those payments within the scope of Accounting Standards Update (&#8220;ASU&#8221;) 2014-09, Revenue from Contracts with Customers (&#8220;Topic 606&#8221;).<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses - Clinical Trial Accruals</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses - Clinical Trial Accruals</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company's activities have largely consisted of research and development efforts related to developing its proprietary device technology and DNA medicine candidates. For clinical trial expenses, judgements used in estimating accruals rely on estimates of total costs incurred based on participant enrollment, completion of studies and other events. Accrued clinical trial costs are subject to revisions as trials progress. Revisions are charged to expense in the period in which the facts that give rise to the revision become known. Historically, revisions have not resulted in material changes to research and development expense; however, a modification in the protocol of a clinical trial or cancellation of a trial could result in a charge to the Company's results of operations.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is computed by dividing the net loss for the period by the weighted average number of shares of common stock outstanding during the period. The outstanding Pre-Funded Warrants (see Note 7) are included in the weighted-average common shares outstanding in the basic net loss per share calculation for the three months ended March 31, 2025 given their nominal exercise price.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Diluted net loss per share is calculated in accordance with the treasury stock method for the outstanding Warrants, stock options and RSUs and refle</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cts the potential dilution that would occur if securities or other con</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">tracts to issue common stock were exercised or converted to common stock. The calculation of diluted net loss per share requires that, to the extent the average market price of the underlying shares for the reporting period exceeds the exercise price of the options or other securities and the presumed exercise of such securities are dilutive to net loss per share for the period, an adjustment to the net loss used in the calculation is required to remove the change in fair value of such securities from the numerator for the period. Likewise, an adjustment to the denominator is required to reflect the related dilutive shares, if any. For the three months ended March 31, 2025 and 2024, basic and diluted net loss per share were the same, as the assumed exercise or settlement of common stock warrants, stock options, service-based RSUs and performance-and market-based RSUs would have been anti-dilutive.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurs stock-based compensation expense related to service-based RSUs, performance-based RSUs and stock options. The fair value of restricted stock is determined by the closing price of the Company's common stock reported on the Nasdaq Capital Market on the date of grant. The Company estimates the fair value of stock options granted using the Black-Scholes option pricing model. The Black-Scholes option pricing model was developed for use in estimating the fair value of traded options, which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of subjective assumptions, including the expected stock price volatility and expected option life. The Company amortizes the fair value of the awards on a straight-line basis over the requisite vesting period of the awards. Expected volatility is based on historical volatility. The expected life of options granted is based on historical expected life. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant. The dividend yield is based on the fact that no dividends have been paid historically and none are currently expected to be paid in the foreseeable future. The Company recognizes forfeitures as they occur.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementAccountingPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for collaborative arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementAccountingPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-term Investments and Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Schedule of Summary of Investments</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of available-for-sale securities as of March&#160;31, 2025 and December&#160;31, 2024:</span></div><div style="margin-bottom:3pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:25.839%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.812%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2025</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Maturity&#160;(in&#160;years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Market&#160;Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">---</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,926,415&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,305,472)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,620,943&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 1</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,980,607&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,268&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(276)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,989,599&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency mortgage-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,243,914&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(407,359)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">836,555&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,150,936&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,268&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,713,107)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,447,097&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:25.839%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.812%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2024</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Maturity&#160;(in&#160;years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Market&#160;Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">---</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,926,415&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,445,706)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,480,709&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 1</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,980,273&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(281)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,989,742&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency mortgage-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,260,745&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(430,964)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">829,781&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,167,433&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,750&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,876,951)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,300,232&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*No single maturity date.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following table presents the Company&#8217;s assets that were measured at fair value on a recurring basis, determined using the following inputs as of March&#160;31, 2025:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:35.796%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.541%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.541%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.737%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.689%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2025</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices<br/>in Active Markets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other Unobservable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Mutual funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,620,943&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,620,943&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,989,599&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,989,599&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">836,555&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">836,555&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,447,097&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,620,943&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,826,154&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in affiliated entity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,308,975&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,308,975&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,756,072&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,929,918&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,826,154&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock warrant liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,542,316&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,542,316&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,542,316&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,542,316&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s assets that were measured at fair value on a recurring basis, determined using the following inputs as of December&#160;31, 2024:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:35.796%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.541%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.541%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.737%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.689%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices<br/>in Active Markets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other Unobservable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Mutual funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,480,709&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,480,709&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,989,742&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,989,742&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">829,781&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">829,781&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,300,232&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,480,709&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,819,523&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in affiliated entity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,613,844&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,613,844&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,914,076&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,094,553&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,819,523&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock warrant liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,255,188&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,255,188&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,255,188&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,255,188&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Fair Value Measurement Inputs and Valuation Techniques</a></td>
<td class="text">The following assumptions were used to estimate the fair value of the warrant liability:<div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.016%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.905%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.198%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">March 31, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">4.0%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">4.4%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Expected volatility</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">94%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">111%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Expected life in years</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">4.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">5</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Dividend yield</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8212;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the change in fair value of the Company&#8217;s total Level 3 financial liabilities for the three months ended March&#160;31, 2025:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:83.110%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock Warrant Liability</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,255,188&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-394">Decrease in fair value of liability</span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,712,872)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2025</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,542,316&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Certain Balance Sheet Items (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CertainBalanceSheetItemsAbstract', window );"><strong>Certain Balance Sheet Items [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock', window );">Schedule Of Prepaid Expenses And Other Current Assets</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid and other current assets consisted of the following:</span></div><div style="text-indent:-4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.289%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.291%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid clinical expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,013,742&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">627,962&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other prepaid expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,207,926&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,889,503&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,221,668&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,517,465&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of Accounts Payable and Accrued Liabilities</a></td>
<td class="text"><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable and accrued expenses consisted of the following:</span></div><div style="text-indent:-4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.289%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.291%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade accounts payable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,054,582&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,091,503&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,322,421&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,007,180&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,542,785&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,101,330&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,919,788&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,200,013&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CertainBalanceSheetItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Certain Balance Sheet Items</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CertainBalanceSheetItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Prepaid Expenses And Other Current Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockByClassTextBlock', window );">Schedule of Summary of Common and Preferred Stock Authorized, Issued and Outstanding</a></td>
<td class="text"><div style="margin-bottom:10pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the Company's authorized and issued common and preferred stock as of March&#160;31, 2025 and December&#160;31, 2024: </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"></td><td style="width:42.095%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.473%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.473%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.136%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.106%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outstanding as of</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Authorized</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Issued</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common Stock, par value $0.001 per share</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">600,000,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,674,355&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,674,355&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,099,991&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series&#160;C Preferred Stock, par value $0.001 per share</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,091&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,091&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockByClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-4<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-5<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481142/505-10-45-2<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-10<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-8<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-6<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockByClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock', window );">Schedule of Basic and Diluted Net Loss Per Share</a></td>
<td class="text"><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted net loss per share for the three months ended March 31, 2025 and 2024 are calculated as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.128%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.960%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,694,697)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,469,871)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Shares used to compute net loss per share, basic and diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Weighted-average common shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,478,176&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,291,512&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Weighted-average shares underlying pre-funded warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,135,477&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Weighted-average common shares outstanding used to compute basic and diluted net loss per share</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,613,653&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,291,512&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Basic and diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.51)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.31)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</a></td>
<td class="text">The following table summarizes potential shares of common stock that were excluded from the diluted net loss per share calculation because of their anti-dilutive effect: <div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.128%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.960%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,000,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,748,184&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,355,178&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service-based restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">573,720&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">392,120&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance-and market-based restricted stock units</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible preferred stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,450,979&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,747,573&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the effect of income (loss) on an entity's diluted earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Weighted Average Assumptions</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average assumptions used in the Black-Scholes model for option grants to employees and directors are presented below:</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.07%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.21%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life in years</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Significant Assumption Used in Monte Carlo Simulation Method</a></td>
<td class="text"><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The significant assumptions used in the Monte Carlo simulation method were as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:80.040%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.760%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.60%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life in years</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.61</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Share-Based Payment Award, Equity Instruments Other Than Options, Valuation Assumptions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Future Minimum Rental Payments for Operating Leases</a></td>
<td class="text"><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">As of March&#160;31, 2025, the maturities of the Company's operating lease liabilities were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.449%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.351%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2025</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,637,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,592,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,992,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,319,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,132,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total remaining lease payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,672,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: present value adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,401,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,271,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,576,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,695,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.0%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Segment Reporting Information, by Segment</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Detailed information regarding the Company's single operating segment's revenues, expenses and operating loss are as follows:  </span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.075%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue from collaborative arrangements </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,343&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Less: </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;INO-3107</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,507,342&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,645,664&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;INO-3112 and other Immuno-oncology</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,315,084&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,020,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other programs (a)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,425&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">623,666&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Engineering and device-related</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,061,810&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,751,261&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">553,394&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,060,487&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other unallocated expenses </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,545,847&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,811,962&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,024,970&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,571,179&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,115,872&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,484,969&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">808,077&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500,290&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(177,833)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of common stock warrant liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,712,872&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) on investment in affiliated entity</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">695,131&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(126,018)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized gain on available-for-sale equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140,234&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500,877&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(482)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(682,218)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,694,697)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,469,871)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:24.75pt"><span><br/></span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Net of contributions received from grant agreements and recorded as contra-research and development expense.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation, Liquidity and Risks and Uncertainties (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 16, 2024</div></th>
<th class="th"><div>Apr. 18, 2024</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,694,697<span></span>
</td>
<td class="nump">$ 30,469,871<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_WorkingCapital', window );">Working capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,749,913,959<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,730,219,262<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents, and short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 68,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,102,149<span></span>
</td>
<td class="nump">$ 5,225,133<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ino_UnderwrittenRegisteredDirectOfferingMember', window );">Underwritten Registered Direct Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ino_A2024SalesAgreementMember', window );">2024 Sales Agreement | Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ino_December2024OfferingMember', window );">December 2024 Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Consideration received on transaction</a></td>
<td class="nump">$ 27,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,800,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common stock | Underwritten Registered Direct Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in transaction (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,536,258<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.693<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common stock | December 2024 Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in transaction (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrants to purchase common stock | Underwritten Registered Direct Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in transaction (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,135,477<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.692<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ino_December2024OfferingWarrantsMember', window );">December 2024 Offering Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in dollars per share)</a></td>
<td class="nump">$ 3.76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ino_December2024OfferingWarrantsMember', window );">December 2024 Offering Warrants | December 2024 Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in dollars per share)</a></td>
<td class="nump">3.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in dollars per share)</a></td>
<td class="nump">$ 3.76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ino_December2024OfferingWarrantsMember', window );">December 2024 Offering Warrants | Common stock | December 2024 Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of securities called by warrants or rights (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_WorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Working Capital</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_WorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476173/280-10-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476173/280-10-65-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-9<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-1<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477123/405-50-65-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482477/820-10-65-13<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482477/820-10-65-13<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-5<br><br>Reference 53: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 54: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 55: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 58: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 59: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 60: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 61: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 62: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 63: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 64: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 65: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 66: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 67: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 68: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 69: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 11.M.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480530/250-10-S99-5<br><br>Reference 70: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 71: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 72: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 73: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 74: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 75: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 76: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 77: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 78: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483194/926-20-65-2<br><br>Reference 79: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483194/926-20-65-2<br><br>Reference 80: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483194/926-20-65-2<br><br>Reference 81: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 82: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 83: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 84: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 85: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 86: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-6<br><br>Reference 87: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 88: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 89: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 90: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 91: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 92: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 93: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 94: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 95: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 96: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 97: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 98: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-3<br><br>Reference 99: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br><br>Reference 100: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ino_UnderwrittenRegisteredDirectOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ino_UnderwrittenRegisteredDirectOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ino_A2024SalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ino_A2024SalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ino_December2024OfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ino_December2024OfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ino_December2024OfferingWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ino_December2024OfferingWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-term Investments and Fair Value Measurements - Summary of Available-for-sale Securities (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt Securities, Available-for-sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">$ 30,150,936<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,167,433<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross&#160;Unrealized Gains</a></td>
<td class="nump">9,268<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,750<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross&#160;Unrealized Losses</a></td>
<td class="num">(1,713,107)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,876,951)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Market&#160;Value</a></td>
<td class="nump">28,447,097<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,300,232<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=ino_MutualFundsMember', window );">Mutual funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt Securities, Available-for-sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">25,926,415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,926,415<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross&#160;Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross&#160;Unrealized Losses</a></td>
<td class="num">(1,305,472)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,445,706)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Market&#160;Value</a></td>
<td class="nump">$ 24,620,943<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,480,709<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_DebtSecuritiesAvailableforSaleContractualMaturity', window );">Contractual Maturity&#160;(in&#160;years)</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt Securities, Available-for-sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">$ 2,980,607<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,980,273<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross&#160;Unrealized Gains</a></td>
<td class="nump">9,268<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,750<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross&#160;Unrealized Losses</a></td>
<td class="num">(276)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(281)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Market&#160;Value</a></td>
<td class="nump">2,989,599<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,989,742<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember', window );">U.S. agency mortgage-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt Securities, Available-for-sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">1,243,914<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,260,745<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross&#160;Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross&#160;Unrealized Losses</a></td>
<td class="num">(407,359)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(430,964)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Market&#160;Value</a></td>
<td class="nump">$ 836,555<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 829,781<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_DebtSecuritiesAvailableforSaleContractualMaturity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-for-sale contractual maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_DebtSecuritiesAvailableforSaleContractualMaturity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=ino_MutualFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=ino_MutualFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-term Investments and Fair Value Measurements - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($) </div>
<div>position </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain', window );">Realized gain on investments</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss', window );">Realized loss on investments</a></td>
<td class="nump">700<span></span>
</td>
<td class="nump">691,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Net unrealized gain (loss) on available-for-sale equity securities</a></td>
<td class="nump">$ 140,234<span></span>
</td>
<td class="nump">$ 500,877<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions', window );">Number of securities in a gross unrealized loss position | position</a></td>
<td class="nump">19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized loss</a></td>
<td class="nump">$ 1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Decrease in fair value of liability</a></td>
<td class="nump">$ 3,712,872<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalanceShares', window );">Investment owned (in shares) | shares</a></td>
<td class="nump">597,808<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479536/321-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedBalanceShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of investment owned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477439/946-210-55-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedBalanceShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Short-term Investments and Fair Value Measurements - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">$ 28,447,097<span></span>
</td>
<td class="nump">$ 28,300,232<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=ino_MutualFundsMember', window );">Mutual funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">24,620,943<span></span>
</td>
<td class="nump">24,480,709<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">2,989,599<span></span>
</td>
<td class="nump">2,989,742<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember', window );">U.S. agency mortgage-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">836,555<span></span>
</td>
<td class="nump">829,781<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">28,447,097<span></span>
</td>
<td class="nump">28,300,232<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Investment in affiliated entity</a></td>
<td class="nump">2,308,975<span></span>
</td>
<td class="nump">1,613,844<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">30,756,072<span></span>
</td>
<td class="nump">29,914,076<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CommonStockWarrantLiabilityFairValue', window );">Common stock warrant liability</a></td>
<td class="nump">9,542,316<span></span>
</td>
<td class="nump">13,255,188<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">9,542,316<span></span>
</td>
<td class="nump">13,255,188<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Quoted Prices in Active Markets (Level&#160;1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">24,620,943<span></span>
</td>
<td class="nump">24,480,709<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Investment in affiliated entity</a></td>
<td class="nump">2,308,975<span></span>
</td>
<td class="nump">1,613,844<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">26,929,918<span></span>
</td>
<td class="nump">26,094,553<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CommonStockWarrantLiabilityFairValue', window );">Common stock warrant liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Significant Other Unobservable Inputs (Level&#160;2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">3,826,154<span></span>
</td>
<td class="nump">3,819,523<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Investment in affiliated entity</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">3,826,154<span></span>
</td>
<td class="nump">3,819,523<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CommonStockWarrantLiabilityFairValue', window );">Common stock warrant liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Investment in affiliated entity</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CommonStockWarrantLiabilityFairValue', window );">Common stock warrant liability</a></td>
<td class="nump">9,542,316<span></span>
</td>
<td class="nump">13,255,188<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">9,542,316<span></span>
</td>
<td class="nump">13,255,188<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Mutual funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">24,620,943<span></span>
</td>
<td class="nump">24,480,709<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Mutual funds | Quoted Prices in Active Markets (Level&#160;1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">24,620,943<span></span>
</td>
<td class="nump">24,480,709<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Mutual funds | Significant Other Unobservable Inputs (Level&#160;2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Mutual funds | Significant Unobservable Inputs (Level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">2,989,599<span></span>
</td>
<td class="nump">2,989,742<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Certificates of deposit | Quoted Prices in Active Markets (Level&#160;1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Certificates of deposit | Significant Other Unobservable Inputs (Level&#160;2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">2,989,599<span></span>
</td>
<td class="nump">2,989,742<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Certificates of deposit | Significant Unobservable Inputs (Level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | U.S. agency mortgage-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">836,555<span></span>
</td>
<td class="nump">829,781<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | U.S. agency mortgage-backed securities | Quoted Prices in Active Markets (Level&#160;1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | U.S. agency mortgage-backed securities | Significant Other Unobservable Inputs (Level&#160;2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">836,555<span></span>
</td>
<td class="nump">829,781<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | U.S. agency mortgage-backed securities | Significant Unobservable Inputs (Level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CommonStockWarrantLiabilityFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock Warrant Liability, Fair Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CommonStockWarrantLiabilityFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482736/825-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=ino_MutualFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=ino_MutualFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-term Investments and Fair Value Measurements - Schedule of Assumptions Used To Estimate The Fair Value Of Warrants (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>yr</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>yr</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_WarrantLiabilityMeasurementInput', window );">Warrant liability, measurement input</a></td>
<td class="nump">0.040<span></span>
</td>
<td class="nump">0.044<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_WarrantLiabilityMeasurementInput', window );">Warrant liability, measurement input</a></td>
<td class="nump">0.94<span></span>
</td>
<td class="nump">1.11<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Expected life in years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_WarrantLiabilityMeasurementInput', window );">Warrant liability, measurement input</a></td>
<td class="nump">4.7<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_WarrantLiabilityMeasurementInput', window );">Warrant liability, measurement input</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_WarrantLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant Liability, Measurement Input</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_WarrantLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-term Investments and Fair Value Measurements - Changes In Fair Value Of The Company&#8217;s Total Level 3 Financial Liabilities (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList', window );">Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">Change in fair value of common stock warrant liability<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balance</a></td>
<td class="nump">$ 13,255,188<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Decrease in fair value of liability</a></td>
<td class="num">(3,712,872)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending balance</a></td>
<td class="nump">$ 9,542,316<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of income or comprehensive income that includes gain (loss) from liability measured at fair value using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Certain Balance Sheet Items - Prepaid and Other Current Assets (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CertainBalanceSheetItemsAbstract', window );"><strong>Certain Balance Sheet Items [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_PrepaidClinicalExpensesCurrent', window );">Prepaid clinical expenses</a></td>
<td class="nump">$ 1,013,742<span></span>
</td>
<td class="nump">$ 627,962<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Other prepaid expenses</a></td>
<td class="nump">1,207,926<span></span>
</td>
<td class="nump">1,889,503<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expense and other assets, current</a></td>
<td class="nump">$ 2,221,668<span></span>
</td>
<td class="nump">$ 2,517,465<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CertainBalanceSheetItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Certain Balance Sheet Items</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CertainBalanceSheetItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_PrepaidClinicalExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid Clinical Expenses, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_PrepaidClinicalExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Certain Balance Sheet Items - Accounts Payable and Accrued Expenses (Details) - Nonrelated Party - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_AccountsPayableAndAccruedExpensesLineItems', window );"><strong>Accounts Payable and Accrued Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrentAndNoncurrent', window );">Trade accounts payable</a></td>
<td class="nump">$ 5,054,582<span></span>
</td>
<td class="nump">$ 5,091,503<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedSalariesCurrent', window );">Accrued compensation</a></td>
<td class="nump">6,322,421<span></span>
</td>
<td class="nump">10,007,180<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent', window );">Other accrued expenses</a></td>
<td class="nump">1,542,785<span></span>
</td>
<td class="nump">1,101,330<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 12,919,788<span></span>
</td>
<td class="nump">$ 16,200,013<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_AccountsPayableAndAccruedExpensesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts Payable and Accrued Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_AccountsPayableAndAccruedExpensesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableTradeCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableTradeCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalariesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedSalariesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Debt (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 01, 2024</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfConvertibleDebt', window );">Repayment of convertible senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 16,415,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member', window );">6.50% Convertible Senior Notes Due 2024 | Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 78,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt interest based on the fixed rate (in percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,700,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfConvertibleDebt', window );">Repayment of convertible senior notes</a></td>
<td class="nump">$ 16,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseOperating', window );">Non-cash interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 178,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseOperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as operating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseOperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity - Summary of Authorized and Issued Common and Preferred Stock (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Summary of common and preferred stock authorized, issued and outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares, authorized (in shares)</a></td>
<td class="nump">600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares, issued (in shares)</a></td>
<td class="nump">36,674,355<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares, outstanding (in shares)</a></td>
<td class="nump">36,674,355<span></span>
</td>
<td class="nump">36,099,991<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Summary of common and preferred stock authorized, issued and outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">1,091<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">1,091<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity - Offering of Common Stock, Warrants, and Pre-funded Warrants (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 16, 2024</div></th>
<th class="th"><div>Apr. 18, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ino_UnderwrittenRegisteredDirectOfferingMember', window );">Underwritten Registered Direct Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_ClassOfWarrantOrRightCommonStockOwnershipPercent', window );">Class of warrant or right, common stock ownership (in percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.99%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrants to purchase common stock | Underwritten Registered Direct Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common stock | Underwritten Registered Direct Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_ClassOfWarrantOrRightCommonStockOwnershipPercent', window );">Class of warrant or right, common stock ownership (in percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.99%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ino_December2024OfferingWarrantsMember', window );">December 2024 Offering Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in dollars per share)</a></td>
<td class="nump">$ 3.76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_ClassOfWarrantOrRightCommonStockOwnershipPercent', window );">Class of warrant or right, common stock ownership (in percent)</a></td>
<td class="nump">4.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_ClassOfWarrantOrRightCommonStockOwnershipPriorToIssuancePercent', window );">Class of warrant or right, common stock, prior to issuance (percent)</a></td>
<td class="nump">9.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_ClassOfWarrantOrRightCommonStockOwnershipMaximumPercent', window );">Class of warrant or right, common stock ownership, maximum percent</a></td>
<td class="nump">19.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ClassOfWarrantOrRightCommonStockOwnershipMaximumPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Common Stock Ownership, Maximum Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ClassOfWarrantOrRightCommonStockOwnershipMaximumPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ClassOfWarrantOrRightCommonStockOwnershipPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Common Stock Ownership, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ClassOfWarrantOrRightCommonStockOwnershipPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ClassOfWarrantOrRightCommonStockOwnershipPriorToIssuancePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Common Stock Ownership, Prior To Issuance, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ClassOfWarrantOrRightCommonStockOwnershipPriorToIssuancePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ino_UnderwrittenRegisteredDirectOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ino_UnderwrittenRegisteredDirectOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ino_December2024OfferingWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ino_December2024OfferingWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - At-The-Market Sales Agreements (Details) - Common stock - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 13, 2024</div></th>
<th class="th"><div>Nov. 09, 2021</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">2024 Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_StockSalesAgreementMaximumAuthorizedAmount', window );">Maximum authorized amount</a></td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage', window );">Sale of stock, sales proceeds of any common stock, percentage (in percent)</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_StockSaleAgreementAggregateNumberofSharesIssued', window );">Aggregate number of shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">518,670<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_StockSaleAgreementWeightedAveragePricePerShare', window );">Stock sale agreement weighted average price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock', window );">Aggregate proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_StockSaleAgreementRemainingCapacityAmount', window );">Stock sale agreement, remaining capacity, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 57,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">2021 Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_StockSalesAgreementMaximumAuthorizedAmount', window );">Maximum authorized amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage', window );">Sale of stock, sales proceeds of any common stock, percentage (in percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_StockSaleAgreementAggregateNumberofSharesIssued', window );">Aggregate number of shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">543,620<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_StockSaleAgreementWeightedAveragePricePerShare', window );">Stock sale agreement weighted average price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.76<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock', window );">Aggregate proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,200<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Sales Proceeds of Any Common Stock, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_StockSaleAgreementAggregateNumberofSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Sale Agreement, Aggregate Number of Shares Issued</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_StockSaleAgreementAggregateNumberofSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Sale Agreement, Aggregate Proceeds From Issuance Of Stock</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_StockSaleAgreementRemainingCapacityAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Sale Agreement, Remaining Capacity, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_StockSaleAgreementRemainingCapacityAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_StockSaleAgreementWeightedAveragePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Sale Agreement Weighted Average Price Per Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_StockSaleAgreementWeightedAveragePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_StockSalesAgreementMaximumAuthorizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Sales Agreement, Maximum Authorized Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_StockSalesAgreementMaximumAuthorizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ino_A2024SalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ino_A2024SalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ino_A2021SalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ino_A2021SalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Stock Options and Restricted Stock Units (Details) - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>May 16, 2023</div></th>
<th class="th"><div>Jun. 24, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ino_A2023IncentivePlanMember', window );">2023 Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,166,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for grant (in shares)</a></td>
<td class="nump">24,460<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of shares of unvested restricted stock units and options outstanding (in shares)</a></td>
<td class="nump">464,887<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockOtherSharesOutstanding', window );">Common stock, other shares, outstanding (in shares)</a></td>
<td class="nump">732,165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period (in years)</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm', window );">Maximum contractual term (in years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ino_A2016IncentivePlanMember', window );">2016 Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of shares of unvested restricted stock units and options outstanding (in shares)</a></td>
<td class="nump">90,642<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockOtherSharesOutstanding', window );">Common stock, other shares, outstanding (in shares)</a></td>
<td class="nump">902,123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period (in years)</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm', window );">Maximum contractual term (in years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ino_A2022InducementPlanMember', window );">2022 Inducement Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">166,666<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for grant (in shares)</a></td>
<td class="nump">85,378<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of shares of unvested restricted stock units and options outstanding (in shares)</a></td>
<td class="nump">18,191<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockOtherSharesOutstanding', window );">Common stock, other shares, outstanding (in shares)</a></td>
<td class="nump">52,634<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ino_A2007IncentivePlanMember', window );">2007 Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockOtherSharesOutstanding', window );">Common stock, other shares, outstanding (in shares)</a></td>
<td class="nump">61,262<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm', window );">Maximum contractual term (in years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award maximum contractual term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockOtherSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of other common stock instruments held by shareholder, including, but not limited to, exchangeable shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockOtherSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ino_A2023IncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ino_A2023IncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ino_A2016IncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ino_A2016IncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ino_A2022InducementPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ino_A2022InducementPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ino_A2007IncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ino_A2007IncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Schedule of Basic and Diluted Net Loss Per Share (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (19,694,697)<span></span>
</td>
<td class="num">$ (30,469,871)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_WeightedAverageNumberOfSharesOutstanding', window );">Weighted-average common shares outstanding (in shares)</a></td>
<td class="nump">36,478,176<span></span>
</td>
<td class="nump">23,291,512<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_IncrementalCommonSharesAttributableToBasicAndDilutiveEffectOfPreFundedWarrants', window );">Weighted-average pre-funded warrants (in shares)</a></td>
<td class="nump">2,135,477<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding used to compute basic and diluted net loss per share, basic (in shares)</a></td>
<td class="nump">38,613,653<span></span>
</td>
<td class="nump">23,291,512<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares outstanding used to compute basic and diluted net loss per share, diluted (in shares)</a></td>
<td class="nump">38,613,653<span></span>
</td>
<td class="nump">23,291,512<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_EarningsPerShareBasicAndDilutedEPSAbstract', window );"><strong>Net loss per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in dollars per share)</a></td>
<td class="num">$ (0.51)<span></span>
</td>
<td class="num">$ (1.31)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in dollars per share)</a></td>
<td class="num">$ (0.51)<span></span>
</td>
<td class="num">$ (1.31)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_EarningsPerShareBasicAndDilutedEPSAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Earnings Per Share, Basic and Diluted EPS</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_EarningsPerShareBasicAndDilutedEPSAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_IncrementalCommonSharesAttributableToBasicAndDilutiveEffectOfPreFundedWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Incremental Common Shares Attributable To Basic And Dilutive Effect Of PreFunded Warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_IncrementalCommonSharesAttributableToBasicAndDilutiveEffectOfPreFundedWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_WeightedAverageNumberOfSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Number Of Shares Outstanding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_WeightedAverageNumberOfSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Anti-dilutive (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded (in shares)</a></td>
<td class="nump">12,450,979<span></span>
</td>
<td class="nump">1,747,573<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded (in shares)</a></td>
<td class="nump">1,748,184<span></span>
</td>
<td class="nump">1,355,178<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ino_ServiceBasedRestrictedStockUnitsMember', window );">Service-based restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded (in shares)</a></td>
<td class="nump">573,720<span></span>
</td>
<td class="nump">392,120<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Performance-and market-based restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded (in shares)</a></td>
<td class="nump">128,800<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded (in shares)</a></td>
<td class="nump">275<span></span>
</td>
<td class="nump">275<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ino_ServiceBasedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ino_ServiceBasedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Weighted Average Assumptions (Details) - Stock Options - Employees and Directors<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">4.07%<span></span>
</td>
<td class="nump">4.21%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">107.00%<span></span>
</td>
<td class="nump">105.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life in years</a></td>
<td class="text">5 years 7 months 6 days<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=ino_EmployeesAndDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=ino_EmployeesAndDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Non-cash stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,399,349<span></span>
</td>
<td class="nump">$ 2,525,433<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total unrecognized compensation cost related to unvested stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Period over which total unrecognized compensation cost related to unvested stock options will be recognized (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.60<span></span>
</td>
<td class="nump">$ 6.77<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPercentage', window );">Threshold, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ino_ServiceBasedRestrictedStockUnitsMember', window );">Service-Based Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total unrecognized compensation cost related to unvested stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Period over which total unrecognized compensation cost related to unvested stock options will be recognized (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, restricted stock units (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.95<span></span>
</td>
<td class="nump">$ 8.39<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Performance-and market-based restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPercentage', window );">Threshold, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Performance-and market-based restricted stock units | December 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardUnderlyingCommonStock', window );">Underlying common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,314<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ino_RestrictedStockUnitsRSUsMilestoneBasedMember', window );">Milestone-Based RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Non-cash stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, restricted stock units (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue', window );">Grant date fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 643,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ino_RestrictedStockUnitsRSUsMarketBasedMember', window );">Market-Based RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Non-cash stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, restricted stock units (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue', window );">Grant date fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 269,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ino_RestrictedStockUnitsRSUsMarketBasedMember', window );">Market-Based RSUs | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ino_RestrictedStockUnitsRSUsMarketBasedMember', window );">Market-Based RSUs | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ino_RestrictedStockUnitsRSUsTotalShareholderReturnMember', window );">Total Stockholders Return</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPercentage', window );">Threshold, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options | December 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardUnderlyingCommonStock', window );">Underlying common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,686<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ino_RestrictedStockUnitsPerformanceBasedMember', window );">Restricted Stock Units, Performance-Based</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsGrantDateFairValue', window );">Grant date fair value</a></td>
<td class="nump">$ 34,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantDateClosingSharePrice', window );">Grant date closing share price (in dollars per share)</a></td>
<td class="nump">$ 1.78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ino_StockOptionsPerformanceBasedMember', window );">Stock Options, Performance-Based</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value (in dollars per share)</a></td>
<td class="nump">$ 1.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsGrantDateFairValue', window );">Grant date fair value</a></td>
<td class="nump">$ 38,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=ino_EmployeesAndDirectorsMember', window );">Employees and Directors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Non-cash stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="nump">$ 2,400,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=ino_EmployeesAndDirectorsMember', window );">Employees and Directors | Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">547,000<span></span>
</td>
<td class="nump">1,000,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=ino_EmployeesAndDirectorsMember', window );">Employees and Directors | General and Administrative Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">821,000<span></span>
</td>
<td class="nump">1,400,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=ino_NonEmployeeMember', window );">Non Employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Non-cash stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,000<span></span>
</td>
<td class="nump">$ 103,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments, Grant Date Fair Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantDateClosingSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grant Date Closing Share Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantDateClosingSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Grant Date Fair Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Threshold, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardUnderlyingCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement by Share-Based Payment Award, Underlying Common Stock</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardUnderlyingCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=ino_ServiceBasedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=ino_ServiceBasedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=ino_December2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=ino_December2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=ino_RestrictedStockUnitsRSUsMilestoneBasedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=ino_RestrictedStockUnitsRSUsMilestoneBasedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=ino_RestrictedStockUnitsRSUsMarketBasedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=ino_RestrictedStockUnitsRSUsMarketBasedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=ino_RestrictedStockUnitsRSUsTotalShareholderReturnMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=ino_RestrictedStockUnitsRSUsTotalShareholderReturnMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=ino_RestrictedStockUnitsPerformanceBasedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=ino_RestrictedStockUnitsPerformanceBasedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=ino_StockOptionsPerformanceBasedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=ino_StockOptionsPerformanceBasedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=ino_EmployeesAndDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=ino_EmployeesAndDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=ino_NonEmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=ino_NonEmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Significant Assumption Used in Monte Carlo Simulation Method (Details) - Market-Based RSUs<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">4.60%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">90.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life in years</a></td>
<td class="text">3 years 7 months 9 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=ino_RestrictedStockUnitsRSUsMarketBasedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=ino_RestrictedStockUnitsRSUsMarketBasedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="5">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,310,237<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,199,056<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,090,902<span></span>
</td>
<td class="nump">$ 20,913,790<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Affiliated Entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CollaborativeAgreementExpensesToReimburse', window );">Expenses to reimburse</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CollaborativeArrangementTerm', window );">Collaborative arrangement, term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_GrantProceedsReceived', window );">Contra-research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 286,000<span></span>
</td>
<td class="nump">140,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=ino_PlumblineLifeSciencesMember', window );">Plumbline Life Sciences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalanceShares', window );">Investment owned (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">597,808<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Non-controlling interest (in percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_PlumblineLifeSciencesMember', window );">Plumbline Life Sciences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_TheWistarInstituteMember', window );">The Wistar Institute</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CollaborativeAgreementAmendedAmount', window );">Collaborative agreement, amended amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_TheWistarInstituteMember', window );">The Wistar Institute | Affiliated Entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CollaborativeAgreementAwardedAmount', window );">Awarded amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,400,000<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CollaborativeAgreementAmendedAmount', window );">Collaborative agreement, amended amount</a></td>
<td class="nump">$ 12,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CollaborativeAgreementAwardedOptionAmount', window );">Awarded option amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 475,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued liabilities, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 470,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementAmendedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Amended Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementAmendedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementAwardedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Awarded Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementAwardedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementAwardedOptionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Awarded Option Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementAwardedOptionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementExpensesToReimburse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Expenses To Reimburse</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementExpensesToReimburse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeArrangementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeArrangementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_GrantProceedsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Grant Proceeds Received</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_GrantProceedsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedBalanceShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of investment owned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477439/946-210-55-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedBalanceShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=ino_PlumblineLifeSciencesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=ino_PlumblineLifeSciencesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ino_PlumblineLifeSciencesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ino_PlumblineLifeSciencesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ino_TheWistarInstituteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ino_TheWistarInstituteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2023</div></th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Lease cost | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 515<span></span>
</td>
<td class="nump">$ 837<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Operating lease, remaining lease term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Operating lease, remaining lease term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=ino_SanDiegoOfficeMember', window );">San Diego, California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_LesseeOperatingLeaseAreaofLandUnderLease', window );">Area leased (in square feet)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=ino_PlymouthMeetingPennsylvaniaMember', window );">Plymouth Meeting, Pennsylvania</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_LesseeOperatingLeaseAreaofLandUnderLease', window );">Area leased (in square feet)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=ino_SanDiegoCaliforniaMember', window );">San Diego, California | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_LesseeOperatingLeaseBaseRatePercentageIncreaseDecrease', window );">Lessee, operating lease, base rate percentage (in percent)</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=ino_SanDiegoCaliforniaMember', window );">San Diego, California | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_LesseeOperatingLeaseBaseRatePercentageIncreaseDecrease', window );">Lessee, operating lease, base rate percentage (in percent)</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_LesseeOperatingLeaseAreaofLandUnderLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Area of Land Under Lease</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_LesseeOperatingLeaseAreaofLandUnderLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_LesseeOperatingLeaseBaseRatePercentageIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Base Rate Percentage, Increase (Decrease)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_LesseeOperatingLeaseBaseRatePercentageIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=ino_SanDiegoOfficeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=ino_SanDiegoOfficeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=ino_PlymouthMeetingPennsylvaniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=ino_PlymouthMeetingPennsylvaniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=ino_SanDiegoCaliforniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=ino_SanDiegoCaliforniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Summary of Future Minimum Lease Payments (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">Remainder of 2025</a></td>
<td class="nump">$ 2,637,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2026</a></td>
<td class="nump">3,592,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2027</a></td>
<td class="nump">2,992,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2028</a></td>
<td class="nump">2,319,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2029</a></td>
<td class="nump">2,132,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total remaining lease payments</a></td>
<td class="nump">13,672,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: present value adjustment</a></td>
<td class="num">(2,401,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">11,271,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: current portion</a></td>
<td class="num">(2,575,902)<span></span>
</td>
<td class="num">$ (2,497,360)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liabilities</a></td>
<td class="nump">$ 8,695,055<span></span>
</td>
<td class="nump">$ 9,367,827<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term</a></td>
<td class="text">4 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative Agreements (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from collaborative arrangements</a></td>
<td class="nump">$ 65,343<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_ApolloBioMember', window );">ApolloBio | Collaborative Arrangement, Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CollaborationAgreementAdditionalRevenueToBeAchieved', window );">Additional revenue to be achieved</a></td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CollaborationAgreementRoyaltyPeriod', window );">Royalty period (in years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from collaborative arrangements</a></td>
<td class="nump">$ 65,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_CoalitionforEpidemicPreparednessInnovationsMember', window );">Coalition for Epidemic Preparedness Innovations | Collaborative Arrangement, Product | Lassa Fever and MERS Vaccine</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CollaborativeAgreementFundingToBeReceived', window );">Collaborative agreement, funding to be received</a></td>
<td class="nump">$ 56,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment', window );">Collaborative agreement, period to receive funding for research and development (in years)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CollaborativeAgreementFundingReceived', window );">Collaborative agreement, funding received</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_BillAndMelindaGatesFoundationMember', window );">Bill and Melinda Gates Foundation | Collaborative Arrangement, Product | DNA-Encoded Monoclonal Antibody Technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CollaborativeAgreementFundingReceived', window );">Collaborative agreement, funding received</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39,000<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="nump">$ 2,200,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborationAgreementAdditionalRevenueToBeAchieved">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Additional Revenue To Be Achieved</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborationAgreementAdditionalRevenueToBeAchieved</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborationAgreementRoyaltyPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Royalty Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborationAgreementRoyaltyPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementFundingReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Funding Received</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementFundingReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementFundingToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Funding Received for Research and Development</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementFundingToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Period to Receive Funding for Research and Development</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ino_ApolloBioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ino_ApolloBioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ino_CoalitionforEpidemicPreparednessInnovationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ino_CoalitionforEpidemicPreparednessInnovationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ino_LassaFeverAndMERSVaccineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ino_LassaFeverAndMERSVaccineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ino_BillAndMelindaGatesFoundationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ino_BillAndMelindaGatesFoundationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ino_DNAEncodedMonoclonalAntibodyTechnologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ino_DNAEncodedMonoclonalAntibodyTechnologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Geneos Therapeutics, Inc. (Details) - Geneos Therapeutics, Inc. - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Noncontrolling interest, ownership percentage by parent (in percent)</a></td>
<td class="nump">23.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investment in Geneos</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_EquityMethodInvestmentsMinimum', window );">Equity method investments, minimum</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_EquityMethodInvestmentsMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investments, Minimum</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_EquityMethodInvestmentsMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481664/323-10-45-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=ino_GeneosTherapeuticsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=ino_GeneosTherapeuticsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from collaborative arrangements</a></td>
<td class="nump">$ 65,343<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Less:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">16,090,902<span></span>
</td>
<td class="nump">20,913,790<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">9,024,970<span></span>
</td>
<td class="nump">10,571,179<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">25,115,872<span></span>
</td>
<td class="nump">31,484,969<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">808,077<span></span>
</td>
<td class="nump">1,500,290<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(177,833)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of common stock warrant liability</a></td>
<td class="nump">3,712,872<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_ChangeInValueOfInvestmentsInAffiliatedCompany', window );">Gain (loss) on investment in affiliated entity</a></td>
<td class="nump">695,131<span></span>
</td>
<td class="num">(126,018)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Net unrealized gain on available-for-sale equity securities</a></td>
<td class="nump">140,234<span></span>
</td>
<td class="nump">500,877<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense, net</a></td>
<td class="num">(482)<span></span>
</td>
<td class="num">(682,218)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(19,694,697)<span></span>
</td>
<td class="num">(30,469,871)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_ResearchAndDevelopmentCostAxis=ino_INO3107Member', window );">INO-3107</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Less:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">3,507,342<span></span>
</td>
<td class="nump">7,645,664<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_ResearchAndDevelopmentCostAxis=ino_INO3112AndOtherImmunoOncologyMember', window );">INO-3112 And Other Immuno-oncology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Less:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">1,315,084<span></span>
</td>
<td class="nump">2,020,750<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_ResearchAndDevelopmentCostAxis=ino_OtherProgramsMember', window );">Other programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Less:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">107,425<span></span>
</td>
<td class="nump">623,666<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_ResearchAndDevelopmentCostAxis=ino_EngineeringAndDeviceRelatedMember', window );">Engineering and device-related</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Less:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">5,061,810<span></span>
</td>
<td class="nump">3,751,261<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_ResearchAndDevelopmentCostAxis=ino_StockBasedCompensationMember', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Less:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">553,394<span></span>
</td>
<td class="nump">1,060,487<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_ResearchAndDevelopmentCostAxis=ino_OtherUnallocatedExpensesMember', window );">Other unallocated expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Less:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">5,545,847<span></span>
</td>
<td class="nump">5,811,962<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ino_ReportableSegmentsMember', window );">Reportable Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from collaborative arrangements</a></td>
<td class="nump">65,343<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Less:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">9,024,970<span></span>
</td>
<td class="nump">10,571,179<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">25,115,872<span></span>
</td>
<td class="nump">31,484,969<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">808,077<span></span>
</td>
<td class="nump">1,500,290<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(177,833)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of common stock warrant liability</a></td>
<td class="num">(3,712,872)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_ChangeInValueOfInvestmentsInAffiliatedCompany', window );">Gain (loss) on investment in affiliated entity</a></td>
<td class="nump">695,131<span></span>
</td>
<td class="num">(126,018)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Net unrealized gain on available-for-sale equity securities</a></td>
<td class="nump">140,234<span></span>
</td>
<td class="nump">500,877<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense, net</a></td>
<td class="num">(482)<span></span>
</td>
<td class="num">(682,218)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (19,694,697)<span></span>
</td>
<td class="num">$ (30,469,871)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ChangeInValueOfInvestmentsInAffiliatedCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of the change in fair value of the investment in affiliated entity. This investment is measured at fair value on a recurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ChangeInValueOfInvestmentsInAffiliatedCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479536/321-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ResearchAndDevelopmentCostAxis=ino_INO3107Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ResearchAndDevelopmentCostAxis=ino_INO3107Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ResearchAndDevelopmentCostAxis=ino_INO3112AndOtherImmunoOncologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ResearchAndDevelopmentCostAxis=ino_INO3112AndOtherImmunoOncologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ResearchAndDevelopmentCostAxis=ino_OtherProgramsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ResearchAndDevelopmentCostAxis=ino_OtherProgramsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ResearchAndDevelopmentCostAxis=ino_EngineeringAndDeviceRelatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ResearchAndDevelopmentCostAxis=ino_EngineeringAndDeviceRelatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ResearchAndDevelopmentCostAxis=ino_StockBasedCompensationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ResearchAndDevelopmentCostAxis=ino_StockBasedCompensationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ResearchAndDevelopmentCostAxis=ino_OtherUnallocatedExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ResearchAndDevelopmentCostAxis=ino_OtherUnallocatedExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ino_ReportableSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ino_ReportableSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>67
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( !> K5I&QTU(E0   ,T    0    9&]C4')O<',O87!P+GAM
M;$W/30O", P&X+]2=K>9BAZD#D0]BIZ\SRYUA;8I;83Z[^T$/VYY><@;HBZ)
M(B:VF$7Q+N1M,S+'#4#6(_H^R\JABJ'D>ZXQW8&,L1H/I!\> \.B;=> A3$,
M.,SBM[#IU"Y&9W7/ED)WLCI1)L/B6#0ZL2<?J]P<"A#G>B4^BQ-+.9<K!?^+
M4\L54Y[FRF_\9 6_![H74$L#!!0    ( !> K5J,7*_9\0   "L"   1
M9&]C4')O<',O8V]R92YX;6S-DL%.PS ,AE\%Y=XZ;;<=HBX7$">0D)@$XA8E
MWA;1M%%BU.[M2</6@> !.,;^\_FSY%9[H8> 3V'P&,ABO)E<UT>A_98=B;P
MB/J(3L4R)?K4W _!*4K/< "O]+LZ(-2<;\ A*:-(P0PL_$)DLC5:Z("*AG#&
M&[W@_4?H,LQHP X=]A2A*BM@<I[H3U/7PA4PPPB#BU\%- LQ5__$Y@ZP<W**
M=DF-XUB.3<ZE'2IX?7QXSNL6MH^D>HWI5[2"3AZW[#+YI;F]V]TS6?-Z7?!U
M436[F@O.Q6KU-KO^\+L*N\'8O?UGQIMOQA=!V<*ONY"?4$L#!!0    ( !>
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M=0WY;$[34#[S]2>V VHJ/X^'2?87K;?/-AHUY*6)Y-%.#"6(@GC[2]]V+^)
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M+L(,0B\=;NFX)"D.PQ 1=XR2GJ")GZ"_O16@?OU3W]6YK!UZVY,^.6X+^JT
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MYJRIN=%B6Q_7/ FM15E?;AC-F30"\/]*"/U\8Q;H3OSF_P-02P,$%     @
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M0AO@_HQSM9WH ]H_,.E?4$L#!!0    ( !> K5H;HNHQD@<  (HV   8
M>&PO=V]R:W-H965T<R]S:&5E=#4N>&ULO5M1DYLV$/XKC-MI<S-QC"00)KV[
MF<0&FH=V;NYZZ4.G#P1T-A,,+N"[7']]%^S81I)UIMTT#SFP=[\5^G8E\4F^
M?"JKS_52B,;ZLLJ+^FJT;)KUV\FD3I9B%==ORK4HX)N'LEK%#=Q6BTF]KD2<
M=DZK?$)MFT]6<5:,KB^[SVZJZ\MRT^19(6XJJ]ZL5G'U_%[DY=/5B(R^?G";
M+99-^\'D^G(=+\2=:.[7-Q7<3?8H:;8219V5A56)AZO1._(VHE[KT%E\S,13
M?71MM8_RJ2P_MS<?TJN1W;9(Y")I6H@8_CR*F<CS%@G:\=<.=+2/V3H>7W]%
M#[N'AX?Y%-=B5N:_9VFSO!I-1U8J'N)-WMR63S^+W0.Y+5Y2YG7WO_6TM?7L
MD95LZJ9<[9RA!:NLV/Z-O^PZXLB!."<<Z,Z!R@[\A /;.3#9@9UP<'8.CN0
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M/OYS>IN?R]N^C@,(DW>V>Y?=;N_;#F\.H+;:73+EQ0O</KQ@(N\>3YA93((
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M&O)2/H*72YPC44U$C3JN8( #B3.[FL<R/74%Z3QY9C[FYBL.5H_0D_K\<"I
M9XUTOFTQGD+V+>PE3?(.6HB_?MX3T7WS'<(.@_V7<X1A%H5_2B,SP3TIV(5"
M8Y;/H@B!7Q>RP#4H;10K>X?6$0PJT;#:KP"PI\D2<S>T=S&YFT_ C:O9 STD
MKSQ]B>F]D8%/6.[2 '_3'6WM+(SBP L-TK(W>YC!Q#^$D8^"+AMG81P\Z=--
MMV@[.8+]"@2'U.S=S*[V7YK$<R9:2X=&@=,X>^J2+KJ&"XLGLPLLGVL(+#>C
M=*T*2??;+-Q)N"%QY/QWWWF')H,IC:Q=6V@RAEKT JU>A=@6S:4Q?J.10I4
MQ87^'9(,E=VZNFUVF"PH<%NHQ*8+4#2V)7C^>P,/<?4=1E,ESPZL#UBC:C[8
MO^$L99G%UD7L&+!HKC>@,5+U&?<UT+#_S*G#EZX @YV['8"\C#=8)E]C0KKF
M;4>WE^1)NAL^34\W;-RFEMP3:5E@Z='AAW<]<NG6FEZ"K>--<6$#)#<^EE!8
MZ7@"OA<6Q&I?>(/MOP[._@-02P,$%     @ %X"M6KX;R+BA"@  Y1T  !@
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M>]*Q/3F&_I^#\__1&&:UXFMC>:B5Y<8"8.EYQ[C.V T\@:X!?X79:!F.W!6
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M=A;;'8G-_#G(:.= AL LQ5/WP1QRUI&5AVQ/Z5,7[ F/N),^?Q[]E';'>+]
M?[YY^^?!1^<L.X\OQOIYUNU)5TZ("0T*X4IO^ZWL&*@/#Z :$=J^[82T#'2&
MKC'[NJHU%JJ6_&\R.\L6RTF:IJ$^C^'$)WKB#)*=8+[VJ3CL43+E7@AOO6\X
M'?"-"15VZ"04^",<6%IU':7]I8:0G'3J%G4=WB/C/:3MF_:X.CYYV[[3/YOW
M[R4IKJG(06!%KFF\F$>@^S>HGUC5A;Z_4Y9>D3!LZ-E&[0UHOU(D<)CX \8?
M IM_ %!+ P04    "  7@*U:=9U;L_<*  !O(P  &0   'AL+W=O<FMS:&5E
M=',O<VAE970Q,RYX;6SM6MMR&[D1_1445]F5JD84;Z)$6U*5?*MU*HY<UCK[
MD,H#. .26,\,:  CFOGZG 8PX% <4=)NUI6'E"UI+D"C+Z=/-T!>K)3^8A9"
M6/:MR$MSV5E8NWQQ<F+2A2BXZ:JE*/%FIG3!+6[U_,0LM>"9FU3D)X->;WQ2
M<%EVKB[<LX_ZZD)5-I>E^*B9J8J"Z_4KD:O59:??J1]\DO.%I0<G5Q=+/A>W
MPGY>?M2X.XE2,EF(TDA5,BUFEYWK_HM7(QKO!OQ#BI5I7#.R9*K4%[IYGUUV
M>J20R$5J20+'GSOQ6N0Y"8(:7X/,3ER2)C:O:^GOG.VP9<J->*WR7V5F%Y>=
M\P[+Q(Q7N?VD5C^+8,\IR4M5;MQOMO)CAV<=EE;&JB),A@:%+/U?_BWXH3'A
MO/? A$&8,'!Z^X6<EF^XY5<76JV8IM&01A?.5#<;RLF2@G)K-=Y*S+-7MU:E
M7Q8JSX0V/[&W7RMIUQ<G%I+I_4D:I+SR4@8/2!FR#ZJT"\/>EIG(MN>?0*.H
MUJ!6Z]5@K\ /7'?9L)^P06]PND?>,)HY=/*&SS"3_5U9P?YY/356 QS_:C/;
M2QVU2Z6$>6&6/!67'62$$?I.=*Y^_*$_[KW<H_,HZCS:)_W)H7FZE!]_.!_T
MSU[6]O^R$&RF<N2E+.=,&L;KW&1JQBS>OE;%DI?KG_"JL@NEY;]%QGB98;"I
M<)FJHJ#4PA,X8":TQD-#*S)N2 CBF"YB(-W -R(5Q53H^NGH!;NIK+%X1VKX
M>=>;Y=[[I>Y)VI%"NI(NSMZ$+;EF=SRO!#OH=7N]/EMBK%EP+=BXUTMZ_H<-
MQ\GX;)0,3T_O7?8FDV0RZ;-;H:4P[#7[&.U[?(4^IO?#[PG^W<PPE8R#94TU
MG3]^Y5KSTAIV4VZLZH^]54DS#"S-E8$"]"B.=+;'!0Z-$(S"/.B]_)M$F#,$
MVMWW7S)9>L@/&)^J.W'496\Y?!H4J&.*47L66" ^O,0@:27/F?@F="J-0/AE
M*AHN@*4'P^X9S##5]#=0,+.*I4);U G&L]_ ;*!VU!.'PNB#@J_95$2Q )ME
M9+E%(4A(M16@#.F:KA$!F["JM)(464K-'=&K73].NNR]-TO<856Z@HY ?*F8
M@&FN-*#&S"5Q@9,"0%I!*@+D=]YVFN^L<Q -V/=HK\![.E\[ $>'UE;X(#YL
MXYWD+.5FD0MCXN,NNV8^;=FA57-!*J,VV 63D,%G,YE+:&@<AI1[RZW5<EHY
M]<DW .Z16ZU4&V6<.Y=*>U?-&NHB0,Y#WZQW$5POBT)DM$R^I@C#[1B$WWQF
ML=Y<WI'!WH'TQE2 4UR(A 4+5JK*H>6J9(72] 80&G4GD[^P0Z43D)".V A4
M18%F!M&A\BVRS>HDE9#*RU34-%6[-F$3$GITC[X"[2%J#9[9RL.FG=ZV3>Q6
M"PFK@.P4;D&?4L<OA1%SC]"-I7&IV'9 9<Y L9 ) Q9H$G#5D$:Q@=GB6TK1
MA^)]9P.KEI@\[K.,KR-O8RQE6?!"S0J-!*/'T+XP]ST#-)EM%%*2^K4SV)K=
M$QKM:*)\FXRT2)7.R $,2)P"CB@I%,GM92R;<5DSI3-J$[WR7I%)%90IC2LL
MI5&YS#C%?LIS-]YU.9XPMI)O%0"\40.9K9&\W%3:F];0(<1+4-K,F" &U,(E
M!%"!P$B5.6\]L7HEQ"'1W"=R*&P2HMQ00)?(_QH8SUG__!'F]\/^..VCH!V_
M(][*'J@ ;0L]A_Y=57P:_^_JLK\41-*OWT'HK,KS[T>:+=[[SOSI:>+_3!<\
MT *A2'IM\'H<ZX3C=G8$55$L'N@%#B.X5A3&@K;6-%D+)*9V/84A@>39G!LC
M9](K(EQ;?O0 S5I'>]@-P_F^1<$K@;XE8S.MBM;"V&8X97 &?H $9/"2R^P8
M:Z=\*2WN?Q<G/Z/9?S:UMIG01J#7]AA,<@RY7Z#0+4<SQ:[G6@1_$[]6<[ .
MZP_;"!:#A'9A(!B7]1;I#36$-3U$<2 73.TXN-Q;J7/D^08B* <1+&;<"&1
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M>,^+TME::"@^UA3^H=6YK/*VDDR0.*5L V$_+FSD-J'"T]JM(&<;&Z"T]-9
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M3[IR5(X6X'UI;>@^T ']C[">_Q=02P,$%     @ %X"M6C)XS02G"0  ]Q@
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M5]ZD./S,AEG:,&.[HR*V\I4,\N3(V;5PM!K2Z()=Y=TP3AM*RE5P>*NQ+YS
MFT+.K9,4''&Z=$HAY,$?[09(IS6[69+T,DJ:W2-I3UQ8$U9>O#:YRN_NWX55
MK6FSQK27LP<%7D@W%GO3H9A-9@</R-MK7=UC>7OWR/OHEM+H[Y+0,!1GUGA;
MZ%Q&<)A<7#KEX7I\8!?BC3;29%H6X@H/8UC$?T[G/CA@Z;_;(A0-V-]N -77
M<U_)3!T/*M+EKM7@Y/$?TR>3%P^XM]^ZM_^0]%_*Y.])$J?YM<PRK!8OM:U6
M$E61J3KH3!9>7-7?5[9&7,=#\3[D8W%N*'.3H0@KA<=E)<VM@!SE5"ZT"59(
MT5.5LO!>9RCYGEH41%C]HNJ=QW\<SF:3%^TNOI^^^,=0K%<Z6XFU]$)".I#*
M6I$.RC'9149/Q<X]"Z(WF^([:QM%8_$7]CI>#8]+3XBBFRU[[D9HZ:0A2Q"?
M;BTM4#=947M*B2.JH06YN@:M5D,P@JD70&7M%)N;V;)4CL"KOZN^>+)O^O2%
M%XWD#,NI"I0X__!QM'\XF7# $8=DNM/!.JW8@3,\ET/Q6>JU1 V]LV8I_DD_
MI/-"9K(6.V!5;(H.@)V8?F'EK4!$4]S>HGU <A371(QE[.T)F>>:T("ZRVQM
M NN&.:=>R['X#*,X09P<QH=3A4P!DZRQ ]1<A;52YDY\24TOL%;\;0%&V)=9
MD]=9@)!E8>=0?[D"W8L]X=62%:4,;D8R0_T0#@5,Q2]6M9$,*QD8:U4AC5%Y
MM+^2+I!3:U1"JYT?9KJ"X8AG$WZ62!;S6ABKOM6RP'*/$HB)3<8F*+"AF?6H
M5G3L3L@0(@&?G(1O<Z(#$*V( J#.UU4%;8U#XU[D),&7HSY78E&342B2"K2J
MYX5B[2FBC<[H#5R[D_^^91I:HV[R6=U41 64_:PF2,7P-8E$=D2N/91 0TVU
M&V@I!!L.T:+FZE4+F!*]23'J\D-%+LX^?CE_-9H^$RN%O;:P2UM[@4'"DXW)
MW;[GC<;M,IFNR!2[IK'%V]IE6%K_-!TP<T*'28,+"PP_X/XN:^1D.^8#R@B!
MKH>,!L8Q_& &Y*@'9]D1+8<C^X&2C0W\W'#CB_;(-)S )UH"0:A[2^R3<=7"
MC@9_&^4: W%Z=28^VTIGXG!R.!:?E"[GM?.IT2R<+7NA8? [E=DE^C<1LD_6
MC*B-2@="[\,_X4;86$2$0KHG5FQZ/FY\T]0I$!ARH\-(C,G M=*9Q/P-A\UU
MH<-M#)+W-</Q@V64$73I.4Q4X+I\T_X\5A4G?X5HBS).2K&]7+ #:=#9%X@:
M#3P 7 7-%NT.2795DQ#NJM.G#W55<&6O<WUJ6EO36>GAW;[;]=H=DCKH-+=O
M!M0ZN1%OM6JGVS/8VF11]7_6AL&P=W]O_%'O_;VQ7?MP;]S2#K^\_?=H;SK!
M9$)E^NK#J=!E60/E +&L0,7.<B/H6F.NO%Z:J#@0>6&-&N%]IARP*&M"U_Q6
MO+O\,NRWS\21=450[%KI71[3!(2@0Q'E)Q!ADXC)E$M(69(9"-.CV60\P4&@
M*'B*+90GV'VK=4P_'%71@I4M&)> $SLF@KQ1?IAL(=NRE4:(F@KPE<KT0D,*
MA ,RX C?;ZVT!6;4>& =NFB%*%W'=M?$DY),Y>]R"DS'6UO2RAS'B;LF_4Q9
MG1B?Q"<2P6GQJZ(N<A<,:P2!>L^VX#E[*XM 7?4V,@J=W')B!"G0>RE8J/B,
MQOTEQQ7M&8U5&!R#O2PH4&R^KX'CWLJYZG5G'&A'I+34^2A@S, F7\__!EE$
M4[CW0:7NNPI=2V64 _,1%<.O9HU,,P!"[%JTW/9XH&W6=E[H92P\*(*/R5\>
M*B@J38?B\$TGXA9\AJ N0JJZA78^]*J"?;[?!H (M;(0! 9<@=YUD<JNTJX]
M,'%,I ^C8$?\AD:=$ >2:]528!%Y*&_JS#<!ZB#8\_[5SW/G =<ZD>A=H+2T
M_.C)P7!";1_+'J'\:5YIQM-A).U[\-I-<M2&7!Z;D*.4UI@-SBR8A<-  7]=
MZ5R52#!.E BGR@U5Z;DQ*)C88_KE#R:YUI@XBDT:[\Y=;27]JIZ=L]>7Y^#C
M"JVUEH9Q&;FY'Q^:F3B:/=;\X7@ ^"RE-H#->[0_*198&'O_Q>M/5T"I9^BT
M4X4#52]C[/I3>)I]<?Z&9;T9DMKH?91W\*0A/+J-\Z%E[0#RM1H1NJE(M8U\
M@8BV,[D/F"Q)GZ1Y&Z71#>-I,)K&PS]?SS:&>>R+\VV:9"/+;YXFNHG)NH8X
MFK& 0<6^M@RTA7R11]34!OLV)^C9<$.CP8"5-8.>#K&ADXJUK8N\/Q/SQOYH
M%+,#3W_H<1AFI5LRS6[-,.J#JF+=%"/"%.+A1!:W7G,/AQS9E5$*_<.Q2T,Z
MWI 'OUWN!K I:>[TW;#85.GFJ$B[MHV+&\V.(\H#AV^[%1J[RP6.8(Z8%![S
MQ'8/VS00( A/QQV&]?;I?J'YR%M8KT:V[J6JL>$E,?MC658OQ(4"3',IWG+B
MWL#QO#\='@[3&[F6KID#4Z3O)"#*CG/%>-9:2$6(X96:^!8 O;HXG?NX)G?$
M.!KC<#RC:[-@MVH^F2G)0..^UYPETHQ%$Q P$U2V,G3BBJ>Y%68W2H.*NIL#
M!"?0\J@!!46MS'?)PMZ=?TF"C+H)(^ZKZ=A"\X,DGK/)A0(YH4ZV($19A-DP
M>#'76T9IK)U2?E5I+FTM Q/"2S[40AI*@'6CZ>>%&L61J_M2D8IV^JQ)00H[
MD5KW80-XF+;1;MR$Q30[_+]:7L3_H]3M]IY1Y]ML>;]?'0R<\;;/EKN]C]$8
M+Y;\R=W'",7OTNW3]JO^:?R8W2V/_Q* JTNT'$RY"VR=C)\>#.)\W]P$6_&G
M[;D-.(ORY4I)G"UH =XOK W-#2EH_]=Q\C]02P,$%     @ %X"M6J@QG<-7
M P  4 <  !D   !X;"]W;W)K<VAE971S+W-H965T,3DN>&ULC55-<],P$/TK
M.V:&4QH[3DJA))EI4Q@X,-.A?!P8#HJ]C@6R9*15/OCUK&3'#4,I7!*M=M_;
MMY)V/=\9^]W5B 3[1FFW2&JB]C)-75%C(]S8M*C94QG;"&+3;E+76A1E!#4J
MS;/L6=H(J9/E/.[=VN7<>%)2XZT%YYM&V,,U*K-;))/DN/%>;FH*&^ERWHH-
MWB%];&\M6^G 4LH&M9-&@\5JD5Q-+J]G(3X&?)*X<R=K")6LC?D>C+?E(LF"
M(%184& 0_+?%%2H5B%C&CYXS&5(&X.GZR/XZULZUK(7#E5&?94GU(GF>0(F5
M\(K>F]T;[.LY#WR%42[^PJZ+G4X3*+PCT_1@5M!(W?V+?7\.)X#GV5\ >0_(
MH^XN451Y(T@LY];LP(9H9@N+6&I$LSBIPZ7<D66O9!PMW^K"- @?Q![=/"5F
M#/MIT:.O.W3^%_04WAE-M8-7NL3R=WS*2@8Y^5'.=?XHX3MAQS"=C"#/\O-'
M^*9#>=/(-_UG>7 C7:&,\Q;AR]7:D>4'\?6ADCO&V<.,H4DN72L*7"3<!0[M
M%I/ETR>39]G+1_3.!KVSQ]C_>1W_CX8/-<+*-*W0!_".-X0&="3Y)6/)AO9"
M 585QKX XB.R[!K!KI9%#=+%UUX"MP[N6XZZ1\F89P2.!'DR]C"@0Y8R6JWB
M8*DW8-K66/):D@SNK9!*K!4R"1!+W HKC7?PS5OI2AE[U05G)X-.JN!)%'.,
M@ QW'J'EAF B<O##"\NV.D!KS5;&D<$3JU<:!*$;PPHM\9P")S=:5K(0FH"#
MO/8NED78L$)^( Y;$5(QG\7"</1/KKY7W.?Z32.+*PIO8_5,"VL$ <YX6R"8
M*A8IUE)).AQ9_CQY!Y4US4#/-?;+,=QX#'; B=*T<9XQ[=7=1VZ4R8NS2=Y+
ML=B8+3/%#/L"NU#/W6DY>@47L^PLS\YFYV<7@;#@LY;!)Y3JY;I W!\;2S6V
M[+3<GW?@#IK7J+&2Q#D=C\!PU5&_ .ZROA;F9X?OGD&XO'"YHS^4:,,8O0DZ
MVE;Q,QD_U$KIR91KT&[B+'><PVOJ!MZP.WPNKKHI>1_>?6MXS&PD/S.%%4.S
M\<5Y K:;WYU!IHTS<VV()W!<UOS)0QL"V%\90T<C)!@^HLM?4$L#!!0    (
M !> K5J:VWL^J@,  &,(   9    >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM
M;)U6;6_;-A#^*P=UZS8@M6S928/4-N"7;2VP;D&SK1^&?:#)DT5$(E62LIO^
M^MY1EB-O3H#MBR62=\\]]^B.Y^G>NGM?( ;X7)7&SY(BA/HF3;TLL!)^8&LT
M=));5XE 2[=-?>U0J.A4E6DV'%ZEE= FF4_CWJV;3VT32FWPUH%OJDJXAR66
M=C]+1DFW\4%OB\ ;Z7Q:BRW>8?BCOG6T2H\H2E=HO+8&'.:S9#&Z64[8/AK\
MJ7'O>^_ F6RLO>?%.S5+ADP(2Y2!$00]=KC"LF0@HO'I@)D<0[)C_[U#_RGF
M3KELA,>5+3]J%8I9<IV PEPT9?A@]V_QD,\EXTE;^O@+^]9V?)F ;'RPU<&9
M&%3:M$_Q^:!#S^%Z^(1#=G#((N\V4&2Y%D',I\[NP;$UH?%+3#5Z$SEM^*/<
M!4>GFOS"_&<T:#W\7J 3-39!2W\![XP<3-- \&R4R@/4LH7*GH :PWMK0N'A
M1Z-0G?JG1.O(+>NX+;-G =\+-X#QZ *R87;Y#-[XF.LXXHV?P/O5&DD,G2WI
M9$M9!G3H _RUV/C@J#[^/I=TBSDYC\D]<^-K(7&64%-X=#M,YB]?C*Z&;YYA
M/#DRGCR'_M^^SO^$HA\2>'1U :% 6-FJ%N8!N-U1P1DO^#YI=Y,?(%CJ@!UU
M=@W"*)"VJM!)+4K]!8%LA EZB^85]XV"&IVW)AZ2K3 2'<<D9(U^P$&Z\-]Y
M6!4:<[B3&@DCUQ)^R^F7/-94%+^(QM$^O&TJ% UH#]3@3']IA5-@<UAK1WUO
MG>=%R_>?$=3!)"*NQ4XK6 [@(Y)PCB&C'(70U/N&47C=X[-0.^VM>WB,V859
MQ*!4O;(XEN^IN@66"K+QMQTLW98^D()<EOBIT>'A$8]3(P+"OZ+BW:$+)![I
MSEK3"5T0\I[O)7V:'UUWTC8F>/Z2H.EYXJ )R8>*-=2F"R0\!SK$KS 45O4-
M&VIK!XN[%8RS,2G68,N#]# -,S<T0TKK/?9$/\G[Y8OK;/3ZC>^C%D+!!I%O
M>-7(-K=OALR%,%"0A/_2,M;:&B56&R)TV)V<IE\0@+&!KDJ%$ NZ<5QK9S,_
M==WKLHR^+:,H7L]KPX,L4B06/5MIJ0K8UA?"(;/N0I[71?C3DHB$P6Y*O15Q
M8)$0.6G><3QWG:2]BY\Z;QO'&W]J^O+M##CN'B?HHAT<C^;M^"6)M]IX*#$G
MU^'@-0TLUXZT=A%L'<?(Q@8:2O&UH'\!Z-B SG-K0[?@ ,?_%?.O4$L#!!0
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M.HE _LQ>)A3EUOJL$%F*<2.<,&@IPG_MM$6L>T2Z-Q31 ^.#%[Z'&FT#"N8
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M&["^T;@@C"]TP.&?FHM_ %!+ P04    "  7@*U:GGF+YST"  "1!0  &0
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MTGPL0-H \SX70A\G=H/A\Y/^ 5!+ P04    "  7@*U:ZK6! 7$0  "',
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M_[@AER85$/\;HTO@)2@6*9>\"X'REZ;SQI/S06\$HXH5WL)\9HO\XPAXMG-
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MK;Q,=RLO#UZ#W.@:T:^]E^?)E._&2"+8_;,J-/(2+1FZ:#EXPO#=T%./[1E
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MI1F[%^-+7JJ,%?1>(%GF.1'K&YKQU57/[FT&'MALKO3 8'RY(#,ZH>K3XEY
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MD_#S";'C0>SX%/MJC0U8M!R(+,DEU2PG5!3DFO'60$$.$W=,_^D5OK,6/:M
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MK %^+R4673^Q"PS7N-5_4$L#!!0    ( !> K5H#1X8,)0,  &8'   9
M>&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;(U5;6_:,!#^*Z=,K39I)2^\M*.
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MEAE]"%%9 SI/I32'C0W0?%HG_P!02P,$%     @ %X"M6E[^,'(/ P  S 8
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M\W1]5EP:HK>DU+@W&@2@V]G9&E;5?EXME*7IYY<E?6Y0NP#:7RIEMX8KT'W
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M_?NB*-3+AS+![FVXL_\#4$L#!!0    ( !> K5JH6#>O:@4  !<@   9
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M7*#.[QB3SSM%@>9_ 1;_ E!+ P04    "  7@*U:44^M':@#  #<#   &0
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M^0'2+,#YA1!ZWS$.R@^:T7]02P,$%     @ %X"M6LWB'*V$"   8T@  !D
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M<ERZ0UE93;N<_.QL52AM+RSJ$C[+'1I+@EL#3.9PQ[B&;TQ4"/?(3*6QWKN
M1<'D!@UYG!K]MH:O!<)"E5LFWSY^2*+!^).!K\HR 5]PAP*&<,<EDQEW*YRE
M7'#+">ALB99Q8<XGH252+K4P.Q"8UP2B=P@,X5Y)6QBXE3GF?_4/28Q&D>BH
MR#SJ!+QG^A*&@QY$_2B&I]42SGXZ[\ =-DH//>[P'=P3>7NPQ-1ZD6^_5]R^
MP0JS2M=:/-^DQFJJUC_:Q*AC7+7'<#?XVFQ9AM. KJA!O<-@]O'#8-3_U,'@
MJF%PU84^^W'6O>;TWGKPZ'+77&Y@S@PG<D]2I2XV2P52C6PKZVP4';O@S-W%
M'OQ"SP6<?5'&G/=@99GUM05J3?:9*A&4]H6DL7 /P Z/Z\^WK]:M..A;696H
M/6*K5MULZB(&RF/M>.U\#5,"%*:DYX)N7O8">Z8UH\3$D6Z'C'$C8]Q9"&TR
MNH,_7+(<*/I_T73!1%8)/X'G1R4$T+M%!/)6<>+_H9!&C0*C3NGGN.%2.G8I
M$_0<8%N"-<3(0[C6LIL-AE$<#Y)D$NY:@H^;X./.X$O,J'N9EI-_YY#K=&K0
M^"2=B^%X$"7CJ#V=I$DGZ4R'GJU_$2+YAQ _QU?1<##Z6^#PI O0O=CX7F>H
MGBMIZX;0K#;M]*;N(C_,ZUY,;R"=D &!:W+M7XZ)MZ[[6SVQ:NM[2JHL=2@_
M+.B3 +4SH/VU4O8X<0&:CXS9GU!+ P04    "  7@*U:\6$4'X8"  "2!@
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MCF,3;P-^%K!5>V-B,ID+<6\F-_G(\8P@X)!IP\#PM8$Q<&Z(4,;?EM/ICC3
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M3Q5O>I$G WU/N& '.>8%^NMWF0'="RCXWP.UNZMILV%:-96M>(DCV!ARKN+
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MONA(EIN*^)%)55^;9J(^@8#K">K]C#'YUM%%=O51%?X%4$L#!!0    ( !>
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M#-#],>=JUS!W$_8N:OT#4$L#!!0    ( !> K5KAD$Q,PP0  /\;   9
M>&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;+6976^C.!2&_XK%CG9;*0V?29IN
M$BDMC':DZ:J:3G<O5GOA@A-0 6=LD[3[Z\<VA$!*/$'KZ44+A/,<^[S^R%O/
M=IB\T!@A!EZS-*=S(V9L<V.:-(Q1!ND0;U#./UEADD'&;\G:I!N"8"2#LM1T
M+&ML9C#)C<5,/GL@BQDN6)KDZ($ 6F09)&^W*,6[N6$;^P=?DG7,Q -S,=O
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MEM>9-;,@FA5!U_6\@ <J!"WJQ93@A#!U@-R_I%2\K*@3='-1YO\!4$L#!!0
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MB'&GRZKGK09:%+9M?!0:FU#[N,7O!)#& -^OA="'@5F@^?*8_0=02P,$%
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M:5)H"#?&'D;:JTHE:*CT92%XE#.JNBU0+^RETS@46IL$MR'!O0KI5V4,1=I
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MA/2&$5X*67>G>J)%:0O\6FAL%W:884,':1QP?2.$/DW,!NU?A/@O4$L#!!0
M   ( !> K5HL[FQ;F0D  "97   9    >&PO=V]R:W-H965T<R]S:&5E=#0X
M+GAM;-6<76_;.!:&_PKA72PZ0!M;HB3'V<1 $G5G!]AT@F8S<['8"T5F8J&2
MZ)%HIUGTQP_U$5.4Z%,S<SS&YJ*U9?$E^4J'Y"-2/'_FQ9=RR9@@7[,T+R]&
M2R%69^-Q&2]9%I4G?,5R^<LC+[)(R*_%T[A<%2Q:U(FR=.Q.)L$XBY)\-#^O
MC]T6\W.^%FF2L]N"E.LLBXJ7*Y;RYXN1,WH]\#EY6HKJP'A^OHJ>V!T3]ZO;
M0GX;;U462<;R,N$Y*=CCQ>C2.0N#H$I0G_%+PI[+SF=25>6!\R_5EY\6%Z-)
M52*6LEA4$I'\;\.N69I62K(<O[6BHVV>5<+NYU?U?]25EY5YB$IVS=-?DX58
M7HQ.1V3!'J-U*C[SYW^RMD)^I1?SM*S_)<_MN9,1B=>EX%F;6)8@2_+F_^AK
M:T0G@=0Q)W#;!&X_0; C 6T3T'X";T<"KTW@U<XT5:E]"",1S<\+_DR*ZFRI
M5GVHS:Q3R^HG>77=[T0A?TUD.C&_$SS^\N%*.K<@USR3MU,9U1?D _D4%454
M717R+F0B2M+R!WGT_BXD[_[ZP_E8R-PKC7'<YG35Y.3NR,DA-SP7RY)\S!=L
M84A_#:>G0/JQK/6VZNYKU:]<4#!D\0FASGOB3ES/5!XX^4U4;)/[AN3A_LD]
MH#9T>R%IK4=W7<AE5+ /#\,+>2FO8O[$9*P*\O!"NN?=1B_UX<OGJ%B0__Q+
M2I*?!,O*_YHN;Y._9\Z_:I_.RE44LXN1;(!*5FS8:/ZWOSC!Y.\F;S'%0B0Q
MS7=OZ[L'J<\_\?Q#')5+4M:1U!@;=RZ R4I0TM;*1BRHQ:IF?C-WZ&Q&O=GY
M>--U:7B>Z[N^1^GV/,T ?VN #QKP;RZBE*SS@L7\*4_^UZN^_%(*V4.DD9"_
M""[/W+"R^EP;1OBJ.JLTN03F:^N2/W1I-JG^>BXA9:I9&6RM#$ K;UF1\ 7A
M&U:0YV42+Z5?&.;*/B5-R0,C'9EW24Y>6%24QJ8<+*>M]7"EG;H8)"!9W;R;
MXANI--HUF6ZOR10LWJ_UR$$:%LFK(D="Y$DVIX(LI./D,4H*LHG2-:OM7/ T
ME8:2E;Q\9=7,&JT%L[.UMA&;=N_JDZ!W1P_/"4ZF4W/0GVY=.86#?BD+M^3I
MXGU5VUAV(M(:4VU!&=O:-F(.U:KK]ZJ+E*-FRVQKRPRTY4[J)3%KQU.?92@6
M25S=//4PB]SGB3"V=*"JK4N88B&2F.:F,U&#T\F1!S5M 9"L1U4+L=1T\SMD
MX!RI8X<SMC;=&0YL7%/7CI6M[J>K_'3_3WIWN*#6_L/5=IN"&&]PI'+H%T01
MDP."P9Y=^WOIZ[8=;XQ?5^VX19</E\/:;VKH]&?];M!PUND);8:\[9]C'@,X
M"GT<F'WD'5T_><IEEQ?E"Y)%Q1<FVG;8[)K1'E0<0E4+L=1TAQ5;.?ZQ.T!4
MRD)5"['4=/,5C3DPF7Q:9P\RKOEC$]HEX6M1"GFC)_E3'?W-87/(HQ)4J^9W
M@YF>#CNX0X"2HTC)@5%I;RB =:S-F1JPH.\,4HZZ,XJ6'!B7WM!0DF\D9#&K
M[\ =#RBOX%RM?<14"['4=,<5B#FS8S><J-"&JA9BJ>G/U16VN2"9S._S!2O2
MEZJ9E./93+K>W-C?:3-A55M'6[5NF^G,J./U6@:L3'6K%&2Y,&3=)*D,?YYO
MGQG<W1O'2+",M3>8:B&6FFZAXBK7/7*HNZB\A*H68JGIYBN&<F&&>M/T!ZQI
M[2<=\']_8(25H6Z2XB07YJ3+-.5Q#?%EYQ[44)]]K3X;1TNPN+5;PVF@@5N'
M8!Y7,8\+3RC]:5@.E\/:6'^(Y9.36?]I/%:FNKF*:5R8:7Z1IE7],CQ AT6L
MG0F& _3)R;1OS"'@Q57PXL+P\J/I)C-Z@PHOK5HW' ./#I]=8N6JNZ, QH4!
MYJ8!EN^,45!Q!%4MQ%+3_5,XXAX;1UQ4'$%5"['4](4Q"D<HC"-O&J/ FM;+
M72;FY0>]*,?*5#=*P0B%8>1/ZWGA<EB;ZYAZWJ"__@4K4]U<A2D4G@?9K^>%
M1:R=<4T]+^T;<PB$H)V%:S!"-.W;1ME3S9+!$UBPHK5+</GH[@DLK'+HSBFN
MH#!7[#UF@76L_3*L) M,K=DA.((JCJ P1PS&+.0;N4GR)%MG1H]0:0!5+<12
MTYU4T$"#(X]>*"IPH*J%6&JZ^0I,* PF>_8;J%1"#5,J@^@^!)%01234DDBJ
MZ(Z^[HQN5#9!50NQU'0G%9O08[,)16435+402TU?/*[8Q(/99+_HAD6L%XQ/
M]EE'B96G;HQB$6^?U6?UNLEJ2IE)IOC,Q+HPKZ='Y0E4M1!+3?=188=W[-D1
M#Q594-5"+#7=?(4V'HP.>Z^(@'6L/:0F[!L$^$%>F^F\-P/#2[,D^N=V#>,>
MJQU@/6N/4)>)8:GI7BK4\8Z]3,Q#I2-4M1!+33=?T9$'3ZF\<;4#K&KMZ'"%
MF.L'I_W9)ZQ,=:L4RW@PRYC?B'A/NNNCZA&]T3!4Q$%5"['4=%\5#'FGQXY_
M5'Y"50NQU'3S%3]Y\$L_>S^%:W6ZS\VH-WAL=@UG9VW.(?C&5WSCPWS3,2=.
M>5DUDG6;2%:R';!Y;:[-1U_U/CWM>0>7QM8[+#7=.X5 /HQ V@AIST82EK1^
M:1:5A+#4=#L5"?G')B$?E810U4(L-=U\14(^QKLV-NV!Z2T8+^BW!ZC[#&"I
MZ1XJ8O*1IGO\X01-];9 OZ.!L[,VYQ (Y'=V(8!G>SYFJY2_,%:2:H%]F!0L
M%MPX:W<%*UF'*2K+8*GI+BJ6\8\]T^.C8@^J6HBEIINOZ,B'Z>A-ZU1@36L_
MA\O1',^X3<;P1+=WHNZ"8AD?GMC9$<CD6_4^/8N*>-G\P#8LY:OZSONX>_$L
MG)FU/:C<@J6F&ZVXQ3_VO(^/.N^#JA9BJ>D;O2@N"F N^F-+PF%Q6V.#X9LR
MOC<=QKSA/&<"Q'R@2"> 26=WS/_(<CE>3.OCEXLLR9-2M+N2 5$/9V?M#RH%
M8:GI5BL*"HY-00$J!:&JA5AJNOF*@H+O+'7[8U&/.DG4JFGO%+N.(>J'Y_6'
M!+H;BF<"F&?D>(>\1KZQOJ@3/JAJ(9::;IVBG>#8$SX!*B2AJH58:KKYG5W:
MOK,OP%O&Z;"FM9_!D/!=0^P.3W,F=!BZX\X&HADKGNJ-6$M9IW4NF@TUMT>;
MS5ZOG;.PWA.U=_S2.;NLMSX=*YEF!]F;J'A*\I*D[%%*3DZF\AH6S::LS1?!
M5_4VI0]<")[5'Y<L6K"B.D'^_LBY>/U29;#=&G?^.U!+ P04    "  7@*U:
M15MY-L("  "N!@  &0   'AL+W=O<FMS:&5E=',O<VAE970T.2YX;6R-5=N.
MVC 0_14KE:I6*B2$6W<+D8#=JBMU)03:]J'J@TDFQ,*Q4]N0Y>\[=D+*MMFH
M+^#+G#/GC.W)K)3JH#, 0YYS+O3<RXPI;GU?QQGD5/=E 0)W4JER:G"J]KXN
M%-#$@7+NAT$P\7/*A!?-W-I:13-Y-)P)6"NBCWE.U7D)7)9S;^!=%C9LGQF[
MX$>S@NYA"^:I6"N<^0U+PG(0FDE!%*1S;S&X74YMO OXQJ#45V-BG>RD/-C)
M0S+W BL(.,3&,E#\.\$*.+=$*.-7S>DU*2WP>GQA_^R\HY<=U;"2_#M+3#;W
M/GHD@90>N=G(\@O4?L:6+Y9<NU]2UK&!1^*C-C*OP:@@9Z+ZI\]U':X X>@5
M0%@#0J>[2N14WE%#HYF2)5$V&MGLP%EU:!3'A#V4K5&XRQ!GHJV1\:&W1%\)
M6<D<SUI35ZX>V;*]8"F+J3!DH?'4"K?Q9$.9((]2&" KJKC$T/S(*]PCF$PF
MY-T=&,JX?H]$CU0=P-1)-MLG/?,-2K<"_+B6N:QDAJ_('+ITF2;W(H'D)=Y'
MRXWO\.)[&782HJ8^&0X^D# (QQU\PZ:.0\<W?*V.&570V_U;QX525.P![[$A
MNS.YCEO3LUM>E%0EY,=7I"0/!G+]LZU 5?Y1>W[[=F]U06.8>_@X-:@3>-';
M-X-)\*G#W:AQ-^IBCS9,'WJI L"#-X#\ABAJH$UF132HZFY;PBD*^L%H,O-/
M+0+&C8!QIX#[YP*?,=;L).T]X\R<VY)7)(/AB^0W[:DG3>K)_Z7F++7^R1FH
M:KW"W3S#"DBF)*^N\@U)Z%EWG,ZT43CM9+YC)Y: 2,B9 4_:E$U;ZO)75?RK
M'I*#VKM.J4DLC\)4[:19;9KQHNI!?\*K3HYO:\^$)AQ2A ;]*1Z+JKIC-3&R
M<!UI)PWV-S?,\(,"R@;@?BJEN4QL@N83%?T&4$L#!!0    ( !> K5H61"CB
M:0<   I-   9    >&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;+6<:V_:2!B%
M_\J(7:U:J0VVN6<3I#2^C=2NHJ3=?ECMA\$,8-47=CPDC;0_?L?&P3A,)J ]
M::0"QN=Y;3B8=WS,7#SDXD>QXER2GVF2%9>=E93K\VZWB%8\9<59ON:9>F:1
MBY1)]5 LN\5:<#:O1&G2=2QKV$U9G'6F%]6R&S&]R#<RB3-^(TBQ25,F'C_Q
M)'^X[-B=IP6W\7(ERP7=Z<6:+?D=E]_6-T(]ZNXH\SCE61'G&1%\<=FYLL^I
M,RX%U1I_QORAV+M/REV9Y?F/\@&=7W:L<HMXPB-9(IBZN>?7/$E*DMJ.?VIH
M9U>S%.[??Z+[U<ZKG9FQ@E_GR?=X+E>7G7&'S/F";1)YFS^$O-ZA0<F+\J2H
M_B</VW4'5H=$FT+F:2U66Y#&V?:6_:Q?B#V!XN@%3BUPCA7T:D'ON:#_@J!?
M"_K/!<,7!(-:,#BVPK 6#(\5C&K!Z%C!N!:,CQ5,:L&DLL/V_:O>?)=)-KT0
M^0,1Y=J*5MZI'%2IU7L>9Z79[Z10S\9*)Z>W/&&2S\D-$_*1?!4L*UAEPX*\
M<[ED<5*\)Q_)MSN7O/OU_457JIJELAO5_$];OO,"WR9?\DRN"N)E<S[7Z*_-
M^MYK>N^5^HX!T%4OUNX5<YY>L4^.D7BU69Z1GOV!.);3U^V06?Z%B9U\H)&[
MQ\MUU3VSW.614>X?+W<T\N!XN:V1A\?++8V<'BVWAP8C]'8?G5[%ZYWZT2%_
M?5:K$BIY6ORM^\ALN7T]M_QZ.R_6+.*7'?7]57!QSSO3WWZQA];O.KLA82X2
MYB%A/A(6(&$A$D9!L):A^SM#]TWTZ544Y9M,%JJ)B7A\SV8)U[G7"#G5O5O8
ML(*5C=G]U.[9EM,;773O]XV)+.IIBMJ3B348MHOZR*(!$A8B810$:WENL//<
MP.BY6T5D(EH1ELU5DWJONN^UZJ4EX3]5/U_P0N= (_)4!VYA@WTS#*V)^G.>
M67!PX!K'FMB]T<1JK^@A-\]'P@(D+$3"* C6\N!PY\&A^;BW6,1)7'V7>YF,
MY:/.<T;$J9Y#PEPDS$/"?"0L0,)")(R"8"WOCG;>';U1$SI"&AH)<Y$P#PGS
MD;  "0N1, J"M0P]WAEZ;#P8>_7W/I&YZD/C=+81A;8--6).]2\2YB)A'A+F
M(V$!$A8B871\T*FI,47Y;]>HM:PYV5ES8K3F=9XD;)8+5IZ?)4RH@^V2E\WJ
M!R*Y2,F[."./JILMM.?)C.Q3_8J$N4B8AX3Y2%B A(5(&#7;;K UE>'8:EO-
MV5[K%0MG4K"/XI51E_8\KY%\JH%K6FLT-1[N?T2WWJS7:PW/^M;!>AYTZWPH
M+8#20BB-HFAM/^ZE#[;1CS?))IV5"\GG>,')713S+-(/^LVDD_V'I+E0F@>E
M^5!: *6%4!I%T=I>=AHO.V\T%*O!*&LC:2Z4YD%I/I060&DAE$91M+:UFZ3+
M-N8.4YK=\T)6'4+^D"F/EZUNL6*JECX3AB9<-6V_!QA,1F-K_+Q7@*974)H/
MI0506@BE412M;=4FP[+-(=8?>?8Q*KM<-5B+LR6),S4V4^:M++OF(E(FUGL6
MFFO5--O9,ZUU9@^?YUK0JAZ4YD-I 9060FD416M[MLG ;',(=DH7#,V^H#07
M2O.@-!]*"Z"T$$JC*%K;RTV69@_?J@N&1FQ0F@NE>5":#Z4%4%H(I5$4K6WM
M)FJSC<''L=?'F"DG^WAT>**L9QV> 7.A9;V:]NRRB,.R/K1L *6%4!I%T=KN
M:W(QVQR,?5UQ\CTN)!.$9H6,Y4;J[0<-QJ T%TKSH#0?2@N@M!!*HRA:V\A-
MBF9/WJI#@&9H4)H+I7E0F@^E!5!:"*51%*W]RX F7G->B]=:"?%2\#H?9NIF
MKCS/TK*#T'G;3#[5VU":"Z5Y4)H/I07.82QI]W1]3PBM2U&TMF^;&,XQQW"Z
MWH+\2XZZ,-*,/MFXT%P.2O.@-!]*"Z"T$$JC*%K;W$TNY[Q5+N= <SDHS872
M/"C-A]("*"V$TBB*UK9VD\LYYESNR#,29LK)/CZ,XVSM&0EH64]7UM&=D8"6
M#:"T$$JC*%K;?4W4YIBCMJL')EYI:J&9&I3F0FE>3=MWI]/7NK-_V&'J;!Q
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M=;U25KQ1GI305U,=IR93GN>ITLHK22B;D2EG*F4+8$D*DOQ"/E$A:*$E.8]
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MA,5(,*/Z@Z;Z@U.UDP&F.IBP"!,6(\$,=8:-.D/KL_''"HH5!%N0K-)'0+&
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M<SI:#U2KCD4S?X=KO7I@M[X'^]GA;[CLQ&.?%51:A$J+L6BF-JT[#_Q3];,
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M?MQJF#=@8'D@T]_--;[:>(7LKP-L3?=5"#92O!*QD>)S#8A[WH 1Q^[5QO(
M UL%K'8@OSL/U)2;$X:PJI@W; ?C2!QC"-2BNT:C")F="#[N]<%V21C&L1L!
MS.T@##$$=B..8 [  X:$8?D>W'D?!9OW5-#\AW+\&U!+ P04    "  7@*U:
MEXJ[',     3 @  "P   %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">, ?0(8@S
M9?$6!/D!5J(/V!(%BD6=OZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]$%)I6M6X
M 4BV)8]ISI%"KM0L'C6'TD!$VV-#L%HL/D N&6:WO606IW.D5XA<UYVE/=LO
M3T%O@*\Z3'%":4A+,P[PS=)_,O?S##5%Y4HCE5L:>-/E_G;@2=&A(E@6FD7)
MTZ(=I7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0
M   ( !> K5K*V8Q$K@0  ,LD   /    >&PO=V]R:V)O;VLN>&ULQ9K?;]LV
M$(#_%<(ORX"ZMGXE;5 72).U,Y E1AVTCP,MG6TB$NF1E-/DK]]1;C:JL0]]
MN?K)%D53GRCSOB.I=P_&WB^,N1??FEJ[R6#M_>9\-'+E&AKI7IL-:#RS-+:1
M'@_M:N0V%F3EU@"^J4?I>'PZ:J32@_?OGMN:V5%\8#R47AF-A:'@BX(']__Y
M<"BVRJF%JI5_G RZ[S4,1*.T:M035)/!>"#<VCS\::QZ,MK+>EY:4]>30;([
M\06L5^6+XGF O),+UY5XN?@L$60R.!UC@TMEG>]J=.U+9-P"5MX=M=Y\5+4'
M>R4]?+*FW2B]"LW@78RBV^CZX?ESUXGG]F>ZT2R7JH0K4[8-:+_K1PMU -1N
MK39N(+1L8#*X-%NPX7[P M-J=V\>H:*>LN<*3]AIU>%QHN@*M(-*X#=G:E4A
M1R4^R%KJ$D0$F1*0Z5$@YP$'?QI!9@1D=D3(O],(,B<@\V-"9A%D04 6QX3,
M(\A3 O*4%_+6KJ163]T)(74E;C=@=]4BP#,"\(P7\(-TR@FS%#,+#JMV-5Z)
M:_5/JRKE(\@W!.0;YD=M51?EQ459FE9[C,ABAD^\5!!WXUN"\"TOX7QMK!^B
M-1HQU5MP/M1WW1/_*%4OBH^I,#YF[DC4)2K[O\#=65!,<<#$_9B0IN%7S39(
M':\JKF 1_P,32BX)LUWFWI3W:U-78-UOX@\<'OXQ9J.<DC!+Y0;;O3;.B1E8
M?*;20DQ&B21A-DG7:T,,,EV8;K EUU6*^2B'),P2^1P*D6TFK7\4=U8B7_EC
M>$XH@23,!L%>:U043G!\A/@'^H?@EU 229@M<HG)MUR88+8MB(N5!>B(8S[*
M'PFS0*:Z- V(._FMWV>4,1)F97P"#<:)NS4F!!MH47#N%<JC?!UGTY0L4F99
MS&$5:B#3[N?]89M2DDB9)3&3CV+;A;ONYT%E5\J5M7%M+_:EY'2$V1A3[13:
M(D25*F0L%Q;#R^K%P$@I<Z3,YB#3O]YT)*4TDG)KA$JO^IB435+N*<GA]$J<
MW,D8DU)*RJR4?:E,X$,*]WL,22DE95;*RYQF+R)EE939*H>2F^^@,28EFI19
M-&0&(4[B=1%*-]FOU\V^)YY1WLF8O4.'RWAA)*/,DW'/5<APV<,DE\*8Y4-C
MQBLX&26?[*CR*6),2CX9LWQHS-,8DY)/QBT?$O,LQJ3TDW'/: B5#\4LQJ04
ME'&OC)&8%S$FI:",74']11UQ<@7(7?<B>T[9)^>VS[Z<:"CF;=-(^QCO<.24
M@')F 1W O%TNP:+38TQ*0/D1%LO"_]$/<;H[_"O&I 24<POHP$,/Q>)V$V.2
MNS', MJ3"B,D-ERU.)Y,C$D)*&<6T%[,"\PUAY6JVW@A-Z<$E/^*V<^^K'TH
MOH+J#2%*0#FS@ C,&VGC'86<$E!^K#D0_D/5*EXPRBD!Y<P".KS.VZDHWM&D
M+%1P[\^04[5AC$E9J&#?HR$P>\LQ!66A@OV%@/VKTM^SCQB3LE#!;*&#"\$[
MSAB3LE#!/0W:-S_?D\85Y#L!G8-&SR_/5+!4&JH;O(##\E+6Y<R*\+';[\N+
ML$2_;.OZ$LMN];61U?.[.,_O$;W_%U!+ P04    "  7@*U:O '6P> !  #L
M(   &@   'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QSS=H[3L- %(7AK41>
M )/[F/!00D5#B]B %28/D<269Q#)[HE"$8Y%08/F5-;8\O7?^)-E>_Z2=FW9
M=H>\V?9Y<MSO#GG1;$KI'T+(RTW:M_FFZ]/A?&35#?NVG)?#.O3M\KU=IZ#3
MZ2P,/V<TC_.?,R>OIS[]96*W6FV7Z:E;?NS3H?PR.'QVPWO>I%2:R6L[K%-9
M-.&XN^[.X;*1F_/D9O+\MFB&YS=I0NT@A2"M'V009/6#'(*\?E"$H%@_: 9!
ML_I!MQ!T6S_H#H+NZ@?=0]!]_2"9HHQ3@J01U@1:"W(M!%X+@BT$8@N2+01F
M"Z(M!&H+LBT$;@O"+01R"](M!'8+XBT$>BOJK01Z*^JM!'KKZ&&;0&]%O95
M;T6]E4!O1;V50&]%O95 ;T6]E4!O1;V50&]%O95 ;T.]C4!O0[V-0&]#O8U
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M:X8B:X8B:X8B:X8B:_:?LKX;L_SK%^CM-:UUV1SR6?>5PN034$L! A0#%
M  @ %X"M6D;'34B5    S0   !               ( !     &1O8U!R;W!S
M+V%P<"YX;6Q02P$"% ,4    "  7@*U:C%ROV?$    K @  $0
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M=#(N>&UL4$L! A0#%     @ %X"M6M]0TELP!0  _1,  !@
M ("!P10  'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( !>
MK5IE"; 3#0,  ,P(   8              " @2<:  !X;"]W;W)K<VAE971S
M+W-H965T-"YX;6Q02P$"% ,4    "  7@*U:&Z+J,9('  "*-@  &
M        @(%J'0  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%
M  @ %X"M6J/]!BG1"   *RT  !@              ("!,B4  'AL+W=O<FMS
M:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( !> K5I;L.!*F0<  $80   8
M              " @3DN  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"
M% ,4    "  7@*U:OAO(N*$*  #E'0  &               @($(-@  >&PO
M=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ %X"M6JK2ZP+D!
MK0L  !@              ("!WT   'AL+W=O<FMS:&5E=',O<VAE970Y+GAM
M;%!+ 0(4 Q0    ( !> K5HJ\UC\(PT  *-(   9              " @?E%
M  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ %X"M6KLB
M=FGA @  K08  !D              ("!4U,  'AL+W=O<FMS:&5E=',O<VAE
M970Q,2YX;6Q02P$"% ,4    "  7@*U:%<HH);P#   4"   &0
M    @(%K5@  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    (
M !> K5IUG5NS]PH  &\C   9              " @5Y:  !X;"]W;W)K<VAE
M971S+W-H965T,3,N>&UL4$L! A0#%     @ %X"M6I4XK3VH!0  \0X  !D
M             ("!C&4  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"
M% ,4    "  7@*U:<2<:3:<+  !D)P  &0              @(%K:P  >&PO
M=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( !> K5H4W%'>+ 8
M +\.   9              " @4EW  !X;"]W;W)K<VAE971S+W-H965T,38N
M>&UL4$L! A0#%     @ %X"M6M*UC39I#0  D"4  !D              ("!
MK'T  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4    "  7@*U:
M,GC-!*<)  #W&   &0              @(%,BP  >&PO=V]R:W-H965T<R]S
M:&5E=#$X+GAM;%!+ 0(4 Q0    ( !> K5JH,9W#5P,  % '   9
M      " @2J5  !X;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%
M  @ %X"M6IK;>SZJ P  8P@  !D              ("!N)@  'AL+W=O<FMS
M:&5E=',O<VAE970R,"YX;6Q02P$"% ,4    "  7@*U:+X=<%S,&  #@#
M&0              @(&9G   >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+
M 0(4 Q0    ( !> K5J>>8OG/0(  )$%   9              " @0.C  !X
M;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @ %X"M6A.MA^M$
M @  B@8  !D              ("!=Z4  'AL+W=O<FMS:&5E=',O<VAE970R
M,RYX;6Q02P$"% ,4    "  7@*U:ZK6! 7$0  "',   &0
M@('RIP  >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( !>
MK5H@<FGN3@8  $D3   9              " @9JX  !X;"]W;W)K<VAE971S
M+W-H965T,C4N>&UL4$L! A0#%     @ %X"M6H2D';<? P  <@<  !D
M         ("!'[\  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4
M    "  7@*U:[=0-#,,"  !A!@  &0              @(%UP@  >&PO=V]R
M:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( !> K5IOV7D=" 0  -()
M   9              " @6_%  !X;"]W;W)K<VAE971S+W-H965T,C@N>&UL
M4$L! A0#%     @ %X"M6@-'A@PE P  9@<  !D              ("!KLD
M 'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4    "  7@*U:7OXP
M<@\#  #,!@  &0              @($*S0  >&PO=V]R:W-H965T<R]S:&5E
M=#,P+GAM;%!+ 0(4 Q0    ( !> K5J[?X,(=@0  /,(   9
M  " @5#0  !X;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%     @
M%X"M6LGEW8"Q"   &5<  !D              ("!_=0  'AL+W=O<FMS:&5E
M=',O<VAE970S,BYX;6Q02P$"% ,4    "  7@*U:J%@WKVH%   7(   &0
M            @('EW0  >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4
M Q0    ( !> K5I13ZT=J ,  -P,   9              " @8;C  !X;"]W
M;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @ %X"M6LWB'*V$"
M8T@  !D              ("!9><  'AL+W=O<FMS:&5E=',O<VAE970S-2YX
M;6Q02P$"% ,4    "  7@*U:A_W]W:$#  #1#P  &0              @($@
M\   >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( !> K5I4
M^5.K9 ,  ' (   9              " @?CS  !X;"]W;W)K<VAE971S+W-H
M965T,S<N>&UL4$L! A0#%     @ %X"M6O%A%!^& @  D@8  !D
M     ("!D_<  'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"% ,4
M"  7@*U:?;B5++0"   Z!P  &0              @(%0^@  >&PO=V]R:W-H
M965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    ( !> K5I&OLLPQ ,  (P2   9
M              " @3O]  !X;"]W;W)K<VAE971S+W-H965T-# N>&UL4$L!
M A0#%     @ %X"M6DS(O%(V P  8 T  !D              ("!-@$! 'AL
M+W=O<FMS:&5E=',O<VAE970T,2YX;6Q02P$"% ,4    "  7@*U:!!-!0\(#
M  "7$@  &0              @(&C! $ >&PO=V]R:W-H965T<R]S:&5E=#0R
M+GAM;%!+ 0(4 Q0    ( !> K5KAD$Q,PP0  /\;   9              "
M@9P( 0!X;"]W;W)K<VAE971S+W-H965T-#,N>&UL4$L! A0#%     @ %X"M
M6@['S6,9!0  ER(  !D              ("!E@T! 'AL+W=O<FMS:&5E=',O
M<VAE970T-"YX;6Q02P$"% ,4    "  7@*U:.6.G>7D#  "%#   &0
M        @('F$@$ >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4 Q0
M   ( !> K5K!6-1>^@,  +X4   9              " @986 0!X;"]W;W)K
M<VAE971S+W-H965T-#8N>&UL4$L! A0#%     @ %X"M6B,M>_S[ @  +@@
M !D              ("!QQH! 'AL+W=O<FMS:&5E=',O<VAE970T-RYX;6Q0
M2P$"% ,4    "  7@*U:+.YL6YD)   F5P  &0              @('Y'0$
M>&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4 Q0    ( !> K5I%6WDV
MP@(  *X&   9              " @<DG 0!X;"]W;W)K<VAE971S+W-H965T
M-#DN>&UL4$L! A0#%     @ %X"M6A9$*.)I!P  "DT  !D
M ("!PBH! 'AL+W=O<FMS:&5E=',O<VAE970U,"YX;6Q02P$"% ,4    "  7
M@*U:8J]2VPT%  # )   &0              @(%B,@$ >&PO=V]R:W-H965T
M<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0    ( !> K5K87B"<LP,  "(.   9
M          " @:8W 0!X;"]W;W)K<VAE971S+W-H965T-3(N>&UL4$L! A0#
M%     @ %X"M6D^"]:(J!0  Y"$  !D              ("!D#L! 'AL+W=O
M<FMS:&5E=',O<VAE970U,RYX;6Q02P$"% ,4    "  7@*U:!-RCUXX"  #O
M!@  &0              @('Q0 $ >&PO=V]R:W-H965T<R]S:&5E=#4T+GAM
M;%!+ 0(4 Q0    ( !> K5I*[D*Q20<  -LH   9              " @;9#
M 0!X;"]W;W)K<VAE971S+W-H965T-34N>&UL4$L! A0#%     @ %X"M6C*U
M8"!! P  KA0   T              ( !-DL! 'AL+W-T>6QE<RYX;6Q02P$"
M% ,4    "  7@*U:EXJ[',     3 @  "P              @ &B3@$ 7W)E
M;',O+G)E;'-02P$"% ,4    "  7@*U:RMF,1*X$  #+)   #P
M    @ &+3P$ >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ %X"M6KP!UL'@
M 0  ["   !H              ( !9E0! 'AL+U]R96QS+W=O<FMB;V]K+GAM
M;"YR96QS4$L! A0#%     @ %X"M6A34<>30 0  K2   !,
M ( !?E8! %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     #\ /P P$0  ?U@!
#

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>204</ContextCount>
  <ElementCount>249</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>73</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="ino-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ino-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>9952151 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ino-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>9952152 - Statement - Condensed Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations</Role>
      <ShortName>Condensed Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ino-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>9952153 - Statement - Condensed Consolidated Statements of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ino-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>9952154 - Statement - Condensed Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ino-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>9952155 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ino-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>9952156 - Disclosure - Organization and Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/OrganizationandOperations</Role>
      <ShortName>Organization and Operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ino-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>9952157 - Disclosure - Basis of Presentation, Liquidity and Risks and Uncertainties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertainties</Role>
      <ShortName>Basis of Presentation, Liquidity and Risks and Uncertainties</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ino-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>9952158 - Disclosure - Critical Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CriticalAccountingPolicies</Role>
      <ShortName>Critical Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ino-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>9952159 - Disclosure - Short-term Investments and Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurements</Role>
      <ShortName>Short-term Investments and Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ino-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>9952160 - Disclosure - Certain Balance Sheet Items</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CertainBalanceSheetItems</Role>
      <ShortName>Certain Balance Sheet Items</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ino-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>9952161 - Disclosure - Convertible Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ConvertibleDebt</Role>
      <ShortName>Convertible Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ino-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>9952162 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ino-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>9952163 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/NetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ino-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>9952164 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ino-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>9952165 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ino-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>9952166 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ino-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>9952167 - Disclosure - Collaborative Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CollaborativeAgreements</Role>
      <ShortName>Collaborative Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="ino-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>9952168 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="ino-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>9952169 - Disclosure - Geneos Therapeutics, Inc.</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/GeneosTherapeuticsInc</Role>
      <ShortName>Geneos Therapeutics, Inc.</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="ino-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>9952170 - Disclosure - Segment Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/SegmentInformation</Role>
      <ShortName>Segment Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="ino-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="ino-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="ino-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>9955511 - Disclosure - Basis of Presentation, Liquidity and Risks and Uncertainties (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesPolicies</Role>
      <ShortName>Basis of Presentation, Liquidity and Risks and Uncertainties (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.inovio.com/role/CriticalAccountingPolicies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="ino-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>9955512 - Disclosure - Short-term Investments and Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsTables</Role>
      <ShortName>Short-term Investments and Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurements</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="ino-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>9955513 - Disclosure - Certain Balance Sheet Items (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CertainBalanceSheetItemsTables</Role>
      <ShortName>Certain Balance Sheet Items (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inovio.com/role/CertainBalanceSheetItems</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="ino-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>9955514 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inovio.com/role/StockholdersEquity</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="ino-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>9955515 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/NetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inovio.com/role/NetLossPerShare</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="ino-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>9955516 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inovio.com/role/StockBasedCompensation</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="ino-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>9955517 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CommitmentsandContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inovio.com/role/CommitmentsandContingencies</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="ino-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>9955518 - Disclosure - Segment Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/SegmentInformationTables</Role>
      <ShortName>Segment Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inovio.com/role/SegmentInformation</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="ino-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>9955519 - Disclosure - Basis of Presentation, Liquidity and Risks and Uncertainties (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails</Role>
      <ShortName>Basis of Presentation, Liquidity and Risks and Uncertainties (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesPolicies</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="ino-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>9955520 - Disclosure - Short-term Investments and Fair Value Measurements - Summary of Available-for-sale Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails</Role>
      <ShortName>Short-term Investments and Fair Value Measurements - Summary of Available-for-sale Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="ino-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>9955521 - Disclosure - Short-term Investments and Fair Value Measurements - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails</Role>
      <ShortName>Short-term Investments and Fair Value Measurements - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="ino-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>9955522 - Disclosure - Short-term Investments and Fair Value Measurements - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails</Role>
      <ShortName>Short-term Investments and Fair Value Measurements - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="ino-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9955523 - Disclosure - Short-term Investments and Fair Value Measurements - Schedule of Assumptions Used To Estimate The Fair Value Of Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAssumptionsUsedToEstimateTheFairValueOfWarrantsDetails</Role>
      <ShortName>Short-term Investments and Fair Value Measurements - Schedule of Assumptions Used To Estimate The Fair Value Of Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="ino-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9955524 - Disclosure - Short-term Investments and Fair Value Measurements - Changes In Fair Value Of The Company???s Total Level 3 Financial Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsChangesInFairValueOfTheCompanysTotalLevel3FinancialLiabilitiesDetails</Role>
      <ShortName>Short-term Investments and Fair Value Measurements - Changes In Fair Value Of The Company???s Total Level 3 Financial Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="ino-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9955525 - Disclosure - Certain Balance Sheet Items - Prepaid and Other Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CertainBalanceSheetItemsPrepaidandOtherCurrentAssetsDetails</Role>
      <ShortName>Certain Balance Sheet Items - Prepaid and Other Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="ino-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9955526 - Disclosure - Certain Balance Sheet Items - Accounts Payable and Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CertainBalanceSheetItemsAccountsPayableandAccruedExpensesDetails</Role>
      <ShortName>Certain Balance Sheet Items - Accounts Payable and Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="ino-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>9955527 - Disclosure - Convertible Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ConvertibleDebtDetails</Role>
      <ShortName>Convertible Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inovio.com/role/ConvertibleDebt</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="ino-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>9955528 - Disclosure - Stockholders' Equity - Summary of Authorized and Issued Common and Preferred Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails</Role>
      <ShortName>Stockholders' Equity - Summary of Authorized and Issued Common and Preferred Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="ino-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>9955529 - Disclosure - Stockholders' Equity - Offering of Common Stock, Warrants, and Pre-funded Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/StockholdersEquityOfferingofCommonStockWarrantsandPrefundedWarrantsDetails</Role>
      <ShortName>Stockholders' Equity - Offering of Common Stock, Warrants, and Pre-funded Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="ino-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>9955530 - Disclosure - Stockholders' Equity - At-The-Market Sales Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/StockholdersEquityAtTheMarketSalesAgreementsDetails</Role>
      <ShortName>Stockholders' Equity - At-The-Market Sales Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="ino-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>9955531 - Disclosure - Stockholders' Equity - Stock Options and Restricted Stock Units (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/StockholdersEquityStockOptionsandRestrictedStockUnitsDetails</Role>
      <ShortName>Stockholders' Equity - Stock Options and Restricted Stock Units (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="ino-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>9955532 - Disclosure - Net Loss Per Share - Schedule of Basic and Diluted Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/NetLossPerShareScheduleofBasicandDilutedNetLossPerShareDetails</Role>
      <ShortName>Net Loss Per Share - Schedule of Basic and Diluted Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="ino-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>9955533 - Disclosure - Net Loss Per Share - Anti-dilutive (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/NetLossPerShareAntidilutiveDetails</Role>
      <ShortName>Net Loss Per Share - Anti-dilutive (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="ino-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>9955534 - Disclosure - Stock-Based Compensation - Weighted Average Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/StockBasedCompensationWeightedAverageAssumptionsDetails</Role>
      <ShortName>Stock-Based Compensation - Weighted Average Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="ino-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>9955535 - Disclosure - Stock-Based Compensation - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/StockBasedCompensationNarrativeDetails</Role>
      <ShortName>Stock-Based Compensation - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="ino-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>9955536 - Disclosure - Stock-Based Compensation - Significant Assumption Used in Monte Carlo Simulation Method (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/StockBasedCompensationSignificantAssumptionUsedinMonteCarloSimulationMethodDetails</Role>
      <ShortName>Stock-Based Compensation - Significant Assumption Used in Monte Carlo Simulation Method (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="ino-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>9955537 - Disclosure - Related Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/RelatedPartyTransactionsDetails</Role>
      <ShortName>Related Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inovio.com/role/RelatedPartyTransactions</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="ino-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>9955538 - Disclosure - Commitments and Contingencies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails</Role>
      <ShortName>Commitments and Contingencies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="ino-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>9955539 - Disclosure - Commitments and Contingencies - Summary of Future Minimum Lease Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CommitmentsandContingenciesSummaryofFutureMinimumLeasePaymentsDetails</Role>
      <ShortName>Commitments and Contingencies - Summary of Future Minimum Lease Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="ino-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>9955540 - Disclosure - Collaborative Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CollaborativeAgreementsDetails</Role>
      <ShortName>Collaborative Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inovio.com/role/CollaborativeAgreements</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="ino-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>9955541 - Disclosure - Geneos Therapeutics, Inc. (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/GeneosTherapeuticsIncDetails</Role>
      <ShortName>Geneos Therapeutics, Inc. (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inovio.com/role/GeneosTherapeuticsInc</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="ino-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>9955542 - Disclosure - Segment Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/SegmentInformationDetails</Role>
      <ShortName>Segment Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inovio.com/role/SegmentInformationTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="ino-20250331.htm">ino-20250331.htm</File>
    <File>ino-20250331.xsd</File>
    <File>ino-20250331_cal.xml</File>
    <File>ino-20250331_def.xml</File>
    <File>ino-20250331_lab.xml</File>
    <File>ino-20250331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>ino-20250331_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="521">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="30">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>73
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ino-20250331.htm": {
   "nsprefix": "ino",
   "nsuri": "http://www.inovio.com/20250331",
   "dts": {
    "inline": {
     "local": [
      "ino-20250331.htm"
     ]
    },
    "schema": {
     "local": [
      "ino-20250331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "ino-20250331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "ino-20250331_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "ino-20250331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ino-20250331_pre.xml"
     ]
    }
   },
   "keyStandard": 204,
   "keyCustom": 45,
   "axisStandard": 24,
   "axisCustom": 1,
   "memberStandard": 29,
   "memberCustom": 38,
   "hidden": {
    "total": 6,
    "http://xbrl.sec.gov/dei/2024": 5,
    "http://fasb.org/us-gaap/2024": 1
   },
   "contextCount": 204,
   "entityCount": 1,
   "segmentCount": 73,
   "elementCount": 542,
   "unitCount": 8,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 521,
    "http://xbrl.sec.gov/dei/2024": 30,
    "http://xbrl.sec.gov/ecd/2024": 4
   },
   "report": {
    "R1": {
     "role": "http://www.inovio.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets",
     "longName": "9952151 - Statement - Condensed Consolidated Balance Sheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations",
     "longName": "9952152 - Statement - Condensed Consolidated Statements of Operations",
     "shortName": "Condensed Consolidated Statements of Operations",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20250331.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.inovio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss",
     "longName": "9952153 - Statement - Condensed Consolidated Statements of Comprehensive Loss",
     "shortName": "Condensed Consolidated Statements of Comprehensive Loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ComprehensiveIncomeNetOfTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20250331.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
     "longName": "9952154 - Statement - Condensed Consolidated Statements of Stockholders' Equity",
     "shortName": "Condensed Consolidated Statements of Stockholders' Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c-24",
      "name": "us-gaap:SharesIssued",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-24",
      "name": "us-gaap:SharesIssued",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows",
     "longName": "9952155 - Statement - Condensed Consolidated Statements of Cash Flows",
     "shortName": "Condensed Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:Depreciation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20250331.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.inovio.com/role/OrganizationandOperations",
     "longName": "9952156 - Disclosure - Organization and Operations",
     "shortName": "Organization and Operations",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertainties",
     "longName": "9952157 - Disclosure - Basis of Presentation, Liquidity and Risks and Uncertainties",
     "shortName": "Basis of Presentation, Liquidity and Risks and Uncertainties",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.inovio.com/role/CriticalAccountingPolicies",
     "longName": "9952158 - Disclosure - Critical Accounting Policies",
     "shortName": "Critical Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurements",
     "longName": "9952159 - Disclosure - Short-term Investments and Fair Value Measurements",
     "shortName": "Short-term Investments and Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.inovio.com/role/CertainBalanceSheetItems",
     "longName": "9952160 - Disclosure - Certain Balance Sheet Items",
     "shortName": "Certain Balance Sheet Items",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OtherCurrentAssetsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OtherCurrentAssetsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.inovio.com/role/ConvertibleDebt",
     "longName": "9952161 - Disclosure - Convertible Debt",
     "shortName": "Convertible Debt",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.inovio.com/role/StockholdersEquity",
     "longName": "9952162 - Disclosure - Stockholders' Equity",
     "shortName": "Stockholders' Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.inovio.com/role/NetLossPerShare",
     "longName": "9952163 - Disclosure - Net Loss Per Share",
     "shortName": "Net Loss Per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.inovio.com/role/StockBasedCompensation",
     "longName": "9952164 - Disclosure - Stock-Based Compensation",
     "shortName": "Stock-Based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.inovio.com/role/RelatedPartyTransactions",
     "longName": "9952165 - Disclosure - Related Party Transactions",
     "shortName": "Related Party Transactions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.inovio.com/role/CommitmentsandContingencies",
     "longName": "9952166 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.inovio.com/role/CollaborativeAgreements",
     "longName": "9952167 - Disclosure - Collaborative Agreements",
     "shortName": "Collaborative Agreements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.inovio.com/role/IncomeTaxes",
     "longName": "9952168 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.inovio.com/role/GeneosTherapeuticsInc",
     "longName": "9952169 - Disclosure - Geneos Therapeutics, Inc.",
     "shortName": "Geneos Therapeutics, Inc.",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.inovio.com/role/SegmentInformation",
     "longName": "9952170 - Disclosure - Segment Information",
     "shortName": "Segment Information",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20250331.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R23": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesPolicies",
     "longName": "9955511 - Disclosure - Basis of Presentation, Liquidity and Risks and Uncertainties (Policies)",
     "shortName": "Basis of Presentation, Liquidity and Risks and Uncertainties (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsTables",
     "longName": "9955512 - Disclosure - Short-term Investments and Fair Value Measurements (Tables)",
     "shortName": "Short-term Investments and Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.inovio.com/role/CertainBalanceSheetItemsTables",
     "longName": "9955513 - Disclosure - Certain Balance Sheet Items (Tables)",
     "shortName": "Certain Balance Sheet Items (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ino:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ino:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.inovio.com/role/StockholdersEquityTables",
     "longName": "9955514 - Disclosure - Stockholders' Equity (Tables)",
     "shortName": "Stockholders' Equity (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfStockByClassTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfStockByClassTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.inovio.com/role/NetLossPerShareTables",
     "longName": "9955515 - Disclosure - Net Loss Per Share (Tables)",
     "shortName": "Net Loss Per Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.inovio.com/role/StockBasedCompensationTables",
     "longName": "9955516 - Disclosure - Stock-Based Compensation (Tables)",
     "shortName": "Stock-Based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.inovio.com/role/CommitmentsandContingenciesTables",
     "longName": "9955517 - Disclosure - Commitments and Contingencies (Tables)",
     "shortName": "Commitments and Contingencies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.inovio.com/role/SegmentInformationTables",
     "longName": "9955518 - Disclosure - Segment Information (Tables)",
     "shortName": "Segment Information (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails",
     "longName": "9955519 - Disclosure - Basis of Presentation, Liquidity and Risks and Uncertainties (Details)",
     "shortName": "Basis of Presentation, Liquidity and Risks and Uncertainties (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "ino:WorkingCapital",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20250331.htm",
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails",
     "longName": "9955520 - Disclosure - Short-term Investments and Fair Value Measurements - Summary of Available-for-sale Securities (Details)",
     "shortName": "Short-term Investments and Fair Value Measurements - Summary of Available-for-sale Securities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails",
     "longName": "9955521 - Disclosure - Short-term Investments and Fair Value Measurements - Narrative (Details)",
     "shortName": "Short-term Investments and Fair Value Measurements - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleRealizedGain",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleRealizedGain",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
     "longName": "9955522 - Disclosure - Short-term Investments and Fair Value Measurements - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)",
     "shortName": "Short-term Investments and Fair Value Measurements - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-73",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20250331.htm",
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAssumptionsUsedToEstimateTheFairValueOfWarrantsDetails",
     "longName": "9955523 - Disclosure - Short-term Investments and Fair Value Measurements - Schedule of Assumptions Used To Estimate The Fair Value Of Warrants (Details)",
     "shortName": "Short-term Investments and Fair Value Measurements - Schedule of Assumptions Used To Estimate The Fair Value Of Warrants (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c-94",
      "name": "ino:WarrantLiabilityMeasurementInput",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-94",
      "name": "ino:WarrantLiabilityMeasurementInput",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsChangesInFairValueOfTheCompanysTotalLevel3FinancialLiabilitiesDetails",
     "longName": "9955524 - Disclosure - Short-term Investments and Fair Value Measurements - Changes In Fair Value Of The Company\u2019s Total Level 3 Financial Liabilities (Details)",
     "shortName": "Short-term Investments and Fair Value Measurements - Changes In Fair Value Of The Company\u2019s Total Level 3 Financial Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.inovio.com/role/CertainBalanceSheetItemsPrepaidandOtherCurrentAssetsDetails",
     "longName": "9955525 - Disclosure - Certain Balance Sheet Items - Prepaid and Other Current Assets (Details)",
     "shortName": "Certain Balance Sheet Items - Prepaid and Other Current Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "ino:PrepaidClinicalExpensesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ino:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "ino:PrepaidClinicalExpensesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ino:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.inovio.com/role/CertainBalanceSheetItemsAccountsPayableandAccruedExpensesDetails",
     "longName": "9955526 - Disclosure - Certain Balance Sheet Items - Accounts Payable and Accrued Expenses (Details)",
     "shortName": "Certain Balance Sheet Items - Accounts Payable and Accrued Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:AccountsPayableTradeCurrentAndNoncurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:AccountsPayableTradeCurrentAndNoncurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.inovio.com/role/ConvertibleDebtDetails",
     "longName": "9955527 - Disclosure - Convertible Debt (Details)",
     "shortName": "Convertible Debt (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RepaymentsOfConvertibleDebt",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-102",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20250331.htm",
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails",
     "longName": "9955528 - Disclosure - Stockholders' Equity - Summary of Authorized and Issued Common and Preferred Stock (Details)",
     "shortName": "Stockholders' Equity - Summary of Authorized and Issued Common and Preferred Stock (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockByClassTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockByClassTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20250331.htm",
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.inovio.com/role/StockholdersEquityOfferingofCommonStockWarrantsandPrefundedWarrantsDetails",
     "longName": "9955529 - Disclosure - Stockholders' Equity - Offering of Common Stock, Warrants, and Pre-funded Warrants (Details)",
     "shortName": "Stockholders' Equity - Offering of Common Stock, Warrants, and Pre-funded Warrants (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c-109",
      "name": "ino:ClassOfWarrantOrRightCommonStockOwnershipPercent",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-109",
      "name": "ino:ClassOfWarrantOrRightCommonStockOwnershipPercent",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.inovio.com/role/StockholdersEquityAtTheMarketSalesAgreementsDetails",
     "longName": "9955530 - Disclosure - Stockholders' Equity - At-The-Market Sales Agreements (Details)",
     "shortName": "Stockholders' Equity - At-The-Market Sales Agreements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c-110",
      "name": "ino:StockSalesAgreementMaximumAuthorizedAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-110",
      "name": "ino:StockSalesAgreementMaximumAuthorizedAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.inovio.com/role/StockholdersEquityStockOptionsandRestrictedStockUnitsDetails",
     "longName": "9955531 - Disclosure - Stockholders' Equity - Stock Options and Restricted Stock Units (Details)",
     "shortName": "Stockholders' Equity - Stock Options and Restricted Stock Units (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c-114",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-114",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.inovio.com/role/NetLossPerShareScheduleofBasicandDilutedNetLossPerShareDetails",
     "longName": "9955532 - Disclosure - Net Loss Per Share - Schedule of Basic and Diluted Net Loss Per Share (Details)",
     "shortName": "Net Loss Per Share - Schedule of Basic and Diluted Net Loss Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ino:WeightedAverageNumberOfSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20250331.htm",
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.inovio.com/role/NetLossPerShareAntidilutiveDetails",
     "longName": "9955533 - Disclosure - Net Loss Per Share - Anti-dilutive (Details)",
     "shortName": "Net Loss Per Share - Anti-dilutive (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.inovio.com/role/StockBasedCompensationWeightedAverageAssumptionsDetails",
     "longName": "9955534 - Disclosure - Stock-Based Compensation - Weighted Average Assumptions (Details)",
     "shortName": "Stock-Based Compensation - Weighted Average Assumptions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c-133",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-133",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.inovio.com/role/StockBasedCompensationNarrativeDetails",
     "longName": "9955535 - Disclosure - Stock-Based Compensation - Narrative (Details)",
     "shortName": "Stock-Based Compensation - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20250331.htm",
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.inovio.com/role/StockBasedCompensationSignificantAssumptionUsedinMonteCarloSimulationMethodDetails",
     "longName": "9955536 - Disclosure - Stock-Based Compensation - Significant Assumption Used in Monte Carlo Simulation Method (Details)",
     "shortName": "Stock-Based Compensation - Significant Assumption Used in Monte Carlo Simulation Method (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c-148",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-148",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.inovio.com/role/RelatedPartyTransactionsDetails",
     "longName": "9955537 - Disclosure - Related Party Transactions (Details)",
     "shortName": "Related Party Transactions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-161",
      "name": "ino:CollaborativeAgreementExpensesToReimburse",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20250331.htm",
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails",
     "longName": "9955538 - Disclosure - Commitments and Contingencies - Narrative (Details)",
     "shortName": "Commitments and Contingencies - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LeaseCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LeaseCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofFutureMinimumLeasePaymentsDetails",
     "longName": "9955539 - Disclosure - Commitments and Contingencies - Summary of Future Minimum Lease Payments (Details)",
     "shortName": "Commitments and Contingencies - Summary of Future Minimum Lease Payments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.inovio.com/role/CollaborativeAgreementsDetails",
     "longName": "9955540 - Disclosure - Collaborative Agreements (Details)",
     "shortName": "Collaborative Agreements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-180",
      "name": "ino:CollaborationAgreementAdditionalRevenueToBeAchieved",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20250331.htm",
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.inovio.com/role/GeneosTherapeuticsIncDetails",
     "longName": "9955541 - Disclosure - Geneos Therapeutics, Inc. (Details)",
     "shortName": "Geneos Therapeutics, Inc. (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c-189",
      "name": "us-gaap:MinorityInterestOwnershipPercentageByParent",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-189",
      "name": "us-gaap:MinorityInterestOwnershipPercentageByParent",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.inovio.com/role/SegmentInformationDetails",
     "longName": "9955542 - Disclosure - Segment Information (Details)",
     "shortName": "Segment Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfReportableSegments",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfReportableSegments",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20250331.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "ino_A2007IncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20250331",
     "localname": "A2007IncentivePlanMember",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityStockOptionsandRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2007 Incentive Plan",
        "label": "2007 Incentive Plan [Member]",
        "documentation": "2007 Incentive Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ino_A2016IncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20250331",
     "localname": "A2016IncentivePlanMember",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityStockOptionsandRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2016 Incentive Plan",
        "label": "2016 Incentive Plan [Member]",
        "documentation": "2016 Incentive Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ino_A2021SalesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20250331",
     "localname": "A2021SalesAgreementMember",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityAtTheMarketSalesAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2021 Sales Agreement",
        "label": "2021 Sales Agreement [Member]",
        "documentation": "2021 Sales Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "ino_A2022InducementPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20250331",
     "localname": "A2022InducementPlanMember",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityStockOptionsandRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2022 Inducement Plan",
        "label": "2022 Inducement Plan [Member]",
        "documentation": "2022 Inducement Plan"
       }
      }
     },
     "auth_ref": []
    },
    "ino_A2023IncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20250331",
     "localname": "A2023IncentivePlanMember",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityStockOptionsandRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2023 Incentive Plan",
        "label": "2023 Incentive Plan [Member]",
        "documentation": "2023 Incentive Plan"
       }
      }
     },
     "auth_ref": []
    },
    "ino_A2024SalesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20250331",
     "localname": "A2024SalesAgreementMember",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails",
      "http://www.inovio.com/role/StockholdersEquityAtTheMarketSalesAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024 Sales Agreement",
        "label": "2024 Sales Agreement [Member]",
        "documentation": "2024 Sales Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "ino_A6.50ConvertibleSeniorNotesDue2024Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20250331",
     "localname": "A6.50ConvertibleSeniorNotesDue2024Member",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "6.50% Convertible Senior Notes Due 2024",
        "label": "6.50% Convertible Senior Notes Due 2024 [Member]",
        "documentation": "6.50% Convertible Senior Notes Due 2024 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting Policies [Abstract]",
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ino_AccountsPayableAndAccruedExpensesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inovio.com/20250331",
     "localname": "AccountsPayableAndAccruedExpensesLineItems",
     "presentation": [
      "http://www.inovio.com/role/CertainBalanceSheetItemsAccountsPayableandAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts Payable and Accrued Expenses [Line Items]",
        "label": "Accounts Payable and Accrued Expenses [Line Items]",
        "documentation": "Accounts Payable and Accrued Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "ino_AccountsPayableAndAccruedExpensesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inovio.com/20250331",
     "localname": "AccountsPayableAndAccruedExpensesTable",
     "presentation": [
      "http://www.inovio.com/role/CertainBalanceSheetItemsAccountsPayableandAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts Payable and Accrued Expenses [Table]",
        "label": "Accounts Payable and Accrued Expenses [Table]",
        "documentation": "Accounts Payable and Accrued Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.inovio.com/role/CertainBalanceSheetItemsAccountsPayableandAccruedExpensesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CertainBalanceSheetItemsAccountsPayableandAccruedExpensesDetails",
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accounts payable and accrued expenses",
        "totalLabel": "Total",
        "terseLabel": "Accounts payable and accrued liabilities, current",
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r52"
     ]
    },
    "us-gaap_AccountsPayableTradeCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableTradeCurrentAndNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/CertainBalanceSheetItemsAccountsPayableandAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CertainBalanceSheetItemsAccountsPayableandAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade accounts payable",
        "label": "Accounts Payable, Trade",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r95"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accounts receivable from affiliated entity",
        "terseLabel": "Accounts receivable",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r951"
     ]
    },
    "ino_AccruedClinicalTrialExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20250331",
     "localname": "AccruedClinicalTrialExpenseCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accrued clinical trial expenses",
        "label": "Accrued Clinical Trial Expense, Current",
        "documentation": "Accrued Clinical Trial Expense, Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedSalariesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedSalariesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/CertainBalanceSheetItemsAccountsPayableandAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CertainBalanceSheetItemsAccountsPayableandAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued compensation",
        "label": "Accrued Salaries, Current",
        "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r759"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accumulated other comprehensive loss",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r14",
      "r66",
      "r132",
      "r601",
      "r642",
      "r646"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive loss",
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r9",
      "r14",
      "r469",
      "r472",
      "r542",
      "r637",
      "r638",
      "r925",
      "r926",
      "r927",
      "r938",
      "r939",
      "r940",
      "r941"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional 402(v) Disclosure",
        "label": "Additional 402(v) Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r861"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r804",
      "r1064"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r661",
      "r938",
      "r939",
      "r940",
      "r941",
      "r1005",
      "r1065"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation, Amount",
        "label": "Adjustment to Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r874"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation:",
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r874"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote",
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r874"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment To PEO Compensation, Footnote",
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r874"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r42",
      "r388"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_AffiliatedEntityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "AffiliatedEntityMember",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Affiliated Entity",
        "label": "Affiliated Entity [Member]"
       }
      }
     },
     "auth_ref": [
      "r703",
      "r751",
      "r817",
      "r978",
      "r1019",
      "r1020",
      "r1022"
     ]
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table",
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r907"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Amount",
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r833",
      "r843",
      "r853",
      "r885"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined",
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r836",
      "r846",
      "r856",
      "r888"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Pension Adjustments Service Cost",
        "label": "Aggregate Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r908"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Adjustments to Compensation",
        "label": "All Adjustments to Compensation [Member]"
       }
      }
     },
     "auth_ref": [
      "r874"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Executive Categories",
        "label": "All Executive Categories [Member]"
       }
      }
     },
     "auth_ref": [
      "r881"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Individuals",
        "label": "All Individuals [Member]"
       }
      }
     },
     "auth_ref": [
      "r837",
      "r847",
      "r857",
      "r881",
      "r889",
      "r893",
      "r901"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Trading Arrangements",
        "label": "All Trading Arrangements [Member]"
       }
      }
     },
     "auth_ref": [
      "r899"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Allocated share-based compensation expense",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r417",
      "r422"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.inovio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.inovio.com/role/NetLossPerShareAntidilutiveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive securities excluded (in shares)",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r188"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.inovio.com/role/NetLossPerShareAntidilutiveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities [Axis]",
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.inovio.com/role/NetLossPerShareAntidilutiveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.inovio.com/role/NetLossPerShareAntidilutiveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities, Name [Domain]",
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "ino_ApolloBioMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20250331",
     "localname": "ApolloBioMember",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ApolloBio",
        "label": "ApolloBio [Member]",
        "documentation": "ApolloBio [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r459"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r105",
      "r127",
      "r154",
      "r193",
      "r201",
      "r219",
      "r223",
      "r268",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r460",
      "r462",
      "r514",
      "r597",
      "r696",
      "r770",
      "r771",
      "r804",
      "r824",
      "r972",
      "r973",
      "r1023"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "ASSETS",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r133",
      "r154",
      "r268",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r460",
      "r462",
      "r514",
      "r804",
      "r972",
      "r973",
      "r1023"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Current assets:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets measured at fair value",
        "label": "Assets, Fair Value Disclosure",
        "documentation": "Fair value portion of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r489",
      "r490",
      "r792"
     ]
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsFairValueDisclosureAbstract",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets:",
        "label": "Assets, Fair Value Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Gross\u00a0Unrealized Gains",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r239"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Gross\u00a0Unrealized Losses",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r240"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Cost",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r236",
      "r284",
      "r596"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleSecuritiesAbstract",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Debt Securities, Available-for-sale [Abstract]",
        "label": "Debt Securities, Available-for-Sale [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair\u00a0Market\u00a0Value",
        "netLabel": "Short-term investments",
        "label": "Debt Securities, Available-for-Sale",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r237",
      "r284",
      "r489",
      "r589",
      "r792",
      "r795",
      "r952",
      "r1009",
      "r1010",
      "r1011"
     ]
    },
    "us-gaap_AwardDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardDateAxis",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Date [Axis]",
        "label": "Award Date [Axis]",
        "documentation": "Information by date or year award under share-based payment arrangement is granted."
       }
      }
     },
     "auth_ref": [
      "r979",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994",
      "r995",
      "r996",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1002",
      "r1003",
      "r1004"
     ]
    },
    "us-gaap_AwardDateDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardDateDomain",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Date [Domain]",
        "label": "Award Date [Domain]",
        "documentation": "Date or year award under share-based payment arrangement is granted."
       }
      }
     },
     "auth_ref": [
      "r979",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994",
      "r995",
      "r996",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1002",
      "r1003",
      "r1004"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price",
        "label": "Award Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r896"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value as of Grant Date",
        "label": "Award Grant Date Fair Value"
       }
      }
     },
     "auth_ref": [
      "r897"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r892"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing, How MNPI Considered",
        "label": "Award Timing, How MNPI Considered [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r892"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Method",
        "label": "Award Timing Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r892"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Considered",
        "label": "Award Timing MNPI Considered [Flag]"
       }
      }
     },
     "auth_ref": [
      "r892"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Disclosure",
        "label": "Award Timing MNPI Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r892"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Predetermined",
        "label": "Award Timing Predetermined [Flag]"
       }
      }
     },
     "auth_ref": [
      "r892"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.inovio.com/role/StockBasedCompensationSignificantAssumptionUsedinMonteCarloSimulationMethodDetails",
      "http://www.inovio.com/role/StockBasedCompensationWeightedAverageAssumptionsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Axis]",
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Securities",
        "label": "Award Underlying Securities Amount"
       }
      }
     },
     "auth_ref": [
      "r895"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r894"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures",
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r893"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table",
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r893"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Presentation and Liquidity",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "ino_BillAndMelindaGatesFoundationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20250331",
     "localname": "BillAndMelindaGatesFoundationMember",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bill and Melinda Gates Foundation",
        "label": "Bill And Melinda Gates Foundation [Member]",
        "documentation": "Bill And Melinda Gates Foundation [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertainties"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Presentation, Liquidity and Risks and Uncertainties",
        "label": "Business Description and Basis of Presentation [Text Block]",
        "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r78",
      "r79"
     ]
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amounts accrued for purchases of fixed assets",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r19",
      "r20"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r125",
      "r757"
     ]
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "crdr": "debit",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash, cash equivalents, and short-term investments",
        "label": "Cash, Cash Equivalents, and Short-Term Investments",
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable."
       }
      }
     },
     "auth_ref": [
      "r924"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash and cash equivalents, beginning of period",
        "periodEndLabel": "Cash and cash equivalents, end of period",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r75",
      "r150"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "(Decrease) Increase in cash and cash equivalents",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r75"
     ]
    },
    "ino_CertainBalanceSheetItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inovio.com/20250331",
     "localname": "CertainBalanceSheetItemsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Certain Balance Sheet Items [Abstract]",
        "documentation": "Certain Balance Sheet Items"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CertificatesOfDepositMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CertificatesOfDepositMember",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Certificates of deposit",
        "label": "Certificates of Deposit [Member]",
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r818",
      "r819",
      "r820",
      "r821"
     ]
    },
    "ino_ChangeInValueOfInvestmentsInAffiliatedCompany": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20250331",
     "localname": "ChangeInValueOfInvestmentsInAffiliatedCompany",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/SegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Gain (loss) on investment in affiliated entity",
        "negatedLabel": "(Gain) loss on equity investment in affiliated entity",
        "terseLabel": "Gain (loss) on investment in affiliated entity",
        "label": "Change in Value of Investments in Affiliated Company",
        "documentation": "The net result for the period of the change in fair value of the investment in affiliated entity. This investment is measured at fair value on a recurring basis."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changed Peer Group, Footnote",
        "label": "Changed Peer Group, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r872"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year",
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r869"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested",
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r867"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.inovio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails",
      "http://www.inovio.com/role/StockholdersEquityAtTheMarketSalesAgreementsDetails",
      "http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Domain]",
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r129",
      "r130",
      "r131",
      "r154",
      "r182",
      "r183",
      "r185",
      "r187",
      "r195",
      "r196",
      "r268",
      "r321",
      "r323",
      "r324",
      "r325",
      "r328",
      "r329",
      "r358",
      "r359",
      "r362",
      "r365",
      "r372",
      "r514",
      "r652",
      "r653",
      "r654",
      "r655",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r684",
      "r705",
      "r727",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r911",
      "r933",
      "r943"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityAtTheMarketSalesAgreementsDetails",
      "http://www.inovio.com/role/StockholdersEquityStockOptionsandRestrictedStockUnitsDetails",
      "http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Line Items]",
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r130",
      "r131",
      "r195",
      "r358",
      "r359",
      "r360",
      "r362",
      "r365",
      "r370",
      "r372",
      "r652",
      "r653",
      "r654",
      "r655",
      "r783",
      "r911",
      "r933"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails",
      "http://www.inovio.com/role/StockholdersEquityOfferingofCommonStockWarrantsandPrefundedWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Warrant or Right [Axis]",
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "ino_ClassOfWarrantOrRightCommonStockOwnershipMaximumPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.inovio.com/20250331",
     "localname": "ClassOfWarrantOrRightCommonStockOwnershipMaximumPercent",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityOfferingofCommonStockWarrantsandPrefundedWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of warrant or right, common stock ownership, maximum percent",
        "label": "Class Of Warrant Or Right, Common Stock Ownership, Maximum Percent",
        "documentation": "Class Of Warrant Or Right, Common Stock Ownership, Maximum Percent"
       }
      }
     },
     "auth_ref": []
    },
    "ino_ClassOfWarrantOrRightCommonStockOwnershipPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.inovio.com/20250331",
     "localname": "ClassOfWarrantOrRightCommonStockOwnershipPercent",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityOfferingofCommonStockWarrantsandPrefundedWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of warrant or right, common stock ownership (in percent)",
        "label": "Class Of Warrant Or Right, Common Stock Ownership, Percent",
        "documentation": "Class Of Warrant Or Right, Common Stock Ownership, Percent"
       }
      }
     },
     "auth_ref": []
    },
    "ino_ClassOfWarrantOrRightCommonStockOwnershipPriorToIssuancePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.inovio.com/20250331",
     "localname": "ClassOfWarrantOrRightCommonStockOwnershipPriorToIssuancePercent",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityOfferingofCommonStockWarrantsandPrefundedWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of warrant or right, common stock, prior to issuance (percent)",
        "label": "Class Of Warrant Or Right, Common Stock Ownership, Prior To Issuance, Percent",
        "documentation": "Class Of Warrant Or Right, Common Stock Ownership, Prior To Issuance, Percent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails",
      "http://www.inovio.com/role/StockholdersEquityOfferingofCommonStockWarrantsandPrefundedWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Warrant or Right [Domain]",
        "label": "Class of Warrant or Right [Domain]",
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails",
      "http://www.inovio.com/role/StockholdersEquityOfferingofCommonStockWarrantsandPrefundedWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant exercise price (in dollars per share)",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r373"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightLineItems",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityOfferingofCommonStockWarrantsandPrefundedWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Warrant or Right [Line Items]",
        "label": "Class of Warrant or Right [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of securities called by warrants or rights (in shares)",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r373"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightTable",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityOfferingofCommonStockWarrantsandPrefundedWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Warrant or Right [Table]",
        "label": "Class of Warrant or Right [Table]",
        "documentation": "Disclosure of information about warrant or right issued that give holder right to purchase security from issuer at specific price within certain time frame."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Amount",
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r873"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Name",
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r873"
     ]
    },
    "ino_CoalitionforEpidemicPreparednessInnovationsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20250331",
     "localname": "CoalitionforEpidemicPreparednessInnovationsMember",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Coalition for Epidemic Preparedness Innovations",
        "label": "Coalition for Epidemic Preparedness Innovations [Member]",
        "documentation": "Coalition for Epidemic Preparedness Innovations [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ino_CollaborationAgreementAdditionalRevenueToBeAchieved": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20250331",
     "localname": "CollaborationAgreementAdditionalRevenueToBeAchieved",
     "crdr": "credit",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional revenue to be achieved",
        "label": "Collaboration Agreement, Additional Revenue To Be Achieved",
        "documentation": "Collaboration Agreement, Additional Revenue To Be Achieved"
       }
      }
     },
     "auth_ref": []
    },
    "ino_CollaborationAgreementRoyaltyPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.inovio.com/20250331",
     "localname": "CollaborationAgreementRoyaltyPeriod",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty period (in years)",
        "label": "Collaboration Agreement, Royalty Period",
        "documentation": "Collaboration Agreement, Royalty Period"
       }
      }
     },
     "auth_ref": []
    },
    "ino_CollaborativeAgreementAmendedAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20250331",
     "localname": "CollaborativeAgreementAmendedAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative agreement, amended amount",
        "label": "Collaborative Agreement, Amended Amount",
        "documentation": "Collaborative Agreement, Amended Amount"
       }
      }
     },
     "auth_ref": []
    },
    "ino_CollaborativeAgreementAwardedAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20250331",
     "localname": "CollaborativeAgreementAwardedAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awarded amount",
        "label": "Collaborative Agreement, Awarded Amount",
        "documentation": "Collaborative Agreement, Awarded Amount"
       }
      }
     },
     "auth_ref": []
    },
    "ino_CollaborativeAgreementAwardedOptionAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20250331",
     "localname": "CollaborativeAgreementAwardedOptionAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awarded option amount",
        "label": "Collaborative Agreement, Awarded Option Amount",
        "documentation": "Collaborative Agreement, Awarded Option Amount"
       }
      }
     },
     "auth_ref": []
    },
    "ino_CollaborativeAgreementExpensesToReimburse": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20250331",
     "localname": "CollaborativeAgreementExpensesToReimburse",
     "crdr": "debit",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expenses to reimburse",
        "label": "Collaborative Agreement, Expenses To Reimburse",
        "documentation": "Collaborative Agreement, Expenses To Reimburse"
       }
      }
     },
     "auth_ref": []
    },
    "ino_CollaborativeAgreementFundingReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20250331",
     "localname": "CollaborativeAgreementFundingReceived",
     "crdr": "debit",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative agreement, funding received",
        "label": "Collaborative Agreement, Funding Received",
        "documentation": "Collaborative Agreement, Funding Received"
       }
      }
     },
     "auth_ref": []
    },
    "ino_CollaborativeAgreementFundingToBeReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20250331",
     "localname": "CollaborativeAgreementFundingToBeReceived",
     "crdr": "debit",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative agreement, funding to be received",
        "label": "Collaborative Agreement, Funding To Be Received",
        "documentation": "Collaborative Agreement, Funding Received for Research and Development"
       }
      }
     },
     "auth_ref": []
    },
    "ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.inovio.com/20250331",
     "localname": "CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative agreement, period to receive funding for research and development (in years)",
        "label": "Collaborative Agreement, Period to Receive Funding for Research and Development",
        "documentation": "Collaborative Agreement, Period to Receive Funding for Research and Development"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementAccountingPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CollaborativeArrangementAccountingPolicy",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration Agreements and Revenue Recognition",
        "label": "Collaborative Arrangement, Accounting Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for collaborative arrangements."
       }
      }
     },
     "auth_ref": [
      "r110"
     ]
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Agreements",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r109",
      "r112"
     ]
    },
    "us-gaap_CollaborativeArrangementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CollaborativeArrangementMember",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement, Product",
        "label": "Collaborative Arrangement [Member]",
        "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity."
       }
      }
     },
     "auth_ref": [
      "r459"
     ]
    },
    "ino_CollaborativeArrangementTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.inovio.com/20250331",
     "localname": "CollaborativeArrangementTerm",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative arrangement, term (in years)",
        "label": "Collaborative Arrangement, Term",
        "documentation": "Collaborative Arrangement, Term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r459"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r313",
      "r314",
      "r749",
      "r964",
      "r969"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://www.inovio.com/role/StockholdersEquityAtTheMarketSalesAgreementsDetails",
      "http://www.inovio.com/role/StockholdersEquityOfferingofCommonStockWarrantsandPrefundedWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r814",
      "r815",
      "r816",
      "r818",
      "r819",
      "r820",
      "r821",
      "r938",
      "r939",
      "r941",
      "r1005",
      "r1063",
      "r1065"
     ]
    },
    "us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Summary of common and preferred stock authorized, issued and outstanding",
        "label": "Common Stock, Number of Shares, Par Value and Other Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockOtherSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockOtherSharesOutstanding",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityStockOptionsandRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, other shares, outstanding (in shares)",
        "label": "Common Stock, Other Shares, Outstanding",
        "documentation": "Number of shares of other common stock instruments held by shareholder, including, but not limited to, exchangeable shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails",
      "http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value (in dollars per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r60"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares, authorized (in shares)",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r684"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares, issued (in shares)",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r60"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares, outstanding (in shares)",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r60",
      "r684",
      "r702",
      "r1065",
      "r1066"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r600",
      "r804"
     ]
    },
    "ino_CommonStockWarrantLiabilityFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20250331",
     "localname": "CommonStockWarrantLiabilityFairValue",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": {
       "parentTag": "us-gaap_FinancialLiabilitiesFairValueDisclosure",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock warrant liability",
        "label": "Common Stock Warrant Liability, Fair Value",
        "documentation": "Common Stock Warrant Liability, Fair Value"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure",
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r878"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Net Income",
        "label": "Compensation Actually Paid vs. Net Income [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r877"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Other Measure",
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r879"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return",
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r876"
     ]
    },
    "us-gaap_CompensationRelatedCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CompensationRelatedCostsPolicyTextBlock",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-Based Compensation",
        "label": "Compensation Related Costs, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r90"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive loss",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r138",
      "r140",
      "r144",
      "r590",
      "r609",
      "r610"
     ]
    },
    "us-gaap_ConvertibleDebtMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertibleDebtMember",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Debt",
        "label": "Convertible Debt [Member]",
        "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r331",
      "r332",
      "r342",
      "r343",
      "r344",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782"
     ]
    },
    "us-gaap_ConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertiblePreferredStockMember",
     "presentation": [
      "http://www.inovio.com/role/NetLossPerShareAntidilutiveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible preferred stock",
        "label": "Convertible Preferred Stock [Member]",
        "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option."
       }
      }
     },
     "auth_ref": [
      "r358",
      "r359",
      "r362",
      "r818",
      "r819",
      "r820",
      "r821"
     ]
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails",
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Axis]",
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r158",
      "r159",
      "r334",
      "r360",
      "r549",
      "r567",
      "r594",
      "r760",
      "r762"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover [Abstract]",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.inovio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "ino_DNAEncodedMonoclonalAntibodyTechnologyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20250331",
     "localname": "DNAEncodedMonoclonalAntibodyTechnologyMember",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "DNA-Encoded Monoclonal Antibody Technology",
        "label": "DNA-Encoded Monoclonal Antibody Technology [Member]",
        "documentation": "DNA-Encoded Monoclonal Antibody Technology [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Disclosure [Abstract]",
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebt"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Debt",
        "label": "Debt Disclosure [Text Block]",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r152",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r319",
      "r320",
      "r330",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r346",
      "r353",
      "r354",
      "r356",
      "r522"
     ]
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Axis]",
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r51",
      "r52",
      "r94",
      "r96",
      "r160",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r337",
      "r342",
      "r343",
      "r344",
      "r345",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r802",
      "r934",
      "r965",
      "r966",
      "r967",
      "r1015",
      "r1016"
     ]
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, face amount",
        "label": "Debt Instrument, Face Amount",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r331",
      "r522",
      "r523",
      "r779",
      "r780",
      "r802"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt interest based on the fixed rate (in percent)",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r332"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Line Items]",
        "label": "Debt Instrument [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r160",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r337",
      "r342",
      "r343",
      "r344",
      "r345",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r355",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r802",
      "r934",
      "r1015",
      "r1016"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Name [Domain]",
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r160",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r337",
      "r342",
      "r343",
      "r344",
      "r345",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r802",
      "r934",
      "r965",
      "r966",
      "r967",
      "r1015",
      "r1016"
     ]
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "documentation": "Disclosure of information about long-term debt instrument or arrangement."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r34",
      "r37",
      "r49",
      "r86",
      "r87",
      "r160",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r337",
      "r342",
      "r343",
      "r344",
      "r345",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r355",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r802",
      "r934",
      "r1015",
      "r1016"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedGain": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleRealizedGain",
     "crdr": "credit",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Realized gain on investments",
        "label": "Debt Securities, Available-for-Sale, Realized Gain",
        "documentation": "Amount of realized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r265"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleRealizedLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Realized loss on investments",
        "label": "Debt Securities, Available-for-Sale, Realized Loss",
        "documentation": "Amount of realized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r265"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Securities, Available-for-sale [Table]",
        "label": "Debt Securities, Available-for-Sale [Table]",
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of securities in a gross unrealized loss position",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions",
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r286"
     ]
    },
    "ino_DebtSecuritiesAvailableforSaleContractualMaturity": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.inovio.com/20250331",
     "localname": "DebtSecuritiesAvailableforSaleContractualMaturity",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contractual Maturity\u00a0(in\u00a0years)",
        "label": "Debt Securities, Available-for-Sale Contractual Maturity",
        "documentation": "Debt Securities, Available-for-sale contractual maturity."
       }
      }
     },
     "auth_ref": []
    },
    "ino_December2024Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20250331",
     "localname": "December2024Member",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "December 2024",
        "label": "December 2024 [Member]",
        "documentation": "December 2024"
       }
      }
     },
     "auth_ref": []
    },
    "ino_December2024OfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20250331",
     "localname": "December2024OfferingMember",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "December 2024 Offering",
        "label": "December 2024 Offering [Member]",
        "documentation": "December 2024 Offering"
       }
      }
     },
     "auth_ref": []
    },
    "ino_December2024OfferingWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20250331",
     "localname": "December2024OfferingWarrantsMember",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails",
      "http://www.inovio.com/role/StockholdersEquityOfferingofCommonStockWarrantsandPrefundedWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "December 2024 Offering Warrants",
        "label": "December 2024 Offering Warrants [Member]",
        "documentation": "December 2024 Offering Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Depreciation",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Depreciation",
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r29"
     ]
    },
    "us-gaap_DerivativeLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock warrant liability",
        "label": "Derivative Liability, Current",
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset."
       }
      }
     },
     "auth_ref": [
      "r134"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-Based Compensation",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r386",
      "r390",
      "r418",
      "r419",
      "r421",
      "r789"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement [Abstract]",
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.inovio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.inovio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.inovio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://www.inovio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Quarterly Report",
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r828"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.inovio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r860"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.inovio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year",
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r871"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareAbstract",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share",
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/NetLossPerShareScheduleofBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic (in dollars per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r180",
      "r182",
      "r185",
      "r186",
      "r187",
      "r192",
      "r449",
      "r458",
      "r486",
      "r487",
      "r591",
      "r611",
      "r763"
     ]
    },
    "ino_EarningsPerShareBasicAndDilutedEPSAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inovio.com/20250331",
     "localname": "EarningsPerShareBasicAndDilutedEPSAbstract",
     "presentation": [
      "http://www.inovio.com/role/NetLossPerShareScheduleofBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share",
        "label": "Earnings Per Share, Basic and Diluted EPS [Abstract]",
        "documentation": "Earnings Per Share, Basic and Diluted EPS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/NetLossPerShareScheduleofBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted (in dollars per share)",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r182",
      "r185",
      "r186",
      "r187",
      "r192",
      "r449",
      "r458",
      "r486",
      "r487",
      "r591",
      "r611",
      "r763"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Loss Per Share",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r24",
      "r189"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.inovio.com/role/NetLossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Loss Per Share",
        "label": "Earnings Per Share [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r179",
      "r188",
      "r190",
      "r191"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of exchange rate changes on cash and cash equivalents",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r515"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total unrecognized compensation cost related to unvested stock options",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r420"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Period over which total unrecognized compensation cost related to unvested stock options will be recognized (in years)",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r420"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.inovio.com/role/NetLossPerShareAntidilutiveDetails",
      "http://www.inovio.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.inovio.com/role/StockBasedCompensationWeightedAverageAssumptionsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Options to purchase common stock",
        "terseLabel": "Stock Options",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "ino_EmployeesAndDirectorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20250331",
     "localname": "EmployeesAndDirectorsMember",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.inovio.com/role/StockBasedCompensationWeightedAverageAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employees and Directors",
        "label": "Employees and Directors [Member]",
        "documentation": "Employees and Directors [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ino_EngineeringAndDeviceRelatedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20250331",
     "localname": "EngineeringAndDeviceRelatedMember",
     "presentation": [
      "http://www.inovio.com/role/SegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Engineering and device-related",
        "label": "Engineering And Device-Related [Member]",
        "documentation": "Engineering And Device-Related"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.inovio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.inovio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line Two",
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.inovio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.inovio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.inovio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.inovio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r826"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.inovio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.inovio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.inovio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r826"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.inovio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.inovio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r826"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.inovio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.inovio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r910"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.inovio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r826"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.inovio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r826"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.inovio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r826"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.inovio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r826"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Footnote",
        "label": "Equity Awards Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r865"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table",
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r906"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments",
        "label": "Equity Awards Adjustments [Member]"
       }
      }
     },
     "auth_ref": [
      "r906"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table",
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r906"
     ]
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://www.inovio.com/role/StockholdersEquityOfferingofCommonStockWarrantsandPrefundedWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component [Domain]",
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r117",
      "r141",
      "r142",
      "r143",
      "r161",
      "r162",
      "r163",
      "r166",
      "r173",
      "r175",
      "r177",
      "r194",
      "r272",
      "r278",
      "r300",
      "r374",
      "r433",
      "r434",
      "r445",
      "r446",
      "r447",
      "r450",
      "r457",
      "r458",
      "r467",
      "r469",
      "r470",
      "r471",
      "r472",
      "r474",
      "r485",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r525",
      "r527",
      "r542",
      "r607",
      "r637",
      "r638",
      "r639",
      "r661",
      "r727"
     ]
    },
    "us-gaap_EquityMethodInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityMethodInvestments",
     "crdr": "debit",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment in Geneos",
        "label": "Equity Method Investments",
        "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized."
       }
      }
     },
     "auth_ref": [
      "r193",
      "r211",
      "r223",
      "r267",
      "r919",
      "r961"
     ]
    },
    "ino_EquityMethodInvestmentsMinimum": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20250331",
     "localname": "EquityMethodInvestmentsMinimum",
     "crdr": "debit",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity method investments, minimum",
        "label": "Equity Method Investments, Minimum",
        "documentation": "Equity Method Investments, Minimum"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquitySecuritiesFvNi": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquitySecuritiesFvNi",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment in affiliated entity",
        "label": "Equity Securities, FV-NI, Current",
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r513",
      "r758"
     ]
    },
    "us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquitySecuritiesFvNiCurrentAndNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Investments in affiliated entity",
        "label": "Equity Securities, FV-NI",
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r489",
      "r513",
      "r594",
      "r595",
      "r792",
      "r811",
      "r813",
      "r1009",
      "r1010",
      "r1011"
     ]
    },
    "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquitySecuritiesFvNiUnrealizedGainLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/SegmentInformationDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net unrealized gain on available-for-sale equity securities",
        "negatedTerseLabel": "Net unrealized gain on available-for-sale equity securities",
        "verboseLabel": "Net unrealized gain (loss) on available-for-sale equity securities",
        "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)",
        "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)."
       }
      }
     },
     "auth_ref": [
      "r612",
      "r960"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Valuation Assumption Difference, Footnote",
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r875"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneous Compensation Analysis",
        "label": "Erroneous Compensation Analysis [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r833",
      "r843",
      "r853",
      "r885"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneously Awarded Compensation Recovery",
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r830",
      "r840",
      "r850",
      "r882"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Executive Category:",
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r881"
     ]
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAdjustmentOfWarrants",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 7.0
      },
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/SegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Change in fair value of common stock warrant liability",
        "terseLabel": "Change in fair value of common stock warrant liability",
        "label": "Fair Value Adjustment of Warrants",
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r6"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r491",
      "r492",
      "r795"
     ]
    },
    "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByBalanceSheetGroupingTable",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]",
        "label": "Fair Value, by Balance Sheet Grouping [Table]",
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r46"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r344",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r488",
      "r490",
      "r491",
      "r492",
      "r493",
      "r500",
      "r501",
      "r503",
      "r554",
      "r555",
      "r556",
      "r779",
      "r780",
      "r785",
      "r786",
      "r787",
      "r792",
      "r795"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Frequency [Axis]",
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r489",
      "r490",
      "r491",
      "r493",
      "r792",
      "r1010",
      "r1013"
     ]
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term Investments and Fair Value Measurements",
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r496",
      "r498",
      "r499",
      "r500",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r588",
      "r792",
      "r796"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 1",
        "verboseLabel": "Quoted Prices in Active Markets (Level\u00a01)",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r344",
      "r378",
      "r383",
      "r490",
      "r501",
      "r554",
      "r785",
      "r786",
      "r787",
      "r792"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Significant Other Unobservable Inputs (Level\u00a02)",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r344",
      "r378",
      "r383",
      "r490",
      "r491",
      "r501",
      "r555",
      "r779",
      "r780",
      "r785",
      "r786",
      "r787",
      "r792"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Significant Unobservable Inputs (Level\u00a03)",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r344",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r490",
      "r491",
      "r492",
      "r493",
      "r501",
      "r556",
      "r779",
      "r780",
      "r785",
      "r786",
      "r787",
      "r792",
      "r795"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsChangesInFairValueOfTheCompanysTotalLevel3FinancialLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability."
       }
      }
     },
     "auth_ref": [
      "r494",
      "r497",
      "r502"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Frequency [Domain]",
        "label": "Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r489",
      "r490",
      "r491",
      "r493",
      "r792",
      "r1010",
      "r1013"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "crdr": "credit",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsChangesInFairValueOfTheCompanysTotalLevel3FinancialLiabilitiesDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Decrease in fair value of liability",
        "negatedTerseLabel": "Decrease in fair value of liability",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3)."
       }
      }
     },
     "auth_ref": [
      "r495",
      "r502"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "crdr": "credit",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsChangesInFairValueOfTheCompanysTotalLevel3FinancialLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r494",
      "r502"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Measurements, Fair Value Hierarchy [Domain]",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r344",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r488",
      "r490",
      "r491",
      "r492",
      "r493",
      "r500",
      "r501",
      "r503",
      "r554",
      "r555",
      "r556",
      "r779",
      "r780",
      "r785",
      "r786",
      "r787",
      "r792",
      "r795"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Measurements, Recurring",
        "label": "Fair Value, Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r792",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1013"
     ]
    },
    "us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsChangesInFairValueOfTheCompanysTotalLevel3FinancialLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "label": "Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of income or comprehensive income that includes gain (loss) from liability measured at fair value using unobservable input (level 3)."
       }
      }
     },
     "auth_ref": [
      "r495",
      "r502"
     ]
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instrument [Axis]",
        "verboseLabel": "Financial Instrument [Axis]",
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r285",
      "r287",
      "r288",
      "r355",
      "r370",
      "r475",
      "r508",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r608",
      "r776",
      "r792",
      "r793",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r805",
      "r912",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r956",
      "r957",
      "r958",
      "r959",
      "r1006",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013"
     ]
    },
    "us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Financial assets and liabilities that are measured at fair value on recurring basis",
        "label": "Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinancialLiabilitiesFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinancialLiabilitiesFairValueDisclosure",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Financial Liabilities Fair Value Disclosure",
        "documentation": "Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities."
       }
      }
     },
     "auth_ref": [
      "r1007",
      "r1008",
      "r1012"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r837",
      "r847",
      "r857",
      "r889"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount",
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r837",
      "r847",
      "r857",
      "r889"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r837",
      "r847",
      "r857",
      "r889"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery, Explanation of Impracticability",
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r837",
      "r847",
      "r857",
      "r889"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r837",
      "r847",
      "r857",
      "r889"
     ]
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year",
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r870"
     ]
    },
    "us-gaap_GainLossOnSaleOfOtherInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainLossOnSaleOfOtherInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Loss on sales of short-term investments",
        "label": "Gain (Loss) on Sale of Other Investments",
        "documentation": "Amount of gain (loss) included in earnings for investments classified as other."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "ino_GeneosTherapeuticsInc.Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20250331",
     "localname": "GeneosTherapeuticsInc.Member",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geneos Therapeutics, Inc.",
        "label": "Geneos Therapeutics, Inc. [Member]",
        "documentation": "Geneos Therapeutics, Inc. [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/SegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "General and administrative",
        "terseLabel": "General and administrative",
        "label": "General and Administrative Expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r707"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and Administrative Expense",
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "ino_GrantProceedsReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20250331",
     "localname": "GrantProceedsReceived",
     "crdr": "credit",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contra-research and development expense",
        "label": "Grant Proceeds Received",
        "documentation": "Grant Proceeds Received"
       }
      }
     },
     "auth_ref": []
    },
    "ino_INO3107Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20250331",
     "localname": "INO3107Member",
     "presentation": [
      "http://www.inovio.com/role/SegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "INO-3107",
        "label": "INO-3107 [Member]",
        "documentation": "INO-3107"
       }
      }
     },
     "auth_ref": []
    },
    "ino_INO3112AndOtherImmunoOncologyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20250331",
     "localname": "INO3112AndOtherImmunoOncologyMember",
     "presentation": [
      "http://www.inovio.com/role/SegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "INO-3112 And Other Immuno-oncology",
        "label": "INO-3112 And Other Immuno-oncology [Member]",
        "documentation": "INO-3112 And Other Immuno-oncology"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement [Abstract]",
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs, by Report Line [Axis]",
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r301",
      "r308",
      "r310",
      "r495",
      "r497",
      "r502",
      "r632",
      "r634",
      "r712",
      "r755",
      "r794",
      "r1034"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Service Share-based Compensation, Allocation of Recognized Period Costs, Report Line [Domain]",
        "label": "Statement of Income Location, Balance [Domain]",
        "documentation": "Location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r308",
      "r310",
      "r495",
      "r497",
      "r502",
      "r632",
      "r634",
      "r712",
      "r755",
      "r794",
      "r1034"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Disclosure [Abstract]",
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r155",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r438",
      "r439",
      "r440",
      "r441",
      "r657",
      "r791"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accounts payable and accrued expenses, including due to affiliated entity",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accounts receivable from affiliated entity",
        "label": "Increase (Decrease) in Accounts Receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "ino_IncreaseDecreaseInAccruedClinicalTrialExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20250331",
     "localname": "IncreaseDecreaseInAccruedClinicalTrialExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued clinical trial expenses",
        "label": "Increase (Decrease) In Accrued Clinical Trial Expense",
        "documentation": "Increase (Decrease) In Accrued Clinical Trial Expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Changes in operating assets and liabilities:",
        "label": "Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20250331",
     "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease right-of-use assets and liabilities, net",
        "label": "Increase (Decrease) In Operating Lease, Right-Of-Use Asset (Lease Liability), Net",
        "documentation": "Increase (Decrease) In Operating Lease, Right-Of-Use Asset (Lease Liability), Net"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses and other current assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "ino_IncreaseDecreaseinDeferredGrantFundingCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20250331",
     "localname": "IncreaseDecreaseinDeferredGrantFundingCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Grant funding liability, including from affiliated entity",
        "label": "Increase (Decrease) in Deferred Grant Funding, Current",
        "documentation": "Increase (Decrease) in Deferred Grant Funding, Current"
       }
      }
     },
     "auth_ref": []
    },
    "ino_IncrementalCommonSharesAttributableToBasicAndDilutiveEffectOfPreFundedWarrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.inovio.com/20250331",
     "localname": "IncrementalCommonSharesAttributableToBasicAndDilutiveEffectOfPreFundedWarrants",
     "calculation": {
      "http://www.inovio.com/role/NetLossPerShareScheduleofBasicandDilutedNetLossPerShareDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/NetLossPerShareScheduleofBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average pre-funded warrants (in shares)",
        "label": "Incremental Common Shares Attributable To Basic And Dilutive Effect Of PreFunded Warrants",
        "documentation": "Incremental Common Shares Attributable To Basic And Dilutive Effect Of PreFunded Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Individual:",
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r837",
      "r847",
      "r857",
      "r881",
      "r889",
      "r893",
      "r901"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r899"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r829",
      "r905"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Adopted",
        "label": "Insider Trading Policies and Procedures Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r829",
      "r905"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted",
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r829",
      "r905"
     ]
    },
    "us-gaap_InterestExpenseNonoperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpenseNonoperating",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/SegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Interest expense",
        "label": "Interest Expense, Nonoperating",
        "documentation": "Amount of interest expense classified as nonoperating."
       }
      }
     },
     "auth_ref": [
      "r205",
      "r930"
     ]
    },
    "us-gaap_InterestExpenseOperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpenseOperating",
     "crdr": "debit",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash interest expense",
        "label": "Interest Expense, Operating",
        "documentation": "Amount of interest expense classified as operating."
       }
      }
     },
     "auth_ref": [
      "r205",
      "r592",
      "r928"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest paid",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r148",
      "r149"
     ]
    },
    "us-gaap_InvestmentIncomeInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentIncomeInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/SegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest income",
        "label": "Investment Income, Interest",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r193",
      "r204",
      "r223",
      "r770",
      "r929"
     ]
    },
    "us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentIncomeNetAmortizationOfDiscountAndPremium",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Amortization of discounts on investments",
        "label": "Investment Income, Net, Amortization of Discount and Premium",
        "documentation": "Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "us-gaap_InvestmentOwnedBalanceShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentOwnedBalanceShares",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment owned (in shares)",
        "label": "Investment Owned, Balance, Shares",
        "documentation": "Number of shares of investment owned."
       }
      }
     },
     "auth_ref": [
      "r673",
      "r674",
      "r736",
      "r740",
      "r742",
      "r816"
     ]
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments, Debt and Equity Securities [Abstract]",
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Short-term Investments and Fair Value Measurements",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "documentation": "The entire disclosure for investments in certain debt and equity securities."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r114",
      "r233",
      "r234",
      "r509",
      "r510",
      "r1032"
     ]
    },
    "ino_LassaFeverAndMERSVaccineMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20250331",
     "localname": "LassaFeverAndMERSVaccineMember",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lassa Fever and MERS Vaccine",
        "label": "Lassa Fever And MERS Vaccine [Member]",
        "documentation": "Lassa Fever And MERS Vaccine [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease cost",
        "label": "Lease, Cost",
        "documentation": "Amount of lease cost recognized by lessee for lease contract."
       }
      }
     },
     "auth_ref": [
      "r531",
      "r803"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeaseDescriptionLineItems",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, Lease, Description [Line Items]",
        "label": "Lessee, Lease, Description [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r530",
      "r536"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeaseDescriptionTable",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, Lease, Description [Table]",
        "label": "Lessee, Lease, Description [Table]",
        "documentation": "Disclosure of information about lessee's leases."
       }
      }
     },
     "auth_ref": [
      "r530",
      "r536"
     ]
    },
    "ino_LesseeOperatingLeaseAreaofLandUnderLease": {
     "xbrltype": "areaItemType",
     "nsuri": "http://www.inovio.com/20250331",
     "localname": "LesseeOperatingLeaseAreaofLandUnderLease",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Area leased (in square feet)",
        "label": "Lessee, Operating Lease, Area of Land Under Lease",
        "documentation": "Lessee, Operating Lease, Area of Land Under Lease"
       }
      }
     },
     "auth_ref": []
    },
    "ino_LesseeOperatingLeaseBaseRatePercentageIncreaseDecrease": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.inovio.com/20250331",
     "localname": "LesseeOperatingLeaseBaseRatePercentageIncreaseDecrease",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, operating lease, base rate percentage (in percent)",
        "label": "Lessee, Operating Lease, Base Rate Percentage, Increase (Decrease)",
        "documentation": "Lessee, Operating Lease, Base Rate Percentage, Increase (Decrease)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Future Minimum Rental Payments for Operating Leases",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r1018"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofFutureMinimumLeasePaymentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofFutureMinimumLeasePaymentsDetails_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total remaining lease payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r534"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofFutureMinimumLeasePaymentsDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r534"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofFutureMinimumLeasePaymentsDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2029",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r534"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofFutureMinimumLeasePaymentsDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r534"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofFutureMinimumLeasePaymentsDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r534"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofFutureMinimumLeasePaymentsDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remainder of 2025",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r1018"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofFutureMinimumLeasePaymentsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Less: present value adjustment",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r534"
     ]
    },
    "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseRemainingLeaseTerm",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease, remaining lease term (in years)",
        "label": "Lessee, Operating Lease, Remaining Lease Term",
        "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r536",
      "r1017"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r51",
      "r52",
      "r53",
      "r55",
      "r56",
      "r57",
      "r58",
      "r154",
      "r268",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r461",
      "r462",
      "r463",
      "r514",
      "r683",
      "r764",
      "r824",
      "r972",
      "r1023",
      "r1024"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and stockholders\u2019 equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r97",
      "r603",
      "r804",
      "r935",
      "r962",
      "r1014"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r124",
      "r154",
      "r268",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r461",
      "r462",
      "r463",
      "r514",
      "r804",
      "r972",
      "r1023",
      "r1024"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Current liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities:",
        "label": "Liabilities, Fair Value Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.inovio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongtermDebtTypeAxis",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term Debt, Type [Axis]",
        "label": "Long-Term Debt, Type [Axis]",
        "documentation": "Information by type of long-term debt."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r965",
      "r966",
      "r967"
     ]
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongtermDebtTypeDomain",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term Debt, Type [Domain]",
        "label": "Long-Term Debt, Type [Domain]",
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r30",
      "r965",
      "r966",
      "r967"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.inovio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r315",
      "r316",
      "r317",
      "r318",
      "r385",
      "r423",
      "r493",
      "r583",
      "r631",
      "r633",
      "r647",
      "r675",
      "r676",
      "r735",
      "r737",
      "r738",
      "r739",
      "r741",
      "r753",
      "r754",
      "r775",
      "r783",
      "r788",
      "r795",
      "r796",
      "r800",
      "r801",
      "r807",
      "r974",
      "r1025",
      "r1026",
      "r1027",
      "r1028",
      "r1029",
      "r1030"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measure:",
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r873"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Measure Name"
       }
      }
     },
     "auth_ref": [
      "r873"
     ]
    },
    "us-gaap_MeasurementInputExpectedDividendRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputExpectedDividendRateMember",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAssumptionsUsedToEstimateTheFairValueOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividend yield",
        "label": "Measurement Input, Expected Dividend Rate [Member]",
        "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year."
       }
      }
     },
     "auth_ref": [
      "r1009",
      "r1010",
      "r1011"
     ]
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputExpectedTermMember",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAssumptionsUsedToEstimateTheFairValueOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected life in years",
        "label": "Measurement Input, Expected Term [Member]",
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date."
       }
      }
     },
     "auth_ref": [
      "r1009",
      "r1010",
      "r1011"
     ]
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputPriceVolatilityMember",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAssumptionsUsedToEstimateTheFairValueOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility",
        "label": "Measurement Input, Price Volatility [Member]",
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns."
       }
      }
     },
     "auth_ref": [
      "r795",
      "r1009",
      "r1010",
      "r1011"
     ]
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAssumptionsUsedToEstimateTheFairValueOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate",
        "label": "Measurement Input, Risk Free Interest Rate [Member]",
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss."
       }
      }
     },
     "auth_ref": [
      "r1009",
      "r1010",
      "r1011"
     ]
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputTypeAxis",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAssumptionsUsedToEstimateTheFairValueOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Input Type [Axis]",
        "label": "Measurement Input Type [Axis]",
        "documentation": "Information by type of measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r491",
      "r492",
      "r493",
      "r795"
     ]
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputTypeDomain",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAssumptionsUsedToEstimateTheFairValueOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Input Type [Domain]",
        "label": "Measurement Input Type [Domain]",
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r491",
      "r492",
      "r493",
      "r795"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.inovio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r315",
      "r316",
      "r317",
      "r318",
      "r385",
      "r423",
      "r493",
      "r583",
      "r631",
      "r633",
      "r647",
      "r675",
      "r676",
      "r735",
      "r737",
      "r738",
      "r739",
      "r741",
      "r753",
      "r754",
      "r775",
      "r783",
      "r788",
      "r795",
      "r796",
      "r800",
      "r807",
      "r974",
      "r1025",
      "r1026",
      "r1027",
      "r1028",
      "r1029",
      "r1030"
     ]
    },
    "us-gaap_MinorityInterestLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MinorityInterestLineItems",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncontrolling Interest [Line Items]",
        "label": "Noncontrolling Interest [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-controlling interest (in percent)",
        "label": "Subsidiary, Ownership Percentage, Noncontrolling Owner",
        "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MinorityInterestOwnershipPercentageByParent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MinorityInterestOwnershipPercentageByParent",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncontrolling interest, ownership percentage by parent (in percent)",
        "label": "Subsidiary, Ownership Percentage, Parent",
        "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MinorityInterestTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MinorityInterestTable",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncontrolling Interest [Table]",
        "label": "Noncontrolling Interest [Table]",
        "documentation": "Disclosure of information about noncontrolling interest, including, but not limited to, name of subsidiary, ownership percentage held by parent, ownership percentage held by noncontrolling owner, amount of noncontrolling interest and its location in statement of financial position, explanation of increase (decrease) in noncontrolling interest, noncontrolling interest share of net income (loss) of subsidiary and its location in statement of income, amount of noncontrolling interest represented by preferred stock, description and dividend requirement of preferred stock, and nature of noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r44",
      "r64",
      "r67"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MNPI Disclosure Timed for Compensation Value",
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]"
       }
      }
     },
     "auth_ref": [
      "r892"
     ]
    },
    "us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. agency mortgage-backed securities",
        "label": "Mortgage-Backed Security, Issued by US Government-Sponsored Enterprise [Member]",
        "documentation": "Debt security collateralized by real estate mortgage loan issued by U.S. government-sponsored enterprise (GSE), including, but not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and Federal Home Loan Bank (FHLBank)."
       }
      }
     },
     "auth_ref": [
      "r953",
      "r954",
      "r955",
      "r977"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Material Terms of Trading Arrangement",
        "label": "Material Terms of Trading Arrangement [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r900"
     ]
    },
    "ino_MutualFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20250331",
     "localname": "MutualFundsMember",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Mutual funds",
        "label": "Mutual Funds [Member]",
        "documentation": "Mutual funds."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Named Executive Officers, Footnote",
        "label": "Named Executive Officers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r874"
     ]
    },
    "us-gaap_NatureOfOperations": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NatureOfOperations",
     "presentation": [
      "http://www.inovio.com/role/OrganizationandOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization and Operations",
        "label": "Nature of Operations [Text Block]",
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r111"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by (used in) financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r147"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash flows from financing activities:",
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash (used in) provided by investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r147"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash flows from investing activities:",
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r76",
      "r77"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash flows from operating activities:",
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      },
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://www.inovio.com/role/NetLossPerShareScheduleofBasicandDilutedNetLossPerShareDetails",
      "http://www.inovio.com/role/SegmentInformationDetails",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "terseLabel": "Net loss",
        "verboseLabel": "Net loss",
        "negatedLabel": "Net loss",
        "label": "Net Income (Loss) Attributable to Parent",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r77",
      "r100",
      "r122",
      "r137",
      "r139",
      "r143",
      "r154",
      "r165",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r176",
      "r177",
      "r184",
      "r268",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r449",
      "r458",
      "r487",
      "r514",
      "r606",
      "r704",
      "r725",
      "r726",
      "r822",
      "r972"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLossAvailableToCommonStockholdersDilutedAbstract",
     "presentation": [
      "http://www.inovio.com/role/NetLossPerShareScheduleofBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Numerator:",
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]",
        "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r116",
      "r117",
      "r118",
      "r119",
      "r120",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r171",
      "r178",
      "r192",
      "r230",
      "r231",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r299",
      "r300",
      "r309",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r511",
      "r512",
      "r524",
      "r525",
      "r526",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r585",
      "r586",
      "r587",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r650"
     ]
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting Standards Update and Change in Accounting Principle [Table]",
        "label": "Accounting Standards Update and Change in Accounting Principle [Table]",
        "documentation": "Disclosure of information about change in accounting principle or amendment to accounting standards or both. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards and other change in accounting principle."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r115",
      "r116",
      "r117",
      "r118",
      "r119",
      "r120",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r171",
      "r178",
      "r192",
      "r230",
      "r231",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r299",
      "r300",
      "r309",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r511",
      "r512",
      "r524",
      "r525",
      "r526",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r585",
      "r586",
      "r587",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r650"
     ]
    },
    "ino_NonCashInterestIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20250331",
     "localname": "NonCashInterestIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Non-cash interest on senior convertible notes",
        "label": "Non-Cash Interest Income (Expense)",
        "documentation": "Non-Cash Interest Income (Expense)"
       }
      }
     },
     "auth_ref": []
    },
    "ino_NonEmployeeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20250331",
     "localname": "NonEmployeeMember",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non Employee",
        "label": "Non Employee [Member]",
        "documentation": "Non employee."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-GAAP Measure Description",
        "label": "Non-GAAP Measure Description [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r873"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-NEOs",
        "label": "Non-NEOs [Member]"
       }
      }
     },
     "auth_ref": [
      "r837",
      "r847",
      "r857",
      "r881",
      "r889"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r864"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount",
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r863"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO",
        "label": "Non-PEO NEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r881"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted",
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r900"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated",
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r900"
     ]
    },
    "us-gaap_NoncontrollingInterestAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NoncontrollingInterestAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncontrolling Interest [Abstract]",
        "label": "Noncontrolling Interest [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other income (expense):",
        "label": "Nonoperating Income (Expense) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonrelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonrelatedPartyMember",
     "presentation": [
      "http://www.inovio.com/role/CertainBalanceSheetItemsAccountsPayableandAccruedExpensesDetails",
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nonrelated Party",
        "label": "Nonrelated Party [Member]",
        "documentation": "Party not related to reporting entity."
       }
      }
     },
     "auth_ref": [
      "r936",
      "r937"
     ]
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://www.inovio.com/role/SegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of reportable segments",
        "label": "Number of Reportable Segments",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r766",
      "r774",
      "r945"
     ]
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/SegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "terseLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/SegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Operating expenses:",
        "terseLabel": "Less:",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r765",
      "r944",
      "r946",
      "r947",
      "r948",
      "r949"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofFutureMinimumLeasePaymentsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating lease liabilities",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r529"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofFutureMinimumLeasePaymentsDetails": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofFutureMinimumLeasePaymentsDetails",
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liability",
        "negatedLabel": "Less: current portion",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r529"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofFutureMinimumLeasePaymentsDetails": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofFutureMinimumLeasePaymentsDetails",
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liability, net of current portion",
        "netLabel": "Long-term operating lease liabilities",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r529"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease right-of-use assets",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r528"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of operating lease right-of-use assets",
        "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction",
        "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r932"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average discount rate",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r533",
      "r803"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average remaining lease term",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r532",
      "r803"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsInc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geneos Therapeutics, Inc.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r92",
      "r648",
      "r649"
     ]
    },
    "us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAccruedLiabilitiesCurrentAndNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/CertainBalanceSheetItemsAccountsPayableandAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CertainBalanceSheetItemsAccountsPayableandAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other accrued expenses",
        "label": "Other Accrued Liabilities",
        "documentation": "Amount of expenses incurred but not yet paid classified as other."
       }
      }
     },
     "auth_ref": [
      "r95"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other assets",
        "label": "Other Assets, Noncurrent",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r126"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign currency translation",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r607"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive loss:",
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Unrealized gain (loss) on short-term investments, net of tax",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r135",
      "r136",
      "r266"
     ]
    },
    "us-gaap_OtherCurrentAssetsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherCurrentAssetsTextBlock",
     "presentation": [
      "http://www.inovio.com/role/CertainBalanceSheetItems"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Certain Balance Sheet Items",
        "label": "Other Current Assets [Text Block]",
        "documentation": "The entire disclosure for other current assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/SegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other expense, net",
        "label": "Other Nonoperating Income (Expense)",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Performance Measure, Amount",
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r873"
     ]
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherPrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/CertainBalanceSheetItemsPrepaidandOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CertainBalanceSheetItemsPrepaidandOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other prepaid expenses",
        "label": "Other Prepaid Expense, Current",
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r922",
      "r963"
     ]
    },
    "ino_OtherProgramsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20250331",
     "localname": "OtherProgramsMember",
     "presentation": [
      "http://www.inovio.com/role/SegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other programs",
        "label": "Other Programs [Member]",
        "documentation": "Other Programs"
       }
      }
     },
     "auth_ref": []
    },
    "ino_OtherUnallocatedExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20250331",
     "localname": "OtherUnallocatedExpensesMember",
     "presentation": [
      "http://www.inovio.com/role/SegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other unallocated expenses",
        "label": "Other Unallocated Expenses [Member]",
        "documentation": "Other Unallocated Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount",
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r835",
      "r845",
      "r855",
      "r887"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Amount",
        "label": "Outstanding Recovery Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r838",
      "r848",
      "r858",
      "r890"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r838",
      "r848",
      "r858",
      "r890"
     ]
    },
    "srt_OwnershipAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "OwnershipAxis",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncDetails",
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ownership [Axis]",
        "label": "Ownership [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_OwnershipDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "OwnershipDomain",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncDetails",
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ownership [Domain]",
        "label": "Ownership [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r862"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of capital assets",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "us-gaap_PaymentsToAcquireShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireShortTermInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of investments",
        "label": "Payments to Acquire Short-Term Investments",
        "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term."
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Issuers, Footnote",
        "label": "Peer Group Issuers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r872"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Total Shareholder Return Amount",
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r872"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Actually Paid Compensation Amount",
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r864"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO",
        "label": "PEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r881"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Name",
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r874"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Total Compensation Amount",
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r863"
     ]
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityStockOptionsandRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Axis]",
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r979",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994",
      "r995",
      "r996",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1002",
      "r1003",
      "r1004"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityStockOptionsandRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Domain]",
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r979",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994",
      "r995",
      "r996",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1002",
      "r1003",
      "r1004"
     ]
    },
    "ino_PlumblineLifeSciencesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20250331",
     "localname": "PlumblineLifeSciencesMember",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plumbline Life Sciences",
        "label": "Plumbline Life Sciences [Member]",
        "documentation": "Plumbline Life Sciences [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ino_PlymouthMeetingPennsylvaniaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20250331",
     "localname": "PlymouthMeetingPennsylvaniaMember",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plymouth Meeting, Pennsylvania",
        "label": "Plymouth Meeting, Pennsylvania [Member]",
        "documentation": "Plymouth Meeting, Pennsylvania [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Prior Service Cost",
        "label": "Pension Adjustments Prior Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r865"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Service Cost",
        "label": "Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r909"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Benefits Adjustments, Footnote",
        "label": "Pension Benefits Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r864"
     ]
    },
    "us-gaap_PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockMember",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock",
        "label": "Preferred Stock [Member]",
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company."
       }
      }
     },
     "auth_ref": [
      "r814",
      "r815",
      "r818",
      "r819",
      "r820",
      "r821",
      "r1063",
      "r1065"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, par value (in dollars per share)",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r358"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Preferred stock, shares authorized (in shares)",
        "label": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r684"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Preferred stock, shares issued (in shares)",
        "label": "Preferred Stock, Shares Issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r358"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Preferred stock, shares outstanding (in shares)",
        "label": "Preferred Stock, Shares Outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r684",
      "r702",
      "r1065",
      "r1066"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock",
        "label": "Preferred Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r599",
      "r804"
     ]
    },
    "ino_PrepaidClinicalExpensesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20250331",
     "localname": "PrepaidClinicalExpensesCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/CertainBalanceSheetItemsPrepaidandOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CertainBalanceSheetItemsPrepaidandOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid clinical expenses",
        "label": "Prepaid Clinical Expenses, Current",
        "documentation": "Prepaid Clinical Expenses, Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.inovio.com/role/CertainBalanceSheetItemsPrepaidandOtherCurrentAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CertainBalanceSheetItemsPrepaidandOtherCurrentAssetsDetails",
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Prepaid expenses and other current assets",
        "totalLabel": "Prepaid expense and other assets, current",
        "label": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r924"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of common stock, net of issuance costs",
        "verboseLabel": "Proceeds from issuance of stock",
        "label": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfDebt",
     "crdr": "debit",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of debt",
        "label": "Proceeds from Issuance of Debt",
        "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt."
       }
      }
     },
     "auth_ref": [
      "r931"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "crdr": "debit",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from sale of stock",
        "label": "Proceeds from Issuance or Sale of Equity",
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r652"
     ]
    },
    "ino_ProceedsFromPaymentsForStockOptionsExercisedAndExerciseOfWarrantsNetOfTaxWithholdings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20250331",
     "localname": "ProceedsFromPaymentsForStockOptionsExercisedAndExerciseOfWarrantsNetOfTaxWithholdings",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Taxes paid related to net share settlement of equity awards",
        "label": "Proceeds From (Payments For) Stock Options Exercised and Exercise Of Warrants, Net Of Tax Withholdings",
        "documentation": "Proceeds From (Payments For) Stock Options Exercised and Exercise Of Warrants, Net Of Tax Withholdings"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromSaleOfShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromSaleOfShortTermInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Proceeds from sale or maturity of investments",
        "label": "Proceeds from Sale of Short-Term Investments",
        "documentation": "The cash inflow from sales of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Axis]",
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r226",
      "r584",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r756",
      "r784",
      "r806",
      "r807",
      "r808",
      "r810",
      "r812",
      "r970",
      "r971",
      "r976",
      "r1033",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1059",
      "r1060",
      "r1061",
      "r1062"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Domain]",
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r226",
      "r584",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r756",
      "r784",
      "r806",
      "r807",
      "r808",
      "r810",
      "r812",
      "r970",
      "r971",
      "r976",
      "r1033",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1059",
      "r1060",
      "r1061",
      "r1062"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Fixed assets, net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r535",
      "r593",
      "r605",
      "r804"
     ]
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure",
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r862"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure, Table",
        "label": "Pay vs Performance [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r862"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.inovio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Axis]",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r315",
      "r316",
      "r317",
      "r318",
      "r377",
      "r385",
      "r413",
      "r414",
      "r415",
      "r423",
      "r493",
      "r557",
      "r566",
      "r583",
      "r631",
      "r633",
      "r647",
      "r675",
      "r676",
      "r735",
      "r737",
      "r738",
      "r739",
      "r741",
      "r753",
      "r754",
      "r775",
      "r783",
      "r788",
      "r795",
      "r796",
      "r800",
      "r801",
      "r807",
      "r816",
      "r968",
      "r974",
      "r1010",
      "r1026",
      "r1027",
      "r1028",
      "r1029",
      "r1030"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.inovio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Domain]",
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r315",
      "r316",
      "r317",
      "r318",
      "r377",
      "r385",
      "r413",
      "r414",
      "r415",
      "r423",
      "r493",
      "r557",
      "r566",
      "r583",
      "r631",
      "r633",
      "r647",
      "r675",
      "r676",
      "r735",
      "r737",
      "r738",
      "r739",
      "r741",
      "r753",
      "r754",
      "r775",
      "r783",
      "r788",
      "r795",
      "r796",
      "r800",
      "r801",
      "r807",
      "r816",
      "r968",
      "r974",
      "r1010",
      "r1026",
      "r1027",
      "r1028",
      "r1029",
      "r1030"
     ]
    },
    "srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name of Property [Axis]",
        "label": "Name of Property [Axis]"
       }
      }
     },
     "auth_ref": [
      "r750",
      "r752",
      "r1067",
      "r1068",
      "r1069",
      "r1070",
      "r1071",
      "r1072",
      "r1073",
      "r1074"
     ]
    },
    "srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RealEstateAndAccumulatedDepreciationNameOfPropertyDomain",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name of Property [Domain]",
        "label": "Name of Property [Domain]"
       }
      }
     },
     "auth_ref": [
      "r750",
      "r752",
      "r1067",
      "r1068",
      "r1069",
      "r1070",
      "r1071",
      "r1072",
      "r1073",
      "r1074"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r830",
      "r840",
      "r850",
      "r882"
     ]
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://www.inovio.com/role/CertainBalanceSheetItemsAccountsPayableandAccruedExpensesDetails",
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party [Domain]",
        "label": "Related and Nonrelated Parties [Domain]",
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r232",
      "r384",
      "r546",
      "r547",
      "r598",
      "r604",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r701",
      "r703",
      "r734"
     ]
    },
    "us-gaap_RelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyMember",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party",
        "label": "Related Party [Member]",
        "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family."
       }
      }
     },
     "auth_ref": [
      "r156",
      "r157",
      "r546",
      "r547",
      "r548",
      "r549",
      "r598",
      "r604",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r701",
      "r703",
      "r734"
     ]
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transaction [Line Items]",
        "label": "Related Party Transaction [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r232",
      "r708",
      "r709",
      "r712"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://www.inovio.com/role/CertainBalanceSheetItemsAccountsPayableandAccruedExpensesDetails",
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party [Axis]",
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r232",
      "r384",
      "r546",
      "r547",
      "r598",
      "r604",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r701",
      "r703",
      "r734",
      "r1022"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Related Party Transactions",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r543",
      "r544",
      "r545",
      "r547",
      "r550",
      "r658",
      "r659",
      "r660",
      "r710",
      "r711",
      "r712",
      "r731",
      "r733"
     ]
    },
    "us-gaap_RepaymentsOfConvertibleDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RepaymentsOfConvertibleDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.inovio.com/role/ConvertibleDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Repayment of convertible senior notes",
        "terseLabel": "Repayment of convertible senior notes",
        "label": "Repayments of Convertible Debt",
        "documentation": "The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r74"
     ]
    },
    "ino_ReportableSegmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20250331",
     "localname": "ReportableSegmentsMember",
     "presentation": [
      "http://www.inovio.com/role/SegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reportable Segments",
        "label": "Reportable Segments [Member]",
        "documentation": "Reportable Segments"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails",
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Domain]",
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r158",
      "r159",
      "r334",
      "r360",
      "r549",
      "r567",
      "r594",
      "r761",
      "r762"
     ]
    },
    "ino_ResearchAndDevelopmentCostAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inovio.com/20250331",
     "localname": "ResearchAndDevelopmentCostAxis",
     "presentation": [
      "http://www.inovio.com/role/SegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research And Development Cost [Axis]",
        "label": "Research And Development Cost [Axis]",
        "documentation": "Research And Development Cost"
       }
      }
     },
     "auth_ref": []
    },
    "ino_ResearchAndDevelopmentCostDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20250331",
     "localname": "ResearchAndDevelopmentCostDomain",
     "presentation": [
      "http://www.inovio.com/role/SegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research And Development Cost [Domain]",
        "label": "Research And Development Cost [Domain]",
        "documentation": "Research And Development Cost [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails",
      "http://www.inovio.com/role/SegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Research and development",
        "terseLabel": "Research and development expenses",
        "label": "Research and Development Expense",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r425",
      "r755",
      "r770",
      "r1031"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Expense",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Expenses - Clinical Trial Accruals",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r424"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date:",
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r831",
      "r841",
      "r851",
      "r883"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date",
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r832",
      "r842",
      "r852",
      "r884"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement does not require Recovery",
        "label": "Restatement Does Not Require Recovery [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r839",
      "r849",
      "r859",
      "r891"
     ]
    },
    "ino_RestrictedStockUnitsPerformanceBasedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20250331",
     "localname": "RestrictedStockUnitsPerformanceBasedMember",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Stock Units, Performance-Based",
        "label": "Restricted Stock Units, Performance-Based [Member]",
        "documentation": "Restricted Stock Units, Performance-Based"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://www.inovio.com/role/NetLossPerShareAntidilutiveDetails",
      "http://www.inovio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Performance-and market-based restricted stock units",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "ino_RestrictedStockUnitsRSUsMarketBasedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20250331",
     "localname": "RestrictedStockUnitsRSUsMarketBasedMember",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.inovio.com/role/StockBasedCompensationSignificantAssumptionUsedinMonteCarloSimulationMethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Market-Based RSUs",
        "label": "Restricted Stock Units (RSUs), Market-Based [Member]",
        "documentation": "Restricted Stock Units (RSUs), Market-Based"
       }
      }
     },
     "auth_ref": []
    },
    "ino_RestrictedStockUnitsRSUsMilestoneBasedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20250331",
     "localname": "RestrictedStockUnitsRSUsMilestoneBasedMember",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone-Based RSUs",
        "label": "Restricted Stock Units (RSUs), Milestone-Based [Member]",
        "documentation": "Restricted Stock Units (RSUs), Milestone-Based"
       }
      }
     },
     "auth_ref": []
    },
    "ino_RestrictedStockUnitsRSUsTotalShareholderReturnMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20250331",
     "localname": "RestrictedStockUnitsRSUsTotalShareholderReturnMember",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Stockholders Return",
        "label": "Restricted Stock Units (RSUs), Total Shareholder Return [Member]",
        "documentation": "Restricted Stock Units (RSUs), Total Shareholder Return"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails",
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "netLabel": "Accumulated deficit",
        "negatedTerseLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r88",
      "r602",
      "r641",
      "r646",
      "r656",
      "r685",
      "r804"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r161",
      "r162",
      "r163",
      "r166",
      "r173",
      "r175",
      "r177",
      "r272",
      "r278",
      "r300",
      "r433",
      "r434",
      "r445",
      "r446",
      "r447",
      "r450",
      "r457",
      "r458",
      "r467",
      "r470",
      "r471",
      "r474",
      "r485",
      "r525",
      "r527",
      "r637",
      "r639",
      "r661",
      "r1065"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/SegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Revenue from collaborative arrangements",
        "terseLabel": "Revenue from collaborative arrangements",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r103",
      "r193",
      "r202",
      "r203",
      "r217",
      "r223",
      "r226",
      "r228",
      "r229",
      "r375",
      "r376",
      "r584"
     ]
    },
    "us-gaap_RevenuesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenuesAbstract",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Revenues:",
        "label": "Revenues [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Adopted",
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r900"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Terminated",
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r900"
     ]
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consideration received on transaction",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "documentation": "Cash received on stock transaction after deduction of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails",
      "http://www.inovio.com/role/StockholdersEquityAtTheMarketSalesAgreementsDetails",
      "http://www.inovio.com/role/StockholdersEquityOfferingofCommonStockWarrantsandPrefundedWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Domain]",
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares issued in transaction (in shares)",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock, price per share (in dollars per share)",
        "label": "Sale of Stock, Price Per Share",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.inovio.com/20250331",
     "localname": "SaleOfStockSalesProceedsOfAnyCommonStockPercentage",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityAtTheMarketSalesAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock, sales proceeds of any common stock, percentage (in percent)",
        "label": "Sale of Stock, Sales Proceeds of Any Common Stock, Percentage",
        "documentation": "Sale of Stock, Sales Proceeds of Any Common Stock, Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "ino_SanDiegoCaliforniaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20250331",
     "localname": "SanDiegoCaliforniaMember",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "San Diego, California",
        "label": "San Diego, California [Member]",
        "documentation": "San Diego, California [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ino_SanDiegoOfficeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20250331",
     "localname": "SanDiegoOfficeMember",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "San Diego, California",
        "label": "San Diego Office [Member]",
        "documentation": "San Diego Office [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.inovio.com/role/CertainBalanceSheetItemsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accounts Payable and Accrued Liabilities",
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.inovio.com/role/NetLossPerShareAntidilutiveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.inovio.com/role/NetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]",
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246"
     ]
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Summary of Investments",
        "label": "Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r459"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock",
     "presentation": [
      "http://www.inovio.com/role/NetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Basic and Diluted Net Loss Per Share",
        "label": "Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table Text Block]",
        "documentation": "Tabular disclosure of the effect of income (loss) on an entity's diluted earnings per share."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r25",
      "r942"
     ]
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r1007",
      "r1008"
     ]
    },
    "ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.inovio.com/20250331",
     "localname": "ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
     "presentation": [
      "http://www.inovio.com/role/CertainBalanceSheetItemsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Prepaid Expenses And Other Current Assets",
        "label": "Schedule Of Prepaid Expenses And Other Current Assets [Table Text Block]",
        "documentation": "Schedule Of Prepaid Expenses And Other Current Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]",
        "label": "Related Party Transaction [Table]",
        "documentation": "Disclosure of information about related party transaction."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r48",
      "r708",
      "r709",
      "r712"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "presentation": [
      "http://www.inovio.com/role/SegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r27",
      "r28"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://www.inovio.com/role/SegmentInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Segment Reporting Information, by Segment",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r27",
      "r28"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAssumptionsUsedToEstimateTheFairValueOfWarrantsDetails",
      "http://www.inovio.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.inovio.com/role/StockBasedCompensationSignificantAssumptionUsedinMonteCarloSimulationMethodDetails",
      "http://www.inovio.com/role/StockBasedCompensationWeightedAverageAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r387",
      "r389",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416"
     ]
    },
    "ino_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.inovio.com/20250331",
     "localname": "ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Significant Assumption Used in Monte Carlo Simulation Method",
        "label": "Schedule Of Share-Based Payment Award, Equity Instruments Other Than Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Schedule Of Share-Based Payment Award, Equity Instruments Other Than Options, Valuation Assumptions"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of Weighted Average Assumptions",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r91"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityAtTheMarketSalesAgreementsDetails",
      "http://www.inovio.com/role/StockholdersEquityStockOptionsandRestrictedStockUnitsDetails",
      "http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock by Class [Table]",
        "label": "Stock, Class of Stock [Table]",
        "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r33",
      "r34",
      "r35",
      "r36",
      "r37",
      "r84",
      "r86",
      "r87",
      "r88",
      "r129",
      "r130",
      "r131",
      "r195",
      "r358",
      "r359",
      "r360",
      "r362",
      "r365",
      "r370",
      "r372",
      "r652",
      "r653",
      "r654",
      "r655",
      "r783",
      "r911",
      "r933"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockByClassTextBlock",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of Summary of Common and Preferred Stock Authorized, Issued and Outstanding",
        "label": "Schedule of Stock by Class [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r31",
      "r32",
      "r33",
      "r34",
      "r35",
      "r36",
      "r37",
      "r59",
      "r60",
      "r86",
      "r87",
      "r88"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.inovio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r825"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.inovio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r827"
     ]
    },
    "us-gaap_SegmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentDomain",
     "presentation": [
      "http://www.inovio.com/role/SegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments [Domain]",
        "label": "Segments [Domain]",
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r103",
      "r104",
      "r105",
      "r193",
      "r198",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r223",
      "r224",
      "r225",
      "r229",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r311",
      "r312",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r767",
      "r770",
      "r771",
      "r777",
      "r809",
      "r1033",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1059",
      "r1060",
      "r1061",
      "r1062"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://www.inovio.com/role/SegmentInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Information",
        "label": "Segment Reporting Disclosure [Text Block]",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r193",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r213",
      "r215",
      "r216",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r229",
      "r766",
      "r768",
      "r769",
      "r770",
      "r772",
      "r773",
      "r774"
     ]
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingInformationLineItems",
     "presentation": [
      "http://www.inovio.com/role/SegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting Information [Line Items]",
        "label": "Segment Reporting Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeriesCPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SeriesCPreferredStockMember",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Series C Preferred Stock",
        "label": "Series C Preferred Stock [Member]",
        "documentation": "Series C preferred stock."
       }
      }
     },
     "auth_ref": [
      "r920",
      "r921",
      "r975"
     ]
    },
    "ino_ServiceBasedRestrictedStockUnitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20250331",
     "localname": "ServiceBasedRestrictedStockUnitsMember",
     "presentation": [
      "http://www.inovio.com/role/NetLossPerShareAntidilutiveDetails",
      "http://www.inovio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Service-based restricted stock units",
        "terseLabel": "Service-Based Restricted Stock Units",
        "label": "Service-Based Restricted Stock Units [Member]",
        "documentation": "Service-Based Restricted Stock Units"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.inovio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash stock-based compensation",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.inovio.com/role/StockholdersEquityStockOptionsandRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award vesting period (in years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r789"
     ]
    },
    "ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20250331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsGrantDateFairValue",
     "crdr": "credit",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Grant date fair value",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments, Grant Date Fair Value",
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments, Grant Date Fair Value"
       }
      }
     },
     "auth_ref": []
    },
    "ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantDateClosingSharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.inovio.com/20250331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantDateClosingSharePrice",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Grant date closing share price (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grant Date Closing Share Price",
        "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grant Date Closing Share Price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average grant date fair value, restricted stock units (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r405"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.inovio.com/role/StockholdersEquityStockOptionsandRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares of unvested restricted stock units and options outstanding (in shares)",
        "verboseLabel": "Number of shares outstanding (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r402",
      "r403"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationSignificantAssumptionUsedinMonteCarloSimulationMethodDetails",
      "http://www.inovio.com/role/StockBasedCompensationWeightedAverageAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividend yield",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r414"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationSignificantAssumptionUsedinMonteCarloSimulationMethodDetails",
      "http://www.inovio.com/role/StockBasedCompensationWeightedAverageAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r413"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationSignificantAssumptionUsedinMonteCarloSimulationMethodDetails",
      "http://www.inovio.com/role/StockBasedCompensationWeightedAverageAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r415"
     ]
    },
    "ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20250331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue",
     "crdr": "credit",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Grant date fair value",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Grant Date Fair Value",
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Grant Date Fair Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAssumptionsUsedToEstimateTheFairValueOfWarrantsDetails",
      "http://www.inovio.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.inovio.com/role/StockBasedCompensationSignificantAssumptionUsedinMonteCarloSimulationMethodDetails",
      "http://www.inovio.com/role/StockBasedCompensationWeightedAverageAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r387",
      "r389",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416"
     ]
    },
    "ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.inovio.com/20250331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityStockOptionsandRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum contractual term (in years)",
        "label": "Share based Compensation Arrangement By Share based Payment Award Maximum Contractual Term",
        "documentation": "Share based compensation arrangement by share based payment award maximum contractual term."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityStockOptionsandRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares authorized (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r790"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityStockOptionsandRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares available for grant (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average grant date fair value (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r408"
     ]
    },
    "ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.inovio.com/20250331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPercentage",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Threshold, percentage",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Threshold, Percentage",
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Threshold, Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardUnderlyingCommonStock": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.inovio.com/20250331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardUnderlyingCommonStock",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying common stock (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Underlying Common Stock",
        "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Underlying Common Stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.inovio.com/role/StockBasedCompensationSignificantAssumptionUsedinMonteCarloSimulationMethodDetails",
      "http://www.inovio.com/role/StockBasedCompensationWeightedAverageAssumptionsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Domain]",
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting percentage",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage",
        "documentation": "Percentage of vesting of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r979"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationSignificantAssumptionUsedinMonteCarloSimulationMethodDetails",
      "http://www.inovio.com/role/StockBasedCompensationWeightedAverageAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected life in years",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r412"
     ]
    },
    "us-gaap_SharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesIssued",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Shares, Issued",
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_ShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Short-term investments",
        "label": "Short-Term Investments",
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r99",
      "r923"
     ]
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.inovio.com/role/CriticalAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Critical Accounting Policies",
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r151"
     ]
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementBusinessSegmentsAxis",
     "presentation": [
      "http://www.inovio.com/role/SegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments [Axis]",
        "label": "Segments [Axis]",
        "documentation": "Information by business segments."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r103",
      "r104",
      "r105",
      "r121",
      "r193",
      "r198",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r223",
      "r224",
      "r225",
      "r229",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r302",
      "r311",
      "r312",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r767",
      "r770",
      "r771",
      "r777",
      "r809",
      "r1033",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1059",
      "r1060",
      "r1061",
      "r1062"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails",
      "http://www.inovio.com/role/StockholdersEquityAtTheMarketSalesAgreementsDetails",
      "http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Axis]",
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r129",
      "r130",
      "r131",
      "r154",
      "r182",
      "r183",
      "r185",
      "r187",
      "r195",
      "r196",
      "r268",
      "r321",
      "r323",
      "r324",
      "r325",
      "r328",
      "r329",
      "r358",
      "r359",
      "r362",
      "r365",
      "r372",
      "r514",
      "r652",
      "r653",
      "r654",
      "r655",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r684",
      "r705",
      "r727",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r911",
      "r933",
      "r943"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://www.inovio.com/role/StockholdersEquityOfferingofCommonStockWarrantsandPrefundedWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Components [Axis]",
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r60",
      "r63",
      "r64",
      "r117",
      "r141",
      "r142",
      "r143",
      "r161",
      "r162",
      "r163",
      "r166",
      "r173",
      "r175",
      "r177",
      "r194",
      "r272",
      "r278",
      "r300",
      "r374",
      "r433",
      "r434",
      "r445",
      "r446",
      "r447",
      "r450",
      "r457",
      "r458",
      "r467",
      "r469",
      "r470",
      "r471",
      "r472",
      "r474",
      "r485",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r525",
      "r527",
      "r542",
      "r607",
      "r637",
      "r638",
      "r639",
      "r661",
      "r727"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r161",
      "r162",
      "r163",
      "r194",
      "r527",
      "r584",
      "r651",
      "r672",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r684",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r703",
      "r706",
      "r707",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r727",
      "r817"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Cash Flows [Abstract]",
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Financial Position [Abstract]",
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Comprehensive Income [Abstract]",
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Stockholders' Equity [Abstract]",
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r161",
      "r162",
      "r163",
      "r194",
      "r232",
      "r527",
      "r584",
      "r651",
      "r672",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r684",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r703",
      "r706",
      "r707",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r727",
      "r817"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Price or TSR Estimation Method",
        "label": "Stock Price or TSR Estimation Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r834",
      "r844",
      "r854",
      "r886"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "ino_StockBasedCompensationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20250331",
     "localname": "StockBasedCompensationMember",
     "presentation": [
      "http://www.inovio.com/role/SegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "Stock-Based Compensation [Member]",
        "documentation": "Stock-Based Compensation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock for cash, net of financing costs (in shares)",
        "label": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r59",
      "r60",
      "r88",
      "r652",
      "r727",
      "r744"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting of RSUs, net of tax payments (in shares)",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture",
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r59",
      "r60",
      "r88"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock for cash, net of financing costs",
        "label": "Stock Issued During Period, Value, New Issues",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r59",
      "r60",
      "r88",
      "r661",
      "r727",
      "r744",
      "r823"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "crdr": "credit",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting of RSUs, net of tax payments",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r59",
      "r60",
      "r88"
     ]
    },
    "ino_StockOptionsPerformanceBasedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20250331",
     "localname": "StockOptionsPerformanceBasedMember",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Options, Performance-Based",
        "label": "Stock Options, Performance-Based [Member]",
        "documentation": "Stock Options, Performance-Based"
       }
      }
     },
     "auth_ref": []
    },
    "ino_StockSaleAgreementAggregateNumberofSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.inovio.com/20250331",
     "localname": "StockSaleAgreementAggregateNumberofSharesIssued",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityAtTheMarketSalesAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate number of shares issued (in shares)",
        "label": "Stock Sale Agreement, Aggregate Number of Shares Issued",
        "documentation": "Stock Sale Agreement, Aggregate Number of Shares Issued"
       }
      }
     },
     "auth_ref": []
    },
    "ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20250331",
     "localname": "StockSaleAgreementAggregateProceedsFromIssuanceOfStock",
     "crdr": "debit",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityAtTheMarketSalesAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate proceeds",
        "label": "Stock Sale Agreement, Aggregate Proceeds From Issuance Of Stock",
        "documentation": "Stock Sale Agreement, Aggregate Proceeds From Issuance Of Stock"
       }
      }
     },
     "auth_ref": []
    },
    "ino_StockSaleAgreementRemainingCapacityAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20250331",
     "localname": "StockSaleAgreementRemainingCapacityAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityAtTheMarketSalesAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock sale agreement, remaining capacity, amount",
        "label": "Stock Sale Agreement, Remaining Capacity, Amount",
        "documentation": "Stock Sale Agreement, Remaining Capacity, Amount"
       }
      }
     },
     "auth_ref": []
    },
    "ino_StockSaleAgreementWeightedAveragePricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.inovio.com/20250331",
     "localname": "StockSaleAgreementWeightedAveragePricePerShare",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityAtTheMarketSalesAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock sale agreement weighted average price (in dollars per share)",
        "label": "Stock Sale Agreement, Weighted Average Price Per Share",
        "documentation": "Stock Sale Agreement Weighted Average Price Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "ino_StockSalesAgreementMaximumAuthorizedAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20250331",
     "localname": "StockSalesAgreementMaximumAuthorizedAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityAtTheMarketSalesAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum authorized amount",
        "label": "Stock Sales Agreement, Maximum Authorized Amount",
        "documentation": "Stock Sales Agreement, Maximum Authorized Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Inovio Pharmaceuticals, Inc. stockholders\u2019 equity",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r63",
      "r64",
      "r80",
      "r686",
      "r702",
      "r728",
      "r729",
      "r804",
      "r824",
      "r935",
      "r962",
      "r1014",
      "r1065"
     ]
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stockholders\u2019 equity:",
        "label": "Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders' Equity Note [Abstract]",
        "label": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stockholders' Equity",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r153",
      "r357",
      "r359",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r371",
      "r374",
      "r476",
      "r730",
      "r732",
      "r748"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails",
      "http://www.inovio.com/role/StockholdersEquityAtTheMarketSalesAgreementsDetails",
      "http://www.inovio.com/role/StockholdersEquityOfferingofCommonStockWarrantsandPrefundedWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Axis]",
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental disclosures:",
        "label": "Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tabular List, Table",
        "label": "Tabular List [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r880"
     ]
    },
    "ino_TheWistarInstituteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20250331",
     "localname": "TheWistarInstituteMember",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "The Wistar Institute",
        "label": "The Wistar Institute [Member]",
        "documentation": "The Wistar Institute [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.inovio.com/role/StockBasedCompensationWeightedAverageAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of Individual [Axis]",
        "label": "Title and Position [Axis]"
       }
      }
     },
     "auth_ref": [
      "r950",
      "r1021"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.inovio.com/role/StockBasedCompensationWeightedAverageAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of Individual with Relationship to Entity [Domain]",
        "label": "Title and Position [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Amount",
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r872"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Vs Peer Group",
        "label": "Total Shareholder Return Vs Peer Group [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r879"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangement:",
        "label": "Trading Arrangement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r899"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangements, by Individual",
        "label": "Trading Arrangements, by Individual [Table]"
       }
      }
     },
     "auth_ref": [
      "r901"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.inovio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instrument [Domain]",
        "verboseLabel": "Financial Instrument [Domain]",
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r355",
      "r370",
      "r475",
      "r508",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r608",
      "r792",
      "r793",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r805",
      "r912",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r956",
      "r957",
      "r958",
      "r959",
      "r1006",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adoption Date",
        "label": "Trading Arrangement Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r902"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Arrangement Duration",
        "label": "Trading Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r903"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration Date",
        "label": "Trading Arrangement Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r903"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r901"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title",
        "label": "Trading Arrangement, Individual Title"
       }
      }
     },
     "auth_ref": [
      "r901"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Available",
        "label": "Trading Arrangement, Securities Aggregate Available Amount"
       }
      }
     },
     "auth_ref": [
      "r904"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Termination Date",
        "label": "Trading Arrangement Termination Date"
       }
      }
     },
     "auth_ref": [
      "r902"
     ]
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r459"
     ]
    },
    "ino_UnderwrittenRegisteredDirectOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20250331",
     "localname": "UnderwrittenRegisteredDirectOfferingMember",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails",
      "http://www.inovio.com/role/StockholdersEquityOfferingofCommonStockWarrantsandPrefundedWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underwritten Registered Direct Offering",
        "label": "Underwritten Registered Direct Offering [Member]",
        "documentation": "Underwritten Registered Direct Offering"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Security Market Price Change",
        "label": "Underlying Security Market Price Change, Percent"
       }
      }
     },
     "auth_ref": [
      "r898"
     ]
    },
    "us-gaap_UnrealizedGainLossOnInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrealizedGainLossOnInvestments",
     "crdr": "credit",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Unrealized loss",
        "label": "Unrealized Gain (Loss) on Investments",
        "documentation": "Amount of unrealized gain (loss) on investment."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year",
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r868"
     ]
    },
    "ino_WarrantLiabilityMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://www.inovio.com/20250331",
     "localname": "WarrantLiabilityMeasurementInput",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAssumptionsUsedToEstimateTheFairValueOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant liability, measurement input",
        "label": "Warrant Liability, Measurement Input",
        "documentation": "Warrant Liability, Measurement Input"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantMember",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails",
      "http://www.inovio.com/role/NetLossPerShareAntidilutiveDetails",
      "http://www.inovio.com/role/StockholdersEquityOfferingofCommonStockWarrantsandPrefundedWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants to purchase common stock",
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r814",
      "r815",
      "r818",
      "r819",
      "r820",
      "r821"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "calculation": {
      "http://www.inovio.com/role/NetLossPerShareScheduleofBasicandDilutedNetLossPerShareDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/NetLossPerShareScheduleofBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted (in shares)",
        "totalLabel": "Weighted-average common shares outstanding used to compute basic and diluted net loss per share, diluted (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r181",
      "r187"
     ]
    },
    "ino_WeightedAverageNumberOfSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.inovio.com/20250331",
     "localname": "WeightedAverageNumberOfSharesOutstanding",
     "calculation": {
      "http://www.inovio.com/role/NetLossPerShareScheduleofBasicandDilutedNetLossPerShareDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/NetLossPerShareScheduleofBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average common shares outstanding (in shares)",
        "label": "Weighted Average Number Of Shares Outstanding",
        "documentation": "Weighted Average Number Of Shares Outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "calculation": {
      "http://www.inovio.com/role/NetLossPerShareScheduleofBasicandDilutedNetLossPerShareDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/NetLossPerShareScheduleofBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic (in shares)",
        "totalLabel": "Weighted-average common shares outstanding used to compute basic and diluted net loss per share, basic (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r180",
      "r187"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasicAbstract",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average number of common shares used to compute net loss per share",
        "label": "Weighted Average Number of Shares Outstanding, Basic [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract",
     "presentation": [
      "http://www.inovio.com/role/NetLossPerShareScheduleofBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Denominator:",
        "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ino_WorkingCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20250331",
     "localname": "WorkingCapital",
     "crdr": "debit",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Working capital",
        "label": "Working Capital",
        "documentation": "Working Capital"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested",
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r866"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "13",
   "SubTopic": "10",
   "Topic": "480",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481766/480-10-25-13"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "405",
   "Topic": "942",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478353/942-405-50-1"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "250",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-5"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-16"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-12"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/275/tableOfContent"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/470/tableOfContent"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481284/470-20-25-10"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/942-320/tableOfContent"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-6"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/275/tableOfContent"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/808/tableOfContent"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1403",
   "Paragraph": "b",
   "Publisher": "SEC"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-7"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-6"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/320/tableOfContent"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-10"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481664/323-10-45-1"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477123/405-50-65-1"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482736/825-10-45-1A"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-5"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-1"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/850/tableOfContent"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(d)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column J))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column K))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-3"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-8"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-14"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-9"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r895": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r896": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r897": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r898": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r899": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r900": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r901": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r902": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r903": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r904": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r905": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r906": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r907": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r908": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r909": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r910": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r911": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r912": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r913": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r914": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r915": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r916": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r917": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r918": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r919": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r920": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r921": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r922": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r923": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r924": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r925": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r926": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r927": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r928": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r929": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r930": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r931": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r932": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r933": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r934": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r935": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r936": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r937": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r938": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r939": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r940": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r941": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r942": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r943": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r944": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r945": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r946": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r947": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r948": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r949": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r950": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r951": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r952": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-1"
  },
  "r953": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r954": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r955": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r956": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r957": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r958": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r959": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r960": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-4"
  },
  "r961": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r962": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r963": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r964": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r965": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r966": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r967": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r968": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r969": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r970": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r971": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r972": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r973": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r974": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r975": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r976": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r977": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r978": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r979": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r980": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r981": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r982": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r983": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r984": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r985": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r986": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r987": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r988": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r989": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r990": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r991": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r992": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r993": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r994": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r995": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r996": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r997": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r998": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r999": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "940",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/940-320/tableOfContent"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1062": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1063": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1064": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1065": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1066": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1067": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1068": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1069": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1070": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1071": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1072": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1073": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1074": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>74
<FILENAME>0001055726-25-000026-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001055726-25-000026-xbrl.zip
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M5FILDO1_FZZG:?]G$D;QE'^8 0B7*%S:ZH=%;@C(@ ! +1*NX&$4SU<AE1\
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M(UHNWXZU 6J&I!/Y?D@4A>>A8PT3;>8_H988@#  32/04OYAY%)"\?N1B>J
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M[]7QZ!KH0Q^3V1.!AB]X[7SB^^*O$T8UC$I=JR.O)JYO\N*$C2NPIP_+G]=
MQM;UE5])%7GEY^NFDJ5*O5[+--7ZSW6]GL^BU(I66_W5W%1%#&-DC%:<TOY<
M;<9-]V1LLZ?5?=V.LZLU49AA  ;1-Q@W#(4VF#VV\,T,K*&@RN(6EZTX46PD
MBCEG.$.TE6V*423,I<MGPV_=ECLGH&D'8Z>3AIV+=C)[3YZ(-]FU5^'Y724M
M*"&>?H&LCN* XX#C@"O$* XX#CBF %>DK(+5#EEBW@F#P!\)-#P%YA -N NT
M><UC'+87]LEX/,]#Q/,\"90WG@0FU/(%B*4%C^&$?SC1L#4)87,D:/^TW D"
MI1F&!/YO9T^[K<NE1E4758V5MH!'.*OGO,+.UK+PBG%87ME4,:2NL%8QY&PT
M>-$"-+/BVVDGS\.$:MB-TYQ-D.8<S,F0T.,0S$VU00*Z_A@-R,NZ39>GP17#
ML^G9US-H)FU!LYI6>(49BZ9(>33G8L>\XK2TK4&2(RUI>$9#[\+7C+S:OG 3
MA'D39#6-_D8\L$%<*O1->^1X3AC%083+JF21G]Q/( JLVER YX[<JF-?!DG1
M1*/&2B>]/(W'BR>FS8(_9V*J@ADAB7I-%N4:*_77"BKZ3[] 5D>=D:>TZ3J?
MO^2\\[8*>>O2:8 DD7=A5H%7 UM7%V59%^NUO/PFIB^7<9K;5^7N37/U4D.5
M1:T.)ELUYQN/1Z.Y FH1=CVOU5H$"]S$9[>))O&]W33(>=:DR%1VZ+4665-V
M:,K:LQ)#69G;H I%TL&*7E&P-7.]-UX4Y3P(\+5*.1@!&M)&[5($ BR@;BF:
MAT*+J@D.)3+A7>*?O-_M<'$;8Y.=YPM(7.P:+JL%8P=OG) P2NB+QXEW\VT[
MWA, $<]Q8F60@C6K0I!+C;I4%Z4:*VU[>7CX:+YJ7C1$"\CKDB0J^Y\(7G98
MN$BVPQOB/3$;>/['KO(]AF,21KKUO6G$>/MD04,M1K(@S_K(QV_<D83>EO!8
MJKY6$^OJ<G(V(R6W"RC:BV:YMX9X*P3L=F%@.H'PA.V[!'\ FYUUU!.>Z>61
M:%JN<J\:S<5CWP.$';\ L&FKM*;]GTELKG4'?\1@SAS_P7;A8DU6\CC0X@8_
M>S2U62-D(*6-9D4U-[."F_O%-O=_,T$=O,.V*>\%($UGZE&BFC ' U !M"(@
M?+*K+BBL*;>_,^!X_E6L=3L>Y=ON8.:SAQVO.05P*R[3F%4=U$J-JJ&+LBIS
M_Z 81)7GN=+!R:L.;H-2%26YSMV&BW4;;DD$1!H06,=?H D>46, W9I/IN-B
M]<,RT%0Y!,I)RM<+(;$F 2TZS'V'W8)'<77FWA2.7YYNG>]3%*#.WN7LV !N
MUB1147G;[C.DJ,V>PT$H"A99:N"Y09WQTZ<":HFB.1)QSD%R:" *'KFPFZ,'
M25A#F,Z'?>-CONGMCV5^E$L-K;Y/(U+N!C!(+MNFE[U!+AEENX*MN!11X<8_
MOR7$ <?** XX#C@.N$*,XH#C@&,*<$6*1:[.;,=8)!Y6Y7;/X9Q+^&7;^_FX
M2UMZUT!+.]_#D24LR62(54.#__;I,Y\)22<*LG+NXMR5-1BQ'W=II88JB5K5
M$.NUY:-MYKF+>4O@] MD=10''-LG'(>1DQG-3V%, B$<F@%9*J^>9>MS8NE5
MV]N3W[?<?VD%I,C=O*$C4>2FMFR[_?QLAHX5UWMUL.NNO<]A[7E:=V=BP]V1
MH(?2:J.GI*RUY=IFX $4PG0:2CBKS#9]<\I"SLNXCJEVU4*JI894T9<MQ_U-
MR0*X8YPMV=G:3FQIY,X/M=T8<\>%K)4/F$]:69&KS"I;,F_#G'Z!K(ZZ!'?D
M#_H'L0435F4^$L&;C/K@F<S=Z4-V#(5)"(,B'S\=@XC [*SC^#%LNS+<F[DD
M;V8*M.V+F<7 V$0VQ<DX6ZO_8QF1+4$]E3S-6/#<4KG3'206"#4"PNXD"B/
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MS>&61"L[TQ8U^L7/RCEZ.'I8M#4X=CAV.'8X=EC&3K93L=IVQV)@8L5-FF_
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MF\<SGL0]P(F6U#P%OZ!29]XFB7^&/2>BC7$BSCENTW"/,.4%H#,P(IN<H &
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MYU+UI<:N1N QXEHL/YS %RZ=,^0X\&Q/^DM"7T^@)@<:+>[/<H#'X&M4V05
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M,W%N,&A8U94CUC&&QQ6SJJ9?>;T4QV:(_*$T=)Z1=P.<S=P%UCS6:F+S5YG
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M@_1X&0:0D92YX<[ 7,/,7T=Z/.#5 %^L,/;A[9ND!T1H]&"C R%'\[(*G"/
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MR:2EX+"%R;)2<L^N1<X\7N:^MK'P!7TF<P0=-3I !X;H&C&;^8YB -TP^,7
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M3/_\(A2Z0T8390Z'RMK^66=#_>=!6ZSWW*LWI<I\H^'D#N X+/__;=TD32#
MC =K9J\81K[*1I!'.&MOH@XG??@_79+R]@)'IS44<;44,3D%16 7Q8[:'T[4
M\2B=8U83BFATKTQL^A"& P[2OLZM8#4ZU#%T*/[S422)NF'K&]]C&1ZSC C/
M7CBURYC/^MS?<)8]<*KXI^PKLSU9)!>_BL; 9H#R2L? )L1_F N8Z-P33^4_
M(,%RU =E8*CV1V-5RVCT4W):;#;.'TU'WD66-'B5H5:> *^P2V=/[4XT=:#E
M=5&J!UXU.L;QY4&Z;F7ML)L%3TJ4R1][R8;7,R(\EX;!%.0S5W13).#S B\Q
M[@GCBC]LBJ#>6?,/(@7F(XUB^KKXYC">&RHS!$M3^A H7=5Z Q B:?]*,Y_^
M*I O7X <$_D6QE_ 0_[-'#L+[T;(H\9=K?MSK;'NK.8&1T:JEKA42;.[;9&R
M>'?)7SS$(,F-$KT"CI MCJ2#<E>UDAA#:8DS/LUJ18+5X;HP=O =JT.MIPX'
MZ4X@%2G'NR'C!9ACKYFJLN7L2:AJW#G-:JNBJK%6:&%>*%5=@#$:R844]]_@
MQ>^T\3G20WE&2KY8YUFY>WBS(R??@^.=VSXF=<:._ER.[L.75@.E='*Y*FDJ
M&WE/KB*R?)-G>(  O.#(?I6@J;=.4)@1D-OH/]'F/R<S(%DD(%2!M/3L%DC[
MZI<AA'[60GHX3WV0SD,X(#&A0E0ZD[[<,)"&@53,0":54VY_/Q:RYT)R.1FV
MRVKWKI^!'*"S_41^V&BY:TYQZ[[U8'GM7@YX;%-$M?51UUI$);\63*_'\>&0
M>I^S7'84(VN_A[ZJ!3:;;3;;;+;9;&T7V&RVV6RSV5>^66F3G=B!P$<?!__M
MVXSDSO(,V4WI,>AW]?$OWD00YV_>4Q(&]3])]RY)]RD9#]-](L?#= =,['ZV
M"&;#""/17X')!_MW(PWB<GHG\G9QO-^:Z'@8-.DJZ"T2;0LV93/==V5?,\.)
M]Y92&"4WO=O>F#.K10QMN>DWTIC*!S+,IM](#> <<?Y?4^N,IM](TV_DE.&.
MH&EQWLC$H^1POHZ$,ZW;*TSB.E#/NUL!R$M/EAF/6K=:1P5 X?_'SN2J2<BW
M0=H22-L_-=(6EB*,QY65(IP/62\@\_ <J"EF.E4K>UY-W9#6'=10O$QP&ORH
M/U:U<7JB5)UJAYJ*M0,P;U@_S)MT$/-Z@X&J94S-JQ/F-:9()A(^QMK1I\:#
M(D[N5\;\:EH1:-U1#>E2:]T.1CUUU*W*VK@P@^(UX-VXAGC7;=WV)C@@O-YX
M=P&V0=%DB*/BX;>B421;)$1V<5*COQ&]%E<7GH=><3!T=ZR.#_=*-79#3?&N
MUZF5;VG2;]I<7+#!<,_GN!D8H%\[;,$<1\J"QDXHIL/BG@T5T6&:WK!QV6A0
M:W6L,0,.0*ON>=!J6'^T:C+WFLTVFSW,6+V W@8_;$\W#PE;':WX^/*E2PU-
M5LREZ*K]04>=C"85F1#U*HP]FK7;(/I^G9_.@^AC'M4=J8-1NLG:->!YI07@
MZ7G'\4^24XAWK_G&\]AABNJDM;50O'>"AE*IA$TJD)BTRY9&?##<F6F[OL.^
M+A"[F>42)+_SP=SWMNNYLH\!FW_3-]@S-6->ZV22KH.83-)U$(_H0KBAARG1
M]^U5=<!?D/':TN-J\[;^#8ACMDEM=]#I%(VGK<GT6:PYP8WIUD8Q+.!G+O?@
M""?_++)GA?V%OX<#V3T[8X:Y&AM@GIAM'IN WE:HX"4V9#X55#!<X,8><U:P
M\KDRW? 1]8"-O-$VO%O4JLA=_-V-%\4X;&T[^#SX!"_[HKMS_4_E7E\;H"MB
MEOT?S)-?SF%?^+PG3,KEZY/ @84!=_88GP$?7W5L6_QF>*%/:\2KWYO A6\>
M9TO;Q+(=NHX6CQ>L[#DS^;NV7Z>\Z B09V;::RSOL1WL# LG)]<G7QE?H.?H
M6%(0C)Y_61JS)9\@;]G*,]X+]TG@TR[PN&CRL&^:&WR Y2Z8@ZRVK3Q8"DH!
MO%"5R\1W<32AA;KPM#]]PV&T&L,"D4B0\J>_LQG5$NFNZZ_D@@#U0(#*Q2.B
M17" '_.SC35*IN%M:&W!->+]IK%@\1/35W#P5#F5 1#X1'_1G;F+1X]3NAT=
MJ>(&*82:Z\(7(,/H0MJ):P!J2$@!BAOV//Z@MO)1+BFR5'@.IP%XS=* _3@H
M%2-7\#4'N\%MX'.3R)3SG-A]_%&.X?YQL\!R$@-K!6#%BH-H'7T"KOK7]B/<
MX# =&/M&V1C,G!,>48F7HGM\WC3PF@1!  \S@&O-Y2V)QRY *^&5:(!9\EJ7
MX]J4,<!G'52)< LF/TX4Z7QDM>\XP!/AXV!OP&>FC-]GB)?8L"_&J#9LX7L@
MF>)'[["9_631V<.E"V;@)2[.P(:[-XH]@[>T$Z'*A&S9LW@P)0?O$#E(HHET
MR]\DH=R%!$ #ZS,DR"X#SFLVSAR/X46T1U5D7^L(K?-.UN(<XPR/<SCD:8*F
MGX+:"+9:F_:&,5>T)H0#!OQQ"6/6B M$)%-@BR_![+#H[G/5X%.!!72N+1V$
M2-?N7$[1XZC;'E557ZBUA]JD;D6/L*CNUI=?HL.O9(3Q--5E1<U*<SUZ3;7G
M*9#B=Q^TGL7F@O#BL@HM=T.:ICIU/Z =KSJUR18IX87]GFV6'#+H]1+0]% ?
MM46C!=*A_EAI:S]ECP162-1I=8>UQD\TT>C])MM0^016,AHH+&*<X,E]@H-[
M$.?V'8XM<%+?=$-KI=NZ[;<[Z4%9?SOG--_7C"3]&B))#Y&DFVYINPN27"";
MOK2:T P?5A5SDZ^4P'J)?L]')#!Y,+\%YY)+8GUL,; ?&ZYJ_,>5GG>_EN>-
M7<([Z?R[*^6HEZ;X?HRY]@U+V3#=R:^D/&SK]26R'$\ZLM ,*IINIZ)I&2KZ
MP9R5%DN[@.W,WLU]!T\C)*5AZW;0'N8&FL^@OU[586?KH.<Z[!$>]F"/P[Y
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M_X39+V%V4G@NT1.@+IB\B]:VD%WZ$/JG/00<6-AMIT=AQ/$/<&KA6Z*A#D?
M1^P@) -J@QHJSSLPC6Y53"-GP.BQF ;V6\F8&'0HS^COP3-RQI<>:^>#["&G
M\9V3;$WBZQ?[.9I;2->@[W\=I)3"7UB_)9C(B># 0^A[0H/JFK?A08QV=>P>
MZ,&ANPG^E06F4487+-=?8W<WNEOHP=03FQSPCF?X*ZGLYLXRQ5S(C0672*/
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M)]DEKC65IXD>%=J \H#VE+$=7$F^*R?W_L@N>["5N>UC8H[$IM33KY[YR1%
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MYB)V<3;JU!"D)96L4$>X7#TKL&$YT<DM'4_/VE?XW'_\_/GC_8_O=[!DY(T
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M;'3Z+ \7!T4@^)"H29[I:(L%>?D#*!>>0N1R0^T(Y"AL/A>S@[C5B54/6-2
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MD@HT@;38]SWN;,?M[QS"WVA\Y-;&&L,.=J#K9/?54,CI*(JQ'=>+L$<ZC'Q
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MZ3/8P;JR8,_""?#+Q^^/(+]<XN>!>R&,I\;<A\)IIRJXLHCS"^WI:G2Z;HR
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MBK>#"S@?T'F#451B)_5%7L-_8E]BS#^9+)9L3C!<!+"A(!-R!*8/RAHUDS)
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M;5Y\"M+D$SR;3ZI;?$F9L62D@(H6IVE)]N<8F'&:1V23L R ]T"!3L#R5^%
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MX@9\Y0XL&>3I$R"=7/35#L7HWBS?PYH=[#UMY..A_N\<*&>:!6=T74:+-6-
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M LXYF96&FNNR25N2\V[(22PECYS(@B&G)?S_65):/[(V*-04ND*3&^H,JQ9
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MD,SPTI.R[M 9!N7>P%,29-K9^I]F(*R[ZEWL!$73HLXKH?T9Z[)T;F.N5A7
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MC\Z#8NGL&G0R20R DZ GDK/+_CD:8RHNJ;=.EA-U?1Y+QS;*8NPH-7&O4O-
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M1Q!AMN5,6W796(],C]%#)VG-S4L%T]H[+6?R_8=C,8I-MKZM_*#^W/#-*?H
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M@%ZX3D2O<X.8Z8W=66).-IP].FENA0[4/B=Y264#VFOFXMUK&^]TCD@,HK^
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MZ82=,0(Q<S@ 1JU5)#*>O@U-V:J\Q>.'AWCZ^'$6UC,@US=5,="1/)?*$S*
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M!&$3K[%RFTKS5^PUID5E7AV)CU/Y7BLD^V#PK]>/%F80N;P/<258E:$KDQ-
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MV<%(8<+W%*&'M.*FR\TU3)1" 9Z<:+9)$+NG['.Q@TMQ+EK=]\98LNSE=2N
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M4*:S1=6W6@Z>#1WX&8*A+#?CA<1JO\$:N,^$NP0WFX"__K5EOC[ !] E0H_
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M3@QB%Q9UCV344W:J9(R1@Q=02;/C2AI1J0BZAI=HHOZ G/IJ;."HS8:I#ZB
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ML<B>,O>/>IA1"GA!P.Y-65#=,]QXW4AO$OWZ8MW<GN(^9N"@%+&C-5=+R*L
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M/#VQ@2G=[BBD ORR""*>I,7Y0Y"H;S,PV\5ALMQQ4DW4C1"A6BZ.A6A[*:J
M04%TK8:WNAO6Z2:['+@^,%N5K&ERV!6P?(H#2J4.&3%P_(T2B!78/B#[W3&X
M&V$'%!>BJ[-3;A*.@KHSN9@.Z2?A9M$*L"[T1FX5.PZ!1IA;:G$6HJD"\J0&
M/#ZS,=+($'')Y\8/81$KH>B3-HA,K',*\4GS)=_>U3[;<C;)I-X!4_"S@!C
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M]3L+>6VZCVP=(=%HBM=37D4W/@G[B>.5HT0<'5QKJB#;/*12C$*9\G&F-?H
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MXK8.N+H NMAW29&]YJ)8@FY1#9M8[TF.U<*XG(,!\F2B1G+3I:H"$FRR )R
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MJXWS)ZR4B#OA;N4 [H:QMLRRQSV Q\'ZO72G/IH WL%W#>"MFI/J&1@,'J[
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M?WW;O7Y_>;86"]_1QDCL;.3E0J6^];Q=?BG#";GT(\CR1Y1#1$4W.,V)JM0
M)S=E. $$@CCBP:\%+T(?%CW@4P'#V008>.&%1?W;];Q"09L\-D^ ;ZQ=;S4[
MW\1KW3JL'S6/OLFKFO5V\&W>U#[2G3KX%J[TKX$![#]FQ_QRGK-5V8GK("O:
MFT-6;!#)O(F PXLP5\</%4;9Q(#>A',O:!$G]8\TKN?SKQO-]R32.UIK1'O9
M7A67[JONZ?^]/_O]_.V9=U;WKGZ#NL_+G[3_>Y\ ^4:D"&MQ5/)0)S09Q9$G
M\_SCL%R^"OL?9PIA#;!Z0Q4^ L)+?.%QG.O&^FN,X2)561QAC:=5$/07S'/_
M8'>&G7<3[SF9FFS87AJ;=7?M&& SV"K4K4+=*M2_K4*].+L^N_1>GY]=;17I
MTU&D%PH *J_!A_'T-&A5=M;.11KKOTSUGXH/09=V^WVH-PZ0('ZV4L'=#P*X
M"6#&H\%@'%5C,/9Z2337_S?,QZ-?_A]02P,$%     @ %X"M6FJ9=3!J$@
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MO7PB^/U0_:X$'76/>MU^+T-JINQWCXZ[ZTJZ<DF6UO#T,/JQ@["4@HY#26X
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M"#(1!@QE$R(2ZYTF,D0C(&#FGNHWN]Q&LCZ1M4.AJ;[)ZL'I.M)O+=,;(%6
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MZ##@Z]RF'6U^"C!6^6S*J7>'4Z 4[/NDB8H6J:.3(MO:15L/WOPTWP?/VM\
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M &.C K*K#;#(#8^:EQR;^X_W(CH:4C04? _1A!5$+4'PB%Y#CLZ"PI0)4<C
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M:>V<$>W+2]?&^YM$L66<]QT"GQ2OG6X\1!-T;; 9A"5?@*?V@YC7U-^WNVE
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MVFC.H8<P[IY1K?7\ (V:*FGWI+JZ</"/\6@RN1K;4^?U/*];+-;))9(7K5E
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MM(;6S0,$3]MH8LE@4$X;UUN>]RZ<IT:0QVBA#\=JA=?Y[7OS0L=5CL-5HZG
M3':\""BFY'H8&W(1,8%+S!B9+8^F=4Q@6\Q[I-I>JNAVJ>(^VOK.('X3X<O!
MI);JT0O[#2!GQKN4'?AB(RB;&!W )H/@4FD7ZNC+UAQ\$-0>2+93/=_N&==4
M23OHR+JVJ9W%A-**"$:%^JIQ!Y%+2\Y&REZ;XE3NN\'E 74:;*O6QS8:W$0G
M.[JU?9)#,B4Z"\7E&I0-N6:#%+ 0G*O#:@QKW6MD%8YCX\36LNZC<^ZZ%9]$
M805/3 %WEOP_BQ8B4P5<\4I9;J5H/L-X+9AC8T(;J?<03;YV[>>^M7NRXUFM
M\_,ID\<@C067.9+;X'EVAD?%6R<CNB%[8O9O#^IJ7-!Q;2KROVJGUN'TVVW$
M;XA/A'<Z^)J;88&#TLG3'A@$,&.#C$J0?7:+3BMK/+H\:_<$Z4-'HQX%W$>H
M9OD:W"^+$Q^+$3XB*$[+IY<B0X@Y [.%6Y4UB\'WY7#?#^VH:-.G6M::*/L:
M9KZXJSTJ=.9>G,\WW]\GF#^-7DVF@W/:EC^=XK=_^JXL7J)=C3C?%MYN!Y\W
M%6:KWMRUE\/S,*DC4LZ_X' 2YB\F/?CS#/;SRZM?>1\N9_66?X9QOCJ"HY#)
M,YTA"Q- 9:;!R?D[E<@,\\;DUOO.]JBWW92ONA@\B&6R#LR\R$*2Z&(FDR46
MKD 9EL#%6L-3DL"46-"V=<*W&?B==03?+4MO;_7[4?:AW$F^MH?-TA2U+&W>
M638E=-)HX-&[FN,T$+-E$!0+V7H7..>-F;L.R[[*J/;$C-NE?"TTU$=UZ0I<
MRZQ9!V0]E5*M1[6?NJDVVNM B2U$OUMR1"906\W!<%[[)V8)P48&TH08:V=B
M=+O86/98\+1K3FPB\1UPX<-@\L?K,>*;6FY,=O4'LHV_C=[FM6!>@LEAUG7,
M0P@I@D@*+8O)Z=2Z%7QW=+MW=%OI] &J-%)(#TG@VTC?CP<)_SDZH^.W1G&6
M((,/628ZTU-MT*6C@RB\ !$,UZ((E73KDI9.P(Z6,-NK80?;S*N_OF":D@-.
M#OP"H>+1*>4YI%@,J!(+>)L"[:]:$CS&A.W[Z+F+ZFA9LJ4">LCHK4/X<O!U
MD'&8KVU\2J&1=.H"+\+7JW\"HO4:++?*&9V"EJWK ;JC.WK*;*F0AMF_FD>X
MG3RXC?HD,>N$X!%R9AQ4G5/@JZ/G'0_..F:9OQ4D6YFD>>@Y>VCGN9_03'.A
MKS5-&H;>ZT70.OCW6JYS)H%G*8TNAM,)B:?& L(PTW?&%Y@KV8<3W"*<OO4C
MMPZ1MUWTEF'O2IM;#WYVY\%7S,1:0R0#(T>K'D9!&' L>1#>)1]X"5J7#F]M
M]R=NLP<]^)1YH,EX7:)& UR9/-\EG0X*R)5,O@A)+Z-HL::=!(A[U.?UG:8'
MT1Y*=/<#SF9!OP_CZ>7L;G)(L\34\\OK/YG%'C3)B*&0H),V=3L-$%&1]&0Q
M=-!R3T=\8X.G.[I=1X#[HL5H)^KIP;FZCF=A]W5!U%.0]RZ:_01W^]+?/339
M0OB[H45D&9,7'-"K",K3+ARL"E!AA6RT8[)U5?ZNZ/! 6'=_;-A$YCVPX.UH
M.+X&:GD'SDEGD$!E;GDMUV3@ZNPD)U.V9&\8'EOWOUH)9/=>T[8:&K46;Q_7
M<VZ>CL3WC"\NQN/J  XS04[S+TZR32Q(AJ!SF#5*94"NN@2941C!G$1E6]=*
M=\2V.V;LP)+M53']$*@N_B-YCN,!3A803[A"9"HF,$8H0H4U0L@UV&R"MB03
M;UKWE%V-Y%C)L:W0>S@_WDU/<;R =JW><B5KM2(P7#EP102":FCU6GB0HO#
M<I$\M[YZL0&\HR1-7^KIX\K..HG<Q7UBF8PJ1 TL\SH%#3/$&"5XM(I)65M;
MM<XU;P#O*)G4EWK6QOM;AG='PZ^UU1_AKM<4MPC:KOZ@[4.Q'0 VJBNNGW]U
MW?B*&]I:C(CUFEY"4"QH"+X@V.1SBI84:DKC5VH-E!;S5J\^=A[I\;1]9>X,
MY)G3YER@=7(#(FKC,BW;\-9'SPH8NZK*;:'C5;-.MY'JH815;ZYCYM%G+AD=
M?EAUB+6AAR./GM;BD\HR1"F2:>WMWD6QKT+9K?5Z+T\VEF\/)NI-1&_#^3+[
MW0573U'0=9CV$PO=5F?W4F!+@>^2$$J5Z*-ED#SSH*+1E?>^5KP(3$5DPOE=
M$^&!*.BN>+")G!M?W'UF_J;9-7/K(PX'H_';T10G+R^PJF<1H^,IV6R#AUSK
M%,A@YN"\5>"YR#D:Y<7MG-KJ;&S'Y^T^TME&.Z.>1=M#].K7T?!SO1E8!7!5
MOLV%5LXPR)K8K7RL(WZTA90#<CKO6,BM;8!5.([%"MA:QCT$&&YC6MZZZ("J
M)RM@-:+]V #;:^P!"FPA[AYL@#7HDLF6:9WID,,$2A@/SDD+,J)W=/H)E5MG
M0'=)@@?._UUQ8!,I]Z#[6]&695M'%ND\,@5LC5PI3*8.?+# B^7,:,E*\P#(
M2B![Z,G00$NW)VML+>(>#OZ;A]SKD/#9>8UI$L6=*B9E6F1QH)BM[:ES 2E8
M;0-AG6H^27L=EGW;@7T$BQXIZ=X9</W.U*R347Y/%A/]('S&DU G*03&P+!
MR\<8"&E,@,D59C@16+5NQMP=W3&RI)DV>C@QWH]'B18Y>4URJ6-8:L%T'1@4
MIR<E95^<(F2.-DB%/($W(8%,HNC$N&>Q];&Q'LUQ\**1M'MP(3[@E_E%B<F[
M<NN(.Q&^-LCS$1@Y1Z!L8> (+L@0F)$EIR!:WSJZ!\YQ,*&5O'MH*;C<KA99
MUG?D;(?I8/CYA$=A,\8,.BL.BO8JB$IY"$G(.NDBJ=3Z1NLZ+,=!@B:2OLL
MU;Z!5^U6=SHZHX^?+)JB7IR?A_'EJ#R[F)Z.QH/_QAR&>3[(:][ACKY\3R3
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M*8WN5?V*DPGBKQ@F])A)&@^^W.28CUP'E 7$[+I<+ G(2K1TO*20O4.FFF<
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MG9)Z8,Y=8835ZU\V]N\ MZ>.G1M"W4\[SP9*OGUE<@<:ZJ/1UH:P2Q#6L&S
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M+^QQ^(+8^ZJN_MQ^I+B$GW[X'U!+ P04    "  7@*U:P2!5\1XI!@"'!0<
M$P   &EN;RTR,#(U,#,S,5]G,2YJ<&?LNP54W,V6Z-N-NP1W#81@P1T2W-TU
MT+@TH9'&28*[NR6X$]PAN$-P=W<G.(_O?'/GG+EWWMR9<\^];]ZZLUFKUX_:
M5?7?M?>N_N^J!<^SSZL +%E)&4D $ @  %]^ ,_K:-HR8F)&RJI*DC+R$G]1
MH$G+6X'M8;   #NP$T152I126T>7$G$$  - !B  V   8Y#C)P4U277 B\A(
MB%$ZOG0"_ NYGOYC=@!@@EE:F9(2\!\3;- GB-.+@<HOS&%JY@AZ8;\7MH4Z
M??JC_?2%<4UL_F 8N#\8\F+@"Q/^P19_,M-?^OS)[_]@4SNPZ0O_8?,G4SO3
M/[CKA8-<G,U>&%;^A0-<K,R@+SSYPK2VSG96+WSSQU@[,V-'   .[8]V)S.0
MY0N_>V$TB+JJV L+ @!(:!9_PR9_PTYFKDY_+$K,_I,;Q,K"THGR#8B!DHV/
MCY=2V@QJ:^;DQ*QL#+(QAIA2BMG;?3(&NP$ ?Z[Y+_+J#]]2OCB9FXV/FYN9
MG87M;QSU;RK_G?)';/^D"Y6_Q R(/_37MG^MGWT6 ,![]>*;J+^VF20# '7^
M  #A_%_;:+\! )@O<:L=_9OUX/^1+Y9.3I_X65FA4"B+E1F(Y0^'_K/\3SO\
M.^1OGL?RQW3_[!Y*<3-S8V=;)\H__ :RM[5WAE Z?C(&F5$R__=)_'</_-?M
M8%(U,S>#F(%?1FB^9)D5V.(EW&!3*R<K>S"E%?C_+8A_Y[#_3O[,ZQ?!R7D"
MX!JQ +!&<0&P1T, .!Q4 *Q^QHL&^,]QDT?6!/RQ\[0H=O[,^[\(\'^<%2;R
MCP]'*XN_C!-35:<$.4-<_M3]L2T!\  4 "8 %T $( ?0 -X F 'L !Z  . ]
M0 (@"U "J -T (8 $, 28 >  *  3\ 70  @%! %B >D #(!.8!"0!F@$E '
M: :T WH @X!?@"G  F 5L 4X )P"K@'W0" 0$8@.Q $2 2F KX&,0'8@+U 8
M* &4!ZH"=8 ?@19 ,- 9Z GT!88"8X IP._ 0F %L '8#NP'C@'G@&O /> Y
M\ X&%@8-!A>&#(8.AA6&%^8#C!R,.HP!C 6, XP[C!],!$P23!9,"4PM3#O,
M(,P4S"K, <P5+  6%18?E@J6&9875@Q6"587UAP6 NL-&P*; )L%6P;;"-L+
M.P&["GL(>PN' (<#1PG'#"< )PVG 0>"<X#SA@N#2X$K@*N%ZX*;@%N#.X5[
M@D>')X5GA.>'EX'7AK> A\('P"? Y\'7P'?#3\%OP5\C("#@(] C\"!((^@@
M6"-X((0AI".4(_Q$&$/80+A"1$0D0F1$%$)40C1&=$(,0$Q&+$%L0QQ'W$*\
M04)%HD!B1Y)$TD4"(WU%2D J0FI%&D?:0;I'QD)^C<R/K(1LBNR&'(F<@]R(
M/(J\A7R/@HU"CR*$HHYBC?(%)0FE#*4;91'E A45E1J5#U4%U0KU,VH2Z@_4
M/M0UU%NT5VAOT<30]-&<T2+0\M%^HLVA7:"CH].AOT?717="CT O1.]$7T:_
MP<#!8,&0P3#%\,%(Q:C%&,<XQD3&?(WY =,0TQTS ;,*<Q3S$ L9BPY+#,L8
MRQLK%:L!:P;K"AL'FPU;"=L..PR["+L?>_<5XBNZ5Q*O3%_YO<I^U?EJ P<6
MAP9'# >$XXN3@].-LX6+@$N/*X-KC1N*6XH[@GN*]PJ/$T\3SQ4O%:\%;Q4?
M%I\.7P;?%C\2OQ)_&O^.@(S@ X$903!!&<$XP6]"$L+WA&:$(83EA%.$=T24
M1!)$-D311'5$2\1PQ&^)58BAQ!G$W<2')+@D B0@DA"22I)Y4AC2MZ2JI!ZD
MV:1#I%=DY&129)_(DLDZR0[)\<G?DUN3QY&WDN]1X% (4UA1Q%&T4>Q3XE%^
MH+2E3*+LHCRE(J62IG*F^DXU0G5/34^M0?V5NIQZB0:%AI?&G":.IH/FE):"
M5H'6D[:8=OXU\FO>UY:O$U_WOOY-1T^G11=(5T>W2T](+T/O3E],O_@&_8W(
M&X<W66\F&1 8>!EL&-(9?KV%><OUUO)MZMM11AA&;D8KQG3&,29X)CXF,%,6
MTPPS&O,'9A?F8N8U%GP6>9:O+'4LQZRTK+JLT:R]K$_ON-[9OLMYM\#VBDV6
M[2M;(]LY^UMV$'LJ^R0'.H<DAP]'/<<9)R.G&6<&YRP7#I<"5R!7!]<C-P\W
MA+N,>X^'EN<C3QK/#"\NKS)O&&\?'SR?*)\/7S/?+3\WOQ-_)?^) +. C4"1
MP*X@O:"98([@AA"UD+'0=Z%584KAC\+?A%=%J$2,1;)$UM_3O#=]G_=^YP/#
M!^L/)1^.1=^)0D1K1'^+\8MYB?T4AQ67$@\1'Y%X):$AD2*Q+$DM:2%9+'DJ
MQ27E(?53&EY:3CI:>D:&3 8D4RAS*LLCZR7;)8<FIR:7(K<N_U8>(M^H *,@
MJQ"KL*CX6A&L6*<$4))1BE5:4J97=E!N4D%0459)5=E695/U5.U5PU$S4BM2
MNU8758]47]!XH^&LT:&)J:FO6:CY6TM<*T9K59M5VTM[4(=8QTJG7A=15U,W
M3_=*3T(O7F]+GTL_0'_:@-[ U:#?D-C0UK#%"-/(V*CJ(_Q'K8]%'Q^,E8RS
MC*],9$S23$Y!8J!$T('I>],XTSTS(;,8LQUS(?,8\UT+(8M8BSU+$<L$RT,K
M,:L4JS-K:>M,Z]\V2C;Y-L^V6K;E=DAV'^T:P*_ -N N>W)[5_NQ3XR? CZM
M.O [Q#N<0N0@>8Y 1P/'>B?<EV)JR/F-L[_SFHNP2ZK+#5036N6*[0IV'7)[
MZQ;LMN,NZ9[K ><!\NCPI/+\XKGF]<'KNS?0V\2[PX?&Q\]GZ[/4YX(O*%]L
MO@Q_??<UYNNEKY9OHQ^9WV>_#7\I_^( C !(P$R@0&!F$%R05=!(,$=P<O!3
MB&G(0.B[T(30AS!0V$ X6WA2^'.$><1()'=D1A1"%#AJ.EHDNB &.\8]9B-6
M(;8VCC(N).XRWBB^/X$S(3,1)=$Y<35)/JD^F38Y*ODAQ3)E*E4TM3R--"TX
M[7>Z:?IXQON,LDRRS-#,NV]6WV:_2WVOS:++2LA&R';)WL[1S.G-Y<TMS"/.
M"\U[S ?GKQ:H%G05\A06%I$611;#%#L7[Y7HE_PJ%2^M+V,N^UZ.7Q[Z _##
M^<=^Q<>*Z4JYRHXJWJJRZM?5:34X-2&UP%JWVM,ZR[K5>IWZL0;9AHY&@<::
M)I:F_&:JYM06O);(5I16O];G-O>VJY^??AZV6[1O=!AU+'1J=TYVJ72-=,MU
M]_5(]G3V?NAMZQ/J:^[G[V\8X!VH&^0>K!WB&JH9YAJN&>$>J1WE&:W_Q?>K
M<4QPK'5<9+Q]0GRB9U)F<G!*<6IL6F-Z=D9_9G76='9WSG;N;-YE_G[A\R+\
M8L@2UE+",NERU@K#2ODJ]VK+FOC:T+K:^L(&:.-@TW'S8<MO&WT[88=BIW"7
M?;=Y3W+OU[[>_M;!IX/[PX C[*.TXS?'U2?O3X9.M4^WSB!GS^=A%T07^9><
MEQU7RE?+UW;7][]#;HAN"FYY;WOOM.YV[J$/B ])CPR/C4]R3XO/=L_/SPL
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M>A/,DY*3L&O/_6,1+=6<JS9GR-K3%SM.;>MXT/)M=9IS.''.D::?Q;B0BFH
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M"&?#<&=I'&*4;7"OI&B0OZ#>=R6GZV16NX1V69(-#-EMNLFPZ/9J]1J4,A?
M5,P5QQ5PKX61TO)N90#H(\ )_D.]9;S:%(-X/*%5/?3:6FYHDA'F;Q9MS&@H
M[![J"<$]+,S6;4Q#2T;"@:,_HPAS<+*2]16ZFK$+Q3YLI OP8("+CGO[^TMO
M8[OJ;DD;RR*YW!/04X7U4^AM8\/6ADU7]_U?S?S@X!PJ_E'%&,^'JZ@QI^<0
MH\B<M\';(.G@(91+),LZ%K51FQI96&UH4OMMG.^P-F5X@HV7W=5F0KERB'4'
MMQP9::Z4QI'TBAENRE9<"CW(+&B(_!>9OQ 5)KXLOX6GE02BEK\NV<_.]V*(
M6G%V=-GM'7"G'+>X<X)J<=0/S4E]-";)FKX&1ZUJ"INT/68'KO@?&C_[+ZY6
MX-RB79GOX:>\\G%P"D:]9X>SZ*M#=K<[KYNZQ<M:M<>]N*PS5$Q.*NFID1QE
M&!WI[/,]:*-[:#T_,@-SLPQ8CGPR"IG/\X=4P;Y5]DVX7E]H/K._*6:P>TW7
MZ!;?>"QW.)NP=T0\-C^*7>#@5*5-FHXV0O%:GQETGC3XR?"[2W-XGX+N%"B&
M*)ON$8NDCNGPR?9P,3&^;+2"P-5PW593V6PB,90^SU9N)G$LF4_^QQR09W.[
MZ)%=)K#O_-C8/10SR'NXSTY\$^6L)?S>;M?K>"(\8YQ WG;F=&/8ZOX)EZ\$
MKPK?!^'H4\R'&%CO<HTV_<U"6[VD'! 1=<25J]WZ=687FWIIA3.AE,>[PQC/
M/5;W(:O+BX^URRIS.KKW*EOSD%U$?V\>JS0%/%$;3'4_MY*.2JMB5<.KI 2G
MBV(#_>^5C35M@GS<E3J?0SOYSW,KK?^^0N-L ';@/T\9]8+-D,_G_] 90XE_
M&]72S>Q&8CD+UT_,]F_LF^3<(I6:$@8N4R!.>! (*M&O"I+GK]W8OR9>2%UI
MJ:FO3"#C^CKE7J;LDSY_I5M/JEZZO1@VQ[#REO7\7EN2@,+!<?-SZK**^@&D
MZ>8W#=6Z5![G=-)$- $UQQ))\D(6ZS&;8XK_N_C,I76-*HHIQ)U!( ]LLY+'
ME8CV5AV]<K4JCXQ6MQ"9B%'^)F(@4(D887BK76Y=^@$B*7%$R2I4X.Q-CXT\
M-VC&-CMPQL.NW6=0*DLX]S@"F4N@1+C;E!_$=LYW0^CYF-:SO+UGHXHHV.O7
M.O\Y+3G]CO\'*"I,:<[!(:HSIQ[' 6KNSF9Q!?]0O5P5WP9EL$CTT>Y;J'#W
MEEL^8BY\'9W^9&0S[.D'_],YTIMN"-282D%>/)ITL179X:]";^&R2CNH]XUU
M%.WP^% 0AT?P?#BDL6X<I0 #]'E^P47BUG)GV+J>;5/84-QI]^-YEK?W*<G9
MK5MU)G6I*"4]O>KO*[!= E7/G@%)",'=JRC('%'@Z!8?R[3?C3WK2/O.X*,D
MV&_2X'SAS*<P:W3M[.NC@0BBU3Z,Z.A4+[SCC)O#3O]2>@,VU-Z'S20(;67T
M=^Q)JUQA"=@E*SQTL[>6!V=\>28J@<6?3[!Q)= 1<DX @0(<]@[K;,BFFK<.
M4C/K:^$:MOFX>O)//7N_WWTDS185#&TBD+>;''G4/W^X1*'D:Y5S=.9:]H*J
M6I.D&S 9UJ4-Z.P;WY%[>J@Z3MR1NVULZH-ME^;XSE@68XMW&X\4/<^.=XJD
M=B)(5JX(AL01#VC/*<@@1&>C9)(2O<)/?-"-#)+,::,OOCB?Y+M6E%OR'KTI
MXA^I84^OM-MNC)\!?2*WK(?4V'?8QCLKXT."3VVDK&-8%+/2H@_!6$T>:=+)
M"YD^J2*,BY&,ML)?IZ*> 0TFQA=WK?V5E]C 08>[9X"(<F.1196S7 %F49D1
ME7YC^RVL1<A/ 2R1)()FHT +LUGMUHFF5*F [ 8!?YG 12ZNUOPR0;ZKJ$NQ
M>( #S74069I\<W_ZTHPT-2S[#Z&U^ZUP!_>%[&*Y_*6#WR:#=6V95I57)\BW
MSP#%KD4WA_&AP2;.$T^,)]"=^Y4=4R;ZSFE&9I?,U*6(Q'[\GLBNC^C&I<25
M7AZ["I";W[[-T<6:@UL,,9M]>&MR1XY>?&4T<<^]0?@+%$R4OL$-YMMSCIK7
M&D>I'@&FS?>A^1PPK7,Y?.&Y;B1P.F-S/+FN!/4VC2X71P6AVN\>/[;D-J_S
MZ0M7_FQZQ!Z-R(WVDQO<E2.*KF!#%%YW!=2#]4D6*WLEH-F'PO:=A'4XF.$Q
MBL+0#!)7;@QWGRSM?JUR>5[HVFU5IX! &_IVP7(0>@@QAXM368Y_R=Z20O[%
MU&!^\&E#FHLJP?Y68+#E7!I%X=R=*ZLP123D$+YT/KS0>@C?>I#9!KN)5[N<
MJIU70$"D@E/\%68JQSGMZ"#'_5R"LMTS (R^,KZ$[KMHIZ%.X_W]ZXC$^93;
M!5@QPY0=C_;W+>>/5"]3^#L5=4S;^[.Z0(RQ[LSR/&=/JE[]VK/R@+[!*_<2
MXP@TU_.5<1/XY(>'A7YIQ7GHK66J-RY_E:2U/*W?$+T].HL(GS1JPK8,38JG
MQNRZ^=9- &K,^= 0_.0CI5(*T[OYLM/AY&E#0F/G)S3;P4O.R@F9KTV#52)R
MTT.]LHI&NWH!WEE@^/Z;'?9O::\!,31$-%'B&U'(86CH29]_=B]*(QD$21O,
MO<C->^^"?^3W.,KWQU8/5WN,Q&4AK_S+Z[9ADQ_US2VN;#?[8QLH*%$9]&1\
M4B2CHCKZAE:YL0M1F;$N%L9K*<LHH0;;*Q0>J=>0\E5!6=B9AYBENZ?^.]\'
M?(K'Z<P8O3:C.1%EGZ\OM7[C- 8U+.\S@+;.NZW2^]LS #[P&>"<OYEP,G.M
M-$FQ^N,9<%SC&_1Y1*2?>:7\,+- I/UE!R[9\-S7WCN"C\M7T.'SKKB;A[8_
MZ<C4O-ED2\CN"?<04Y*PU@_7C%[]CC:\NIROV><D2R'H1]CH6R"+J1[R6_:1
MS</BL4W+![&Q 0BM%G^/C0T0%P=B8\']%;&GEK.;B&/%#T>@RGN"+27DX%HM
MA4XC&H5O#.LAVY!P&Y50G0#71O-RJBXOE:;+V/KZ1(PIBW^QSI+2%8DSV$+A
MH3W6'GE('OO?L4RKV]=-5X^Q5X@W3"+WI1_7*3DBS^6@!_?T^YBGVCZ_=;UE
MP(\^IH\?GE QGPZT>8/0-L#G1W<6%G:CD^2&WI_6EII;BSV)ME<T6C7/-?./
MSX]&PY?3Z3=&KG8/F"B[C=36UJ'  [IUM%9!]+Y(HB@'E@03]GQ3LT*..BP9
M(3(MZ+7+$;# I5=S_2H@Y<>98:_LD9!:5$^>%@6CDW[W)@VYI&YMUCGX&W7I
MQX]-B HIO_H ME02D>E)'M)[1U-C-\,&^6:WPWT]@@'",H RX\KHSRU#&FN8
M=!G5_C_[AL;F/F?5(+X;)BGQ_=<B\(]&*0+WUJ-] ^RJ9*\/.1?X/W0*.(A=
MFOF(04 E4N[SJ=4JPIHDB] \2_EL%M#+=PZ!Q=I\Z<M9ZV]S=2I68+^5BB/3
MHCI_;: H!0EMXQ^>V-;SCTMZH6E3J:S?G3%R^I42AS<+37/:HJO'.*\C2(]5
MJR5H/I"R<?AA2> X23*/HP\Z#K9@:ZPU%3XE'M7?4R0^F Y]HV7X1[@,7@?\
M<'QMQ2FAY\%5V\"-;A:?3\L_*B()(KI,8#D$KJV?77]D>\-%KM@\2C4$-[ZV
M6S_ 2K;@G%OZ.OT@?=69&]:.V:P0SX-_0[DYR0LG++G+_QP!_8"O^%,;B^LA
MNN/5W)?>O*5RU5X^J8-(3O57"^A-PV!\*$WJL$&=W;&I1?\^VE(G7^EF)4&^
M@,M*KPA?N5[<9H*;P=(W*T$U>^LW(_4W]^M;_/AX]37+A8T:CEOZF2V1XG>2
MC=<>C]2_*\.TFK]-R'E0O2YV4,*:^!)IEJ!=' 9JWCG O7O3#75,M9)@:=%<
MTA4F_V6[-"S!HURAV2MNP,U27W5[OTQ(V'!&S^K15.7G>26SO8Y(VV@D,=XU
M%9&.A$ H-GQSP:<PE[R5H)05([K6P'Y+Y%^/;ZX_@9B[_ZL47?:3E&XUH!V7
M#14)U7NF.7UIL:^!FAX"I??6H@DDNTHDKQ_M$KB2,]+2Y#2[4J=_!AA.MRZ%
M^U3!+8)^Y[[5ZV[6BRZ:_[W<K"VW7Z!TKE8'CJDHOS:>$FN*JV_F/8'&[,JK
MLV(XTJ#68<R86X#UEI5FSKT,RQ\>)A-<[ ^74A9+%;04C?VS7MEK]V_FA.64
M!O=\"1IU<2$@KP/G1=1XUR\/?XW CN%VC&([J*T=4_XEL%#BE,=D;NO-K<^F
M[H&@.DH+?:<]6,Z9I]([1=O+UZ<(&*O3PH:@,991+%J-<[TN=U#,YS=#9V24
M+'Y5O'VK*0D6_BX1H]Y=>AB.M_!FP7R?+;W"3S]WY'MPQI?H.T96OIE:QCB'
M;-#];RZ&&O@Z[0XVS_/=N%S"O.6'!H(EO!1KH:SJ0["\"/*:LR17\E)J>1JT
M_/*VZLIG^%$?$_/P8A3M87$OGE2@V5$$T25D?@%#D8H%2O5^+L@_O-+=@R,B
M3"XWLS#%@XT$M4XN";8IE$=Y62A15BCG[)9KR.IH?(D[;^5(BOXML_=;P;;F
M:F& Z<6NGDA#O(F1;UZPCYY/_7E02 O.%S*APV> W,C68\CW&WO"0ON09T#*
MZ-.NS_>IB?N9HGY6BY9APN[^7G1=5?.U^@C25GX=N=%(JC"D]);CX4Z.IB)M
MDV? =M7+GJ?8=7812EYYRA]^!IP1/0/N;$VR/:2> 8.<)Y?*SP ?*]OE]96@
MF7OGR96]K#P),:B#?9?-8Z.U_>68&G4Q9G#;O5C),^ F0.F^1P<#Z1D NY>Y
MK[URG$40:*ABF3>N*M:"RG"0GL,UAHS)A0JKD$;:\*K<]]L3^&33;F9G_'#H
MP6&[E<"BQ2IILC$F(_1KW)Q\^NZ1\)MO>U?)&>$R90IP0^+,5"WNYX(((^,R
ME&%"['T?#R*OS_O<=RR])I/O[L34PAU +E#\PI!>31<P'SB1-\R_82LI-5-8
M!TKA-,TS(R"Q9^1Q5R:@NN2-G)S:T2U'P3K:TI"</->\M-1<;V;IZ7;MOF8H
M=#I-;(1C-;7YB"H:H)F::<2L&Q&;4GTCRT=(I%^FP?.FW4@^[NS\.YZA!'>[
MQ%OXKD6>R#('L"2&$GLY#?M >GQU2:D2M8IC:<WKH:PZ694X(RN)LL"&1@^1
MB"E<NBYSQGZT7WT@M"<2*0\22[*N$.XH]\]^_AWNYSSB82.O, =^;322R,2.
M)_.QS;UI((#PN[1G_FS1"0W((+A%;C!.H;Y>B[Y#3M-'*T^>WZGP%P+AWCZ*
MH.'6J!O/O$%%TZCZBM[9:S67)'J/6&5X4'633F4X<>--6G.PT-3$HZ6LVO!E
M1".AM'%\D!"W0A!:H8/DG@7Y&*7]<X/;=<?OADBLB,/>L>Z\NV>1K(L<^\!A
M@BO"]IATI-+QYZ257W.J<>-V;4$=:_;69)IWLB_#H-/#0*ZIF<%$N2&3JT'!
M:9G]V+E6:KACW(^J[_B% V5"ZS-&;V_HFN?UP.B%DIH:;T8T[MV-]&Y]W%Q&
MND[ 10L*2I'3Q#P,W#0\$?0?X_CX9][V;1P0+J8KYD5<<R\@55^9@S.^1[B&
M,+[[P.G3NFK7\L@35Q'<USTA"-\G2WT$7X ZPLC5UQI"A+BX;$]4T>5):CKH
MV\):^M VE)=.;[32-]39Y[-^TM.79<<U[SRGOU&E5)TUL80M3(&E%VD'53/=
M:TVE,7.9H3>(UT%LID?NM9)4B5'@_*TTV5H.S7?-2UJQ!0JBXY/HKMO,>,GD
MT48O9M'@(_:O8RA9'Q-WK8-PO^Z81 LZGX1!2!%-)(EL].:6IB?=8577:UQB
M^_I#1XQ+T*XL$"$A*F!!:RVJK:]3J-$7\ .5D%<=XLO]/Y*6GP$_C,!H"#>6
MNXY.A&SSON1CDU/$3GDXF7A1:W/Y_BN^F7@^.26@4J<Z=2]E^7;KYK% ,4'L
MLSSB*QNET3C&J3U?J\/O:/M9C0OZ'HRKC4OJ[EPM4V5*[%Q."W,G\S!EKPNM
MW.,.BO6R6BU;HP)RY0E:[%3V"#=GR#(DV/9>MUQV:VV+IFV);^$%,E/^Q]^Q
M6&0GC?F.G!%173;I+5/)8?"V0L\ WRLN>5>5&.3"+=, )A=9S3K5_AYGUJ )
M2-AG- CL>FBS0_W@W4'IX@(3N&J"Z(@A,<B\9Q_-8,C@.YW%)U3E.&-!GS?#
MNE*H6-(LO;AG4I182:@_<!/_K5*%&5RVL,GIG3=JI?\#UXU,*+XIN':$A9EJ
M,BD;%3@Z)F9-%S'E2"XJ31<AO?33?^7SM_]I'?IO%T8P8M6L[N;7ZU7::1E2
M!MN.KOM$* GE:T<2H9;L<=^34*:(4)@\51%+?O82$O:Q((B"CSL.?^N-Z792
M%'RZ:;ZF^SG?8^YP>>YZ3[4YH=8"YV+3WWD;&J>*J8S#!H3 #<D?SF_%5PA$
M",BV?O]U*]32-SH5.\:-T,-:<LMW.:T\M X@N'@I[<Z9S9LCEG_.U$3B;S;^
MPDGZ/WHY!KMN;2"FA!W1EM W2J;OS1Y?XG_ '@NGL3?^^7 ^0Y3>&"L *4*,
MWL48&PHU-Y-MF3Q17M9OS1W9/-4]X/#M,!C0R\0.*L;@^M:[0:Y*S-5= MK*
M++ ),V,<I$H=4A5H@G1,A*_8S*M4ERUICN$R.9G]AK&RT2$,3Y%V6N;]EOA&
ME0/R@>PVMS "K*_;Q;X$/$#:P2_H^-]W1A'[I]QH,/<=(R)32.VR6A07%E;C
MBRX,_4X =ZA9-H0EOC,^HD#(=Q-37U7?A2 _VHN$"OHM8,,\/IV$+E'&@ZJY
MS5$_F+#>:66MU>/WR>'#B'R/1D I+VWT9J7SV97^< I/?A0T;-XRC,[9F:7S
M"%_D@^423W:%[7)^?@7GV3"K'% O@S!UAE66Z7A8Z-Y,J/_&6U!G-/_+6FIM
MU)^;4MMQ&;[\@E_/_.KXV\0<\AE?B2$U(^%#N'GP3C''II7XN>2$%)/B"6D
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M@?^6+:ND45UR]V*< KM^Y3)"U\^BE8EYL]B^RJ[<ZSAQT&[*ZC'E+B=M7F"
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M@F9/SD!!(.>\)R>Y/[AOCL<^1K;Q'YKM^PE3(;HZA41V?WUB/U:5SL(P\["
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M.]39I[(E,Q0SYG2?YRJ$YHY=?^<>R\'\?8,SK7E!WT>A(+]& ^/Q.&D9KN/
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M<F9(+.6_F!=)\]^3&D'' \AZ\(NN^8LZ*7B',@;^W<&*E^L4M[DE  HB*V]
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MV!!Y+.->.KD<):^9-AN?19%$6R4H?V:J]0D^!^R;_W:X_0/7WVX,S18Z*^"
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M4<_8NA79[+<#PG6IJ6R=J?J2^N$.O]%*^8T71<97):IB3QES4PCMAI?;*=F
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M0H]GQB7/J%.%3Q-5$>S=:8YJ0Z$WC(;[4[]AYJ5D,\;LU.5\<QJR&97T6$U
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M(2ZVC)W9ZU$?$9?\C:#EGZC\V%_TZG5>7<B7B-;%;OWA;>T\1?LY"1M:G]>
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MZ-W?H]H*@=2OTH-B]6PBA@*)LHF[,9FWX9)V !$+P_Z,ZE741"OOT]SR'H(
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M\(N&3Z%V)\AU0;T?J8.&WP8QO8F(P0\%KYG\""Z9WY1P_(K*6<Q5!OJXFGW
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M5G]66NOT.?PE%!KK=-6AYF 3(S@83'EF\FWCW,'C5I#&6-3F>H#..';*J?]
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ML7 %KCM]G9T6Y\P<D?AYCQ%3<D*%M0=SF0X!Z@*ZJ^V:^YFYV?+MI8?<AJC
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M,%+%39*5:J!OP9?JY1*O#:Q\EY)BO5FZ(RZW<^DYW[%L6A7E95$&BYQ/N3E
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M;>,'CZ9ND8(K/"-E.R7"+7=](SG-*P.#1W"159@W[D*8;^JZ\)%6/<[90H6
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MTM@-5<4),'6XJTK6)1NZ)AMJ1B>!%0N$8-UBZ)8@=W(%0&SLN\P;9>R18/A
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MTJ/0DC:]7W-((YLV/C?G?L*HBDTJC9&)[SO_Z:KLJDH+46MHX/;HI'G9]7X
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MT']LPRU=@CY6\&C"@F:1PU#*(,2?QX[#$%FM#9O_8:SG-3S@ 9[YY(=;>J-
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M @F=#=Z4FUVCY11J 5G6TRV\E7573;Q&/D3.-1GH[=7J=Y_\X,S$8^FGNS&
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MVSC]H=Z9MD\7 FV.^4DQ70E)%5)#N5,UERFN2:DIE):(=L%Z7WC*R67$>O]
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MH%%\(\.!9!Q'PQ&)XWGTJADE8M26/#YU#L,V[Q,HW55B]OQH!A1U3<(@@]1
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ME;<_EGM'/MZ>B^EH!@FE)HXCVUSJS]=RI'6]RYI=WK8;.WF_H/5BR+ 2VK8
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MQFQ7^V]:_?_WQ%>$L$6HK+]TX:X3E+0Z/'V"GI_OI(=KU6!B4I[.9S;14Q%
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MMTZD"'*GD?*^=%P7I#@D]H@-UI5A27@@2]*L-ICEK:?*Y#T]2&[4O6F<!YI
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M-%)%A0$@^H/SX:9B[KX*RT6=/MX6-V7_,HUM14.6_=M8C>CYRC'ZI<.,]>M
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M'&G%9/1M#LSHHJ? 4OWR]Q(I"3%?7SPKJMXVFSH21>AU-F9W5$[P)MRWWN3
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MW*\FK."^268.[7<(=NPTRHAPL7.KU+[O&<G!7/&H%!C%M43BT6=H3?^*0C=
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M*'  ^S+:J[&05M=@26W:)\6U<]1ZUY*(D+GI-G$T#B'4!S&F%-)#6UB-=G]
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M6+8T_F;] J5K[NNF;9)G*^:3_8EE;75TN<[#35Y??"+K U;F-XZ$&J>"=-_
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MN+2P]5TQ8@3<?&V>(_L]4LWG?^=JY^?O( ]P%HCDO<XC8_F)OJ:*= <,$@S
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M4DN_5A P64-87;ZIBO-1WEUBL@9YZJUQTJPO&S^KVJMQ+%>%Y-H?D)[D4!=
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MZ(/;- DZ'@W\N&1DV#[&SYYZU"?J2P@][I,P"7@4JO:?18G2V;Z)//&FJ#A
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M<]G[]K?FC'YWZLP5=&)-:I>>!)>\8$F,:2Z81[^ U$9R^[52U1A;G"T\KPP
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M4+[J'UVG%POWD)B"!?--) W*HSJSE8]0KJ,$%)Y7W3YH(SSPRJ E8Y"ZO.I
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M_<:&1Z@,BZ+X6* 2^#R#>*EJ<P0YN<*IW/92+"IGBJJ*IV-J^LL^!$V59\T
MOL-HY<&)O!PEE*#16/K.H+O#![/D6H_B":C23QJ0%K?'HW/M:L>=4CV,N7!L
MH@R=;VXT>68C+K-=XNH*7KE]WC$I7!"NP[A)]$09!EY-\_ZX(#;A2[#G'C1T
M<-+L,OG6(LI0[.OU."%?K'9,9CO_#PX8BGU9/,1@LV-C"/7XV%YEU_C8YNR@
M!Y>NC"OQ!C+X#D^.7I4I]77^3$OGM-FSVN0''_J?(KD)O520X&^U7MU\DQQ
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M$_)4^FCZS@<PA>0::2-QTOJ0]_^2'Z1#4 K$TRRG8L4O:V:"1?:I!SX(CQ^
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M!=4K!_H*9V4'5$S6A)$M2RS=QIS6=0,MEA;+1JMHMJ#;C$PKINO9AVT48'H
M;GWJU9*HT'RWR1*8K"SZ#N,4Q'6'09)X[H8Y;LN.<R\QAL&C+,,E,<PE(U"I
MNV<U3E;(#+0MGFQS+S_")"K7B8FS_B225>B(,;(133%Z@W.'@>8B67SV2UG_
M@TUNUDO:)-ZU_-4$8^%'\_/S<P&9OZ^VLI=8B9=[<BY'I?,&-"RX!NIQFV$1
MBPF".PF+:NJ+M8L.5X7-E%B6[N1*(PPD&14\,_T=C*J,]<-K287J$5_\1#$?
M]N!'_" NDQ_IQ3F" DC;27X<7.P;4>_OPW&&X_"G=$LHL$MI@??N,!+9I,@B
M+]:>D959VE'JF('P(Y@!_&^;2],%&L5A^AD\S?$\13ZRKY+6:S3AL*33,$+2
M:,6K[+Z2Z:E#6.Q;&DJ7G0&J2:K<:,F# AS+I@!ND24L50M].?!CWD?3G,^V
MT+4\];<\*&%G#A.&U]&P;IQOH^1" B)1J0Z)73[ECT?9J*KJ7\4A+OTX5!J/
M93@K%WXF+;8B_2BGVF5M2RL6>H:<#<3#7B'J1IWD#!<KE=MK-I8M#"U)@HRU
M\%E^_1NJ1W0UH[[?84!H;&V]Y2!H924GG-10=(]-FH9GY-)I8X%7!*@V--/6
ME!)R\+T1.EU&R_.9M/G<QLMA/O7%ZEK'O)],3&DQE][P'N1"QCTA6[Y'X$PA
M2TQ*O%R?H[_MW8M)P_(:U0D>@]8VCK,P(XL%Q3+I#^[-X$6/I\KY$^>/66+H
MLO5-*FB/J3PI>BH*.]^Z\\2!?E5:IH@\*6O5=[0@=OPQ]AKW^,O-[Y=>CI+S
M&7JQR6 &Y<G&"^^W<%#U.FV"E=H)[,MKS&7) 8$[<1KT8&)\:J\WTGJI36/^
M;_QG+,<13U=P? F5RS C"Q@34)R+5G[2N2TPFLK%2OW5\_5*[JC]PF5!'\55
MZ&GD.T]W@5SD0+3V52EK1#:3W:0?JKH*8E' &9K?W"=RAR%S>=#L#G 1\HMH
M='<'$1_3'Z,I=GVJ#BYW8^WVO7%M5"KDGNSS02F.A]X#[C"4]M==!$^^7.,E
MFV37-!Y,:4^B;'$L6]V(OU474L.H#3\>ED0!>YQ)F+]D0/K9.GEADY23@IJQ
M;]03/WC."9VNKPB[SK..J'U)0+.]TU9-KF(GWG;BA($A#IR9,WV=+:)((S!2
M16AJN.?MW!0ENF'^](K;KDI@N/%@->T\208LN6=2Z0X5\(!SO6=;W5;&V#@E
M.DO@OK N^+G$E,1-#XWU$(YKXVP?16ZP9)1JQ\_T(ELCKQYN*2?U7)#[95=9
M54C2)4_K89#QSI.<)ZA)U%,#J+N'CM:V/4">.$G4/5$EHR0 ]O.4,[."@)YM
M,?Z,$LB4=>?SJ:X=4:.A1QZ9%[M)/MWCBD%IW36 C#-[Y.!P*F5!0NA2Z+N@
MV-E&L;>&G!]JA5J&]>Y%L*\>3K<_>=".H\RA9TE"XL_IN9;-I'RMN<9A]TJ]
M!X+%I3!ISI$3::FMB1+8%PTWU'1TJ+0T-"C%<T*RT/ LJ6"N['.1-XY2[]E#
MSW8M-0*FO4]L&PN1)+7S(\;7[9;B6C ](6,U2<8HG_*&9XD7UQ33K^#!63YL
M;BNU-!+GS ]H)&9T:QO%/C>8:%X$IB^*T0%M/'<A)OB8O']P4F_UFRUD;J%1
M?N;?N6!\5_.9-?LD4&S-@=YD 0&9"]2-+4=-B=\EDMBSQGF[R06NI=UW:E])
M:-*LD$O-7P1JZ['P@A%J:-I\]>>Q!Q;V+P>8(#?$I#U+*$VR<\BZBH),P<0@
MGS<SB.@?@BP%Y[)+C$/KW#M4$KAC]$ _!L^CY.H>4GSG49;/+[%=CYO$1BTL
M#'JS5Y?QUQP&RBQ&G922<5I_B^5X;(L[#,_230_/7 NG#9LYF#]*[:-_D_/+
M\W) W/DN@3HU+R)DZGNU1,#<]>D"280GZF49T/GD92<0X7@O_CO[K3'#U<R#
MLZ]S#K"%=XDH0&C!P?:2,G1\S0[(KORNE]DPX/N J.:-5T'JSRA/LR#S(.%!
MEM2<Q%Q7C^&TWPB8LP(QG#QI$%K E\:FLT8[9 .7DE7R4PG8&^&5=NRCK":L
M;1$H'<'7+[(02JHO-LVBMV$@L2&1.HN9+FLHR%3A5)%XK3727* MQV+SKJ$"
MY3FQD[NKEK0$[?.SWFK._M3,-)Z<3%&2-9J,"%AIS[75.G:X1=QAA%:94#6]
MWL=[_X+X 2PN(B^VY08QY7A[AS%["3L=40B&J4$DE^A_+55P>'KXD06]!^TX
MF@QTP"-HDD!T5E8H*]VOB+=SA&IGSDME7E(,'.&-BA7B&M*VCM'WCAOQ*+I(
M$E?!4:)MW%&O/%/HP<^_J^E'W*]8&/J>)>:>1FI1.6]PB/--K?\14&KGON-C
MKXB0U,R6[/QT& R^7JF26CJ9&JVBS1\+I;Y@>U4C5O#$!UK8W*MF\XY0/2(N
MSD9&SQA+,ETCC_?CO.&D\=ZW%=;6215B!87**"Z+;!6H&R"[>M-F;V/X0"5V
M*>.>O/O'&6GF>G4RD0<\P;5DFL,KR%WG)W0#YL!J' >^D!ZK:8?:/G[K@FC;
M-ICC!J&)#8=@11T\J>GSM(>2HS^A>1#A*SV1ZH4 ELB,+ KNB"S<TO5;)F\>
MV,-R7EFEA4 ](Z=QK_T*3@VLT@9!8>MWOKQ=I2=OW_F+IC^)JV7W"B>B((-"
M35&6JG087R4TA9MZ AARU]_CU0EBEK<\MCWINEI372#91WB 52TGH9=BDQH&
MOFE[S:KY7GIBV'Q)?1I^^YGFJ#B3KH\-UYKJ',TA80GI'O\S=B4" RX _%XS
M$BH'60*81]6!Q_PE&10+<8%-HO9$JT!'"1Y#[X1"P1WA!PQJF;TBI=V[98)0
MFZ.%0WE;,:HDJU-<N6!H>-I;TR,[HA1Y._CG?B7980IQHL'"-TK$M"%+)D7!
M#XP)."T;F[&8"ES1F?PIX1V#'US<>73RUH*.MH><8[\"H!<:W'7C@*O5&!JD
M(?]?>T9UAS%OY<OA4/ASV\%!;QW4:1%PV$7S[*R:>"TNRKCL:VU$M(#(<%*(
M41,%+DYUHR*ERZ/;UP=>63HT<B^CLP":O)J[)GE  L*P84!,8-ADM]EOA7>L
MG^ >=F-,/ !06P%ZBA ;:"V@T':H6^ \V=.+;$UZROTY_B)NNR4XFIG\S<XQ
M;1$C"2B*?GU,2OL;5);@1_?#T7\E2>:D1N_Q*YTL>"HF^;1I4D]HY,7C;Y^>
M*E@(HA\R$-!?#NU\I:J^>CN_=-,_3=ZI(5C@3L=D2,G2Y569_4U&!Q_O 0PG
M3NL>Q.H+LW>2O5"R5#A_MC?R2L&G9]_PTC$P&TNX"LG.*/;H?Y'WEE%Q/UNZ
M, DAA!!" @DNP5T;U^ . 8*[>V/!+2%XXPZ-!'<(--Y !_?&O7$+T+A#0][_
MF7/F77-FW7?NW+7FWEGKOOVIZDOUJJJ]]V_74T\]NV=\;>-D>VR>P&;?.K-,
M#G1PMG>C,()5A/9YQ_(?6TU(-:FO1I,SM.GB'=7KS)+>KD,:6RFF)CH,P? ]
M;?'[2B%%F"AY11T3)>7YULN4508AN-!4L1/GX<:[%";(4YTAB'&76Y1?F]N.
M*\(OIZ[9U\]X*:A ($OX^V2XI\Y^+V?,@$O*^8LV>*)YUZ+F6Y].L>;%3U&H
MXPK=02'K:*=AL_N\9Z!1FVJ:UV8*XC_%Z/L;]>C?OI&LO/PGK>&/Z@G_BO4X
M'VU21BI1 N^^7Q>3*R>&K?Q3]Y\'QMWJC,PR02@C_Z!5'G97>=[W@GR%8-J:
MGILS'F*!SVT"C<)8&WX2>*WY!*8"O:V!@;+7;)&*P49-/TV>.Q/L3.SMV7I4
M>W^#W:> ZO1#VK<OU%4Q^D5N__I]X'+].U/MY!ICQY^M<_9"$'5?6#Z_MR6R
M$J;/M1L.;-J[/!Z'8GOX*:/BWH@47;>@?VI@.R6I-N0SD=TG><K^*,,*V*@+
M5D8TT7)9E%A?W],'&IX@,7K^Q^HM_\>:$DU!LB9=BP\ M3N(WJR8@!=J+VJ0
ML+T-?,<Q!#\^<]TIH=.QF<2 0\RNY@C'LEH,C^1B27-8-,IT<KQWP_RR_&X"
M#5(#B>=?#OW=<4[4NH4?9+=]C"GPDG;-+MS\GAP'V3XDG#GSGWN>.8N7?H79
MF+]BZ(0*-[YKU7W9$3I%0\/Y\YS)W#ZK^*^E,4Q,&' >/K-4/3I"5189!=7/
M?^O?<^+]B/G#;HWS4E=@O?='_UQ<.) T')C+MP[32S/]_[8O9C8OL'_ D?/"
M$.SK*?-%.<AH9Y72#WSE5K,FHHB.\??I_S/@F.SQ[YY6/CVV_1\.3UW0 =K
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MT3-]6QI8<&R)7&]LK@P$_[(IA&MUJ=?$]IM=J-+/ZK]@FHPP#28Z<_?-P1E
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M+4#M(?*6<:)VEF_=>Y5TNGOF+KJ+WFT!MJ$AU%6J3X+%O*WWX^>%=N);!*T
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M%KWS!^TW>5F0\)J5P--5NHW>AT=;6&[FUB;*D-COG;3A'?W:?^E]=>NF-^_
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M0RIU+EECHA^[)[[->/N6N(CY9'6R_N%%NXJVV:EG30.7\&!WNZ?967%0Z,9
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M-$L*!0&STQ44TTT1.O\U\?7O2>E);OE]Q&^9EV="V[2R7]S_/!?\Q_;CN5D
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MUBCY,^,97=G($7+EP*H7<*%GIKWX$1),, @PL#A;:]A\QU2DL>V1SG!N_-#
M$N'G*7E+(L"@68.F6?@L++295^Z6X5/\P8*9E..^B@N)H0S'?ICY6%,1F+DO
M7_9JF/YLNF%+[=6KS;$3Z.33:[1<X/(>46V,IG+?0 AWFB/8L6EO7[/!##U
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M4I5-'+(FM_917IXY1_M)?KCJB'-:"(RT [O:!+'9W%A?Z5:[?I.C(D]2E $
MYN5!&C\B(#XP&$Q P.]FR$[>",8)26V9<G( HU'DZH<"!C\S[12[>OU1D7R[
M3*/BAZ;&P,%RZ04\/0NPO?<^#5-3JYC:\O%XEE"]+^11K!W:YO"C#?[/%5/1
M %UQ;L8#)CP7Z>75XM]+.74',A/ N,<'@3E^'"L6F]#:U7B)2>3HQG<)'W]$
M69F; <O0$WG^E-P]L/Z(YMF!R8DM53UBH*EY7L]P7AUQ36J/A;=AIGECLK6C
M',.G07!98:Y@>ID?S5'&KC\?P,CT8F\+G7DY@'2@.9^(Z Z+A>;'K&5^;UF[
M=V5WNW^(^QQJ] @(N*[N8I%7ZIVEA<%D.L.7ANJY_N>G1O$%@8$0MW4,G*?8
MZZ-?K(!87_-ZJ=#WJN&=XXS1J/[<_I52;2C87^#SP#.!1%- 4JV5VK5RP]80
M[9Y209T%Z*2@@O(.T#MG\*5@!<[TOET3C[4B',8QXAJ84/U4.RGJK&@Y,T9W
M#^W;^-VV-?S9EJ.<RL;/=*'D@)=4<L<7[#=3"AXCET[U#J6Y!S8NT]SO$J Q
M,3)M]?[[7=\LZ\QS9OSXHGW<ATTG]6YL/91O7<4Z7\_P_,R(Y3(W'CC4CZLF
M8A ?Z0/ 8(F:W[XM0%UW-<@@/ZSW (P^ACUBC1OEN\7W1-TE,1L2JL/J[[2U
M-$<V+OI9P?ZO(7'!^GH0\YNNY7=Q(9&SU8KAI2FF>WJN-K;M^*2HA%G\-' V
MUZJ7H$>K;P%/F!/3\ZD+,W83TZ7'\/.V"W*+W;FEXSV2EB!1=G3YDMI006C3
MS?/^VZ=MJ6I9E^[Q>J=&W((MMI/Q^$;L.:EZQIS&=P#]TY /ECS>S0U))LMH
M,Y:?>P2/:@Y\XQ(6^PRH"P^I"S%AOO7[O?O3X>GL12!/3YM359.8)Z'3$S)8
M,[N X6FNAM9DA[WV5EUFVQ/Z>8R#?K+REO,SQB2D80%8A$Y69G>1P&(YSF]1
M+)Z-8O]KF[G9CD2%P"69%+,<P3"/109@M3;#+HWO=('-RZLJJ6\^"N]]G0 9
MWA"^F^QUMBSK7%GP[(X-?1"%-ALMZ3@G\9<A+;"X/G.0-RQZ_ZV9 LF%:*^,
M[(L S3@5O5]E'1DZB3H^(LU]''H.'Y9$.BH\KHKQ7HP5G*:P4#,/H,6(F!0'
MPN2%8N40I<*3P'X= _IL1(U)TSEV=&$S9W%^@\9^AHQTO01\C5O)WC.9^U,T
MBQA>6J=.>$\HZL!_Y_ \(27SY>"OZ&Y<6@LH!2?S^(S"1%W /#JCBB.C$&K(
MP!*DL84O\;G)AU86KKO#*>E"J%X7+ ;4I^D*)"6ML2 +TH_2CQNBJX 57QV[
M&)5ZS\/F;3E^ YG[GWZKW(@AKWVSUG- W$=KL43(IJ6NRJK?]63#BCEQD62)
MS)^!0N& J4O,^:7$.Z5UQ ^C0:S7WNI2\82:0W,G/=[>'8#3V'>JF()3J2),
MI*-R*Q_5P!6XO3.XCO;N#.F@3U(3:KHNARM&5!RT_A-QG.A;$O^V"=<TX9SL
M,)EY7T$.:98L+VXDG6]C13>A*TK\, %.KADL2IWQ)%H !N.O"/)F\_^NH9DZ
MSP!)=UBJ-5'08ZL.D\+A3'_,AFN.YAMD8072<?HQX"L3KSH0:;Z/*W*B@)[>
M$OZ.V7%C&NBI8I>KD6)%CI/+78XH":^>^J=V*2.PI_&O4@I#)D6":30JACM,
M3&]--*>G+4T3X[8+-MNR-.,KYHLP.,UF?O+A,[Q&/\P7.B"3O^IDSY\#[Y6:
ML[W8>C"6OF2[D!],ZWI-]H12N=>*3DV96GYJ[ X0Y*>V?3,]W&%OM+:S^L9D
M(8R=4'F*2Q:\NT//2\ZV]9.LSH6EGIK7P/PQQ X4)TP87:'Z<$1O*\U'%9/F
M$U.<:6O-)FJ=INTED*3T).X=V^I =N1<7NJN(6*R7$*7-8[5$].*R%B\W;@A
M"42_@=$2+/5GY4N_>76I;A\W86-"ON,$^= %KMMV:OAX,;-IG>;05-VFV0O-
M+,KFRJI@"%B*5?'O9+."S0JV&V),EJAV474R?+$9\] @S.4?8&E<7VU;N!)A
M< <P/K\# !4NGUF=JF(Q%<V%;[Q-\**3QLA'7B+M:-K=CT^?B@;D^X?N$1JH
M]R;6T?F2;QM S3,B+*A\UW"W1B6ZSO\"G'NYN.HR@VSX>LU?:44.(1"ANS,#
M-$3M&8O(Z[PA9-YL;P>KK:]:ASK8P;[3FI>Q==VC3LW=+?9]7GJK;9_A;PQE
M,?FD-D[)N2787W2[)R=AJVV(QT.N ^6(K<D"HU(%,Z=/-O2Z.QI?VX JZ0.-
MS^-05Z;=Q]PV@Z CPMS _"-XWLW$'4"Y7G+9BW+S3V1C/MJ:]>:RKEQT"814
M43O \>1)IN+MTDUQ:Z"<4L;)Y/#=:JL24P"&+M'9\%,-QST32$%G1L6<MZU1
M'I_/Y>!^6<DLGEE;>D&<+O'1=+A6F;8/U):H_WGUJ_YPQS4;G.K-67:MDULJ
M;8>U;M^X14P',C'::+#I9L%Z1L66I<VG5EQG:4$XFLHD_>N8@X8]>_TLY<'>
ML\8R>2._68\%"=TKB7:QQN+DW'2&":\@WK+#-\MI^TW7MU[CJ.,BWEL;SR"O
M"9/D+X@5OHLVVRU]WFDTKQW?4!-Y03R/(%%BFH/?%#5GSK='U_J_O^FS;>P;
M+[L=W.^?,8-&.YZ8/J,I;:A>V<+3C^D3J5GAB376:3VUF_J]PGJ!]'D8\J8P
MB=][-4[SQ;>'GPOU=_F6N0CHT)?R>FB\BU3/[BSNLD$I.T*=?K" R@+&5E1N
MC]ZQ>.AJOP3GG5ZYIVT;1&<':=3ZNHYM^M!H06RW60T[@7*<.+&H4_:^C:.6
M[BB35UU<]%R:'.2_ VSIQB'/"*=^YU%#-8GP;YB"5%-RC/F<F3T@Q,<G4BJB
M#0JC\^ ?IC*M8EIGI+LT'D($2G_5,Z&2%\777L^W79\'XZ6!>$26<M5%O<!-
M(,Q)91"IMR>JKGPLKWO&]=7L31F:ZG9M^&3AV5;CR277C%G%*]#B,5?R':#B
MG&)*P#0_"94[(1%Y0OD_R'O+J#BZ;EN8. 0+#L&"0W!W"! @N&LC"=*X0^.0
M!(+3N%MP;:RQ1H/3:' :: @.C;N3F^><]QWC?>YW[CAGG"M_OEU58^RJ'R6[
M:N]:>ZZUYAPS[=>:F1LHETHC"\ <^031[_C6PH<U)OZND?X5(4GN8QNJPK*D
MHG@JX&>&$&%Z+&WV)X8?O=\TTF$&*C^V7Z[J5_J-EO\;C:A]ITQ8NYN.V'D@
MKV>1H\C$@C[!Q5=17# J;XUAB4=%@;'!,#N KJMF.G$EQL)0E41!CWY>Q;%X
M\*8H?:'9IC)4*ZU*4]IX_SOHB63YR?$O]P+SS!$5PM/^J I&@?6OU5X)<$*V
M"8HE+&7-83P,TO?/.''0'"GKXP\VEK89O:@=/>@KAT=/9*4](T,=_<#OHI>'
M'L8D::\&QOKZ<U("9 D1@\4;"PX>8TD'B3!+^@L'ONP%@70Y-5R5YCG6MT5#
M;Y8&/;JT@@)QK!F;_02Y(F1,@D/OVLO6R7.+#ZP79V14;5--7V3VP@D-L(Q/
M2!UUA%<B>MCIC6""D2;65B\<]?-B57)"+6<T[=CTVFJ))+N?!!;^1K-)=J-Z
MZQ*U.K5"7T@FOQ25S]!J2=RHRNZA(IZ.BK%W=E"ST@DOAJKBJWD@^1L]4#$=
M-%5RTD:._BYAU'EP+:??:,J<#]\0OKBY)X"<LIH;5IFG9$B5Q(B]*9<XPRK]
MXAAJ74 C!;"1G@CQJ_3I9&QBA1J%Q6K/@]*TQ9J.6P/B+:J2IW:(<>J3T9N,
MS"VF.G/27D'&>07V!1ZO&X<)F[<.#G7)TR,'R^]35"'MX7ZJ1"R!>VT8] ^F
M.LI+*0=D^P0);^Q(V^B^$+A<;SKI]*UBF>9Q=:J/#@]+G!"'1;<BO@S!@1*+
M/@(^$581*N:P.=LWO]'&=W:B&!;#KZ%NO]9/)M=>P*^=G'#N5;IO):7G TPC
M,D6C&J&ZO2F=ZAN)EU<.,>0"RZL7IKQ6O2OLTGWQ/0V2.X2V2EOG8,GN4OTA
M N?ERG85$8$3 >EDB<+6;W#C]+?NK"JNBY6JPR.4MIUL?0>JP\-HJ@=[BZ+E
M0PY.^8?537H1QC+$Q3.G?7NJPG[WPSH$-"N=@T49;.^+ADW&9?EAW^/:PC\)
M+087VEF+"EAC/])_:PTA+^;KX8X,\L,-+U8UMZ**9X'(DU2,T6<[\4%'Z*$$
M<8-R%JK'%_7[=(63)!04RJUPR$12:VK=77KRQ>*#S21NPI7#36#H-27ES+1V
M -X2_('<M\8T(N/N)2/(\4!A&0GW8M>?5/O.E2"9K66,'24["B9;7)F,(=B*
M7$*R.V:AKV^E;M"8,=:H673(YUN=L<["[6#VCI4^@F ]K!'U?IL/EB]0.T'*
MW>)%C;AZ:OK 6N$/F]L!G\ L+UO4FD^^CS(?MQA/)99_._[1GZ+&BB&R.=ME
M@#UXV;S#@#%KU&:WD-MFL\@>'@-=!XWX[_IO= Q2OFD'%,WV7 NQ/<,R%KFZ
MLWR;BB*B)7T[GFOX.G%7&JOKU2S$B"Z$]+-!L'G4TV=_0:W^)B2)&E@%"PX-
M"[X--PW+H.5R8-]76L[/_QWHFDCU<&1O8D[<-'PQTYV2]-[TE=FI&H6?/%5N
MGQX0\G' /SF!*3Q8OG".8HR$K^*$(KZI\W'[;S2'I=%8Q^QY6V/:XSX##%3]
M'6%QM[C]A6B&$/S]\@VY$G.;\%"R6;EMS_L'BI Q:3NB@A %FG2>"&L+(6"$
ME$L\2QX36#_*.*UGC?L-#<C*C,3*T>#1U;_'(8\M[3U,1#< H%\&%K.^_]@:
M=N_[SIO0_?6UL,'*R]DMSU^OQ1S?V<XGRX"LRZ(34&MQ?H_5#AMGG9B<9@+C
M'HIGW]G'RE+=SR$+ ].!DQ^KC')ZQW8N_'E+]#/]9%JBT/L@L\"UN($UU:Q&
MB60G_?AAMG7U-+'@_P#/K79K5:NK.F6?ATCE0"2_9 P\L=D76-V;:'!BQ5I[
M>NRZO[^&ZG5B?'AXGM"A<(_Q2,_DW&3"=(0<='*H.A;S>>+-C=[+<?BJ7FS)
M&,O&"=[Q#[$45WDV-2[H59*-)DX^Z>=L09(3]FY>[PYJUI:6CEG/ &/D@YZG
M9V#2M>G$/_!RA]M87_[DPD7,^4L:XQC<7%2KUTFL,,:YQ <QD3$RR=K#J'X?
M9+C019>O_@G)6JFTD0M>[&<,LK^8@UWE+.YI'TNRD(FB-PX>#%>Y(,\13:!&
MV[.ES&PNBI$P:OZ2=>( BQ%+XXJY;TA$9B@U9F=D^(U,V5LI&K0!JP&RLO]6
MS/^_^K0JSO^F,O!.(^Z?@<E.!VO4X4K4CC=!ET64RO$A2W_;_5]P9L>WH;+2
M3!T%S3D9F*G$1<N75%2"7:*[2.D;F>YJHO&=/BTEJVPDTU!E1^BQ!$%C\1+M
MRXL]ZT!&#GWS0XW6G:NVXJ\N^!DIOH1O9!?PPZ%>?<1;D,KQY]E<0!1K'8NH
M)-9']VI\*R#H],\66#:V.?KYY-^N+B;JMOZP=:)'=N"];SO_&\WIB9(EVSG*
M_PF1LO8(6X76.A<.+A4)+=O[$Z5?O1CF[#EU:^+ZA6F]!S*SJAY);1&WJB;S
M*MV=J/D-EC6Y3_TH$8VCAX[B@P^/8L.DD&E[,\289Z8E7C!=/%IKB\0/F,=Y
M5\U.&II#:R66+@WF,#!\$A(0W:0 9N7;[R)F52,3C'M:/?"<\P1:>_OA_Z7V
M0(U=@ZF-+;E*(VS$U&%5U/G]E+-VH0 )W.H@. A<].1,DRM6P74@M([/%I"V
M*$W+/2BKFGTE,?L;;>2%:7)"C_XQ7V50M@\WA07#<S6-V#IO^\]GI].4)*@>
M':8 X9"]\5.B&MK'3+R(71A@UC5-5',);@%!=,2V"'N,.>[#P;WE^ GW>"-\
MH32^&?$K?Y$&P__)9.8*\D'X@5=V'?CSN;\&U&0/SI3R_7KJ($,Y,V')HUG=
M=+=+'8-)'-[\;=VK[U4@L7[OQ>/M+.J8R3D_$TPBM)F^E6V=OO%*K&%NG6)T
M*71O7D$V-*3J\&(*YTG9;S1/0A#@;:(;H";I2[I1!E7.1)[]GI1T:^5U:R1O
M(\XL^S<?(GCK#^;%4Y?:80'F_T(TPK_2(R7YZ,A6GCK%M(W<"NL=43$\^AKV
M;VU=H->LMQ.Y(+E_TW(E/CTHDAAQJ7C/[6MUWZ$7^*(9]LBS[C\\/9[&LNSQ
MDU*)X1W./F77(A[8V-_(D_XA5?&O]$B#\8/[XN/+K])9;VNN@">/%?[C2(#_
M3O55\=(8<N/NY[&FX_/8H@W($5_,"I:_"Q5$*Z1"@NDK3;=86J:[F67T-F/\
M^C,.L1!O?ZG<DAW,R*8$H=@X# S>< S,IMC8!-YP3&@-)E2H1524%UJ+H"A_
MM/P,B3P2N_1T>C\>^/5 =6)76?R#<3^YK1/ME(=9=!,XNE3(O@F]>J:1U70E
M-WU<^IEOW#^3YLQ4M]J/G_?#9:P](#.O>1*Z<T^)"P3/[?#A SL9KFD$V#8?
M1HYJ":KU)*]Y!VD+\&8= M\Y<O1P2$OO24NKTM-S#L3&MKR*;?GKIB*AHJ*B
M;P3D:4,"4!)'FXL5[ZRCC5UR3#Z6"98;U;!Z-5?A&3WU#XS_53 T0?QQ,)01
M]"2?:4J6/;>*%_U_RN'Q_9OCJ=)T6><8(_-6O% 21T?[YS\:U(2\.6<G8"&F
MYCJP3WDP?_#O?JG$I]_^TSY<Y1GP4$A;WIB*%P@T.$6D/6O;.S?+E2,1V%K<
M!SF" 2,_%OUZIZU=$YL\3]:6*AXM&\3ZBL85;[L-J/\\VX.ZCG9SR(MF8Y"#
MA?&]CL^1R.7A#Y09\*G70)>EWVB<Y2>!G _UOJW<$WZ5%),B'K7E'(&2(K?V
M:C?X$7<1F*N@QLUC@?+90CV]]WK=\/XB&.>H2\;=:%HZDY41K\9D^LYDG][=
M<5PCMCX -<3WY:F)4:/8"+.WZ^*]KG%67'EWQY_G''%NDRS]U;.++9X$U3B<
M[;(\)F.QQHHF7WPMN-+LD2Z/;WT'C#+?=>'(]EY!)F\5SW+R-_6GZW2!Y,3%
M=^0XX\5!QA:KS77M-A[B%!SYCBJ.:M8RWO [VN2%FPZ/NENGR5SORDE_2%V5
M%7;EY/E>, @:^Y'YHSLHF0S=WF+?[#@)%3GG]3FBB#'HJ65LJS1WJ+9'KFLC
ML(Y)E=*C\IQJ!>5763<CF$.3.30X":B9T)BMPG*8-(DF1=\X5_87N@K)DN*Q
M_@)S%5954#MP>GYDFS4W?<UN5\%!F=&XP031ZHD[OE*VSF@SDGM+$)!^9OND
MNA%K I&V ;,N;!2KS1F?'RF? @25NC23O__IBXB*(\DXE]=,TO?R-1 K_/+$
MU@OU>?54U?Y>SD4OF*'>#-VBV\MCY8$3Q\PX(\/2=;09OT62PX%9"W>#2<<M
M>;&N>]] < 91Z>U 9$23?DP24^LQW'PV(L#K7EJ&JL1H9+SOM9@XM&B1%L\E
MJ45M;EQ>4)O7R^V@RE[3R<[L9KO:N IN6EV)8D3C6^]MU,H?''U_0O,5;;,7
MMLBJZPAU):\ :>Q5%0F$*FA/--N^ #FR;9PT/)5X-6JI_-1J8#GV*:"DV4_D
M? TO).LCN)6VBR*%<,]@;DAEKR$QYED(7DM*\T_$5#-8_S$K;#%6?N*$)"W+
MS]^*Y0D9^+@0G,E#W<@>7C&7P4UD<NS4J\2_L"3 FN1C3'#3Y!%56TR5[3^4
MOV'LEYXS%[D9OY6@46U"<F6G^BVJV$S7"DD-@1:T%K)GE.&N=9PDF-I $C:4
M K&&!IDE#H&';_U;\CF0VTK^AK_1>+5#&1(KS'ZC<3<-X0D2</.2J'YO(XS2
MGTM++7EWF)":+_B=V#R =*4"8BI002'DMF"WRS1!I-N.;!BJ8G<V!J 6YE]I
M9N:3O-DU')5XSI]FP+M>6=^QKV@*>F52F["=8CG=D)>A/_ZG\RQIT"C$(MI:
MVO>Y>:=F?2(2*WN-* )\"X^3:4$[F8@YM^1<0>8GY<3TDY0S(1VD?A:D@R,L
M8=#JQG='PTLJZW>" TN;O]%V34.>O.3/9]7]$ 4?&-Y@8F&(10Z,RL0M#@]D
M#:PSN=)ZTGHR>6IZ(!OG< [.K18T4$*,D(;F@"/L?D:A'!W3+_/RG>H".Y[Y
MU&B(\C@"+CD'.5A]*8-(RJ'BI'LESK@E"URZS'PLSDUI= @>CW"@O$Q*B%<O
M*KBH)&=BSQ=]J5)AZQ-#BMJE"KZK=-1."##FESV83"DP:]NU:CCQ3S[@%IUM
MSF@I.#^_\2VL*G'++YFS.:M\O6A_C/(]+_SEZDD3EU7P0R-=T)J6:WL00&4\
M&.W]' EI,I7$"R^7AMAJEW=K9@G10G0A7EW,K+.?7PM]"GD#1%^+X'Z%1OP)
M#P@$6I[IO%X;%1J<A1:GQ"ZR@H]Z^]6\S"?;4:R-?!L3NHA:MQ1+4KE7T3V_
M#O#[QJO+>_HBD/0'C1:%'AD>"5>RH&!!6^YS5]<$3LS!GB7$/<09P)M[\KJ1
M:\UL5B*_^&B$[EG4IJ/7<-G/H"695]64D0VD1K:3(3:1(Y^5="?/;FL/R\FI
M8 #_"[GF\H@ES<QLN!_^N<->7J-#08: 6$79=J4G@/_E;F3F%D<$=P2RXRX>
MM?P^@_:P@[4N(+)WQQIT8/0\<ZIY2W.*]O/)5;JP05W 2QLJ%BB7$I ,)T3U
MN)_=7K2;WI4O3K]9>D7_N6'?CI^0>L5)2C42:U$0>[H_0Y#*Y/ T8'Y=),/
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M/UW<[VR/N=]&DYZSYY-6^:CEN66VC,+W6_<27%/Z\U@O0,8(3\6[<-BH6GE
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M@N>O-"1L[-#GL%XI<'I>BD=W.RORH \\F\)'3R7P#5-(_;9PCK@VK>TUZ5X
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ML0-TLZCZ5%7?R^BV):*7KQ PUA3H^!/H[:QFN93GZPL5/T=JNA:R]"P2*$2
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M@1Q4.5-@:''*DS>]J-B7*6H(E5NO!Q>E9K_..UIS21H5&+#BF9"S5".(P?B
M5F'PQI,%*^3U3ZP&>])NC.;\F:O#@-(E;,O8F?F&[JP,RQ7S[4<IG5=LVN\?
M2B/Z^O;8*;V>Q*>;Q*7OYV?OQXL2I'%XS_]&JP?G+6?9^\2PDVETKJE.B]-]
M-G>-P0U/_^09WWW^2BEE()BH:$@_IH@GGGFWB]VP3O5>YNMDFE&?$F7A6;M
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MLQ4[WZ+G RVW.0(8USFF+,0O;(TQ4QU#[(':OK9';^I.Z)=%W?NZN^#>MZI
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M;I5K5L2>00FOENU"!7.7:4,XKGFH%T-,[T8Z\V-EP0=S7T.R<L#:PH<#R'N
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MD:)0&CU>^[]WZ?[OOO%%QBO,3,AW,)?=[,LSZNE4$PCM3Q1W%%!J_:7WB=O
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MJZXN%780K+49TL3EVYP["!;L;,DQ)B30[UMD$7W)F2^E;) ,&%562[:!+9F
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M_&E?.7A/ _=K;YV=#A:)A\7&$GO7:@VLUM%SI(+*.#:-Z_:DT\9["VA]T+Z
M6%7998N\H17]3F"*CY1PYU"[1 #$!01B0($"&:V<?(7%6T.NB7+0"IQU_I>\
MLIL%N[?POH.(13=]^U'K6B';23V8OL J3Z'3,.LZZM<+^/8:QY',.RX4@?D^
M?@R%0/3)XE=_@TJ;>=)&Q^@5 ZR>UT8[8: R&2H[E:5WN!VO!L-;GZ3JQU']
MC#W::WY]X(YT3WW\783_7>A73D841KD5: 6L4G? Y.:6NH.U_*2MJ/Q5E7#.
M)4U?H=*S]F!PH/7\"[/L^HT/BFBS<2:9=S*4;NN58E78^L8<8CY&B$%?J'UC
M-/>K6X4\U08G ?:.)6UJ1F?@VZU=;HWYD0"<@'/VVVG'2[=^!R1IJZ,F=!#8
M.9?DQL^-*L9>@78<55WNZ)N;54]NOB>AGB!S3-J/9K999V*[<NKAB8F>:K:+
M&W;E-.OQ!,5DZ>I;W:[Q=I0O&#J4.#38,W2,ZPDS0]H+=W(*<0OVI@J>:U6[
M#D[29_HOY91)LE$ME^OJ1;)ROA/1*OJ)=]!V.LQV42B(U $KD)3+HM54+-V8
M[95H[XK8"M4H[GXJ[QL?<WY'O7<]-\@<LE":.PG%D[<[,IB>U<6:EF/9+P.[
M^,KSG_GR*U!Z][I;K&^4*V@VK"POC9^I&D1R&V[2(<2LY1C)/S+6B=5# UK+
M<\>;GR'57O<B)\:CL,2VU[P<Q<<Q'B&HE9O]^HM%S2:YM03QS^Y-UR<#I_>
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M'FQ?[8,?S!:8<EI8&C,,+4UY3%JC:I>P>Z'_'+>V)XE))[Z7A3A->K"4LNW
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MHJ=@7&$"[(7X\P4\;B9E1M2^KK2Q;U?BW&D#716R4X@DGP)E<G!>DD<'+&P
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M_2<#0SCB82;1Y?\=]/0;:>FW#O3_.O?6=_W7O3H<OOP%^YC-$S$Q^PYWXUS
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M7=>H1&B?-G:9+N^D,9Z+@(&+A@O5HAMW7@.9.J(ZI4MKMC'?JZ:5V:)[++P
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MYH3TLCAF87TQ.W:]:_W<3FH7.]3EPGFGGNM:H?/"3;@^I[M",K"1"R_HO(&
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MVKK7*0E6,GO+Q2#&Y)^JC*H=I#]8]8'VVCMJZ?8J=OR+&^XI-32Z;1GGC.-
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M9??-&3[[.YAKMDMREV#GC9FAX2->4]G#Z^ 5N7IN&TY1$D&31W[&9Z2U=[B
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M(T3?+TG,\"33)EQ+/MMWOHK=$*MR7&,P02$&]ZA6?YKZV)5 %_X[$G655#F
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M7NLQ99^\'J4Z8^EPY()G)UCPF/&()4$TO9:&'[8I4M'LS1A<0% -\_:U6AE
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MR"Y908#:7+1F>A*;@OV%<W[C4(OM*W-4Q>(-@.QP@8N7UA-HF)*QIM'D=UA
MQ#9\#/5<20V::S[9'@'L7[ECKS\=U";)^1^H= 5XPDD4QSS[#RY<%^J:R7[B
M\+)"/T-]MYI["N$].XVG11U[8KQ@:4N[7--ZCM.BL>]?X44S.<>8#8'OO^RM
MS43@;N'C,LX]G[6CJPQR5CDMQ1O95BZ?]XY',(K2*B)K\-JLMV1O+T/6DS-I
MS%GGDN&GYS_XK^V,02H/8'YQH]+[NR @%B1M.L'0<0_;Z0CB&]2V[X-_6_AP
MU33<TEZEQSS&OX+2EK67E'3>CQYFAYX0*4W&1PRWF?<6=4?C_:3@D<8\=L&$
MV=W B+5/3393:IS9+GU?*M-4^#A4(5$MB-IRK5$.^T248+P5]0O_T]2AH4DQ
M>$$K)G&E>. (/?%P QO2^.3[\#Y:<@I\[;NI9-Y*F7?^<*\'$' =]I2F;W[G
M>LD] 'X%/:GR) ,?M9UW&%SDOT &Y9A,!"@X6Q/E5SAX%RBY4W2!]WWNWI>@
M.NG'D#)\H@_X^2 WE!Q2;"PW+:RV+8"\/7?]"=UZY@G!Y HRY]I?7?%.H*^D
M'3_8.1EO8I88H45\GG]Z)A9-!E>DP)@U5Z1&5$G;C@#]&7UI4=!CCNN.:\V#
M"VE#Q#<SSHZD<1''C@&C&.!1IZKL<41CIF%7^%5I'S WT[6CGIIUQ[>G#80\
M%T8W'95X-4J#-[&%P_-+L^?&B[YOKX@D'^I1W8%:V;:9O('T*M!F'1Z@N-YX
M8'$K@B@LZA)]FMQ6->HY/J^+4#!2Q+BT#CL:YVXYFU7= #[#;,;W)@(S( 0A
M)B2T(=,_N;5W-];.HC!F[5;04"SZ%'/ :31[=!9,?WQYF80JUM[=/$WMO6I[
MH^B/I3+IW+WZ/GH#F'*^;O#U7;@D*[X!E,[> +Q+2V"7Y+B=8. "WD,A\$I7
MH06^^X\' Z7Z-P!KH.+L2:G2(.@TEGD3'@3%X]<V]_M2;P FU($[4Z<1,POU
M,HI;FN5%=<A3(;T; / &@*WD2X7%73:^OK:] 03=D2(C,UB>)1U>J D_BHF2
MM9)7C9TX=^@*HF8=0Z7$4\.P78^J)"4V,+F>'J7>0E-?("?[-X#$LIB3_B5Y
M*&RU7H*IZE7JK:\G](=UM-N^T@%,.W1 206ES/EYK"Z_RA&&W3V$&-EW<@,X
MN 8*K!R[=V0JM3.B_<.5+Y^4]"9H';A=V\L??RE+U>^$@8[T+R8F^T+0M8(5
M:/VTHQ'DA:OU#<"X"ZEZV710$ \';G;(>8N"YT3W5X9W#)[\"&C6XCZ65=SH
M'\B.37$Q-I38V #=?V6=(Y@KN>E^N]LR-95K?,YCKK6Z-*XOR<]\O@J8[R.W
MTD&2CVK<$^ BLEIUR@B\ 5@045Z?OPF,48J(8E/>40A9ERPU*Y),592I)_S%
ME2J K'7'(KQVL&U;5K$Y/0,Q_2O[HG$OIK=.]A/O=/S6TAR?X+A_TECM27H]
M-=@@(O-=R%6 Y4"R?;;LRYL]3)!7QF"W0I# X^\U!RKT]Q6_D0Y6$TG6\LO?
M66$0V]WNR46DEB[O7A;0G!1<AP],<-T NE5.2?OJ='-7G=).."ZS4[I"LI9H
M^Z[&/TON4$P*Z8$E272:%6EC.%0D:?!7Q/Y0D2=V$"9?6^'QT2-924XR$J$Q
MFLK^PTQ9C7LY,U;R#4?;SQ;F=)0HX?6]:K0D>AN$I?:%;'$#(_='F!X 5[9N
MK2&2/[2-R514M_WPGHYO4LWJ<6:@A85,RAW*!P-"RH]KJBFN=),I&,^MRG^@
M%49E2BV#BF!AOW^K-#:!/MA4ZKUO#'9%%Z?1?HSM_=:6$%G$Z6<?EFV:-4BW
MY]GB;$E[6$7*DLS=P1G-'Z0[X#:*UI/@%(-NYU<4PLF/8D0N]:"?6AHS.P]_
MB0]5-#(&Y@E4IJY,Q(3411[\@?> /ZB;SR8//M]F_:,HP=>'_-W%UE%/X]?T
MBZVI\7>O/JP\I=MQ<^&]Z^LTSLAV?4R\4!([LR]]X _MD3G\O.[(_B2$Z"AU
M9BRC\I@WA"D+2=]![)GHH\I]<"BB=JUZ1)/Y@=DW42;7K5NOW%]Q$8E\O>2\
M,^^#LVI;T/DN>:$A&'-="V0<V\EG+P F#C:%3SNZ.1<+#L3U C,LK1P;$^GJ
M"^L9S;_=9T\96KKC4?'$<X#_SR"K^#(A1W(O"P_]CF_Y]@@2H8C RP99!QLM
MOT+5CZ6[M2R4+C3< !Y=/7H\1SLAK=R/'Q1RR$&.!5_EJN5L>8^IM^+_YA$8
M/%R[)7'@7HZ\;+L!5!PI_+BT!JX@\#PAJ0HN1Q^9?5I"V' /C[>F+TYU] -H
MV1C]<@MR<\) Q0M'OQ905YZ0*ZC51&'CZH@B7Q32=L12(8#(OU*+_FNIKNVC
M37#T;^TA-/D=GP_$\7@;S^90:HVF<@\_DQ5\8,6U_9:3ILBG>(.//S#<=5GV
M5 U.A7_5,;T\/0<_L)BE2T7XBS(\GL^I\SRS<GP,+;'\)P7IUCS><(C*I ^@
M.!X:H^_[4=WR@3JA)Q9B&<@LY@]F^.17*R57%R(%)SZB"?\]GM#/D#9K,!7I
M]B>!\./SR#R&0:SS;)<CSK9"Q?\37.IB E':-F/,60*Z?9U!9!0KO23$>9SW
MU:KIRIX]0'Q^O^-<^'MX3FNNM)I@CO!,;;*.DF6WPL>'<Q@J!ZE9+%VS\PZ0
M#UZ];]B4B6K9E9CU+I\)+!DQ#)=X[5HQ035KI';*USIBM-,S0MD>E:&SRR6Y
MD<.JI$PZ6-C'W2N</(%'9.<G9GT[D[;8&;>P.-;PEKC%6PJ=.18Y2T-VM?J#
M\L+9#"S#8F%5YH(LWW.ESGG6B-D<:)X.$PB8'XX,W4U[9Y_T9?+U%ST+YRNV
MUG+;)^93;NNSD+=.(*? UO%YY2NR<%D^QIK/Z:>0&+S!D1^L'[D*NWT2!'2X
MZA]KMN*IY-V<H^*3C\ND3_P@4%30;\Q='A4J'R#C'#CQ+>&V9P81A^Z=L#>$
M2FFAV2X,')V6^ETR!=)EVOW]WQ7Y>%NE31+7,#J5/C2&TL@,63Z^><(R%B90
M5O]54RJ7QF2U0#>,LUA3*Z/$,CO8J$1!0U(L#X;NM5"H29RM'"IO5R/K'W>R
MA=+F.4"><=$2?)H.>_X,PB+,Z6A#[4CMP *!V'N,;#+-Y X#GX?S2;H53)GS
M\OI6J"ZGG8\85X7KVQPQ:ST[4M"4P:L'OC>]SV6-V&?P>BZD:YD\IT DG]2-
M$;^KHQI>!GE7XS>M[#]J[UEY.=[@@U,Q]V]X?/M>O;6ITF*=J)K\\Z?V"T%I
M%SJ6,XR=G5OE N]ANCQJA=][N\3<]QJR&_F!A 8;V-E)VV@U])U@.MFCLF;%
MC_C/**$G3;SM+'_,2Q47DOHVI$22++F&EK.*,S(,POK#7B79Y0TX5QK.(MY5
M6--MH1BDR[2H647/*?$^TW_ %8*.=1B.5F"RD+^@P($QEF9WJ*'#7[!L=!:=
M#YO. KE3%WL<"Z/,C6J?%)ZJI35/U9,BZ+_*H?4S"9\-T'IX]O?0PDCA0G!'
M\.$*VY1$""$I>'B*T_CC6\1%9O&V*/@&P 9NWI63S>,B-+))LHB*^IAHH.>0
M,>L]MCX*R0NDT]$5$,MPUG+(?3VV4.I2,SS)"%G>_A Q'T08H@7T+;5_"^UW
MRD*]Z).@EP1TA(K*>KAK3A_H<5D29OB#,V%B^[_8@^*++XQP.4\9\.8W /77
M9&NYU/K+?B"9YA7E40K//T"N_NT:/> )'!+\\]:1RR8J_5/SPW,OQN21)U7(
MWY\RQ)!,CX<1S:;-Q,&6/D=24=MRB@4NI -Y7+I=(RFJ5&J#Y7ET&_@1H;R3
M-QC$!H>03Y^/P/*,<$:A,7%);1:\9L)8J;/?S)6U@%8@8XO]Y-1M0CYCJT:7
M/R5G<*-\Q%9CT]P <R"E=2SL)V-,\'&IWG2.H:M<O:?JV:%ID9UT.%KC.^S6
M ,%HNOW4F\II:(,0\)[:P$S-#U$<Y2.+Z(A*_0<R/9MKF\8@?[Q4Q!;DS2+N
M50[:Q#:I-$E1KW6J_GIF]UY^M[,569'/8V9)74+AL^@&4^&CMTC;/ =>$D&%
M@K(_CUK(?4.M4=.Q&CRFOOS=V+M*5?22HL?\D1^+AFP/_\[OT7#I0XV#PQ3E
M1 7?CS; \M2R+1YZZPG&"?&1![A;CJ$&R74MX;J\FQS'2SM>'%)UAI^ZTNET
MF_!UY:78."+IY$R$4Y_;\8K^2<[PE WH6<;JC(YXASLT 8*;RBX]$O#'&%]'
MS.@H@MS?UUT-$.YBMPDBF(>I0,6^GLC$E,>W8]2]\CY%KM+PHVO8)]G[8AY]
M%_8/KBJS+8L.TD;*)RR6S[!<,>#W$?MK?QYU>S;RL\YUR%<UT+L5B^> 8S/_
MG);YE:\^SR[%;-QAJ+S]7,0T;:"7KF[1[TX?W.%EZ:_)1_P_5QE0'VJ 8$Y1
M8B/QQ[LZ)K()) ^'@UCB,E1^C26WV-T:FGL;"1/IO10;__ZF1[I&E65E2_%U
MQF15][D0T9N)J%;NRN*0@,6QW14K>,!P3[O#FL#<;HO^AY2MS* ?6KQT.<TN
MV"@C]UV-W8<LC5M:CDB.L7?JZ94QRO)F-/+OX77U@GN651F#]17RC;]UALN'
MJK]:C/BJ=B>)'8*KZ[)UD931L!K#0MS3WLF*%T?AR[*V#30"]&%]3FWB,55?
MNFP6Z8YX)A_'D[GGI1@>2&^/!"(<AKJ]IM-&S**CLQ?2?O>9E!"(._^B=)[
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MUKC:)Q(\=_DP\F8'(SC;N^*,5&=1'AK?-:BG[[$I:%G5U[/V71AB_Z+TE.4
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MGXP8O9N>)?!LI>;OJ0N:@V2NNW(_*6>Y)5%> ]8[Q"VS1FKO=@^O*4_Q]\*
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MT6'2(7C+O>9;ETX6D\8Y3?/=H!"QK;U;ZHFN:8:*GU_/Q-F&H ; =7@&O,V
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MG7:LUI2)QU1]Z*:U<NI$EYWM4VBW:H>(RLC3T72U]QP857+XOLMT#KW6RW1
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M"_NA8MS&B6,LZ3 1>-?(Y*/-5'*H](EMK]GC?30A?N9CYX*5)[^V-J]F6%K
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M8 ^J1M"5/CHBHD8RO98:0?!D'KU7_9"Y#,62&.Z>;X?,L8DZ8C]_?6107:B
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M,2!'T&3H6_)'F_&;(."YF5F<E$?$YVDM]2VWKW[55\XS.,Q5_@:O7W0T+"?
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M/N=_I-VL<SD)REW&<HFK7)8TU7IFF[^MX= 2=D.IB<,OVEZFIJ0QI#BJVY#
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M04*N+C\EZ^?*EUW6[6<.R(Q@V&J3HY4>;PQYLJ?[:F#:)L^_MJC 0UW:\S)
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M>VOF_ NE%JI_]?2FY-(F>S!X1,L*;$)!Z+-GSE-\0A&M)0H?XU0S?0*P[ '
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M,W5[AMF6N,#4O-N*O-N$PR' N:_J5:EJ[[']*:,]@#YY!&=N9Y&]R^;E\^?
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M#09(,'_J580QE:RD?5Z^<P.LLCN(8"#AF_GT,U=,C'B7W37(P'I^YP+G?YQ
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M9T1&U*Q:W\>IAB%R2L)>K4D$5Y;<WMQ-C/K!)3_Q3#$WSXS FSW/VTQ)FJ7
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M;QZ\"<H6!D-Y(!R<3J#(RQ0)R=04G=0D'W>PMPPL9BF+YTE,FV1]_5RTT/?
MPZ_/P!(R\?])E+)PLV_W*.(HO0JZV4Q*TMT@_%>1"<):\5\"DXBY#XH@\'1+
M3<-]A\.5A9'N]/T$?%RG^>=F;VO3#OW-Z!TU:OIP&.H:L*[P@/75#([LU).
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MS-JW*VW0Y>3 .; =?%G=ZBU'FI_:1DW3([U436"U89]%20\XJC@_,A2%OD+
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M*9RUXQ&!$'"I2)0\?ICAI9 [!@Q\#R['UJ@B[C.L8^]Z(7K)WH."[B(E=',
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M$",Y+/"AU_Q#,U--?JV8J[MUVB3U@FSE=/VLT,"DEWX#T65A9KN&484CI6^
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M>C,3;G,S^7EW\QX(Q+Q0U_%]JG5BT_:WZ>T:(::*0@HE[U'>V\LZ91NVOUQ
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M:&IHS_K WE"FSC"R$86YI\UXZ%*?OZV V5:J@]JU(KXT&K$WQF?DATJN\$=
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MXJ;AYFT XX+W)B^0?8S5_PX*.FWJ$R$SQ;-DT8][ELP3;\ 5\Z6("WV\9_K
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M%G!]K*2>B;\<UE9G>X9\NB0@+P*IIA2IT1%,>F5!GAUL)N+$A_65$LE67SS
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MA#=CT5*M-HE7HR\K99#::>I<U]7,D=Y3*^F+]/LCKGZX(%*]S4OL6V%/<Y5
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ME':.WB"(JBYGBJ-],T3O2T3.B;W,,6\]7S89($L?7=C%>MA:(HA#7"^:YLE
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MBA?P\N6M?HYGXYK?S&D5*1(=U,GRM+B*-S.; X2^T!GP89^4JQ<7BY),0W"
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M793J#@C/3DD),A\22+".//"5@W.L8=KC,ZMA56C4)ELDLS&,RM5&Z^A 2<(
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M)DJU:R8<!:V"%YUBSU=W]D*)\BD-"]/[/KE,-HXS($TU2V\L=N0*M9HU<\N
M\^=+"_Q'^35;'D#\!4'3ZZI #>>"_  A]@586F3:GN75(C/(^"CB5_S&@E#>
MDOD7=24?"A[ BB-VZ(4+2QJ%%R-A@W,=EL-,<<$L_D/J[WDM] )#>.GR7OU,
MOR]E..5J0:^"EGBWR^@:9.4;62Q(1E*[+#AG\A8B/$/24(K/RT5E"=XX0O@!
MB +OSI)W%\5MU]BG]8'7S:=..,5QL/4R-7[$%'Z+L(O;RXWY=^HVWC8R2M,0
M[2NEY_SJ&Q9TBSTGT/7ROOWKL>2-Q-[4$6<Y)T2[GHRO-&F$MG8!D"MC9'MM
MG>:6.^_]R.'FC,#%,LSW>6^J))14=W=!/*>I[?(#K)E2<+$(- B J&)KM6VS
M))PX?&:I:2RM"F,[7V/%V5M:[[I]Q2-;OX$@*:6]%ZUVA,UH!Y*RB"=5;HRM
M9FNR[KIJ$+Z9DF\4FQ.XANYO-"LX/IN^HB![@=]*WI[77(,X[VW7RTB1,OVK
M9AEL$<3-UZF"H>LN [9QL,EU5_-@\@H&VOY]7Y'Q"483]C?5LC_94"Q)Z<-3
MO1.-,>U&;^+-U2#@PR]#QOZULI7IEXP*Y,WP#F*H9E1!BE_)F,4/AG9>>-X:
M$+>&R=IDILQ9HUT%<S?.ZG"62"(C@<)$+'9;)#^;$GP2G_^HXD6,FDO9H-UC
M7%4324]13RY57B:MY%%HDZ:7[?K#_DJX,%.>2XF.)X)86\N$Y_261:EW;@@>
MQV^@%^E8"OMFGZV;#3Z%?_B.^J4<?W@N%';DLMK:27OAG4497L%>QI)82?6U
M-^!C\;/NMZ9.2=][)_",R'##:2O9%4W>8PJ_DB,/>"^^4 #$N]3K/"B?-M<K
MG8P),3K7SRK\1/ \+2VIM43+*[V\DS CO%R[YR A11I^$V(I0W79GV&Y<(1S
MR U)8VGM:4I;C1F<^BBS>R>67;Q6,R.ETG*;Q;H=51^;[# V=*Z$&>RI,I.H
M'YQ\5C#NXL9^OC1[-B<0*21_NWZ?OA?U0/%L(*3$[,::I(^TP-OA4=%%ZC%"
MB.GCW/KY:+G0P$C1$\SX9\;DT#K?Q,X#AUNS6=*-[7>^.Y._G./U_](Y<O=;
M62"<Z&/-F V$>I8\CR^'UO0OD^N\*327# +CV9LLSQVQHH2#5$MQ#J-T#<U(
MC39Y(TJ@2<D-]W48QE&3@@U/,+1\N4\PDEF_+&7L==/9G&?R?A(;],V$ZH"Q
MS7R?B87\".!MOS*$6FZ:&@\$3JPM,O67!-NB<QL(R+)XV1Y9]ZX>+Y<M*H0W
M1T/R.2>[OCCAL/-Y'*7%!E6W.'E-\',R]R KX6KW(SAZLO4.TTA1>FWPTO B
M2TS O4?,7ET8715@*_,$;E=A4#\PV=JX?LZI%)FY-6"C]KB-PU1:,(Y%%<QA
M&^3A%U?VFL*_[=2PG-Y;ZK30.?IQ^"%F3F%O80G:U[))$C\"NU6LX;@W8.&5
MSKY6R\R32SI*PD6RF6+5H:_DT\HKLIZ*GQ_EU/9A5C-"Q?_KGO7S6Z@N>DZW
ML5.#?#Y]+D2).F1P,I@\HEVUF\I^5'L3^'+.WSQ\/9$>IB-$+Z-C\W=;B?]>
M"N'/!(K9>J6W? J..K@K.7=Y8S\WDRQ--7WGRM;B,$!2\56MFIJ/'"3"\HSH
MP8+I.U.2,N*'6(KH;K$BEV=R\!"BZ#E_RQGR6&EKM6H",5!9B'Q.9FVR0JJT
MM48R.L$JEW&H,L]P<B#4SD:[T9MV^8B>R\S[P!;]18A(_=TH=?H#39G>:EG0
MS F\70EKWSC^#&D@-=G4>1-Q7L(9@>8WF@M2D@Z<+SKHK9@DI^8N7 $C8*<I
M[I3J.S 7)TT0X2LG9CDQTRI:&M5 #7JB/":&C"8*958XD?#A=03$6![:%TVG
MZEJ7N(?!67-,T'&=ZD($'=SS1&T@ 9&N$Q%:YF1B.\"2$3Z(Z 0J_RZN1S>/
MP.@C&4>9#.JP01<9MW[.?EG.DA="\\2\K]:N;H176_HT?BC!$+-LZ0<JO)\/
M[>E\&6N\B?%@'R7'AZECHG"')'CTX;F_ZU<'DCS!*)Z<')Q"M]^9.FC!%%9<
MU'KR4=J)>Z!/$;3T:!G69U:@AI]F#;6Q'H T"Y 9:AOH)3@ X8?Z>E(MS6<;
MDB:*&V;DF /D<8U$L=**FS\1<@/T\WLD?J1X5-@WP7&,%UR#:,X?H?M\J_DS
MUV='/D(9.=0>)L9$26#,_=S>FX@.\5-3]BFK]7VM<'G;=?MW3%)&EI,:.WX;
MB*?DE6$Q0*0P7DS@R5>FK:/C,P W\U%=E@= ;]$.LO!<3LWLM$?)GCN67[]J
M"@[$\N(1H-0J0S6>ZMCM*(DU%4<:WBXH>4C0YJG!DM+?Q=/':(?Z[OT1P=%I
M5HV&N0U+<+O8C#-Z2&9;W:)6?L1(R1JDD+%!%S.*A&ABS_K"(QZ])8CL.J2:
M2QITH5YB9NO%&O >LQ>.R"'$#P8%"0:%-00F#( 44LT:!OCS0R;TIQ\V;&[6
M+\S!\KF5XW"TCCOOF?;P&[6I';38MM]X@U]HLTO.:VRYEYY@5'T1/.7+ZOZ0
M*L*[^]=\0?4CDH655PNM5RRS3S"A*:9YGG^U+%86(%8<)?1-/["H@LK/!(Y#
MPS.:/(8/31Q3C9&CVTW7%KT-X96,-IL FBGK072KB+&B#J&LX6XPN#8:^S88
MN1KGL0>N!P)V]S16'/"%_V]INOT7K(,42W&W%$R2X 6B"634YTKWP9'WX2O%
M+IH.^S+85:9:XR "[RTN,8YM)"!^W,=\_U#SW\$(+#R6:5>6BCG,;CR3FCB4
MP\IVD)K8N)>1DE,QWMLSO+Q)&DY)UQGT]^5\]D(9N,^-RZ0V/^I;=;%QRL"U
M:M#]58%!EO*'@&P00K>1]=>A\:4^[5?H@BZ41':#8<T]M\^,6DE;A6BDZB2[
M4=_W[6FG4<<F-(6XA68FCS1G58T.?DQNESL/NSF[=Q=<-BW!&%<=8P<U&^^F
M?<3[A)XTYG&G#+V-^?"V;W>'VI?KEM##O[*^?9[K;#V3*_,/&"DJ+) [;SG<
M7@K&N\XM2:S/K\+[C4T(UP[\52]M @\JM&Y@V;9[YWZ]'JC3^L=U>$LY*3;1
MPS5A76>3N^%PEQ_3@]W.?XG"E@M0[Q4D:*$])827&&@/6<9RLUX[.ZT@L($Y
MKP-W5#_$E&WZZ4:)VTH&33\;HK)E@R91YEH3LMXE,UA"(\7 #DBI8LSX'L$:
MMW!3[2@#\./U;=)Y" ^.B+A/,+)+"DO-93JJ8&\H_W6[\A97M>B&>),X7]!,
M6I\LRP1)_UGW:,<-^T1_W9@'EV?M#[VY/E!>HDKL5GIN48T>!(_B1$=F;VB9
M$!=A8_APX$/%IRI1_A"//N'FRL^T(O^)M=,'S[O'=)\Q4ELU(5Q6%+N)*925
ME?/U2[\[QR_7$#]A<=D6TFR%)QCI.VGOP'F#E878HNO?1-0^L\S_3,"KS6%/
M,%+5[89562UFN@._D P_<V@:_J.UT19Z,_=/!36_^<"=,F^:)LK#+(-'S@VU
ML 1G;YR*O%EQ[^K])YC>EE"(X]_2^XN6G]C4.CCW.-F$M94E\Z[BK2<')_*H
MS-)>:(UV"38[3IH')2=_>-=W;=K$D1<;04+/0=*ZX>9Z_0%U!.((H?*7+R[?
M/-RKJV:D@]_B>&RQT$<V8G4ZD<;V:25FW.*NLE@2OCOLXO3$%$J6(XABZ6/8
M9/K8%E?A<+K_PIUD0D<FV&C:S4-5<TF!);QP:+X"11+688;GF@% -!_V7!TK
MBNUEIT#X,G%V2B20QP%E_AIF+B7D;R]C0J$]"XE_C,/ /\SL:$W@)UTI79O,
M@/1'[W6:F4KNE$H9)PL;7WO0;50SLG;WH0GH!933+/$.8<D>&]%UC )"+$Z[
M$4'\U@EU0S8C:]\OP(@8Q1PCJIEV2F:GT^QSUFV"AIF)4L0>+S/+BL^B8J08
M)5FZ3M[?!_C34#'EHNE(C1<?-ST:I]RFX36Y)Z_.>RNY+4AO5X%1WR\<JOAT
M82FG=N>=J$UH!PU-Q&\R]!B@I$3;7']0?.CS0XO;:0'\.+KQ7M%S_R.E5$C]
M:C]7'KB;YP4Z$)IGKKT7^OBN55@A*C?N_." !:KG<(]CU5/W8"E\[NB3D1%X
MQU NY%_F5K?R1XG#I$V2,#L9522XG>9]MT!7EU3VZP&_LK,:NQRI^CDTF7DI
MC;$I37Y!GW!/H8QJ8OYE]D3U4K"8NOE<;[?+<:<1W3;^1BQ;,FR>^48T?I,\
M=&^CS'W']0&0VG?$EG5O-RZ-%N3[_YGD\+^P#D0M\XB$\290]\SY<NPDG\=T
MB+=^3SH)(LXGB( /)*DCU1*'88!1D P^$S,&4?/3^04*$&SYR^:YB=(9R'Q8
M5X?<I;%#3/REU=S#FL1.T<@1("MHTSE7K2JS,K#4GN.9L;"I=Q2"I+AT+*4!
MJ:MVBCT:^%Y9)_-I?B1BP.Q<]R,Y:L0ZO[890W@);UC_]KAE;0A2]PMI$WL2
M2E+G!W3T42WV6 7:BGIC:6E'W@CW*@_/M\:KB-LAV5'4A:L##=7W=>R7&$&@
MO56=_)>O+^NSQKH6^8SY%]Q;7\OQ]I&41,UHHA8\D^'/^M%KC$SC2 ==";J9
M09?"_?%]Z=K<8X5%\@FF3C"0/E*A@,E E"(FF/IS+0V<B@1=[V++AXC,(Q85
MI.CJAI8&Z1M;POX;A(5W(6@$P+3:IESQ#1W,TO.1[ D"T?V=OCTO9JGGEJ#P
M>P#?N,F^NJ<#,I [2J,W<.Y#]Z(\\?6;9:FF!8;<VF6:7D2=707N4M;$M((1
MRK>K;(T'UH>=*&[Q50EEZMP@=D/:J"*/K'SHDOIL/6F.._3*P0K:;Q.05/?V
M'0^!^C4"^Y!Y,Y9#?U_T1%)IK[*XV>B[!OX"&LW;VR:S2-9ROQGY4&7/WKNL
MJ_IJ=(6/!KO;_;L,@-LV6@?G1?7CG;LSK/N]VD$[I,'"JMAJ8$_X\',+QLJ!
M$^>K7I3GV 9DU#K-*&VDKLT,VSEI4B8^A&-)S%W,!0NZBU4__\ EU)ZASGYT
M9L*B3-2>?[DD(?LF48X&,;EODXSTN8W( >+"E1U0ZG"+VX%KGTJ=7M/U2W*7
M[OM@WOP?]F$"0R2.<9@"GO98%YT\O)/]4SSL^+L';R'8/?G9LDK.M.YMOE6]
MQT87M5JV.N.\OAJ=1^JIH=W#.BP%U-4$).IO/L["ISRP/M(H(9M^9Z#&^\IC
M7N!?9[G*0_AIW.&!OA@"7=3GY@YN-J .&5(N3.C9L)0&O&N/[->(7&*HS2<%
M:5^6*&"?] L.])'%N?-M(/TG+@TU89<=URM+HTWE&SY\9KA'@7D&=8B]CT?>
MTZZ4IY,\?GTND..QV6N_Q:BFP^.?94'M5Z8HGZ#V;H0-[UD['WH+D^>M*O\F
M?\(654Q@S=W4X%D+;.>HS;_0#F,*F<7WA]D)]7A= A?9:"0ME:<51+3H'DHS
MM.@VM0G>S,A8C="/FN0^*!<Q,^>NR]#8C:DX!'^N@SD:[E^9YM.TECE#PM9.
M9X"KCM)+68FA!26&A2!K'PD>LI%,@HNAPTJ676H])BX<V@Q 0$,( H-.F,4Q
M[EON]Y&MUODM>H.J2?%J5O+Z\O4H3)@%9P!@#V4/W9V*K) $=NZA%-U=:]%P
M0-]^-=.WI4GB6DNPW\$33+U./"Y%$E-T%P*#NO KW@$QS?<RI]JA^4$T!/#?
M'IP:D?'AM/)MR^:T]K4#AI")_LTV8E2 !7VBLP0H]1W\F+Y,35P\5E.RA'O[
M<JII C1J0KF9,7=/A/I:KV=E(5('-Y?&EO]2V'9YUY!#,''*8U!U*8JX\+P<
M@[[(26/3]63/Z.2\H!WL"C*CM*^ ;9!\IBKMS=9+94)Q^_9.[3)DX&AKRZIU
M=$A2>8-SN7!@CYZ!$$+\9I9FM]=X&)JL"YEK^*)"B_F2HGR+@E%^"%&$>7*N
M-;VYH6E;XO"(M]_.JDRGD"/0 EXW$VY*RR,YMTX7/I)--6@JB3:FP__-B1QC
MNA0!T,6HRB"G! K6\YTO(2ZF_5F4Z>5/$M@86JX#.-T 4.8,WH)B:46J'H'L
M]K1F>%W'4R,;Z3Z"'L(&0G'[9,N&O7>GY]FOSW?4*F3S8$?%<2R[7VH$\+KZ
M).? P&XN7>-NSD[]>=E4.I>WH20"IP?;3<V.X_ I_)FI:;2%5"R8H6U?)M]V
M%=4<=)S"#O=]G?M6.4ID= PJG7E#R*].A1=SL1Z $')I;$=/R9-'(BF=9YM"
M$6U0()V']X. DHN,S9>-'.S+I?^NS'4)+/%HE%'$K2.C7K%WS5CGX^V:;PP*
M-T83*"O(XL:1EF069UAS=#)EK0UH\]QKV-OF9I?>4)'U@T[O)%]"T@S H"3Q
MC=)KJ'?&M(9S.*,C?QQ)_(!Z69%S2^_(,[8^K8I-5IQU,W8W5EB.H#-YV;%!
MS8H<L_DQ9UH+K;K'^T=<6K>:X44FVVIPD(!: 5E]T<GBF0V1G2>!@8!$1,^(
ME6ED,7P/W8>#/6$<3V]:YIFLH:ZJR.J>=Y#O9MSJFER#^$/6[#A$U[(>>1]"
M9"+:3"TW]Y-O@)R9V33DIH9XVK.M++8SHZ7<*[(V-H0*-*06YQ#M=E15%\G;
M9NUTW*/K ]JQ'V,=QO8QPJ\DUM6L V>1^8&]J,_EM9(:(WL6VD%EJ-X6MAMV
MT HI4EG<+:NDHU%B;35RNT0=+M-0I(5-WN=)!86DX^,'H9[-\^UVV;5*,S5;
M*P)+ U/=AM,P$H6K;C6'%D0IZ_2VEH,-JD@R\V(E;\GY&8_E^V&@&4NM4%7B
MV+FRLOF3U\>NLN:+3(R'H4.': ]*3-*'>]9^O"&R*DLCHSYN_"!WT<8NS.9K
MZVJ;_U"L>]UZ_!!EO&([ LRO%R$R36HMS!NR<(^X%=!1VTW)F7KMH825(QI)
M7Z6Y8Z%K_XR>3J<>$9T]CC^! D[<5R2L89"@BPX3OO*;P*LN.F! ]#>,K5?B
MUJ?]+%LTS"Q;_?D+[3J0\8,D2Z:QR815NIK+_*'1AE2%6V$*(N:Z:C,V03[,
MB&0$1A)'^;;7-5[Q95'YDEK]!>D9XK)PQBO9%_.'%^K?+)=R!S3=V=/4OGS;
MPC=A<Q(@+DW5C9#^D)ZI14A09+6]#VSF<-G5[)GYE$P)LO(H4WJ,,+/&FK>=
M3F6.:$9#3U^2WE[0W2>0'N]S>C-J)Z,+QJ#EN>#4UAP!.?B_@9: T6ZSHR(J
MD9X%CSSZ3 ?7$"=P6RE/-#@[-;8*<05/JE.PH[S<NJCXN>DZT2EVB),C3O?V
MK*MBE4?5AY\V3D[)A2-/YA0>E1^L-5X</23Y9EP.Z SYDKAH\U:=V\RUW;<0
M-@\!=.9@>1[\;F[W,DBC41/:47(BK/+(TPTOK!4@KBF1MOB5<6CX3GZ1>\;T
M?I2U%Y'<'=5(4M>]7;HZ[F2%)<XS:2]OM+&]*N98RJ(L9VQ"'8B?-'6R%R&[
MQC*.D#X.D?G"CLA[GBQ!W @Y/\7$SCF5<:)5;P2T#(T@C"INEO=O5NFE@+/$
M=8IQG'H*BO<4-)\M3UJ6J:]@@+(3YD+0Y;W#AD-/*;]3O8 EJZ\=_";[" ,O
M$?#S)UE<(B5 (BT(!#H#_<G#LJ,QF/\[G5MVQ>UJDF >Z^BXQ?>K8+[.%]R$
MMM/C D -[=**VQ-,@+>L7Q=G9=I8[77E"FF3(L:I;.QL51V6!VX[+N'ZE4SG
M([VJL![]OZL7L0_.1]HHP5%'O:0A'@-6.3IXWH"*D*7<.TCP&DF5]DXT@=2<
MW7H]Z'&OV?UZ(42G6CV.^3?"S^\9^@7,K?K2.,\2)X=WP>4Q#MIKWO!TM\.E
MGG?&2,$LT3SOOUI9)L#+XC_X^+3HYY_<XP(=U\Y\B(*Y%,%YEDN[\[G5CZ0N
M=;-ZA^4^@BV2#1,IPP"';I'-<EYKKPN*9JT-,YC&J$SI"M6$A6VN_2X&^^\C
M\PHN6T$#%EY'3O(@8>,AB](1#2538<$/53PZEVSU^MRK33E G#P>N:#]$+\&
MD#,BKC&; T]^(K(Q62S!=^Y0-YKP5&DS?Y7O.9D$\*9!*F"Z#5@V,+F93E1S
MQIWN:!MQ&CC7O@I+BLOG**4L9%J"5,RIN&:5! 4(#/#I%FSW"$BA^XZNC6_;
M@\<?5L:#8F26G=5&G3A//+VP>] 2NQ/A*<6I6)(D6/)IYCHVE1US<RFHUPHN
M4[ <7Z8[P#<[]ME&2(C?F\%;[2<8602EHXCZ]L!\=?-?F2I^TT=M8.,_N]N/
M&W([%1G)?W:WGV :7\%Y+OU3O6CPM.(!7>CNXV,)"_2/OD\;RZ_"1>6%NP5>
MAM9X\[9M]]P%. POL0Q_XZ%8"IT["Z8_1-_1%@MA7KQ9\/O'[7U! UR]*Z[I
MLVPMK\XO3_"2K._DA]JT3.<3QJP"(K#"IEK'6*C#$4!<%T0](AOSE)&'^F$U
M^VER?&0<-L>2(Y9ZS=/S<2+[C.^N%=3RJF8J4Q9U#Q[4RJ<%^59CNK5[&.SC
M-1SJC>T0+@6'=:*!73Q\^YS53S 3C$>*836"L=[#"_//"">S(;@(K7SK\ ;#
M* HSCG4>1JLO4093<QXAS+%58 J86ML9KG$<J_&!MYH"3=4:J9:7Y*FUJ9,*
MVL-6;#+ZPU:<&W36ZM7ZALB?(?"?'93@/_]$4B)'F.2&RE>D2Y[+$J7-+$>9
MM :[*=9+7Y6H> Y=\R257WLTRQ,0*LG/ZU-\9(KD-:#\T(\LZE+%^MQ]R\MT
M*-#]\N32^) A]\I7U**L;\Q=L_JUP;MUP_[U,D0(AX#-I%'@;?<C-6,!WZ"<
M'+4DB*!8U]^<RO;SYGD  \(5G.NHWD%G^8+\WKZ3)E3 *:;\=4XC1W5;^."0
MB#ZQ77BH8./K&L-)W()<>/:$13>T.4K/*:W2#[41>-\ZS2Q,Z=\.&-O,_-Q"
MJ_L?$DYM10[+Q1]T ]1KM;NI')3TW>2I@S2'_*7[Y9%[H+/3PL;U5L>A>N-W
M&?MV/:6I$QC_( ,LG?X[PHK?+<-OZDB67CKO'_"S\GQ-VTULLTZ&&\R1#\7%
M$4>_K7UO5A\&DDW,U,-/6XL;B%'A4M+E1SQ">DU8+C(L4 Y9:L'.-)NV@L%U
MC%S.MNTSJ=H@7#"Z_>LDVC"XJ$02HUB^7"KJB:\.^/AW5(-N%-,?=F4O39E@
MY[N$LOS;/X8NZ2*0ZDQS&9IO?!-!L5B\@PF.%BI=V]-*"-N.50#+#-XR #_H
M;MH*B;77P&L2W\[J>%O:AES!";=)O8:W)G/7(XA& 8CA\P(R4DZU/)VBI.,X
MO6S\:4EB]HK61D@.T2=7JQX^@Z.<MM.F3V\UM%3YIQ;/*RT6ESP]S%0QLS!6
MN_$99X2W!.-V Q1N42*3X)P]6%0C=DH[T5+/4"LU0WE7XTFC8PE$\B)%?./E
MD:0-]O@N_Z5L[5O@)/TA$7Y9R0)3204W[D5=9=;;E0\-FR?SS+D<CKR "]9[
M0$H?=]#A)&58'+"%I6=(O9!%AJ'VP7OE4*=4CL"<Z3W7)*F4E?V9^-$)<820
M%;FOZ@C&S'?5MH)!DQTENC[,AK7]F9@\RYA^8>&U&VC42&*[\>A=#$O./_%#
M&NV$[G<'.L)FDWMEVXK%%=U'1E/<Z/M_S 2.T:%"V(0E5]RS0F$$$GE"?QT)
M@ 1>*^6EF?Q,U_M1JY2:3/+[UGVY,N=QUED'W@[W5%;P\ ?_REC/MV[DJJ^N
M6:BQZ5:.I/A63LS2>@-7("M#+_]3+?6SRXS M%EOO8RE:UOW'^O!$U*1G]8K
MX$W/15"%#<K)&)]@MDVKVR>F#U7Y2*LYM%]G!$4!FN?K"0NTV1PMI.17_15D
MOI1&D0+I\BSQ6XB^>S7W9>R':^:>&LWP^#%]) G"'6AE:E_6ZTI\]6HJM0LE
M_\O< _QY33G5T2"A4.-RFYCRO)D=MQWFC0]Q2NV9#)E?3%QE2'4,UEU@8*.K
M;^G08ED3250P"+DNMTI]<M6N<^^F52RBM<*IX_MI/]Y%G>2(1ZU61R,8$OYU
MOGN-AMDM5MY=FA^YFA5+\K^8<_+S@I:WYR$O0N1JEC^%J9OO3>\>*P;FFM<L
MQ7)5()1W"6VEI7(S>S.C@ZD^%4S>(+MY@126*=FR?4[:2N4SF9=0U'<,OH""
M1 -+.-BQF;^Z'(VU*QJ7.49\.P/(Z"_)L<GI#[T"$+V5?"\_PEP/*5:X52+N
MVRZV,O64L^&BD*D5Y"M]:UN0V-L![Q&,(4F*LC5)H(J?:G&!0%'433!G#(BC
M#2S&-?0['B-O0FCGY"'N?3A)R?S6'+F""NW? +MJR!#K>18R1)4)LOL4B18T
M?%5;[[W607M)Q+VK%HT(",GLEM*?D<PD__YQC(O&",_H%<B!!OSS\[/.;OGY
MA2X,0'VET7:U 5IK+KB4!)D=&Q:;)XVIG(Z:I06";@<3_<K-2*/J2UIKCI&:
MM &]TD,&P7@W_+,TVJO>!&UW_O.+1\#JK5U348':J1N\,!%+HO"1<7,].:^5
M0CC'H:!U],0I#23*O"U*="QNP_[-L/^#NK,.BNM9WSR$! D0( 1W#P&">Y#@
M3H#@%FP&=P8+[C:X6X!@P66PP=W=F2%X<'?+)G?W=^_-]]Y;N[6UM;7;-35U
MZM3\,75.]]O]]OOIYR'SULROVLQ. MKQ^/" SH /0%'W#ST[F ]T\"_"4WO>
M[$:O1HN,SX,?XP['*2PNV@@K0S$E([KN,MT-*&#;F*/Z4VUR?8#L!N21GP@H
M.@[ V_87.]_S36J484B GP@!97PU#W]3,Y2>_'*PAS\#<H/4IT"]\<N^H[3E
ME4CB8$4A1P83HNL;Q#:_9RL3YMGT$MCJ8")=N,[;WCZA"QXIOW=OB^=M><R=
MMOI^LK0*%07%SBQ\UF_3F?# E[T\DXC!;?'4NL?<P]GB=%DJ2N\:_>$%&G$G
M*>SK?1^9L!XN_;H=51NP/N N&=>2X4EBVWNL-3BS.-(R?7OY^14W<#@XXRM^
M*V;XSA 91YWC" +2@L!9K2BMU %.? 0Z9P/A=/@'$2I!R/==%]C13X2GTS\1
MW!@V&$#0!R5HYD^$E;3LHZ=/#7,3L/J5#EQO,UT%?R)T<(LLH]V@P<M_(JB5
M__"YIB^\ZT DV,Y'.L6%ZC\6_M:%.U94OO+W%G.U:IO>:_S^B%;\>"PJ><LH
M>A]X..=3/.?4=H^K]K"2'9.Y>'0A<.CZ$\'?TJ<9&\?[?^N_H+_P% =IPZ*^
M#DVWVWJ'3@O@<GL'F+U>=\'C*3;>XM^*JR_7L(\S+PBTEJ3E<);Y\<I_A!*)
MU%;4^<V"Q7;JY3U9SP+3G5!JK?0WD*K<1X=U=BQU>-M(Y@ 7K!*W+8RWO:YX
MPUXC(.!"X-BH?P.[38=R-BG?JE&M/A">)2BQ;6-A[!0M!R@7SW795U"]MLOG
MIAN$% PDL+?ARA;:13&OL <&7NS _'&(K"/]D5=-#:.LV$=(G20IY5]]X9!D
M-F4@C4VI>AJ; @WSBZA"0V^(@0H*UE0L_&7BT3R;#+F5Y07N9\W]1$ GIM/"
M_.L=Q&^RGV%COY'#K8?AY$E#7LZ_(8=M3K3()^6_.BZ!QZ])7-X;*1>:X]SV
M)U'Q.[;G1K=&0Y?K+83\9YI>HAK?E/7Y6I:U06EB\(2,_-$ >4@I3Z-W&YL*
M796_HR 1%"8DB9KO=QET<S2$8KY,8E)\&M<!(&+2KF"&[,^F>-"7 =">D^!M
MH9RA?4EYP?C^OE.4RL?Q/C%+B''Y"'%1Z"+"L?:1JV2[;,_JIE&I^0F7PU*
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MQXJU1%#)*_P7_U7C_G_+?*Y6.,IP4K[J>^5%VW%JZ3ANUG\ZL8V)]4]^:JT
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M,QEPV>!=>'JZ:?CP/S%8PX_UGJ<@N6N\4H=%]RFLP<?_K,EC$Q[6"=T2_T3
M)HF]TF^YSL]/:I#\LRCO6__M/U7Y:?):(JJXR')X4.PONW)9@TX;D@8L=#E0
MH1,S\XP!+(76O4H.SBX;;_J4^EYV<ZI"+&O[=L^&Z0K*>^3Q-I(@@U-JC3K:
M5GJ%QASA/8*)&Z]9/E:]\G_Y6_$T#BV/#1>-AHK])1"P/ N)OE4C6^0XH#_U
MX1[ACC0'_4H:]^?;W/;0N0B]!H!ILSDE7"J^0>806BSR+_DT-[K]]\*]Z\R?
MU/PT+FR^2YPUUY'5PV#@KMUT&T-96WAG_XZ5T^BJ(5[#=)$DJAJ;2*;DB]+.
M<>+W?!FF"Y\UZ'.>'L4B%:O2'9I4:Q1KEX&B2E[9J=08')!,;PI<;L.+V;2*
M';^>0&6??4NB ?>X^\VOI;'%Z(=J([;$OD*Z>N;:9>*I;%-DS$W6_VE9"$F:
M0EQOG#T<NHOZCO5)5GV/Z(N)3.:.+AHSRG)JOM(N9;T<__Q(IS&1?P-3,",<
M,1]A3+2D7E;P-A)72]6\>S+-U9H1K-5']PW"4F#?9_P:,08JU?L(B6]\0">+
M\)\9X'?KY$<H9\CO6-8A-I1<\^3;L?IR&V!/C;&\,O#T8&W-68B_X^3:??W)
M+MH%2)77)ZM>NH/PLZ\SOWX%L\ZIIBLH[@#GVY65@659_^S-DP'+*,/DFJ2!
ML:%KO$7-3X61.11/V$S8N?Q;>4GT$)#?N.0"R>LYO&-%R:Z!KJ=VWWXB,)S^
M1-C3??^ 5][5!X%G6.YEM+"J3]]-@83,>,-(@E)J$ZA8%''U^E,C.B#AC-Q/
MV<_&6;*H5R-'TD+A(W"X^XLIP9T"+G;-Q'-;>G-NX0U3I&!P04SO0F1A'Q>X
MN\M5=<'\^&/(UPRIF9),.C(B;5NLSM7=]>+IO@E_@=JB6?],@?%H!>[=V5"J
MBJ=BR^*D*@A22*>H-93":?_CZ3Z)R$HM-#U-"IXX @G4W\.!3/4"U9^>^ PW
M2D7S?BT;%-_O(].=/IL_XW=G! Q_",5X)QSVVK2>\JKS4L;K<'\!*O $8E^3
M49]O!^#Z0D%Q7J\8TM7D_#1LWL136P!;A3$L*B=\8K!3 J,6WFLK1KLF>CA\
MB RGQSH-]'\T_G0?%O& QEG?[WNH-*8+CU]2],R]PGUQ6J<LOOOY;>$W; *)
MFGM<#Q(>2\3'H",UDE<9#=[('=[5\'R(9W3XK("AXNX^69&=$;<&"E;1\54)
MB;S!%BL_N"*^;]%?ZC2.!(]%G%D*QNX7QAM?1A1A$9([LEC+2U!=GCV5Q,#H
M)"B;V%9?[R_-$>, :>)H,H5%9I>+^%9SO^E6J1$G47N3<S 7(X&.9G5@!Y[B
M8^[-&U::<= BU=_OE>O@XQ27)M/1!46GHB+%!N/N&+,#WY(4-VY:L!X(+J(S
M04FBR^MY>:D&XN8\"MF+S4PX1=3+8NN $;W=/PZXK95HS=>^(=4XJQ>B0AU'
MCZK7)S,.''6M%JPX"TXNFS$>#[?,S9][/9MB,Z*SX+BM:[_Q$7]'+F#-WP"5
M)6U,H<7Z0DVF4^K+$N$=HFQ:/77WOMPUA$8EMZ51X)L"_A-C"EM]NMR@[8R5
MSS=]0/6Q(JMKVW?1'29,)+5PJO(SI1WK+%<:<,?JFP%/[HS^\<[58HEA5=C0
M9ED7N/=C6/; 1A5H&#M L,:%Q,4>5C8/!]_QFX!"K+A>+!AKD2>%339X"7-(
M;8@;>W"M@S?K&)^:B>@VKB_L)3:KGKC'PFXS$>-D_C%J&25WXD'"\2RY=6.?
MJV+X%7.K9\]YOE$B_EC!U+/7ZC!(@<^GO;/-^S(_CK!'+:0X*[[:J2I=465;
M>/1\OT+3$R3O!*H;ZB%=[),!.*24J*&GF)P]%M/>^M J4$NMBW-BDJA&?I:E
M91_ CKG.*&->4!""N4#=8)G:YALG=0<FU<Z%MJG%IN9:<9FW3KR-^26V1%_B
MP;K?>'=<;<D0]W<.I'TP8_L #IRW=9J8,7G)/=IG]R/Q/8O!E\)]R6T=]09$
M9,TW1JL+"]>ZQ7=HH(R<YCO>.F@^V,'<I3RV:\M:K)<#C[DT,1ACF4,-$9OQ
M1#O%;MWZ'!U)JX0&*YYCTK^.SH.,K%Q7!))V!W#$SS@E<2JBF4[AHZ7?8V$I
M4YH^PR"3V#"25ID<J%U[,C&+$45>_GR(']&1'T/BOPM'AV8&!>J.]&?"4U/3
M1^#WO[XLBH]L#O1Y+D Q<+CG>L)U"7$;0^%Y&ST \6MM9AC7)<*:"< MA$8C
M8&O+KQ'5ULP&(2-RF>H Y:CBP'F);B'"Y:+%/9AY8H5"?L?!!R-<4;&46;R0
MG9Z]WZ&V:GVC/\M@!8VK++I/+XZ>$4'R_%"<0A3U5'*264CB/M8>YH)[_]7@
MU"?Q5WIR6S)]2]02URO+"_Q<,05TR\^O(P9,QW)"^<3E52UK2IB.1>GV=!PA
MP<BOM_@(2=/DOK)(W*G5JL@RU4"EB=)K/.&^>IGIV<D#MN*'SOOA2Q0+4,OS
MIQ</ANRZ2N_3ISO7Q*DLO>0D,T>O.ZU[.;H\SA/E>!W-=1#].=SRHA#I0_^K
MATW6+PN=]X("[Z!'%,?1Q1J[DOEVS9X[D0=H5Z[+(JL4JE_81OX488'LEP4N
M!U7T!%\_3-K[A'^,(9#[3RN&9X)"?X %23W?__">HD56N22Y/EAH:RI?]N99
MP]^?^3I4^;W/=N1A!G1V4H]=#_@797FDSFFT[TMU*COD\TL/H<%LX400D. '
M<5+K+L+@LDD!NX_Q4IW4S"QOC=^#\%=,35!<J1B\VB(T-/.M"HQSEFA4=:(+
M2WCK[SP3,P/U#'O#P>*HH[:'^X!CHR^7"R$_; @=^EWX\+HU6<Y9(3!(O9VG
M\Q _%U%FXY3V%#[#)T;GV0)(=%0_48:,+[=I*?W&*#.@L[M7_]6D1LRY!#>G
MVH%:0LXLM794\0Q;)1_1JRAYUL*W@FC15201OO'-61++_7<RF!FH_U^4_G__
M2XI;Y<R^9GQ@[>&DL?ZHV$7+RF3*XNBA,?93NP:MM,H[#(>G",1U7[%KZY:E
MIEG6M$B+E3\_VULJQ@O-]W?+RT);YP,$?R*B3F-\UBF3'SGO+[/QQ)Z-QX'*
M]240"!(U3S(& O[&TE_5U/<?G J*S!BH)S]0"V\LD66ZN-LJP8T-;T*LF'*I
M#*H2HNK3OL$F8W<65BF! 8IF1)WZ+*: #*;A.7L0<HIFUV<JG:?/9H4(E>XJ
M4JT:LD9(JE)!4^Z"K)H6+L*J<Z/'_"1/>\A]VP!VKZOXB;+$)J?DF22ESJ-\
MD9]?.JB\K]1/"IU"IE^]N7FW )/-S(ZEH@+]^AB__%V%H@*!@+IO6TAL[_J^
M8PKA#]MZ*Z"[.GNS4: E5SOTT:]9Z.!PV;@\AO1,7_.9H%X@1+B8,B40?2%@
MY$#20R?\#^(/9=_)*EH97:4/7<O:\*NM9(3_V9JFXY9=1.9QR+L?+K*:;C];
MV%.'-1%V*WVI>RFU\Q,!8RG8-VOZMVA"RUMPCUEY'2<2E*\I_ZT3P EW['/N
M2YID"<NI/I,+)+GA3V2$^XFDR/J%,?1O9G:^AR-&5<QS6\_,W575$>K;Y%^0
M@Z<3<@<L'M0#!BU@<+2><)*4TA'&DZN]=)$!%JN7*"P=Z%!L*"YG)3'GW.FG
M[E':83&%-;']T=%1F*"@2'Q-?7S-C2 S]&!S_HJ_4K>E')3\P6U2>U(;&$(2
MDYK^J#N5G!--5<@9V]]!J+! *IF6;[J.@'K*OERDTL5MD1.-$T.BT4)L\+WR
MR!#P(.(W8.@IL Y<R:F_S>7?=YLK-2E2?UWK#?)NR^XG^HRIM2+H^*X"2!<Q
MR#Z?U,U#R,Q<^^#*XIJBOP]M28DR,?^1_'X7.T#A4$, G_&Y(K=0;!PSW)PP
MJ&# PE/B1L#W:$9(;$#EQ8L]09N-29T:HJR>]1HWW9EJM\@6XD9F@%1&GI#\
M]-M._#>Z96R"@3'S_J))G 0K@:GCI$'_$MH(BKWO\3ZES13G5NC4<FA5&;LC
MO_[DC^U.EV:AV$T3_KH;+(L1*/HT-#,U<QPG]CO6,J)XC6V7%6:[(%MP?HU>
M[:Q?'E7OY :D#@#)Z9;&<,2(8C/)\U]VW'-3#36ITMB(><=&5ZBJRSGLJ&S9
M/7N@3!N_6 \03QN!JJ7*&\^D?J6.L\('<*:Y_[K05MC@H&9@R!:1D6]QN9,_
M/%GGZJF.MZ@;[;GG"7=@,(?@*VF$8SS6L('(J?N5D<8[.$\-G\R"=["S5'6.
M1>40_F.8^?S\K\E#[^&_IP+PH%UURCW(NP\C%V-KO2H66%V/SB5WY%BP(,1S
MC3]-E=#5!);8MR>]:)<8[BCT?-"(.Q %_S41_!+2=M6BD0S(S&@S1(D-%IJ'
MO7$G15Z>) BWTIKB\V_5U);7:DHMWDEA"0KO^T0.R1A.603@8E1WKJ@J3]H<
M_" _O8P9M!BF:X?D@3R:TVAPN-W3=!;(Q#8Q6\P2(@-^2&%O:K%AR]"Q?EBE
MJWS9#%KDVZMND_V1I$V;YEY0]>YT0"@"GY:_5*N*/:%FOHH+K*IH[*ZPF6:!
M^C5)C1$C= #^$X$+V<S5_5*MI>7N>YV@KAQ2$IE:B8/*#U/"Q?=Y7ZLN308L
M88&="B?G&E,7=I%43)$@5GG5Y% 4<S3;A*XU)I-=]1PYPCVU?)WGB4S=</8.
MG5IQ#.S>Y<]/?R47F&,Q$1QY]3E[\"M HA!P45#5Y)YA6.J6P";+?DVM1SWS
MQRS_=>I24EELOR2X4^6M:,2*=2D8Q6!$UN#,_#<[^"=@4!=5II>5I#D5%'>7
M:HX%YW[R!"+W)V#PK;A$PX/"4/%%P1UX5Z37B]QW(?2?7D<;/PTNP4N<W[N"
MO_>Q@<8$!$#@KY@-/ 7YB!3]1,BEY,ZYE7GH]QF65M%>+JOHX3N@+Q\8H,_K
M'/=-(VN:(6)2IKEF1Z%"CAM;S'S$1!7C8W.]/<G$F<RFF/@(:9YRYNE#+./:
M<I*U+%5_MY4^G0)ML%ZFH4(=4Z:)ZA=U*5//H@8"B:AC4D,]E#AVXCB($&0A
M[*ZSKM*[Y(.>J=RHU#5QBV7:QCWPNNE3&0W,/83:>JX"6TV<UY 73T,#9>[?
M#ZUF):DRO=3]G*^#(,X<&Q81AHX=+XC]*V\8._JM;ZA+X$5D<-<'BQ0B'_.L
M2-V#L?""46N1\P;U]FK*SP^%7P*[8%5&]_("%4I3@62;<=JE/QPHK\)&-TG]
M!LH3'3%I2CA2,%H9/GRJQJ_B'WZA!+9"2\IC"'(E2.K5!B\+/\BZ@=#QK'M(
MJZ!AZ WG*2DXZ'XM[_]T@=+WA$E^)X@\4*FWTQ6B8P8=;S<=:\RY"3RPB<<'
M#;7GEU9"/#)"<%) ^! $ESJ&-V?K_5FL'Y.\._\+/YCYW\0/GM)ZB+:T&=;\
M1  \:"=U+Z%RM];9CPL0$G] 6QL$YL5PN*>T-WVEFEKT?E>@I4?#SC3^H82Q
M';_9[8(:X7@8%FN_;&JZ(?$3@1$'MQ%'\"86%QH/_=5*F&]5]5NP0% )Y1QV
M@L\V1-47IE/<>>'2;^8@F4<O9LL&">2;'1-%AHF]BVNR XY!HGE4%S=^)1]\
M'VEC1&4&%@(E^S/O4U-TDUT? $"?15WM%N+R]LUJH?3*1M(6L8HR7N-NW:!B
M';?/3!\M#?-TZE(Z"*@95DW88KK,VV%MF^_*5;7@N2D(W,>N7)>XCV[E$\0$
M=K:S3,0ZI9-[9&[,A]0ZO(K*2@I!LFBIU]&<,?7A[4,_2)JUM8GYQ>S09M?<
M*%%]J4.1^=9Q4-<1/R$@ + 1$ $X./A&./@ ?,"O)NK]IUS!FYQ;'?U =/LZ
M7C*HEH"X<,%":=CW@02'"^WZ^H58RR8P%<C6<,6S*VSZ'8XSY T1&X(@KMB(
M54\/I#>\9U>!1U<9R-@3VP5TJ+>_L<2]<.-U6"">G(9J2#_!_935/"FU\129
M65]43.%MNWF#84956!@B[X=XOGB1QOGT$.#MZ&CU7+VFJ5YKE^TA=%%O:(BY
M29!7Z)W93GK D 7TG=Z4MO\:G]]FOQ&@F*7M.;N_X($MH5Y>J$P5/R*D9J+V
MX(;^^M*N?7+TNV?:#ZNM&[^9EXI, Y8/>L[&'KJ\G*D#5.3R2IF$Y7)F9_ME
MS)'^.!(.W3Q/=?*]B$>7VX;E:[,(")):=IM879FZZF\#34&6D#,-%JY;)G::
M1BP)""?#6Z*OER$S+GAU?/V+1)2+T_]W=1Y^]W+]J^XKGYD#NLJF(3N3YU6[
MH26?Q[<5@E+@O<&5G6&+/8AR&&?BFDS=#7J!L>PQ$_W*# &"OIT>;J?7OY4Z
M?KV+FHG^=5O=/E-S;:P7(Z1!Z"^G6Y3:1<:5-:8Y.E[?U)#:=4'=R_;1M7XB
MY*O#X?>#]9TL<^T?W9QM+S(C@RHC=6>J=/VB2K0X+P+\@)'<>"K1*KW(6YLQ
MS#M2)DCB!@AOEBM&MGVOPI/$\;YY\NQZ[E_:(]%7+XE5B7RL8ZMGEENL419#
MZ7 V<D119I<P823: ]CU3.@P.PM7O4^,T4\0E-W%S(2UX#01&ZA%<^=RXXOP
M8XC=(TMEO+QV_\P2[(C\)A7VKK[RLF>8[$L3D#1FD'T8P?90<I(L[>Z]1=GL
MN("\P[G7>+]%BUE 7D:/%GD!O3],X50C U5TK5ZJ?41N_R6"O '<_4O"$YE^
MW:;"#&JD.''"]4B9C9@!7P3$C,CA7[GV;Y>F7UEV)OS:])G/ \WA2<&\TMB"
MM2T6Y84KEHO49=C$@8$&^% X/PV\F*TFH3C03<C\\8 4'S&EBS6NNX^HV[%V
MPC(FG H1&W]%5$NR]4L$)Z?W%"='FM)CZ_': <$BB>J6 VBY-V"\#RAN<QV!
MW6-"%%DSD3)6@WLJ671F/]^H!S/YB1!'U>TG@8NQ2<OZ123N+='W$&_A]P34
MKC=/_^8BU?_K.W,A*!.>:A-S#H)"QWX%/N!G)&#5R12,K,=^CG@I!E CIY"@
M<.NCK,R0'ON)35D)\H7@.(3IK<R:$Q+1\PAR<*&KS*7? 7IH57K)G@"*)3I)
M^46D%&E7;..S8GGIG1OY(NG.0>#KEJ58J.P>7RF/5*KTA'E!B+5H#>=O4_EE
MQ</5UD)4K/^",3%)[QY._!HH[)KF3K+?-&6">G\B?/YDB[)T"+D'#I87BEHG
MGG-[)T7UWK7M*J^,6236S<@*81KFYSFT'MW&7W,NFMG4_I:?:UOR7--U;=V\
M_8EPHL9<&_V/$F"]_>7R=1+\J-&[[?[C$ O-_#_KSXEOSSS00LGNL'1_(J"E
MC5@:Z)I[$;=]339I,]KS6>74_L(@])]* ?]'Y0ITYEM81I<3+QY/5BY-D!Q*
M5RX=T:QW<?VEWYQ9P:7E2J=F-B3STA1%_.+*M,/ 1A4^#+&Y1\^^)1MKJA[Y
M'#%V@ P7FK<:ZNET!>KI2*^%H.T*-G,9,W4EV<7-,6%<^>'=-?>,:4D\-S//
M-TFP1XR16406Q[0W+\A-6(IJ;M!.%V"72I= [H3J_4L.?KW,U+>&C:SD8FH+
M:;("2*'K!.;K.)%/M5[P0 V-+@U9&HE_2!T<(C,"AO<RU?PF4T[\,D<9:QK?
M7)_5'78:D/)=TR<]E""/8.I @#7\TD]5980^E$MO![GZC!1?8:E=^DT3=EXC
MV>WAIX[7E2*Y\5XD =#6IWF+:B[X6S,Z7GTTJQXAM3%1(7.C3=.96RM]]A,!
MI&SA0(PN;6&#XU>!I_<V=NHZBC_"GS 8-2\O)._9\WWL@ :),=(G!H304.CQ
MZ/Y0[=^>ZO\A R9T0]<"UGEO!4#YN/Z7$SRRJMMX"F3XGEHP[G8$?YAG(R9C
M(N2U'Q*Y/![W/6T(5^Q/A.%Y-TJT%[*A(-12FB.B??6  _0:@76+L\Q?R4\O
MFC''NQ39X.D&*/:F\Y8Q(PTPQDN<7>EK'0T^9;W\;-%\N$==H?\'+DCA1_\U
M!WE:7"EQ6AXJ#K#E6:^"_7SP>Q#?EK\*FE$,&9@?04$_5'N.!S8"&35OD2^J
MM2W\J@67_WJ6JLB;_47O3(TU&,J-?H*>_.+#]?&KQ$T0(*NJB^_T)7KY2U\8
M%:Q^F42MMJ!S1]^.)459<\VOMF!5%04Q*:NR2[.<UYJ4JB_$D%=')W61MH,4
MJ$G]! &+J(>TDD56ORMSMT[P[1$&SQD(X%4R%Z2,TC#=;2#5%VC&MNKBI;5P
M32+@,1)_\9BT-?I\5$S$TISQW"9KZN:67^=5=<J0R]&ZHSJ3*?O5-SG<&:C4
M!A4@OVFJ=Y-T9K^#UDF<V?0]+8#^[=K^-E;YOZ 7$2^ACI>#DX+/(+<ESA=E
M(=$X!3LN'7+4%/HC6\SQFETK#K'Q]1$Q0X9\EIW,HQ.(LI:V:1=;;$\R6U,*
M[=@3SEF![S"7/5!Y41R>,)($FP_LF6<P#].-,7":GEWZ]C0):3X7E>!4P)0T
M@S_D>TI8VBS!, T;/0:'M*>;YOB=^./<X \&A6"%5U7.08\!%"%]?9IXT5B>
M'PO1TQ/  'U*WQ]WRI"%3*=OSLOA4Y6)D9?EHVOG6^38D9NN_68'/7)HS_FZ
M-UY;O:NP[)/!C7(S$TXV<FFZJGG1;0R"VG*]A7WJRL/-J<U"DE=Q-3))8Z;G
M@*#4"T9PREJNMH,.A@_FA%+S4^"C8JYS.]LQ5Q[XC?!W=8] B^LF*XO165SY
M=Z5'SUJZAXU%K<<F#SN8=EHXDSV?('-$:IXU+.6M+.1K2%;]K:[Y_PV+\1M+
M4SR SO=)'%TN[@I5S=7JS!((J2^BQS[U05VI'N?,XA0)R>C.*E<C !9XG$9C
M4M8F%IJ4&9N/?0BQ6^X46*\)WMJZ[-+OG-3KPUWL^+'7P<Q7IE\(X+ &Y79?
M9^JSSR,?5TRZTR7CQ8%'A9WB.\'N]1^* H\2#C.G]$M @_I"[.I=A\B9%Z4%
M<,L%B:65TH[.=7K6U_9]S+-<RS;! @L>>:1]N$&?$_D>/** HI;/M3$7Y"%O
M:Q?TVZ<\D^MO9-EUTA7UP<,O>FV4&24BA7': 50H:UL$G%KD65+%-??[P2.N
MX0>6=51[9?.+-HI?+GA<)?<46%H$OYV/2EDK>:)Y=GD2W@=Y"ZRY4_%35F'X
MJHQIP"W,RAQ+*Q<JF&,&GSY\]H6-P9.767/OE&QL&1R<$ZIF&HZ.;<NF7FJ!
M];)BI\>EZ%QQ/DO[NT6%OC4^=,;09C:]*.LY!^#TRTU%PP67W;_=O3E,U'<(
M1">R84T$8TBM["#$Z C)%P8#$[\636%W&'Y8W:"I#VR6I*C38)^ELR1"5ZC;
M _E\;V%L(N94VGO 2@K@SW=1XFC5Q(JK&/H5LL@-^'/?TI;9UD:ZE'],D?*H
MRTUJ[N204FC_,/9_2W$#\B/G^_FH%45#K\])F^2;G!(##[*?" I;57>1P)\(
M).>J2&:Y_[[X/L6]/ -AR!54.NI-IZ0BODLMYOC0B!@2\2*O>C&)__U75Q_4
M1P(?S 48J>[\#OX.V7")=G+^U$*N%\.B&FX#MNA!*%P?*Z+2J>:.I;C6HA6)
M!2D '<-8BV-REIJ!@0F7;&V'XEE_^[>U)M><J$5R 1*_YG0U2R?\Z31#](K*
M2J(3E#*+R.CAQR_'"]_](<8%.5.]$]'(ZB=UM/A4P<;/M8J?'Q8>?(%GU_]$
ML*V7&A@D?*>DNU*F-QXF2V5^?UW'^T$&!RNC4*S6+Q&,8]NXT1>)L*9:Q4:2
M&NOA=A^(O^(_HYU;HS/,/E]FC/;$G/D]&T;,"$95HS2S:J^80_]3T4]B8H>C
MHRW=?ZYQGMT,8:?$$(;Y183Y<6+'Q-N+B>WOBRG\^N6OMK]WKL^^R MZO2W4
M-KLXQV#.:'*>E3"VRP3: &%7(-,06)X,*AT.#V.BO#W<'SF%4G)EVTEJ4<XN
M+C[O[M/!M"K)*1<3HE9?FW;G6W4@)_EJP$X>"P#@KZ:F!\WNP0>V"@9T&^,K
MW^)S)-N:[B-!XX,BHU)M1X64AH^FF+=@4%X1E9:1'<JWKMMZW<I-@CL,RI4"
M*#*(!,D8P*+J;IH+P]@G/J[)Y-Z7/XR^Y27G "$<R-G?HUQ8C G+=C'I\HIT
M5V]IF97H9UV9]+.W]5:M+ZG% &?(*?K? P!6O?]JZ/OGY23K$M*ZCZOP+C3V
M>B=#M^DO4 @2V6Q?F[CA&I*C\%Y]VZO:ZCG4OT A,?@7_Q$S,;JR4^I)4Z[%
MG[$<^3;+CFO"34;.N/&)</D1B?]#6B_!!Q,Y47;T^9)5O!AC G"W(C=_]YY6
M&N?P*U$+Z@.O!1%M:^_UW:B*N83G23E3!&"4U#RV_-2>P2-ZA@]K"C<G)]K?
M]/%W4S*BT5Y-6V/#BBU?GU399![U'IJU@TK&<X!XNVZ*RY-X-B,Y$*[2DRX/
MSB=)-C1%&/PG;.ZZ2#C2G_QECZ\DWGZD LM7+LX(-0GJ%CL+YXV8/Y@%]%N4
MJ1?:#H!'/SE67A-4S5&?N6WB.Z(9Q^@!2FP;AU0/3,)G9 LJF!VQR?P6 FH/
MZQ=:7'QA7M 1>?\9'="0HE)_E?RO']E?P(2-TTF-XCHWJ;$T^]>WZ(GR'))H
M_&%XI1T0UR:*U@!;J/J.EI!4CQ!W$]\WFK=52R6\3RO4^"*-TMD+!^V>6R^G
M5%%)V&]\"MOXHF&<DPB&S.[$JW#\@.HVI:6+[Y)JE$TT[I<G3U\+8EKA9G;J
MQ8'E @\VCEZ=B$!>!>QKE;$-:4PK'2\$:X7ZM2\#PA-:9EJ30!G3V.O.FA8-
M1I-I(:&[<_!W^A\PR9+H"7W-9@@'?R*(3-87B&!O-DJU9 K<7Y"L^OG3-":%
MS\[;R(;U_:B]U*3(Z#2SDG8B2NJ&5<3T&18S.9&%NUH.L'ABIWMAQ,K\&GVP
MT]'^%Q_^WL\87C]A';3H9&.D90?S=8/%.8P0$(#4G-0@'!R *[4K  !T!=EQ
M:Y:?L\J1F(/L'8F5+9=;CP[9I&VA0Z&-:.8LG*"7YM*K#Y(87V\$A9E2^\*G
M8@T9B$_O:3Q?<4PR^2KZV D?>U7MK^<<6)4-C_9%%XVJ5S;HM."[O"@:O#:C
MU<H4B3 AJM#A(>#/OWSSH9S!]B%\)H^?1*W"W<?==N4R'Z;-?=A(U:>2]W0>
M3I*[#<N:Q94R,DOOBROCB#%";_3<8"/W$;YX,S\LJY%AA^E!>.\BT$*U^*-.
M8_.HKKJQ_$K^(WSZYD[(09V(T,J8S1EU/@"GT/[8>;)KG7H'^=@J8,R\H\RT
M=+G9<3&></Q9OS,X=G 7HXX3R:\7/OR#TW5W[7@^TAK%\E&9#J02G/_&91W(
M#\Q2-<(!&.%O# >S<5($87#(TW[H(HU7?%?5\11;RDGYW1EA#P:V.'9"C3+7
M5QQQ#%%5>2H,AS B3N&^[]),#0IU'OED9\OO/M3M;5KTWTK+P_!%MNQ"H.A]
M="5?NH^3:H9F8_R73EC;"6](R Q4&H&OM]$4#GD/BW,6@.96QAR(JK.;5EAJ
M8[92QM#:O.,2C9WB0G,M$/"=<%JX=O'TCA%XI-&1B('BY0ETA/@?(>511BNU
M.S7S=VO\F^&,#\/O_>6K,L&6"WB"/,#SP^%65'#Q;)?N-&MI;5<#=I=P]FPE
M<D[0'FZH7X\T@QU3D BJV.L#X](N0@R'$,$PO%</G :#B+N>LJVOK#Z?DER!
MNE3&"'GI,&_K(6]3XCIX:56ZA'E%-%[2H^8FW4EM."Z%:CTG*P%X4,*_/9JZ
M'FG8)"XIXK.ZG(<J2Q'1;D=>*(4DP6\549.%-*Q73A<F7G?XYH._9 2O:_#-
M*,SY7*H<H"0NVHPM/8QV5@W$CGM T8ISOW$*@?IG^_0B3]TL /BNX#JGEYJ5
MLQ$A#F4>FOB[ -"3+H.D>JNM.:_<DSN'J#I.(QY/18T^&*J94^!%4C&JDWM6
M:Y@<;CQ9L)>0J'LDL,2\&C+<DHM0PG'X=OQN*A$6Y57FBL0#<->W^,:I$[=.
M&LTH=B,_.5^AF \"QK!?/&]!C5K(6"TC$N2$EF>*:EE-!.W'WD\+JEO 6A:C
M@$BUUQ'0D%A&8R(K'H/F2F.N,G>!GO6+D$%3VL&/*&L:[[B2<NZW/]MHJ(N<
M2]Q1!T?MWR7#22#$S*/'N_+X>_,Q;BFU23%5GD@!H?+%WV< _74^# @-$<F=
MSSCY^YB59MO_( 8+*609JFG3%1>AND,:.9I3Z:D&X(V=A2<$X(JPY"=YQ47=
M)H3M9U/3*7>7!?X<C$;%"7V*GR0/>E4/P.HXY^U0JOL9Z^!D^+"+:#PC1""W
M1:][GW6]+FI6&I]\[BGL#$]1]HS?^,..$>&+D?@8J7I9O[(+Q:,\R"*,)P0"
M6H:UV'S[Y')4>A#L/"H.1L;4%&+UW:R:VC B+\P+"OVL1!.V[]&1$D@W3,5Z
MR(3;Z3"FX51BVQP[7PR@=OCM' @H U 3_'I0HS@C1.A5:+XQ4$&.)Y?"J=%6
M[W\BW*I4)3!S]GM#&F^S$&*R<VO-7)5V9( 1VQ2S-L$Y]3B"M96M;/JIG5T"
MN3HCAR=*2PNC$R15:7"A]X;3Y6;L.G8XSRBPZ2Q=V AU&DYQ7N<%4XRXX_1O
MP'.#V5&:3Z X?C)N8K[QAUL& T@M+04\)>*+I;.5L<  C=W02&09927SQPSX
M/#-&Y F>U>67O(@J4O R,^_HZYN$CFR'N%S-G+P%Q'9>96\.[L_[M21&7_<)
MDQ.UZ JS9\[:]9I-9^TD"RTHXN71C//)/PN^';S\Q_&2_Q53'UVT%G3#",R3
MNZ\K/Q%>%;-X,AGQYEB=&+6*.&=0K"72/IN,_4]:2TIC?W @=%6N4P+748LB
M4$)OJCVZ\C#$!*_@1T&0W6%)?7940Q"4VX)CG_=DJ<;'1;_YWJ:;9>%?#\*P
M&#\F@^G?P,O8IZ1GYGP 7$*-M]E)%N*J>[LLXS!>F>M7.:[ 'TM[;]WH 0OC
MD/Q;HVO'D-KEJ-:3AJB'M X---+41<W>7;BI(VJT\%#G A\L.WCW)"3$.WGE
M>4X)R2WCS9?B)0K%7EO%O5LD0U7R)* Q;UED-;/>7<@9[[MZUNE.F/UA24P!
M=&)JQN?IY<B"M!-J'V/<M)L:S6KJXE;LJ#(A9W-LS:LZQ@Y"+Y+8F  I"84U
M9!B^@0KV,VT?><,=T8&'B;JKX]IO(\^K'Y/:)OWB[_)LCE8M/A"WS(T.>SM#
M[LA]8&%>>&<U%)DLWGW95]2B=I[_X#^\N7\BY/3]1+#WF3&[^_U YGK^A#_P
MIA^XQB)9_.\4Y[X'GW?F&S^Q%B+#*A0Q%1[8C>[VDJM;89%^!(=,95=3F%Y(
MKPGGZ]K_Y<6Y*%WO)R7#HJB*G-_6=DV/6=BH1&7CI7;#0^E^K:\7,L-2NIN9
MN L(RR9K2165-K!URXW>L:?LBAYY'Y;-""74"_<F][^ZL<$LHH/&+7GI?=HG
MBF1V#"-GH/8V(L^?6GV'QS'AV.7\#J/%B/#M*[SZYZ6X1P2']^/P?% ?9]WB
M6@G;PLN60LYCB6>)DSI)J&88ME^Z!^_Y1K2^OBZ;H;[XG"2LJ[5G[+*?3LG5
M4NY0)YA>Q*7QM</R@2$1$C"]"&12YO8;FN0 CV DHNE8GB&%8>F9[I]HE]L>
M+Y707@!Q_2T0H!%U#*:*-E6"4467;?;FF"R2A=9(7,=<%9$C:Z41 Y'3A/*X
MTD1+W6:4P#@T/:V5+,&/S&QZ^<:4O1^1IQ\[O0Z)/2% L\SA09F/[(+9^75S
M&N,P+QH#,3O59@_@6SS.ZR* #[D^?Q$R&LN'Y-2TQ-CZD*IW246D<9;9?R^:
MFQ8"O*<]YLPA>&7*.=514?VFSH^N<F8K:1Q5X.$=N+28@K<:7D+!I,3L%RJ^
M@QE7=H%48@A+K])QLZ,)Q)SX]7JHNT/D$W;7]>1/^/BNJZF-J\W7 %MO"93]
M_T6NY-?P5&>5(V@R'CT[V%3\/IY27]^HJRLW8&JNYK?14N*,@JL[8+R*&K11
MD]"^X!-LOZ)@:R]L$*C 81@9HCWLB!8: \6.9T?C;?RMEGD[NFQ=WUAFXQVG
M[)"P))D^:-<[;91:ERUD;;VG\$+@Y<[2B'AL_>I ?'"SR6I'7DTRLRCE!)MT
MP-"H^C *!:A8_<E7R^_D8!$?+YN<-'"WG12 .%W7T0HKUZ5<8RF0Q"<.PN7X
M&3$YR]:X(L^14]:RQ^I,\96 [<T[#LZU"I>UW1?-@IPU-?7,CTICAR ?'Y;3
M:B1/17D'K7#&E23^+VEL242Y['&,N3%:ZTF,B/VT8%$0&YOK2P)C A#(H'/F
M!C:W0[5G.Z9B<OD3P8EJ\)!^K/.#1E^D4U"4T9=OG.?8%C<V X1;E?8!5<%9
M;8ZX!>S-;IXQ$N(R=5R7J@?1=9[?\TNLR,IGYC-U S),+,"!]_J]VC$"R\%
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M-2,./I-([.*<J;32PHWA-;%P4@VV:H>8\;?V$;?/192,.K295Y=6KX3B 42
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M(6VVM2.--3_&8HVHAG11ST3/-<=25=2XH<+OY:1Q(;ULRS$R0(I*Q8CYH=6
M/*"G>8FSR1O<(5VJ_+,9%H"W.D,T9PQS<3]V.GRPA^6K4S;+B6,IC2!,OFIZ
MOA)^6#6?=,B.']3.*Z\!+\.Q.,=^WZ-S5MY?*^\QN=KTT]_X4+5_A'GY8%DU
M(BGD[ $TMHNR/^#OL%N0GR=_TH3<G \EN,@N3JS-K2+X!X>NAZT AAL;I.:\
MB(,(J6.Q^X\Q IC(JJ%UR_:UY\5JL&[SOZUCZO$Y@L[1B]]X*O(45G)SU6'.
M,QW"/@HK5;MS7#[3$.NP/K,9I'TA;7)3RSKQJ,-HQ806WH=##/7>%2)5-*P
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MY_HK[H?09E NX\5FV7R8#3KIX<B';JP>MJ$1X7L4=J_1N]MO?(]AL'-T0P#
M$7$U]^%O9N =+?LE=2$2AM8D=N,N*M;,WWN4I>!G!C.NQR/*4FEQ,:27ASVD
ME]<PU 8N4*.OK6]@Z!1/XI[=<&I$"(BEI:+]@_-F89 H;5.WA3UM.R%&2KRK
M?WPC9XC]SY:$<K-2DE?))U/?)N:RO@99$&YOW3*G%,?$094[)2]O530?AL<Q
M>5Q.#GZ$$>>NW3%@#UA/AT>B*!ECBCN,T',$DAS=M-(.3=RTIAW=V3?G/"X'
M6%_ID>R7S2XP6+])%LIJ4QB3%M#$G7R[9T3/081.XTHS?N&^[2B"5D9 9<(4
M&CM :K^D;C^=NB]0!-;&DBT\%E"4*G >][@4W+ _C<S4N9EG80&5Z\5IKQFA
M$BY'C70$4#TQ>K*"@KH2<1$GAK^6$5QOL9:14L^PG#:R[@ZR</!N!',Y(WLI
M9A$^WV%(S3KB)+QL5^&L?NL,]8S*G;IT?/)&6+.S@0#G<B]5J0[*&5*_EN5E
MD=1@38D4B1M3Q-[LB??Y<;5>@O/(YRR;FC-@N,RTSBI6;)GVLS& @&*N*[0G
MJF^'U_+2 _GUHHFEBK^+7"\,:,G+Z6YW+FN[;XYXN%J-AFFW(P]9C7AO<[.F
M;K=S<QTC2ZJV)O[D5H)@E6L C8"8I[("K]*#4VZ!^1/1;9=P3!XVV,=K+KZN
M2UEMWT*>'#<F=$FG#3EIPT%0NG("S\0@:QI<YIH8VJ&.#>@5YW'"F<@Y,^_5
M+OSWKUW^>VD,V>7IHLI!D'!WRI!)>4=YG4E=W$>3B.E,SG /AA!IQO40R[#L
M1*9' :+4+X $((,=2A[K*PFR_L1&/AL).-;CJ.0S@*Y9@Q,2[V+HFYM0=YQG
M=>XPH1(+Z^I3Q+:\-#OI^\ADI@UO'B:R*WCIBNYYQ96R2[6OG]AN)(_"7>+$
MS&5ERD?]-M-HZV.^KU\(R-214U\"N@".=2.J$RI:_AU:T#05=V]EMXUB1'X#
MKZN&WIX%=[0>?;_='C@5W(/_HZT:BJV*J'RH%J.V;-A9GI']%%O(S;FB_3%+
M@F7V _8ON*B\PK]7BCLM?/@/\K\_::*EEZ:ADO"WZTR[\WW;'[,&_[#C06V_
MNO>WQN$\1%:]9U17H+1,&39KML,V ;0OG>6AZ'35A5YY.:2]V[Q))NH B5Y\
M55?)O>?+V&1+]^K=?Y>O,O^_';J*P+G6"QD]38RA::-+3,[Z1,=0IR]'@@S_
M(P1#_\G)&8; [KI9):&?)@-+G\:I18B%<1F7Q\W@H53!9UNS$XX[:C[@WHCI
M(;HD)1MA6!CFDWWJO>-1LCQ0*WO-U1AUF9I?/[&-BGHD!E,N#ZOE4"6LR3L+
MBUG2[&"-\9T$FC(9:RH7#G<GMTX<P.7L%5QI^#HP?JZT%RHK0?<AMS)T0)S%
M0U\SP#.,:0<3JR+.,J_06@0+,<YD<$8^F@A@P,1?H?*9''CJ[>'NC72P1!*Q
MA<]C">%K% B"EUUX]*QWA#B^)#)$+"L*)1$.>^$W>!#]6)%S-\4-N=5]$_$0
M-3?75TW\!4:0/SUV#[4)E+WS" [^HV($P,=-6']+.(;M'.2<N>! (GZV@XPT
M<T:K&9OQ'*$**8/7\5:,\YCWZD/!V \\O<S=GZAR79PY=;&\6O/?LGCZ.)H3
M#_T<IQ&G%;OS +EV\PM[)OP81)79C4;>C5>7=6GV+(6**+MPJS]/-AV[#IMV
MUB@:,Z$8G/'1-!C41KA R8Q5RF53OVO'9"_!C*,)LR$]%@X*&."SG(!J0$H^
M3]F,.78G!I=49)JNU1(?[F%>^%YZB,+XU$,&RZN3"UBLZ.?=P /LTA0<DK@S
MY1:2JKT5"0-]AI8T-R]=2@9RX3-?3#3+1VF)-OQDDC,EDUP.3C+V02]0.5##
MDN-YW9;/)13-_#9N)0):]V\VDWIFK_#7[U&^:8FX>+9../#IO-DL)RT=IS6F
MO)7 Y;T[Y*JZ\DC/*/$&F"+A/>#&QAL*^U^!/"W@9I?%4')!ZE2W[]*!%NV,
MWFW=<BJ[:7:JT$UC:G:JWO7$3:P80BHUNHXX)E<PS.]KSG*/]_1D=YZZMNEK
M7\DRV"W,9B-;3=+>L4*%ZZ?KMQU%LZT@AN%_7!M*/A^+TV@:PF%MEC(^<II]
MYNFB"8LCDV//]:@T&,A/Y OL=@"G-J:I%;RP^"BXY#S;SO52FO;N,=(P^+2/
M5"JJHYG0;L!Y8OXY]*=&@'9&TPQ%Z*H"2%=C@_.!V)?!#6=*/VDBTA;IBZPD
M\I]S8"Z"I*0TD:2D>B</)@D"]I<<TOO['JLH[JOS Q%\@A^SKK_Q>H-"3B#7
M+%;O$%+9]%/>N;%1=6%OB WI\@]5TYRA[ E3[XUDH4]3FG1.;#L97>@\S<E#
M7]>#-D_RKZ7LJS4/O!B62E/&0 $ZMV_U-GMW==5SMU^<#NE[^C-^Z89B\F,*
MLWD0:^LNDTC_5,0"CJ(B]&MYTO#MM5-M--EF4M?G$O/BNAJ36$@&+.8'U'!'
MK"<_O\O-A![)<H_ARM(&V>_=-=R9Q4JE_U%K:KXW(UD[;6%O?VUPD;GU'N7#
M^#GP'-LAW\K;S9EP4'+VH7VT\I#WEQ(.S>\]0QA/\5H2.N6TKAM:@"#+;AV-
MU\8!XHY9/"^_R.)\(A.*]Z;=1>Y/\_LTSMF^BMS+'E0D$1&M6SV8N4=Y25.;
M,3SO2]5C?-CFRU/,F48:R:J3 V(;>NS)"S_7<+>T(A\ J$?/S?-QK%=- 06[
MP9.)WT)(0PHG$M,VS]8)32.->MY_SNY:VCJ0DL?3J'89L-B>JP=NN3N>ZR%%
MS&]ICOEJM=Y?J%%A*:<V6\5%/STU**]_CQ7PL5N2Y@&QHSQ/"L>,=>9SAE>[
M7)#7E>G'?=R1_TDMQ[]L8NBCW7G1W.:Y23=/ZV21E/"^%@3E336 54U7FHMY
M;OA,<C,GB$@A6O82AC:L[60%W^I)00](-*B()&<%<I_'^T1L^4]]N53RG;A'
MR1?ROSZ$&UZ\*RW=ND=Q-[&G,/<IGYQE=CI*Y6)-'+$9>)OY]8J!*;U_-9",
M%_UI)&&I8L:XE\F@N\[PV_:7[\<KT?W?IVE[8BZ'>ZC\+RI=XN*B!@E5-M;Q
MRO@YM:+MM2P8G<I*"WX8B-7JVM&SXE.67>7A)?<BVA'D?_CRO1E:TY+PXV2+
M,B"N.@%DY'MV9,74$<FK!I<56T ?G3Y'?<):[TK6_+(ZEEI P:672BUDVGH8
M3XB],8QB:'(#%[7@N)HANW7VW-X F@3Z,57\73^'K]_N3#6DJ,01U?6B4^%9
MHEW#A?L3;!S>="_])0)Z8.A\YT^!6RJ?0Z]6U(PQ;5X@0[=U.J^RTMI;[2N]
MU$2+4F8V%H.!>.F5KK7]D;B%\!8V/R73(XAY]M?O\G1R%MNIF>(E!*_[?W&U
ML>F*%U(TCGMP'   4%O_DYAAN1$SZ^=&V#W*WKO'=Z%N2.=:*9L%A._P;,9G
M<",59#K]<I<].?VQ%59?U.=A.5>;7C,DU9&DDO)(:U_=%@D9]#8FUX4&<5CS
M,4M(B9 J9G'?R7(='_W2DYPL:R@KBQLMB^="WN*-O9(HVE6.">OM.4CWDZ4[
M)@A0CB,NE%FS(AV3:%H9QOPBB7;]N,\\?>W+S060TQ?]DP.]A?[X]^N\:\[M
M*M-.6^$I=7IG^MW1.MVH/H" B.)LHLP0K$69/7YA"XO[K5="9%<O1YW7E L1
ML\SR9(\)LW)\KW9\M!?S:#99A%H2YM[J2VG$X!YB<'CG0PUZW2XD9.TK7?Z9
MLL9JD?*(M+Q6EZ&4"H7+S8D;Z80S;BWV &!U/B,8[KE#WMSDQ6SO>I9:<G*R
MAX'EG[<W?/JFKH&_:!@Y\OQ )>!)QES2\I5@O5]1??A#PQZS5@EEC?FWEU@'
M\X+"SVI9G*U*:\I->3Y^@CXQK2T\?8QI]W:,Z[3+Y!D_<\>"C.%K/3[>*H00
MO!36"5Z6\1:U6R=R>^./F3K^842X<#*.GY^ IRK%N9*<$',U6O;U]M5,N*HB
MJ4N&2;J.^NO>?S7Y7@=N8[OCVBR,S[8ZG-Y-Z(Q.N)$3*)MQ)Y:0Z2;VK5#U
M&B_U?F3-,ROD!6"DFF:1N- 49">;EQ/)XTMC9[E./%EHN$=)P$0";UU@?JT^
MBC>BN@)?4$N 1]\S2NY1RKS9S_<+6Y>OZ@BRS^=E,A"%$)T(C-(2(P?[YY#)
M&J[9\(7T6OL[-DSS9XXFU0OTI7/5'""68+E1O=Y^U?=! 6<F)^*J$J1LX[W_
M'#T"R'_Q@VW;:1NLZG$M?2)O!1.>LZA)U.2VM5/SD@1,^94CGO#H']U:S:$=
MP",.K%ZTC *3"#):5?T>-:9ACJC/']*.TF\+?_7AC7J^6M=Z\,6V5A*M.J;?
MY2S_5@"!OAB]<H_2(64<(]-9YZ=_ICD)B"KE4V;_YI(R)!74MCW/>$7#D#70
M%=G3Y4[GIRKKJR^6R]W>;G+3Z1^>7RACGODL2=H3-2>2?'SK-QLR5_WRVU?#
MXU>K[GR&NDM5 &E^19OZ7T.H9=Q#4\+S2L_?!")<.@AT6O:J?DL-?Z/W+&D9
M@T/*&NHT2$_%'3#H4.F&0]SM]YIH=N1JL^H>Q?<J[<(_ZW\U_F%/+]\/3_E-
M"R5=GT\L0A^#4_ZO[Z2\<UX;%JAJVPH<*IN]-61[;2>;[;KF$5E2)Z\VWY61
MC( E%644<V\I<RN]"#R55WU@LN;UL=[S\1_!'8=L^]&Y[AZ%]5#-SUD)>\Y9
M=MR$\;<7;NK;D!IE@8B>H1@[GLR.)A[Z=JMF1;,]KVZ-I\0"A>WH@:3ENU@T
M*&1*?DPCLUDGFQ44OH"(>Y2G^ .NHC85B,6M!%#R&$G$-QY[-4V$WLP0<VEU
M64YOIX2&S67YD 1Z1G9\_2M&6SMSN:.YN&;M!]4NLZ5/!Y<XM8*>Y))]WOKG
M&< XNV^-P"*PTO\\!= D2^6_V1!E,C^)UJ4]#B;5*&F'8<S8:"I!;!)-OW-_
M8@/0NA7-5,S,31,_4=+$5Y4+P[*B^+J)5+YRF<%N)>NZ1PGZ_&\0*CSR:PS_
M?N)2%"[LYJ6K,-;H-COIHW5N)1>Z'R7P;BN][L]#P*H#Q>QAS=KP'G,*D=SJ
MIM.]I7[/0QX?'9+8H<^E,4QT&%1<I&74E,_(&X\:6R'E5E&A]9 K=)K<0YV0
M[N(QV QRYQIF"R(J,MJ3M1B4 6($3O#I0'^(OWFR&L[GSA"G!4LK,E9!+:7Y
MMYGJDW5WXTYP]X+=8/-[ZVRFEGG$QC3XXJ(RW<>0ER3\5LAD=81B,*%^-=-C
MO?[<N<;PQ\/C(#U1J5L$]4A/8Z*% [O[%9'OWZ+>P#:&.^W>H@V66HW 4,TP
M<HJZ+*+-VE9#@]4I=6*F<+,RM7>%34/08\D55!"M91I#QCA\1EM@:X%%^$Y(
M<G+E)E_$VF\\L\WG8H_]AE:7=115*G-[4=JA^GG76>!<QM04<1:0?;N9QIW+
ME$E-T=K.QEN VY.,+QDJMO/*.<TI^#M'5/'!RVQ3IO?2C8J41+VHF+5Y_R+1
M\'!;QWD9L^]XHL[S?,,^=Z@3<9XTAV2(GBQW8"HY::GNWV$1%DXL2-0*M\U+
ML!/)<9-15%A-2(/9^I2KA60J]MNZ"-F$ZN3H^:IE042V1XR$_QP^UL1_D3"5
M/X2OS_2H@SXB5FO3)$H=K&X2\\:<;00XW5TA35$W+UNYO>Y1U*T;%*47=/$"
M>Q675H\3**O/.-2][&6,J*V^$2+DZ7\#F*6YF!H=%RWCO6VD9@#46@%?FB;@
MC$(@ICB^1S=<E'&0H="9Z=N7=,S0I.?:GR] ZY.& -,K&I^LTW:#/J2]VGO;
M#?O1(2.FT50?]6SIP6;)P;=^?$Y[/_-7<=^=.%XVN6F9;A7&A 1;KD:R>H1A
MZ=SF-+\2GB+&EU?;AAO$S0LJ*)D;#$>-7"6::'GUFM@0^ZE-=:;S#FHIZ9PX
M:^O\K.3BN?1@(!1>V.MM+*\Q9]S#G[4I)2+E(D5W>;_]L9E4,X)B-$B[JDC+
MADR$2;.9T;,6>V/PND$SU/YC%MQ_]!&1'/26QN2!WY<0K?E[E";H7O,4O9\+
M^ Y<.GO]::8<"-%6I,^=;6X<'C)-3!U6D[;:35Q;O\I8@,\<50VO[>TAF0&-
MK<+G6FEI>U*(+U\2-NIA^[;F7[,*!UW7+?47<T/G'W;#'8?6>\@5;EPV_,=K
MF@2XO.?33F\2%Z?W7B+<=K& EPMGNZ4_/)I$ G).?4D;&A9J2SS8V7O'^-TJ
M+IWKV4CJ,:J$A552\X'-%=$J5!R<XPD;2\&?4V!YGNAP);A3Y_'&L/_X=WK5
M"A%9+7_]%O%$7K]] :Z2G!F#;I+F!AD<9/>,32GPY<9HES=ZWI':,OPJV4M>
MB.6-T:JO8:@5)_5=G^/(SX_VPG/#70! 3OC#<1+-6@^BXC?<^$Y>?,KCM102
ME0\AO4ZK5KVR*=!,(#T("%PWFWVH36#.+IE=G5E3J;&P9#!&(IL_&%3RD>;C
MJ70IX[NW*456-Y0UKP7>WKDQKYVR,C&WO@B6#YC'MEMH)X_*MQB*AL1,<"W9
M[5G4?VMSM/;QYC*S'JW^Q7(=KU3I(Q3?9T3S]Y. 3??67Q]23O6*D47@#AB]
M%/WS>;L'U-34?SQH1_T+5L-JXS&X' >'.KD<%^1/_LSEQ3(/LZ0B_&K5?,XU
MG4\,"F%%.D#]G=W4)")E%6M]&QD>/>=7.\W?>M6[D&4Z06JOEB",D(]1-1XY
M46O)N2YN0=-"6'<31YTLAKS-63U=D:L[EQ5PS>U= G*/.[/2$=+C'M:1QH2J
M?WZR#W5\_GNU$%+Y&T]W:K<@5MR$CHB:4>6^M7A(L<& L?W/@C.+)QO\Q=5G
M-)XY3\PI8PI"N$#&/O8?;G&4IIPD7AH^LZWW4 GZ%0!G4QH:'H=F"AM11'ML
M1AO&N#,#G2EY(N\^<$&R3D?,[VY/^0Y117Y'R1H7ZH=:(^L2 .U[%+TSP_U%
M-3\<O-^Q%@/(^5_7BS826Z(5\F$4,\YZ**1 :N3-2 EDNY\44%M]6E,&Q1[@
M4WNC9* TN$<WP/O.KO6[9_V9'H:60TA0)W;5D42>:\VW"0N%,?0/*K/]\V.K
M)%\-:*("<YD?16*>FA'X\A)1/\ANQ-MR!_FVIW/M-IO6I052"EJX]M"HR9K2
M\AKOAO6@Z@BF30MC]'(Z#@LI( &N!R54,,W&?-,:Z62UV:'*L08Q* HVC5+$
M_,CLP<P,;:^U7G72Z7,ED"FO-Q%F1DK?YYD<D';.;T"=Q^#+GMW:(I3+M[&P
MM84E"^$?$C&5V<X0Y#X-^39Y,=@&[TA4*.E7/VC 4%$]M1+R('Y@&]&OCW8D
M01$O-#SZ']CW[UFJ8HQCK2/]Z9G!PL?NY3WR;[/P,@RJ;R[$.L177.^M!S.U
M.#7!;_VH#+29@=STJ7D3J9CZWU-5>DF7F31QBAEE:6/A1/^*TZ)__]HUU:S3
MQ9RP5*L$?S$%T1@4$[+AR7\0[G5&%2LG\#V5^@^1%V7LDZ#@KOF$A]Y.7A2_
MTE:Z>NV;LK8=?7"G79Z.=.]*]4;#!'$K1>*X!E*6.ZG"E0+[!X\D[\DMIT<+
M6N:"S/*3XMZ3DJ H58 &+\J/ASHRZP+7:G?I9P_W>YS\EJD/[D+YK-WO4<[^
MCE1)3_R[GT-UF1+F])-FR>J'9WKFAK:PRG\2,W/8X+&F'&HX-VC*F3AJ8Q#V
M[7WX;F_[<6I+D8[)3B7?0JZ+:$2UJ>Q]B/(/2I[#L^$34X#)OL6.3=3$1,.T
MD0Q#";BF2DQ^8]K)(@([G,#Z0N^5%8DE%5YY2)>41MC@SXZSM7#=*BC>;$(B
MYS^C9UZ,,WJV>CD(W?,7Z5L=MIOR.9G"ID(+[=Y*K\D;:/:13\8.+-DXRL+>
M)F/%-(UI'_A2&!V.W[+N0'^N7S044TP%K__/UA3$R0];):]!IWMG>^0-LZPR
MU1X^&"4N6=Q?W\R6"Y5P:$=:*#.I0J)D4*<Z+5FE1(MF)NCB6Y5$>YMB#-:<
MAI[($^$N\_T^JC#[,"QWH91F?-^9.96Z5&;GZIH&Q#T*FI^D-0O(CV*RQ)WH
M1]6D^79S%+A[M+%9L(57-SFM9'!])\G"<44:W2[T-%,FFB\9A<Z1X"M-;&XD
MK1/P3;1J^(O81_5&L=_#(K4_KZ+[)MZ._O4?4G%;Y)C)U@"%(G;+0/&2AN,S
M0_*%=EN[A->I11MR(<^HQAOFE*UU YT7:' S6G$5Y7%-B!>>LPV\R@ZB.S"A
M2160^A=<;%?OA.]:;0BS\N/LF1_%"ZZ8XHU.)\/\$CW/U<NX6D&7$=):$77;
M-DET R3Y5_"GL513=->EN T296,GWK4B9UDMQ&HEI'#8;2V1D8[_F9;BB@!E
MB'A4US!C'YRDXLM_7 HC=L]IXTA#RZ'X:1)U7SD(^\9A*%!^'1F4_QQ#<[6^
M-I_SJ!I3[94UC'&99!F'-&YU'?+22)7P,.O=/Z=56;_GV!'F#934^?6UC:#G
M XU4G^;FU$R.B#LF(W1"#3<.]DT40+H?UM[I^+W/1,KQ;7:;;$LHXT8FKLO5
MT!6^8X@K54W9E7K]&Q7&<M3-W0H^RQBRSE!)RR^I(63:.&7[-O0!0Z?6T01,
M9EMCL"']!"&#/ZF,HTRJ(4E'N)DH@B/_0X(\3H_@G^GO(\(KD5O8U3U*5<W(
M3C-J'4R1(FEHTUV"O=1Z9E2;=$KM%?[KNR^CQ+[/SEB KGNI-0*HM7GE\BPJ
M/^,JIE(+']?3"?P(</ES)%W+K810_33LIEK'9O)+8(KR/R :#XG/Z?A?\]P,
M/[M[FS:;RI\?1SQD,N@@^/U1#ZF^-,<[A;:KA>TKRHR2E1#&EI<PYX/L)U<M
M=A N-U<,;,&/;2*DAWOK%U?E^[J _^;D]']7)Y8^. M3MK_FRE/;UBHCPY-%
M-=^@Y+J+UDN/U5T?F7/6_]'.>48U@65Q7(H*,J&,R-#KB-*DA+JAB".(R)!1
MAIJ 0C 02I $0^B,0"@#*$7I"8@%I"<0D C,$ @" :1*( 3I)1"ECB#@JK,?
MUMD]^W'W[#F\3_]/]]QWWCOW_.X]]_QSWDM><DE1'0AZ<7_9 6>;%2S;4,37
M_7@BCAD:]SX8'HR4831UL[_\*P_1ID^ <8OZ)V $1M\.'_>!+SQR"IF9YWJ_
MD(K]]!"5380N'(9T\'RE9;+YR8&\1O[+Z!'@5XGS[I5X^9JQ\=W['Y8#IKD9
M] 0 S.RKO,'_A1!'_UAKCB?X/)]A9_WL9Z&X'/C.CVT2A+I%9\KI;I.9)J?[
M,K!-D> A;B::)",LN;K]]M7O$^R+?67!3_W?_;"K,)@- #]+)(RMG^S$IW@M
M1&_C]9?8FC?V]-<\/QZ![0-ZTMJD[=@3;4P3/YO6C:L=G;\..*UK!T?R+MJ3
M,KP3&V!RUV$8)/?YR,N<;Q/X=E?2)AP9;)BBT#RL+A0&9B&E-T;D:PA#&QF7
M9X!]I5LRR>1(2W[77CZ"_"O[!6J9J C0<N#$U[,OVX]'."LIK:O@.A>['U9I
M=I;3J/<F$>"?76LJB"$O' S7AJN-5MS;'?S$\H:V'S4Z$&\G>#PHP!ISX2_5
M#O#>ZKEF]I?:2IP0EIS'&/1+KNH]V:(E#N7(P&IT8)NLFH$QW&90'?S-CR@7
MK/&VF9J/:AJX[O:-='KUSX9O^,M?)\[)(Y23C?1'Z5]E^(9RE_PWM-/4ZM*^
M\R_49>BI=UC.U$;#<@[4OS!0/A!_?_1)E5)0FE"=%$7[)'"GL>RM7]5%] T]
MZD3G*AQL1LJA"!E/V29OZ]FFA%U[;F6V?@PUQ>H81-@D+DZAG9;OM4^-%!U5
M7>/U]VT[[S.VJK98BJE\%0^/,$H>@)0FQ)<4DHI)S44YN:;88P2PC[>V!2!]
M7U07%>)T!*L)B4+@A RH1&7V:DX7*)Z<R[;D_584!1V2A&E<$:7QRJ](?&JE
M$(R$WT(+6\YNB0M01 1,.7%[#202:8>T S++ P522:2]U.C^X[+7:LRL1J,+
M]NDZM+?[\^<<&]L^6XF/0.KJC]>X]?FT9F[I#Z^R,(A=/$3B1ZFGE2X&!LLZ
M86A85[<(!9BF6SY[@.34&.@QXQER2FI] 236Z&65[ZZ*+W6]HK18W6T\GM*P
M)((TG.G&&VV<1S"O=XK7-S%:7!DM ^2/1^IOU</(U0YF!6QD:)+RK]1PF[NN
M.8G=I65-=WD]([$A3N),YYS).'K0 HK@R;0IUA/LH[CS%G*F YX\ U.SP*8.
MD@Z8[4N=#$;#NN>Q_&^[[9'.*Z^] L*,^]>9X?FWT7TCSC/5)HR)(H/SA1$"
M)$A<;IE[L2$Q?6F\ :K2KF)8NP9'_YY,8\2&0A^I/O SAE'OU4,C(/&8<9+8
MN/<@?U#JY&*!MJX?_>32OD8,M9<)%#(U.:%E,SNMWFN+M.BHY5 ZN2JHQ*RB
MG>;&7)\_#*X[+JX2J2=O7TFECN:Y+,],.W@E3E<! 'JI"(7E=)!_+CT?%71)
M'[C80)9S!U^*(NFW,9[F%3T2<O6U]CLJ5LV4&/\)6FI8O06.I^8'(NCJE3:<
M$6^/&/E6+P&6H4PQ@G[Q^#IW*_VS123]RV'^N9F8 0P!:B[]DZT-@-*[+W[N
M%:6O9;RH,11L[]>C :I O[L9:*\G]F1DDV3/;H^GP5[JG JD!&07B_;IJ0!P
M9.M1K*=TY] L3WCF>5^KKX=$#L:;6%"6 80(M\-4<=S0 :@U-CTROC0> ,@>
MRH&5A\)IY;EKGLUR Y)0=XEX,_MGH65,-+8<V\/S38 &_@M>!>X[)Z5OJYVQ
M_(XK=]YTU2G)42'9L\;%"A;"=^&"L(<^.I!'6=8UFM"YPRVO5VCW&9?:O[D:
M/H:)TCRA]067(&6%3I]QJ45ZK4^Z19;C6/,78"%#'G*?"<O\(. KV OA>JI?
MY3HYZ&QR*8'NDQR7%VJ];:<4:P@,H82HQAPMIWT'9AG![MP2X%'6D>=WPJF<
M/H8XX93VK_V%$P_+;F+F(<5F%0-#ZL5J\A))L[KDAY6*# VU4E_+J./PLWFD
M+1KMH"J]6$E40CIH1-5:?4&Z>F%=7N]QYR(*\]A#&>!?K2, JG[I4A^HH"06
M*=XE-I8S=D;Y4S'.A7_BSTQ&(^']OQG+L9:B+'VCMM5J;1D<%G%8RB3L1V]*
M8VKO-7SV4./( >:WN4VWQX.W<7'0RHD;BU;FP4 7Q#Y,Q1Y7CLX,4*^0UG%+
M_'*5:]=;@/WO)IO[(PJ)>83Z>O(TP"C8&@&5ONH3<26W_:8D2TS W;NK J"6
M_4NA$E&#/W3260N4Z=ZM0[GP_]:&_\^B0 C],YQ.9FIWF'ME$&[>>8",VLVX
M-3>L*W!Y+F!N$:>[V9Q/Y7.JN4>=NBG@5I=(#!!V2-=/>*@I\3+!,NH?'8A<
M6UIB(M>OPB<-[V5H\_,;\'ZOV0T"@4BD>D&6;6%]O5=Q!2,O0MVM%S* \I;Q
M#?)4T8N<M#%4$_,3%HY+;@;<<37(>:"#,<"SU%[W1'N$]0AIOUA^R /I\*GZ
M83R\EKG!'//W*@Y6$^P%"QJ 3%).E9D7=+::GJY*&W0^)@Q?\S>]?@*L(&"1
MJH Z^\8W/*PD[(K_<^O=%M@?8O>Q^;M$\1XS+SM8N):BD'3E$B%NZLYS0U R
MF44!"0,W<Q*:Y]NGN!XJSC6PKWPO9N/K%-ME5,:(<JSY)GI/&FUN<+'&2K"W
M0SI:^5QOFSI[-XD.9\9&^V]=C,U;_L"8G(70]3A]"!E[*8MGNN3\H32MS=J0
M/5F@MI10R^,8!8??JO?A2#$9MNT2GIX;FTS\(%3W &^+)P.DXDHT!Y7HICVJ
M=>T-:;LO<IHM=\7@YQ$Y%@WZ;M.I';2+%HP9/V9R0N(XK\:\+6</:$UG!<S^
M:7]S'2C#/#.Z7"+JSGB+G/6X-XLB):5WD@C2"9UZ,=K)V&TEKQM"I@^0KEPE
MO',BNXHB^\'PCT>L-PF:5YNV?7?"QFEW"9H5PV\AF4%5:/!-F^]CS@%OZ#?6
MQO3_;GJ_8Q1ISHQ[Z=>AE27(.1@T,VYQ5-/!O"6ELI9X)(+PL?V-'E>1DJYF
M3[2R$<X-,[@,&<N:'=*[@]=YH(V^LP CR*F)IC$>M+5FMFLN$[H5TIZJ'H/(
MQZF)R(-V\D/R9[%T:*L&-<\<:2<2>$8VW2MD;*5E,1&3,DQ6<V9"YQ/&7D@$
M%21,*IA6#\=):-V+"[=4YM/Z*4WHITZ-'AN=H:S'!!F_T#9]=T7NI@E<D\0!
MG0+TE<.W1%,:73IDW4TBS!OTI90N%)3TI((,)TY#?9=R!VDS$N8^(R"%T!K:
MNOUSGFXUF3L^PTE\Q7?X9G#B,+XBG+SX=-+9]CN&,\D2T4I'X,)<<!$QN!@<
M?G/E/^Y1',I#>2@/Y:$\E(?R_TN:?63\'5!+ P04    "  7@*U:19TZD6[N
M  #Q20D %    &EN;RTR,#(U,#,S,5]L86(N>&ULU+UK<]PXDB[\?7\%WMEX
M-WHBA&Y>P-OLY81\Z^,(VU+(ZIZSX3A1@:O$F1)+0[)D:W[] 4A6%4M510(H
MD.K]T&Y; I&9#YF)1"*1^1__Z\?#$CSQLLI7Q7_^R?_9^Q/@!5VQO+C[SS_]
M=OL!IG_Z7__U+__R'_\?A/_GS<TG\&Y%UP^\J,';DN.:,_ ]K^]!?<_!7U?E
MW_,G#*Z7N!:K\@'"_VH>>[MZ?"[SN_L:!%X0;89M?EO^)4P#%J HA!3%%"+,
M.,Q$Y$%?9%$<"S_BC%S<_24C ON)_&40)!%$$8TA1B*&*//]@#">94PTDR[S
MXN]_47\07'$@Q2NJYI__^:?[NG[\RR^_?/_^_><?I%S^O"KO?@D\+_QE,_I/
MW? ?!^._A\UH/\NR7YK?;H=6^;&!<EK_E__S^=-7>L\?,,R+JL8%502J_"]5
M\\-/*XKK!O51OL#)$>I?<#,,JA]!/X"A__./BOWIO_X%@!:.<K7D-UP ]?_?
M;CZ>))G]HD;\4O []6ZO>9FOV-<:E_4G3/A2<M_,5C\_\O_\4Y4_/"[YYF?W
M)1?'IUV6Y=ZLBLM,<>G'BLM_/47LES/8=\1O?<BK ^8:<;^XXG$(TR_.V+V5
M%H)/SW"/S-DLMQ_4^X+-]>UN29W-^O0<N_HL5C5>SO!9[,CT6%ZJ'WR2?^O(
MJ(D&C&E#IS/=/5;YCYH7C+?6<F]JD+/__)/\VV)=P3N,'Q>7[&_KJE:K7W6[
MNN%T5=!\R:62?90KY@/_M*KDS]_BZOZZ7#WE<LXWS[]5G'TLKAYY*6U]<7=)
MZ_PIKW->79*J+C&M%[X?,R\.Y&J69'+Y(SB$&6+2C*=1D&*YMJ4)7M1;O5CP
M O[V=2-"P^?T3/[) .'ZA*4H>;5:E[1=8R7CRK]H9?FO'LN@7H%RPS20YA8L
M)</JI^KO5+(-UI);D!=@M>$7X"W#?_F/7W:XO-(+7?Z/>$W+<][0EE\@&08M
MQ^ GQ?.?U:\5VV##-R#/X*??VG?V9[#E'NS8!]\V OS?DZ]O1?=872K?:56^
MQ'=%9\%W9\\J"7 #KL 5:1#NZ$ND _0+7];5YB=0_:0Q:I.R^,O!5W]9;K##
M)1WY-+H1ORA>^&,-][X24:X>Y@.Y7LVG,.U')87_$UB5C)=R(W0$R*WYJ,IZ
M<2/5@W_F#X27B]B+HL1/?;EE(41N38( DDSXD+!09 '%7A)Z.B;\Q;P36UWI
M:M=Y5><4+\%GCJMUR9N-W;=WJP><%Z=U<1"+8>MWAH1F!LM:.&U#<T*4(=L@
M'^G9!?FOG4UX.=LL:GQ"A(WFG?JUF;)L]/>&+QM76>[OGF]+7%1JU5X5U;N\
MHG*-ER_H5KIB;R1??U^0+!&,I!'DC <0I2&#<N\?0!IP1ACQLI1YBR=>DI6N
M5V1 W>2C[/.@_6UVO("&&=#GQLQ[,4%4SRF9""4SU3T-#]CQ ;XI3D##BD.O
MP0( 1\Z ">59UW@+2%XNW393F!F9O%@MOJP*M?Q_+.1:R*O.+7C_XY$7%5]@
MG,8<BQ3B2 BYR_+D$HU0!!D+DI $E/.,+@Z"$"<59HR>EG;H15@&-$5R )LM
M4=[Q %8%J'B1KTH@WZXT3G5.U#9J57--VS(*Y+ A<8*+E=506#3[C@W=[;:D
M(_UG1P"P+@#>Q&YG 6*/XAR :)M-72E;&RE'*[L7>6$;G_[7T<=G,72Z0FRL
MFO9X.S_I\@GG\M]+_F%5?L5+_HZ3^BNGZ[+=N5#Y+:P;<_IK*;<\OQ4EQ\O\
MGYRI#= ;+E;2F.(?"Z) %H& (4VEO0O#&!*B+%] 0N9%B,=^NNC' L<#%B[X
MLK"+9B:Q(?YO_^K'WK_O6 "*!UT+Z/8]: :#9L/6RK8J=L".GPNPY1=*VE!Q
M+'^VXQ(T;((7+^ "D(95('EU&.=Q"9VKP(X3GN:-Y+B$\2!TXW1R,[/*>+YX
MNY*NT#8^&W,2Q1X*U'OCTB!&#&:8"1AY7&XWA?0*6: 3K3F8>>)X34-+)U8Z
M(O^P23I+*C.SHBV0ME$XR?P1Q:XX_?EN]?2+?*;5:?F7G2H?SC2+.IX48*-2
MIP?8>1O*BU'_O?_'.G^2JEG4U8UT:,J<2G54O[@LV/X/>B/;8T_I_$B%K:16
MM_^7_UZN5?[(^Q_T7H6/;J1JOQ>"RV^/Q6D2XLB'(4XRB 0+(:&4P<0C-$MB
M%$>4+^KM:=_HPCDO^T8*?N)D=$ ??MJP\&>P84J=<S4[/%RP]B]\Q[^9/S/S
MF]9S?/ZX[\_0E$G.+MISKQZ#%V#'.VB'J/?XXH?[3[1"[3Z W4=Q ;:B@8UL
M0 D'6NG<^52O\U8<.5\S,S^KE_8Z+^:E._=*7-@M<)^XW/KQ[1G@)T7M4XY)
MOLSKY\^X5D[H\ZUR3G?!\B@+$,JR&(JTR4A,4YAQE93"8QR$D<]0($Q2,BQX
MF/KLC]YSMEYRL!+@P[I6 ?7/>9$_K!^D=2KDR@6N\7-[W"_=[]ZI?<.[X<IC
M\PKTEH^)@35; UIF+EZ"=0&V'%VHY C");8YNP ;_L"WAD,PR8'&&0@YLL<V
M',QJ5,^ Z*5E/&<J\VWM;8F5R?SZ_$!6RT60ACQ*B( TBN6V-B4<IO)G$(L
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M?O^,<'RP;;1I]<C+^OE:OK/ZLF"J1.JCFOT+KQ<L$ E!80"#-%6KN)] +'\
MTR25KG%,DH0GIJ&FT^0FCS-]R'^H](FNT$[!-2V/%E2Z820WXIO&D%JJ%Z"A
MVUP0VU)N@LLN0TCC$CJ+'PV0FCEX-"[T8>1(XQG+1,\N)2OGU2(-I ZS((*1
M'Z80Q53ZX $6,(TCQ@7E 6*>R;E0;^Z)SX':NK_+'3W#W,P>"'K*:2F:F2Y^
MTI#'/"GRD'-7>8Z]F>=-73P4Z2 ;\<@0VX/50BXH=4Z67-U?Z+RK#'L1H8F
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M5+L; D7*O00%W.=F";C..9S:XWQYIN*B_X7[UZ1GDE\5?$,'55$ZTL9XKZ2
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M#B$*XQ02X7&8I"Q#G$>Q-)U&+NU)4E-[I%O"8$/9/JY^&B]-A]()"H;^H!T
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M#Y"?JM ;XUB@C">Z]W^<,4&2)$Y\<%'%$9GQL]Q05=JUNBBI90 J0V_M8@"
M_MFI\H/N.!-==%]5<-4MHAS7')R5U&71P#&1Z;/^SPIZ,FW__--VVOL+G1=?
MEJO57:&MPYVL)^9UB@HQSM-($(YBH<N>4Z[U.,I1DO"0I01C/[/)_1BB.TWZ
MA^9 'ZSH?:QJGN^B8G,04C-]=X*0E>9KRMX'3?LG#4[E-2ELFMF58]1DFLKJ
M2/<'R4UJ!4R%/[0'QN_9Q&&LRBK3R-U)*?314)L1T>0A8I&'C%*!..&^/K)A
MB,0)1F$D?19&619SH_W=C-S(^WS+@*<Y\%H6AO-R;( S":A<P@&-H'J1L,AF
M-8 $$B*YA,8V)K+[90%&/J:"]H8Z@XM,&-N8"K0?S!B_99G'L2RV/8)O"^7:
MB\:=W9ZEAHQ%+,]4P!M*B7!(E*'CE*J_1A%-DH@03F!Y6H,T1T_7JK?R>47;
M^R!JZC_].S"M8A Z,T?'*1PP:]<E[=TV<#34?QKE!-I86%<I#8/TIDU9,!7_
M*"7!^$4[.Z!/36X+M52U(51=*)4?]4W%%=61-^\T)6 D$)RF% 5AKNMT9*8B
MHCA'64(2Y?70U(]!K6S,28_N!>5K911J^EY]V*'\?V4K/#G_4_U%P2^J7,ZF
M2P0PF1. L9GE& <YBR/G'1-77LN&I_FX\FI.1NG- !??D5$!$)[4NL !.30S
M%BM8GIIN7EX6U4$:7>C6.9\7RS]N"[DLG^G>36Y*,A8DD4 I#6*$B8@0"7",
MJ$PBAG&6B<"HG320[MB7XQTN/#Y?L<529R*L@!Z(*8B&!ZSNH0&>N'91J9IC
M:1:\#@_C7(K#Y'9U_FI(==H#61@41R>TP-<M"XCO7JKA4LH654LKR:I3X;:K
M (YQE,L(I6D0*(N12D08)TBDA.7J9RRBQ@<SP^1&SZ+1)6,-!U6'HY:'^F8"
M6%3;C]SPR8Q;/(#680 *VT+C?DR Y<;.L+F@Z-CFUP5>?&PDZ5 )<O\BTQ8B
M&PET5(YL]I:ECR3*N5C=[-?P-+^76<X#PG&.DB#*$8X91YED,>(\Q )G(8[2
M"'8JTT-M]/.8FK9WXQV4C@'=H1Z\#%T@-Q@ #=L9X8<-&MS5&9;/E7O30VE:
MEV98Y",WQN 5RVG6_]K,UV^[[)3/KU_G)X=(^'$0I,IC05F@V[U%%*.,*FWW
M!2.Q^E.2IQBFWJ:D1]?US@V=+K>B4LX7\^J,0%034(!3KTT1-3, 8Z $LP8U
M!WLY9Y__CK[>.AR*#931U91L4[+3CLT&@G$T1QOZOJ7A:#HP*=/T.F?B="J,
MHJ952]1]*E</2QV&=?[]9KE:?UVN_R'6>DK 8S'_[^I 9[[DGY=E\R/]7#"C
M:19'+">(\H0A["<9RN,L1&DF)<,I"^,(5)L[+?LCQV0U34^/6?#^>)JS)V^M
M6?4V1;GE:R])3OUEI<>-+"HKMUZJ)VM!FXX@R]J']/Z8+Q9>+KS.,OJP&9+C
M_$Z_+X;&]8?]+0 Z; :9@<T';OH5:Z:KF2IO8NWM^&X'B7HJ=O ZO#NT]>\"
MN:L=8UKFI]UWWN7#'.U>[\.%W1[X3;R*8B,^*RS;+&X];/YFHZSHLR@__<D6
M&SXO'G6IG_H__D#_G&5AX),X($C*G"*<)1C1- F0H-+'<>*K[2R#^=$67(SN
M4C<\>?K73&TVW>:Y=&>7@&F<-G#K0XE$$H9XK/X'"QJC7$\ 97XDLR3+8Q\V
M/W!DL*TFB?T@4)MMN2,#"-LW][!KV5%>S_K):QFZ\K8L>2U/GF+*W8YX 2*.
MMC4;#B;=FRZ Z'"#N62IB^NMZSP9%8;IW:H43VK#4GK:_'1;>IV)S,]3KJ^+
M(H1CP1%)&$4BDSA-I, Q"RQ+KTWHCWY_U"DRWF.C3?=R4(=MA+/A >QXZ$%O
MFQP =TE]-D1\]Z7:1M3?JVH; DU/ 3=H&=LN:6M]#WY?+E_G7/"?WWY3-NZV
MJ(] M=G3@YZK<Z-9%I$P)&&&?)SY".N.J+F4 2)$1+FN-4H(FU4'#69VR)PT
MR 1M&3#/,54A;U4G]V&C-_-Y\9/WTC"EI_S,6X8\NN4(VM[,&&0S(S0.=##[
MHU&K4F#N.UA]^*U%<,N+=SV,FD5?,B@ SAJ0&1.>N-,8%)#CEF+@%>Q,SMU^
MEK ND)J%0>)3(@0B3#+=:C%!&4THXHQB'E(6D!!D6T[0&-F(5(6*5=S09$$O
M"Z"5.(6+F3FX4%J8WF^);=/QJSI$=[K=(XTC)3Y%85)M[1'Q4"W['K7<\C?Z
MGOA.?A,ORW*M.P]\%X]UW:OOIWXJX@#E!$N$:12C/%1J& 4TY3Q,_5P:S? :
M)C5R5%$3UIYQN27MK1K:P,W[/%R&F[43$(";\U;^'57O^Y#\\&UX4#17V^YY
M0M-NLX,"'VVKPV_8J7&G39P>Y:KOZ9Z6"_7^JK[QG84XYE$:^XC3.%3^>NJC
MC&4Q8CC+,D:"G&<I9$\=(CCR!EN=ZF]G$NA\I&J <X>-O_XE"X/T;]649VB6
MQB":9KKN$B.8QG\Y .93/PA@53>5S)'"#Y*;5.U-A3]4?N/W8"9 ,#[[MEF(
MP,_CX+HL'\KG8LT_+^BCR>9\_NVQ;R9T3U5-%05[DW3U!.IYH5,/S'2V1_Q^
M+74C.?!*85!H[W?-@8,SNF'Q3BCG2K!_>UR^_F_U<J.7C._4L6?)211P6*16
MY0R>A"O9]6)QS?_K8:G/WYHT74,%.WYS9.52!#LS:U8ZB<=HJ)>)S,-:=9FX
M,(T:D-1A4G*_9%;*=&*YR13IO"A=)>IYZL+)93^_;?_X'W,5U9;LZ>V+>%7R
M_CE?S<(H\8,P3Y ?*9\5DXPCDJ8YBOT(A]@73&)B-6:KE^S(6MD9*+6E7;EG
M7Z__[OVN&0!>:AF":>:MNH<(ILF7H&,_<,M(6->3M_J)OL\(+B,@SL[B,GO;
MSF3<%JP4="4^BOJ_M\5]*5[HG']L"A[:UA(%KQJEU+W39WG$@CA1P:X@,M:=
M\"@B?J;^)XI%@%F0LC1N.^&9&1$[1HPT9K\U'LRL-$QX35^8.N);5BUCFFQN
MCU:<P(R+)>QFQF9$**V,3\N/]Z'EZ"==[=%"VW!3(5LWX[GN1Q1LD"X#Q)&!
MLF1B4H-U&5"'!NS"U>P,VC7G588I7=PK2K?%#7V9K^EBEL0^%R(,49!3/58A
M3E$N"$61\GS2( TRX0-;5YVA!-$CJPS/'5U/@XF4*K&:-,P&G4/*S,@XD!X8
MC.S$UA2U!;D9$!ML* :$<F0)SE&95-4'1#W4Y:'';3M-E?/7*F.V<W[7E$S-
M! DSHOP(E&"&$>:!1(3$ 8J%S+!/N(QC4-?L/F(C!R<W#H?^]F)FIKNND( I
M\([J=JC3VY77D'79"6I8.&>]GWI(3=SM:5CHX_Y.!N]<.K3NIIL6WSF57345
MD6?^^4']::63P)9%/8)IQD4FL"*&4A();0THRCB72,I 2!S0()*PYD_.61S=
MAG0+#+H'W-IQ[OZ]=J+73U3MD'LOU3/2H,F][K^EF95ZWR\$LVT3?)P+IM:Y
MQL_YZ#IG#+[3_#K7 )\?8N><DIV!_W5>+/6\E+8K8*W7D52FF''EHH4Q1UBJ
M:"L38:JB+1$F1/AAGH'J)TY2&3N?28-8K-7KBSKSKNE@:64[3\-D9OXN%AYF
MP6SE!INE7KD<69;3-"8U#KUB'NIW_\-V*JICCOFZM0VZXDI]5U$PY>1]W':9
M!);D@-8<<[?=LE'MKWN,>#M.1JG+L<+ T>\UC/:DO^]6L!SJ@=TBMC<?;>^A
M.M^WU;U9&O T#I,(R8P%".<103D).(HR2@F3*4X9:$;V.4(C;V1;"UZWMH?>
M3YP!Q_0&XG*1H7<,+<4F67[7?-KE/4*_6,YN"LZ0F?@NH%_8X]/^@>?A'5X_
M%8_S0E2#+I0Y^"AT7XIO=>N<)E\FXHD0^GB0RS1&./(SE*4^0S1*<2AC23DU
M:C)@1&UDA>W0KW8U7G& FEY!YIU,AU'K5V+G6, TN0N#HNW5Q%%#W:*SZS >
MYHU=G>)BU]>U'Q\W75V-Q>QIZCJ\QF0]78W%Z;9T-7\);MCVH_C'4E1!>G,=
MNGI8?A/SYWRC+,@LC_.4D"A!+&0JI(X"@JB($_4GF6:<4H&)49T0B.K8AJ[-
MI5@OO;*E::[/YN -V[E1(+GHZ+#EX<K;PO2P]+Z-"9.Y^1L%+CLSZ @VD%D$
MB]]C'LW7FLQ,@L7KFDOXRW"S^8LHQ'+U\"1*^B(VZSE;*5?SWYI-/&%Y',B(
M(A&$$ND<--UO*D BBE,J_31*@\344O81&MDXUJ2]+FT=RK#S4\1A, W;1%?"
MP\S@6;DM/+Y> ,RMG2L@[ S<!8" C)J)E#UVK/?UR4R7B1!=:V7T/+R*Y;>"
MEXNWQZ8%\-NO_US?E\IMO'DJ'N_9VK2BI7^5D>V/(BX4=1U=M QXO]+RGV+M
M55QX-T_Z4LF\RF4 DWY[Y!8.F$4R1.*JG6?FI@K&3%JKBIB!I2>KCC$3L5LI
M8_B&Y5VFH/I8N3ZY>MFL']0R=9U,)OTL"@(D?1H@3+,,*4<B0'E":8HCY6]@
M(X]BB-#(&MTAZU5T/4W8JB;F+%1FQ\(N (#IL)WL\#O- <%<76N>(S/MS>:
ML$>7FT//P_?9VX+/7^=\0^L:+,-]=?^MT:]?6F*&@_Q.R#6\-]J+!-.C'1UG
MNG.>?:O-[6"IR3:STR)T-Z\S3UB6-S 52VRJ4\@JD^Q$O\(FSF$X2 .>")3&
M3,7#F#-$,--5GGX<AWZ4D"R$[%[&E$=6K X?;2'67DO.Q7(%+,8RQ]1LFQL%
M*9B^7M_=W'K7ZW4YSS=U2Z+UTKNG5;V:^U%28(%=%5(8TYVVM (*QU&Q!7@!
MF#%9E>O9-T$7GU:Z ^IUP3L$/PI%BLWK;O_T6=S)^U+WV5N_?5P^TWDQBT*9
MY2PB*..Z23*.U9_RF*%08)(2EG',C6XD+F%B9!.C2>J.7BU1[_>:K*&W?!&\
M_29F*M!@U@:.E[&)<2%PG[51ZW<LC?K;SLI<1'H2@^,"G-;V.%G+LEI$CQK)
M#T>-=+*7?W[;/=(,V:GFCVS+XJ]7J\US/3E)WS@PQ;/N^A/,>(X)DR1%2<PS
MA).4HMR7 F4D$AD.\\ WNSX=G]4)[EPU+6\QE\)K)TD!*T'&^TYFCM6/@3[,
M-G8'1.TUS^D6A>1OWLE!4O7$J$[SC@[_]4UG]4VU" [K1D9'V57]R'B,3EM'
M,CK@1_4DXU.$>Z1J3^$;MKXKFPE4U1$(D305"55A*Z5$>9O21R3%!(42RTSZ
M08P#:>IMGB(PLMEM2%;Y? U5T,'K65R&W<1+I869.0M!03Y@GS07^'<GEYW,
M=^L3JNN7]3YGV=-V63RJW^?GCR*O#F2;Z(,P$@M"8T3TP&',9:S\):S[96!&
M&"8)IQG$7SI-9F2ETT21INIILE?-D3\HA!N R<Q=N5QXF Y6<C] Y8;WI^T5
MRU57VM-$INU%VROH40?:_J=A:LK%?/:I&H%]S;GZY*MJ5LU=6<V,4,S/)!<1
MEBQ /%+1#<XRCBB1^BA&13R<A;',C8I4A@B-'994I+V&]I5745<(>2U],W4=
MA*M?85V" %-9>_F-U=94N)Y;%[5$K;/J#SM5'5QX$F4U%:]55^/GX>F)W\1*
MZ.9\=;JX6"Q?M-^L1Z(VVP9.$LI32E$0^6I/E57#/"Q11.,XB90BAZ'1*&T3
M8B,K;DN^+4%H&:C'&\,V6R/L^C78-2(P+9X<#/,<1I>@V.4Q7@@.*)?15-J>
M?,;!)2;+:305IIO7:/R.Y4EM.S'OR[P0M^J/JYG(L!\1D:F(@:N((28<Y22/
MD/)!1!(P+D@"JI8])C&R)=M-=_Q=D_0JFK8#,'>X&)YH7B0M\"02)JC]P,HC
M65S/I-P1>)^QDT<"GITL>?RDJV*QSYM"#\M]6/XLO@DFU#_QF1\)P94C@6@2
M*O\B82G*<)H@QGV:I2J09Y%1CRP0U9'5<[_.A^[J?&3-BDYLR(57-MQ<6A]U
M"M9AUV,4L&#:?;8>JN%"ET/]++QO(^)T:1W9A7@YKB-K<6M9\:0*R[;.#-UW
M9L:L+^N!!5Q?=FJM=ZXOZQ%ON+ZL[V5WV>"MUTT)(QBG* UQ@+ 0#&5QDB+"
M@R"+6<Z2!%^:#SY)\'8N*]KJB+0',#,?R T,,&MIBX"3S/!1#DQ["+U[=GC_
MP:G!&_ ,\4]EE35W7=#%VVJ^>A!_KG]6;/[3-%?\W/MCGX>6Y;(0R\WJ(%>@
M8<,\D_RL_/TZZ4ITX"EHO]3>[YH'KV+"4>+YD(Q6*>AG%YTL&7U(K&Y:^N"S
M=OOG=HIN6_J];3&7QASG-(D0BP57T4F&$8W"!&5Y$(0BRE)?YK ._&=I07Y5
MK7KP[T8SMX-!#*L\AF$*\@1SEH5(.1GZ"C;D*ISS,R3S1&21D'X<@O+VG8!D
M<PLK5NY ,?,DG(@*,UV[7X1MWXDQF@X.2N9Z7O<1G?>9VGU.W+.SN\^^ '<A
M*NO(UANZ6+SIH0=_7U6#<:O$J'JVZ+=U 78L8*N.?KC2W6X;KNKQ&J^K?_/J
M0< =UE3\N]Z4@!&'0 R'G9/QX(,>MU@A-X(K8X>(E8,#)#69VV,'0=<9LES!
MSD6JFG%+I:UZ4G&5T:4,UYW\/"]HP>9T<5LHVU4=9:UT++0Z_4]-C)T)'(>Q
MC) ?ZHPM$C&4^90AG=I.8RKC+ 4=2KAD;F3KM27L[2A;'F(X_20Y"20+(Q]A
MD6L/CA"4AS1!44)BFC#,6)# '-WW^BA6OO&/^EG,?,CW@AJV_9S">#7"\=48
M:#AR59VR-JEW.P:HAP[Q*#0L4XUWTX4T,WH&5KVEKC[]:Z/SL-H@CT;8ESQC
M2/!,&4\_RE 64MW!36 >\8RH"!AF-TU)CVX3O]Q>_WS[Y?;A]M-W[_KK1^_[
MP]W-__F/NR\?/WW[_M>_9&&0_LW[]']_NWWX!S _V11;,^,W!EXPP];AH+IC
MJ^F.$E-#A765V6Q*=MI<9R 81]G/T/?M;,FV_JAS:?"?\_73;\4R7RDSIUL=
M5)<(JV]"2ZY8JD(T_==-J7OY_DQ7\]5V_ERUUBS+TI!A3E'(68QP$G.4*2<.
M19&(&//3E/E\]B+*^5))1LNUF?$9A5>(YAUR;*R$/XO'>5'H0ZV<JG\PS<(>
M]R/Y,HC4!Z&(16F.<$@H(B'+44[\3# :,C^.FX_TJ3 <.OV#?**67_,+DSHU
MX0?Z.F;[R[OC#?2RMX6W5U[WQO@/Q;+7Y;F^0UYY^UQ?>5NVO8KOJ]W@RWI9
M=YO9J,@ZVOG&X7'2;7)4F _WU'&)P1,1KQDK-X+?J'^>,[IX*%6PT)RWM_-G
MN9_[:L\4* SC".'4#U'.18)B/Q3$SX,@H-S,A3<C.+KCWK#@L88';ZV9V-[Z
MF:?1&8#7;T/= P(SABT2+7&OHMY>>PT/\K7Z=3+.*'2+C%TJX:4(@7(%S07N
M21(T6&2R[$!S@;II@8"WX!T)?E6+/F^>F^9O:4RB1!DQQ.,@0S@7/J)9F"/B
M1PDG,A%4$M-6!'LKCYWM5],R;SBP+W:_5;I(&)@!:L@X[%]WEOD+.@KLKS=9
M*X&38G1[")Q^ 'XK_DVLVN*&CT+7.\^+RDI^5#\TO0/O6V-D9>B0]O9H>YJX
M^<5V+PS#U]BN$(!ID*7PH.MH$\FL+I][%Y[LJME$O.[%LM'S<"U\*/EU65[S
MY0M4]X[?'%GC6E) !3LAX;!:728<3)D>2EH=PG3[>)G)"M*G\R)9:=&)Y2;3
MG?.B=#6FYRFXGMR_OM0SMPVUHWU^9)VXIV_>ZTH/CI#+\EF?X76F%IOKR%:Z
M8<VP$0RF#[TRN1LC?DH8*TW8+C+9[_\AV]W?^J-_@Q_/?*?%Q[EX7-[0Q5Q]
M@F).&P^>ZAKM-)8H$'J.A<\2/<<B13[F?AP',9>I4>#21V1DA5%DO8JNBJ*W
ME,V/&LY",WSDXD)@F"*=E-5B"M99H<U/55P(;W>68@D"Z AE2+J>@Y.SKTYV
M7#+$?/>09/!9N\O89AKJ/2W7;U6^"675\3,PZ6!HF3'CH7J,0$7:Z](>)>'
M5%!'URV#Y":].3$5_O 2Q/@]RXXF[$GPS4+<R>M7.E_H+?CSLOQ.%Z(9-C47
M![<KU3:]2UDG24XD20D*<!@CG J,<D(2E)$@PT'"4YI24/^3"QD:>R-NV-/M
MWK]OGI]I^:;_N!O^#NTI?2G^9C9F2E2!NWT'T"UO2%EII+GS=NP=7"XW'K7G
MM)[ -5RN&K]<RLZT;6(<@7?45,;5NO#0XJ-@E<.@O\R=E-50],:9]!E- \(B
MY*>90#B/0T322/U)T$QR09E@1N6*_61&MFHM84]3]EK2YJYV#S[#$88;J6%6
MY[3 %D%&C^3F888;!.P"#>"G!P48PW+UA!@]+T\69 P+T TS#)Z^L*;\BZ K
M\6W^^+2^D[^M=!-ZL9X)/X\#'$@D*<L1SF2,")49XCD.?!J(2&1&7:^,J(UL
MB';EQ M-W"LU=;24:*/^0C4#0/^J'SHSY\D9(# ;M<.BHGOE?6O!4+2]BO@(
M!=9],KHNLCY)ZWT*K?O$/EMLW?N2=<\6[<.\BO(-='!_ZMV1=77;M63Q5D]J
M.9SPTC(#[MJRC\#PX?ZEPL/TTEANMX?^?4)>TJYE?\&I6[6<%.=$FY;3S\$]
M^?]<EO]4FGM#7^9KNIAA0O/8)SZBG.N69IP@FJ<92D22)HS[+,V,YCT<+SVR
M\C7$/%93,W=8#P 8=L_MQ8*I52O1S842F;O=]I+9N=JF$H)\[--"]/C5!R],
MYDN?9K3K/Y]YPB)16PD=WA9\PZJTA'OU%=JK0)PKMS@-4!C$*<(RSQ"E/$:8
M<![*5(I4^J;Z?I;*R*JOR7H[NIXF#,@Z/HO-L"EP(C',*IP2UB),/R\U(,7:
MA?1VE@/TR6%IU$-"]65/GWUWNJ3I(?;W<J4''[ZP*_S/F]6\T",UQ&-U%5!-
M*A.9H&GF9[I0CR*,18ZH[E(2992G?A*+*#&:X&9$;>S;CX84:(:;&4QFH;@S
MX8&7%(9RV_>,[Y/'=?OXD[3>IY-\G]AGF\KWOF31Y^RI>+PM/NM2L^O5G?S[
M:ET\?ESK&;_E/\I/_UJ_7?]1\I7Z,;\M;EY+_H^RV3I,.YY9KC^R+M\\Z;1-
M/0JW,U^5KO0]W-_%JCIW^E@-8])SK>?+TON'H&7;CZ"*>U?5@RKZ56O<Z.A,
M_5$_!&B/9@O]\)G %*C#C,AX@#O,"W(!G5UO-5NBTW59NQ"6O7YKEZX%#XIN
M"U;J\\J/HO[OO/@HI"C5[] O)=UVDF\K#V4>R2".)4KB)$<XIR'*,E\@&?N)
M"J'4'U-N&BB!*(]L]2J*V]D9B[8T^$JI%%MLJA_JK^Y1*:M;9*5AHIJ69AYK
MP( >CKI&@P]FOEHVO \M(S]I.]3RXM7(-MQ8E,/"8#,/VT:#SRZ4<PPC*-BS
M@J(G (2M-UE0:"5F-U"T6P#N>5:;^J<_2Z;V>V9\U;/_UMB7/'^*DLW5KVM%
MS-RS.Q!MV%^SEPIFQBHZGJ%8(+?IM 16SM#!4I.Y.*=%Z#HN9YZ NR/G)_55
MQP$X%J%@J4!^1G+="X\AX@<1HK[(./:YGR?YY:-")S@R&1C_"#A',4!MV)EP
MAP5,[2:%P<5X4"@<(PP''7LFZ/$9$W BZ'0'1^:"F$T#O>#(2"]\7XH7.M]V
MW6B;[K?.:>2+(.4,HX3S"&'*)2*$,I3F5"C;%249-C9>_:1&-EX-\5WW'WC?
MGP&HABV6.P!@%JN5?=O-IJ5L$=L,@&!NK]R!86>O+@ %9+3,Y.PQ6@,+3&:T
MS 3I&BW#-ZS:ERTWQ7IU3]]T$HTRBDWSH)9$G6X5)ECF>J QYS1%&$<YRF+A
M(QS$<9B%(8XI,[XB-R(YLA%KF? :+JJ^NFVOJMW4FH%<+5LXAPV<>Y" $=&[
MX@-J<>88)^LV9\-X.6MR!A"YO]&9R4)3-CL#"';0\ SRIF6;Y;87?*>M\[8;
MY:ZKPXR'/$RC/$.Q2 )E(2.)* LERE.:RRB1:1K'L[6>I-)O*X%T009S2]WX
M%[P>WK/8L0!LL&L(7K]E'!$2F'G<C9KH]F;O7.$9="Z!M[.%2>VJ0:TAU6E;
MSL*@.&HB"WS=LD)G_23*QA!U"#5.FS)27Y6PC;>?Q)F/LSQ%+/.56Q4)C+*
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MD0'/,V!NHCGUT3,0M]-)7SK322\;R08!-PA]E@0916D<!0@3&JL8-LM1'LA
MA+E@C/J0B9@C06L[%7,\X!(29)CC #',]%UBJGXK9<10+-/ SZDD7( VCK&
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M(BPSH3QYDJ%8V:>41RQ-&9X5U<:F3*.Q#@Z0-?H=)?7OZ!%QX]_73E'S0G$
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MTSO5<$W7'7Y7?-.!L.[OH9R"^>JW8IFO1/FJX^&J'8_Z9R62>JOZFC=TP?1
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M)D?Y6*/F4H\)\(]7\O)."4QC@CQB8<O(1V"UO_I5_%']TVH6)Y$0(B"(YWZ
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MI:RNA?53U:74I=/RC#Z+F2T:'VJ883HS1>]B=]7!1#T(,*--US-BXITG[4&
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M''MA8-KU4-*J4OC@1(#/7^=\0Q=>OYR@*YO3(EG=SQPL-=EES&D1NC<O9YZ
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MQU(Z[*\Q()254IU:;S)EZA&FJT1]CUF&$WN5L@>](76EOK:&WY2);/-+56C
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M0GP<) G+<R^E)#0J23D:AV-[0ND/6:)G.A>H:/2]3FK6<=)UK2Q4RJI:-*;
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M<AP&+,%$^E+G&5 <2)FD"9,T3HTB&T]2&%E3;HM[-$21HEIO\/!*)ONX].M
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M6@$)27.7,6GUT+N8$E9Q@X+=HML-A[/UZOP[ESOO*70=:E=NK?$QQ!G!7XI
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MRV1'NT21C3<IR&!"*26V?P/>DH-N?*[AT#JBRKN(*=^=K[P1Q*XHV>KH?+'
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M54*,K2W4+2)&+@4\7K%W3.XY7,H=P&1W))^?R%HJ7QB'A+6 3.@ SM-A7ZQ
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M8//N%][EJ&B1E#1)032L#JX7&4)F%C1/PG-#%KZYH7N<JI$[<@P.OH'TTT6
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MM)TD&5X/+-?M9(6&6 5EA46;$P_)M\X>/$#.N/@Y5M,WK4TCL1^,((HRXV(
MBW,9T9@DO<M:@N.*@2J.[+#0FU2:I?,<I4^MW9\[">EF/$C3X^IXF7=@?*X,
MGG]S5K&_&Z*R>A>VS>[.^[%<%H1>[?K"K1 4W KFZ\PQ<AR=T18H !+11PP%
M6_<'.(;>?LS7@7"Y=4=\(MWU8>(NN27^WBZW=P8;/M_A<L/XQ)?(&+,6LF-L
MVWX^<B2FN @4UR@KF[^\W(.LD7%W,I3<#\\F"NO+6FYE>)GRF=C"O'6L ..&
M/-E 0O.U8D@DSI6VWL;FPZ0?(&?<([<'S!VEH!ZQMLTHDL\KI$Z&@W;!;Y]T
M19L=:*.1,UZL%*V?W]Q#RKBWB?U@[ #%](BOMV?KU3K,<[VV,*A]J/==].]H
MKZ"7$*7V8$/(+JB8BAH<9%?H&??&L1^D':JB#N!V/<Z^UR%@VEJ;N0,?-0?E
ME(.H' .*TVI?!L^-&Z#SYAZ4C7MG.1H$!U!;=V"\Y2EDZW0PQ(-0B*"$Y>!M
MEB!*#C[ZP*\,MQT$A =Y<^9/#KZCU-1%"'L7/SOG(;&BDRP,8J[%!XH7<,&0
MKRJ\<)D99*[UX\#[J=D+;O8_!=P.4$^W4+OJ/61,&)Q44*JPE+0"HO D)Y58
M,LJF$%IG2AXA:2_0N?\4H#M440V1-W )T=M"U!%[BW)%\+N1QJM=N<Q9+88Y
M_U[+ J*#%Q^D?*B-*$Y4/,2M0^%#G22=ZK!J B//$21902.<9-FV/J6&+1[:
M)>5WHGV[?#_]]'GW$"<BQ?..? K!:^5><@*\\1I,B#(@BRG+UKS>3\W8-_?-
M4''/)=JQ"N@@IKB3DTUY Q8?,PD)1/ >5*&O/ \(.08NE% FBM:50_<2T\4=
MV-':W@=$3Q9]KQ@Z;^4K*,CFSD-];TS1CB0!24%^J.4<5>:L6O\3H*B'4J)&
M"M\'1@=(?^1>(B_(8ZP>;%7GN7-Q[COLZENT+$'94G/31=?93Q%"3@Y0.(W*
M.:Z%?,2MVF^E#F%RB$(7@TFW Z-S49>W/=K)"_VZF->W,)L-50*/]:DZ!%$+
M])1W$"Q)S(0:!2NM$V=#E;W>1=#(%YO#'&#M5- !GF[P<-ZR1V:T*!,XD2F.
MS5J#4]% T%Y@5-JB:8VC.PD9VY-NINA%:ZEW )W=OMK94:^9,\XK,LS>U-&H
MQ(97=*#[9) ;=*'Y4-UK!(P+E08*7;22;@?0N)(<.2_259%<.YG!:MHHJK "
M(67B(FF5C,:8RH %-T^ R&"G47N('"?E#F#RX2RNIGD:EM\_A(N2WXUQ%9Y$
M@2*12:V=VA4ZB,D8B"Y;I24:KD-K1^8^8D:NG!G(B6DB^AXP=$E^[3GXMER9
MR+3;8](Y=#&J_[^]+VMN*T?6?)__@CO8EY>)D+>ZCJBR'+:J.OI)@57F%,7C
M)BE7Z?[Z27#10I'4X2$H0)Z*CG;)(@WD\B&1"20RD73Y43C/"T+ :E-2.PU^
M?J"I=)K"\U15=FW*J'\35&5U43DT_WT".OAK.IK/X^1+O!K-\JOQ\&XTC7Z^
M#B;7V[-.1BIGD)2!YJH[%NRY\XC)8'3PT9+-ES];0_3^,U9&3V$]=R<7>@.&
M:JLA__7N;8&+PA&-35YHL'4'\/!<+F3A7(I>FB1,*.X@[:6H<AK?"QX^#U-"
MJY!Z_W><^M$L?IZ.<G6=]7'7ZM,9N<181.F<12F8G(D#[J(CGB.MK'=:8DY-
M\731(80V>!PY$"E]0%A4;95WSJT,/HA6SO^:P#S?1M]71<0NL>/)LR1RJQ.(
M@KP!:1(G4$P&BR P=YM-1;>W<3YPW@:/)X]#V,F%_VJ -1UUTXMN761LS6KR
MGC(,WJS%-B%N$@=Q6HRLTU8)*WTPHBC.MI+18$#YDK [7C6O!86_V;]'US?7
M:Q85D]&D*!%F48'#&C@R-.;BL08^"%(GBDNB[_'T#?IS+XBZ(U3Q6BI]G<TO
MOL7?[/3/.,\!VNSL:AH7UQ=%\_&>G^4DB7<',O<R&78A%P8GPB$I\L[I"$2@
M@3DD7'Z\R)+#Q:OTU2O/Q3 C1&(+:P2<4.Y%!%/M&6+1)?A+(L859_:5EN<Z
M!!>'E.<Z1 4-A*>[:PBI)&0NF@#DYWL*(BQR2AFD7:XLA&T@I/B)[.LKSW60
MNGN7YSI$]@V :$LAH20E8_D>-'(.KF(($AFG/)+6)"V-CC;^_UN>ZR#U/E^>
MZQ!9MX"6)U>BQ.#HLO%-+#,@$T'61(X"X\S'X%(BQ<$RZ.+Y)4MQ':359V^=
M#Q%Q QC9??>5 H]24(R$S9V9G4X0%5".$AA;%C2SWI=NT'[<K7.5,EQ';4M%
M9-\"B'I<@7F:2+(,I: (XHEA9"D3R%B# Z-6N'^NG8>I?\"U\P&ZJ-U=,FOU
M<8R[LK/8&DNE-R@&IA#7>5<7%!:><R(Y'ZEA?<Z/=D[0_J7R(5KL2HNT 5R0
MK4R 3^>L(PJYR,'E,X(B&X-%A MO>73$ZS[9!SLGJ+P5G187QXNT@=UH>[E"
M9RPX8 0DDDGGPH!$/,'()!Z$8=X3?<HXZ=<V^K:=RI4Y7N:5#<KR#?MC]"]/
MR>_+=JRZBAD>B14J()Q2+MW+)-)2>Q1BE)QQQ?1FJ<:M%J;_C.U$3 -5VYU<
MSK71<V^6%[RM>SN=I[/)[<-JDO=]P@A/CI'@$7#B$<\_N2@)BM)Q(JB")=?G
MEO_PF9NXYR^%IM/*O3:JUGS=+96S*_CIRL[CLM)'EQZ5>B&$N:2\0]XYC#AF
M(=_C:0@;" T&-FO<ZTKUP&F;N, O;9U.(/'FP/2OF.^'P=S^B%-8&8M<J_NR
M:+",O)01,:)S[S"3;VVD0YJ"ZQ>YUPK[05C:-VL3M_(G@U(Q>3>'I+M%LKVG
MX>(?7#IF"<$^G\ 'B"X] >8L#B@2SG7R1%K-C[-.>V:O7 /QI8Q4*?DWA[ O
M,<>VH\G56_O=^IP"L?014_")*2405MSE4J(1V(L2<>>EYE''P/ODL/6>L'(Y
MPQ/CJ(247TN"T#(CZGL>-M>J^A)G<S#(\U4UL]\GH[*90@=,=YI6?P/9?9G<
M(:$,(9)Y9(T!VQ2H1$8&C(*15F!PR4/Q+K'U<H>H!+<Q18AK,8:MWMB =$P8
M"1ZPA. D"5.<V5>:.W0(+@[)'3I$!0V<:'X>VTD^[EVV'$LLT< 5<MPS,,')
M ^U>(1DHR0U:713%ZU\^F+_=#*&#E+I9RW*HA!M"Q[JSF.?2"<:09'F+YD0B
M&YA&BID4N&;,\M*OQ1]34!<APS6Y Q(#Q-K Y1C[.,DG7J,?,?.QNLBA2G*M
M+4=&Y99-5&-DK<O/"J0(G$810I^@?M?X;2A^B+ZZPL*K#P BM_%@P X&(Q)R
M5 (/0J9<]MX@"  M-M@+R?L<.N\:O^[1<CD '"^\^@"@].,DW/A%7/> "8LM
MI01CY&2^XQ<L(1NC0\$S([UP(>D^]?-V3E#W-+B@#3A>?/4Q@-4V' =M8C ,
M_"2?<H* "6#2J$4F<B:I$EH1TP\"6\>O>XA;#@''"Z\!WW#[B5$BA/(@ ^Q=
M2>;FL[F?F,*(.)T\4T9R43H9[Y5U5STFECA>Y@T 9W$K\<;.8LA%NN)DME++
MU$ZN%D;QS>W]5S[;V\4Q]%]V&A[W('C0\R0")(B6$FF.'>)><3"=C"!OP2^G
MW!.N2U=:*,Y$BYD8!P%K\XRDJI9_(IC_L*-Q-AP?NNDO^?'MI4[:F0"Z *8%
MXD%II 6Q2&(=3;+,B.*]#D_%2XL)(RV _BB=OV;L+P]J/TYF\^G-XM7QHKW,
MQ3<[65TP?.HF/^)L'E<2N\0T*F>5190:B)P(=TB;D%TQ<)<)TX:'XD])7HJY
M%M-?JJR.DZ*B@>7RL)!"YNQIPR///(/H@B#G?$(\>H-,;GT4%3>!<Y8(9Z7=
MZN>(:C&EYAAXEM5" [ :O-X6?_P!"PJ8_ARGHRZ02^] D,)'E S.R8V*(<L-
M1S19K6FBE'K1BJ'=0G^+63I5;.FQNJV=OS.4[U4J^-MNLKC_O;'CBSB]ODS4
MN>2$1)XZC;@%;6C'X:\X)6&)4;Q71;3"9+68"S0$K;4UUF;&T*<X_[6;S=8)
MFNO#HBZ!"$8>]IIWH_%-=F8>?V]XSM"1$Q;(&BK)<J&\H?=VFO/1[N:ZRPQ1
MN;HMXP8I$0GBC'CD))5(&0NPHT2(4/HYURY:CO4 0)P?)Z"$F(5Z%U5>= ]<
MG56&S$K^]Z5UA&681X9DX#GS+VID<'#(Y_KV3L-GN'1GDL'$5FY)40)'F]O[
MRRBN 1_U$:- / M1N(0"$1'Q;.4UA&M(D*B-%S2RXDOO$0%UD?1"2M\'M8,T
MT !\-AX^/#Y&>Q"ZK01VWZ=XX=/<)P-2<!H"%R _DGT*CY&C0:,HI5&"$JI]
M:=R5H;QRJY53F+X**JT<T_3E^%(HSG6T$B668FX[$Y$VQJ!\X2P\E1)O-O?9
M&JSTG:^N-:R!@^[$2JD,-+#STT7(9<>K/65YW3"?3T?N9K[<;18>^=G*(Q_]
MB.]36O2$^#R-'QZUW+ZT/EEM,$&"6I9OLF&O<-@BH36W,2F(U'0/.):EJJY%
MK S:B@I^1<[ 0@"7T0BN%T_5-+A+W/,$S,6 +(U**.\EPZ4/- \BL.[M3T4@
MGUZ=P[':P<HZ)597XMRRRV IDI$1&:_Y*CM0@URU,$;%Q*VPI:L"'TABW>N@
M=O%:1*45$9OWE4U'_]$6$L/[SU_O) B;B58>''[E%4A0B8 T"PHIY[A.4BFG
M0P^GH/^,=6]V*F_X)U), YOY5LXN/0202OJ(/ L^6WD+]MX01'2D@"'I%2W=
MO6LK(75"HU-J?+-S\M'B;Q!#*QE=4F$<8SX@3RW.73 HTEA3Y(V@B1ILM$\G
M1M&*E#K12D4<#5'!J[C%.YO,1V$5416[J=LV:/G;N&=)/_6-FZ:2 :(R#HA%
MG.F(K'(8$3 ST1LBX#>OY,;M/O/_H52_1G\S'<U'<?;^;S^^ 5'F,BKY/OQF
MJ;WSM$G0\K& !<)!  &";Y[;>RKP%H4SB%@O(?B&=5/\.459#AJ]FSL$<;M?
M_[^XBAO84X_D^<WM]@$6;ZHCQ8XE$("-#D1!=$!.>8H,U]%)$I/=?$-Z--I/
MR$XKY0Q>'J5=FY!I=O4\>%5(B! IJH2HCPEQ##;)D<01B5IS!;$@%J6WPN=H
MJHOC9L#3"]0#-=D ,E>'_JNWJ(Q[HY*B*!HB<Z8S2 :K7/U+".P$P8$6/QQ_
M2$"+F!NJV\UCPL&";@ E[R&&Z6YC?%#S:_U\G7!A,'8@DB1RE4D//#""-"$0
MS@4:G"M=>FHG,77O $^*GC(*&(RD'W'JNA)IW''Z8^27.;_;"L:MG\0[IS0%
MBQR%T(@++)'1/K=,CM$2J;0PST74_6>K>^%V$M2<2-15X;,6V#9>OGS]?<6.
M=#(P)@/"G*3<<(3 :L 8,:5M8E(D6[QEZ%Z"ZMZ.G=0DE5-$ QO<V_R2<#H?
M0<SS>4W"PQYL03@&"X0BB?.YI9$:.6L2PD0[DVA2.)1_B+>7I+KW7R=%5DEE
M-("M(T.97^^>XK HN!/&(I8?M7*K)=+&,A0(C9A93<N#L!3MK=1E>>V'(L/
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MW<7?,A%P.V^?<L_'66X.E<6YO*U^^'DN>?&IF_\[SK]$WUU-1O\3PZ657N/
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M3 W#7"V_<ND]XU@FX"SDDW87)40_DB$;# ]$)LR*5P ;3&S=TZ23@O%E%-@
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M&1WS-.KB1XI;":E[T%(0"YNAP?%BKWR3>O[7!,;Y-OJ^[$0*$3?'-L?;,@O
M1J2CCB@$L+W4F/#D*&30[>FC2>MBHX "NQ+2; 4&J\L>C35/UG.DG(*%H7U
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M[_06??5!_L/96?P__^O_ 5!+ P04    "  7@*U:'B20)08(   J)P  %0
M &EN;RTS,S$R-3$P<65X,S$R+FAT;>5:6V_;.A)^WU_!3;&G"6 [OJ5IG#1
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MOT(7YBC,),;.&WDK,QF:SM%>6UK:Z<<;Q5['FCJ2*\F$W*^_E623D! (O7)
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MT#$&2Z[7I]QRU5Y\NHO_ _L?#OX%4$L! A0#%     @ %X"M6E\51#+3Y@$
M+)\1 !               ( !     &EN;RTR,#(U,#,S,2YH=&U02P$"% ,4
M    "  7@*U::IEU,&H2  !"P@  $               @ $!YP$ :6YO+3(P
M,C4P,S,Q+GAS9%!+ 0(4 Q0    ( !> K5KZ%K]6$AD  +;K   4
M      "  9GY 0!I;F\M,C R-3 S,S%?8V%L+GAM;%!+ 0(4 Q0    ( !>
MK5J$7_7@3E4  +>[ P 4              "  =T2 @!I;F\M,C R-3 S,S%?
M9&5F+GAM;%!+ 0(4 Q0    ( !> K5K!(%7Q'BD& (<%!P 3
M  "  5UH @!I;F\M,C R-3 S,S%?9S$N:G!G4$L! A0#%     @ %X"M6D6=
M.I%N[@  \4D) !0              ( !K)$( &EN;RTR,#(U,#,S,5]L86(N
M>&UL4$L! A0#%     @ %X"M6B2&/0?TBP  %WL& !0              ( !
M3( ) &EN;RTR,#(U,#,S,5]P<F4N>&UL4$L! A0#%     @ %X"M6AXDD"4&
M"   *B<  !4              ( !<@P* &EN;RTS,S$R-3$P<65X,S$R+FAT
M;5!+ 0(4 Q0    ( !> K5JJ8S.$^0<  $8E   6              "  :L4
M"@!I;F\M,S,Q,C5X,3!Q97@S,3$N:'1M4$L! A0#%     @ %X"M6NLV6XD8
M!@  =R   !8              ( !V!P* &EN;RTS,S$R-7@Q,'%E>#,R,2YH
8=&U02P4&      H "@"0 @  )",*

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>ino-20250331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:ino="http://www.inovio.com/20250331"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="ino-20250331.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <instant>2025-05-09</instant>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:December2024OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-16</startDate>
            <endDate>2024-12-16</endDate>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-16</instant>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ino:December2024OfferingWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:December2024OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-16</instant>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ino:December2024OfferingWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:December2024OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-16</instant>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:December2024OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-16</startDate>
            <endDate>2024-12-16</endDate>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:UnderwrittenRegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-18</startDate>
            <endDate>2024-04-18</endDate>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:UnderwrittenRegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-18</instant>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:UnderwrittenRegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-18</startDate>
            <endDate>2024-04-18</endDate>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:UnderwrittenRegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-18</instant>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:UnderwrittenRegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-18</startDate>
            <endDate>2024-04-18</endDate>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:A2024SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:A2024SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-01</startDate>
            <endDate>2024-03-01</endDate>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ino:December2024OfferingWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-16</instant>
        </period>
    </context>
    <context id="c-109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:UnderwrittenRegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-18</instant>
        </period>
    </context>
    <context id="c-110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:A2024SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-13</startDate>
            <endDate>2024-08-13</endDate>
        </period>
    </context>
    <context id="c-111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:A2024SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:A2021SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-09</startDate>
            <endDate>2021-11-09</endDate>
        </period>
    </context>
    <context id="c-113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:A2021SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2023IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-16</instant>
        </period>
    </context>
    <context id="c-115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2023IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2023IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2016IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2016IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2022InducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-24</instant>
        </period>
    </context>
    <context id="c-120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2022InducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2007IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2007IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ino:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ino:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ino:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ino:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ino:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:NonEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:NonEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ino:RestrictedStockUnitsRSUsMilestoneBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ino:RestrictedStockUnitsRSUsMarketBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ino:RestrictedStockUnitsRSUsTotalShareholderReturnMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ino:RestrictedStockUnitsRSUsMarketBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ino:RestrictedStockUnitsRSUsMarketBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">ino:December2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">ino:December2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ino:RestrictedStockUnitsPerformanceBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ino:StockOptionsPerformanceBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ino:StockOptionsPerformanceBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:PlumblineLifeSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:PlumblineLifeSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:PlumblineLifeSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="c-162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:TheWistarInstituteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c-163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:TheWistarInstituteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:TheWistarInstituteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-01</startDate>
            <endDate>2024-08-31</endDate>
        </period>
    </context>
    <context id="c-165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:TheWistarInstituteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:TheWistarInstituteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:TheWistarInstituteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:TheWistarInstituteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:TheWistarInstituteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:TheWistarInstituteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ino:SanDiegoOfficeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ino:PlymouthMeetingPennsylvaniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ino:SanDiegoCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="c-178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ino:SanDiegoCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="c-179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ino:PlymouthMeetingPennsylvaniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:ApolloBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:ApolloBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LassaFeverAndMERSVaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LassaFeverAndMERSVaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LassaFeverAndMERSVaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="c-186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c-187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ino:ReportableSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ino:ReportableSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ino:ResearchAndDevelopmentCostAxis">ino:INO3107Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ino:ResearchAndDevelopmentCostAxis">ino:INO3107Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ino:ResearchAndDevelopmentCostAxis">ino:INO3112AndOtherImmunoOncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ino:ResearchAndDevelopmentCostAxis">ino:INO3112AndOtherImmunoOncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-197">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ino:ResearchAndDevelopmentCostAxis">ino:OtherProgramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ino:ResearchAndDevelopmentCostAxis">ino:OtherProgramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-199">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ino:ResearchAndDevelopmentCostAxis">ino:EngineeringAndDeviceRelatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-200">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ino:ResearchAndDevelopmentCostAxis">ino:EngineeringAndDeviceRelatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ino:ResearchAndDevelopmentCostAxis">ino:StockBasedCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ino:ResearchAndDevelopmentCostAxis">ino:StockBasedCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ino:ResearchAndDevelopmentCostAxis">ino:OtherUnallocatedExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ino:ResearchAndDevelopmentCostAxis">ino:OtherUnallocatedExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="position">
        <measure>ino:position</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="y">
        <measure>utr:Y</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="segment">
        <measure>ino:segment</measure>
    </unit>
    <dei:AmendmentFlag contextRef="c-1" id="f-26">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-27">2025</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-28">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-29">0001055726</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-30">--12-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList contextRef="c-1" id="f-394">http://fasb.org/us-gaap/2024#FairValueAdjustmentOfWarrants</us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList>
    <dei:DocumentType contextRef="c-1" id="f-1">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="c-1" id="f-2">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-3">2025-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="c-1" id="f-4">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-14888</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c-1" id="f-6">INOVIO PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-7">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-8">33-0969592</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-9">660 W. Germantown Pike</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c-1" id="f-10">Suite 110</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-11">Plymouth Meeting</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-12">PA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-13">19462</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-14">267</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-15">440-4200</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-1" id="f-16">COMMON STOCK, $0.001 PAR VALUE</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-17">INO</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-18">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="c-1" id="f-19">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c-1" id="f-20">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c-1" id="f-21">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c-1" id="f-22">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-23">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="c-1" id="f-24">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-2" decimals="INF" id="f-25" unitRef="shares">36674436</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-3" decimals="0" id="f-31" unitRef="usd">39915447</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-4" decimals="0" id="f-32" unitRef="usd">65813297</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments contextRef="c-3" decimals="0" id="f-33" unitRef="usd">28447097</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments contextRef="c-4" decimals="0" id="f-34" unitRef="usd">28300232</us-gaap:ShortTermInvestments>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-3" decimals="0" id="f-35" unitRef="usd">1310237</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-4" decimals="0" id="f-36" unitRef="usd">1199056</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-3" decimals="0" id="f-37" unitRef="usd">2221668</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-4" decimals="0" id="f-38" unitRef="usd">2517465</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-3" decimals="0" id="f-39" unitRef="usd">71894449</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-4" decimals="0" id="f-40" unitRef="usd">97830050</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-3" decimals="0" id="f-41" unitRef="usd">3347824</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-4" decimals="0" id="f-42" unitRef="usd">3659818</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent contextRef="c-3" decimals="0" id="f-43" unitRef="usd">2308975</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent contextRef="c-4" decimals="0" id="f-44" unitRef="usd">1613844</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-3" decimals="0" id="f-45" unitRef="usd">7741757</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-4" decimals="0" id="f-46" unitRef="usd">8113840</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-3" decimals="0" id="f-47" unitRef="usd">1979654</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-4" decimals="0" id="f-48" unitRef="usd">1979654</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="c-3" decimals="0" id="f-49" unitRef="usd">87272659</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-4" decimals="0" id="f-50" unitRef="usd">113197206</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c-5" decimals="0" id="f-51" unitRef="usd">12919788</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c-6" decimals="0" id="f-52" unitRef="usd">16200013</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c-7" decimals="0" id="f-53" unitRef="usd">469637</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c-8" decimals="0" id="f-54" unitRef="usd">1351163</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <ino:AccruedClinicalTrialExpenseCurrent contextRef="c-3" decimals="0" id="f-55" unitRef="usd">1819237</ino:AccruedClinicalTrialExpenseCurrent>
    <ino:AccruedClinicalTrialExpenseCurrent contextRef="c-4" decimals="0" id="f-56" unitRef="usd">2021860</ino:AccruedClinicalTrialExpenseCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent contextRef="c-3" decimals="0" id="f-57" unitRef="usd">9542316</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent contextRef="c-4" decimals="0" id="f-58" unitRef="usd">13255188</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-3" decimals="0" id="f-59" unitRef="usd">2575902</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-4" decimals="0" id="f-60" unitRef="usd">2497360</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-3" decimals="0" id="f-61" unitRef="usd">27326880</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-4" decimals="0" id="f-62" unitRef="usd">35325584</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-3" decimals="0" id="f-63" unitRef="usd">8695055</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-4" decimals="0" id="f-64" unitRef="usd">9367827</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities contextRef="c-3" decimals="0" id="f-65" unitRef="usd">36021935</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-4" decimals="0" id="f-66" unitRef="usd">44693411</us-gaap:Liabilities>
    <us-gaap:PreferredStockValue contextRef="c-3" decimals="0" id="f-67" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="c-4" decimals="0" id="f-68" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockValue contextRef="c-3" decimals="0" id="f-69" unitRef="usd">36674</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-4" decimals="0" id="f-70" unitRef="usd">36099</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="c-3" decimals="0" id="f-71" unitRef="usd">1801789329</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="c-4" decimals="0" id="f-72" unitRef="usd">1799362625</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-3" decimals="0" id="f-73" unitRef="usd">-1749913959</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-4" decimals="0" id="f-74" unitRef="usd">-1730219262</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-3" decimals="0" id="f-75" unitRef="usd">-661320</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-4" decimals="0" id="f-76" unitRef="usd">-675667</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity contextRef="c-3" decimals="0" id="f-77" unitRef="usd">51250724</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="0" id="f-78" unitRef="usd">68503795</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-3" decimals="0" id="f-79" unitRef="usd">87272659</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-4" decimals="0" id="f-80" unitRef="usd">113197206</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-1" decimals="0" id="f-81" unitRef="usd">65343</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-9" decimals="0" id="f-82" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-1" decimals="0" id="f-83" unitRef="usd">16090902</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-9" decimals="0" id="f-84" unitRef="usd">20913790</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-1" decimals="0" id="f-85" unitRef="usd">9024970</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-9" decimals="0" id="f-86" unitRef="usd">10571179</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses contextRef="c-1" decimals="0" id="f-87" unitRef="usd">25115872</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-9" decimals="0" id="f-88" unitRef="usd">31484969</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-1" decimals="0" id="f-89" unitRef="usd">-25050529</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-9" decimals="0" id="f-90" unitRef="usd">-31484969</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest contextRef="c-1" decimals="0" id="f-91" unitRef="usd">808077</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="c-9" decimals="0" id="f-92" unitRef="usd">1500290</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpenseNonoperating contextRef="c-1" decimals="0" id="f-93" unitRef="usd">0</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating contextRef="c-9" decimals="0" id="f-94" unitRef="usd">177833</us-gaap:InterestExpenseNonoperating>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c-1" decimals="0" id="f-95" unitRef="usd">-3712872</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c-9" decimals="0" id="f-96" unitRef="usd">0</us-gaap:FairValueAdjustmentOfWarrants>
    <ino:ChangeInValueOfInvestmentsInAffiliatedCompany contextRef="c-1" decimals="0" id="f-97" unitRef="usd">695131</ino:ChangeInValueOfInvestmentsInAffiliatedCompany>
    <ino:ChangeInValueOfInvestmentsInAffiliatedCompany contextRef="c-9" decimals="0" id="f-98" unitRef="usd">-126018</ino:ChangeInValueOfInvestmentsInAffiliatedCompany>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss contextRef="c-1" decimals="0" id="f-99" unitRef="usd">140234</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss contextRef="c-9" decimals="0" id="f-100" unitRef="usd">500877</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-1" decimals="0" id="f-101" unitRef="usd">-482</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-9" decimals="0" id="f-102" unitRef="usd">-682218</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="0" id="f-103" unitRef="usd">-19694697</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-9" decimals="0" id="f-104" unitRef="usd">-30469871</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-105"
      unitRef="usdPerShare">-0.51</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-106"
      unitRef="usdPerShare">-0.51</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-9"
      decimals="2"
      id="f-107"
      unitRef="usdPerShare">-1.31</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-9"
      decimals="2"
      id="f-108"
      unitRef="usdPerShare">-1.31</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="0" id="f-109" unitRef="shares">38613653</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="0" id="f-110" unitRef="shares">38613653</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-9" decimals="0" id="f-111" unitRef="shares">23291512</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-9" decimals="0" id="f-112" unitRef="shares">23291512</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="0" id="f-113" unitRef="usd">-19694697</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-9" decimals="0" id="f-114" unitRef="usd">-30469871</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-1" decimals="0" id="f-115" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-9" decimals="0" id="f-116" unitRef="usd">32403</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-1" decimals="0" id="f-117" unitRef="usd">14347</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-9" decimals="0" id="f-118" unitRef="usd">-46016</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-1" decimals="0" id="f-119" unitRef="usd">-19680350</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-9" decimals="0" id="f-120" unitRef="usd">-30483484</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesIssued
      contextRef="c-10"
      decimals="INF"
      id="f-121"
      unitRef="shares">9</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity contextRef="c-10" decimals="0" id="f-122" unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="c-11"
      decimals="INF"
      id="f-123"
      unitRef="shares">36099991</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity contextRef="c-11" decimals="0" id="f-124" unitRef="usd">36099</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-12" decimals="0" id="f-125" unitRef="usd">1799362625</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-13" decimals="0" id="f-126" unitRef="usd">-1730219262</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-14" decimals="0" id="f-127" unitRef="usd">-675667</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="0" id="f-128" unitRef="usd">68503795</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-15"
      decimals="INF"
      id="f-129"
      unitRef="shares">518670</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-15" decimals="0" id="f-130" unitRef="usd">519</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-16" decimals="0" id="f-131" unitRef="usd">1101630</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-1" decimals="0" id="f-132" unitRef="usd">1102149</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="c-15"
      decimals="INF"
      id="f-133"
      unitRef="shares">55694</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-15" decimals="0" id="f-134" unitRef="usd">56</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-16" decimals="0" id="f-135" unitRef="usd">-74275</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-1" decimals="0" id="f-136" unitRef="usd">-74219</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-16" decimals="0" id="f-137" unitRef="usd">1399349</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-1" decimals="0" id="f-138" unitRef="usd">1399349</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss contextRef="c-17" decimals="0" id="f-139" unitRef="usd">-19694697</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="0" id="f-140" unitRef="usd">-19694697</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-18" decimals="0" id="f-141" unitRef="usd">14347</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-1" decimals="0" id="f-142" unitRef="usd">14347</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:SharesIssued
      contextRef="c-19"
      decimals="INF"
      id="f-143"
      unitRef="shares">9</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity contextRef="c-19" decimals="0" id="f-144" unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="c-20"
      decimals="INF"
      id="f-145"
      unitRef="shares">36674355</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity contextRef="c-20" decimals="0" id="f-146" unitRef="usd">36674</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-21" decimals="0" id="f-147" unitRef="usd">1801789329</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-22" decimals="0" id="f-148" unitRef="usd">-1749913959</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-23" decimals="0" id="f-149" unitRef="usd">-661320</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-3" decimals="0" id="f-150" unitRef="usd">51250724</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="c-24"
      decimals="INF"
      id="f-151"
      unitRef="shares">9</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity contextRef="c-24" decimals="0" id="f-152" unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="c-25"
      decimals="INF"
      id="f-153"
      unitRef="shares">22793075</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity contextRef="c-25" decimals="0" id="f-154" unitRef="usd">22792</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-26" decimals="0" id="f-155" unitRef="usd">1740954074</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-27" decimals="0" id="f-156" unitRef="usd">-1622965136</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-28" decimals="0" id="f-157" unitRef="usd">-662601</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-29" decimals="0" id="f-158" unitRef="usd">117349129</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-30"
      decimals="INF"
      id="f-159"
      unitRef="shares">543620</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-30" decimals="0" id="f-160" unitRef="usd">544</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-31" decimals="0" id="f-161" unitRef="usd">5224589</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-9" decimals="0" id="f-162" unitRef="usd">5225133</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="c-30"
      decimals="INF"
      id="f-163"
      unitRef="shares">34558</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-30" decimals="0" id="f-164" unitRef="usd">34</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-31" decimals="0" id="f-165" unitRef="usd">-174282</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-9" decimals="0" id="f-166" unitRef="usd">-174248</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-31" decimals="0" id="f-167" unitRef="usd">2525433</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-9" decimals="0" id="f-168" unitRef="usd">2525433</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss contextRef="c-32" decimals="0" id="f-169" unitRef="usd">-30469871</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-9" decimals="0" id="f-170" unitRef="usd">-30469871</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-33" decimals="0" id="f-171" unitRef="usd">-46016</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-9" decimals="0" id="f-172" unitRef="usd">-46016</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-33" decimals="0" id="f-173" unitRef="usd">32403</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-9" decimals="0" id="f-174" unitRef="usd">32403</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:SharesIssued
      contextRef="c-34"
      decimals="INF"
      id="f-175"
      unitRef="shares">9</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity contextRef="c-34" decimals="0" id="f-176" unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="c-35"
      decimals="INF"
      id="f-177"
      unitRef="shares">23371253</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity contextRef="c-35" decimals="0" id="f-178" unitRef="usd">23370</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-36" decimals="0" id="f-179" unitRef="usd">1748529814</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-37" decimals="0" id="f-180" unitRef="usd">-1653435007</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-38" decimals="0" id="f-181" unitRef="usd">-676214</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-39" decimals="0" id="f-182" unitRef="usd">94441963</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="0" id="f-183" unitRef="usd">-19694697</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-9" decimals="0" id="f-184" unitRef="usd">-30469871</us-gaap:NetIncomeLoss>
    <us-gaap:Depreciation contextRef="c-1" decimals="0" id="f-185" unitRef="usd">371367</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-9" decimals="0" id="f-186" unitRef="usd">424473</us-gaap:Depreciation>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c-1" decimals="0" id="f-187" unitRef="usd">372083</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c-9" decimals="0" id="f-188" unitRef="usd">335257</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c-1" decimals="0" id="f-189" unitRef="usd">-3712872</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c-9" decimals="0" id="f-190" unitRef="usd">0</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:ShareBasedCompensation contextRef="c-1" decimals="0" id="f-191" unitRef="usd">1399349</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-9" decimals="0" id="f-192" unitRef="usd">2525433</us-gaap:ShareBasedCompensation>
    <ino:NonCashInterestIncomeExpense contextRef="c-1" decimals="0" id="f-193" unitRef="usd">0</ino:NonCashInterestIncomeExpense>
    <ino:NonCashInterestIncomeExpense contextRef="c-9" decimals="0" id="f-194" unitRef="usd">355654</ino:NonCashInterestIncomeExpense>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium contextRef="c-1" decimals="0" id="f-195" unitRef="usd">386</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium contextRef="c-9" decimals="0" id="f-196" unitRef="usd">684651</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <us-gaap:GainLossOnSaleOfOtherInvestments contextRef="c-1" decimals="0" id="f-197" unitRef="usd">-482</us-gaap:GainLossOnSaleOfOtherInvestments>
    <us-gaap:GainLossOnSaleOfOtherInvestments contextRef="c-9" decimals="0" id="f-198" unitRef="usd">-691168</us-gaap:GainLossOnSaleOfOtherInvestments>
    <ino:ChangeInValueOfInvestmentsInAffiliatedCompany contextRef="c-1" decimals="0" id="f-199" unitRef="usd">695131</ino:ChangeInValueOfInvestmentsInAffiliatedCompany>
    <ino:ChangeInValueOfInvestmentsInAffiliatedCompany contextRef="c-9" decimals="0" id="f-200" unitRef="usd">-126018</ino:ChangeInValueOfInvestmentsInAffiliatedCompany>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss contextRef="c-1" decimals="0" id="f-201" unitRef="usd">140234</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss contextRef="c-9" decimals="0" id="f-202" unitRef="usd">500877</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-1" decimals="0" id="f-203" unitRef="usd">111181</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-9" decimals="0" id="f-204" unitRef="usd">145854</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-1" decimals="0" id="f-205" unitRef="usd">-295797</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-9" decimals="0" id="f-206" unitRef="usd">-1897016</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c-1" decimals="0" id="f-207" unitRef="usd">-4161751</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c-9" decimals="0" id="f-208" unitRef="usd">-3160238</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <ino:IncreaseDecreaseInAccruedClinicalTrialExpense contextRef="c-1" decimals="0" id="f-209" unitRef="usd">-202623</ino:IncreaseDecreaseInAccruedClinicalTrialExpense>
    <ino:IncreaseDecreaseInAccruedClinicalTrialExpense contextRef="c-9" decimals="0" id="f-210" unitRef="usd">657104</ino:IncreaseDecreaseInAccruedClinicalTrialExpense>
    <ino:IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet contextRef="c-1" decimals="0" id="f-211" unitRef="usd">-594230</ino:IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet>
    <ino:IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet contextRef="c-9" decimals="0" id="f-212" unitRef="usd">-11791</ino:IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet>
    <ino:IncreaseDecreaseinDeferredGrantFundingCurrent contextRef="c-1" decimals="0" id="f-213" unitRef="usd">0</ino:IncreaseDecreaseinDeferredGrantFundingCurrent>
    <ino:IncreaseDecreaseinDeferredGrantFundingCurrent contextRef="c-9" decimals="0" id="f-214" unitRef="usd">-87489</ino:IncreaseDecreaseinDeferredGrantFundingCurrent>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-1" decimals="0" id="f-215" unitRef="usd">-26874027</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-9" decimals="0" id="f-216" unitRef="usd">-28759956</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireShortTermInvestments contextRef="c-1" decimals="0" id="f-217" unitRef="usd">0</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:PaymentsToAcquireShortTermInvestments contextRef="c-9" decimals="0" id="f-218" unitRef="usd">9751047</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:ProceedsFromSaleOfShortTermInvestments contextRef="c-1" decimals="0" id="f-219" unitRef="usd">7620</us-gaap:ProceedsFromSaleOfShortTermInvestments>
    <us-gaap:ProceedsFromSaleOfShortTermInvestments contextRef="c-9" decimals="0" id="f-220" unitRef="usd">55169260</us-gaap:ProceedsFromSaleOfShortTermInvestments>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-1" decimals="0" id="f-221" unitRef="usd">59373</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-9" decimals="0" id="f-222" unitRef="usd">35578</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-1" decimals="0" id="f-223" unitRef="usd">-51753</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-9" decimals="0" id="f-224" unitRef="usd">45382635</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:RepaymentsOfConvertibleDebt contextRef="c-1" decimals="0" id="f-225" unitRef="usd">0</us-gaap:RepaymentsOfConvertibleDebt>
    <us-gaap:RepaymentsOfConvertibleDebt contextRef="c-9" decimals="0" id="f-226" unitRef="usd">16415000</us-gaap:RepaymentsOfConvertibleDebt>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-1" decimals="0" id="f-227" unitRef="usd">1102149</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-9" decimals="0" id="f-228" unitRef="usd">5225133</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <ino:ProceedsFromPaymentsForStockOptionsExercisedAndExerciseOfWarrantsNetOfTaxWithholdings contextRef="c-1" decimals="0" id="f-229" unitRef="usd">-74219</ino:ProceedsFromPaymentsForStockOptionsExercisedAndExerciseOfWarrantsNetOfTaxWithholdings>
    <ino:ProceedsFromPaymentsForStockOptionsExercisedAndExerciseOfWarrantsNetOfTaxWithholdings contextRef="c-9" decimals="0" id="f-230" unitRef="usd">-174248</ino:ProceedsFromPaymentsForStockOptionsExercisedAndExerciseOfWarrantsNetOfTaxWithholdings>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-1" decimals="0" id="f-231" unitRef="usd">1027930</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-9" decimals="0" id="f-232" unitRef="usd">-11364115</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-1" decimals="0" id="f-233" unitRef="usd">0</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-9" decimals="0" id="f-234" unitRef="usd">32403</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-1" decimals="0" id="f-235" unitRef="usd">-25897850</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-9" decimals="0" id="f-236" unitRef="usd">5290967</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-4" decimals="0" id="f-237" unitRef="usd">65813297</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-29" decimals="0" id="f-238" unitRef="usd">14310862</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-3" decimals="0" id="f-239" unitRef="usd">39915447</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-39" decimals="0" id="f-240" unitRef="usd">19601829</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-1" decimals="0" id="f-241" unitRef="usd">0</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-9" decimals="0" id="f-242" unitRef="usd">442976</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:InterestPaidNet contextRef="c-1" decimals="0" id="f-243" unitRef="usd">0</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c-9" decimals="0" id="f-244" unitRef="usd">533487</us-gaap:InterestPaidNet>
    <us-gaap:NatureOfOperations contextRef="c-1" id="f-245">Organization and Operations&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Inovio Pharmaceuticals, Inc. (the &#x201c;Company&#x201d; or &#x201c;INOVIO&#x201d;) is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer and infectious diseases. INOVIO's platform harnesses the power of in vivo protein production, featuring optimized design and delivery of DNA medicines that teach the body to manufacture its own disease-fighting tools. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;INOVIO uses proprietary technology to design DNA plasmids, which are small circular DNA molecules that work like software the body&#x2019;s cells can download to produce specific proteins to target and fight disease. The Company's proprietary investigational CELLECTRA devices are designed to deliver the plasmids into the body's cells for optimal effect, without the use of chemical adjuvants, lipid nanoparticles or viral vectors. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;INOVIO's lead candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease of the respiratory tract caused by HPV infection. In its completed Phase 1/2 clinical trial of INO-3107 for the treatment of HPV-6 and HPV-11-associated RRP, 81.3% of patients experienced a reduction in the number of surgical interventions in the year following administration of INO-3107, when compared with the year prior to treatment. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to its development efforts with INO-3107, INOVIO is actively developing or planning to develop DNA medicines for other indications, including HPV-related oropharyngeal squamous cell carcinoma (OPSCC) and anal dysplasia; glioblastoma multiforme (GBM), a deadly form of brain cancer; and a potential vaccine booster to protect against the Ebola virus. The Company was previously conducting clinical trials of a DNA medicine candidate for the treatment of HPV-related cervical high-grade squamous intraepithelial lesions (HSIL) but announced in 2023 that it was ceasing development for this indication in the United States. However, its collaborator ApolloBio Corporation continues to conduct a Phase 3 clinical trial of this candidate in China and plans to seek regulatory approval for and potentially commercialize the candidate in that jurisdiction. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, Coherus Biosciences, Defense Advanced Research Projects Agency (DARPA), HIV Vaccines Trial Network, International Vaccine Institute (IVI), Kaneka Eurogentec, National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID), Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter BioLogics, the University of Pennsylvania and The Wistar Institute.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;INOVIO was incorporated in Delaware in June 2001 and has its principal executive offices in Plymouth Meeting, Pennsylvania.&lt;/span&gt;&lt;/div&gt;</us-gaap:NatureOfOperations>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock contextRef="c-1" id="f-246">Basis of Presentation, Liquidity and Risks and Uncertainties&lt;div style="margin-bottom:3pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited condensed consolidated financial statements of Inovio have been prepared in accordance with U.S. generally accepted accounting principles (&#x201c;U.S. GAAP&#x201d;) as contained in the Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") for interim financial information and with instructions to Form&#160;10-Q and Article&#160;10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The condensed consolidated balance sheet as of March&#160;31, 2025, the condensed consolidated statements of operations, the condensed consolidated statements of comprehensive loss, the condensed consolidated statements of stockholders' equity and the condensed consolidated statements of cash flows for the three months ended March 31, 2025 and 2024 are unaudited, but include all adjustments (consisting of normal recurring adjustments) that the Company considers necessary for a fair presentation of the financial position, results of operations, cash flows and changes in stockholders' equity for the periods presented. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The results of operations for the three months ended March 31, 2025 shown herein are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2025, or for any other period. These unaudited financial statements, and notes thereto, should be read in conjunction with the audited consolidated financial statements for the year ended December&#160;31, 2024, included in the Company's Annual Report on Form&#160;10-K filed with the U.S. Securities and Exchange Commission (&#x201c;SEC&#x201d;) on March&#160;18, 2025. The balance sheet at December&#160;31, 2024 has been derived from the audited financial statements at that date, but does not include all of the information and footnotes required by U.S. GAAP for complete financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These unaudited condensed consolidated financial statements include the accounts of Inovio Pharmaceuticals, Inc. and its subsidiary. As of March&#160;31, 2025 and December 31, 2024, the Company consolidated its wholly-owned subsidiary Inovio Asia LLC. All intercompany accounts and transactions were eliminated upon consolidation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Liquidity &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company incurred a net loss of $19.7 million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for the three months ended March 31, 2025. The Company had working capital of $44.6 million and an accumulated deficit of $1.7 billion as of March&#160;31, 2025. The Company has incurred losses in each year since its inception and expects to continue to incur significant expenses and operating losses for the foreseeable future in connection with the research and preclinical and clinical development of its product candidates. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 16, 2024, the Company closed an underwritten public offering (the "December 2024 Offering"), relating to the issuance and sale of 10,000,000 shares of its common stock, par value $0.001 per share, and warrants to purchase 10,000,000 shares of common stock (the &#x201c;Warrants&#x201d;), at an offering price of $3.00 per share and accompanying Warrant. The exercise price of the Warrants is $3.76 per share. The net proceeds from the December 2024 Offering were $27.6&#160;million, after deducting the underwriting discounts and commissions and offering expenses paid by the Company. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 18, 2024, the Company closed an underwritten registered direct offering (the &#x201c;April 2024 Offering&#x201d;) relating to the issuance and sale of 2,536,258 shares (the &#x201c;Shares&#x201d;) of its common stock, par value $0.001 per share, at a price of $7.693 per share and pre-funded warrants to purchase up to 2,135,477 shares of common stock (the &#x201c;Pre-Funded Warrants&#x201d;) at a price of $7.692 per Pre-Funded Warrant, which represents the per share price for the Shares less the $0.001 per share exercise price for each Pre-Funded Warrant. The net proceeds from the April 2024 Offering were $33.2&#160;million, after deducting the underwriting discounts and commissions and offering expenses paid by the Company. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Going Concern &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s cash, cash equivalents and short-term investments of $68.4 million as of March&#160;31, 2025 are expected to be sufficient to support the Company's planned operations into the first quarter of 2026. The Company's current financial resources may not be sufficient to support its planned operations beyond this date without securing additional financing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In order to continue to fund future research and development activities, the Company will need to seek additional capital. This may occur through strategic alliance and licensing arrangements, grant agreements and/or future public or private debt or equity financings including At-the-Market Equity Offering Sales Agreements (&#x201c;Sales Agreements&#x201d;). The Company has a history of conducting debt and equity financings, including the receipt of net proceeds of $60.8&#160;million from equity offerings during the year ending December 31, 2024, and the receipt of net proceeds of $1.1&#160;million and $6.1&#160;million under Sales Agreements during the three months ended March 31, 2025 and year ended December 31, 2024, respectively. However, sufficient funding may not be available in the future, or if available, may be on terms that significantly dilute or otherwise adversely affect the rights of existing stockholders. If adequate funds are not available, the Company may need to delay, reduce the scope of or put on hold one or more of its clinical and/or preclinical programs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s ability to continue its operations is dependent upon its ability to obtain additional capital in the future and achieve profitable operations. The Company expects to continue to rely on outside sources of financing to meet its capital needs and may never achieve positive cash flow. In light of these factors, management believes that there is substantial doubt about the Company's ability to continue as a going concern beyond the first quarter of 2026. The Company's condensed consolidated financial statements as of and for the three months ended March 31, 2025 do not include any adjustments that might result from the outcome of this uncertainty. The Company has evaluated subsequent events after the balance sheet date through the date it issued these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;The Company is, and from time to time&#160;may in the future be, subject to various legal proceedings and claims arising in the ordinary course of business. The Company assesses contingencies to determine the degree of probability and range of possible loss for potential accrual in its consolidated financial statements. An estimated loss contingency is accrued in the consolidated financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Legal proceedings, including litigation, government investigations and enforcement actions, could result in material costs, occupy significant management resources and entail civil and criminal penalties, even if the Company ultimately prevails.&#160;Any of the foregoing consequences could result in serious harm to the Company&#x2019;s business, results of operations and financial condition.</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c-1" id="f-247">&lt;div style="margin-bottom:3pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited condensed consolidated financial statements of Inovio have been prepared in accordance with U.S. generally accepted accounting principles (&#x201c;U.S. GAAP&#x201d;) as contained in the Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") for interim financial information and with instructions to Form&#160;10-Q and Article&#160;10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The condensed consolidated balance sheet as of March&#160;31, 2025, the condensed consolidated statements of operations, the condensed consolidated statements of comprehensive loss, the condensed consolidated statements of stockholders' equity and the condensed consolidated statements of cash flows for the three months ended March 31, 2025 and 2024 are unaudited, but include all adjustments (consisting of normal recurring adjustments) that the Company considers necessary for a fair presentation of the financial position, results of operations, cash flows and changes in stockholders' equity for the periods presented. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The results of operations for the three months ended March 31, 2025 shown herein are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2025, or for any other period. These unaudited financial statements, and notes thereto, should be read in conjunction with the audited consolidated financial statements for the year ended December&#160;31, 2024, included in the Company's Annual Report on Form&#160;10-K filed with the U.S. Securities and Exchange Commission (&#x201c;SEC&#x201d;) on March&#160;18, 2025. The balance sheet at December&#160;31, 2024 has been derived from the audited financial statements at that date, but does not include all of the information and footnotes required by U.S. GAAP for complete financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These unaudited condensed consolidated financial statements include the accounts of Inovio Pharmaceuticals, Inc. and its subsidiary. As of March&#160;31, 2025 and December 31, 2024, the Company consolidated its wholly-owned subsidiary Inovio Asia LLC. All intercompany accounts and transactions were eliminated upon consolidation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Liquidity &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company incurred a net loss of $19.7 million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for the three months ended March 31, 2025. The Company had working capital of $44.6 million and an accumulated deficit of $1.7 billion as of March&#160;31, 2025. The Company has incurred losses in each year since its inception and expects to continue to incur significant expenses and operating losses for the foreseeable future in connection with the research and preclinical and clinical development of its product candidates. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 16, 2024, the Company closed an underwritten public offering (the "December 2024 Offering"), relating to the issuance and sale of 10,000,000 shares of its common stock, par value $0.001 per share, and warrants to purchase 10,000,000 shares of common stock (the &#x201c;Warrants&#x201d;), at an offering price of $3.00 per share and accompanying Warrant. The exercise price of the Warrants is $3.76 per share. The net proceeds from the December 2024 Offering were $27.6&#160;million, after deducting the underwriting discounts and commissions and offering expenses paid by the Company. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 18, 2024, the Company closed an underwritten registered direct offering (the &#x201c;April 2024 Offering&#x201d;) relating to the issuance and sale of 2,536,258 shares (the &#x201c;Shares&#x201d;) of its common stock, par value $0.001 per share, at a price of $7.693 per share and pre-funded warrants to purchase up to 2,135,477 shares of common stock (the &#x201c;Pre-Funded Warrants&#x201d;) at a price of $7.692 per Pre-Funded Warrant, which represents the per share price for the Shares less the $0.001 per share exercise price for each Pre-Funded Warrant. The net proceeds from the April 2024 Offering were $33.2&#160;million, after deducting the underwriting discounts and commissions and offering expenses paid by the Company. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Going Concern &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s cash, cash equivalents and short-term investments of $68.4 million as of March&#160;31, 2025 are expected to be sufficient to support the Company's planned operations into the first quarter of 2026. The Company's current financial resources may not be sufficient to support its planned operations beyond this date without securing additional financing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In order to continue to fund future research and development activities, the Company will need to seek additional capital. This may occur through strategic alliance and licensing arrangements, grant agreements and/or future public or private debt or equity financings including At-the-Market Equity Offering Sales Agreements (&#x201c;Sales Agreements&#x201d;). The Company has a history of conducting debt and equity financings, including the receipt of net proceeds of $60.8&#160;million from equity offerings during the year ending December 31, 2024, and the receipt of net proceeds of $1.1&#160;million and $6.1&#160;million under Sales Agreements during the three months ended March 31, 2025 and year ended December 31, 2024, respectively. However, sufficient funding may not be available in the future, or if available, may be on terms that significantly dilute or otherwise adversely affect the rights of existing stockholders. If adequate funds are not available, the Company may need to delay, reduce the scope of or put on hold one or more of its clinical and/or preclinical programs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s ability to continue its operations is dependent upon its ability to obtain additional capital in the future and achieve profitable operations. The Company expects to continue to rely on outside sources of financing to meet its capital needs and may never achieve positive cash flow. In light of these factors, management believes that there is substantial doubt about the Company's ability to continue as a going concern beyond the first quarter of 2026. The Company's condensed consolidated financial statements as of and for the three months ended March 31, 2025 do not include any adjustments that might result from the outcome of this uncertainty. The Company has evaluated subsequent events after the balance sheet date through the date it issued these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;The Company is, and from time to time&#160;may in the future be, subject to various legal proceedings and claims arising in the ordinary course of business. The Company assesses contingencies to determine the degree of probability and range of possible loss for potential accrual in its consolidated financial statements. An estimated loss contingency is accrued in the consolidated financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Legal proceedings, including litigation, government investigations and enforcement actions, could result in material costs, occupy significant management resources and entail civil and criminal penalties, even if the Company ultimately prevails.&#160;Any of the foregoing consequences could result in serious harm to the Company&#x2019;s business, results of operations and financial condition.</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-5" id="f-248" unitRef="usd">-19700000</us-gaap:NetIncomeLoss>
    <ino:WorkingCapital contextRef="c-3" decimals="-5" id="f-249" unitRef="usd">44600000</ino:WorkingCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-3" decimals="-8" id="f-250" unitRef="usd">-1700000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-40"
      decimals="INF"
      id="f-251"
      unitRef="shares">10000000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-41"
      decimals="INF"
      id="f-252"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-42"
      decimals="INF"
      id="f-253"
      unitRef="shares">10000000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-43"
      decimals="2"
      id="f-254"
      unitRef="usdPerShare">3.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-43"
      decimals="INF"
      id="f-255"
      unitRef="usdPerShare">3.76</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-44" decimals="-5" id="f-256" unitRef="usd">27600000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-45"
      decimals="INF"
      id="f-257"
      unitRef="shares">2536258</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-46"
      decimals="INF"
      id="f-258"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-46"
      decimals="INF"
      id="f-259"
      unitRef="usdPerShare">7.693</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-47"
      decimals="INF"
      id="f-260"
      unitRef="shares">2135477</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-48"
      decimals="INF"
      id="f-261"
      unitRef="usdPerShare">7.692</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-48"
      decimals="INF"
      id="f-262"
      unitRef="usdPerShare">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="c-49" decimals="-5" id="f-263" unitRef="usd">33200000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments contextRef="c-3" decimals="-5" id="f-264" unitRef="usd">68400000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-50" decimals="-5" id="f-265" unitRef="usd">60800000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-51" decimals="-3" id="f-266" unitRef="usd">1100000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-52" decimals="-5" id="f-267" unitRef="usd">6100000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c-1" id="f-268">Critical Accounting Policies&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaboration Agreements and Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company assesses whether its collaboration agreements are subject to Accounting Standards Codification ("ASC") Topic 808: Collaborative Arrangements (&#x201c;Topic 808&#x201d;) based on whether they involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within the scope of Topic 808 and the Company concludes that its collaboration partner is not a customer, the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Company presents such payments as a reduction of research and development expense. If payments from the collaboration partner to the Company represent consideration from a customer, then the Company accounts for those payments within the scope of Accounting Standards Update (&#x201c;ASU&#x201d;) 2014-09, Revenue from Contracts with Customers (&#x201c;Topic 606&#x201d;). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and Development Expenses - Clinical Trial Accruals&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company's activities have largely consisted of research and development efforts related to developing its proprietary device technology and DNA medicine candidates. For clinical trial expenses, judgements used in estimating accruals rely on estimates of total costs incurred based on participant enrollment, completion of studies and other events. Accrued clinical trial costs are subject to revisions as trials progress. Revisions are charged to expense in the period in which the facts that give rise to the revision become known. Historically, revisions have not resulted in material changes to research and development expense; however, a modification in the protocol of a clinical trial or cancellation of a trial could result in a charge to the Company's results of operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:CollaborativeArrangementAccountingPolicy contextRef="c-1" id="f-269">&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaboration Agreements and Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company assesses whether its collaboration agreements are subject to Accounting Standards Codification ("ASC") Topic 808: Collaborative Arrangements (&#x201c;Topic 808&#x201d;) based on whether they involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within the scope of Topic 808 and the Company concludes that its collaboration partner is not a customer, the &lt;/span&gt;&lt;/div&gt;Company presents such payments as a reduction of research and development expense. If payments from the collaboration partner to the Company represent consideration from a customer, then the Company accounts for those payments within the scope of Accounting Standards Update (&#x201c;ASU&#x201d;) 2014-09, Revenue from Contracts with Customers (&#x201c;Topic 606&#x201d;).</us-gaap:CollaborativeArrangementAccountingPolicy>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c-1" id="f-270">&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and Development Expenses - Clinical Trial Accruals&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company's activities have largely consisted of research and development efforts related to developing its proprietary device technology and DNA medicine candidates. For clinical trial expenses, judgements used in estimating accruals rely on estimates of total costs incurred based on participant enrollment, completion of studies and other events. Accrued clinical trial costs are subject to revisions as trials progress. Revisions are charged to expense in the period in which the facts that give rise to the revision become known. Historically, revisions have not resulted in material changes to research and development expense; however, a modification in the protocol of a clinical trial or cancellation of a trial could result in a charge to the Company's results of operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock contextRef="c-1" id="f-272">Short-term Investments and Fair Value Measurements&lt;div style="margin-bottom:3pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of available-for-sale securities as of March&#160;31, 2025 and December&#160;31, 2024:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.839%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.394%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.809%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.809%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.809%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.812%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contractual&lt;br/&gt;Maturity&#160;(in&#160;years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&#160;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&#160;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;Market&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;---&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,926,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,305,472)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,620,943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,980,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(276)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,989,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. agency mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,243,914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(407,359)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;836,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,150,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,713,107)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,447,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.839%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.394%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.809%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.809%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.809%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.812%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:20pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contractual&lt;br/&gt;Maturity&#160;(in&#160;years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&#160;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&#160;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;Market&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;---&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,926,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,445,706)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,480,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,980,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(281)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,989,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. agency mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,260,745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(430,964)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;829,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,167,433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,876,951)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,300,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*No single maturity date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;During the three months ended March 31, 2025 and 2024, the Company recorded gross realized gains on investments of $200 and $200, respectively, and gross realized losses on investments of $700 and $691,000, respectively. During the three months ended March 31, 2025 and 2024, the Company recorded net unrealized gains on available-for-sale equity securities of $140,000 and $501,000, respectively. No&#160;material balances were&#160;reclassified out of accumulated&#160;other comprehensive loss for the three months ended March 31, 2025 and 2024. Interest and dividends on investments classified as available-for-sale are included in interest income in the condensed consolidated statements of operations. As of March&#160;31, 2025, the Company had 19 available-for-sale securities with an aggregate total unrealized loss of $1.7 million. All of these securities had been in a loss position for longer than 12 months as of March&#160;31, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company periodically reviews its portfolio of available-for-sale debt securities to determine if any investment is impaired due to credit loss or other potential valuation concerns. For the debt securities where the fair value of the investment is less than the amortized cost basis, the Company has assessed at the individual security level for various quantitative factors including, but not limited to, the nature of the investments, changes in credit ratings, interest rate fluctuations, industry analyst reports, and the severity of impairment. Unrealized losses on available-for-sale debt securities as of&#160;March&#160;31, 2025&#160;were primarily due to changes in interest rates&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;and not due to increased credit risks associated with specific securities. Based on the credit quality of the available-for-sale debt securities that are in an unrealized loss position, and the Company&#x2019;s estimates of future cash flows to be collected from those securities, the Company believes the unrealized losses are not credit losses. Accordingly, at March&#160;31, 2025, the Company has not recorded an allowance for credit losses related to its available-for-sale debt securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The following table presents the Company&#x2019;s assets that were measured at fair value on a recurring basis, determined using the following inputs as of March&#160;31, 2025:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:35.796%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.541%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.541%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.737%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.689%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices&lt;br/&gt;in Active Markets&lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Other Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,620,943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,620,943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,989,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,989,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;836,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;836,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,447,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,620,943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,826,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in affiliated entity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,308,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,308,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,756,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,929,918&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,826,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock warrant liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,542,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,542,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,542,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,542,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the Company&#x2019;s assets that were measured at fair value on a recurring basis, determined using the following inputs as of December&#160;31, 2024:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:35.796%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.541%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.541%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.737%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.689%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices&lt;br/&gt;in Active Markets&lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Other Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,480,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,480,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,989,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,989,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;829,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;829,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,300,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,480,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,819,523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in affiliated entity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,613,844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,613,844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,914,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,094,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,819,523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock warrant liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,255,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,255,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,255,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,255,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Level 1 assets at March&#160;31, 2025 consisted of mutual funds and the Company&#x2019;s investment in its affiliated entity, Plumbline Life Sciences, Inc. (PLS). See Note 10 for additional information. The Company accounts for its investment in 597,808 common shares of PLS based on the closing price of the shares on the Korea New Exchange Market on the applicable balance sheet date. Unrealized gains and losses on the Company's equity securities are reported in the consolidated statement of ope&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;rations as unrealized gain or loss on available-for-sale equity securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;or as a gain or loss on investment in affiliated entity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2 assets at March&#160;31, 2025 consisted of certificates of deposit and U.S. agency mortgage-backed securities held by the Company that are initially valued at the transaction price and subsequently valued, at the end of each reporting period, typically utilizing market observable data. The Company obtains the fair value of its Level 2 assets from a professional pricing service, which may use quoted market prices for identical or comparable instruments, or inputs other than quoted prices that are observable either directly or indirectly. The professional pricing service gathers quoted market prices and observable inputs from a variety of industry data providers. The valuation techniques used to measure the fair value of the Company's Level 2 financial instruments were derived from non-binding market consensus prices that are corroborated by observable market data, &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;quoted market prices for similar instruments, or pricing models such as discounted cash flow techniques. The Company validates the quoted market prices provided by the primary pricing service by comparing the service's assessment of the fair values of the Company's investment portfolio balance against the fair values of the Company's investment portfolio balance obtained from an independent source.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no Level 3 assets held as of March&#160;31, 2025 or December 31, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 3 liabilities held as of March&#160;31, 2025 and December 31, 2024 consisted of liabilities associated with the Warrants to purchase common stock issued in the Company's underwritten public offering that closed in December 2024. See Note 7 for additional information about the liability-classified warrants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company reassesses the fair value of the common stock warrant liability at each reporting date utilizing a Black-Scholes pricing model. The following assumptions were used to estimate the fair value of the warrant liability:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.016%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.905%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.381%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.198%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%"&gt;March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;4.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;4.4%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;94%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;111%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Expected life in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;4.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in these assumptions as well as fluctuations in the Company's stock price between the valuation dates can have a &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;significant impact on the fair value of the common stock warrant liability. Expected volatility was based on historical volatility. Historical volatility was computed using daily pricing observations for recent periods. The Company believes this method produced an estimate that was representative of the Company&#x2019;s expectations of future volatility over the expected term. Expected term is calculated based on the remaining contractual term of the Warrants. The risk-free rate was based on the U.S. Treasury rate that corresponds to the expected term of the Warrants. As a result of these calculations, the Company recorded a decrease in fair value of the liability of $3.7&#160;million on the condensed consolidated statement of operations for the three months ended March&#160;31, 2025. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the change in fair value of the Company&#x2019;s total Level 3 financial liabilities for the three months ended March&#160;31, 2025:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:83.110%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.690%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Common Stock Warrant Liability&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,255,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-394"&gt;Decrease in fair value of liability&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,712,872)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,542,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="c-1" id="f-271">Short-term Investments and Fair Value Measurements&lt;div style="margin-bottom:3pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of available-for-sale securities as of March&#160;31, 2025 and December&#160;31, 2024:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.839%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.394%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.809%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.809%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.809%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.812%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contractual&lt;br/&gt;Maturity&#160;(in&#160;years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&#160;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&#160;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;Market&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;---&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,926,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,305,472)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,620,943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,980,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(276)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,989,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. agency mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,243,914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(407,359)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;836,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,150,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,713,107)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,447,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.839%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.394%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.809%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.809%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.809%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.812%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:20pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contractual&lt;br/&gt;Maturity&#160;(in&#160;years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&#160;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&#160;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;Market&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;---&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,926,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,445,706)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,480,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,980,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(281)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,989,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. agency mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,260,745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(430,964)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;829,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,167,433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,876,951)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,300,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*No single maturity date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;During the three months ended March 31, 2025 and 2024, the Company recorded gross realized gains on investments of $200 and $200, respectively, and gross realized losses on investments of $700 and $691,000, respectively. During the three months ended March 31, 2025 and 2024, the Company recorded net unrealized gains on available-for-sale equity securities of $140,000 and $501,000, respectively. No&#160;material balances were&#160;reclassified out of accumulated&#160;other comprehensive loss for the three months ended March 31, 2025 and 2024. Interest and dividends on investments classified as available-for-sale are included in interest income in the condensed consolidated statements of operations. As of March&#160;31, 2025, the Company had 19 available-for-sale securities with an aggregate total unrealized loss of $1.7 million. All of these securities had been in a loss position for longer than 12 months as of March&#160;31, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company periodically reviews its portfolio of available-for-sale debt securities to determine if any investment is impaired due to credit loss or other potential valuation concerns. For the debt securities where the fair value of the investment is less than the amortized cost basis, the Company has assessed at the individual security level for various quantitative factors including, but not limited to, the nature of the investments, changes in credit ratings, interest rate fluctuations, industry analyst reports, and the severity of impairment. Unrealized losses on available-for-sale debt securities as of&#160;March&#160;31, 2025&#160;were primarily due to changes in interest rates&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;and not due to increased credit risks associated with specific securities. Based on the credit quality of the available-for-sale debt securities that are in an unrealized loss position, and the Company&#x2019;s estimates of future cash flows to be collected from those securities, the Company believes the unrealized losses are not credit losses. Accordingly, at March&#160;31, 2025, the Company has not recorded an allowance for credit losses related to its available-for-sale debt securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The following table presents the Company&#x2019;s assets that were measured at fair value on a recurring basis, determined using the following inputs as of March&#160;31, 2025:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:35.796%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.541%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.541%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.737%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.689%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices&lt;br/&gt;in Active Markets&lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Other Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,620,943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,620,943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,989,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,989,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;836,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;836,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,447,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,620,943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,826,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in affiliated entity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,308,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,308,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,756,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,929,918&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,826,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock warrant liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,542,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,542,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,542,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,542,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the Company&#x2019;s assets that were measured at fair value on a recurring basis, determined using the following inputs as of December&#160;31, 2024:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:35.796%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.541%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.541%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.737%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.689%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices&lt;br/&gt;in Active Markets&lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Other Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,480,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,480,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,989,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,989,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;829,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;829,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,300,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,480,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,819,523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in affiliated entity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,613,844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,613,844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,914,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,094,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,819,523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock warrant liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,255,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,255,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,255,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,255,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Level 1 assets at March&#160;31, 2025 consisted of mutual funds and the Company&#x2019;s investment in its affiliated entity, Plumbline Life Sciences, Inc. (PLS). See Note 10 for additional information. The Company accounts for its investment in 597,808 common shares of PLS based on the closing price of the shares on the Korea New Exchange Market on the applicable balance sheet date. Unrealized gains and losses on the Company's equity securities are reported in the consolidated statement of ope&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;rations as unrealized gain or loss on available-for-sale equity securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;or as a gain or loss on investment in affiliated entity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2 assets at March&#160;31, 2025 consisted of certificates of deposit and U.S. agency mortgage-backed securities held by the Company that are initially valued at the transaction price and subsequently valued, at the end of each reporting period, typically utilizing market observable data. The Company obtains the fair value of its Level 2 assets from a professional pricing service, which may use quoted market prices for identical or comparable instruments, or inputs other than quoted prices that are observable either directly or indirectly. The professional pricing service gathers quoted market prices and observable inputs from a variety of industry data providers. The valuation techniques used to measure the fair value of the Company's Level 2 financial instruments were derived from non-binding market consensus prices that are corroborated by observable market data, &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;quoted market prices for similar instruments, or pricing models such as discounted cash flow techniques. The Company validates the quoted market prices provided by the primary pricing service by comparing the service's assessment of the fair values of the Company's investment portfolio balance against the fair values of the Company's investment portfolio balance obtained from an independent source.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no Level 3 assets held as of March&#160;31, 2025 or December 31, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 3 liabilities held as of March&#160;31, 2025 and December 31, 2024 consisted of liabilities associated with the Warrants to purchase common stock issued in the Company's underwritten public offering that closed in December 2024. See Note 7 for additional information about the liability-classified warrants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company reassesses the fair value of the common stock warrant liability at each reporting date utilizing a Black-Scholes pricing model. The following assumptions were used to estimate the fair value of the warrant liability:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.016%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.905%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.381%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.198%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%"&gt;March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;4.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;4.4%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;94%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;111%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Expected life in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;4.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in these assumptions as well as fluctuations in the Company's stock price between the valuation dates can have a &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;significant impact on the fair value of the common stock warrant liability. Expected volatility was based on historical volatility. Historical volatility was computed using daily pricing observations for recent periods. The Company believes this method produced an estimate that was representative of the Company&#x2019;s expectations of future volatility over the expected term. Expected term is calculated based on the remaining contractual term of the Warrants. The risk-free rate was based on the U.S. Treasury rate that corresponds to the expected term of the Warrants. As a result of these calculations, the Company recorded a decrease in fair value of the liability of $3.7&#160;million on the condensed consolidated statement of operations for the three months ended March&#160;31, 2025. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the change in fair value of the Company&#x2019;s total Level 3 financial liabilities for the three months ended March&#160;31, 2025:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:83.110%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.690%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Common Stock Warrant Liability&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,255,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-394"&gt;Decrease in fair value of liability&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,712,872)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,542,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock contextRef="c-1" id="f-273">&lt;div style="margin-bottom:3pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of available-for-sale securities as of March&#160;31, 2025 and December&#160;31, 2024:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.839%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.394%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.809%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.809%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.809%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.812%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contractual&lt;br/&gt;Maturity&#160;(in&#160;years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&#160;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&#160;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;Market&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;---&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,926,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,305,472)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,620,943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,980,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(276)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,989,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. agency mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,243,914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(407,359)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;836,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,150,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,713,107)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,447,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.839%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.394%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.809%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.809%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.809%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.812%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:20pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contractual&lt;br/&gt;Maturity&#160;(in&#160;years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&#160;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&#160;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;Market&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;---&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,926,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,445,706)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,480,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,980,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(281)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,989,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. agency mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,260,745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(430,964)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;829,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,167,433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,876,951)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,300,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*No single maturity date.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-53" decimals="0" id="f-274" unitRef="usd">25926415</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-53" decimals="0" id="f-275" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-53" decimals="0" id="f-276" unitRef="usd">1305472</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-53" decimals="0" id="f-277" unitRef="usd">24620943</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <ino:DebtSecuritiesAvailableforSaleContractualMaturity contextRef="c-54" id="f-278">P1Y</ino:DebtSecuritiesAvailableforSaleContractualMaturity>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-55" decimals="0" id="f-279" unitRef="usd">2980607</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-55" decimals="0" id="f-280" unitRef="usd">9268</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-55" decimals="0" id="f-281" unitRef="usd">276</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-55" decimals="0" id="f-282" unitRef="usd">2989599</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-56" decimals="0" id="f-283" unitRef="usd">1243914</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-56" decimals="0" id="f-284" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-56" decimals="0" id="f-285" unitRef="usd">407359</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-56" decimals="0" id="f-286" unitRef="usd">836555</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-3" decimals="0" id="f-287" unitRef="usd">30150936</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-3" decimals="0" id="f-288" unitRef="usd">9268</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-3" decimals="0" id="f-289" unitRef="usd">1713107</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-3" decimals="0" id="f-290" unitRef="usd">28447097</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-57" decimals="0" id="f-291" unitRef="usd">25926415</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-57" decimals="0" id="f-292" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-57" decimals="0" id="f-293" unitRef="usd">1445706</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-57" decimals="0" id="f-294" unitRef="usd">24480709</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <ino:DebtSecuritiesAvailableforSaleContractualMaturity contextRef="c-58" id="f-295">P1Y</ino:DebtSecuritiesAvailableforSaleContractualMaturity>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-59" decimals="0" id="f-296" unitRef="usd">2980273</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-59" decimals="0" id="f-297" unitRef="usd">9750</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-59" decimals="0" id="f-298" unitRef="usd">281</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-59" decimals="0" id="f-299" unitRef="usd">2989742</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-60" decimals="0" id="f-300" unitRef="usd">1260745</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-60" decimals="0" id="f-301" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-60" decimals="0" id="f-302" unitRef="usd">430964</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-60" decimals="0" id="f-303" unitRef="usd">829781</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-4" decimals="0" id="f-304" unitRef="usd">30167433</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-4" decimals="0" id="f-305" unitRef="usd">9750</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-4" decimals="0" id="f-306" unitRef="usd">1876951</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-4" decimals="0" id="f-307" unitRef="usd">28300232</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain contextRef="c-1" decimals="-2" id="f-308" unitRef="usd">200</us-gaap:DebtSecuritiesAvailableForSaleRealizedGain>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain contextRef="c-9" decimals="-2" id="f-309" unitRef="usd">200</us-gaap:DebtSecuritiesAvailableForSaleRealizedGain>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss contextRef="c-1" decimals="-2" id="f-310" unitRef="usd">700</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss contextRef="c-9" decimals="-3" id="f-311" unitRef="usd">691000</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss contextRef="c-1" decimals="-3" id="f-312" unitRef="usd">140000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss contextRef="c-9" decimals="-3" id="f-313" unitRef="usd">501000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="c-3"
      decimals="INF"
      id="f-314"
      unitRef="position">19</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:UnrealizedGainLossOnInvestments contextRef="c-1" decimals="-5" id="f-315" unitRef="usd">-1700000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="c-1" id="f-316">&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The following table presents the Company&#x2019;s assets that were measured at fair value on a recurring basis, determined using the following inputs as of March&#160;31, 2025:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:35.796%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.541%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.541%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.737%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.689%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices&lt;br/&gt;in Active Markets&lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Other Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,620,943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,620,943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,989,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,989,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;836,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;836,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,447,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,620,943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,826,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in affiliated entity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,308,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,308,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,756,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,929,918&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,826,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock warrant liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,542,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,542,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,542,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,542,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the Company&#x2019;s assets that were measured at fair value on a recurring basis, determined using the following inputs as of December&#160;31, 2024:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:35.796%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.541%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.541%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.737%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.689%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices&lt;br/&gt;in Active Markets&lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Other Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,480,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,480,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,989,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,989,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;829,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;829,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,300,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,480,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,819,523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in affiliated entity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,613,844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,613,844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,914,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,094,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,819,523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock warrant liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,255,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,255,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,255,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,255,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-61" decimals="0" id="f-317" unitRef="usd">24620943</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-62" decimals="0" id="f-318" unitRef="usd">24620943</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-63" decimals="0" id="f-319" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-64" decimals="0" id="f-320" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-65" decimals="0" id="f-321" unitRef="usd">2989599</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-66" decimals="0" id="f-322" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-67" decimals="0" id="f-323" unitRef="usd">2989599</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-68" decimals="0" id="f-324" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-69" decimals="0" id="f-325" unitRef="usd">836555</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-70" decimals="0" id="f-326" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-71" decimals="0" id="f-327" unitRef="usd">836555</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-72" decimals="0" id="f-328" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-73" decimals="0" id="f-329" unitRef="usd">28447097</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-74" decimals="0" id="f-330" unitRef="usd">24620943</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-75" decimals="0" id="f-331" unitRef="usd">3826154</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-76" decimals="0" id="f-332" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-73" decimals="0" id="f-333" unitRef="usd">2308975</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-74" decimals="0" id="f-334" unitRef="usd">2308975</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-75" decimals="0" id="f-335" unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-76" decimals="0" id="f-336" unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-73" decimals="0" id="f-337" unitRef="usd">30756072</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-74" decimals="0" id="f-338" unitRef="usd">26929918</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-75" decimals="0" id="f-339" unitRef="usd">3826154</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-76" decimals="0" id="f-340" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <ino:CommonStockWarrantLiabilityFairValue contextRef="c-73" decimals="0" id="f-341" unitRef="usd">9542316</ino:CommonStockWarrantLiabilityFairValue>
    <ino:CommonStockWarrantLiabilityFairValue contextRef="c-74" decimals="0" id="f-342" unitRef="usd">0</ino:CommonStockWarrantLiabilityFairValue>
    <ino:CommonStockWarrantLiabilityFairValue contextRef="c-75" decimals="0" id="f-343" unitRef="usd">0</ino:CommonStockWarrantLiabilityFairValue>
    <ino:CommonStockWarrantLiabilityFairValue contextRef="c-76" decimals="0" id="f-344" unitRef="usd">9542316</ino:CommonStockWarrantLiabilityFairValue>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="c-73" decimals="0" id="f-345" unitRef="usd">9542316</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="c-74" decimals="0" id="f-346" unitRef="usd">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="c-75" decimals="0" id="f-347" unitRef="usd">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="c-76" decimals="0" id="f-348" unitRef="usd">9542316</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-77" decimals="0" id="f-349" unitRef="usd">24480709</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-78" decimals="0" id="f-350" unitRef="usd">24480709</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-79" decimals="0" id="f-351" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-80" decimals="0" id="f-352" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-81" decimals="0" id="f-353" unitRef="usd">2989742</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-82" decimals="0" id="f-354" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-83" decimals="0" id="f-355" unitRef="usd">2989742</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-84" decimals="0" id="f-356" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-85" decimals="0" id="f-357" unitRef="usd">829781</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-86" decimals="0" id="f-358" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-87" decimals="0" id="f-359" unitRef="usd">829781</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-88" decimals="0" id="f-360" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-89" decimals="0" id="f-361" unitRef="usd">28300232</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-90" decimals="0" id="f-362" unitRef="usd">24480709</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-91" decimals="0" id="f-363" unitRef="usd">3819523</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-92" decimals="0" id="f-364" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-89" decimals="0" id="f-365" unitRef="usd">1613844</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-90" decimals="0" id="f-366" unitRef="usd">1613844</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-91" decimals="0" id="f-367" unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-92" decimals="0" id="f-368" unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-89" decimals="0" id="f-369" unitRef="usd">29914076</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-90" decimals="0" id="f-370" unitRef="usd">26094553</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-91" decimals="0" id="f-371" unitRef="usd">3819523</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-92" decimals="0" id="f-372" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <ino:CommonStockWarrantLiabilityFairValue contextRef="c-89" decimals="0" id="f-373" unitRef="usd">13255188</ino:CommonStockWarrantLiabilityFairValue>
    <ino:CommonStockWarrantLiabilityFairValue contextRef="c-90" decimals="0" id="f-374" unitRef="usd">0</ino:CommonStockWarrantLiabilityFairValue>
    <ino:CommonStockWarrantLiabilityFairValue contextRef="c-91" decimals="0" id="f-375" unitRef="usd">0</ino:CommonStockWarrantLiabilityFairValue>
    <ino:CommonStockWarrantLiabilityFairValue contextRef="c-92" decimals="0" id="f-376" unitRef="usd">13255188</ino:CommonStockWarrantLiabilityFairValue>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="c-89" decimals="0" id="f-377" unitRef="usd">13255188</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="c-90" decimals="0" id="f-378" unitRef="usd">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="c-91" decimals="0" id="f-379" unitRef="usd">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="c-92" decimals="0" id="f-380" unitRef="usd">13255188</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="c-93"
      decimals="INF"
      id="f-381"
      unitRef="shares">597808</us-gaap:InvestmentOwnedBalanceShares>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock contextRef="c-1" id="f-382">The following assumptions were used to estimate the fair value of the warrant liability:&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.016%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.905%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.381%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.198%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%"&gt;March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;4.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;4.4%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;94%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;111%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Expected life in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;4.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <ino:WarrantLiabilityMeasurementInput contextRef="c-94" decimals="3" id="f-383" unitRef="number">0.040</ino:WarrantLiabilityMeasurementInput>
    <ino:WarrantLiabilityMeasurementInput contextRef="c-95" decimals="3" id="f-384" unitRef="number">0.044</ino:WarrantLiabilityMeasurementInput>
    <ino:WarrantLiabilityMeasurementInput contextRef="c-96" decimals="3" id="f-385" unitRef="number">0.94</ino:WarrantLiabilityMeasurementInput>
    <ino:WarrantLiabilityMeasurementInput contextRef="c-97" decimals="3" id="f-386" unitRef="number">1.11</ino:WarrantLiabilityMeasurementInput>
    <ino:WarrantLiabilityMeasurementInput contextRef="c-98" decimals="1" id="f-387" unitRef="y">4.7</ino:WarrantLiabilityMeasurementInput>
    <ino:WarrantLiabilityMeasurementInput contextRef="c-99" decimals="0" id="f-388" unitRef="y">5</ino:WarrantLiabilityMeasurementInput>
    <ino:WarrantLiabilityMeasurementInput contextRef="c-100" decimals="3" id="f-389" unitRef="number">0</ino:WarrantLiabilityMeasurementInput>
    <ino:WarrantLiabilityMeasurementInput contextRef="c-101" decimals="3" id="f-390" unitRef="number">0</ino:WarrantLiabilityMeasurementInput>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="c-1" decimals="-5" id="f-391" unitRef="usd">3700000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="c-1" id="f-392">&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the change in fair value of the Company&#x2019;s total Level 3 financial liabilities for the three months ended March&#160;31, 2025:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:83.110%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.690%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Common Stock Warrant Liability&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,255,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-394"&gt;Decrease in fair value of liability&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,712,872)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,542,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-4" decimals="0" id="f-393" unitRef="usd">13255188</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="c-1" decimals="0" id="f-395" unitRef="usd">3712872</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-3" decimals="0" id="f-396" unitRef="usd">9542316</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:OtherCurrentAssetsTextBlock contextRef="c-1" id="f-397">Certain Balance Sheet Items&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid and other current assets consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-4.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:69.539%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.289%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.381%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.291%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid clinical expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,013,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;627,962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,207,926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,889,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,221,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,517,465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:-4.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:27pt;text-indent:-31.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts payable and accrued expenses consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-4.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:69.539%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.289%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.381%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.291%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trade accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,054,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,091,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,322,421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,007,180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,542,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,101,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,919,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,200,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:OtherCurrentAssetsTextBlock>
    <ino:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock contextRef="c-1" id="f-398">&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid and other current assets consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-4.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:69.539%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.289%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.381%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.291%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid clinical expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,013,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;627,962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,207,926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,889,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,221,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,517,465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ino:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock>
    <ino:PrepaidClinicalExpensesCurrent contextRef="c-3" decimals="0" id="f-399" unitRef="usd">1013742</ino:PrepaidClinicalExpensesCurrent>
    <ino:PrepaidClinicalExpensesCurrent contextRef="c-4" decimals="0" id="f-400" unitRef="usd">627962</ino:PrepaidClinicalExpensesCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent contextRef="c-3" decimals="0" id="f-401" unitRef="usd">1207926</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent contextRef="c-4" decimals="0" id="f-402" unitRef="usd">1889503</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-3" decimals="0" id="f-403" unitRef="usd">2221668</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-4" decimals="0" id="f-404" unitRef="usd">2517465</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock contextRef="c-1" id="f-405">&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts payable and accrued expenses consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-4.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:69.539%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.289%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.381%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.291%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trade accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,054,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,091,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,322,421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,007,180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,542,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,101,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,919,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,200,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccountsPayableTradeCurrentAndNoncurrent contextRef="c-5" decimals="0" id="f-406" unitRef="usd">5054582</us-gaap:AccountsPayableTradeCurrentAndNoncurrent>
    <us-gaap:AccountsPayableTradeCurrentAndNoncurrent contextRef="c-6" decimals="0" id="f-407" unitRef="usd">5091503</us-gaap:AccountsPayableTradeCurrentAndNoncurrent>
    <us-gaap:AccruedSalariesCurrent contextRef="c-5" decimals="0" id="f-408" unitRef="usd">6322421</us-gaap:AccruedSalariesCurrent>
    <us-gaap:AccruedSalariesCurrent contextRef="c-6" decimals="0" id="f-409" unitRef="usd">10007180</us-gaap:AccruedSalariesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent contextRef="c-5" decimals="0" id="f-410" unitRef="usd">1542785</us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent contextRef="c-6" decimals="0" id="f-411" unitRef="usd">1101330</us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c-5" decimals="0" id="f-412" unitRef="usd">12919788</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c-6" decimals="0" id="f-413" unitRef="usd">16200013</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:DebtDisclosureTextBlock contextRef="c-1" id="f-414">Convertible Debt&lt;div style="margin-bottom:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Convertible Senior Notes &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In 2019, the Company completed a private placement of $78.5&#160;million aggregate principal amount of its 6.50% convertible senior notes due 2024 (the &#x201c;Notes&#x201d;). The Notes were sold in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. Net proceeds from the offering were $75.7&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Notes were senior unsecured obligations of the Company and accrued interest payable in cash semi-annually in arrears on March 1 and September 1 of each year at a rate of 6.50% per annum. The Notes matured on March 1, 2024 and the Company paid the then remaining $16.9&#160;million obligation in full, including accrued interest.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;For the three months ended March 31, 2024,&#160;the Company recognized $178,000 of interest expense related to the Notes, all of which related to the contractual interes&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;t coupon.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-102" decimals="-5" id="f-415" unitRef="usd">78500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c-102" decimals="4" id="f-416" unitRef="number">0.0650</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ProceedsFromIssuanceOfDebt contextRef="c-103" decimals="-5" id="f-417" unitRef="usd">75700000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c-102" decimals="4" id="f-418" unitRef="number">0.0650</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:RepaymentsOfConvertibleDebt contextRef="c-104" decimals="-5" id="f-419" unitRef="usd">16900000</us-gaap:RepaymentsOfConvertibleDebt>
    <us-gaap:InterestExpenseOperating contextRef="c-105" decimals="-3" id="f-420" unitRef="usd">178000</us-gaap:InterestExpenseOperating>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c-1" id="f-421">Stockholders&#x2019; Equity&lt;div style="margin-bottom:10pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of the Company's authorized and issued common and preferred stock as of March&#160;31, 2025 and December&#160;31, 2024: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.095%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.473%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.539%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.473%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.539%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.136%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.539%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.106%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Outstanding as of&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Authorized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common Stock, par value $0.001 per share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;600,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,674,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,674,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,099,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series&#160;C Preferred Stock, par value $0.001 per share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Offering of Common Stock and Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 16, 2024, the Company closed the December 2024 Offering (see &#x201c;Liquidity&#x201d; in Note 2 above). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Each Warrant issued in the December 2024 Offering has an initial exercise price per share of $3.76, subject to certain adjustments. The Warrants may be exercised at any time, in whole or in part, until expiration on December 16, 2029. In the event there is no effective registration statement covering the shares of common stock underlying a Warrant exercise, the Warrants may be exercised via cashless exercise. A holder (together with its affiliates and other attribution parties) may not exercise any portion of a Warrant to the extent that immediately prior to or after giving effect to such exercise the holder would own more than 4.99% (or, for certain holders who so elected prior to the issuance of the Warrants, 9.99%) of the Company&#x2019;s outstanding Common Stock immediately after exercise, which percentage may be changed at the holder&#x2019;s election to a lower or higher percentage not in excess of 19.99% upon 61 days&#x2019; notice to the Company subject to the terms of the Warrants. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As the Warrants are not indexed to the Company&#x2019;s common stock, the Company recorded a liability for the Warrants at fair value upon issuance on the Company's condensed consolidated balance sheet. The common stock warrant liability is remeasured to fair value at the end of each reporting period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2025 and December 31, 2024, no Warrants issued in the December 2024 Offering had been exercised.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 18, 2024, the Company closed the April 2024 Offering (see &#x201c;Liquidity&#x201d; in Note 2 above). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Each Pre-Funded Warrant issued in the April 2024 Offering has an initial exercise price per share of $0.001, subject to certain adjustments. The Pre-Funded Warrants may be exercised at any time until exercised in full. A holder (together with its affiliates and other attribution parties) may not exercise any portion of a Pre-Funded Warrant to the extent that immediately prior to or after giving effect to such exercise the holder would own more than 9.99% of the Company&#x2019;s outstanding Common Stock immediately after exercise, which percentage may be changed at the holder&#x2019;s election to a lower or higher percentage not in excess of 19.99% upon 61 days&#x2019; notice to the Company subject to the terms of the Pre-Funded Warrants. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As the Pre-Funded Warrants issued in the April 2024 Offering are indexed to the Company's own shares of common stock (and otherwise meet the requirements to be classified in equity), the Company recorded the consideration received from the issuance of the Pre-Funded Warrants as additional paid-in capital on the Company's condensed consolidated balance sheet as of March 31, 2025 and December 31, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2025 and December 31, 2024, no Pre-Funded Warrants had been exercised.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;At-The-Market Sales Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 13, 2024, the Company entered into an Equity Distribution Agreement (the "2024 Sales Agreement") with an outside sales agent (the "Sales Agent") for the offer and sale of its common stock for an aggregate offering price of up to $60.0&#160;million. The 2024 Sales Agreement provides that the Sales Agent is entitled to compensation in an amount equal to up to 3.0% of the gross sales proceeds of any common stock sold through the Sales Agent under the 2024 Sales Agreement, and the Company has provided the Sales Agent with certain indemnification rights. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March 31, 2025, the Company sold 518,670 shares of its common stock under the 2024 Sales Agreement. The sales were made at a weighted average price of $2.16 per share, resulting in aggregate net proceeds of $1.1 million. As of March&#160;31, 2025, there was $57.9&#160;million of remaining capacity under the 2024 Sales Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 9, 2021, the Company entered into an ATM Equity Offering&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;SM&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Sales Agreement (the &#x201c;2021 Sales Agreement&#x201d;) with outside sales agents (collectively, the &#x201c;Sales Agents&#x201d;) for the offer and sale of its common stock for an aggregate offering price of up to $300.0&#160;million. The 2021 Sales Agreement provides that the Sales Agents were entitled to compensation in an amount equal to up to 3.0% of the gross sales proceeds of any common stock sold through the Sales Agents under the 2021 Sales Agreement. During the three months ended March 31, 2024, the Company sold 543,620 shares of its common stock under the 2021 Sales Agreement at a weighted average price of $9.76 per share, resulting in aggregate net proceeds of $5.2&#160;million. The 2021 Sales Agreement was terminated in August 2024 in connection with the entry into the 2024 Sales Agreement described above.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock Options and Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Board of Directors adopted the 2023 Omnibus Incentive Plan (the &#x201c;2023 Plan&#x201d;) on March 24, 2023, pursuant to which the Company may grant stock options, restricted stock awards, restricted stock units ("RSUs") and other stock-based awards or short-term cash incentive awards to employees, directors and consultants. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2023 Plan was approved by stockholders on May 16, 2023. The aggregate number of shares of the Company&#x2019;s common stock that may be issued under the 2023 Plan will not exceed the sum of 1,166,666 shares plus any shares that may return from time to time from the 2016 Omnibus Incentive Plan (as amended, the &#x201c;2016 Plan&#x201d;) as a result of expirations, terminations or forfeitures of awards outstanding under the 2016 Plan as of May 16, 2023. At March&#160;31, 2025, the Company had 24,460 shares of common stock available for future grant under the 2023 Plan, 464,887 shares underlying outstanding RSUs and 732,165 shares underlying options outstanding to purchase common stock under the 2023 Plan. The awards granted and available for future grant under the 2023 Plan generally vest over three years and have a maximum contractual term of ten years. The 2023 Plan terminates by its terms on March&#160;24, 2033. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Following adoption of the 2023 Plan, no further awards may be made under the 2016 Plan, but outstanding awards continue to be governed by their existing terms. At March&#160;31, 2025, the Company had 90,642 shares underlying outstanding but unvested RSUs and options outstanding to purchase 902,123 shares of common stock under the 2016 Plan. The outstanding awards granted under the 2016 Plan generally vest over three years and have a maximum contractual term of ten years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 24, 2022, the Company's board of directors adopted a stock-based incentive plan (the "2022 Inducement Plan"), which provides for the discretionary grant of nonstatutory stock options, stock appreciation rights, restricted stock awards, RSU awards, performance awards, and other awards to individuals as a material inducement to entering into employment with the Company. The aggregate number of shares of the Company&#x2019;s common stock that may be issued under the 2022 Inducement Plan will not exceed 166,666 shares. At March&#160;31, 2025, the Company had 85,378 shares of common stock available for future grant under the 2022 Inducement Plan, 18,191 shares underlying outstanding but unvested RSUs and options outstanding to purchase 52,634 shares of common stock under the 2022 Inducement Plan. The 2022 Inducement Plan can be terminated by the Company's board of directors at any time.&lt;/span&gt;&lt;/div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Amended and Restated 2007 Omnibus Incentive Plan (the "2007 Incentive Plan") was adopted on M&lt;/span&gt;arch&#160;31, 2007 and terminated by its terms on March&#160;31, 2017. At March&#160;31, 2025, the Company had options outstanding to purchase 61,262 shares of common stock under the 2007 Incentive Plan. The outstanding awards granted under the 2007 Incentive Plan are fully vested and generally have a maximum contractual term of ten years.</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:ScheduleOfStockByClassTextBlock contextRef="c-1" id="f-422">&lt;div style="margin-bottom:10pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of the Company's authorized and issued common and preferred stock as of March&#160;31, 2025 and December&#160;31, 2024: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.095%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.473%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.539%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.473%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.539%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.136%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.539%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.106%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Outstanding as of&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Authorized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common Stock, par value $0.001 per share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;600,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,674,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,674,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,099,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series&#160;C Preferred Stock, par value $0.001 per share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockByClassTextBlock>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-3"
      decimals="INF"
      id="f-423"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-4"
      decimals="INF"
      id="f-424"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-3" decimals="INF" id="f-425" unitRef="shares">600000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="c-3" decimals="INF" id="f-426" unitRef="shares">36674355</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-3" decimals="INF" id="f-427" unitRef="shares">36674355</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-4" decimals="INF" id="f-428" unitRef="shares">36099991</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-106"
      decimals="INF"
      id="f-429"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-107"
      decimals="INF"
      id="f-430"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c-106"
      decimals="INF"
      id="f-431"
      unitRef="shares">1091</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c-106"
      decimals="INF"
      id="f-432"
      unitRef="shares">1091</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c-106"
      decimals="INF"
      id="f-433"
      unitRef="shares">9</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c-107"
      decimals="INF"
      id="f-434"
      unitRef="shares">9</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-108"
      decimals="INF"
      id="f-435"
      unitRef="usdPerShare">3.76</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ino:ClassOfWarrantOrRightCommonStockOwnershipPercent contextRef="c-108" decimals="4" id="f-436" unitRef="number">0.0499</ino:ClassOfWarrantOrRightCommonStockOwnershipPercent>
    <ino:ClassOfWarrantOrRightCommonStockOwnershipPriorToIssuancePercent contextRef="c-108" decimals="4" id="f-437" unitRef="number">0.0999</ino:ClassOfWarrantOrRightCommonStockOwnershipPriorToIssuancePercent>
    <ino:ClassOfWarrantOrRightCommonStockOwnershipMaximumPercent contextRef="c-108" decimals="4" id="f-438" unitRef="number">0.1999</ino:ClassOfWarrantOrRightCommonStockOwnershipMaximumPercent>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-48"
      decimals="INF"
      id="f-439"
      unitRef="usdPerShare">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ino:ClassOfWarrantOrRightCommonStockOwnershipPercent contextRef="c-46" decimals="4" id="f-440" unitRef="number">0.0999</ino:ClassOfWarrantOrRightCommonStockOwnershipPercent>
    <ino:ClassOfWarrantOrRightCommonStockOwnershipPercent contextRef="c-109" decimals="4" id="f-441" unitRef="number">0.1999</ino:ClassOfWarrantOrRightCommonStockOwnershipPercent>
    <ino:StockSalesAgreementMaximumAuthorizedAmount contextRef="c-110" decimals="-5" id="f-442" unitRef="usd">60000000</ino:StockSalesAgreementMaximumAuthorizedAmount>
    <ino:SaleOfStockSalesProceedsOfAnyCommonStockPercentage contextRef="c-110" decimals="3" id="f-443" unitRef="number">0.030</ino:SaleOfStockSalesProceedsOfAnyCommonStockPercentage>
    <ino:StockSaleAgreementAggregateNumberofSharesIssued
      contextRef="c-51"
      decimals="INF"
      id="f-444"
      unitRef="shares">518670</ino:StockSaleAgreementAggregateNumberofSharesIssued>
    <ino:StockSaleAgreementWeightedAveragePricePerShare
      contextRef="c-51"
      decimals="2"
      id="f-445"
      unitRef="usdPerShare">2.16</ino:StockSaleAgreementWeightedAveragePricePerShare>
    <ino:StockSaleAgreementAggregateProceedsFromIssuanceOfStock contextRef="c-51" decimals="-3" id="f-446" unitRef="usd">1100000</ino:StockSaleAgreementAggregateProceedsFromIssuanceOfStock>
    <ino:StockSaleAgreementRemainingCapacityAmount contextRef="c-111" decimals="-5" id="f-447" unitRef="usd">57900000</ino:StockSaleAgreementRemainingCapacityAmount>
    <ino:StockSalesAgreementMaximumAuthorizedAmount contextRef="c-112" decimals="-5" id="f-448" unitRef="usd">300000000</ino:StockSalesAgreementMaximumAuthorizedAmount>
    <ino:SaleOfStockSalesProceedsOfAnyCommonStockPercentage contextRef="c-112" decimals="3" id="f-449" unitRef="number">0.030</ino:SaleOfStockSalesProceedsOfAnyCommonStockPercentage>
    <ino:StockSaleAgreementAggregateNumberofSharesIssued
      contextRef="c-113"
      decimals="INF"
      id="f-450"
      unitRef="shares">543620</ino:StockSaleAgreementAggregateNumberofSharesIssued>
    <ino:StockSaleAgreementWeightedAveragePricePerShare
      contextRef="c-113"
      decimals="2"
      id="f-451"
      unitRef="usdPerShare">9.76</ino:StockSaleAgreementWeightedAveragePricePerShare>
    <ino:StockSaleAgreementAggregateProceedsFromIssuanceOfStock contextRef="c-113" decimals="-5" id="f-452" unitRef="usd">5200000</ino:StockSaleAgreementAggregateProceedsFromIssuanceOfStock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c-114"
      decimals="INF"
      id="f-453"
      unitRef="shares">1166666</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c-115"
      decimals="INF"
      id="f-454"
      unitRef="shares">24460</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-115"
      decimals="INF"
      id="f-455"
      unitRef="shares">464887</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:CommonStockOtherSharesOutstanding
      contextRef="c-115"
      decimals="INF"
      id="f-456"
      unitRef="shares">732165</us-gaap:CommonStockOtherSharesOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-116" id="f-457">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm contextRef="c-116" id="f-458">P10Y</ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-117"
      decimals="INF"
      id="f-459"
      unitRef="shares">90642</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:CommonStockOtherSharesOutstanding
      contextRef="c-117"
      decimals="INF"
      id="f-460"
      unitRef="shares">902123</us-gaap:CommonStockOtherSharesOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-118" id="f-461">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm contextRef="c-118" id="f-462">P10Y</ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c-119"
      decimals="INF"
      id="f-463"
      unitRef="shares">166666</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c-120"
      decimals="INF"
      id="f-464"
      unitRef="shares">85378</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-120"
      decimals="INF"
      id="f-465"
      unitRef="shares">18191</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:CommonStockOtherSharesOutstanding
      contextRef="c-120"
      decimals="INF"
      id="f-466"
      unitRef="shares">52634</us-gaap:CommonStockOtherSharesOutstanding>
    <us-gaap:CommonStockOtherSharesOutstanding
      contextRef="c-121"
      decimals="INF"
      id="f-467"
      unitRef="shares">61262</us-gaap:CommonStockOtherSharesOutstanding>
    <ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm contextRef="c-122" id="f-468">P10Y</ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm>
    <us-gaap:EarningsPerShareTextBlock contextRef="c-1" id="f-469">Net Loss Per Share &lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share is computed by dividing the net loss for the period by the weighted average number of shares of common stock outstanding during the period. The outstanding Pre-Funded Warrants (see Note 7) are included in the weighted-average common shares outstanding in the basic net loss per share calculation for the three months ended March 31, 2025 given their nominal exercise price.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Diluted net loss per share is calculated in accordance with the treasury stock method for the outstanding Warrants, stock options and RSUs and refle&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;cts the potential dilution that would occur if securities or other con&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;tracts to issue common stock were exercised or converted to common stock. The calculation of diluted net loss per share requires that, to the extent the average market price of the underlying shares for the reporting period exceeds the exercise price of the options or other securities and the presumed exercise of such securities are dilutive to net loss per share for the period, an adjustment to the net loss used in the calculation is required to remove the change in fair value of such securities from the numerator for the period. Likewise, an adjustment to the denominator is required to reflect the related dilutive shares, if any. For the three months ended March 31, 2025 and 2024, basic and diluted net loss per share were the same, as the assumed exercise or settlement of common stock warrants, stock options, service-based RSUs and performance-and market-based RSUs would have been anti-dilutive.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic and diluted net loss per share for the three months ended March 31, 2025 and 2024 are calculated as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.882%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.128%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.960%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19,694,697)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30,469,871)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Shares used to compute net loss per share, basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Weighted-average common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,478,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,291,512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Weighted-average shares underlying pre-funded warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,135,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Weighted-average common shares outstanding used to compute basic and diluted net loss per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,613,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,291,512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss per share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.51)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.882%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.128%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.960%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;          The following table summarizes potential shares of common stock that were excluded from the diluted net loss per share calculation because of their anti-dilutive effect: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.882%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.128%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.960%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,748,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,355,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service-based restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;573,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;392,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Performance-and market-based restricted stock units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,450,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,747,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c-1" id="f-470">&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share is computed by dividing the net loss for the period by the weighted average number of shares of common stock outstanding during the period. The outstanding Pre-Funded Warrants (see Note 7) are included in the weighted-average common shares outstanding in the basic net loss per share calculation for the three months ended March 31, 2025 given their nominal exercise price.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Diluted net loss per share is calculated in accordance with the treasury stock method for the outstanding Warrants, stock options and RSUs and refle&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;cts the potential dilution that would occur if securities or other con&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;tracts to issue common stock were exercised or converted to common stock. The calculation of diluted net loss per share requires that, to the extent the average market price of the underlying shares for the reporting period exceeds the exercise price of the options or other securities and the presumed exercise of such securities are dilutive to net loss per share for the period, an adjustment to the net loss used in the calculation is required to remove the change in fair value of such securities from the numerator for the period. Likewise, an adjustment to the denominator is required to reflect the related dilutive shares, if any. For the three months ended March 31, 2025 and 2024, basic and diluted net loss per share were the same, as the assumed exercise or settlement of common stock warrants, stock options, service-based RSUs and performance-and market-based RSUs would have been anti-dilutive.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock contextRef="c-1" id="f-471">&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic and diluted net loss per share for the three months ended March 31, 2025 and 2024 are calculated as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.882%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.128%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.960%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19,694,697)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30,469,871)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Shares used to compute net loss per share, basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Weighted-average common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,478,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,291,512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Weighted-average shares underlying pre-funded warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,135,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Weighted-average common shares outstanding used to compute basic and diluted net loss per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,613,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,291,512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss per share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.51)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="0" id="f-472" unitRef="usd">-19694697</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-9" decimals="0" id="f-473" unitRef="usd">-30469871</us-gaap:NetIncomeLoss>
    <ino:WeightedAverageNumberOfSharesOutstanding contextRef="c-1" decimals="0" id="f-474" unitRef="shares">36478176</ino:WeightedAverageNumberOfSharesOutstanding>
    <ino:WeightedAverageNumberOfSharesOutstanding contextRef="c-9" decimals="0" id="f-475" unitRef="shares">23291512</ino:WeightedAverageNumberOfSharesOutstanding>
    <ino:IncrementalCommonSharesAttributableToBasicAndDilutiveEffectOfPreFundedWarrants contextRef="c-1" decimals="0" id="f-476" unitRef="shares">2135477</ino:IncrementalCommonSharesAttributableToBasicAndDilutiveEffectOfPreFundedWarrants>
    <ino:IncrementalCommonSharesAttributableToBasicAndDilutiveEffectOfPreFundedWarrants contextRef="c-9" decimals="0" id="f-477" unitRef="shares">0</ino:IncrementalCommonSharesAttributableToBasicAndDilutiveEffectOfPreFundedWarrants>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="0" id="f-478" unitRef="shares">38613653</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="0" id="f-479" unitRef="shares">38613653</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-9" decimals="0" id="f-480" unitRef="shares">23291512</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-9" decimals="0" id="f-481" unitRef="shares">23291512</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-482"
      unitRef="usdPerShare">-0.51</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-483"
      unitRef="usdPerShare">-0.51</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-9"
      decimals="2"
      id="f-484"
      unitRef="usdPerShare">-1.31</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-9"
      decimals="2"
      id="f-485"
      unitRef="usdPerShare">-1.31</us-gaap:EarningsPerShareBasic>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="c-1" id="f-486">The following table summarizes potential shares of common stock that were excluded from the diluted net loss per share calculation because of their anti-dilutive effect: &lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.882%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.128%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.960%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,748,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,355,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service-based restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;573,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;392,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Performance-and market-based restricted stock units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,450,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,747,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-123" decimals="0" id="f-487" unitRef="shares">10000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-124" decimals="0" id="f-488" unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-125" decimals="0" id="f-489" unitRef="shares">1748184</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-126" decimals="0" id="f-490" unitRef="shares">1355178</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-127" decimals="0" id="f-491" unitRef="shares">573720</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-128" decimals="0" id="f-492" unitRef="shares">392120</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-129" decimals="0" id="f-493" unitRef="shares">128800</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-130" decimals="0" id="f-494" unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-131" decimals="0" id="f-495" unitRef="shares">275</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-132" decimals="0" id="f-496" unitRef="shares">275</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-1" decimals="0" id="f-497" unitRef="shares">12450979</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-9" decimals="0" id="f-498" unitRef="shares">1747573</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c-1" id="f-499">Stock-Based Compensation&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company incurs stock-based compensation expense related to service-based RSUs, performance-based RSUs and stock options. The fair value of restricted stock is determined by the closing price of the Company's common stock reported on the Nasdaq Capital Market on the date of grant. The Company estimates the fair value of stock options granted using the Black-Scholes option pricing model. The Black-Scholes option pricing model was developed for use in estimating the fair value of traded options, which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of subjective assumptions, including the expected stock price volatility and expected option life. The Company amortizes the fair value of the awards on a straight-line basis over the requisite vesting period of the awards. Expected volatility is based on historical volatility. The expected life of options granted is based on historical expected life. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant. The dividend yield is based on the fact that no dividends have been paid historically and none are currently expected to be paid in the foreseeable future. The Company recognizes forfeitures as they occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average assumptions used in the Black-Scholes model for option grants to employees and directors are presented below:&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.730%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.621%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.07%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.21%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total employee and director stock-based compensation expense recognized in the condensed consolidated statements of operations for the three months ended March 31, 2025 and 2024 was $1.4 million and $2.4 million, respectively, of which $547,000 and $1.0 million, respectively, was included in research and development expenses, and $821,000 and $1.4 million, respectively, was included in general and administrative expenses. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At March&#160;31, 2025, there was $1.9 million of total unrecognized compensation expense related to unvested stock options, which is expected to be recognized over a weighted-average period of 1.5 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average grant date fair value per share, calculated using the Black-Scholes option pricing model, was $1.60 and $6.77 for employee and director stock options granted during the three months ended March 31, 2025 and 2024, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At March&#160;31, 2025, there was $2.2 million of total unrecognized compensation expense related to unvested service-based RSUs, which is expected to be recognized over a weighted-average period of 2.0 years.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average grant date fair value per share was $1.95 and $8.39 for service-based RSUs granted during the three months ended March 31, 2025 and 2024, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of stock options granted to non-employees was estimated using the Black-Scholes pricing model. Total stock-based compensation expense for stock options and RSUs granted to non-employees for the three months ended March 31, 2025 and 2024 was $32,000 and $103,000, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Performance-and Market-Based RSUs &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2024, the Company granted performance-and market-based RSUs (such performance-based grants, the "PSU Awards") to key employees under the 2023 Plan. Each PSU was expressed as a target number of RSUs. With respect to the PSU Awards, the Company's Board of Directors established specified performance goals and corresponding performance periods over which the goals must be attained, the satisfaction of which are conditions to earning the PSU Awards and vesting of the underlying RSUs. As of March&#160;31, 2025, 83,800 performance-and market-based RSU's were outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Of the target number of RSUs underlying each PSU Award, up to 70% (the "Milestone-based RSUs") will vest based on the achievement of specified milestones relating to the development, regulatory status and commercialization of the Company&#x2019;s lead product candidate INO-3107 (each, a "Milestone," and collectively, the "Milestones"). Each Milestone has a specified deadline for achievement ranging between the end of 2025 and the end of 2027.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The remaining 30% of the target number of RSUs underlying each PSU Award (the "Market-based RSUs") will be eligible to vest based on the Company&#x2019;s achievement of total stockholder return relative to a peer group consisting of companies in the Russell 2000 Biotechnology Subsector index (the &#x201c;Relative TSR&#x201d;) over the period beginning on June 1, 2024 and ending on December 31, 2027 (the &#x201c;Performance Period&#x201d;), expressed as a percentile ranking.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The number of Market-based RSUs, if any, actually earned based on the achievement of the Relative TSR goal may range from 50% of the target number of RSUs for performance at a specified threshold percentile, to 100% of the target number of RSUs for performance at the target percentile, and up to 150% of the target number of RSUs for performance at or above a specified maximum percentile. In the event that actual Relative TSR performance is between the threshold and target levels or between the target and maximum levels, the number of RSUs earned based on Relative TSR will be determined based on linear interpolation between the specified percentiles. If the Company&#x2019;s actual Relative TSR performance is below the threshold percentile, then no RSUs would be earned based on Relative TSR. The number of RSUs earned based on Relative TSR may not exceed the target number of RSUs eligible to vest based on Relative TSR if the Company&#x2019;s total stockholder return is negative for the Performance Period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company values the Milestone-based RSUs based on the grant date closing price per share. The Company recognizes stock-based compensation expense over the performance period, if it is probable that the performance condition will be achieved. Adjustments to stock-based compensation expense are made, as needed, each reporting period based on changes in the Company's estimate of the number of units that are probable of vesting. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company values the Market-based RSUs on the grant date using the Monte Carlo simulation method, a generally accepted statistical technique used to simulate a range of possible future stock prices for the Company and the peer group. The determination of fair value is affected by the Company's stock price and a number of assumptions including the expected volatility and the risk-free interest rate. The Company will recognize stock-based compensation expense ratably over the performance period of the award. The market-based RSUs will cliff-vest at the end of the three-year period ranging from zero percent to 150 percent of the target number of awards granted. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The significant assumptions used in the Monte Carlo simulation method were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:80.040%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.760%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.60%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.61&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The grant date fair value of the Milestone-based RSUs was $643,000 based on the grant date closing price per share of $10.96. As of March&#160;31, 2025, the underlying performance milestones of the Milestone-based RSUs were determined to be not probable of achievement, and no stock-based compensation expense was recognized for the three months then ended.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The grant date fair value of the Market-based RSUs was $269,000 based on the fair value of $10.69 per share as determined using the Monte Carlo simulation method. For the three months ended March 31, 2025, the Company recognized $19,000 in stock-based compensation for the Market-based RSUs.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;December 2024 Performance-Based Awards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2024, the Company granted performance-based stock options and RSUs (such performance-based grants, the "December 2024 Awards") to key employees under the 2023 Plan. Each award was expressed as a target number of stock options and RSUs. With respect to the December 2024 Awards, the Company's Board of Directors established specified performance goals and a corresponding performance period over which the goals must be attained, the satisfaction of which are conditions to earning the December 2024 Awards and vesting of the underlying stock options and RSUs. As of March&#160;31, 2025, December 2024 Awards were outstanding covering 25,686 shares of common stock underlying stock options and 19,314 shares of common stock underlying RSUs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The grant date fair value of the performance-based RSUs was $34,000 based on the grant date closing price per share of $1.78. The grant date fair value of the performance-based stock options was $38,000 based on the Black-Scholes per share value of $1.46. As of March&#160;31, 2025, the underlying performance milestones of the December 2024 Awards were determined to be not probable of achievement, and no stock-based compensation expense was recognized for the three months then ended.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock contextRef="c-1" id="f-500">&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company incurs stock-based compensation expense related to service-based RSUs, performance-based RSUs and stock options. The fair value of restricted stock is determined by the closing price of the Company's common stock reported on the Nasdaq Capital Market on the date of grant. The Company estimates the fair value of stock options granted using the Black-Scholes option pricing model. The Black-Scholes option pricing model was developed for use in estimating the fair value of traded options, which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of subjective assumptions, including the expected stock price volatility and expected option life. The Company amortizes the fair value of the awards on a straight-line basis over the requisite vesting period of the awards. Expected volatility is based on historical volatility. The expected life of options granted is based on historical expected life. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant. The dividend yield is based on the fact that no dividends have been paid historically and none are currently expected to be paid in the foreseeable future. The Company recognizes forfeitures as they occur.&lt;/span&gt;&lt;/div&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="c-1" id="f-501">&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average assumptions used in the Black-Scholes model for option grants to employees and directors are presented below:&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.730%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.621%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.07%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.21%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-133" decimals="4" id="f-502" unitRef="number">0.0407</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-134" decimals="4" id="f-503" unitRef="number">0.0421</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-133" decimals="2" id="f-504" unitRef="number">1.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-134" decimals="2" id="f-505" unitRef="number">1.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-133" id="f-506">P5Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-134" id="f-507">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c-133"
      decimals="INF"
      id="f-508"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c-134"
      decimals="INF"
      id="f-509"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensation contextRef="c-135" decimals="-5" id="f-510" unitRef="usd">1400000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-136" decimals="-5" id="f-511" unitRef="usd">2400000</us-gaap:ShareBasedCompensation>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-137" decimals="-3" id="f-512" unitRef="usd">547000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-138" decimals="-3" id="f-513" unitRef="usd">1000000.0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-139" decimals="-3" id="f-514" unitRef="usd">821000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-140" decimals="-5" id="f-515" unitRef="usd">1400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="c-3" decimals="-5" id="f-516" unitRef="usd">1900000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-1" id="f-517">P1Y6M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-1"
      decimals="2"
      id="f-518"
      unitRef="usdPerShare">1.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-9"
      decimals="2"
      id="f-519"
      unitRef="usdPerShare">6.77</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="c-141" decimals="-5" id="f-520" unitRef="usd">2200000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-142" id="f-521">P2Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-142"
      decimals="2"
      id="f-522"
      unitRef="usdPerShare">1.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-143"
      decimals="2"
      id="f-523"
      unitRef="usdPerShare">8.39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensation contextRef="c-144" decimals="-3" id="f-524" unitRef="usd">32000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-145" decimals="-3" id="f-525" unitRef="usd">103000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-146"
      decimals="INF"
      id="f-526"
      unitRef="shares">83800</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="c-147" decimals="2" id="f-527" unitRef="number">0.70</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="c-148" decimals="2" id="f-528" unitRef="number">0.30</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPercentage contextRef="c-149" decimals="2" id="f-529" unitRef="number">0.50</ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPercentage>
    <ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPercentage contextRef="c-150" decimals="2" id="f-530" unitRef="number">1</ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPercentage>
    <ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPercentage contextRef="c-1" decimals="2" id="f-531" unitRef="number">1.50</ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-148" id="f-532">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="c-151" decimals="2" id="f-533" unitRef="number">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="c-152" decimals="2" id="f-534" unitRef="number">1.50</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <ino:ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock contextRef="c-1" id="f-535">&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The significant assumptions used in the Monte Carlo simulation method were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:80.040%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.760%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.60%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.61&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ino:ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-148" decimals="4" id="f-536" unitRef="number">0.0460</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-148" decimals="2" id="f-537" unitRef="number">0.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-148" id="f-538">P3Y7M9D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c-148"
      decimals="INF"
      id="f-539"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue contextRef="c-147" decimals="-3" id="f-540" unitRef="usd">643000</ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-147"
      decimals="2"
      id="f-541"
      unitRef="usdPerShare">10.96</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensation contextRef="c-147" decimals="INF" id="f-542" unitRef="usd">0</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-147" decimals="INF" id="f-543" unitRef="usd">0</us-gaap:ShareBasedCompensation>
    <ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue contextRef="c-148" decimals="-3" id="f-544" unitRef="usd">269000</ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-148"
      decimals="2"
      id="f-545"
      unitRef="usdPerShare">10.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensation contextRef="c-148" decimals="-3" id="f-546" unitRef="usd">19000</us-gaap:ShareBasedCompensation>
    <ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardUnderlyingCommonStock contextRef="c-153" decimals="0" id="f-547" unitRef="shares">25686</ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardUnderlyingCommonStock>
    <ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardUnderlyingCommonStock contextRef="c-154" decimals="0" id="f-548" unitRef="shares">19314</ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardUnderlyingCommonStock>
    <ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsGrantDateFairValue contextRef="c-155" decimals="-3" id="f-549" unitRef="usd">34000</ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsGrantDateFairValue>
    <ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantDateClosingSharePrice
      contextRef="c-155"
      decimals="2"
      id="f-550"
      unitRef="usdPerShare">1.78</ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantDateClosingSharePrice>
    <ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsGrantDateFairValue contextRef="c-156" decimals="-3" id="f-551" unitRef="usd">38000</ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-157"
      decimals="2"
      id="f-552"
      unitRef="usdPerShare">1.46</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-147" decimals="INF" id="f-553" unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="c-1" id="f-554">Related Party Transactions&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Plumbline Life Sciences, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company owned 597,808 shares of common stock in PLS as of March&#160;31, 2025, representing an ownership interest of 16.7%. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's investment in PLS is recorded as investment in affiliated entity on the condensed consolidated balance sheet as of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;March&#160;31, 2025 and &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December 31, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2024&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and was valued at &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$2.3 million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$1.6 million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, respectively, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;based on the closing price of the shares on the Korea New Exchange Market at the applicable balance sheet date&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. O&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ne of the Company's directors, Dr.&#160;David B. Weiner, acts as a consultant to PLS.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;The Wistar Institute&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Dr. Weiner is a director of the Vaccine Center of The Wistar Institute ("Wistar") and an Executive Vice President of Wistar.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2016, the Company entered into collaborative research agreements with Wistar&#160;for preventive and therapeutic DNA-based immunotherapy applications and products developed by&#160;Dr. Weiner and Wistar for the treatment of cancers and infectious diseases. Under the terms of the agreement, the Company reimbursed Wistar for all direct and indirect costs incurred in the conduct of the collaborative research, not to exceed $3.1 million during the five-year term of the agreements. In 2021, upon expiration of the 2016 agreements, the Company entered into new collaborative research agreements with Wistar&#160;with the same terms. The Company has the exclusive right to in-license new intellectual property developed under this agreement.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2020, the Company received a $10.7&#160;million sub-grant through Wistar, which was amended in 2021 to $13.6&#160;million, for the preclinical development and translational studies of DNA-Encoded Monoclonal Antibodies (DMAbs) as countermeasures for COVID-19. In August 2024, the sub-grant was amended to a total of $12.5&#160;million in funding through September 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2022, the Company received a $1.2&#160;million sub-grant through Wistar, which was amended in 2024 to $2.4&#160;million with funding through November 2024, with an option for an additional $4.2&#160;million in funding that extends the sub-grant through November 2027. The Company will support the Wistar lead consortium in the research and development of synthetic DNA-launched nanoparticles (DLNPs) for vaccination against HIV infection.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred grant funding recognized from Wistar and recorded as contra-research and development expense is related to work performed by the Company on the research sub-contract agreements. For the three months ended March 31, 2025 and 2024, the Company recorded $286,000 and $140,000, respectively. &lt;/span&gt;&lt;/div&gt;Research and development expenses recorded from Wistar relate primarily to collaborative research agreements. Research and development expenses recorded from Wistar for the three months ended March 31, 2025 and 2024 were $0 and $475,000, respectively. At March&#160;31, 2025 and December&#160;31, 2024, the Company had an accounts receivable balance of $1.3 million and $1.2 million, respectively, and an accounts payable and accrued liability balance of $470,000 and $1.4 million, respectively, related to Wistar.</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="c-158"
      decimals="INF"
      id="f-555"
      unitRef="shares">597808</us-gaap:InvestmentOwnedBalanceShares>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners contextRef="c-158" decimals="3" id="f-556" unitRef="number">0.167</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-159" decimals="-5" id="f-557" unitRef="usd">2300000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-160" decimals="-5" id="f-558" unitRef="usd">1600000</us-gaap:AccountsReceivableNetCurrent>
    <ino:CollaborativeAgreementExpensesToReimburse contextRef="c-161" decimals="-5" id="f-559" unitRef="usd">3100000</ino:CollaborativeAgreementExpensesToReimburse>
    <ino:CollaborativeArrangementTerm contextRef="c-161" id="f-560">P5Y</ino:CollaborativeArrangementTerm>
    <ino:CollaborativeAgreementAwardedAmount contextRef="c-162" decimals="-5" id="f-561" unitRef="usd">10700000</ino:CollaborativeAgreementAwardedAmount>
    <ino:CollaborativeAgreementAmendedAmount contextRef="c-163" decimals="-5" id="f-562" unitRef="usd">13600000</ino:CollaborativeAgreementAmendedAmount>
    <ino:CollaborativeAgreementAmendedAmount contextRef="c-164" decimals="-5" id="f-563" unitRef="usd">12500000</ino:CollaborativeAgreementAmendedAmount>
    <ino:CollaborativeAgreementAwardedAmount contextRef="c-165" decimals="-5" id="f-564" unitRef="usd">1200000</ino:CollaborativeAgreementAwardedAmount>
    <ino:CollaborativeAgreementAwardedAmount contextRef="c-166" decimals="-5" id="f-565" unitRef="usd">2400000</ino:CollaborativeAgreementAwardedAmount>
    <ino:CollaborativeAgreementAwardedOptionAmount contextRef="c-166" decimals="-5" id="f-566" unitRef="usd">4200000</ino:CollaborativeAgreementAwardedOptionAmount>
    <ino:GrantProceedsReceived contextRef="c-167" decimals="-3" id="f-567" unitRef="usd">286000</ino:GrantProceedsReceived>
    <ino:GrantProceedsReceived contextRef="c-168" decimals="-3" id="f-568" unitRef="usd">140000</ino:GrantProceedsReceived>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-169" decimals="-3" id="f-569" unitRef="usd">0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-170" decimals="-3" id="f-570" unitRef="usd">475000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-171" decimals="-5" id="f-571" unitRef="usd">1300000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-172" decimals="-5" id="f-572" unitRef="usd">1200000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c-171" decimals="-3" id="f-573" unitRef="usd">470000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c-172" decimals="-5" id="f-574" unitRef="usd">1400000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c-1" id="f-575">Commitments and Contingencies                                                  &lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company leases approximately 56,600 square feet of office, laboratory, and manufacturing space in San Diego, California and approximately 57,400 square feet of office space in Plymouth Meeting, Pennsylvania under various non-cancellable operating lease agreements with remaining lease terms as of March&#160;31, 2025&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; of 2.2 to 4.8 ye&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ars, which represent the non-cancellable periods of the leases. The Company has excluded the extension options from its lease terms in the calculation of future lease payments as they are not reasonably certain to be exercised. The Company's lease payments consist primarily of fixed rental payments for the right to use the underlying leased assets over the lease terms as well as payments for common area maintenance and administrative services. The Company has received customary incentives from its landlords, such as reimbursements for tenant improvements and rent abatement periods, which effectively reduce the total lease payments owed for these leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The base rent adjusts periodically throughout the term of the lease. Rent payments under the lease will include base rent with an annual increase of approximately two to three percent, and additional monthly fees to cover the Company's share of certain facility expenses, including utilities, property taxes, insurance and maintenance. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company performed an evaluation of its contracts with customers and suppliers in accordance with ASC Topic 842 and determined that, except for the real estate leases described above and various copier leases, none of its other contracts contain a right-of-use asset. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease right-of-use assets and liabilities on the condensed consolidated balance sheet represents the present value of the remaining lease payments over the remaining lease terms. Payments for additional monthly fees to cover the Company's share of certain facility expenses are not included in operating lease right-of-use assets and liabilities. The Company uses its incremental borrowing rate to calculate the present value of its lease payments, as the implicit rates in the leases are not readily determinable.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%"&gt;As of March&#160;31, 2025, the maturities of the Company's operating lease liabilities were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.449%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.351%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remainder of 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,637,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,592,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,992,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,319,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,132,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Total remaining lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,672,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: present value adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,401,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,271,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,576,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,695,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.1 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.0%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease costs included in operating expenses in the condensed consolidated statements of operations for the three months ended March 31, 2025 and 2024 were $515,000 and $837,000, respectively. Operating lease costs consisting of the fixed lease payments included in operating lease liabilities are recorded on a straight-line basis over the lease terms. Variable lease costs are recorded as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2023, the Company entered into agreements to sublease a total of approximately 11,400 square feet in its Plymouth Meeting headquarters with sublease terms through December 31, 2026.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2024, the Company amended the sublease agreements for its Plymouth Meeting headquarters to extend one sublease term through December 31, 2027 and the other through December 31, 2029.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the normal course of business, the Company is a party to a variety of agreements pursuant to which it may be obligated to indemnify the other party. It is not possible to predict the maximum potential amount of future payments under these types of agreements due to the conditional nature of the Company's obligations and the unique facts and circumstances involved in each particular agreement. Historically, payments made by the Company under these types of agreements have not had a material effect on its business, consolidated results of operations or financial condition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Legal Proceedings &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;VGXI Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2020, the Company filed a complaint in the Court of Common Pleas of Montgomery County, Pennsylvania against VGXI, Inc. and GeneOne Life Science, Inc., or GeneOne, and together with VGXI, Inc. collectively referred to as VGXI, alleging that VGXI had materially breached the Company&#x2019;s supply agreement with them. The complaint seeks declaratory judgments, specific performance of the agreement, injunctive relief, an accounting, damages, attorneys&#x2019; fees, interest, costs and other relief from VGXI. In June 2020, the Company filed a petition for preliminary injunction, which was denied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Following an appeal by the Company, in July 2020, VGXI filed counterclaims against the Company, alleging that the Company had breached the supply agreement, as well as misappropriation of trade secrets and unjust enrichment. The counterclaims seek injunctive relief, damages, attorneys&#x2019; fees, interest, costs and other relief from the Company. VGXI also filed a third-party complaint against Ology Bioservices, Inc., a contract manufacturing organization that the Company had engaged to provide services similar to those that were being provided by VGXI, but VGXI later discontinued its third-party claims. The Company filed an answer to VGXI&#x2019;s counterclaims, disputing the allegations and the claims raised in VGXI&#x2019;s filing. In October 2020, the Company filed a notice of discontinuance of appeal with the Pennsylvania Superior Court. A trial date for the litigation has not been set.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company intends to aggressively prosecute the claims set forth in its complaint against VGXI and to vigorously defend itself against VGXI&#x2019;s counterclaims.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;GeneOne Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2020, GeneOne filed a complaint in the Court of Common Pleas of Montgomery County, Pennsylvania against the Company, alleging that the Company had breached the CELLECTRA Device License Agreement, or the Agreement, between the Company and GeneOne. The Company terminated the Agreement in October 2020. The complaint asserts claims for breach of contract, declaratory judgment, unfair competition, and unjust enrichment. The complaint seeks injunctive relief, an accounting, damages, disgorgement of profits, attorneys&#x2019; fees, interest, and other relief from the Company. The Company filed preliminary objections to the complaint, which were overruled by the court. In September 2021, the Company filed an answer to the complaint, new matter, and counterclaims. The Company&#x2019;s counterclaims allege that GeneOne breached the Agreement and assert claims for breach of contract and declaratory judgment.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The counterclaims seek damages, interest, expenses, attorney&#x2019;s fees, and costs. In October 2021, GeneOne filed its answer to the Company&#x2019;s counterclaims and new matter. On February 29, 2024, the Company filed a motion for summary judgment. On April 1, 2024, GeneOne filed an opposition to the Company&#x2019;s motion for summary judgment. On June 28, 2024, the court denied the motion for summary judgment. The court has set a trial date of August 19, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company intends to aggressively prosecute the claims set forth in its counterclaims against GeneOne and to vigorously defend itself against the claims in GeneOne&#x2019;s complaint. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company may be involved in disputes, including litigation, relating to claims arising out of operations in the normal course of its business. Any of these claims could subject the Company to costly legal expenses and, while the Company generally believes that it has adequate insurance to cover many different types of liabilities, its insurance carriers may deny coverage or its policy limits may be inadequate to fully satisfy any damage awards or settlements. If this were to happen, the payment of any such awards could have a material adverse effect on the Company's consolidated results of operations and financial position. Additionally, any such claims, whether or not successful, could damage the Company's reputation and business. Except as described above, the Company is not a party to any legal proceedings, the adverse outcome of which, in management&#x2019;s opinion, individually or in the aggregate, would be reasonably expected to have a material adverse effect on the Company&#x2019;s consolidated results of operations or financial position.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <ino:LesseeOperatingLeaseAreaofLandUnderLease contextRef="c-173" decimals="0" id="f-576" unitRef="sqft">56600</ino:LesseeOperatingLeaseAreaofLandUnderLease>
    <ino:LesseeOperatingLeaseAreaofLandUnderLease contextRef="c-174" decimals="0" id="f-577" unitRef="sqft">57400</ino:LesseeOperatingLeaseAreaofLandUnderLease>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm contextRef="c-175" id="f-578">P2Y2M12D</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm contextRef="c-176" id="f-579">P4Y9M18D</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <ino:LesseeOperatingLeaseBaseRatePercentageIncreaseDecrease contextRef="c-177" decimals="2" id="f-580" unitRef="number">0.02</ino:LesseeOperatingLeaseBaseRatePercentageIncreaseDecrease>
    <ino:LesseeOperatingLeaseBaseRatePercentageIncreaseDecrease contextRef="c-178" decimals="2" id="f-581" unitRef="number">0.03</ino:LesseeOperatingLeaseBaseRatePercentageIncreaseDecrease>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="c-1" id="f-582">&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%"&gt;As of March&#160;31, 2025, the maturities of the Company's operating lease liabilities were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.449%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.351%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remainder of 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,637,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,592,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,992,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,319,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,132,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Total remaining lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,672,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: present value adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,401,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,271,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,576,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,695,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.1 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.0%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear contextRef="c-3" decimals="-3" id="f-583" unitRef="usd">2637000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c-3" decimals="-3" id="f-584" unitRef="usd">3592000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="c-3" decimals="-3" id="f-585" unitRef="usd">2992000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="c-3" decimals="-3" id="f-586" unitRef="usd">2319000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour contextRef="c-3" decimals="-3" id="f-587" unitRef="usd">2132000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c-3" decimals="-3" id="f-588" unitRef="usd">13672000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="c-3" decimals="-3" id="f-589" unitRef="usd">2401000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="c-3" decimals="-3" id="f-590" unitRef="usd">11271000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-3" decimals="-3" id="f-591" unitRef="usd">2576000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-3" decimals="-3" id="f-592" unitRef="usd">8695000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-3" id="f-593">P4Y1M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-3" decimals="3" id="f-594" unitRef="number">0.090</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LeaseCost contextRef="c-1" decimals="-3" id="f-595" unitRef="usd">515000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost contextRef="c-9" decimals="-3" id="f-596" unitRef="usd">837000</us-gaap:LeaseCost>
    <ino:LesseeOperatingLeaseAreaofLandUnderLease contextRef="c-179" decimals="0" id="f-597" unitRef="sqft">11400</ino:LesseeOperatingLeaseAreaofLandUnderLease>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="c-1" id="f-598">Collaborative Agreements&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Advaccine Biopharmaceuticals Suzhou Co., Ltd. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2020, the Company entered into a Collaboration and License Agreement with Advaccine Biopharmaceuticals Suzhou Co., Ltd. (&#x201c;Advaccine&#x201d;), which was amended and restated in 2021 (as amended and restated, the &#x201c;Advaccine Agreement&#x201d;). Under the terms of the Advaccine Agreement, the Company granted to Advaccine the exclusive right to develop, manufacture and commercialize the Company&#x2019;s vaccine candidate INO-4800 within the territories of China, Taiwan, Hong Kong and Macau (referred to collectively as &#x201c;Greater China&#x201d;) and 33 additional countries in Asia. The 2021 amendment related to a collaboration between the Company and Advaccine to jointly conduct a global Phase 3 segment of the Company&#x2019;s clinical trial of INO-4800 that was planned. The parties were jointly participating in the trial and were to equally share the global development costs for the trial, including the Company&#x2019;s manufacturing costs to supply INO-4800. Advaccine agreed to be fully responsible for conducting the trial in Greater China, including its costs and expenses incurred. The Company has discontinued its internally funded efforts to develop INO-4800 as a COVID-19 heterologous booster vaccine. Advaccine continues to develop INO-4800 with its own resources under the terms of the Advaccine Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the 2021 amendment, the Company determined that the global Phase 3 trial component of the agreement was a collaboration and not a contract with a customer and therefore accounted for the 2021 amendment under ASC Topic 808. Reimbursements from Advaccine were recognized as contra-research development expense on the condensed consolidated statement of operations once earned and collectibility was assured. No funding was received from Advaccine during the three months ended March 31, 2024 or 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ApolloBio Corporation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2017, the Company entered into an Amended and Restated License and Collaboration Agreement (the "ApolloBio Agreement"),&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;with ApolloBio Corporation ("ApolloBio"), which was amended in June 2023. Under the terms of the ApolloBio Agreement, the Company granted to ApolloBio the exclusive right to develop and commercialize&#160;VGX-3100, its DNA immunotherapy product candidate designed to treat&#160;pre-cancers&#160;caused by HPV, within the agreed upon territories.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is entitled to receive up to an aggregate of $20.0 million, less required income, withholding or other taxes, upon the achievement of specified milestones related to the regulatory approval of&#160;VGX-3100&#160;in accordance with the ApolloBio Agreement. In the event that&#160;VGX-3100 is approved for marketing, the Company will be entitled to receive royalty payments based on a tiered percentage of annual net sales, with such percentage being in the&#160;low-&#160;to&#160;mid-teens,&#160;subject to reduction in the event of generic competition in a particular territory. ApolloBio&#x2019;s obligation to pay royalties will continue for 10 years after the first commercial sale in a particular territory or, if later, until the expiration of the&#160;last-to-expire&#160;patent covering the licensed products in the specified territory.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; During the three months ended March 31, 2025 and 2024, the Company received $65,000 and $0, respectively, from the ApolloBio Agreement that was recorded as revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Coalition for Epidemic Preparedness Innovations &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company previously entered into agreements with the Coalition for Epidemic Preparedness Innovations (CEPI), pursuant to which the Company intended to develop vaccine candidates against Lassa fever and MERS. As part of the arrangement between the parties, CEPI agreed to fund up to an aggregate of $56&#160;million of costs over a five-year period for preclinical studies, as well as planned Phase 1 and Phase 2 clinical trials, to be conducted by the Company and collaborators, with funding from CEPI based on the achievement of identified milestones. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2022, the Company announced that it and CEPI would discontinue the development of these product candidates targeting Lassa fever and MERS, following the initial analysis of data from the studies conducted by the Company and funded by CEPI. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March 31, 2025 and 2024, no amounts were recorded as contra-research and development expense related to the CEPI grants. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the third quarter of 2024&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the Company received funding of $1.6&#160;million in connection with the final close-out of these grants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Bill &amp;amp; Melinda Gates Foundation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2018, Gates awarded and funded the Company a grant of $2.2 million to advance the development of DMAbs to address issues in infectious disease prevention and therapy. This technology has high relevance for the control of influenza and HIV. This next-generation approach to the delivery of monoclonal antibodies would make the technology accessible to low and middle-income countries. In 2019, Gates funded an additional $1.1 million for the project. During the three months ended March 31, 2025 and 2024, the Company recorded $0 and $39,000, respectively, as contra-research and development expense related to the grant.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <ino:CollaborationAgreementAdditionalRevenueToBeAchieved contextRef="c-180" decimals="-5" id="f-599" unitRef="usd">20000000.0</ino:CollaborationAgreementAdditionalRevenueToBeAchieved>
    <ino:CollaborationAgreementRoyaltyPeriod contextRef="c-180" id="f-600">P10Y</ino:CollaborationAgreementRoyaltyPeriod>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-180" decimals="-3" id="f-601" unitRef="usd">65000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-181" decimals="-3" id="f-602" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <ino:CollaborativeAgreementFundingToBeReceived contextRef="c-182" decimals="-6" id="f-603" unitRef="usd">56000000</ino:CollaborativeAgreementFundingToBeReceived>
    <ino:CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment contextRef="c-182" id="f-604">P5Y</ino:CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment>
    <ino:CollaborativeAgreementFundingReceived contextRef="c-182" decimals="-5" id="f-605" unitRef="usd">0</ino:CollaborativeAgreementFundingReceived>
    <ino:CollaborativeAgreementFundingReceived contextRef="c-183" decimals="-5" id="f-606" unitRef="usd">0</ino:CollaborativeAgreementFundingReceived>
    <ino:CollaborativeAgreementFundingReceived contextRef="c-184" decimals="-5" id="f-607" unitRef="usd">1600000</ino:CollaborativeAgreementFundingReceived>
    <ino:CollaborativeAgreementFundingReceived contextRef="c-185" decimals="-5" id="f-608" unitRef="usd">2200000</ino:CollaborativeAgreementFundingReceived>
    <ino:CollaborativeAgreementFundingReceived contextRef="c-186" decimals="-5" id="f-609" unitRef="usd">1100000</ino:CollaborativeAgreementFundingReceived>
    <ino:CollaborativeAgreementFundingReceived contextRef="c-187" decimals="-3" id="f-610" unitRef="usd">0</ino:CollaborativeAgreementFundingReceived>
    <ino:CollaborativeAgreementFundingReceived contextRef="c-188" decimals="-3" id="f-611" unitRef="usd">39000</ino:CollaborativeAgreementFundingReceived>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c-1" id="f-612">Income Taxes &lt;div style="margin-bottom:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses an estimated annual effective tax rate, which is based on expected annual income, statutory tax rates and tax planning opportunities available in the various jurisdictions in which the Company operates, to determine its quarterly provision for income taxes. Certain significant or unusual items are separately recognized in the quarter in which they occur and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;can be a source of variability in the effective tax rates from quarter to quarter.&#160;Due to the adoption of ASU 2019-12 which removes the exception under ASC 740-20-45-7 to consider all sources of income in order to determine the tax benefit resulting from a loss from continuing operations, ASC 740-20-45-7 no longer applies.&lt;/span&gt;&lt;/div&gt;&#160;For the three months ended March 31, 2025 and 2024, the Company did not record any income tax provision/(benefit) due to the Company&#x2019;s history of net operating losses generated and the maintenance of a full valuation allowance against its net deferred tax assets.</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="c-1" id="f-613">Geneos Therapeutics, Inc. &lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2016, the Company formed Geneos Therapeutics ("Geneos") to develop and commercialize neoantigen-based personalized cancer therapies. The Company's Chief Scientific Officer Dr. Laurent Humeau is on the Board of Directors of Geneos. The Company's director Dr.&#160;David B. Weiner is the Chairman of the Scientific Advisory Board of Geneos.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March 31, 2025, the Company held 23% of the outstanding equity of Geneos on an as-converted to common stock basis. The Company accounts for its common stock investment in Geneos as an equity method investment under ASC 323. Due to continuing net losses of Geneos, the Company&#x2019;s investment had been reduced to $0 as of each of March 31, 2025 and December 31, 2024. The Company has not made any further investment in Geneos. The Company will not reduce its investment below $0 and will not record its share of further net losses of Geneos, as the Company has no obligation to fund Geneos.&lt;/span&gt;&lt;/div&gt;The Company continues to exclusively license its immunotherapy platform and CELLECTRA&#160;technology to Geneos to be used in the field of personalized, neoantigen-based therapy for cancer. The license agreement provides for potential royalty payments to the Company in the event that Geneos commercializes any products using the licensed technology. The Company is not obligated to use any of its assets to fund the future operations of Geneos.</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:MinorityInterestOwnershipPercentageByParent contextRef="c-189" decimals="2" id="f-614" unitRef="number">0.23</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:EquityMethodInvestments contextRef="c-190" decimals="-3" id="f-615" unitRef="usd">0</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments contextRef="c-189" decimals="-3" id="f-616" unitRef="usd">0</us-gaap:EquityMethodInvestments>
    <ino:EquityMethodInvestmentsMinimum contextRef="c-189" decimals="-3" id="f-617" unitRef="usd">0</ino:EquityMethodInvestmentsMinimum>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="c-1" id="f-618">Segment Information&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company operates as one reportable segment in the United States, which includes all activities related to the development and commercialization of its DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's Chief Executive Officer (CEO) is its Chief Operating Decision Maker (CODM), responsible for allocating resources and assessing Company performance using aggregated financial information. Utilizing aggregated financial information enables the CODM to determine the most appropriate resource allocation across the organization, research and development projects or other initiatives consistent with the Company's corporate objectives. The CODM primarily uses total net loss as reported on the statements of operations and comprehensive loss to measure segment loss, supplemented by certain additional significant expense details reflected in the table below. The measure of segment assets is reported on the consolidated balance sheet as total assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Detailed information regarding the Company's single operating segment's revenues, expenses and operating loss are as follows:  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:69.075%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.373%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.522%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue from collaborative arrangements &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Less: &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;INO-3107&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,507,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,645,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;INO-3112 and other Immuno-oncology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,315,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,020,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Other programs (a)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;623,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Engineering and device-related&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,061,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,751,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;553,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,060,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Other unallocated expenses &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,545,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,811,962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,024,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,571,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,115,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,484,969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;808,077&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(177,833)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value of common stock warrant liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,712,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain (loss) on investment in affiliated entity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;695,131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(126,018)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net unrealized gain on available-for-sale equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140,234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(482)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(682,218)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19,694,697)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30,469,871)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:24.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(a) Net of contributions received from grant agreements and recorded as contra-research and development expense.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="c-1"
      decimals="INF"
      id="f-619"
      unitRef="segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="c-1" id="f-620">&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Detailed information regarding the Company's single operating segment's revenues, expenses and operating loss are as follows:  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:69.075%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.373%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.522%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue from collaborative arrangements &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Less: &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;INO-3107&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,507,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,645,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;INO-3112 and other Immuno-oncology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,315,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,020,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Other programs (a)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;623,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Engineering and device-related&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,061,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,751,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;553,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,060,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Other unallocated expenses &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,545,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,811,962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,024,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,571,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,115,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,484,969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;808,077&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(177,833)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value of common stock warrant liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,712,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain (loss) on investment in affiliated entity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;695,131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(126,018)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net unrealized gain on available-for-sale equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140,234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(482)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(682,218)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19,694,697)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30,469,871)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:24.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(a) Net of contributions received from grant agreements and recorded as contra-research and development expense.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-191" decimals="0" id="f-621" unitRef="usd">65343</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-192" decimals="0" id="f-622" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-193" decimals="0" id="f-623" unitRef="usd">3507342</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-194" decimals="0" id="f-624" unitRef="usd">7645664</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-195" decimals="0" id="f-625" unitRef="usd">1315084</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-196" decimals="0" id="f-626" unitRef="usd">2020750</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-197" decimals="0" id="f-627" unitRef="usd">107425</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-198" decimals="0" id="f-628" unitRef="usd">623666</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-199" decimals="0" id="f-629" unitRef="usd">5061810</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-200" decimals="0" id="f-630" unitRef="usd">3751261</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-201" decimals="0" id="f-631" unitRef="usd">553394</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-202" decimals="0" id="f-632" unitRef="usd">1060487</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-203" decimals="0" id="f-633" unitRef="usd">5545847</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-204" decimals="0" id="f-634" unitRef="usd">5811962</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-191" decimals="0" id="f-635" unitRef="usd">9024970</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-192" decimals="0" id="f-636" unitRef="usd">10571179</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses contextRef="c-191" decimals="0" id="f-637" unitRef="usd">25115872</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-192" decimals="0" id="f-638" unitRef="usd">31484969</us-gaap:OperatingExpenses>
    <us-gaap:InvestmentIncomeInterest contextRef="c-191" decimals="0" id="f-639" unitRef="usd">808077</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="c-192" decimals="0" id="f-640" unitRef="usd">1500290</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpenseNonoperating contextRef="c-191" decimals="0" id="f-641" unitRef="usd">0</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating contextRef="c-192" decimals="0" id="f-642" unitRef="usd">177833</us-gaap:InterestExpenseNonoperating>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c-191" decimals="0" id="f-643" unitRef="usd">3712872</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c-192" decimals="0" id="f-644" unitRef="usd">0</us-gaap:FairValueAdjustmentOfWarrants>
    <ino:ChangeInValueOfInvestmentsInAffiliatedCompany contextRef="c-191" decimals="0" id="f-645" unitRef="usd">695131</ino:ChangeInValueOfInvestmentsInAffiliatedCompany>
    <ino:ChangeInValueOfInvestmentsInAffiliatedCompany contextRef="c-192" decimals="0" id="f-646" unitRef="usd">-126018</ino:ChangeInValueOfInvestmentsInAffiliatedCompany>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss contextRef="c-191" decimals="0" id="f-647" unitRef="usd">140234</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss contextRef="c-192" decimals="0" id="f-648" unitRef="usd">500877</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-191" decimals="0" id="f-649" unitRef="usd">-482</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-192" decimals="0" id="f-650" unitRef="usd">-682218</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss contextRef="c-191" decimals="0" id="f-651" unitRef="usd">-19694697</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-192" decimals="0" id="f-652" unitRef="usd">-30469871</us-gaap:NetIncomeLoss>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-1" id="f-653">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="c-1" id="f-654">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="c-1" id="f-655">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="c-1" id="f-656">false</ecd:NonRule10b51ArrTrmntdFlag>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
